date,title,description,close,high,low,open,symbol,volume,id,key,subkey,updated,changeOverTime,marketChangeOverTime,uOpen,uClose,uHigh,uLow,uVolume,fOpen,fClose,fHigh,fLow,fVolume,label,change,changePercent
19-Mar-21,Clovis Oncology’s Rubraca® (rucaparib) Significantly Improves Progression-Free Survival versus Chemotherapy in Patients with Later-line Ovarian Cancer Associated with a BRCA Mutation,"Clovis Oncology, Inc. (NASDAQ: CLVS) announced that the first presentation of data from the randomized, Phase 3 ARIEL4 study of Rubraca® (rucaparib) will take place today in an oral presentation at th...",7.86,8.95,6.36,6.4,CLVS,331763706,HISTORICAL_PRICES,CLVS,,1.6162E+12,0,0,6.4,7.86,8.95,6.36,331763706,6.4,7.86,8.95,6.36,331763706,19-Mar-21,0,0
19-Mar-21,U.S. Food and Drug Administration (FDA) Accepts Bristol Myers Squibb’s Application for Mavacamten in Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM),"Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for mavacamten, an investigational, novel, oral, allosteri...",62.7,62.75,61.365,62.07,BMY,32082150,HISTORICAL_PRICES,BMY,,1.6162E+12,0,0,62.07,62.7,62.75,61.365,32082150,62.07,62.7,62.75,61.365,32082150,19-Mar-21,0,0
19-Mar-21,KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Significantly Improved Progression-Free Survival and Overall Survival Versus Chemotherapy in Patients With Advanced Endometrial Cancer Following Prior Platinum-Based Chemotherapy in Phase 3 Study,"Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Eisai today announced the first presentation of investigational data from the pivotal Phase 3 KEYNOTE-775/Study 309 trial in a...",77.51,78.25,76.0224,77.25,MRK,55558405,HISTORICAL_PRICES,MRK,,1.6162E+12,0,0,77.25,77.51,78.25,76.0224,55558405,77.25,77.51,78.25,76.0224,55558405,19-Mar-21,0,0
19-Mar-21,ADC Therapeutics meldet Finanzergebnisse für das vierte Quartal und das Gesamtjahr 2020 und gibt aktuelle Unternehmensentwicklungen bekannt,"ADC Therapeutics SA (NYSE: ADCT), ein auf Onkologie spezialisiertes Biotechnologieunternehmen und Pionier bei der Entwicklung und Vermarktung hochwirksamer und zielgerichteter Antikörper-Wirkstoff-Kon...",28.07,30.75,27.83,30.63,ADCT,580285,HISTORICAL_PRICES,ADCT,,1.6162E+12,0,0,30.63,28.07,30.75,27.83,580285,30.63,28.07,30.75,27.83,580285,19-Mar-21,0,0
17-Mar-21,"AMC Theatres® to Have 98% of Its U.S. Locations Open Beginning Friday, March 19","AMC Theatres (NYSE: AMC), the largest theatrical exhibitor in the United States, in Europe & the Middle East, and in the world, announced that beginning Friday, March 19, 98% of its U.S. theatres...",13.56,13.66,13,13.24,AMC,78053640,HISTORICAL_PRICES,AMC,,1.61603E+12,0.491749175,0.491749175,13.24,13.56,13.66,13,78053640,13.24,13.56,13.66,13,78053640,17-Mar-21,0.54,0.0415
17-Mar-21,"Transcat, Inc. to Present at Sidoti Spring 2021 Virtual Conference","Transcat, Inc. (Nasdaq: TRNS) (“Transcat” or the “Company”), a leading provider of accredited calibration, repair, inspection and laboratory instrument services and value-added distributor of professi...",49.65,50.35,49,49.57,TRNS,23165,HISTORICAL_PRICES,TRNS,,1.61603E+12,0.110738255,0.110738255,49.57,49.65,50.35,49,23165,49.57,49.65,50.35,49,23165,17-Mar-21,0.16,0.0032
17-Mar-21,Axcella Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update,"Axcella (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases and improve health using endogenous metabolic modulator (EMM) compositions, today ann...",5.57,5.76,5.52,5.63,AXLA,59005,HISTORICAL_PRICES,AXLA,,1.61603E+12,-0.046232877,-0.046232877,5.63,5.57,5.76,5.52,59005,5.63,5.57,5.76,5.52,59005,17-Mar-21,-0.22,-0.038
17-Mar-21,European Commission Approves Expanded Indication for Merck’s KEYTRUDA® (pembrolizumab) in Adult and Pediatric Patients With Relapsed or Refractory Classical Hodgkin Lymphoma (cHL),"Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the European Commission (EC) has approved an expanded label for KEYTRUDA, Merck’s anti-PD-1 therapy, as monot...",77.3,77.5,75.97,76.73,MRK,16730806,HISTORICAL_PRICES,MRK,,1.61603E+12,0.036609897,0.036609897,76.73,77.3,77.5,75.97,16730806,76.73,77.3,77.5,75.97,16730806,17-Mar-21,0.49,0.0064
17-Mar-21,"Cardiovascular Systems, Inc. Announces First Uses of WIRION® Embolic Protection System","Cardiovascular Systems, Inc. (CSI®) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery...",41.88,42.015,40.15,41.05,CSII,167870,HISTORICAL_PRICES,CSII,,1.61603E+12,-0.009694963,-0.009694963,41.05,41.88,42.015,40.15,167870,41.05,41.88,42.015,40.15,167870,17-Mar-21,0.91,0.0222
17-Mar-21,Sage Therapeutics Announces Continued Positive Zuranolone Data for Both 30 mg and 50 mg Doses in Open-Label SHORELINE Study in Patients with MDD,"Sage Therapeutics, Inc. (Nasdaq: SAGE) today reported complete 12-month data from the 30 mg cohort and interim data from the 50 mg cohort of the ongoing Phase 3 open-label SHORELINE Study. This clinic...",78.98,79.73,74.7,74.7,SAGE,516367,HISTORICAL_PRICES,SAGE,,1.61603E+12,-0.071260583,-0.071260583,74.7,78.98,79.73,74.7,516367,74.7,78.98,79.73,74.7,516367,17-Mar-21,2.5,0.0327
16-Mar-21,FSD Pharma Enters into License Agreement to Develop FDA approved Veterinary Drugs for the Treatment of Gastro-Intestinal Diseases in Dogs and Cats,FSD Pharma Inc. (Nasdaq: HUGE) (CSE: HUGE) (“FSD Pharma” or the “Company”) today announces that it has entered into a license agreement (the “License Agreement”) with Innovet Italia S.R.L. (“Innovet”)...,2.07,2.2,1.9525,2.18,HUGE,1442286,HISTORICAL_PRICES,HUGE,,1.61594E+12,-0.063348416,-0.063348416,2.18,2.07,2.2,1.9525,1442286,2.18,2.07,2.2,1.9525,1442286,16-Mar-21,-0.08,-0.0372
16-Mar-21,新研究评估Masimo EMMA®二氧化碳分析仪在评估气管造口术儿童呼吸状态方面的能力,(美国商业资讯)--Masimo (NASDAQ: MASI)今天公布了《国际儿科学》(Pediatrics International)发表的一项观察性回顾性研究的结果。在该研究中，日本大阪妇幼医院的研究人员发现，Masimo EMMA®便携式二氧化碳分析仪“可用于评估气管造口术儿童的呼吸病况”1。EMMA®紧凑型便携式设备可为所有年龄段患者提供无缝主流二氧化碳监测。该设备无需常规校准，预热时间...,229.77,236.92,226.68,236.92,MASI,603695,HISTORICAL_PRICES,MASI,,1.61594E+12,-0.08531051,-0.08531051,236.92,229.77,236.92,226.68,603695,236.92,229.77,236.92,226.68,603695,16-Mar-21,-5.03,-0.0214
16-Mar-21,新研究評估Masimo EMMA®二氧化碳分析儀在評估氣管造口術兒童呼吸狀態方面的能力,(美國商業資訊)--Masimo (NASDAQ: MASI)今天公布了《國際兒科學》(Pediatrics International)發表的一項觀察性回顧性研究的結果。在該研究中，日本大阪婦幼醫院的研究人員發現，Masimo EMMA®可攜式二氧化碳分析儀「可用於評估氣管造口術兒童的呼吸病況」1。EMMA®精簡型可攜式設備可為所有年齡層患者提供順暢主流二氧化碳監測。該設備無需常規校正，預熱時間...,229.77,236.92,226.68,236.92,MASI,603695,HISTORICAL_PRICES,MASI,,1.61594E+12,-0.08531051,-0.08531051,236.92,229.77,236.92,226.68,603695,236.92,229.77,236.92,226.68,603695,16-Mar-21,-5.03,-0.0214
16-Mar-21,Sage Therapeutics Announces Departure of Chief Operating Officer,"Sage Therapeutics (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating brain disorders, today annou...",76.48,81.98,74.7,80.85,SAGE,450971,HISTORICAL_PRICES,SAGE,,1.61594E+12,-0.100658514,-0.100658514,80.85,76.48,81.98,74.7,450971,80.85,76.48,81.98,74.7,450971,16-Mar-21,-2.84,-0.0358
16-Mar-21,Neue Studie wertet die Fähigkeit der Kapnographie von Masimo EMMA® zur Beurteilung des Atemstatus von Kindern mit Tracheostomie aus,"Masimo (NASDAQ: MASI) veröffentlichte heute die Ergebnisse einer retrospektiven Beobachtungsstudie, welche in Pediatrics International veröffentlicht wurde. Forscher des Osaka Women's and Children's H...",229.77,236.92,226.68,236.92,MASI,603695,HISTORICAL_PRICES,MASI,,1.61594E+12,-0.08531051,-0.08531051,236.92,229.77,236.92,226.68,603695,236.92,229.77,236.92,226.68,603695,16-Mar-21,-5.03,-0.0214
16-Mar-21,AVEO Oncology Reports Full Year 2020 Financial Results and Provides Business Update,"AVEO Oncology (Nasdaq: AVEO) today reported financial results for the full year ended December 31, 2020 and provided a business update. “The U.S. Food and Drug Administration’s (FDA) recent approval o...",11.41,12.06,11.03,12,AVEO,2177214,HISTORICAL_PRICES,AVEO,,1.61594E+12,0.316032295,0.316032295,12,11.41,12.06,11.03,2177214,12,11.41,12.06,11.03,2177214,16-Mar-21,-0.8,-0.0655
16-Mar-21,Infinity Pharmaceuticals Reports Full Year 2020 Financial Results and Provides Update on Eganelisib Development,"Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) (“Infinity” or the “Company”), a clinical-stage biotechnology company developing eganelisib (IPI-549), a potentially first-in-class, oral, immuno-oncology...",3.1,3.22,2.935,3.22,INFI,1766032,HISTORICAL_PRICES,INFI,,1.61594E+12,-0.090909091,-0.090909091,3.22,3.1,3.22,2.935,1766032,3.22,3.1,3.22,2.935,1766032,16-Mar-21,-0.12,-0.0373
16-Mar-21,Un nuevo estudio analiza la capacidad del capnógrafo Masimo EMMA® para evaluar el estado respiratorio de niños con traqueostomía,"Masimo (NASDAQ: MASI) anunció hoy las conclusiones de un estudio retrospectivo de observación publicado en Pediatrics International. En el estudio, los investigadores del Hospital de Mujeres y Niños d...",229.77,236.92,226.68,236.92,MASI,603695,HISTORICAL_PRICES,MASI,,1.61594E+12,-0.08531051,-0.08531051,236.92,229.77,236.92,226.68,603695,236.92,229.77,236.92,226.68,603695,16-Mar-21,-5.03,-0.0214
16-Mar-21,Kala Pharmaceuticals Announces Preferred Position for EYSUVIS™ on Cigna,"Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced that...",7.83,8.09,7.64,7.77,KALA,1752008,HISTORICAL_PRICES,KALA,,1.61594E+12,-0.123180291,-0.123180291,7.77,7.83,8.09,7.64,1752008,7.77,7.83,8.09,7.64,1752008,16-Mar-21,0.29,0.0385
16-Mar-21,Moderna Announces First Participants Dosed in Phase 2/3 Study of COVID-19 Vaccine Candidate in Pediatric Population,"Moderna Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that the first participants have been dosed in the Phase 2/3 study, call...",156.02,157.75,145.84,148.5,MRNA,16991621,HISTORICAL_PRICES,MRNA,,1.61594E+12,0.077560605,0.077560605,148.5,156.02,157.75,145.84,16991621,148.5,156.02,157.75,145.84,16991621,16-Mar-21,12.36,0.086
16-Mar-21,Merck Receives Priority Review From FDA for New Drug Application for HIF-2α Inhibitor Belzutifan (MK-6482),"Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted priority review for a New Drug Applicati...",76.81,77.17,76.14,76.15,MRK,14978940,HISTORICAL_PRICES,MRK,,1.61595E+12,0.03003889,0.03003889,76.15,76.81,77.17,76.14,14978940,76.15,76.81,77.17,76.14,14978940,16-Mar-21,0.58,0.0076
15-Mar-21,Novo estudo avalia a capacidade da capnografia Masimo EMMA® para avaliar o estado respiratório de crianças com traqueostomia,"A Masimo (NASDAQ: MASI) anunciou hoje os resultados de um estudo observacional retrospectivo publicado na Pediatrics International. No estudo, pesquisadores do Hospital de Mulheres e Crianças de Osaka...",234.8,235.87,229.67,233.2,MASI,706968,HISTORICAL_PRICES,MASI,,1.61586E+12,-0.065286624,-0.065286624,233.2,234.8,235.87,229.67,706968,233.2,234.8,235.87,229.67,706968,15-Mar-21,4.4,0.0191
15-Mar-21,Gamida Cell Presents Efficacy and Safety Results of Phase 3 Study of Omidubicel in Patients with Hematologic Malignancies at the 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT),"Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to cures for blood cancers and serious hematologic diseases, today announced the results of a Phase 3 clinical study of omid...",9.08,9.3677,8.72,9,GMDA,654580,HISTORICAL_PRICES,GMDA,,1.61586E+12,-0.10805501,-0.10805501,9,9.08,9.3677,8.72,654580,9,9.08,9.3677,8.72,654580,15-Mar-21,0.12,0.0134
15-Mar-21,"First Participants Dosed in Phase 1 Study Evaluating mRNA-1283, Moderna’s Next Generation COVID-19 Vaccine","Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that the first participants have been dosed in the Phase 1 study of mRN...",143.66,143.85,135.01,136.77,MRNA,7361627,HISTORICAL_PRICES,MRNA,,1.61586E+12,-0.007804406,-0.007804406,136.77,143.66,143.85,135.01,7361627,136.77,143.66,143.85,135.01,7361627,15-Mar-21,6.67,0.0487
15-Mar-21,ImmunityBio Announces Positive Interim Phase I Safety Data of hAd5 T-Cell COVID-19 Vaccine Candidate in Oral and Sublingual Formulations,"ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company, today announced it has met the safety requirements for the first 12 participants in its Phase Ib human adenovirus (hAd5)-based...",30.82,32.19,30.185,31.15,IBRX,805652,HISTORICAL_PRICES,IBRX,,1.61586E+12,-0.051400431,-0.051400431,31.15,30.82,32.19,30.185,805652,31.15,30.82,32.19,30.185,805652,15-Mar-21,0.28,0.0092
15-Mar-21,"Chief Medical Officer of electroCore, Inc. Peter Staats, M.D. Describes Potential At-Home Solutions to Reduce Common COVID-19 Symptoms","Amid the vaccine roll out, 97,309 new cases of COVID-19 have been reported to the CDC. Peter Staats, M.D. Chief Medical Officer of electroCore, Inc. (Nasdaq: ECOR), outlines common COVID-19 symptoms a...",2.2,2.22,2.0801,2.14,ECOR,649936,HISTORICAL_PRICES,ECOR,,1.61586E+12,-0.079497908,-0.079497908,2.14,2.2,2.22,2.0801,649936,2.14,2.2,2.22,2.0801,649936,15-Mar-21,0.06,0.028
15-Mar-21,Travelers Institute Announces Spring 2021 Virtual Programming,"The Travelers Institute, the public policy division of The Travelers Companies, Inc. (NYSE: TRV), today announced additional events in its “Wednesdays with Woodward” virtual series. The upcoming webin...",157.34,157.5,155.6,155.97,TRV,873687,HISTORICAL_PRICES,TRV,,1.61586E+12,0.042262851,0.042262851,155.97,157.34,157.5,155.6,873687,155.97,157.34,157.5,155.6,873687,15-Mar-21,0.07,0.0004
15-Mar-21,"Horizon Therapeutics plc Completes Acquisition of Viela Bio, Inc.","Horizon Therapeutics plc (Nasdaq: HZNP) today announced that it has completed the acquisition of Viela Bio, Inc. (Nasdaq: VIE) (“Viela”). “The Viela acquisition provides multiple opportunities to driv...",92.49,93.05,90.46,92.24,HZNP,1401193,HISTORICAL_PRICES,HZNP,,1.61586E+12,-0.031315459,-0.031315459,92.24,92.49,93.05,90.46,1401193,92.24,92.49,93.05,90.46,1401193,15-Mar-21,0.71,0.0077
15-Mar-21,Magenta Therapeutics Presents Final Phase 1 Results of MGTA-145 Stem Cell Mobilization Clinical Trial and Preclinical Data from Targeted Conditioning Program at the European Society for Blood and Marrow Transplantation (EBMT) 2021 Annual Meeting,"Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplants to more patients, today announced availabili...",12.98,13.175,12.36,12.95,MGTA,128122,HISTORICAL_PRICES,MGTA,,1.61586E+12,0.163082437,0.163082437,12.95,12.98,13.175,12.36,128122,12.95,12.98,13.175,12.36,128122,15-Mar-21,-0.05,-0.0038
15-Mar-21,PhaseBio Reports Fourth-Quarter and Full-Year 2020 Financial Results and Recent Business Highlights,"PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiopulmonary diseases, today report...",4.01,4.46,3.9575,4.35,PHAS,434197,HISTORICAL_PRICES,PHAS,,1.61586E+12,-0.026699029,-0.026699029,4.35,4.01,4.46,3.9575,434197,4.35,4.01,4.46,3.9575,434197,15-Mar-21,-0.33,-0.076
15-Mar-21,Twist Bioscience Begins Shipping of Synthetic RNA Controls for B.1.351 and P.1 Variants,"Twist Bioscience Corporation (Nasdaq: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that it has started...",144.47,146.7,138.91,141,TWST,675549,HISTORICAL_PRICES,TWST,,1.61586E+12,0.015963432,0.015963432,141,144.47,146.7,138.91,675549,141,144.47,146.7,138.91,675549,15-Mar-21,3.07,0.0217
15-Mar-21,Scholar Rock Presents TOPAZ Interim Analysis Data for Apitegromab in Spinal Muscular Atrophy at the 2021 Muscular Dystrophy Association (MDA) Virtual Clinical & Scientific Conference,"Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced its oral a...",68.02,68.64,62.06,63.26,SRRK,268586,HISTORICAL_PRICES,SRRK,,1.61586E+12,0.325925926,0.325925926,63.26,68.02,68.64,62.06,268586,63.26,68.02,68.64,62.06,268586,15-Mar-21,3.46,0.0536
15-Mar-21,AVEO Oncology to Regain Ex-North American Rights to AV-203,"AVEO Oncology (Nasdaq: AVEO) today announced that it will regain its rights to AV-203 outside of North America, its clinical-stage potent humanized IgG1 monoclonal antibody that targets ErbB3 (also kn...",12.21,12.79,11.9,12.27,AVEO,3359945,HISTORICAL_PRICES,AVEO,,1.61586E+12,0.408304498,0.408304498,12.27,12.21,12.79,11.9,3359945,12.27,12.21,12.79,11.9,3359945,15-Mar-21,-0.23,-0.0185
15-Mar-21,Sesen Bio Reports Fourth Quarter and Full-Year 2020 Financial Results and Significant Regulatory and Commercial Readiness Progress for the Company’s Lead Product Candidate Vicineum™,"Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today reported operating results for the fourth quart...",2.84,2.9,2.69,2.77,SESN,5386100,HISTORICAL_PRICES,SESN,,1.61586E+12,0,0,2.77,2.84,2.9,2.69,5386100,2.77,2.84,2.9,2.69,5386100,15-Mar-21,-0.02,-0.007
15-Mar-21,"bluebird bio Presents Long-Term Data for elivaldogene autotemcel (eli-cel, Lenti-D™) Gene Therapy for Cerebral Adrenoleukodystrophy (CALD)","bluebird bio, Inc. (Nasdaq: BLUE) announced new data from the clinical development program for its investigational elivaldogene autotemcel (eli-cel, Lenti-D™) gene therapy in patients with cerebral ad...",33.25,33.6337,32.5,32.8,BLUE,1728770,HISTORICAL_PRICES,BLUE,,1.61586E+12,0.28279321,0.28279321,32.8,33.25,33.6337,32.5,1728770,32.8,33.25,33.6337,32.5,1728770,15-Mar-21,0.82,0.0253
15-Mar-21,New Study Evaluates the Ability of Masimo EMMA® Capnography to Assess the Respiratory Status of Children With Tracheostomy,"Masimo (NASDAQ: MASI) today announced the findings of an observational, retrospective study published in Pediatrics International. In the study, researchers at the Osaka Women’s and Children’s Hospita...",234.8,235.87,229.67,233.2,MASI,706968,HISTORICAL_PRICES,MASI,,1.61586E+12,-0.065286624,-0.065286624,233.2,234.8,235.87,229.67,706968,233.2,234.8,235.87,229.67,706968,15-Mar-21,4.4,0.0191
12-Mar-21,Baxter Announces U.S. FDA 510(k) Clearance of AK 98 Hemodialysis Machine,"Baxter International Inc. (NYSE:BAX), a global innovator in renal care, today announced U.S. Food and Drug Administration (FDA) clearance of its next-generation Artificial Kidney 98 (AK 98) dialysis m...",77.96,78.38,77.55,78,BAX,1462524,HISTORICAL_PRICES,BAX,,1.6156E+12,-0.007005477,-0.007005477,78,77.96,78.38,77.55,1462524,78,77.96,78.38,77.55,1462524,12-Mar-21,0.22,0.0028
12-Mar-21,AVEO Oncology Announces Collaboration with Bristol Myers Squibb to Evaluate FOTIVDA® (tivozanib) in Combination with OPDIVO® (nivolumab) in Pivotal Phase 3 TiNivo-2 Trial in IO Relapsed Renal Cell Carcinoma,AVEO Oncology (Nasdaq: AVEO) today announced that it has entered into a clinical trial collaboration and supply agreement with Bristol Myers Squibb to evaluate FOTIVDA® (tivozanib) in combination with...,12.44,13.21,11.35,12.4331,AVEO,15577948,HISTORICAL_PRICES,AVEO,,1.6156E+12,0.434832757,0.434832757,12.4331,12.44,13.21,11.35,15577948,12.4331,12.44,13.21,11.35,15577948,12-Mar-21,0.57,0.048
12-Mar-21,Seres Therapeutics to Present at the 31st Annual Oppenheimer Healthcare Conference,"Seres Therapeutics, Inc., (Nasdaq: MCRB), a leading microbiome therapeutics company, announced that managment will present a corporate overview at the 31st Annual Oppenheimer Healthcare Conference on...",21.37,22.195,20.75,21.87,MCRB,1164375,HISTORICAL_PRICES,MCRB,,1.6156E+12,0.079292929,0.079292929,21.87,21.37,22.195,20.75,1164375,21.87,21.37,22.195,20.75,1164375,12-Mar-21,-1.33,-0.0586
12-Mar-21,Johnson & Johnson erhält für Einzeldosis-COVID-19-Impfstoff bedingte Zulassung der Europäischen Kommission,"Johnson & Johnson (NYSE: JNJ) (""das Unternehmen"") gab heute bekannt, dass die Europäische Kommission (EC) seinem COVID-19-Impfstoff, der in einer Einzeldosis verabreicht werden kann, eine bedingte...",159.6,160.31,159.19,159.28,JNJ,5474849,HISTORICAL_PRICES,JNJ,,1.6156E+12,-0.018389815,-0.018389815,159.28,159.6,160.31,159.19,5474849,159.28,159.6,160.31,159.19,5474849,12-Mar-21,0.46,0.0029
11-Mar-21,Johnson & Johnson meldet den Erhalt einer positiven CHMP-Stellungnahme für seinen Einzeldosis-Impfstoffkandidaten gegen COVID-19,"Johnson & Johnson (NYSE: JNJ) („das Unternehmen“) gab heute bekannt, dass der Ausschuss für Humanarzneimittel (CHMP) der Europäischen Arzneimittelagentur (EMA) eine positive Stellungnahme abgegebe...",159.14,160.63,158.92,159.54,JNJ,6305584,HISTORICAL_PRICES,JNJ,,1.61551E+12,-0.021219017,-0.021219017,159.54,159.14,160.63,158.92,6305584,159.54,159.14,160.63,158.92,6305584,11-Mar-21,-0.01,-0.0001
11-Mar-21,Johnson & Johnson annonce que son vaccin candidat contre la COVID-19 à dose unique a obtenu l'avis favorable du CHMP,Johnson & Johnson (NYSE: JNJ) (la Société) a annoncé aujourd'hui que le Comité européen pour les produits médicaux à usage humain (CHMP) de l'Agence européenne des médicaments (EMA) a émis un avis...,159.14,160.63,158.92,159.54,JNJ,6305584,HISTORICAL_PRICES,JNJ,,1.61551E+12,-0.021219017,-0.021219017,159.54,159.14,160.63,158.92,6305584,159.54,159.14,160.63,158.92,6305584,11-Mar-21,-0.01,-0.0001
11-Mar-21,"Innovative Industrial Properties Acquires Texas Property and Expands Real Estate Partnership with Parallel, a Leading U.S. Cannabis Well-Being Company","Innovative Industrial Properties, Inc. (IIP) (NYSE: IIPR), the first and only real estate company on the New York Stock Exchange focused on the regulated U.S. cannabis industry, announced today that i...",180.73,182.545,176.07,176.17,IIPR,433198,HISTORICAL_PRICES,IIPR,,1.61551E+12,-0.17909702,-0.17909702,176.17,180.73,182.545,176.07,433198,176.17,180.73,182.545,176.07,433198,11-Mar-21,8.71,0.0506
11-Mar-21,Geron Corporation Reports Fourth Quarter and Full Year 2020 Financial Results and Operational Highlights,"Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company developing a first-in-class telomerase inhibitor, imetelstat, to treat hematologic myeloid malignancies, today reporte...",1.89,1.8989,1.82,1.86,GERN,2937360,HISTORICAL_PRICES,GERN,,1.61551E+12,0,0,1.86,1.89,1.8989,1.82,2937360,1.86,1.89,1.8989,1.82,2937360,11-Mar-21,0.06,0.0328
11-Mar-21,Catabasis Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Provides a Corporate Update,"Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a biopharmaceutical company, today reported financial results for the fourth quarter and full year ended December 31, 2020 and provided a corporate updat...",3.46,3.56,3.18,3.4,CATB,3543265,HISTORICAL_PRICES,CATB,,1.61551E+12,0.164983165,0.164983165,3.4,3.46,3.56,3.18,3543265,3.4,3.46,3.56,3.18,3543265,11-Mar-21,0.44,0.1457
11-Mar-21,AVEO Oncology Announces Drawdown of $20 Million Tranche Under Hercules Debt Facility,"AVEO Oncology (Nasdaq: AVEO) today announced that it has completed a drawdown of $20 million under its previously announced $45 million loan and security agreement with Hercules Capital, Inc. (NYSE: H...",11.87,18.24,11.82,17.8,AVEO,36510397,HISTORICAL_PRICES,AVEO,,1.61551E+12,0.369088812,0.369088812,17.8,11.87,18.24,11.82,36510397,17.8,11.87,18.24,11.82,36510397,11-Mar-21,-3.41,-0.2232
11-Mar-21,Kezar Life Sciences Reports Fourth Quarter and Year End 2020 Financial Results and Provides Business Updates,"Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced its four...",6.56,6.57,6.29,6.44,KZR,171639,HISTORICAL_PRICES,KZR,,1.61551E+12,0.154929577,0.154929577,6.44,6.56,6.57,6.29,171639,6.44,6.56,6.57,6.29,171639,11-Mar-21,0.11,0.0171
11-Mar-21,Ocular Therapeutix™ Reports Fourth Quarter and Year End 2020 Financial Results and Business Update,"Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today...",20.31,20.44,19.64,20.01,OCUL,825449,HISTORICAL_PRICES,OCUL,,1.61551E+12,0.137178052,0.137178052,20.01,20.31,20.44,19.64,825449,20.01,20.31,20.44,19.64,825449,11-Mar-21,0.65,0.0331
11-Mar-21,Aerie Pharmaceuticals Announces Presentation at the Ophthalmology Innovation Summit Dry Eye Innovation Showcase,"Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients w...",20.37,20.57,19,19.78,AERI,532636,HISTORICAL_PRICES,AERI,,1.61551E+12,0.245110024,0.245110024,19.78,20.37,20.57,19,532636,19.78,20.37,20.57,19,532636,11-Mar-21,0.76,0.0388
11-Mar-21,Shareholder Alert: Robbins LLP Announces that Vanda Pharmaceuticals Inc. (VNDA) Class Action Survives Motion to Dismiss,Shareholder rights law firm Robbins LLP announces that Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) may face damages caused by a pending securities lawsuit. Vanda Pharmaceuticals Inc. is a biopharmaceuti...,17.88,18.15,17.62,18.03,VNDA,369653,HISTORICAL_PRICES,VNDA,,1.61551E+12,-0.118343195,-0.118343195,18.03,17.88,18.15,17.62,369653,18.03,17.88,18.15,17.62,369653,11-Mar-21,-0.03,-0.0017
11-Mar-21,ADC Therapeutics führt am 18. März 2021 Telefonkonferenz über Finanzergebnisse für viertes Geschäftsquartal und Gesamtjahr 2020 durch,"ADC Therapeutics SA (NYSE: ADCT), ein im Bereich der späten klinischen Forschung tätiges Biotechnologieunternehmen mit Schwerpunkt auf Onkologie und Vorreiter bei der Entwicklung und Vermarktung von h...",25.19,25.96,24.62,25.48,ADCT,132159,HISTORICAL_PRICES,ADCT,,1.61551E+12,-0.1189227,-0.1189227,25.48,25.19,25.96,24.62,132159,25.48,25.19,25.96,24.62,132159,11-Mar-21,0.34,0.0137
11-Mar-21,Johnson & Johnson Single-Shot COVID-19 Vaccine Granted Conditional Marketing Authorization by European Commission,"Johnson & Johnson (NYSE: JNJ) (the Company) today announced that the European Commission (EC) has granted a Conditional Marketing Authorization (CMA) for its single-dose COVID-19 vaccine, develope...",159.14,160.63,158.92,159.54,JNJ,6305584,HISTORICAL_PRICES,JNJ,,1.61551E+12,-0.021219017,-0.021219017,159.54,159.14,160.63,158.92,6305584,159.54,159.14,160.63,158.92,6305584,11-Mar-21,-0.01,-0.0001
11-Mar-21,ImmunityBio Announces Novel ACE2 Decoy COVID-19 Therapeutic that Shows High Binding to SARS-CoV-2 Variants and Neutralizes Live Viruses,"ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company, today announced it is developing a novel hAd5 ACE2 Decoy therapeutic vaccine to neutralize the SARS-CoV-2 virus, including the...",34.03,40.834,33.28,40.834,IBRX,1735369,HISTORICAL_PRICES,IBRX,,1.61551E+12,0.0473992,0.0473992,40.834,34.03,40.834,33.28,1735369,40.834,34.03,40.834,33.28,1735369,11-Mar-21,-4.67,-0.1207
11-Mar-21,"Exicure, Inc. Reports Full Year 2020 Financial Results and Corporate Progress","Exicure, Inc. (NASDAQ:XCUR), a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) technology, today reported fourth quarter and full year financial results...",2.5,2.56,1.94,1.99,XCUR,2418013,HISTORICAL_PRICES,XCUR,,1.61551E+12,0.041666667,0.041666667,1.99,2.5,2.56,1.94,2418013,1.99,2.5,2.56,1.94,2418013,11-Mar-21,0.56,0.2887
11-Mar-21,"Applied DNA Receives Blanket Purchase Order for Linea™ COVID-19 Assay Kits for 10,000 Tests","Applied DNA Sciences, Inc. (NASDAQ: APDN) (the “Company”), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing, today announced the receipt of a purchase order for its Linea™ COVID-19...",9.12,9.35,8.75,8.95,APDN,312991,HISTORICAL_PRICES,APDN,,1.61551E+12,-0.01511879,-0.01511879,8.95,9.12,9.35,8.75,312991,8.95,9.12,9.35,8.75,312991,11-Mar-21,0.42,0.0483
11-Mar-21,Simulations Plus Hosts the Inaugural 2021 MIDD+ Scientific Conference with over 50 Model-Informed Drug Development Sessions,"Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, announced the successful launch of its 2021 MIDD+ Scie...",71.94,72.94,70.78,71.06,SLP,135280,HISTORICAL_PRICES,SLP,,1.61551E+12,-0.035786088,-0.035786088,71.06,71.94,72.94,70.78,135280,71.06,71.94,72.94,70.78,135280,11-Mar-21,2.18,0.0312
11-Mar-21,Johnson & Johnson Announces its Single-Shot COVID-19 Vaccine Candidate Receives Positive CHMP Opinion,Johnson & Johnson (NYSE: JNJ) (the Company) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a Positive Opinion to recom...,159.14,160.63,158.92,159.54,JNJ,6305584,HISTORICAL_PRICES,JNJ,,1.61551E+12,-0.021219017,-0.021219017,159.54,159.14,160.63,158.92,6305584,159.54,159.14,160.63,158.92,6305584,11-Mar-21,-0.01,-0.0001
11-Mar-21,Incyte Announces Data from Multiple Programs Within its Oncology Portfolio Accepted for Presentation at the AACR Annual Meeting 2021,Incyte (Nasdaq:INCY) today announced that multiple abstracts from across its oncology portfolio will be presented during Week 1 of the upcoming American Association for Cancer Research (AACR) Annual M...,79.48,80.48,78.91,78.91,INCY,910204,HISTORICAL_PRICES,INCY,,1.61551E+12,-0.014018112,-0.014018112,78.91,79.48,80.48,78.91,910204,78.91,79.48,80.48,78.91,910204,11-Mar-21,1.13,0.0144
11-Mar-21,PhaseBio Pharmaceuticals and BioVectra Enter into Supply Agreement to Support Development and Commercialization of Bentracimab,"PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiopulmonary diseases, and BioVectr...",4.45,4.5,4.03,4.18,PHAS,507604,HISTORICAL_PRICES,PHAS,,1.61551E+12,0.080097087,0.080097087,4.18,4.45,4.5,4.03,507604,4.18,4.45,4.5,4.03,507604,11-Mar-21,0.38,0.0934
11-Mar-21,Aerie Pharmaceuticals to Participate in the Oppenheimer 31st Annual Virtual Healthcare Conference,"Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients w...",20.37,20.57,19,19.78,AERI,532636,HISTORICAL_PRICES,AERI,,1.61551E+12,0.245110024,0.245110024,19.78,20.37,20.57,19,532636,19.78,20.37,20.57,19,532636,11-Mar-21,0.76,0.0388
11-Mar-21,"Virios Therapeutics to Report Fourth Quarter and Full Year 2020 Financial Results and Provide Corporate Update on Thursday, March 18, 2021","Virios Therapeutics, Inc. (Nasdaq: VIRI), a clinical-stage biotechnology company focused on advancing novel antiviral therapies to treat diseases associated with virally triggered or maintained immune...",6.8,7.0199,5.926,6.04,VIRI,194414,HISTORICAL_PRICES,VIRI,,1.61551E+12,-0.005847953,-0.005847953,6.04,6.8,7.0199,5.926,194414,6.04,6.8,7.0199,5.926,194414,11-Mar-21,0.64,0.1039
11-Mar-21,Real-World Evidence Confirms High Effectiveness of Pfizer-BioNTech COVID-19 Vaccine and Profound Public Health Impact of Vaccination One Year After Pandemic Declared,"The Israel Ministry of Health (MoH), Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced real-world evidence demonstrating dramatically lower incidence rates of COVID-19 disease in...",34.71,35.12,34.66,35.07,PFE,24557862,HISTORICAL_PRICES,PFE,,1.61551E+12,0.028444444,0.028444444,35.07,34.71,35.12,34.66,24557862,35.07,34.71,35.12,34.66,24557862,11-Mar-21,-0.22,-0.0063
11-Mar-21,Greenwich LifeSciences Updates 2021 Timeline & Announces Two Upcoming Presentations at the American Association for Cancer Research Annual Meeting,"Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in pati...",27.3,30.29,27.2,28.5,GLSI,831494,HISTORICAL_PRICES,GLSI,,1.61551E+12,-0.189429929,-0.189429929,28.5,27.3,30.29,27.2,831494,28.5,27.3,30.29,27.2,831494,11-Mar-21,-2.47,-0.083
10-Mar-21,Las soluciones de monitoreo de Masimo promueven la seguridad de madres y recién nacidos,Masimo (NASDAQ: MASI) proporciona una variedad de soluciones innovadoras de monitoreo diseñadas para mejorar la seguridad de madres y recién nacidos durante el parto y los críticos primeros minutos de...,229.19,235,228.03,232.73,MASI,311253,HISTORICAL_PRICES,MASI,,1.61543E+12,-0.087619427,-0.087619427,232.73,229.19,235,228.03,311253,232.73,229.19,235,228.03,311253,10-Mar-21,-1.3,-0.0056
10-Mar-21,Vertex gibt Erteilung des Fast-Track-Status durch die FDA und Start der klinischen Phase-1/2-Studie zu VX-880 bekannt – eine neuartige Zelltherapie zur Behandlung von Typ-1-Diabetes,"Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) gab heute bekannt, dass die US-amerikanische Arzneimittelaufsichtsbehörde FDA (Food and Drug Administration) VX-880 den Fast-Track-Status für ein bes...",214.29,217.72,211.56,217.3,VRTX,1938935,HISTORICAL_PRICES,VRTX,,1.61543E+12,-0.012670475,-0.012670475,217.3,214.29,217.72,211.56,1938935,217.3,214.29,217.72,211.56,1938935,10-Mar-21,0.25,0.0012
10-Mar-21,Merrimack Reports Full Year 2020 Financial Results,"Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) (“Merrimack” or the “Company”) today announced its full year 2020 financial results for the period ended December 31, 2020. “We are pleased that both Ips...",6.45,6.66,6.42,6.45,MACK,32266,HISTORICAL_PRICES,MACK,,1.61543E+12,-0.117647059,-0.117647059,6.45,6.45,6.66,6.42,32266,6.45,6.45,6.66,6.42,32266,10-Mar-21,0.04,0.0062
10-Mar-21,AVEO Announces Appointment of Mike Ferraresso to Chief Commercial Officer,"AVEO Oncology (Nasdaq:AVEO) today announced the appointment of Mike Ferraresso to chief commercial officer. Mr. Ferraresso will be responsible for managing AVEO’s commercial strategy and operations, i...",15.28,15.37,7.87,8.22,AVEO,50864569,HISTORICAL_PRICES,AVEO,,1.61543E+12,0.762399077,0.762399077,8.22,15.28,15.37,7.87,50864569,8.22,15.28,15.37,7.87,50864569,10-Mar-21,7.2,0.8911
10-Mar-21,Zymeworks Announces Five Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2021,"Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced the acceptance of five abstracts for poster presentation at the upco...",34.82,36.31,34.55,35.44,ZYME,375703,HISTORICAL_PRICES,ZYME,,1.61543E+12,-0.135980149,-0.135980149,35.44,34.82,36.31,34.55,375703,35.44,34.82,36.31,34.55,375703,10-Mar-21,0.27,0.0078
10-Mar-21,GlycoMimetics to Share GMI-1359 and Galectin-3 Antagonist Program Data at AACR 2021 Meeting,"GlycoMimetics, Inc. (Nasdaq: GLYC) today announces that an abstract presenting the interim analysis of a Phase 1b proof-of-concept study of GMI-1359, the Company’s dual antagonist of E-selectin and CX...",3.15,3.22,3.04,3.15,GLYC,615952,HISTORICAL_PRICES,GLYC,,1.61543E+12,-0.094827586,-0.094827586,3.15,3.15,3.22,3.04,615952,3.15,3.15,3.22,3.04,615952,10-Mar-21,0.08,0.0261
10-Mar-21,Moderna Announces First Participants Dosed in Study Evaluating COVID-19 Booster Vaccine Candidates,"Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that the first participants have been dosed with the Company’s modified...",129.75,135.715,128.7932,133.62,MRNA,5555909,HISTORICAL_PRICES,MRNA,,1.61543E+12,-0.103874577,-0.103874577,133.62,129.75,135.715,128.7932,5555909,133.62,129.75,135.715,128.7932,5555909,10-Mar-21,-1.12,-0.0086
10-Mar-21,DiaMedica Therapeutics Announces 2020 Financial Results and Provides a Business Update,"DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today provided a business...",8.81,9.2,8.75,8.94,DMAC,57900,HISTORICAL_PRICES,DMAC,,1.61543E+12,-0.060767591,-0.060767591,8.94,8.81,9.2,8.75,57900,8.94,8.81,9.2,8.75,57900,10-Mar-21,0.07,0.008
10-Mar-21,TFF Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial and Business Results,"TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) t...",14.94,16.05,14.35,15.63,TFFP,371864,HISTORICAL_PRICES,TFFP,,1.61543E+12,-0.017105263,-0.017105263,15.63,14.94,16.05,14.35,371864,15.63,14.94,16.05,14.35,371864,10-Mar-21,-0.04,-0.0027
10-Mar-21,Humanigen Reports Fourth Quarter and Year-End 2020 Financial Results and Provides Corporate Update,"Humanigen, Inc. (Nasdaq: HGEN) (“Humanigen”), a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm’ with its lead drug candidat...",16.45,17.06,16.0662,16.69,HGEN,1105177,HISTORICAL_PRICES,HGEN,,1.61543E+12,-0.146784232,-0.146784232,16.69,16.45,17.06,16.0662,1105177,16.69,16.45,17.06,16.0662,1105177,10-Mar-21,0.05,0.003
10-Mar-21,AVEO Oncology Announces U.S. FDA Approval of FOTIVDA® (tivozanib) for the Treatment of Adult Patients with Relapsed or Refractory Advanced Renal Cell Carcinoma,AVEO Oncology (Nasdaq: AVEO) today announced that the U.S. Food and Drug Administration (FDA) has approved FOTIVDA® (tivozanib) for the treatment of adults with relapsed or refractory advanced renal c...,15.28,15.37,7.87,8.22,AVEO,50864569,HISTORICAL_PRICES,AVEO,,1.61543E+12,0.762399077,0.762399077,8.22,15.28,15.37,7.87,50864569,8.22,15.28,15.37,7.87,50864569,10-Mar-21,7.2,0.8911
10-Mar-21,"Riassunto: Vertex annuncia la designazione Fast Track della FDA e l'inizio di uno studio clinico di fase 1/2 per VX-880, una nuova terapia cellulare sperimentale per il trattamento del diabete di Tipo 1",Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) ha annunciato oggi che la Food and Drug Administration (FDA) degli Stati Uniti ha concesso la designazione Fast Track per VX-880. L'azienda ha inoltr...,214.29,217.72,211.56,217.3,VRTX,1938935,HISTORICAL_PRICES,VRTX,,1.61543E+12,-0.012670475,-0.012670475,217.3,214.29,217.72,211.56,1938935,217.3,214.29,217.72,211.56,1938935,10-Mar-21,0.25,0.0012
10-Mar-21,AbCellera-Discovered Bamlanivimab Together with Etesevimab Reduced Hospitalizations and Prevented Death in Phase 3 Trial for Early COVID-19,"AbCellera (Nasdaq: ABCL) today announced that bamlanivimab (LY-CoV555) 700 mg, a human antibody discovered by AbCellera and developed with Eli Lilly and Company (Lilly), and etesevimab 1400 mg (LY-CoV...",32.22,32.89,30.2101,31.03,ABCL,941362,HISTORICAL_PRICES,ABCL,,1.61543E+12,-0.196508728,-0.196508728,31.03,32.22,32.89,30.2101,941362,31.03,32.22,32.89,30.2101,941362,10-Mar-21,1.58,0.0516
10-Mar-21,"Vertex kondigt FDA Fast Track Designation aan en start van een Fase 1/2 klinische studie voor VX-880, een nieuwe onderzoeksceltherapie voor de behandeling van Type 1 Diabetes",Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) heeft vandaag aangekondigd dat de Amerikaanse Food en Drug Administration (FDA) Fast Track Designation voor VX-880 heeft verleend en dat het bedrijf...,214.29,217.72,211.56,217.3,VRTX,1938935,HISTORICAL_PRICES,VRTX,,1.61543E+12,-0.012670475,-0.012670475,217.3,214.29,217.72,211.56,1938935,217.3,214.29,217.72,211.56,1938935,10-Mar-21,0.25,0.0012
10-Mar-21,"Resumen: Vertex anuncia la designación de vía rápida de la FDA y el inicio de un ensayo clínico de fase 1/2 para VX-880, una novedosa terapia celular en investigación para el tratamiento de la diabetes tipo 1",Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) ha anunciado hoy que la Administración de Alimentos y Medicamentos de Estados Unidos (FDA) ha concedido la designación de vía rápida ( “ Fast Track”...,214.29,217.72,211.56,217.3,VRTX,1938935,HISTORICAL_PRICES,VRTX,,1.61543E+12,-0.012670475,-0.012670475,217.3,214.29,217.72,211.56,1938935,217.3,214.29,217.72,211.56,1938935,10-Mar-21,0.25,0.0012
10-Mar-21, ImmunityBio Begins Trading Today on Nasdaq as Large Cap Biotechnology Company,"ImmunityBio, Inc. (NASDAQ: IBRX) today announced it has begun trading as a large cap company with approximately 398 million fully diluted shares outstanding following its merger with NantKwest. The co...",38.7,38.71,33.6843,36.55,IBRX,956490,HISTORICAL_PRICES,IBRX,,1.61543E+12,0.191135734,0.191135734,36.55,38.7,38.71,33.6843,956490,36.55,38.7,38.71,33.6843,956490,10-Mar-21,6.21,0.1911
10-Mar-21,Establishment Labs Reports Fourth Quarter and Full Year 2020 Financial Results; Record Fourth Quarter Revenue of $27.0 Million,"Establishment Labs Holdings Inc. (NASDAQ: ESTA), a medical technology company focused on women’s health, initially in the breast aesthetics and reconstruction market, today announced its financial res...",63.08,64.76,59.5,61.93,ESTA,136193,HISTORICAL_PRICES,ESTA,,1.61543E+12,-0.092635213,-0.092635213,61.93,63.08,64.76,59.5,136193,61.93,63.08,64.76,59.5,136193,10-Mar-21,0.08,0.0013
10-Mar-21,"PolarityTE to Report Fiscal Year 2020 Financial Results on March 30, 2021","PolarityTE, Inc. (Nasdaq: PTE) today announced that it will report results for the year ended December 31, 2020 by press release on Tuesday, March 30, 2021 at approximately 7:00 a.m. Eastern Time. In...",1.28,1.45,1.28,1.39,PTE,3848318,HISTORICAL_PRICES,PTE,,1.61543E+12,-0.058823529,-0.058823529,1.39,1.28,1.45,1.28,3848318,1.39,1.28,1.45,1.28,3848318,10-Mar-21,-0.11,-0.0791
10-Mar-21,"Vertex Announces FDA Fast Track Designation and Initiation of a Phase 1/2 Clinical Trial for VX-880, a Novel Investigational Cell Therapy for the Treatment of Type 1 Diabetes",Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for VX-880 and that the company has initiated a c...,214.29,217.72,211.56,217.3,VRTX,1938935,HISTORICAL_PRICES,VRTX,,1.61543E+12,-0.012670475,-0.012670475,217.3,214.29,217.72,211.56,1938935,217.3,214.29,217.72,211.56,1938935,10-Mar-21,0.25,0.0012
10-Mar-21,Masimo Monitoring-Lösungen bringen Sicherheit für Neugeborene und Wöchnerinnen,"Masimo (NASDAQ: MASI) stellt eine Vielzahl innovativer Monitoring-Lösungen zur Verfügung, mit denen sich die Sicherheit von Müttern und Babys während der Geburt und in den ersten kritischen Lebensminu...",229.19,235,228.03,232.73,MASI,311253,HISTORICAL_PRICES,MASI,,1.61543E+12,-0.087619427,-0.087619427,232.73,229.19,235,228.03,311253,232.73,229.19,235,228.03,311253,10-Mar-21,-1.3,-0.0056
10-Mar-21,Circle Medical to Offer Labcorp’s At Home COVID-19 Self-Collection Test and Announces Clinical Expansion to Austin and San Diego Markets,"Circle Medical, a digital-first primary care practice, will be offering a convenient at home COVID-19 self-collection test kit in partnership with Labcorp (NYSE: LH). Together with Circle Medical’s pr...",232.62,242.36,231.64,241.78,LH,980254,HISTORICAL_PRICES,LH,,1.61543E+12,-0.048588957,-0.048588957,241.78,232.62,242.36,231.64,980254,241.78,232.62,242.36,231.64,980254,10-Mar-21,-6.6,-0.0276
10-Mar-21,LENSAR Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update,"LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or “the Company”), a global medical technology company focused on advanced femtosecond laser surgical solutions for the treatment of cataracts, today announced fi...",8.89,9,8.46,8.46,LNSR,59847,HISTORICAL_PRICES,LNSR,,1.61543E+12,-0.070083682,-0.070083682,8.46,8.89,9,8.46,59847,8.46,8.89,9,8.46,59847,10-Mar-21,0.47,0.0558
10-Mar-21,bluebird bio Provides Updated Findings from Reported Case of Acute Myeloid Leukemia (AML) in LentiGlobin for Sickle Cell Disease (SCD) Gene Therapy Program,"bluebird bio, Inc. (Nasdaq: BLUE) announced today that based on the analyses completed to date, it is very unlikely the Suspected Unexpected Serious Adverse Reaction (SUSAR) of acute myeloid leukemia...",32.48,34.5,31.95,34.31,BLUE,6192993,HISTORICAL_PRICES,BLUE,,1.61543E+12,0.25308642,0.25308642,34.31,32.48,34.5,31.95,6192993,34.31,32.48,34.5,31.95,6192993,10-Mar-21,2.44,0.0812
10-Mar-21,ChromaDex Announces Retail Distribution of Tru Niagen® in Walmart Stores Across the United States,"ChromaDex Corp. (NASDAQ:CDXC) announced today its flagship consumer product and industry-leading NAD+ booster Tru Niagen® will be available in 3,000 Walmart retail stores across the United States begi...",10.75,14.75,10.66,14.26,CDXC,4226075,HISTORICAL_PRICES,CDXC,,1.61543E+12,0.103696099,0.103696099,14.26,10.75,14.75,10.66,4226075,14.26,10.75,14.75,10.66,4226075,10-Mar-21,-0.71,-0.062
9-Mar-21,Masimo監護解決方案促進新生兒和孕產婦的安全,--(美國商業資訊)--Masimo (NASDAQ: MASI)提供旨在加強分娩和出生後關鍵的前幾分鐘內孕產婦和新生兒安全的各種創新監護解決方案。Masimo SET®脈搏血氧飽和度儀能在移動和低灌注下測量，服務於新生兒、初生兒和兒科患者，而其他脈搏血氧飽和度儀無法與之比擬。Masimo SET®不僅幫助臨床工作者減少早產兒視網膜病變(ROP) 1、改善危急型先天性心臟病(CCHD)的篩檢2-1...,230.49,233.5,229.63,229.74,MASI,523452,HISTORICAL_PRICES,MASI,,1.61534E+12,-0.082444268,-0.082444268,229.74,230.49,233.5,229.63,523452,229.74,230.49,233.5,229.63,523452,9-Mar-21,5.86,0.0261
9-Mar-21,Masimo监护解决方案促进新生儿和孕产妇的安全,--(美国商业资讯)--Masimo (NASDAQ: MASI)提供旨在加强分娩和出生后关键的前几分钟内孕产妇和新生儿安全的各种创新监护解决方案。Masimo SET®脉搏氧饱和度仪能在移动和低灌注下测量，服务于新生儿、初生儿和儿科患者，而其他脉搏氧饱和度仪无法与之比拟。Masimo SET®不仅帮助临床工作者减少早产儿视网膜病变(ROP) 1、改善危重型先天性心脏病(CCHD)的筛查2-10，...,230.49,233.5,229.63,229.74,MASI,523452,HISTORICAL_PRICES,MASI,,1.61534E+12,-0.082444268,-0.082444268,229.74,230.49,233.5,229.63,523452,229.74,230.49,233.5,229.63,523452,9-Mar-21,5.86,0.0261
9-Mar-21,"Kiromic to Resubmit Two Expanded INDs to the FDA for Its Allogenic, Off-the-Shelf Gamma-Delta T cell Therapies for Multiple Solid Tumors","Kiromic Biopharma, Inc. (Nasdaq: KRBP), a target discovery and gene-editing company utilizing artificial intelligence and its proprietary neural network platform with a therapeutic focus on immuno-onc...",11.81,12.12,10.76,10.9,KRBP,41147,HISTORICAL_PRICES,KRBP,,1.61534E+12,0.07168784,0.07168784,10.9,11.81,12.12,10.76,41147,10.9,11.81,12.12,10.76,41147,9-Mar-21,0.97,0.0895
9-Mar-21,ImmunityBio and NantKwest Complete Merger,"ImmunityBio, Inc. and NantKwest, Inc. (NASDAQ: NK), today announced the completion of their previously announced 100% stock-for-stock merger. This follows the satisfaction of all customary closing con...",32.49,33.15,29.74,30.34,NK,1109036,HISTORICAL_PRICES,NK,,1.61534E+12,-0.004900459,-0.004900459,30.34,32.49,33.15,29.74,1109036,30.34,32.49,33.15,29.74,1109036,9-Mar-21,4.21,0.1489
9-Mar-21,"Lyra Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results, Provides Corporate Update","Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatme...",14.6,14.86,14.216,14.32,LYRA,65275,HISTORICAL_PRICES,LYRA,,1.61534E+12,0.018841591,0.018841591,14.32,14.6,14.86,14.216,65275,14.32,14.6,14.86,14.216,65275,9-Mar-21,0.31,0.0217
9-Mar-21,DiaMedica Therapeutics Hosting Key Opinion Leader Webinar on DM199 for Treatment of Acute Ischemic Stroke,"DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical stage biopharmaceutical company developing novel treatments for neurological and kidney diseases, today announced that it will host a key opinion...",8.74,8.86,8.38,8.4,DMAC,65936,HISTORICAL_PRICES,DMAC,,1.61534E+12,-0.068230277,-0.068230277,8.4,8.74,8.86,8.38,65936,8.4,8.74,8.86,8.38,65936,9-Mar-21,0.56,0.0685
9-Mar-21,Mirum Pharmaceuticals Reports Fourth Quarter and Year-End 2020 Results and Provides Business Updates,"Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), today announced financial results for the fourth quarter and year-end 2020 and provided business updates. “In 2020, Mirum achieved several critical mileston...",18.5,18.75,17.715,17.79,MIRM,112974,HISTORICAL_PRICES,MIRM,,1.61534E+12,-0.030906234,-0.030906234,17.79,18.5,18.75,17.715,112974,17.79,18.5,18.75,17.715,112974,9-Mar-21,1.13,0.0651
9-Mar-21,Outset Medical Reports Fourth Quarter and Full Year 2020 Financial Results,"Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today reported financial results for...",48.44,50.56,48.25,48.5333,OM,230283,HISTORICAL_PRICES,OM,,1.61534E+12,-0.035444046,-0.035444046,48.5333,48.44,50.56,48.25,230283,48.5333,48.44,50.56,48.25,230283,9-Mar-21,1.5,0.032
9-Mar-21,Gilead’s Investigational Lenacapavir Demonstrates Sustained Long-Acting Efficacy Through Week 26 in Data Presented at CROI,"Gilead Sciences, Inc. (Nasdaq: GILD) today presented additional results from the Phase 2/3 CAPELLA trial evaluating the company’s investigational, long-acting HIV-1 capsid inhibitor, lenacapavir, in h...",64.33,66.655,64.27,65.5067,GILD,8973303,HISTORICAL_PRICES,GILD,,1.61552E+12,0.009731596,0.009731596,65.5067,64.33,66.655,64.27,8973303,64.7695,63.606,65.9049,63.5467,8973303,9-Mar-21,-0.42,-0.0065
9-Mar-21,Applied DNA Launches Linea™ COVID-19 Selective Genomic Surveillance™ Mutation Panel to Boost SARS-CoV-2 Variant Detection and Tracking Nationally,"Applied DNA Sciences, Inc. (NASDAQ: APDN) (the “Company”), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing, today announced the launch of its Linea™ COVID-19 Selective Genomic Surv...",8.54,8.55,7.86,8.0035,APDN,570250,HISTORICAL_PRICES,APDN,,1.61534E+12,-0.07775378,-0.07775378,8.0035,8.54,8.55,7.86,570250,8.0035,8.54,8.55,7.86,570250,9-Mar-21,0.72,0.0921
9-Mar-21,Cyclo Therapeutics Receives Positive Opinion from the Paediatric Committee of the European Medicines Agency on the Agreement of a Paediatric Investigation Plan for Trappsol® Cyclo™,"Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation f...",9.72,11.6,8.82,9.05,CYTH,1760840,HISTORICAL_PRICES,CYTH,,1.61534E+12,0.074033149,0.074033149,9.05,9.72,11.6,8.82,1760840,9.05,9.72,11.6,8.82,1760840,9-Mar-21,1.82,0.2304
9-Mar-21,NeuroRX and TFF Pharmaceuticals Announce Entering Into Feasibility Collaboration,"NeuroRx, Inc. and TFF Pharmaceuticals, Inc. (NASDAQ: TFFP) are announcing that the companies have entered into a feasibility and material transfer agreement (Feasibility Agreement). Under the Feasibil...",14.98,15.03,14.08,14.08,TFFP,455288,HISTORICAL_PRICES,TFFP,,1.61534E+12,-0.014473684,-0.014473684,14.08,14.98,15.03,14.08,455288,14.08,14.98,15.03,14.08,455288,9-Mar-21,1.38,0.1015
9-Mar-21,Feasibility Arrangement for Shelf-stable Powder Form of Messenger RNA COVID-19 Vaccine Candidate Announced by GreenLight Biosciences and TFF Pharmaceuticals,"GreenLight Biosciences, Inc., a privately-held RNA vaccine developer and manufacturer, and TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing an...",14.98,15.03,14.08,14.08,TFFP,455288,HISTORICAL_PRICES,TFFP,,1.61534E+12,-0.014473684,-0.014473684,14.08,14.98,15.03,14.08,455288,14.08,14.98,15.03,14.08,455288,9-Mar-21,1.38,0.1015
9-Mar-21,PerkinElmer Launches Comprehensive Solutions for Detecting SARS-CoV-2 Mutations,"PerkinElmer, Inc. (NYSE:PKI) today announced the launch of two Research Use Only (RUO) solutions, PKamp™ VariantDetect™ SARS-CoV-2 RT-PCR Assay and Next Generation Sequencing-based NEXTFLEX® Variant-S...",125.96,130.17,124.26,124.34,PKI,1176994,HISTORICAL_PRICES,PKI,,1.61534E+12,-0.02189781,-0.02189781,124.34,125.96,130.17,124.26,1176994,124.34,125.96,130.17,124.26,1176994,9-Mar-21,4.4,0.0362
9-Mar-21,Moderna Named Fast Company’s Most Innovative Company for 2021,"Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced it has been named as a top company on Fast Company’s prestigious annual...",130.87,132.3,125.6,127.11,MRNA,7834221,HISTORICAL_PRICES,MRNA,,1.61534E+12,-0.096139236,-0.096139236,127.11,130.87,132.3,125.6,7834221,127.11,130.87,132.3,125.6,7834221,9-Mar-21,7.4,0.0599
9-Mar-21,Labcorp Named to Fast Company’s List of the World’s Most Innovative Companies for 2021,"Labcorp (NYSE: LH), a leading global life sciences company, today announced that it has been named to Fast Company magazine’s list of 2021 Most Innovative Companies. Since 2008, the annual list has be...",239.22,244.99,238.74,242.33,LH,723599,HISTORICAL_PRICES,LH,,1.61534E+12,-0.021595092,-0.021595092,242.33,239.22,244.99,238.74,723599,242.33,239.22,244.99,238.74,723599,9-Mar-21,-1.35,-0.0056
9-Mar-21,Stoke Therapeutics Reports Full Year 2020 Financial Results and Provides Business Updates,"Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by up-regulating protein expression with RNA-based medicines, today rep...",51.88,57,51.07,51.78,STOK,297293,HISTORICAL_PRICES,STOK,,1.61534E+12,-0.144176839,-0.144176839,51.78,51.88,57,51.07,297293,51.78,51.88,57,51.07,297293,9-Mar-21,1.4,0.0277
9-Mar-21,"全球投资者法律顾问ROSEN鼓励Aquestive Therapeutics, Inc.投资者在AQST诉讼的重要截止日期前聘请律师","原因：全球投资者权益律师事务所Rosen Law Firm提醒在2019年12月2日至2020年9月25日期间（含上述日期，简称“集体诉讼期”）购买Aquestive Therapeutics, Inc. (NASDAQ: AQST)证券的人士牢记，首席原告的截止日期为2021年4月30日。 这意味着什么：在集体诉讼期购买了Aquestive证券的人士可能有资格获得赔偿，而且可以通过风险代理费安排...",4.47,4.67,4.3327,4.37,AQST,942807,HISTORICAL_PRICES,AQST,,1.61534E+12,-0.185050137,-0.185050137,4.37,4.47,4.67,4.3327,942807,4.37,4.47,4.67,4.3327,942807,9-Mar-21,0.21,0.0493
9-Mar-21,"全球投資人法律顧問ROSEN鼓勵Aquestive Therapeutics, Inc.投資人在AQST訴訟的重要截止日期前聘請律師","原因：全球投資人權益法律事務所Rosen Law Firm提醒在2019年12月2日至2020年9月25日期間（含上述日期，簡稱「集體訴訟期」）購買Aquestive Therapeutics, Inc. (NASDAQ: AQST)證券的人士牢記，原告代表的截止日期為2021年4月30日。 這意味著什麼：在集體訴訟期購買了Aquestive證券的人士可能有資格獲得賠償，而且可以透過勝訴分成安排，...",4.47,4.67,4.3327,4.37,AQST,942807,HISTORICAL_PRICES,AQST,,1.61534E+12,-0.185050137,-0.185050137,4.37,4.47,4.67,4.3327,942807,4.37,4.47,4.67,4.3327,942807,9-Mar-21,0.21,0.0493
9-Mar-21,Gamida Cell Reports Full Year 2020 Financial Results and Provides Company Update,"Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to finding cures for blood cancers and serious blood diseases, today reported financial results for the year and quarter end...",8.43,8.7538,8.17,8.434,GMDA,530037,HISTORICAL_PRICES,GMDA,,1.61534E+12,-0.171905697,-0.171905697,8.434,8.43,8.7538,8.17,530037,8.434,8.43,8.7538,8.17,530037,9-Mar-21,0.28,0.0344
9-Mar-21,Xeris Pharmaceuticals Reports Fourth Quarter and Full-year 2020 Financial Results and Recent Highlights,"Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use injectable and infusible...",4.61,4.69,3.98,4.3336,XERS,4844149,HISTORICAL_PRICES,XERS,,1.61534E+12,-0.210616438,-0.210616438,4.3336,4.61,4.69,3.98,4844149,4.3336,4.61,4.69,3.98,4844149,9-Mar-21,-0.11,-0.0233
9-Mar-21,Intersect ENT Reports Fourth Quarter and Full Year 2020 Financial Results,"Intersect ENT, Inc. (Nasdaq: XENT), a global ear, nose and throat (“ENT”) medical technology leader dedicated to transforming patient care, today reported financial results for the fourth quarter and...",22.16,24.785,21.89,22.44,XENT,238779,HISTORICAL_PRICES,XENT,,1.61534E+12,-0.084675754,-0.084675754,22.44,22.16,24.785,21.89,238779,22.44,22.16,24.785,21.89,238779,9-Mar-21,-1.02,-0.044
9-Mar-21,Marinus Pharmaceuticals Provides Business Update and Reports Fourth Quarter 2020 Financial Results,"Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders, today provided an update on its clinical...",18.62,19.12,17.03,17.1,MRNS,784338,HISTORICAL_PRICES,MRNS,,1.61534E+12,0.254716981,0.254716981,17.1,18.62,19.12,17.03,784338,17.1,18.62,19.12,17.03,784338,9-Mar-21,1.9,0.1136
9-Mar-21,Taysha Gene Therapies Announces Collaboration to Advance Next-Generation Mini-Gene Payloads for an AAV Gene Therapy for the Treatment of Neurodevelopmental Disorders,"Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric, clinical-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic dis...",26.6,26.78,25.25,25.27,TSHA,42947,HISTORICAL_PRICES,TSHA,,1.61534E+12,-0.052369077,-0.052369077,25.27,26.6,26.78,25.25,42947,25.27,26.6,26.78,25.25,42947,9-Mar-21,1.44,0.0572
9-Mar-21,Rocket Pharmaceuticals Receives FDA Regenerative Medicine Advanced Therapy Designation for RP-L201 Gene Therapy for Leukocyte Adhesion Deficiency-I,"Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders, today announces that the U.S....",53.98,55.26,50.03,50.03,RCKT,547638,HISTORICAL_PRICES,RCKT,,1.61534E+12,-0.035210009,-0.035210009,50.03,53.98,55.26,50.03,547638,50.03,53.98,55.26,50.03,547638,9-Mar-21,5.32,0.1093
9-Mar-21,"Ra Medical Systems to Report 2020 Fourth Quarter and Full Year Financial Results on March 16, 2021","Ra Medical Systems, Inc. (NYSE: RMED) announces that it will report 2020 fourth quarter and full year financial results and provide a business update after market close on Tuesday, March 16, 2021. Ra...",5.81,5.95,5.63,5.95,RMED,203318,HISTORICAL_PRICES,RMED,,1.61534E+12,-0.255128205,-0.255128205,5.95,5.81,5.95,5.63,203318,5.95,5.81,5.95,5.63,203318,9-Mar-21,0.12,0.0211
9-Mar-21,ANI Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Results; Company Positioned for Sustainable Future Growth,"ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (NASDAQ: ANIP) today announced business highlights and financial results for the three and 12 months ended December 31, 2020. Corporate Strategy The...",29.96,31.11,29.0301,30.88,ANIP,63837,HISTORICAL_PRICES,ANIP,,1.61534E+12,0.006044325,0.006044325,30.88,29.96,31.11,29.0301,63837,30.88,29.96,31.11,29.0301,63837,9-Mar-21,-0.38,-0.0125
9-Mar-21,"ANI Pharmaceuticals to Acquire Novitium Pharma, Strengthening R&D Engine and Expanding Generics and CDMO Business","ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (Nasdaq: ANIP) today announced that it has signed a definitive agreement to acquire Novitium Pharma, a privately held, New Jersey-based pharmaceutica...",29.96,31.11,29.0301,30.88,ANIP,63837,HISTORICAL_PRICES,ANIP,,1.61534E+12,0.006044325,0.006044325,30.88,29.96,31.11,29.0301,63837,30.88,29.96,31.11,29.0301,63837,9-Mar-21,-0.38,-0.0125
8-Mar-21,Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4),"Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on March 4, 2021 the Compensation Committee of Puma’s Board of Directors approved the grant of an inducement restri...",10.48,10.9299,10.42,10.86,PBYI,295428,HISTORICAL_PRICES,PBYI,,1.61526E+12,-0.073386384,-0.073386384,10.86,10.48,10.9299,10.42,295428,10.86,10.48,10.9299,10.42,295428,8-Mar-21,-0.38,-0.035
8-Mar-21,Acadia Pharmaceuticals Provides Regulatory Update on Supplemental New Drug Application for Pimavanserin for the Treatment of Hallucinations and Delusions Associated with Dementia-Related Psychosis,"Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Company received a notification from the U.S. Food and Drug Administration (FDA) on March 3, 2021, stating that, as part of its ongo...",45.78,49.23,45.71,49.08,ACAD,2846254,HISTORICAL_PRICES,ACAD,,1.61526E+12,-0.059765866,-0.059765866,49.08,45.78,49.23,45.71,2846254,49.08,45.78,49.23,45.71,2846254,8-Mar-21,-3.2,-0.0653
8-Mar-21,As soluções de monitoramento da Masimo promovem a segurança materna e neonatal,A Masimo (NASDAQ: MASI) fornece várias soluções de monitoramento inovadoras projetadas para melhorar a segurança materna e neonatal durante o parto e os primeiros minutos críticos de vida. A capacidad...,224.63,231.34,223.73,230.21,MASI,326183,HISTORICAL_PRICES,MASI,,1.61526E+12,-0.105772293,-0.105772293,230.21,224.63,231.34,223.73,326183,230.21,224.63,231.34,223.73,326183,8-Mar-21,-5.58,-0.0242
8-Mar-21,"ImmunityBio and NantKwest Begin Dosing Participants in Global Trials for Novel COVID-19 Vaccine; Subcutaneous Route in South Africa, Oral and Sublingual in the U.S.","ImmunityBio, Inc., a privately-held immunotherapy company, and NantKwest, Inc. (NASDAQ: NK), a clinical-stage, natural killer cell-based therapeutics company, today announced the first cohorts of thei...",28.28,30.32,26.5,27.95,NK,1296952,HISTORICAL_PRICES,NK,,1.61526E+12,-0.133843798,-0.133843798,27.95,28.28,30.32,26.5,1296952,27.95,28.28,30.32,26.5,1296952,8-Mar-21,1.48,0.0552
8-Mar-21,Baxter BioPharma Solutions and Moderna Announce Agreement for Fill/Finish Manufacturing of the Moderna COVID-19 Vaccine in the U.S.,"Baxter International Inc. (NYSE: BAX), a global leader in sterile medication production and delivery, and Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeu...",78.28,79.3,77.65,78.21,BAX,1553543,HISTORICAL_PRICES,BAX,,1.61526E+12,-0.002929563,-0.002929563,78.21,78.28,79.3,77.65,1553543,78.21,78.28,79.3,77.65,1553543,8-Mar-21,0.22,0.0028
8-Mar-21,"La Jolla Pharmaceutical Company Announces Financial Results for the Three and Twelve Months Ended December 31, 2020 and Highlights Corporate Progress","La Jolla Pharmaceutical Company (Nasdaq: LJPC), which is dedicated to the development and commercialization of innovative therapies that improve outcomes in patients suffering from life-threatening di...",4.56,4.92,4.44,4.75,LJPC,264470,HISTORICAL_PRICES,LJPC,,1.61526E+12,-0.213793103,-0.213793103,4.75,4.56,4.92,4.44,264470,4.75,4.56,4.92,4.44,264470,8-Mar-21,-0.12,-0.0256
8-Mar-21,Cortexyme Announces Partnership with Parkinson Study Group and Upcoming Alzheimer’s Disease Data Presentation,"Cortexyme, Inc. (Nasdaq: CRTX), a clinical-stage biopharmaceutical company focused on Alzheimer’s and other degenerative diseases, announced that it has partnered with the Parkinson Study Group (PSG)...",36.73,41.97,36.26,39.85,CRTX,405790,HISTORICAL_PRICES,CRTX,,1.61526E+12,0.117432309,0.117432309,39.85,36.73,41.97,36.26,405790,39.85,36.73,41.97,36.26,405790,8-Mar-21,-1.26,-0.0332
8-Mar-21,Henry Schein Announces Reinstatement of Share Repurchase Program,"Henry Schein, Inc. (Nasdaq: HSIC), the world’s largest provider of health care solutions to office-based dental and medical practitioners, announced today that the Company has entered into amendments...",64.79,66.06,62.625,63.2,HSIC,1018829,HISTORICAL_PRICES,HSIC,,1.61526E+12,-0.003384095,-0.003384095,63.2,64.79,66.06,62.625,1018829,63.2,64.79,66.06,62.625,1018829,8-Mar-21,2.22,0.0355
8-Mar-21,Sesen Bio Submits Marketing Authorization Application to the European Medicines Agency for Vicineum™,"Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, announced that on Friday, March 5, 2021 the Company s...",2.45,2.57,2.36,2.45,SESN,3165399,HISTORICAL_PRICES,SESN,,1.61526E+12,-0.137323944,-0.137323944,2.45,2.45,2.57,2.36,3165399,2.45,2.45,2.57,2.36,3165399,8-Mar-21,0.03,0.0124
8-Mar-21,Glaukos to Support World Glaucoma Week with Patient Education Campaign and Free Screening Initiatives,"Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today an...",81.81,87.62,81.65,86.14,GKOS,366202,HISTORICAL_PRICES,GKOS,,1.61526E+12,-0.151612569,-0.151612569,86.14,81.81,87.62,81.65,366202,86.14,81.81,87.62,81.65,366202,8-Mar-21,-3.95,-0.0461
8-Mar-21,"CMS Consolidates SINUVA Sinus Implant Coverage Under a Distinct Code, J7402, and Publishes an ASP Clarifying Payment and Easing Payer Coverage Adjudication","Intersect ENT®, Inc. (Nasdaq: XENT), a global ear, nose and throat (“ENT”) medical technology leader dedicated to transforming patient care, today announced that the Centers for Medicare and Medicaid...",23.18,24.575,23.05,23.84,XENT,408366,HISTORICAL_PRICES,XENT,,1.61526E+12,-0.042544403,-0.042544403,23.84,23.18,24.575,23.05,408366,23.84,23.18,24.575,23.05,408366,8-Mar-21,-0.64,-0.0269
8-Mar-21, Seres Therapeutics Announces Discontinuation of Enrollment in SER-401 Study in Metastatic Melanoma,"Seres Therapeutics, Inc. (Nasdaq: MCRB) announced today that the Company, in collaboration with study partners, The Parker Institute for Cancer Immunotherapy (PICI) and The University of Texas MD Ande...",17.75,19.3499,17.45,18.93,MCRB,1743143,HISTORICAL_PRICES,MCRB,,1.61526E+12,-0.103535354,-0.103535354,18.93,17.75,19.3499,17.45,1743143,18.93,17.75,19.3499,17.45,1743143,8-Mar-21,-1.31,-0.0687
8-Mar-21,"Greenwich LifeSciences Hires Industry Expert, Dr. Jaye Thompson, to Manage Phase III Clinical Trial for Recurring Breast Cancer","Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in pati...",37.2,52.98,22.6,23.01,GLSI,7232325,HISTORICAL_PRICES,GLSI,,1.61526E+12,0.104513064,0.104513064,23.01,37.2,52.98,22.6,7232325,23.01,37.2,52.98,22.6,7232325,8-Mar-21,14.2,0.6174
8-Mar-21,Philip Morris International Announces Yearlong Exploration of Inclusion—Furthering the Company’s Commitment to Equality,"On International Women’s Day, Philip Morris International Inc. (PMI) (NYSE: PM) announced the launch of a yearlong research and convening initiative entitled “Inclusive Future.” Following a year when...",86.36,87.51,85.885,86.14,PM,3841627,HISTORICAL_PRICES,PM,,1.61612E+12,-0.013704888,-0.013704888,86.14,86.36,87.51,85.885,3841627,84.9986,85.2157,86.3504,84.7469,3841627,8-Mar-21,0.2,0.0023
5-Mar-21,U.S. FDA Approves Yescarta® for Relapsed or Refractory Follicular Lymphoma After Two or More Lines of Systemic Therapy,"Kite, a Gilead Company (Nasdaq: GILD), today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval to Yescarta® (axicabtagene ciloleucel) for the treatment of adu...",64.62,64.745,63.3,63.42,GILD,9761404,HISTORICAL_PRICES,GILD,,1.61552E+12,0.014283472,0.014283472,63.42,64.62,64.745,63.3,9761404,62.7063,63.8928,64.0164,62.5876,9761404,5-Mar-21,1.39,0.022
5-Mar-21,"SHAREHOLDER ALERT: Robbins LLP Announces That Athenex, Inc. (ATNX) is Being Sued for Misleading Shareholders","Shareholder rights law firm Robbins LLP announces that a purchaser of Athenex, Inc. (NASDAQ: ATNX) filed a class action complaint against the Company and its officers and directors for alleged violati...",4.315,4.5474,3.93,4.5,ATNX,4827972,HISTORICAL_PRICES,ATNX,,1.615E+12,-0.644855967,-0.644855967,4.5,4.315,4.5474,3.93,4827972,4.5,4.315,4.5474,3.93,4827972,5-Mar-21,-0.165,-0.0368
5-Mar-21,"EMA Advises Use of AbCellera-Discovered Bamlanivimab, Alone or Together with Etesevimab, to Treat Confirmed COVID-19 Patients",AbCellera (Nasdaq: ABCL) today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive scientific opinion for bamlanivimab alon...,28.61,31.7364,26.1601,30.5099,ABCL,1793973,HISTORICAL_PRICES,ABCL,,1.615E+12,-0.286533666,-0.286533666,30.5099,28.61,31.7364,26.1601,1793973,30.5099,28.61,31.7364,26.1601,1793973,5-Mar-21,-1.44,-0.0479
5-Mar-21,"INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Athenex, Inc. (ATNX) Investors","Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased Athenex, Inc. (“Athenex” or the “Company”) (NASDAQ: ATNX) securities between Au...",4.315,4.5474,3.93,4.5,ATNX,4827972,HISTORICAL_PRICES,ATNX,,1.615E+12,-0.644855967,-0.644855967,4.5,4.315,4.5474,3.93,4827972,4.5,4.315,4.5474,3.93,4827972,5-Mar-21,-0.165,-0.0368
5-Mar-21,"INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Aquestive Therapeutics, Inc. (AQST) Investors","Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased Aquestive Therapeutics, Inc. (“Aquestive” or the “Company”) (NASDAQ: AQST) secu...",4.41,4.58,3.9,4.49,AQST,1153074,HISTORICAL_PRICES,AQST,,1.615E+12,-0.195989061,-0.195989061,4.49,4.41,4.58,3.9,1153074,4.49,4.41,4.58,3.9,1153074,5-Mar-21,0.19,0.045
5-Mar-21,"Second Sight Medical Products, Inc. Receives FDA Approval for the Argus 2s Retinal Prosthesis System","Second Sight Medical Products (NASDAQ:EYES) a leading developer and marketer of implantable visual prosthetics that are intended to create an artificial form of useful vision for blind individuals, to...",5.79,9.89,2.07,2.29,EYES,739730593,HISTORICAL_PRICES,EYES,,1.615E+12,1.939086294,1.939086294,2.29,5.79,9.89,2.07,739730593,2.29,5.79,9.89,2.07,739730593,5-Mar-21,4.36,3.049
4-Mar-21,Moderna Announces New Drug Application Submitted to Import and Distribute Moderna’s COVID-19 Vaccine Candidate in Japan,"Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that Takeda Pharmaceutical Co., Ltd (NYSE: TAK) submitted a New Drug Ap...",132.3,135.47,126.69,128.7,MRNA,10929537,HISTORICAL_PRICES,MRNA,,1.61491E+12,-0.086262863,-0.086262863,128.7,132.3,135.47,126.69,10929537,128.7,132.3,135.47,126.69,10929537,4-Mar-21,1.08,0.0082
4-Mar-21,"Glancy Prongay & Murray LLP, a National Class Action Law Firm, Continues Investigation of Ormat Technologies, Inc. (ORA) on Behalf of Investors","Glancy Prongay & Murray LLP (“GPM”), a national investor rights law firm, continues its investigation on behalf of Ormat Technologies, Inc. (“Ormat” or the “Company”) (NYSE: ORA) investors concern...",78.2,81.99,76.41,81.23,ORA,1040199,HISTORICAL_PRICES,ORA,,1.61534E+12,-0.247787611,-0.247787611,81.23,78.2,81.99,76.41,1040199,81.1144,78.0887,81.8733,76.3013,1040199,4-Mar-21,-3.04,-0.0374
4-Mar-21,Alexion Announces Upcoming Data Presentations at the 73rd Annual Meeting of the American Academy of Neurology,"Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced that three abstracts have been accepted for presentation at the 73rd annual meeting of the American Academy of Neurology (AAN), taking place...",148.46,150.15,146.97,148.19,ALXN,3959441,HISTORICAL_PRICES,ALXN,,1.61491E+12,-0.039031653,-0.039031653,148.19,148.46,150.15,146.97,3959441,148.19,148.46,150.15,146.97,3959441,4-Mar-21,0.27,0.0018
4-Mar-21,Puma Biotechnology to Present at the Barclays Global Healthcare Conference,"Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder of Puma, will provide an overview of the...",10.7,10.84,10.21,10.505,PBYI,418051,HISTORICAL_PRICES,PBYI,,1.61491E+12,-0.053934571,-0.053934571,10.505,10.7,10.84,10.21,418051,10.505,10.7,10.84,10.21,418051,4-Mar-21,0.37,0.0358
4-Mar-21,Ocular Therapeutix™ Announces FDA Acceptance of Supplemental New Drug Application for DEXTENZA® (dexamethasone ophthalmic insert) for the Treatment of Ocular Itching Associated with Allergic Conjunctivitis,"Ocular Therapeutix, Inc. (Nasdaq: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, toda...",17.33,18.16,16.85,17.7,OCUL,1339983,HISTORICAL_PRICES,OCUL,,1.61491E+12,-0.029675252,-0.029675252,17.7,17.33,18.16,16.85,1339983,17.7,17.33,18.16,16.85,1339983,4-Mar-21,-0.24,-0.0137
4-Mar-21,"Notice of Lead Plaintiff Deadline for Shareholders in the Athenex, Inc. Class Action Lawsuit","Robbins Geller Rudman & Dowd LLP announces that a class action lawsuit has been filed in the Western District of New York on behalf of purchasers of Athenex, Inc. (NASDAQ:ATNX) common stock betwee...",4.48,4.8911,4.3,4.7272,ATNX,8196195,HISTORICAL_PRICES,ATNX,,1.61491E+12,-0.63127572,-0.63127572,4.7272,4.48,4.8911,4.3,8196195,4.7272,4.48,4.8911,4.3,8196195,4-Mar-21,-0.335,-0.0696
4-Mar-21,"SHAREHOLDER ALERT: Robbins LLP Announces That Aquestive Therapeutics, Inc. (AQST) is Being Sued for Misleading Shareholders","Shareholder rights law firm Robbins LLP announces that a purchaser of Aquestive Therapeutics, Inc. (NASDAQ: AQST) filed a class action complaint against the Company and its officers and directors for...",4.22,4.78,4.11,4.62,AQST,1347733,HISTORICAL_PRICES,AQST,,1.61491E+12,-0.230628988,-0.230628988,4.62,4.22,4.78,4.11,1347733,4.62,4.22,4.78,4.11,1347733,4-Mar-21,-0.51,-0.1078
4-Mar-21,"The Law Offices of Frank R. Cruz Announces Investigation of Aquestive Therapeutics, Inc. (AQST) on Behalf of Investors","The Law Offices of Frank R. Cruz announces an investigation of Aquestive Therapeutics, Inc. (“Aquestive” or the “Company”) (NASDAQ: AQST) on behalf of investors concerning the Company’s possible viola...",4.22,4.78,4.11,4.62,AQST,1347733,HISTORICAL_PRICES,AQST,,1.61491E+12,-0.230628988,-0.230628988,4.62,4.22,4.78,4.11,1347733,4.62,4.22,4.78,4.11,1347733,4-Mar-21,-0.51,-0.1078
4-Mar-21,"Notice of Lead Plaintiff Deadline for Shareholders in the Aquestive Therapeutics, Inc. Class Action Lawsuit","Robbins Geller Rudman & Dowd LLP announces that a class action lawsuit has been filed in the District of New Jersey on behalf of purchasers of Aquestive Therapeutics, Inc. (NASDAQ: AQST) securitie...",4.22,4.78,4.11,4.62,AQST,1347733,HISTORICAL_PRICES,AQST,,1.61491E+12,-0.230628988,-0.230628988,4.62,4.22,4.78,4.11,1347733,4.62,4.22,4.78,4.11,1347733,4-Mar-21,-0.51,-0.1078
4-Mar-21,"SHAREHOLDER ACTION NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Athenex, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm","The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Athenex, Inc. (“Athenex” or “the Company”) (NASDAQ: ATNX) for violations of §...",4.48,4.8911,4.3,4.7272,ATNX,8196195,HISTORICAL_PRICES,ATNX,,1.61491E+12,-0.63127572,-0.63127572,4.7272,4.48,4.8911,4.3,8196195,4.7272,4.48,4.8911,4.3,8196195,4-Mar-21,-0.335,-0.0696
4-Mar-21,"Apollomics, Inc Doses First Patient in Phase 1 Clinical Trial in China of GlycoMimetics’ Uproleselan for the Treatment of AML",GlycoMimetics (Nasdaq: GLYC) today announced that Apollomics has dosed the first patient in China in a Phase 1 clinical trial of APL-106 (uproleselan injection) for the treatment of adults with relaps...,2.97,3.11,2.83,3.05,GLYC,1466806,HISTORICAL_PRICES,GLYC,,1.61491E+12,-0.146551724,-0.146551724,3.05,2.97,3.11,2.83,1466806,3.05,2.97,3.11,2.83,1466806,4-Mar-21,-0.09,-0.0294
4-Mar-21,TFF Pharmaceuticals Provides Update on Clinical Development Programs,"TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) t...",12.96,13.9,12.01,13.7,TFFP,532371,HISTORICAL_PRICES,TFFP,,1.61491E+12,-0.147368421,-0.147368421,13.7,12.96,13.9,12.01,532371,13.7,12.96,13.9,12.01,532371,4-Mar-21,-0.71,-0.0519
4-Mar-21,Masimo anuncia conquista da marca CE para o Rad-G™ com temperatura,"Masimo (NASDAQ: MASI) anunciou hoje que obteve a marca CE para o Rad-G™ com Temperatura, um dispositivo portátil robusto que fornece oximetria de pulso SET® clinicamente comprovada, frequência respira...",230.21,243.32,228.32,240.3,MASI,506219,HISTORICAL_PRICES,MASI,,1.61491E+12,-0.083558917,-0.083558917,240.3,230.21,243.32,228.32,506219,240.3,230.21,243.32,228.32,506219,4-Mar-21,-11.03,-0.0457
4-Mar-21,Masimo gibt die CE-Kennzeichnung für das Rad-G™ mit Temperatur bekannt,"Masimo (NASDAQ: MASI) gab heute die CE-Kennzeichnung des Rad-G™ mit Temperatur bekannt, einem robusten Handgerät, das neben der klinisch bewährten SET®-Pulsoximetrie, der Pleth-Atemfrequenz (Respirati...",230.21,243.32,228.32,240.3,MASI,506219,HISTORICAL_PRICES,MASI,,1.61491E+12,-0.083558917,-0.083558917,240.3,230.21,243.32,228.32,506219,240.3,230.21,243.32,228.32,506219,4-Mar-21,-11.03,-0.0457
3-Mar-21,Masimo宣布Rad-G™ with Temperature通過CE認證,(美國商業資訊)--Masimo (NASDAQ: MASI)今天宣布Rad-G™ with Temperature通過CE認證，這是一款堅固耐用的手持設備，可提供經過臨床驗證的SET®脈搏血氧飽和度、根據脈搏灌注的呼吸速率(RRp®)和其他重要參數，以及臨床級非接觸式紅外線測溫。憑藉其持久的充電電池、堅固的橡膠外殼、輕巧的重量和一體式無創即時前額測溫，Rad-G with Temperature...,241.24,250.63,240.1603,250.63,MASI,311486,HISTORICAL_PRICES,MASI,,1.61482E+12,-0.039649682,-0.039649682,250.63,241.24,250.63,240.1603,311486,250.63,241.24,250.63,240.1603,311486,3-Mar-21,-10.07,-0.0401
3-Mar-21,Masimo宣布Rad-G™ with Temperature通过CE认证,(美国商业资讯)--Masimo (NASDAQ: MASI)今天宣布Rad-G™ with Temperature通过CE认证，这是一款坚固耐用的手持设备，可提供经过临床验证的SET®脉搏氧饱和度、基于脉搏灌注的呼吸速率(RRp®)和其他重要参数，以及临床级非接触式红外测温。凭借其持久的充电电池、坚固的橡胶外壳、轻巧的重量和一体式无创实时前额测温，Rad-G with Temperature外形...,241.24,250.63,240.1603,250.63,MASI,311486,HISTORICAL_PRICES,MASI,,1.61482E+12,-0.039649682,-0.039649682,250.63,241.24,250.63,240.1603,311486,250.63,241.24,250.63,240.1603,311486,3-Mar-21,-10.07,-0.0401
3-Mar-21,Masimo anuncia la obtención del marcado CE para Rad-G™ con medición de temperatura,"Masimo (NASDAQ: MASI) anunció hoy la obtención del marcado CE para Rad-G™ con medición de temperatura, un dispositivo portátil robusto que proporciona pulsioximetría SET®, frecuencia respiratoria plet...",241.24,250.63,240.1603,250.63,MASI,311486,HISTORICAL_PRICES,MASI,,1.61482E+12,-0.039649682,-0.039649682,250.63,241.24,250.63,240.1603,311486,250.63,241.24,250.63,240.1603,311486,3-Mar-21,-10.07,-0.0401
3-Mar-21,U.S. FDA Expands Approval of Pfizer’s LORBRENA® as First-Line Treatment for ALK-Positive Metastatic Lung Cancer,"The U.S. Food and Drug Administration (FDA) approved Pfizer Inc.’s (NYSE: PFE) supplemental New Drug Application (sNDA) for LORBRENA® (lorlatinib), expanding the indication to include first-line treat...",34.39,34.4499,33.44,33.51,PFE,46020164,HISTORICAL_PRICES,PFE,,1.61482E+12,0.018962963,0.018962963,33.51,34.39,34.4499,33.44,46020164,33.51,34.39,34.4499,33.44,46020164,3-Mar-21,0.88,0.0263
3-Mar-21,"INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Athenex, Inc. (ATNX) on Behalf of Investors","Law Offices of Howard G. Smith announces an investigation on behalf of Athenex, Inc. (“Athenex” or the “Company”) (NASDAQ: ATNX) investors concerning the Company’s possible violations of federal secur...",4.815,5.43,4.66,5.36,ATNX,11018049,HISTORICAL_PRICES,ATNX,,1.61482E+12,-0.603703704,-0.603703704,5.36,4.815,5.43,4.66,11018049,5.36,4.815,5.43,4.66,11018049,3-Mar-21,-0.565,-0.105
3-Mar-21,"INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Aquestive Therapeutics, Inc. (AQST) on Behalf of Investors","Law Offices of Howard G. Smith announces an investigation on behalf of Aquestive Therapeutics, Inc. (“Aquestive” or the “Company”) (NASDAQ: AQST) investors concerning the Company’s possible violations...",4.73,5.5,4.69,5.3,AQST,1894357,HISTORICAL_PRICES,AQST,,1.61482E+12,-0.137648131,-0.137648131,5.3,4.73,5.5,4.69,1894357,5.3,4.73,5.5,4.69,1894357,3-Mar-21,-0.25,-0.0502
3-Mar-21,"The Law Offices of Frank R. Cruz Announces Investigation of Athenex, Inc. (ATNX) on Behalf of Investors","The Law Offices of Frank R. Cruz announces an investigation of Athenex, Inc. (“Athenex” or the “Company”) (NASDAQ: ATNX) on behalf of investors concerning the Company’s possible violations of federal...",4.815,5.43,4.66,5.36,ATNX,11018049,HISTORICAL_PRICES,ATNX,,1.61482E+12,-0.603703704,-0.603703704,5.36,4.815,5.43,4.66,11018049,5.36,4.815,5.43,4.66,11018049,3-Mar-21,-0.565,-0.105
3-Mar-21,"Axcella Announces Alison D. Schecter, M.D., as President of R&D","Axcella (Nasdaq:AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases and improve health using endogenous metabolic modulator (EMM) compositions, today anno...",5.68,5.8245,5.53,5.72,AXLA,64526,HISTORICAL_PRICES,AXLA,,1.61482E+12,-0.02739726,-0.02739726,5.72,5.68,5.8245,5.53,64526,5.72,5.68,5.8245,5.53,64526,3-Mar-21,-0.02,-0.0035
3-Mar-21,"SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Athenex, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm","The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Athenex, Inc. (“Athenex” or “the Company”) (NASDAQ: ATNX) for violations of §...",4.815,5.43,4.66,5.36,ATNX,11018049,HISTORICAL_PRICES,ATNX,,1.61482E+12,-0.603703704,-0.603703704,5.36,4.815,5.43,4.66,11018049,5.36,4.815,5.43,4.66,11018049,3-Mar-21,-0.565,-0.105
3-Mar-21,Cerus Corporation to Participate in Jefferies Virtual Global Plasma Summit,"Cerus Corporation (Nasdaq: CERS) announced today that William ‘Obi’ Greenman, Cerus’ president and chief executive officer, and Kevin D. Green, Cerus’ chief financial officer, are scheduled to partici...",6.28,6.38,6.03,6.38,CERS,3038095,HISTORICAL_PRICES,CERS,,1.61482E+12,-0.06547619,-0.06547619,6.38,6.28,6.38,6.03,3038095,6.38,6.28,6.38,6.03,3038095,3-Mar-21,-0.18,-0.0279
3-Mar-21,Magenta Therapeutics Reports Fourth Quarter and Full-Year 2020 Financial Results and Recent Program Highlights,"Magenta Therapeutics (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplants to more patients, today reported financial r...",13.18,13.54,11.67,11.76,MGTA,775076,HISTORICAL_PRICES,MGTA,,1.61482E+12,0.181003584,0.181003584,11.76,13.18,13.54,11.67,775076,11.76,13.18,13.54,11.67,775076,3-Mar-21,1.37,0.116
3-Mar-21,Guardant360® CDx Liquid Biopsy erhält die CE-Zertifizierung für umfassendes Tumormutationsprofiling für alle soliden Krebsarten,"Guardant Health, Inc. (Nasdaq: GH) erhielt die CE-Zertifizierung für Guardant360® CDx für das Profiling von Tumormutationen, auch bekannt als Comprehensive Genomic Profiling (CGP), bei Patienten mit a...",143.7,154,141.81,153.63,GH,1327452,HISTORICAL_PRICES,GH,,1.61482E+12,-0.114275148,-0.114275148,153.63,143.7,154,141.81,1327452,153.63,143.7,154,141.81,1327452,3-Mar-21,-10.93,-0.0707
3-Mar-21,Exicure Granted Orphan Drug Designation by the U.S. Food and Drug Administration for Cavrotolimod,"Exicure, Inc. (NASDAQ: XCUR), a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) technology, today announced that the U.S. Food and Drug Administration (F...",2.23,2.3547,2.15,2.3,XCUR,449359,HISTORICAL_PRICES,XCUR,,1.61482E+12,-0.070833333,-0.070833333,2.3,2.23,2.3547,2.15,449359,2.3,2.23,2.3547,2.15,449359,3-Mar-21,-0.04,-0.0176
3-Mar-21,Taysha Gene Therapies Reports Full-Year 2020 Financial Results and Provides a Corporate Update,"Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric, clinical-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic dis...",25.21,26.4574,23.5821,25.5,TSHA,77324,HISTORICAL_PRICES,TSHA,,1.61482E+12,-0.101888137,-0.101888137,25.5,25.21,26.4574,23.5821,77324,25.5,25.21,26.4574,23.5821,77324,3-Mar-21,0,0
3-Mar-21,Iveric Bio Reports Fourth Quarter and Year End 2020 Operational Highlights and Financial Results,"IVERIC bio, Inc. (Nasdaq: ISEE) today announced financial and operating results for the fourth quarter and full year ended December 31, 2020 and provided a general business update. The Company also an...",6.43,6.78,6.14,6.22,ISEE,951775,HISTORICAL_PRICES,ISEE,,1.61482E+12,0.040453074,0.040453074,6.22,6.43,6.78,6.14,951775,6.22,6.43,6.78,6.14,951775,3-Mar-21,0.16,0.0255
2-Mar-21, Gilead to Present New Data at CROI 2021 Demonstrating the Company's Commitment to Addressing Urgent Global Health Needs,"Gilead Sciences, Inc. (Nasdaq: GILD) today announced the upcoming presentation of new data from the company’s HIV, hepatitis C virus (HCV), and COVID-19 research and development programs at the 28th C...",63.01,63.59,62.35,62.495,GILD,6844248,HISTORICAL_PRICES,GILD,,1.61552E+12,-0.010987286,-0.010987286,62.495,63.01,63.59,62.35,6844248,61.7917,62.3009,62.8744,61.6483,6844248,2-Mar-21,0.55,0.0088
2-Mar-21,Puma Biotechnology to Present at the H.C. Wainwright Global Life Sciences Conference,"Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder of Puma, will provide an overview of the...",9.96,10.64,9.92,10.24,PBYI,432548,HISTORICAL_PRICES,PBYI,,1.61474E+12,-0.119363395,-0.119363395,10.24,9.96,10.64,9.92,432548,10.24,9.96,10.64,9.92,432548,2-Mar-21,-0.25,-0.0245
2-Mar-21,Lyra Therapeutics to Report Fourth Quarter and Full Year 2020 Financial Results and Provide Corporate Update,"Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatme...",15.03,15.67,14.8233,15.3705,LYRA,133350,HISTORICAL_PRICES,LYRA,,1.61474E+12,0.048848569,0.048848569,15.3705,15.03,15.67,14.8233,133350,15.3705,15.03,15.67,14.8233,133350,2-Mar-21,-0.58,-0.0372
2-Mar-21,Quanterix Corporation Releases Operating Results for Fourth Quarter and Full Year 2020,"Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis to advance the science of precision health, today announced financial results for the fourth quarter and 12 months ended D...",77.1,83.75,75.69,83.65,QTRX,406520,HISTORICAL_PRICES,QTRX,,1.61474E+12,-0.013561924,-0.013561924,83.65,77.1,83.75,75.69,406520,83.65,77.1,83.75,75.69,406520,2-Mar-21,-5.56,-0.0673
2-Mar-21,AtriCure to Participate at the Oppenheimer 31st Annual Healthcare Conference,"AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that the company will be participat...",66.73,67.3,65.02,66.13,ATRC,421784,HISTORICAL_PRICES,ATRC,,1.61474E+12,0.069219676,0.069219676,66.13,66.73,67.3,65.02,421784,66.13,66.73,67.3,65.02,421784,2-Mar-21,0.42,0.0063
2-Mar-21,Resumen: La biopsia líquida Guardant360® CDx recibe el marcado CE para el análisis exhaustivo de las mutaciones tumorales en todos los cánceres sólidos,"Guardant Health, Inc. (Nasdaq: GH) ha obtenido el marcado CE de Guardant360® CDx para el perfilado de mutaciones tumorales, también conocido como perfilado genómico integral, en pacientes con cualquie...",154.63,157.595,153,154.02,GH,1123237,HISTORICAL_PRICES,GH,,1.61474E+12,-0.046905819,-0.046905819,154.02,154.63,157.595,153,1123237,154.02,154.63,157.595,153,1123237,2-Mar-21,2.49,0.0164
2-Mar-21,Samenvatting: Guardant360® CDx vloeibare biopsie CE-gemarkeerd voor uitgebreide tumormutatieprofilering bij alle vaste kankers,"Guardant Health, Inc. (Nasdaq: GH) heeft Guardant360® CDx met CE-markering voor het profileren van tumormutaties, ook bekend als comprehensive genomic profiling (CGP), bij patiënten met een solide mal...",154.63,157.595,153,154.02,GH,1123237,HISTORICAL_PRICES,GH,,1.61474E+12,-0.046905819,-0.046905819,154.02,154.63,157.595,153,1123237,154.02,154.63,157.595,153,1123237,2-Mar-21,2.49,0.0164
2-Mar-21,"Epizyme Outlines Clinical Progress, TAZVERIK Development Strategy and Pipeline Priorities During Company’s Strategic Vision Call","Epizyme, Inc. (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering novel epigenetic therapies, hosted a call today outlining the Company’s strategic...",9.55,9.93,9.52,9.78,EPZM,811906,HISTORICAL_PRICES,EPZM,,1.61474E+12,-0.062806673,-0.062806673,9.78,9.55,9.93,9.52,811906,9.78,9.55,9.93,9.52,811906,2-Mar-21,-0.23,-0.0235
2-Mar-21,"Tenax Therapeutics, Inc. Expands Board of Directors","Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceutical company focused on identifying and developing therapeutics that address cardio-pulmonary diseases with high unmet medical need, toda...",2.25,2.2699,2.2,2.24,TENX,85990,HISTORICAL_PRICES,TENX,,1.61474E+12,-0.025974026,-0.025974026,2.24,2.25,2.2699,2.2,85990,2.24,2.25,2.2699,2.2,85990,2-Mar-21,0.06,0.0274
2-Mar-21,Guardant360® CDx Liquid Biopsy CE-Marked for Comprehensive Tumor Mutation Profiling Across All Solid Cancers,"Guardant Health, Inc. (Nasdaq: GH) has CE-marked Guardant360® CDx for tumor mutation profiling, also known as comprehensive genomic profiling (CGP), in patients with any solid malignant neoplasm (canc...",154.63,157.595,153,154.02,GH,1123237,HISTORICAL_PRICES,GH,,1.61474E+12,-0.046905819,-0.046905819,154.02,154.63,157.595,153,1123237,154.02,154.63,157.595,153,1123237,2-Mar-21,2.49,0.0164
2-Mar-21,"VBI Vaccines Reports Fourth Quarter and Full Year Financial Results for 2020, Provides Corporate Update and Outlook for 2021","VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced financial results for the fourt...",3.32,3.59,3.31,3.55,VBIV,5008364,HISTORICAL_PRICES,VBIV,,1.61474E+12,-0.040462428,-0.040462428,3.55,3.32,3.59,3.31,5008364,3.55,3.32,3.59,3.31,5008364,2-Mar-21,-0.3,-0.0829
2-Mar-21,"Sesen Bio Announces Conference Call with Neal Shore, M.D., FACS to Provide Clinical Perspective on the Company’s Lead Product Candidate Vicineum™","Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced that the Company will host a conferen...",2.56,2.75,2.56,2.73,SESN,5401765,HISTORICAL_PRICES,SESN,,1.61474E+12,-0.098591549,-0.098591549,2.73,2.56,2.75,2.56,5401765,2.73,2.56,2.75,2.56,5401765,2-Mar-21,-0.16,-0.0588
2-Mar-21,Eyenovia Announces FDA Acceptance of the MydCombi NDA,"Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose array print (MAP™) therapeutics, today announced that the U.S. Food and Drug Adm...",6.23,6.8988,5.91,6.6,EYEN,829602,HISTORICAL_PRICES,EYEN,,1.61474E+12,-0.018897638,-0.018897638,6.6,6.23,6.8988,5.91,829602,6.6,6.23,6.8988,5.91,829602,2-Mar-21,0.27,0.0453
2-Mar-21,GlycoMimetics Reports Highlights and Financial Results for Fourth Quarter and Full Year 2020,"GlycoMimetics, Inc. (Nasdaq: GLYC) today reported its financial results for the fourth quarter and year ended December 31, 2020, and highlighted recent Company events, including several accomplishment...",3.24,3.55,3.1,3.49,GLYC,1994928,HISTORICAL_PRICES,GLYC,,1.61474E+12,-0.068965517,-0.068965517,3.49,3.24,3.55,3.1,1994928,3.49,3.24,3.55,3.1,1994928,2-Mar-21,-0.35,-0.0975
2-Mar-21,TherapeuticsMD Announces Fourth Quarter and Full-Year 2020 Financial Results,"TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative, leading women’s healthcare company, today reported financial results for the full-year and fourth quarter ended December 31, 2020 and provided a bus...",1.45,1.62,1.4,1.5,TXMD,26897942,HISTORICAL_PRICES,TXMD,,1.61474E+12,-0.110429448,-0.110429448,1.5,1.45,1.62,1.4,26897942,1.5,1.45,1.62,1.4,26897942,2-Mar-21,0.005,0.0035
2-Mar-21,Applied DNA and Evvivax Initiate Phase I of Clinical Trial to Evaluate LinearDNA™ COVID-19 Vaccine Candidate for Feline Veterinary Market,"Applied DNA Sciences, Inc. (NASDAQ: APDN) (the “Company”), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing, and its program development partner, Evvivax, S.R.L. (“Evvivax”), today...",8.49,9.1299,8.42,8.78,APDN,937622,HISTORICAL_PRICES,APDN,,1.61474E+12,-0.083153348,-0.083153348,8.78,8.49,9.1299,8.42,937622,8.78,8.49,9.1299,8.42,937622,2-Mar-21,-0.17,-0.0196
2-Mar-21,"Deciphera Pharmaceuticals, Inc. to Present at the Barclays Global Healthcare Conference","Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) today announced that Steve Hoerter, President and Chief Executive Officer, will participate in a fireside chat at the Barclays Global Healthcare Conferen...",44.31,44.865,43,43.87,DCPH,347350,HISTORICAL_PRICES,DCPH,,1.61474E+12,0.024745606,0.024745606,43.87,44.31,44.865,43,347350,43.87,44.31,44.865,43,347350,2-Mar-21,0.34,0.0077
2-Mar-21,Seres Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Updates,"Seres Therapeutics, Inc., (Nasdaq: MCRB), a leading microbiome therapeutics company, today reported fourth quarter and full year 2020 financial results and provided business updates. “Seres continues...",19.62,21.6,19.06,20.59,MCRB,1048410,HISTORICAL_PRICES,MCRB,,1.61474E+12,-0.009090909,-0.009090909,20.59,19.62,21.6,19.06,1048410,20.59,19.62,21.6,19.06,1048410,2-Mar-21,-1,-0.0485
2-Mar-21,Seres Therapeutics Announces Achievement of Target Enrollment in SER-287 Phase 2b ECO-RESET Study for Ulcerative Colitis,"Seres Therapeutics, Inc. (Nasdaq: MCRB) announced today that the Company has achieved target enrollment of the Phase 2b ECO-RESET clinical study of SER-287 in patients with mild-to-moderate ulcerative...",19.62,21.6,19.06,20.59,MCRB,1048410,HISTORICAL_PRICES,MCRB,,1.61474E+12,-0.009090909,-0.009090909,20.59,19.62,21.6,19.06,1048410,20.59,19.62,21.6,19.06,1048410,2-Mar-21,-1,-0.0485
2-Mar-21,Eagle Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Results and Provides Pipeline Review,"Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced financial results for the three and twelve months ended December 31, 2020, and reviewed key pipeline programs. Bus...",40.4,44.54,40.4,43.92,EGRX,185525,HISTORICAL_PRICES,EGRX,,1.61474E+12,-0.11558669,-0.11558669,43.92,40.4,44.54,40.4,185525,43.92,40.4,44.54,40.4,185525,2-Mar-21,-4.98,-0.1097
2-Mar-21,Axonics® Announces Strategic Alliance for the Manufacture of New Non-Rechargeable Implantable Sacral Neuromodulation Device,"Axonics Modulation Technologies, Inc. (Nasdaq: AXNX), a global medical technology company that has developed and is commercializing novel products for the treatment of bladder and bowel dysfunction, t...",54.46,54.8,52.61,54.04,AXNX,478041,HISTORICAL_PRICES,AXNX,,1.61474E+12,0.030073766,0.030073766,54.04,54.46,54.8,52.61,478041,54.04,54.46,54.8,52.61,478041,2-Mar-21,0.99,0.0185
2-Mar-21,"Public Support Innovative Approaches to Reducing Smoking Rates, Reveals New International Survey from Philip Morris International",A new international survey commissioned by Philip Morris International Inc. (PMI) (NYSE: PM) and conducted by independent research firm Povaddo reveals a public appetite for a better approach to reduc...,85.07,85.85,84.68,84.68,PM,3563601,HISTORICAL_PRICES,PM,,1.61612E+12,-0.028437643,-0.028437643,84.68,85.07,85.85,84.68,3563601,83.5579,83.9427,84.7124,83.5579,3563601,2-Mar-21,0.12,0.0014
1-Mar-21,Masimo Announces CE Marking of the Rad-G™ with Temperature,"Masimo (NASDAQ: MASI) today announced the CE marking of the Rad-G™ with Temperature, a rugged handheld device that provides clinically proven SET® pulse oximetry, respiration rate from the pleth (RRp®...",256.08,256.89,251.01,253.83,MASI,213899,HISTORICAL_PRICES,MASI,,1.61465E+12,0.019426752,0.019426752,253.83,256.08,256.89,251.01,213899,253.83,256.08,256.89,251.01,213899,1-Mar-21,5.35,0.0213
1-Mar-21,Atara Biotherapeutics Announces Fourth Quarter and Full Year 2020 Financial Results and Operational Progress,"Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious disease...",17.105,17.5,16.72,17.14,ATRA,636286,HISTORICAL_PRICES,ATRA,,1.61465E+12,-0.014121037,-0.014121037,17.14,17.105,17.5,16.72,636286,17.14,17.105,17.5,16.72,636286,1-Mar-21,0.325,0.0194
1-Mar-21,Merck Provides Update on KEYTRUDA® (pembrolizumab) Indication in Metastatic Small Cell Lung Cancer in the US,"Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the company is voluntarily withdrawing the U.S. indication for KEYTRUDA (pembrolizumab) for the treatment of patie...",72.38,73.39,72.18,73.21,MRK,12024856,HISTORICAL_PRICES,MRK,,1.61552E+12,-0.029368379,-0.029368379,73.21,72.38,73.39,72.18,12024856,72.5724,71.7496,72.7508,71.5513,12024856,1-Mar-21,-0.24,-0.0033
1-Mar-21,Omeros Corporation Reports Fourth Quarter and Year-End 2020 Financial Results,"Omeros Corporation (Nasdaq: OMER), a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as wel...",19.41,20.4,19,20.4,OMER,1025224,HISTORICAL_PRICES,OMER,,1.61465E+12,-0.136949755,-0.136949755,20.4,19.41,20.4,19,1025224,20.4,19.41,20.4,19,1025224,1-Mar-21,-0.53,-0.0266
1-Mar-21,Quidel Receives Emergency Use Authorization for QuickVue® At-Home COVID-19 Test,"Quidel Corporation (NASDAQ: QDEL) (“Quidel”), a leading provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that it has rec...",166.84,173.5,165.4,170.15,QDEL,812058,HISTORICAL_PRICES,QDEL,,1.61465E+12,-0.030732586,-0.030732586,170.15,166.84,173.5,165.4,812058,170.15,166.84,173.5,165.4,812058,1-Mar-21,2.58,0.0157
1-Mar-21,Genprex to Participate in Upcoming March Investor Conferences,"Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, announced that it...",5.38,5.5,5.12,5.28,GNPX,1008450,HISTORICAL_PRICES,GNPX,,1.61465E+12,-0.044404973,-0.044404973,5.28,5.38,5.5,5.12,1008450,5.28,5.38,5.5,5.12,1008450,1-Mar-21,0.22,0.0426
1-Mar-21,Lantheus Announces Publication of PyL™ (18F-DCFPyL) Results from Pivotal Studies,"Lantheus Holdings, Inc. (NASDAQ: LNTH) (Lantheus), an established leader and fully integrated provider of innovative imaging diagnostics, targeted therapeutics and artificial intelligence solutions to...",19.03,19.41,18.69,18.69,LNTH,485944,HISTORICAL_PRICES,LNTH,,1.61465E+12,-0.032044761,-0.032044761,18.69,19.03,19.41,18.69,485944,18.69,19.03,19.41,18.69,485944,1-Mar-21,0.35,0.0187
1-Mar-21,Arrowhead Pharmaceuticals Files IND to Begin Phase 2b Study of ARO-APOC3 in Patients with Severe Hypertriglyceridemia,"Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has submitted an Investigational New Drug Application (IND) to the U.S. Food and Drug Administration (FDA) for ARO-APOC3, the comp...",83.78,84.45,81.06,81.14,ARWR,567615,HISTORICAL_PRICES,ARWR,,1.61465E+12,-0.014700694,-0.014700694,81.14,83.78,84.45,81.06,567615,81.14,83.78,84.45,81.06,567615,1-Mar-21,4.12,0.0517
1-Mar-21,Ocular Therapeutix™ Announces First Patient Dosed in Phase 2 Clinical Trial of OTX-DED for the Short-Term Treatment of the Signs and Symptoms of Dry Eye Disease,"Ocular Therapeutix™, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, tod...",19.46,19.54,18.58,18.61,OCUL,722405,HISTORICAL_PRICES,OCUL,,1.61465E+12,0.089585666,0.089585666,18.61,19.46,19.54,18.58,722405,18.61,19.46,19.54,18.58,722405,1-Mar-21,1.12,0.0611
1-Mar-21,"AVROBIO Receives Orphan Drug Designation from the European Commission for AVR‑RD‑04, an Investigational Gene Therapy for Cystinosis","AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that the European Commission (EC) has gran...",11.45,11.831,11.2,11.2,AVRO,986024,HISTORICAL_PRICES,AVRO,,1.61465E+12,0.039019964,0.039019964,11.2,11.45,11.831,11.2,986024,11.2,11.45,11.831,11.2,986024,1-Mar-21,0.45,0.0409
1-Mar-21,TherapeuticsMD Announces Participation in Upcoming Investor Conferences,"TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative women’s healthcare company, today announced that the company will participate at the following investor conferences: Conference Cowen Virtual Healthc...",1.445,1.59,1.42,1.59,TXMD,18455207,HISTORICAL_PRICES,TXMD,,1.61465E+12,-0.113496933,-0.113496933,1.59,1.445,1.59,1.42,18455207,1.59,1.445,1.59,1.42,18455207,1-Mar-21,-0.075,-0.0493
1-Mar-21,Gamida Cell Announces Results from Phase 3 Study of Omidubicel to be Presented at the 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT),"Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to cures for blood cancers and serious hematologic diseases, today announced that results from the Phase 3 clinical trial of...",9.83,10.24,9.48,9.56,GMDA,486365,HISTORICAL_PRICES,GMDA,,1.61465E+12,-0.034381139,-0.034381139,9.56,9.83,10.24,9.48,486365,9.56,9.83,10.24,9.48,486365,1-Mar-21,0.47,0.0502
1-Mar-21,U.S. FDA Accepts Merck’s Gefapixant New Drug Application for Review,"Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) has accepted for review the company’s New Drug Application (NDA)...",72.38,73.39,72.18,73.21,MRK,12024856,HISTORICAL_PRICES,MRK,,1.61552E+12,-0.029368379,-0.029368379,73.21,72.38,73.39,72.18,12024856,72.5724,71.7496,72.7508,71.5513,12024856,1-Mar-21,-0.24,-0.0033
26-Feb-21,"Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Brainstorm Cell Therapeutics Inc. (BCLI) Investigation","Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Brainstorm Cell Therapeutics Inc. (""Brainstorm"" or ""the Company"") (NASDAQ: BCLI). Investors who purc...",4.06,4.16,3.91,4.01,BCLI,720687,HISTORICAL_PRICES,BCLI,,1.61439E+12,-0.04245283,-0.04245283,4.01,4.06,4.16,3.91,720687,4.01,4.06,4.16,3.91,720687,26-Feb-21,0.09,0.0227
26-Feb-21,Incyte meldet die von der Europäischen Arzneimittelagentur erteilte Validierung seines Marktzulassungsantrags für Retifanlimab als Behandlung für Patienten mit Plattenepithelkarzinom des Analkanals (SCAC),"Incyte (Nasdaq:INCY) meldete heute die Validierung des Marktzulassungsantrags (MAA für Marketing Authorization Application) des Unternehmens für Retifanlimab, einen intravenösen PD-1-Inhibitor, als po...",78.66,79.64,77.77,79.17,INCY,1691587,HISTORICAL_PRICES,INCY,,1.61439E+12,-0.024190547,-0.024190547,79.17,78.66,79.64,77.77,1691587,79.17,78.66,79.64,77.77,1691587,26-Feb-21,0.21,0.0027
26-Feb-21,ADC Therapeutics kündigt Teilnahme an der Cowen 41st Annual Health Care Conference an,"ADC Therapeutics SA (NYSE:ADCT), ein im Bereich der späten klinischen Forschung tätiges Biotechnologieunternehmen und Vorreiter bei der Entwicklung und Vermarktung von hochwirksamen und zielgerichtete...",26.59,28.92,26.11,28.73,ADCT,200269,HISTORICAL_PRICES,ADCT,,1.61439E+12,-0.06995453,-0.06995453,28.73,26.59,28.92,26.11,200269,28.73,26.59,28.92,26.11,200269,26-Feb-21,-1.89,-0.0664
26-Feb-21,Seres Therapeutics to Participate in Upcoming Virtual Investor Conferences,"Seres Therapeutics, Inc., (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that management will participate in two upcoming investor conferences: Cowen 41st Annual Health Car...",19.04,19.62,17.66,18.93,MCRB,1189643,HISTORICAL_PRICES,MCRB,,1.61439E+12,-0.038383838,-0.038383838,18.93,19.04,19.62,17.66,1189643,18.93,19.04,19.62,17.66,1189643,26-Feb-21,0.25,0.0133
26-Feb-21,Orthofix Reports Fourth Quarter and Fiscal Year 2020 Results,"Orthofix Medical Inc. (NASDAQ:OFIX) today reported its financial results for the fourth quarter and fiscal year ended December 31, 2020. Net sales for the fourth quarter were $117.6 million, earnings...",46.51,48.06,45.945,46.01,OFIX,132845,HISTORICAL_PRICES,OFIX,,1.61439E+12,-0.028410278,-0.028410278,46.01,46.51,48.06,45.945,132845,46.01,46.51,48.06,45.945,132845,26-Feb-21,0.1,0.0022
26-Feb-21,European Medicines Agency Accepts Pfizer’s Marketing Authorization Application for Its Investigational 20-valent Pneumococcal Conjugate Vaccine for Adults 18 Years of Age or Older,Pfizer Inc. (NYSE:PFE) today announced that the European Medicines Agency (EMA) accepted for review the Marketing Authorization Application (MAA) for its 20-valent pneumococcal conjugate vaccine (20vP...,33.49,33.9,33.36,33.84,PFE,41462750,HISTORICAL_PRICES,PFE,,1.61439E+12,-0.007703704,-0.007703704,33.84,33.49,33.9,33.36,41462750,33.84,33.49,33.9,33.36,41462750,26-Feb-21,-0.33,-0.0098
26-Feb-21,EMA Accepts Marketing Application for Somatrogon to Treat Pediatric Patients with Growth Hormone Deficiency,Pfizer Inc. (NYSE: PFE) and OPKO Health Inc. (NASDAQ: OPK) announced today that the European Medicines Agency (EMA) has validated for review the Marketing Authorization Application (MAA) for somatrogo...,33.49,33.9,33.36,33.84,PFE,41462750,HISTORICAL_PRICES,PFE,,1.61439E+12,-0.007703704,-0.007703704,33.84,33.49,33.9,33.36,41462750,33.84,33.49,33.9,33.36,41462750,26-Feb-21,-0.33,-0.0098
26-Feb-21,Exelixis’ Partner Ipsen Receives Positive CHMP Opinion for CABOMETYX® (cabozantinib) in Combination with OPDIVO® (nivolumab) as a First-Line Treatment for Patients with Advanced Renal Cell Carcinoma,"Exelixis, Inc. (NASDAQ: EXEL) today announced that its partner Ipsen received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the Europea...",21.66,22.29,21.4422,22,EXEL,1764646,HISTORICAL_PRICES,EXEL,,1.61439E+12,-0.044130627,-0.044130627,22,21.66,22.29,21.4422,1764646,22,21.66,22.29,21.4422,1764646,26-Feb-21,-0.3,-0.0137
26-Feb-21,Bristol Myers Squibb Receives Positive CHMP Opinion for Opdivo® (nivolumab) in Combination with Cabometyx® (cabozantinib) as First-Line Treatment for Patients with Advanced Renal Cell Carcinoma,Bristol Myers Squibb (NYSE: BMY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended approval of Opdivo® (nivolumab) i...,61.33,62.6999,61.26,62.03,BMY,13229657,HISTORICAL_PRICES,BMY,,1.61439E+12,-0.020131011,-0.020131011,62.03,61.33,62.6999,61.26,13229657,62.03,61.33,62.6999,61.26,13229657,26-Feb-21,-0.77,-0.0124
26-Feb-21,Amneal Receives Approval for Generic Version of Ortho Evra®,"Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced that it has received Abbreviated New Drug Application (ANDA) approval from the U.S. Food and Drug Administration (...",5.39,5.89,4.91,4.95,AMRX,4608235,HISTORICAL_PRICES,AMRX,,1.61439E+12,0.056862745,0.056862745,4.95,5.39,5.89,4.91,4608235,4.95,5.39,5.89,4.91,4608235,26-Feb-21,0.5,0.1022
26-Feb-21,Amneal Reports Fourth Quarter and Full Year 2020 Financial Results,"Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (the ""Company"") announced its results today for the fourth quarter and full year ended December 31, 2020. ""We are extremely proud of the progress our company...",5.39,5.89,4.91,4.95,AMRX,4608235,HISTORICAL_PRICES,AMRX,,1.61439E+12,0.056862745,0.056862745,4.95,5.39,5.89,4.91,4608235,4.95,5.39,5.89,4.91,4608235,26-Feb-21,0.5,0.1022
26-Feb-21,Incyte Announces the Validation by the European Medicines Agency of its Marketing Authorization Application for Retifanlimab as a Treatment for Patients with Squamous Cell Anal Carcinoma (SCAC),"Incyte (Nasdaq:INCY) today announced the validation of the Company’s Marketing Authorization Application (MAA) for retifanlimab, an intravenous PD-1 inhibitor, as a potential treatment for adult patie...",78.66,79.64,77.77,79.17,INCY,1691587,HISTORICAL_PRICES,INCY,,1.61439E+12,-0.024190547,-0.024190547,79.17,78.66,79.64,77.77,1691587,79.17,78.66,79.64,77.77,1691587,26-Feb-21,0.21,0.0027
25-Feb-21,CANbridge Pharmaceuticals and Puma Biotechnology Agree to Terminate NERLYNX® License Agreement and Settle Arbitration,"CANbridge Pharmaceuticals, Inc., a biopharmaceutical company focused on developing and commercializing drug candidates in China and North Asia, and Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharma...",10.55,11.42,10.55,11.2,PBYI,328138,HISTORICAL_PRICES,PBYI,,1.61431E+12,-0.067197171,-0.067197171,11.2,10.55,11.42,10.55,328138,11.2,10.55,11.42,10.55,328138,25-Feb-21,-0.76,-0.0672
25-Feb-21,Puma Biotechnology and Pierre Fabre Amend NERLYNX® License Agreement to Include Greater China,"Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, and Pierre Fabre, a leading French pharmaceutical company, have agreed to extend the terms of the 2019 license agreement which gra...",10.55,11.42,10.55,11.2,PBYI,328138,HISTORICAL_PRICES,PBYI,,1.61431E+12,-0.067197171,-0.067197171,11.2,10.55,11.42,10.55,328138,11.2,10.55,11.42,10.55,328138,25-Feb-21,-0.76,-0.0672
25-Feb-21,Dicerna Announces Full Year 2020 Financial Results and Provides a Business Update,"Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today reported its financial result...",28.31,29.45,27.72,27.885,DRNA,1271335,HISTORICAL_PRICES,DRNA,,1.61431E+12,0.01034975,0.01034975,27.885,28.31,29.45,27.72,1271335,27.885,28.31,29.45,27.72,1271335,25-Feb-21,0.29,0.0103
25-Feb-21,Axonics® Reports Fourth Quarter and Fiscal Year 2020 Results,"Axonics Modulation Technologies, Inc. (Nasdaq: AXNX), a medical technology company that has developed and is commercializing novel implantable sacral neuromodulation (SNM) devices for the treatment of...",50.82,52.83,49.76,52.83,AXNX,910793,HISTORICAL_PRICES,AXNX,,1.61431E+12,-0.038774352,-0.038774352,52.83,50.82,52.83,49.76,910793,52.83,50.82,52.83,49.76,910793,25-Feb-21,-2.05,-0.0388
25-Feb-21,Glaukos Announces Positive Phase 3 Trial Results for iLink™ Epi-on Investigational Therapy That Met the Primary Efficacy Endpoint,"Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today an...",92.11,98.24,91.57,96.67,GKOS,319685,HISTORICAL_PRICES,GKOS,,1.61431E+12,-0.044799336,-0.044799336,96.67,92.11,98.24,91.57,319685,96.67,92.11,98.24,91.57,319685,25-Feb-21,-4.32,-0.0448
25-Feb-21,Puma Biotechnology Reports Fourth Quarter and Full Year Financial Results,"Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced financial results for the fourth quarter and year ended December 31, 2020. Unless otherwise stated, all comparisons are...",10.55,11.42,10.55,11.2,PBYI,328138,HISTORICAL_PRICES,PBYI,,1.61431E+12,-0.067197171,-0.067197171,11.2,10.55,11.42,10.55,328138,11.2,10.55,11.42,10.55,328138,25-Feb-21,-0.76,-0.0672
25-Feb-21,Cerus Corporation Announces Record Fourth Quarter and Full Year 2020 Financial Results,"Cerus Corporation (Nasdaq: CERS) today announced financial results for the fourth quarter and year ended December 31, 2020. Recent developments and highlights include: Record total fourth quarter and...",6.45,6.829,6.1,6.7,CERS,3716849,HISTORICAL_PRICES,CERS,,1.61431E+12,-0.040178571,-0.040178571,6.7,6.45,6.829,6.1,3716849,6.7,6.45,6.829,6.1,3716849,25-Feb-21,-0.27,-0.0402
25-Feb-21,Acceleron Reports Fourth Quarter and Full Year 2020 Financial Results,"Acceleron Pharma Inc. (Nasdaq: XLRN), a biopharmaceutical company dedicated to the discovery, development, and commercialization of TGF-beta superfamily therapeutics to treat serious and rare diseases...",135.87,138.19,133.8,136.76,XLRN,258530,HISTORICAL_PRICES,XLRN,,1.61431E+12,-0.006653019,-0.006653019,136.76,135.87,138.19,133.8,258530,136.76,135.87,138.19,133.8,258530,25-Feb-21,-0.91,-0.0067
25-Feb-21,Aerie Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update,"Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients wi...",15.81,16.57,15.66,16.19,AERI,504896,HISTORICAL_PRICES,AERI,,1.61431E+12,-0.033618582,-0.033618582,16.19,15.81,16.57,15.66,504896,16.19,15.81,16.57,15.66,504896,25-Feb-21,-0.55,-0.0336
25-Feb-21,Lantheus Reports Fourth Quarter and Full Year 2020 Financial Results,"Lantheus Holdings, Inc. (NASDAQ: LNTH) (Lantheus), an established leader and fully integrated provider of innovative imaging diagnostics, targeted therapeutics and artificial intelligence solutions to...",19.15,19.86,18.87,19.62,LNTH,425169,HISTORICAL_PRICES,LNTH,,1.61431E+12,-0.025940997,-0.025940997,19.62,19.15,19.86,18.87,425169,19.62,19.15,19.86,18.87,425169,25-Feb-21,-0.51,-0.0259
25-Feb-21,The Year 2020 Marks the 7th Consecutive Year Certara Customers Received 90 Percent of US FDA Novel Drug and Biologic Approvals,"Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that 2020 marked the seventh consecutive year where 90% of new drug and biologic approvals by the US Food and Drug Admin...",32.97,36.08,32.6101,35.64,CERT,344295,HISTORICAL_PRICES,CERT,,1.61431E+12,-0.085690516,-0.085690516,35.64,32.97,36.08,32.6101,344295,35.64,32.97,36.08,32.6101,344295,25-Feb-21,-3.09,-0.0857
25-Feb-21,"Omeros Corporation to Announce Fourth Quarter and Year-End Financial Results on March 1, 2021","Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its fourth quarter and year-end financial results for the period ended December 31, 2020, on Monday, March 1, 2021, after...",19.24,22.88,18.77,22.43,OMER,1287950,HISTORICAL_PRICES,OMER,,1.61431E+12,-0.144508671,-0.144508671,22.43,19.24,22.88,18.77,1287950,22.43,19.24,22.88,18.77,1287950,25-Feb-21,-3.25,-0.1445
25-Feb-21,Applied DNA Granted U.S. Patent Covering Methods of Utilizing DNA Tagged Submicron Particles for Authentication,"Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA” or the “Company”) a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing, announced today that it has received United States Paten...",9.69,10.26,9.02,9.19,APDN,1304511,HISTORICAL_PRICES,APDN,,1.61431E+12,0.046436285,0.046436285,9.19,9.69,10.26,9.02,1304511,9.19,9.69,10.26,9.02,1304511,25-Feb-21,0.43,0.0464
25-Feb-21,O2TODAY and SINTX Technologies Enter Commercialization Agreement to Fight COVID-19,"O2TODAY (""O2TODAY""), a mask company that develops, manufactures and commercializes face masks for medical and non-medical uses, and SINTX Technologies, Inc. (NASDAQ: SINT) (“SINTX” or the “Company”) (...",2.42,2.95,2.33,2.47,SINT,17384237,HISTORICAL_PRICES,SINT,,1.61431E+12,0.061403509,0.061403509,2.47,2.42,2.95,2.33,17384237,2.47,2.42,2.95,2.33,17384237,25-Feb-21,0.14,0.0614
25-Feb-21,Ocular Therapeutix™ To Report Fourth Quarter and Year End 2020 Financial Results,"Ocular Therapeutix™, Inc. (Nasdaq: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, tod...",18.11,18.995,17.5146,17.86,OCUL,902270,HISTORICAL_PRICES,OCUL,,1.61431E+12,0.01399776,0.01399776,17.86,18.11,18.995,17.5146,902270,17.86,18.11,18.995,17.5146,902270,25-Feb-21,0.25,0.014
25-Feb-21,Exelixis Announces Breakthrough Therapy Designation Granted to Cabozantinib for the Treatment of Patients with Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid Cancer,"Exelixis, Inc. (NASDAQ: EXEL) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to cabozantinib (CABOMETYX®) as a potential treatment for pa...",21.96,22.71,21.79,22.7,EXEL,1379317,HISTORICAL_PRICES,EXEL,,1.61431E+12,-0.030891439,-0.030891439,22.7,21.96,22.71,21.79,1379317,22.7,21.96,22.71,21.79,1379317,25-Feb-21,-0.7,-0.0309
25-Feb-21,Gossamer Bio Announces Fourth Quarter and Full-Year 2020 Financial Results and Provides Business Update,"Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflamm...",9.79,10.63,9.66,10.54,GOSS,803925,HISTORICAL_PRICES,GOSS,,1.61431E+12,-0.055930569,-0.055930569,10.54,9.79,10.63,9.66,803925,10.54,9.79,10.63,9.66,803925,25-Feb-21,-0.58,-0.0559
25-Feb-21,Rocket Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial and Operational Results,"Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders, today reports financial and op...",51.86,56.88,50.75,55.87,RCKT,492424,HISTORICAL_PRICES,RCKT,,1.61431E+12,-0.073100983,-0.073100983,55.87,51.86,56.88,50.75,492424,55.87,51.86,56.88,50.75,492424,25-Feb-21,-4.09,-0.0731
25-Feb-21,Moderna Reports Fourth Quarter and Fiscal Year 2020 Financial Results and Provides Business Updates,"Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today reported financial results and provided business updates for the fourth quarter a...",148.38,160.98,145.86,150.78,MRNA,15172131,HISTORICAL_PRICES,MRNA,,1.61431E+12,0.02479453,0.02479453,150.78,148.38,160.98,145.86,15172131,150.78,148.38,160.98,145.86,15172131,25-Feb-21,3.59,0.0248
25-Feb-21,Concert Pharmaceuticals Reports 2020 Financial Results and Provides Update on Clinical Programs,"Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today reported financial results for the year ended December 31, 2020, and provided an update on its product pipeline. “As we enter 2021, Concert is now a...",6.87,7.16,6.62,7.1,CNCE,363441,HISTORICAL_PRICES,CNCE,,1.61431E+12,0.002919708,0.002919708,7.1,6.87,7.16,6.62,363441,7.1,6.87,7.16,6.62,363441,25-Feb-21,0.02,0.0029
25-Feb-21,Kala Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update,"Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today reported financ...",7.735,9,7.67,8.85,KALA,4994490,HISTORICAL_PRICES,KALA,,1.61431E+12,-0.133818589,-0.133818589,8.85,7.735,9,7.67,4994490,8.85,7.735,9,7.67,4994490,25-Feb-21,-1.195,-0.1338
25-Feb-21,Pfizer and BioNTech Initiate a Study as Part of Broad Development Plan to Evaluate COVID-19 Booster and New Vaccine Variants,Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced today they have begun an evaluation of the safety and immunogenicity of a third dose of the Pfizer-BioNTech COVID-19 vaccine (BNT162b2)...,33.82,34.11,33.54,33.82,PFE,37506087,HISTORICAL_PRICES,PFE,,1.61431E+12,0.002074074,0.002074074,33.82,33.82,34.11,33.54,37506087,33.82,33.82,34.11,33.54,37506087,25-Feb-21,0.07,0.0021
25-Feb-21,Merck to Acquire Pandion Therapeutics,"Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Pandion Therapeutics, Inc. (Nasdaq: PAND) today announced that the companies have entered into a definitive agreement, under w...",74.62,75,74.08,74.205,MRK,10407384,HISTORICAL_PRICES,MRK,,1.61552E+12,0.000670511,0.000670511,74.205,74.62,75,74.08,10407384,73.5587,73.9701,74.3468,73.4348,10407384,25-Feb-21,0.05,0.0007
25-Feb-21,Greenwich LifeSciences Announces Acceptance of Two Abstracts at Upcoming Major Cancer Conference,"Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in pati...",32.63,35.81,32.14,34.5,GLSI,194704,HISTORICAL_PRICES,GLSI,,1.61431E+12,-0.031175772,-0.031175772,34.5,32.63,35.81,32.14,194704,34.5,32.63,35.81,32.14,194704,25-Feb-21,-1.05,-0.0312
25-Feb-21,Xencor and UCLA Enter Collaboration to Discover and Develop Novel XmAb® Therapeutics,"Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, and UCLA Technolog...",46.76,49.46,46.75,48.51,XNCR,223130,HISTORICAL_PRICES,XNCR,,1.61431E+12,-0.035876289,-0.035876289,48.51,46.76,49.46,46.75,223130,48.51,46.76,49.46,46.75,223130,25-Feb-21,-1.74,-0.0359
24-Feb-21,"Glancy Prongay & Murray LLP, a National Class Action Law Firm, Continues Investigation of Velodyne Lidar, Inc. (VLDR) on Behalf of Investors","Glancy Prongay & Murray LLP (“GPM”), a national investor rights law firm, continues its investigation on behalf of Velodyne Lidar, Inc. (""Velodyne"" or ""the Company"") (NASDAQ: VLDR) investors conce...",16.96,17.11,16.2,17,VLDR,3957555,HISTORICAL_PRICES,VLDR,,1.61422E+12,0,0,17,16.96,17.11,16.2,3957555,17,16.96,17.11,16.2,3957555,24-Feb-21,0,0
24-Feb-21,"The New England Journal of Medicine Publishes Results from Pivotal Phase 2 KarMMa Study of Idecabtagene Vicleucel (Ide-cel, bb2121), an Investigational BCMA-Directed CAR T Cell Therapy","Results from the pivotal Phase 2 KarMMa study evaluating the efficacy and safety of bluebird bio, Inc. (Nasdaq: BLUE) and Bristol Myers Squibb’s (NYSE: BMY) investigational B-cell maturation antigen (...",25.92,26.69,25.62,26.3,BLUE,3546208,HISTORICAL_PRICES,BLUE,,1.61422E+12,0,0,26.3,25.92,26.69,25.62,3546208,26.3,25.92,26.69,25.62,3546208,24-Feb-21,0,0
24-Feb-21,Karuna Therapeutics Announces New England Journal of Medicine Publication of Data from EMERGENT-1 Phase 2 Trial Evaluating KarXT in Schizophrenia,"Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological condition...",133.08,135.17,127.97,130.6,KRTX,103549,HISTORICAL_PRICES,KRTX,,1.61422E+12,0,0,130.6,133.08,135.17,127.97,103549,130.6,133.08,135.17,127.97,103549,24-Feb-21,0,0
24-Feb-21,Cerus Corporation and Shandong Zhongbaokang Medical Implements Partner to Establish Joint Venture in China,"Cerus Corporation (Nasdaq: CERS) and Shandong Zhongbaokang Medical Implements Co. Ltd. (ZBK) today announced that they are forming a joint venture (JV) with the intent to develop, obtain regulatory ap...",6.72,6.93,6.5,6.71,CERS,1626236,HISTORICAL_PRICES,CERS,,1.61422E+12,0,0,6.71,6.72,6.93,6.5,1626236,6.71,6.72,6.93,6.5,1626236,24-Feb-21,0,0
24-Feb-21,Moderna Announces Additional Capital Investments to Increase Global Manufacturing Capacity for COVID-19 Vaccine,"Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, announces it is making new capital investments to increase capacity at its owned and pa...",144.79,151,143.47,150.41,MRNA,9757204,HISTORICAL_PRICES,MRNA,,1.61422E+12,0,0,150.41,144.79,151,143.47,9757204,150.41,144.79,151,143.47,9757204,24-Feb-21,0,0
24-Feb-21,"Moderna Announces it has Shipped Variant-Specific Vaccine Candidate, mRNA-1273.351, to NIH for Clinical Study","Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, announces that it has completed manufacturing of clinical trial material for its varian...",144.79,151,143.47,150.41,MRNA,9757204,HISTORICAL_PRICES,MRNA,,1.61422E+12,0,0,150.41,144.79,151,143.47,9757204,150.41,144.79,151,143.47,9757204,24-Feb-21,0,0
24-Feb-21," PhaseBio Pharmaceuticals to Host Virtual Investor and Analyst Day on March 15, 2021","PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiopulmonary diseases, today announ...",4.12,4.25,4.07,4.13,PHAS,111363,HISTORICAL_PRICES,PHAS,,1.61422E+12,0,0,4.13,4.12,4.25,4.07,111363,4.13,4.12,4.25,4.07,111363,24-Feb-21,0,0
24-Feb-21,Zymeworks Reports 2020 Year-End Financial Results,"Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today reported financial results for the year ended December 31, 2020 and provided a...",40.3,42.16,40.16,41.29,ZYME,211242,HISTORICAL_PRICES,ZYME,,1.61422E+12,0,0,41.29,40.3,42.16,40.16,211242,41.29,40.3,42.16,40.16,211242,24-Feb-21,0,0
24-Feb-21,Arcus Biosciences Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Operational Highlights,"Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today reported financial results for the fourth quarter and year en...",35.33,35.77,32.47,33.13,RCUS,479755,HISTORICAL_PRICES,RCUS,,1.61422E+12,0,0,33.13,35.33,35.77,32.47,479755,33.13,35.33,35.77,32.47,479755,24-Feb-21,0,0
24-Feb-21,Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results,"Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced financial results for the fourth quarter and full year ended December 31, 2020. “Acadia delivered strong financial results in the fourth quar...",48.69,50.4,48.3302,49.71,ACAD,1018358,HISTORICAL_PRICES,ACAD,,1.61422E+12,0,0,49.71,48.69,50.4,48.3302,1018358,49.71,48.69,50.4,48.3302,1018358,24-Feb-21,0,0
24-Feb-21,Revance to Participate in Upcoming Virtual Healthcare Conferences,"Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company focused on innovative aesthetic and therapeutic offerings, today announced that the company’s President and Chief Executive Officer,...",26.17,26.77,25.55,26,RVNC,650636,HISTORICAL_PRICES,RVNC,,1.61422E+12,0,0,26,26.17,26.77,25.55,650636,26,26.17,26.77,25.55,650636,24-Feb-21,0,0
24-Feb-21,"VYGR Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Notifies Voyager Therapeutics, Inc. Shareholders of Class Action and Encourages Shareholders to Contact the Firm","Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Voyager Therapeutics, Inc. (""Voyager"" or ""the Company"") (NASDAQ: VYGR) and certain of its o...",6.59,6.83,6.48,6.59,VYGR,407148,HISTORICAL_PRICES,VYGR,,1.61422E+12,0,0,6.59,6.59,6.83,6.48,407148,6.59,6.59,6.83,6.48,407148,24-Feb-21,0,0
24-Feb-21,"TCDA Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Reminds Tricida, Inc. Shareholders of Class Action and Encourages Shareholders to Contact the Firm","Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Tricida, Inc. (""Tricida"" or ""the Company"") (NASDAQ: TCDA) and certain of its officers, on b...",7.66,8.16,7.01,7.05,TCDA,1483024,HISTORICAL_PRICES,TCDA,,1.61422E+12,0,0,7.05,7.66,8.16,7.01,1483024,7.05,7.66,8.16,7.01,1483024,24-Feb-21,0,0
24-Feb-21,Establishment Labs Announces Raj Denhoy Has Joined the Company as Head of Strategy and Investor Relations,"Establishment Labs Holdings Inc. (NASDAQ: ESTA), a medical technology company focused on women’s health, initially in the breast aesthetics and reconstruction market, announced today that Raj Denhoy h...",69.52,76.91,68.75,73.76,ESTA,134930,HISTORICAL_PRICES,ESTA,,1.61422E+12,0,0,73.76,69.52,76.91,68.75,134930,73.76,69.52,76.91,68.75,134930,24-Feb-21,0,0
24-Feb-21,Ocular Therapeutix™ to Participate at Three Upcoming Investor Conferences,"Ocular Therapeutix, Inc. (Nasdaq: OCUL) a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today...",17.86,19,17.84,18.5,OCUL,842894,HISTORICAL_PRICES,OCUL,,1.61422E+12,0,0,18.5,17.86,19,17.84,842894,18.5,17.86,19,17.84,842894,24-Feb-21,0,0
24-Feb-21,Establishment Labs to Announce Fourth Quarter 2020 Financial Results on March 10,"Establishment Labs Holdings Inc. (NASDAQ: ESTA), a medical technology company focused on women’s health, initially in the breast aesthetics and reconstruction market, plans to announce its financial r...",69.52,76.91,68.75,73.76,ESTA,134930,HISTORICAL_PRICES,ESTA,,1.61422E+12,0,0,73.76,69.52,76.91,68.75,134930,73.76,69.52,76.91,68.75,134930,24-Feb-21,0,0
24-Feb-21,Non-Invasive Vagus Nerve Stimulation (nVNS) Enters New Stage of COVID-19 Research,"electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company and the Hospital Clínico Universitario de Valencia in Spain, announced the completion of patient enrollment in SAVIO...",2.39,2.42,2.2,2.4,ECOR,2641487,HISTORICAL_PRICES,ECOR,,1.61422E+12,0,0,2.4,2.39,2.42,2.2,2641487,2.4,2.39,2.42,2.2,2641487,24-Feb-21,0,0
24-Feb-21,Virios Therapeutics to Present at the H.C. Wainwright Global Life Sciences Conference in March 2021,"Virios Therapeutics, Inc. (Nasdaq: VIRI), a clinical-stage biotechnology company focused on advancing novel antiviral therapies to treat diseases associated with virally triggered or maintained immune...",6.84,7.1,6.75,6.88,VIRI,40934,HISTORICAL_PRICES,VIRI,,1.61422E+12,0,0,6.88,6.84,7.1,6.75,40934,6.88,6.84,7.1,6.75,40934,24-Feb-21,0,0
24-Feb-21,"Seres Therapeutics to Host Fourth Quarter 2020 Financial Results and Operational Progress Conference Call on March 2, 2021","Seres Therapeutics, Inc., (Nasdaq: MCRB), a leading microbiome platform company developing a novel class of multifunctional bacterial therapeutics designed to functionally interact with host cells and...",19.8,21.265,19.3,20.81,MCRB,1018886,HISTORICAL_PRICES,MCRB,,1.61422E+12,0,0,20.81,19.8,21.265,19.3,1018886,20.81,19.8,21.265,19.3,1018886,24-Feb-21,0,0
24-Feb-21,Horizon Therapeutics plc Reports Record Fourth-Quarter and Full-Year 2020 Financial Results; Announces Full-Year 2021 Guidance,Horizon Therapeutics plc (Nasdaq: HZNP) today announced record fourth-quarter and full-year 2020 financial results and provided full-year 2021 net sales and adjusted EBITDA guidance. “Our outperforman...,95.48,96.54,85.72,87.2,HZNP,4165437,HISTORICAL_PRICES,HZNP,,1.61422E+12,0,0,87.2,95.48,96.54,85.72,4165437,87.2,95.48,96.54,85.72,4165437,24-Feb-21,0,0
24-Feb-21,Sage Therapeutics Announces Fourth Quarter and Full Year 2020 Financial Results and Highlights Pipeline and Business Progress,"Today, Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of th...",85.04,87.85,78.28,79.84,SAGE,583245,HISTORICAL_PRICES,SAGE,,1.61422E+12,0,0,79.84,85.04,87.85,78.28,583245,79.84,85.04,87.85,78.28,583245,24-Feb-21,0,0
24-Feb-21,"Epizyme to Host Strategic Vision Call on March 2, 2021","Epizyme, (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering novel epigenetic therapies, today announced that it will host a call to discuss the Co...",10.19,10.62,10.01,10.36,EPZM,994910,HISTORICAL_PRICES,EPZM,,1.61422E+12,0,0,10.36,10.19,10.62,10.01,994910,10.36,10.19,10.62,10.01,994910,24-Feb-21,0,0
24-Feb-21,Elanco Animal Health Reports Fourth Quarter and Full Year 2020 Results,"Elanco Animal Health Incorporated (NYSE: ELAN) today reported its financial results for the fourth quarter and full year of 2020, increased guidance for full year 2021, and provided initial guidance f...",31.55,32.21,30.117,31.22,ELAN,5182456,HISTORICAL_PRICES,ELAN,,1.61422E+12,0,0,31.22,31.55,32.21,30.117,5182456,31.22,31.55,32.21,30.117,5182456,24-Feb-21,0,0
24-Feb-21,Easterly Government Properties Reports Fourth Quarter and Full Year 2020 Results,"Easterly Government Properties, Inc. (NYSE: DEA) (the “Company” or “Easterly”), a fully integrated real estate investment trust (“REIT”) focused primarily on the acquisition, development and managemen...",22.78,22.97,22.24,22.31,DEA,648705,HISTORICAL_PRICES,DEA,,1.61482E+12,0,0,22.31,22.78,22.97,22.24,648705,22.0401,22.5044,22.6921,21.9709,648705,24-Feb-21,0,0
23-Feb-21,"Glancy Prongay & Murray LLP, a National Class Action Law Firm, Continues Investigation of Leidos Holdings, Inc. (LDOS) on Behalf of Investors","Glancy Prongay & Murray LLP (“GPM”), a national investor rights law firm, continues its investigation on behalf of Leidos Holdings, Inc. (“Leidos” or the “Company”) (NYSE: LDOS) investors concerni...",93.51,98.83,91.55,97.915,LDOS,3113887,HISTORICAL_PRICES,LDOS,,1.61552E+12,-0.102935533,-0.102935533,97.915,93.51,98.83,91.55,3113887,97.5632,93.174,98.4749,91.2211,3113887,23-Feb-21,-10.29,-0.0991
23-Feb-21,U.S. FDA Accepts for Priority Review Pfizer’s Application for TicoVac™ (Tick-borne Encephalitis Vaccine),"Pfizer Inc. (NYSE:PFE) today announced that the U.S. Food and Drug Administration (FDA) accepted for Priority Review the company’s Biologics License Application (BLA) for TicoVac™, its tick-borne ence...",33.91,34.1899,33.68,34,PFE,37624172,HISTORICAL_PRICES,PFE,,1.61413E+12,-0.090152938,-0.090152938,34,33.91,34.1899,33.68,37624172,34,33.91,34.1899,33.68,37624172,23-Feb-21,-0.35,-0.0102
23-Feb-21,"TherapeuticsMD to Report Fourth Quarter 2020 Results on March 2, 2021","TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative women’s healthcare company, today announced that it will report its fourth quarter 2020 financial results on Tuesday, March 2, 2021, before the openi...",1.61,1.7,1.46,1.62,TXMD,17176627,HISTORICAL_PRICES,TXMD,,1.61413E+12,0.352941176,0.352941176,1.62,1.61,1.7,1.46,17176627,1.62,1.61,1.7,1.46,17176627,23-Feb-21,-0.08,-0.0473
23-Feb-21,Revance Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4),"Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company focused on innovative aesthetic and therapeutic offerings, including its investigational neuromodulator product, DaxibotulinumtoxinA...",25.91,27.55,25.04,27.55,RVNC,834302,HISTORICAL_PRICES,RVNC,,1.61413E+12,-0.059528131,-0.059528131,27.55,25.91,27.55,25.04,834302,27.55,25.91,27.55,25.04,834302,23-Feb-21,-1.05,-0.0389
23-Feb-21,bluebird bio Reports Fourth Quarter and Full Year 2020 Financial Results and Highlights Operational Progress,"bluebird bio, Inc. (NASDAQ:BLUE) today reported financial results and business highlights for the fourth quarter and full year ended December 31, 2020 and shared recent operational progress. “For over...",25.62,26.45,24.24,25.94,BLUE,4484027,HISTORICAL_PRICES,BLUE,,1.61413E+12,-0.437417655,-0.437417655,25.94,25.62,26.45,24.24,4484027,25.94,25.62,26.45,24.24,4484027,23-Feb-21,-0.45,-0.0173
23-Feb-21,Adamas Reports Fourth Quarter and Full Year 2020 Financial Results,"Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today reported fi...",5.14,5.6,5.0727,5.53,ADMS,520508,HISTORICAL_PRICES,ADMS,,1.61413E+12,0.122270742,0.122270742,5.53,5.14,5.6,5.0727,520508,5.53,5.14,5.6,5.0727,520508,23-Feb-21,-0.53,-0.0935
23-Feb-21,AtriCure Reports Fourth Quarter 2020 and Full Year 2020 Financial Results,"AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced fourth quarter 2020 and full year 2020 finan...",62.24,64.37,61.35,64.37,ATRC,714400,HISTORICAL_PRICES,ATRC,,1.61413E+12,0.081494353,0.081494353,64.37,62.24,64.37,61.35,714400,64.37,62.24,64.37,61.35,714400,23-Feb-21,-2.97,-0.0455
23-Feb-21,"Outset Medical to Report Fourth Quarter and Full Year 2020 Financial Results on Tuesday, March 9, 2021","Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced that it will release...",48.77,50.12,46.21,49.12,OM,198476,HISTORICAL_PRICES,OM,,1.61413E+12,-0.084303417,-0.084303417,49.12,48.77,50.12,46.21,198476,49.12,48.77,50.12,46.21,198476,23-Feb-21,-0.89,-0.0179
23-Feb-21,Xencor Reports Fourth Quarter and Full Year 2020 Financial Results,"Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, today reported fin...",48.35,50.99,47.34,48.72,XNCR,280381,HISTORICAL_PRICES,XNCR,,1.61413E+12,0.049262153,0.049262153,48.72,48.35,50.99,47.34,280381,48.72,48.35,50.99,47.34,280381,23-Feb-21,-0.78,-0.0159
23-Feb-21,Resumen: Incyte anuncia la aceptación de la solicitud de NDA y la revisión de prioridad de ruxolitinib en crema indicado para la dermatitis atópica,"Incyte (Nasdaq: INCY) ha anunciado hoy que la Administración de Alimentos y Medicamentos (Food and Drug Administration, FDA) de EE. UU. ha aceptado, para su revisión prioritaria, la solicitud de nuevo...",79.02,79.65,76.69,79.17,INCY,2487423,HISTORICAL_PRICES,INCY,,1.61413E+12,-0.095570562,-0.095570562,79.17,79.02,79.65,76.69,2487423,79.17,79.02,79.65,76.69,2487423,23-Feb-21,-0.9,-0.0113
23-Feb-21,GlycoMimetics Promotes Dr. Eric Feldman to Chief Medical Officer,"GlycoMimetics, Inc. (Nasdaq: GLYC) today announced the promotion of Eric Feldman, M.D., to Senior Vice President and Chief Medical Officer. Dr. Feldman joined the Company in 2019 and was previously Vi...",3.5,3.7,3.36,3.65,GLYC,1349497,HISTORICAL_PRICES,GLYC,,1.61413E+12,-0.150485437,-0.150485437,3.65,3.5,3.7,3.36,1349497,3.65,3.5,3.7,3.36,1349497,23-Feb-21,-0.29,-0.0765
23-Feb-21,MyMD Pharmaceuticals Announces New Data on Its Lead Compound MYMD-1 from a Phenotypic Study Performed by Eurofins Discovery,"Akers Biosciences, Inc. (Nasdaq: AKER), with its proposed merger partner MyMD Pharmaceuticals, Inc. (“MyMD”), a clinical stage pharmaceutical company committed to extending healthy lifespan by focusin...",3.06,3.3672,2.73,3.32,AKER,708472,HISTORICAL_PRICES,AKER,,1.61413E+12,0.471153846,0.471153846,3.32,3.06,3.3672,2.73,708472,3.32,3.06,3.3672,2.73,708472,23-Feb-21,-0.4,-0.1156
23-Feb-21,"Odonate Therapeutics Announces Financial Results for the Three and Twelve Months Ended December 31, 2020","Odonate Therapeutics, Inc. (NASDAQ: ODT), a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer, today announced...",21.74,22.88,20.72,22.41,ODT,765418,HISTORICAL_PRICES,ODT,,1.61413E+12,0.260289855,0.260289855,22.41,21.74,22.88,20.72,765418,22.41,21.74,22.88,20.72,765418,23-Feb-21,-2.34,-0.0972
23-Feb-21,Clovis Oncology Announces 2020 Operating Results,"Clovis Oncology, Inc. (NASDAQ:CLVS) reported financial results for the quarter and year ended December 31, 2020, and provided an update on the Company’s clinical development programs and regulatory an...",6.01,6.5,5.75,6.29,CLVS,10162258,HISTORICAL_PRICES,CLVS,,1.61413E+12,0.231557377,0.231557377,6.29,6.01,6.5,5.75,10162258,6.29,6.01,6.5,5.75,10162258,23-Feb-21,-0.67,-0.1003
23-Feb-21,Masimo Announces U.S. Release of softFlow® High-Flow Nasal Cannula Therapy,"Masimo (NASDAQ: MASI) today announced the U.S. introduction of softFlow®, innovative pulmonary care therapy which provides nasal high-flow warmed and humidified respiratory gases to spontaneously brea...",248.22,251.74,243,247.57,MASI,455750,HISTORICAL_PRICES,MASI,,1.61413E+12,-0.066631571,-0.066631571,247.57,248.22,251.74,243,455750,247.57,248.22,251.74,243,455750,23-Feb-21,-1.8,-0.0072
23-Feb-21,PerkinElmer Changes COVID-19 Rapid Testing Landscape with Highly Sensitive Point of Care Antigen Test for Mass Screening,"PerkinElmer, Inc. (NYSE: PKI) today announced the launch of the PerkinElmer® COVID-19 Antigen Test for the qualitative detection of SARS-CoV-2 nucleocapsid protein antigen in nasal (NS) or nasopharyng...",131.02,131.9551,127.38,128.66,PKI,1300704,HISTORICAL_PRICES,PKI,,1.61413E+12,-0.062200272,-0.062200272,128.66,131.02,131.9551,127.38,1300704,128.66,131.02,131.9551,127.38,1300704,23-Feb-21,1.3,0.01
22-Feb-21,Quidel to Present at Upcoming Conferences,"Quidel Corporation (NASDAQ: QDEL), a leading provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that it will present at th...",163.55,184,163.005,180.3,QDEL,2067496,HISTORICAL_PRICES,QDEL,,1.61406E+12,-0.171856803,-0.171856803,180.3,163.55,184,163.005,2067496,180.3,163.55,184,163.005,2067496,22-Feb-21,-19.04,-0.1043
22-Feb-21,Revance Announces Positive Topline Phase 2 Data Supporting Advancement of DaxibotulinumtoxinA for Injection for the Treatment of Upper Limb Spasticity,"Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company focused on innovative aesthetic and therapeutic offerings, today announced positive topline data from its JUNIPER Phase 2, randomized...",26.96,28.22,26.7801,27.72,RVNC,603555,HISTORICAL_PRICES,RVNC,,1.61406E+12,-0.021415608,-0.021415608,27.72,26.96,28.22,26.7801,603555,27.72,26.96,28.22,26.7801,603555,22-Feb-21,-1.04,-0.0371
22-Feb-21,Pulse Biosciences Reports Fourth Quarter and Full Year 2020 Financial Results,"Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company progressing its Nano-Pulse Stimulation™ (NPS™) technology, today announced financial results for the fourth quarter and ful...",34.45,36.02,33.89,35.46,PLSE,96448,HISTORICAL_PRICES,PLSE,,1.61406E+12,0.62961211,0.62961211,35.46,34.45,36.02,33.89,96448,35.46,34.45,36.02,33.89,96448,22-Feb-21,-1.01,-0.0285
22-Feb-21,Revance Reports Fourth Quarter and Full Year 2020 Financial Results,"Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company focused on innovative aesthetic and therapeutic offerings, today reported financial results for the fourth quarter and full year ende...",26.96,28.22,26.7801,27.72,RVNC,603555,HISTORICAL_PRICES,RVNC,,1.61406E+12,-0.021415608,-0.021415608,27.72,26.96,28.22,26.7801,603555,27.72,26.96,28.22,26.7801,603555,22-Feb-21,-1.04,-0.0371
22-Feb-21,Frequency Therapeutics Announces Publication of Phase 1/2 Data Showing Hearing Improvements in Acquired Sensorineural Hearing Loss Patients Receiving FX-322,"Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage biotechnology company focused on harnessing the body’s innate biology to repair or reverse damage caused by a broad range of degenerative...",52.09,56.47,51.76,54,FREQ,302057,HISTORICAL_PRICES,FREQ,,1.61406E+12,0.544780546,0.544780546,54,52.09,56.47,51.76,302057,54,52.09,56.47,51.76,302057,22-Feb-21,-2.92,-0.0531
22-Feb-21,"Glancy Prongay & Murray LLP, a National Class Action Law Firm, Continues Investigation of Ebix, Inc. (EBIX) on Behalf of Investors","Glancy Prongay & Murray LLP (“GPM”), a national investor rights law firm, continues its investigation on behalf of Ebix, Inc. (“Ebix” or the “Company”) (NASDAQ: EBIX) investors concerning the Comp...",30.5,32.9,24.41,29.44,EBIX,11315296,HISTORICAL_PRICES,EBIX,,1.61462E+12,-0.177897574,-0.177897574,29.44,30.5,32.9,24.41,11315296,29.3494,30.4062,32.7988,24.3349,11315296,22-Feb-21,-20.24,-0.3989
22-Feb-21,Agilent PD-L1 IHC 22C3 pharmDx Receives Expanded FDA Approval in Non-small Cell Lung Cancer (NSCLC),Agilent Technologies Inc. (NYSE: A) today announced that the U.S. Food and Drug Administration (FDA) has approved the company’s PD-L1 IHC 22C3 pharmDx assay for expanded use in patients with non-small...,123.5,126.16,123.09,125.95,A,1340080,HISTORICAL_PRICES,A,,1.61406E+12,0.052766175,0.052766175,125.95,123.5,126.16,123.09,1340080,125.95,123.5,126.16,123.09,1340080,22-Feb-21,-3.37,-0.0266
22-Feb-21,Cyclo Therapeutics Unveils New Corporate Identity and Reaffirms Commitment to Improving Quality of Life and Providing Hope for Patients and Families,"Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company developing cyclodextrin-based products for the treatment of Niemann-Pick Disease...",8.7,9.8899,8.6004,9.52,CYTH,183602,HISTORICAL_PRICES,CYTH,,1.61406E+12,0.702510714,0.702510714,9.52,8.7,9.8899,8.6004,183602,9.52,8.7,9.8899,8.6004,183602,22-Feb-21,-0.6,-0.0645
22-Feb-21,"Robbins Geller Rudman & Dowd LLP Announces Lead Plaintiff Deadline in the Tricida, Inc. Class Action Lawsuit","Robbins Geller Rudman & Dowd LLP announces that purchasers of Tricida, Inc. (NASDAQ:TCDA) securities between September 4, 2019 and October 28, 2020, inclusive (the “Class Period”) have until March...",7.15,7.22,6.6,6.9,TCDA,1205894,HISTORICAL_PRICES,TCDA,,1.61406E+12,-0.07622739,-0.07622739,6.9,7.15,7.22,6.6,1205894,6.9,7.15,7.22,6.6,1205894,22-Feb-21,0.26,0.0377
22-Feb-21,Incyte Announces Acceptance and Priority Review of sNDA for Jakafi® (ruxolitinib) as a Treatment for Patients with Chronic Graft-Versus-Host Disease,Incyte (Nasdaq:INCY) today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the supplemental New Drug Application (sNDA) for ruxolitinib (Jakafi®) for treatm...,79.92,80.49,78.91,80.02,INCY,1750547,HISTORICAL_PRICES,INCY,,1.61406E+12,-0.085269543,-0.085269543,80.02,79.92,80.49,78.91,1750547,80.02,79.92,80.49,78.91,1750547,22-Feb-21,-0.62,-0.0077
22-Feb-21,"Revance Appoints Biotech and Pharmaceutical Executive, Olivia C. Ware, and Fintech and Payments Thought Leader and Entrepreneur, Carey O’Connor Kolaja, to its Board of Directors","Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company focused on innovative aesthetic and therapeutic offerings, today announced the appointment of accomplished biotech and pharmaceutical...",26.96,28.22,26.7801,27.72,RVNC,603555,HISTORICAL_PRICES,RVNC,,1.61406E+12,-0.021415608,-0.021415608,27.72,26.96,28.22,26.7801,603555,27.72,26.96,28.22,26.7801,603555,22-Feb-21,-1.04,-0.0371
22-Feb-21,Aerie Pharmaceuticals to Participate in Upcoming Virtual Investor Conferences,"Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients w...",15.71,16.144,15.16,16.01,AERI,517639,HISTORICAL_PRICES,AERI,,1.61406E+12,0.096301465,0.096301465,16.01,15.71,16.144,15.16,517639,16.01,15.71,16.144,15.16,517639,22-Feb-21,-0.24,-0.015
19-Feb-21,Riassunto: Incyte annuncia l'accettazione e l'esame prioritario dell'NDA per ruxolitinib crema per la dermatite atopica,"Incyte (Nasdaq:INCY) oggi ha annunciato che la U.S. Food and Drug Administration (FDA) ha accettato per la Revisione prioritaria la Domanda per un nuovo farmaco (NDA, New Drug Application) per ruxolit...",80.54,82.48,80.32,82.02,INCY,1552399,HISTORICAL_PRICES,INCY,,1.61379E+12,-0.078173286,-0.078173286,82.02,80.54,82.48,80.32,1552399,82.02,80.54,82.48,80.32,1552399,19-Feb-21,-1.01,-0.0124
19-Feb-21,Incyte annonce l'acceptation et l'octroi du statut d'examen prioritaire à sa demande de drogue nouvelle (DDN) portant sur la crème au ruxolitinib pour le traitement de la dermatite atopique,Incyte (Nasdaq:INCY) a annoncé aujourd'hui que la Food and Drug Administration (FDA) américaine a accepté d'examiner en priorité sa demande de drogue nouvelle (DDN) portant sur la crème au ruxolitinib...,80.54,82.48,80.32,82.02,INCY,1552399,HISTORICAL_PRICES,INCY,,1.61379E+12,-0.078173286,-0.078173286,82.02,80.54,82.48,80.32,1552399,82.02,80.54,82.48,80.32,1552399,19-Feb-21,-1.01,-0.0124
19-Feb-21,Samenvatting: Incyte kondigt acceptatie en prioriteitsbeoordeling aan van NDA voor ruxolitinib crème voor atopische dermatitis,"Incyte (Nasdaq: INCY) heeft vandaag aangekondigd dat de Amerikaanse Food en Drug Administration (FDA) de New Drug Application (NDA) voor ruxolitinib-crème, een selectieve JAK1/JAK2-remmer, heeft geacc...",80.54,82.48,80.32,82.02,INCY,1552399,HISTORICAL_PRICES,INCY,,1.61379E+12,-0.078173286,-0.078173286,82.02,80.54,82.48,80.32,1552399,82.02,80.54,82.48,80.32,1552399,19-Feb-21,-1.01,-0.0124
19-Feb-21,Incyte meldet Annahme des Zulassungsantrags für Ruxolitinib-Creme gegen atopische Dermatitis im Rahmen eines beschleunigten Verfahrens,"Incyte (Nasdaq:INCY) meldete heute, dass die US-amerikanische Arzneimittelaufsichtsbehörde FDA den Zulassungsantrag (New Drug Application, NDA) für Ruxolitinib-Creme, einen selektiven JAK1/JAK2-Inhibi...",80.54,82.48,80.32,82.02,INCY,1552399,HISTORICAL_PRICES,INCY,,1.61379E+12,-0.078173286,-0.078173286,82.02,80.54,82.48,80.32,1552399,82.02,80.54,82.48,80.32,1552399,19-Feb-21,-1.01,-0.0124
19-Feb-21,"INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of bluebird bio, Inc. (BLUE) Investors","Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased bluebird bio, Inc. (“bluebird” or the “Company”) (NASDAQ: BLUE) securities betw...",26.68,27.3199,26.565,27.3,BLUE,4495959,HISTORICAL_PRICES,BLUE,,1.61379E+12,-0.414141414,-0.414141414,27.3,26.68,27.3199,26.565,4495959,27.3,26.68,27.3199,26.565,4495959,19-Feb-21,-0.27,-0.01
19-Feb-21,TFF Pharmaceuticals Announces Positive Preclinical Results with Two Biodefense Countermeasures for the United States Army Medical Research Institute of Infectious Diseases (USAMRIID),"TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented thin-film freeze-drying (T...",16.89,17.475,16.5,17.3,TFFP,338446,HISTORICAL_PRICES,TFFP,,1.61379E+12,0.091790562,0.091790562,17.3,16.89,17.475,16.5,338446,17.3,16.89,17.475,16.5,338446,19-Feb-21,-0.19,-0.0111
19-Feb-21,Incyte Announces Acceptance and Priority Review of NDA for Ruxolitinib Cream for Atopic Dermatitis,"Incyte (Nasdaq:INCY) today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the New Drug Application (NDA) for ruxolitinib cream, a selective JAK1/JAK2 inhib...",80.54,82.48,80.32,82.02,INCY,1552399,HISTORICAL_PRICES,INCY,,1.61379E+12,-0.078173286,-0.078173286,82.02,80.54,82.48,80.32,1552399,82.02,80.54,82.48,80.32,1552399,19-Feb-21,-1.01,-0.0124
19-Feb-21,"Elanco Achieves Important Innovation Milestones, Momentum to Start 2021","Elanco Animal Health Incorporated (NYSE: ELAN) today announces four important innovation milestones, including two product approvals, amid a string of recent progress on its innovation commitments. Fa...",30.1,30.64,29.615,30.43,ELAN,6058441,HISTORICAL_PRICES,ELAN,,1.61379E+12,-0.014407335,-0.014407335,30.43,30.1,30.64,29.615,6058441,30.43,30.1,30.64,29.615,6058441,19-Feb-21,-0.44,-0.0144
19-Feb-21,Pulse Biosciences Announces First CellFX Procedures Performed in Europe as Part of Global Controlled Launch,"Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company progressing Nano-Pulse Stimulation™ (NPS™) technology, today announced that the first CellFX® procedures in the European Un...",35.46,36.76,34.44,34.91,PLSE,118654,HISTORICAL_PRICES,PLSE,,1.61379E+12,0.677388836,0.677388836,34.91,35.46,36.76,34.44,118654,34.91,35.46,36.76,34.44,118654,19-Feb-21,0.71,0.0204
19-Feb-21,Applied DNA to Provide Back-To-Campus COVID-19 Surveillance Testing to LIM College,"Applied DNA Sciences, Inc. (NASDAQ: APDN) (the “Company”), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing, and LIM College, a midtown Manhattan-based leader in education for the b...",11.14,11.3374,10.8583,11.01,APDN,390909,HISTORICAL_PRICES,APDN,,1.61379E+12,1.055350554,1.055350554,11.01,11.14,11.3374,10.8583,390909,11.01,11.14,11.3374,10.8583,390909,19-Feb-21,0.39,0.0363
19-Feb-21,"Legend Biotech Announces Preliminary Results for the Year Ended December 31, 2020","Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global clinical-stage biopharmaceutical company engaged in the discovery and development of novel cell therapies for oncology and other in...",27.18,27.24,26.75,26.77,LEGN,171484,HISTORICAL_PRICES,LEGN,,1.61379E+12,-0.079580088,-0.079580088,26.77,27.18,27.24,26.75,171484,26.77,27.18,27.24,26.75,171484,19-Feb-21,0.41,0.0153
19-Feb-21,"Robbins Geller Rudman & Dowd LLP Announces Lead Plaintiff Deadline in the Penumbra, Inc. Class Action Lawsuit","Robbins Geller Rudman & Dowd LLP announces that purchasers of Penumbra, Inc. (NYSE:PEN) common stock between August 3, 2020 and December 15, 2020, inclusive (the “Class Period”) have until March 1...",280.2,281.395,274,279.36,PEN,418490,HISTORICAL_PRICES,PEN,,1.61379E+12,0.495117656,0.495117656,279.36,280.2,281.395,274,418490,279.36,280.2,281.395,274,418490,19-Feb-21,2.59,0.0093
18-Feb-21,Quidel Reports Fourth Quarter and Full Year 2020 Financial Results,"Quidel Corporation (NASDAQ: QDEL), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today financial results for the fourth q...",210.1,218.4,208.19,217.21,QDEL,788998,HISTORICAL_PRICES,QDEL,,1.6137E+12,0.063851334,0.063851334,217.21,210.1,218.4,208.19,788998,217.21,210.1,218.4,208.19,788998,18-Feb-21,-7.69,-0.0353
18-Feb-21,PPD Awarded US Army Study to Help Develop Post-Traumatic Stress Disorder Drugs,"PPD, Inc. (Nasdaq: PPD), a leading global contract research organization, has been awarded Defense Health Agency funds to support a five-year Research Project Award (RPA) to develop and execute an ada...",36.54,36.95,35.78,36.45,PPD,937855,HISTORICAL_PRICES,PPD,,1.6137E+12,0.048493544,0.048493544,36.45,36.54,36.95,35.78,937855,36.45,36.54,36.95,35.78,937855,18-Feb-21,-0.36,-0.0098
18-Feb-21,Study Identifies Effects of Temperature Changes on SARS-CoV-2 Transmission,"Akers Biosciences, Inc. (Nasdaq: AKER), with its proposed merger partner MyMD Pharmaceuticals, Inc. (“MyMD”), a clinical stage pharmaceutical company committed to extending healthy lifespan by focusin...",3.93,4.08,3.71,3.89,AKER,1329588,HISTORICAL_PRICES,AKER,,1.6137E+12,0.889423077,0.889423077,3.89,3.93,4.08,3.71,1329588,3.89,3.93,4.08,3.71,1329588,18-Feb-21,-0.09,-0.0224
18-Feb-21,Jabil Receives FDA Clearance for Made in USA Protective Face Masks,"Jabil (NYSE: JBL) today announced that together with its subsidiary medical device company, NP Medical, Inc., the company is ready to deliver personal protective equipment (PPE) orders of medical-qual...",43.67,44.435,43.645,43.79,JBL,1297933,HISTORICAL_PRICES,JBL,,1.6137E+12,0.018661068,0.018661068,43.79,43.67,44.435,43.645,1297933,43.79,43.67,44.435,43.645,1297933,18-Feb-21,-0.59,-0.0133
18-Feb-21,Seagen and Astellas Announce Submission of Two Supplemental Biologics License Applications to the U.S. FDA for PADCEV® (enfortumab vedotin-ejfv) in Locally Advanced or Metastatic Urothelial Cancer,"Seagen Inc. (Nasdaq:SGEN) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) today announced completion of submissions for two supplemental Biologics License Ap...",158.62,160.04,156.24,158.66,SGEN,842302,HISTORICAL_PRICES,SGEN,,1.6137E+12,-0.1678296,-0.1678296,158.66,158.62,160.04,156.24,842302,158.66,158.62,160.04,156.24,842302,18-Feb-21,-0.21,-0.0013
18-Feb-21,Agilent Announces Immunoassay Kit to Detect SARS-CoV-2 Antibodies,Agilent Technologies Inc. (NYSE: A) today announced the launch of the Agilent Dako SARS-CoV-2 IgG Enzyme-Linked Immunosorbent Assay (ELISA) kit intended for the qualitative detection of immunoglobulin...,127.68,130.39,127.58,129,A,1941522,HISTORICAL_PRICES,A,,1.6137E+12,0.088398261,0.088398261,129,127.68,130.39,127.58,1941522,129,127.68,130.39,127.58,1941522,18-Feb-21,-2.44,-0.0188
18-Feb-21,"Aerie Pharmaceuticals to Announce Fourth Quarter and Full Year 2020 Financial Results and Host Conference Call on Thursday, February 25, 2021","Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients w...",16.32,16.95,16.11,16.57,AERI,399771,HISTORICAL_PRICES,AERI,,1.6137E+12,0.138869505,0.138869505,16.57,16.32,16.95,16.11,399771,16.57,16.32,16.95,16.11,399771,18-Feb-21,-0.36,-0.0216
18-Feb-21,"Deciphera Pharmaceuticals, Inc. to Present at the SVB Leerink 10th Annual Global Healthcare Conference","Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) today announced that Steve Hoerter, President and Chief Executive Officer, will participate in a fireside chat at the SVB Leerink 10th Annual Global Heal...",45.42,46.6825,44.79,45.88,DCPH,508361,HISTORICAL_PRICES,DCPH,,1.6137E+12,-0.228600543,-0.228600543,45.88,45.42,46.6825,44.79,508361,45.88,45.42,46.6825,44.79,508361,18-Feb-21,-0.98,-0.0211
17-Feb-21,"The Law Offices of Frank R. Cruz Announces Investigation of bluebird bio, Inc. (BLUE) on Behalf of Investors","The Law Offices of Frank R. Cruz announces an investigation of Bluebird Bio, Inc. (“bluebird” or the “Company”) (NASDAQ: BLUE) on behalf of investors concerning the Company’s possible violations of fe...",28.02,29.95,27.72,28.59,BLUE,6816649,HISTORICAL_PRICES,BLUE,,1.61362E+12,-0.384716733,-0.384716733,28.59,28.02,29.95,27.72,6816649,28.59,28.02,29.95,27.72,6816649,17-Feb-21,-0.42,-0.0148
17-Feb-21,"Shareholder Alert: Robbins LLP Announces That Bluebird Bio, Inc. (BLUE) is Being Sued for Misleading Shareholders","Shareholder rights law firm Robbins LLP announces that a purchaser of bluebird bio, Inc. (NASDAQ: BLUE) filed a class action complaint against the Company and its officers and directors for alleged vi...",28.02,29.95,27.72,28.59,BLUE,6816649,HISTORICAL_PRICES,BLUE,,1.61362E+12,-0.384716733,-0.384716733,28.59,28.02,29.95,27.72,6816649,28.59,28.02,29.95,27.72,6816649,17-Feb-21,-0.42,-0.0148
17-Feb-21,"Glancy Prongay & Murray LLP, a National Class Action Law Firm, Continues Investigation of Key Tronic Corporation (KTCC) on Behalf of Investors","Glancy Prongay & Murray LLP (“GPM”), a national investor rights law firm, continues its investigation on behalf of Key Tronic Corporation (“Key Tronic” or the “Company”) (NASDAQ: KTCC) investors c...",7.98,8,7.71,7.87,KTCC,75593,HISTORICAL_PRICES,KTCC,,1.61362E+12,0.032341527,0.032341527,7.87,7.98,8,7.71,75593,7.87,7.98,8,7.71,75593,17-Feb-21,0.14,0.0179
17-Feb-21,"Glancy Prongay & Murray LLP, a National Class Action Law Firm, Continues Investigation of Jianpu Technology, Inc. (JT) on Behalf of Investors","Glancy Prongay & Murray LLP (“GPM”), a national investor rights law firm, continues its investigation on behalf of Jianpu Technology, Inc. (“Jianpu” or the “Company”) (NYSE: JT) investors concerni...",3.7,3.87,3.54,3.57,JT,456941,HISTORICAL_PRICES,JT,,1.61362E+12,0.271477663,0.271477663,3.57,3.7,3.87,3.54,456941,3.57,3.7,3.87,3.54,456941,17-Feb-21,-0.24,-0.0609
17-Feb-21,"INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of bluebird bio, Inc. (BLUE) on Behalf of Investors","Law Offices of Howard G. Smith announces an investigation on behalf of bluebird bio, Inc. (“bluebird” or the “Company”) (NASDAQ: BLUE) investors concerning the Company’s possible violations of federal...",28.02,29.95,27.72,28.59,BLUE,6816649,HISTORICAL_PRICES,BLUE,,1.61362E+12,-0.384716733,-0.384716733,28.59,28.02,29.95,27.72,6816649,28.59,28.02,29.95,27.72,6816649,17-Feb-21,-0.42,-0.0148
17-Feb-21,Altria Presents as Part of the Consumer Analyst Group of New York Conference; Reaffirms 2021 Full-Year Earnings Guidance,"Altria Group, Inc. (Altria) (NYSE: MO) is participating in the virtual Consumer Analyst Group of New York Conference (CAGNY) today. Billy Gifford, Altria’s Chief Executive Officer, and Sal Mancuso, Al...",43.6,43.91,43.23,43.4,MO,5982454,HISTORICAL_PRICES,MO,,1.61655E+12,0.04506232,0.04506232,43.4,43.6,43.91,43.23,5982454,42.6611,42.8577,43.1624,42.494,5982454,17-Feb-21,0.19,0.0044
17-Feb-21,SCYNEXIS and Hansoh Pharma Announce Licensing Agreement and Strategic Partnership for Ibrexafungerp in Greater China,"SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, and Hansoh Pharmaceutical Group Company...",9.35,10.15,9.25,9.9,SCYX,2031216,HISTORICAL_PRICES,SCYX,,1.61362E+12,0.30952381,0.30952381,9.9,9.35,10.15,9.25,2031216,9.9,9.35,10.15,9.25,2031216,17-Feb-21,-0.28,-0.0291
17-Feb-21,"Lyra Therapeutics Announces Appointment of Robert Kern, MD, as Chief Medical Officer","Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatme...",14.18,14.85,13.45,14.67,LYRA,356506,HISTORICAL_PRICES,LYRA,,1.61362E+12,0.23951049,0.23951049,14.67,14.18,14.85,13.45,356506,14.67,14.18,14.85,13.45,356506,17-Feb-21,-0.59,-0.0399
17-Feb-21,European Commission Purchases Additional 150 Million Doses of COVID-19 Vaccine Moderna,"Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that the European Commission purchased an additional 150 million doses...",176.76,178.01,171.62,174.28,MRNA,6554586,HISTORICAL_PRICES,MRNA,,1.61362E+12,0.432530999,0.432530999,174.28,176.76,178.01,171.62,6554586,174.28,176.76,178.01,171.62,6554586,17-Feb-21,-1.77,-0.0099
17-Feb-21,Charles River Laboratories Announces Fourth-Quarter and Full-Year 2020 Results and Provides 2021 Guidance,"Charles River Laboratories International, Inc. (NYSE: CRL) today reported its results for the fourth-quarter and full-year 2020 and provided guidance for 2021. For the quarter, revenue was $791.0 mill...",299.48,303.79,284.9665,285.96,CRL,753180,HISTORICAL_PRICES,CRL,,1.61362E+12,0.189781892,0.189781892,285.96,299.48,303.79,284.9665,753180,285.96,299.48,303.79,284.9665,753180,17-Feb-21,12.74,0.0444
17-Feb-21,"Ironwood Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Results, Exceeding or Meeting Full Year 2020 Financial Guidance; Provides Full Year 2021 Financial Guidance","Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a GI-focused healthcare company, today provided an update on its fourth quarter and full year 2020 results and recent business performance. “The fourth q...",9.73,10.1,9.69,9.89,IRWD,1562130,HISTORICAL_PRICES,IRWD,,1.61362E+12,-0.169795222,-0.169795222,9.89,9.73,10.1,9.69,1562130,9.89,9.73,10.1,9.69,1562130,17-Feb-21,-0.29,-0.0289
17-Feb-21,Labcorp Adds High Sensitivity Antigen Test to Screen for Active COVID-19 Infection,"Labcorp (NYSE: LH), a leading global life sciences company, today announced the availability of a new laboratory-based antigen test that will help doctors determine if an individual is actively infect...",242.95,252.45,235.38,236,LH,1395608,HISTORICAL_PRICES,LH,,1.61362E+12,0.191690783,0.191690783,236,242.95,252.45,235.38,1395608,236,242.95,252.45,235.38,1395608,17-Feb-21,6.58,0.0278
17-Feb-21,Independent Data Monitoring Committee Concludes OlympiA Trial of LYNPARZA® (olaparib) Crossed Superiority Boundary for Invasive Disease-Free Survival vs. Placebo at Planned Interim Analysis,"AstraZeneca and Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the Phase 3 OlympiA trial for LYNPARZA will move to early primary analysis and reporting following...",75.54,76.06,74.37,74.46,MRK,13249695,HISTORICAL_PRICES,MRK,,1.61552E+12,-0.057399551,-0.057399551,74.46,75.54,76.06,74.37,13249695,73.8115,74.8821,75.3975,73.7223,13249695,17-Feb-21,1.29,0.0174
17-Feb-21,Pfizer Initiates Pivotal Phase 2 MagnetisMM-3 Trial of BCMA-CD3 Bispecific Antibody Elranatamab (PF-06863135) in Multiple Myeloma,"Pfizer Inc. (NYSE:PFE) today announced that the first participant has been dosed in the registration-enabling Phase 2 MagnetisMM-3 study (NCT04649359) of elranatamab (PF-06863135), an investigational...",34.89,34.9974,34.46,34.57,PFE,26501081,HISTORICAL_PRICES,PFE,,1.61362E+12,-0.063858331,-0.063858331,34.57,34.89,34.9974,34.46,26501081,34.57,34.89,34.9974,34.46,26501081,17-Feb-21,0.2,0.0058
17-Feb-21,Henry Schein Reports Fourth Quarter 2020 Financial Results From Continuing Operations,"Henry Schein, Inc. (Nasdaq: HSIC), the world’s largest provider of health care solutions to office-based dental and medical practitioners, today reported fourth quarter financial results from continui...",64.87,67.43,63.5001,65.29,HSIC,3463091,HISTORICAL_PRICES,HSIC,,1.61362E+12,-0.014583017,-0.014583017,65.29,64.87,67.43,63.5001,3463091,65.29,64.87,67.43,63.5001,3463091,17-Feb-21,-5.71,-0.0809
17-Feb-21,Pfizer and BioNTech to Supply the European Union with 200 Million Additional Doses of COMIRNATY®,"Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced an agreement with the European Commission (EC) to supply an additional 200 million doses of COMIRNATY®, the companies’ COVID-19 V...",34.89,34.9974,34.46,34.57,PFE,26501081,HISTORICAL_PRICES,PFE,,1.61362E+12,-0.063858331,-0.063858331,34.57,34.89,34.9974,34.46,26501081,34.57,34.89,34.9974,34.46,26501081,17-Feb-21,0.2,0.0058
16-Feb-21,Altria Announces Pricing of Previously Announced Cash Tender Offers,"Altria Group, Inc. (“Altria”) (NYSE: MO) today announced the pricing terms for its previously announced cash tender offers for certain of its outstanding senior unsecured notes (each, a “Tender Offer”...",43.41,43.625,43.1,43.31,MO,6854083,HISTORICAL_PRICES,MO,,1.61655E+12,0.04050815,0.04050815,43.31,43.41,43.625,43.1,6854083,42.5726,42.6709,42.8822,42.3662,6854083,16-Feb-21,0.01,0.0002
16-Feb-21,Astrotech Reports Second Quarter of Fiscal Year 2021 Financial Results,"Astrotech Corporation (NASDAQ: ASTC) reported its financial results for the second quarter of fiscal year 2021, which ended December 31, 2020. Since the beginning of the quarter, we successfully raise...",3.9,4.14,3.61,3.652,ASTC,4433479,HISTORICAL_PRICES,ASTC,,1.61353E+12,1.052631579,1.052631579,3.652,3.9,4.14,3.61,4433479,3.652,3.9,4.14,3.61,4433479,16-Feb-21,0.31,0.0864
16-Feb-21,Astrotech Announces Closing of Approximately $9.25 Million Registered Direct Offering Priced At-the-Market,"Astrotech Corporation (NASDAQ: ASTC), today announced that it has closed its previously announced registered direct offering priced at-the-market under Nasdaq rules of 2,845,535 shares of its common s...",3.9,4.14,3.61,3.652,ASTC,4433479,HISTORICAL_PRICES,ASTC,,1.61353E+12,1.052631579,1.052631579,3.652,3.9,4.14,3.61,4433479,3.652,3.9,4.14,3.61,4433479,16-Feb-21,0.31,0.0864
16-Feb-21,"Masimo to Report Fourth Quarter and Full Year 2020 Financial Results after Market Close on Tuesday, February 23","As previously announced on January 13, Masimo (NASDAQ: MASI) will release fourth quarter and full year 2020 financial results for the period ended January 2, 2021, after the market closes on Tuesday,...",273.52,278.33,268.5,278.31,MASI,221985,HISTORICAL_PRICES,MASI,,1.61353E+12,0.02850267,0.02850267,278.31,273.52,278.33,268.5,221985,278.31,273.52,278.33,268.5,221985,16-Feb-21,-2.2,-0.008
16-Feb-21,Moderna Provides U.S. COVID-19 Vaccine Supply Update,"Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today provided a supply update for the Moderna COVID-19 Vaccine in the United States, r...",178.53,184.18,173.5088,182.41,MRNA,6917541,HISTORICAL_PRICES,MRNA,,1.61353E+12,0.44687576,0.44687576,182.41,178.53,184.18,173.5088,6917541,182.41,178.53,184.18,173.5088,6917541,16-Feb-21,-5.21,-0.0284
16-Feb-21,Altria Announces Early Results and Upsize of Previously Announced Cash Tender Offers for Certain Outstanding Notes,"Altria Group, Inc. (“Altria”) (NYSE: MO) today announced the early results of its previously announced cash tender offers for certain of its outstanding senior unsecured notes (each, a “Tender Offer”...",43.41,43.625,43.1,43.31,MO,6854083,HISTORICAL_PRICES,MO,,1.61655E+12,0.04050815,0.04050815,43.31,43.41,43.625,43.1,6854083,42.5726,42.6709,42.8822,42.3662,6854083,16-Feb-21,0.01,0.0002
16-Feb-21,InVivo Therapeutics Announces Publication in Peer-Reviewed Journal of Neurosurgery: Spine,InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV) today announced the recent publication of a peer-reviewed manuscript in the Journal of Neurosurgery: Spine describing the previously presented complet...,1.78,2,1.62,1.71,NVIV,16347950,HISTORICAL_PRICES,NVIV,,1.61353E+12,1.656716418,1.656716418,1.71,1.78,2,1.62,16347950,1.71,1.78,2,1.62,16347950,16-Feb-21,0.21,0.1338
16-Feb-21,Establishment Labs Announces Participation in the Cowen 41st Annual Healthcare Conference,"Establishment Labs Holdings Inc. (NASDAQ: ESTA), a medical technology company focused on women’s health, initially in the breast aesthetics and reconstruction market, today announced that CEO and Foun...",67.07,70.09,66.995,69.81,ESTA,64342,HISTORICAL_PRICES,ESTA,,1.61353E+12,0.916285714,0.916285714,69.81,67.07,70.09,66.995,64342,69.81,67.07,70.09,66.995,64342,16-Feb-21,-2.42,-0.0348
16-Feb-21,GT Biopharma Announces Closing of $23.7 Million Public Offering,"GT Biopharma, Inc. (NASDAQ: GTBP), a clinical stage biopharmaceutical company focused on the development and commercialization of its disruptive, target-directed Natural Killer (NK) cell engager immun...",6.33,7.0999,5.9,5.9,GTBP,1500070,HISTORICAL_PRICES,GTBP,,1.61353E+12,9.970537262,9.970537262,5.9,6.33,7.0999,5.9,1500070,5.9,6.33,7.0999,5.9,1500070,16-Feb-21,0.76,0.1364
16-Feb-21,"Palantir Reports Revenue Growth of 47% for Full Year 2020, Expects Q1 2021 Revenue Growth of 45%","Palantir Technologies Inc. (NYSE: PLTR): Summary $1.1 billion in revenue for full year 2020, up 47% year-over-year $322 million in revenue for Q4 2020, up 40% year-over-year New contracts in Q4 2020 i...",27.84,30.44,27.3,30.02,PLTR,180294325,HISTORICAL_PRICES,PLTR,,1.61353E+12,0.003243243,0.003243243,30.02,27.84,30.44,27.3,180294325,30.02,27.84,30.44,27.3,180294325,16-Feb-21,-4.07,-0.1275
16-Feb-21,Sesen Bio Announces FDA Acceptance and Priority Review of its Biologics License Application for Vicineum™,"Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, announced today that the U.S. Food and Drug Administr...",3.02,3.54,2.83,3.515,SESN,36659407,HISTORICAL_PRICES,SESN,,1.61353E+12,1.396825397,1.396825397,3.515,3.02,3.54,2.83,36659407,3.515,3.02,3.54,2.83,36659407,16-Feb-21,0.22,0.0786
16-Feb-21,Gamida Cell Announces $75 Million Financing with Highbridge Capital Management,"Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to developing and commercializing cures for blood cancers and serious hematologic diseases, today announced the sale of $75...",11.24,11.96,11.15,11.81,GMDA,1366072,HISTORICAL_PRICES,GMDA,,1.61353E+12,0.22173913,0.22173913,11.81,11.24,11.96,11.15,1366072,11.81,11.24,11.96,11.15,1366072,16-Feb-21,-0.6,-0.0507
16-Feb-21,bluebird bio Announces Temporary Suspension on Phase 1/2 and Phase 3 Studies of LentiGlobin Gene Therapy for Sickle Cell Disease (bb1111),"bluebird bio, Inc. (Nasdaq: BLUE) announced today that the company has placed its Phase 1/2 (HGB-206) and Phase 3 (HGB-210) studies of LentiGlobin gene therapy for sickle cell disease (SCD) (bb1111) o...",28.44,34.36,26.11,33.5,BLUE,18060327,HISTORICAL_PRICES,BLUE,,1.61353E+12,-0.375494071,-0.375494071,33.5,28.44,34.36,26.11,18060327,33.5,28.44,34.36,26.11,18060327,16-Feb-21,-17.32,-0.3785
16-Feb-21,Taysha Gene Therapies Announces Formation of Independent Scientific Advisory Board,"Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS...",29.22,30.18,28.97,29.91,TSHA,24303,HISTORICAL_PRICES,TSHA,,1.61353E+12,0.074264706,0.074264706,29.91,29.22,30.18,28.97,24303,29.91,29.22,30.18,28.97,24303,16-Feb-21,-0.17,-0.0058
16-Feb-21,Kala Pharmaceuticals Announces EYSUVIS™ Now Covered by Express Scripts,"Kala Pharmaceuticals, Inc., (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced that...",9.48,9.68,8.82,9.13,KALA,3378718,HISTORICAL_PRICES,KALA,,1.61353E+12,0.237597911,0.237597911,9.13,9.48,9.68,8.82,3378718,9.13,9.48,9.68,8.82,3378718,16-Feb-21,0.85,0.0985
16-Feb-21,Biodesix Partners with Chicago Public Schools for COVID-19 Testing to Safely Reopen Schools,"Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced that the company has partnered with Chicago Public Schools (CPS) to prov...",26.79,28.36,25.07,25.07,BDSX,118620,HISTORICAL_PRICES,BDSX,,1.61353E+12,0.49081803,0.49081803,25.07,26.79,28.36,25.07,118620,25.07,26.79,28.36,25.07,118620,16-Feb-21,2,0.0807
16-Feb-21,Epizyme Announces Date of Fourth Quarter and Full Year 2020 Financial Results and Participation in Upcoming Investor Conferences,"Epizyme, (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering novel epigenetic therapies, today announced that management will host a conference cal...",10.71,10.86,10.37,10.8,EPZM,952907,HISTORICAL_PRICES,EPZM,,1.61353E+12,-0.088510638,-0.088510638,10.8,10.71,10.86,10.37,952907,10.8,10.71,10.86,10.37,952907,16-Feb-21,-0.03,-0.0028
16-Feb-21,Axonics® Receives FDA Approval for Third-Generation Implantable Neurostimulator,"Axonics Modulation Technologies, Inc. (Nasdaq: AXNX), a medical technology company that has developed and is commercializing novel implantable sacral neuromodulation (SNM) devices for the treatment of...",55.17,56.55,54.22,56.25,AXNX,493561,HISTORICAL_PRICES,AXNX,,1.61353E+12,0.154667225,0.154667225,56.25,55.17,56.55,54.22,493561,56.25,55.17,56.55,54.22,493561,16-Feb-21,0.63,0.0116
12-Feb-21,Exelixis Announces Final Phase 1 Results from Clinical Trial Sponsored by the National Cancer Institute at ASCO GU for Cabozantinib in Combination with Nivolumab with or without Ipilimumab in Patients with Refractory Metastatic Genitourinary Tumors,"Exelixis, Inc. (NASDAQ: EXEL) today announced positive final data for a phase 1 trial sponsored and conducted by the U.S. National Cancer Institute (NCI), including seven expansion cohorts, evaluating...",21.91,21.97,21.26,21.79,EXEL,3557146,HISTORICAL_PRICES,EXEL,,1.61318E+12,0.057943023,0.057943023,21.79,21.91,21.97,21.26,3557146,21.79,21.91,21.97,21.26,3557146,12-Feb-21,-0.16,-0.0072
12-Feb-21,U.S. FDA Approves PANZYGA® for the Treatment of Adults with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP),Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for PANZYGA® (Immune Globulin Intravenous [H...,34.72,34.95,34.36,34.44,PFE,25578646,HISTORICAL_PRICES,PFE,,1.61318E+12,-0.06841964,-0.06841964,34.44,34.72,34.95,34.36,25578646,34.44,34.72,34.95,34.36,25578646,12-Feb-21,0.29,0.0084
12-Feb-21,"Dr. Thomas Cannell, President and CEO of Sesen Bio, to Host Conference Call to Provide a Business Update","Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced that Dr. Thomas Cannell, President an...",2.8,2.95,2.66,2.84,SESN,9290343,HISTORICAL_PRICES,SESN,,1.61318E+12,1.222222222,1.222222222,2.84,2.8,2.95,2.66,9290343,2.84,2.8,2.95,2.66,9290343,12-Feb-21,-0.03,-0.0106
12-Feb-21,Urovant Sciences Provides Merger Update and Reports Third Quarter Fiscal Year 2020 Results,"Urovant Sciences (Nasdaq: UROV) today reported financial results for its fiscal quarter ended December 31, 2020. “The third quarter of fiscal 2020 was transformational for Urovant. In November, we ann...",16.17,16.2,16.17,16.18,UROV,61736,HISTORICAL_PRICES,UROV,,1.61318E+12,0.008104738,0.008104738,16.18,16.17,16.2,16.17,61736,16.18,16.17,16.2,16.17,61736,12-Feb-21,0,0
12-Feb-21,Seagen and Astellas Announce Presentation of Results from PADCEV® (enfortumab vedotin-ejfv) Pivotal Trial in Patients with Previously Treated Advanced Urothelial Cancer Who Were Ineligible for Cisplatin Chemotherapy,"Seagen Inc. (Nasdaq:SGEN) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) today announced results from the second cohort (cohort 2) of patients in the pivota...",165.84,169.69,158.5968,162,SGEN,3000235,HISTORICAL_PRICES,SGEN,,1.61318E+12,-0.129951209,-0.129951209,162,165.84,169.69,158.5968,3000235,162,165.84,169.69,158.5968,3000235,12-Feb-21,-6.18,-0.0359
12-Feb-21,Seagen and Astellas Announce Phase 3 Trial Results Demonstrating Survival Advantage of PADCEV® (enfortumab vedotin-ejfv) in Patients with Previously Treated Advanced Urothelial Cancer,"Seagen Inc. (Nasdaq:SGEN) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) today announced primary results from the phase 3 EV-301 trial comparing PADCEV® (en...",165.84,169.69,158.5968,162,SGEN,3000235,HISTORICAL_PRICES,SGEN,,1.61318E+12,-0.129951209,-0.129951209,162,165.84,169.69,158.5968,3000235,162,165.84,169.69,158.5968,3000235,12-Feb-21,-6.18,-0.0359
12-Feb-21,Canada Purchases Additional 4 Million Doses of Moderna’s COVID-19 Vaccine,"Moderna, Inc., (Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that the Canadian Government has increased its confirmed order commitme...",183.74,185,177.58,184.89,MRNA,5705535,HISTORICAL_PRICES,MRNA,,1.61318E+12,0.489099603,0.489099603,184.89,183.74,185,177.58,5705535,184.89,183.74,185,177.58,5705535,12-Feb-21,0.3,0.0016
12-Feb-21,"Ocular Therapeutix™ Announces Upcoming Presentation of Interim OTX-TKI Phase 1 Clinical Trial Data at Angiogenesis, Exudation, and Degeneration 2021 – Virtual Edition","Ocular Therapeutix™, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, ann...",19.38,20.29,19.08,19.65,OCUL,872886,HISTORICAL_PRICES,OCUL,,1.61318E+12,-0.122282609,-0.122282609,19.65,19.38,20.29,19.08,872886,19.65,19.38,20.29,19.08,872886,12-Feb-21,-0.38,-0.0192
12-Feb-21,"Revance to Release Fourth Quarter and Full Year 2020 Financial Results on Monday, February 22, 2021","Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company focused on innovative aesthetic and therapeutic offerings, today announced that the company will release fourth quarter and full year...",28.97,29.22,28.18,28.57,RVNC,289964,HISTORICAL_PRICES,RVNC,,1.61318E+12,0.05154265,0.05154265,28.57,28.97,29.22,28.18,289964,28.57,28.97,29.22,28.18,289964,12-Feb-21,0.54,0.019
12-Feb-21,"Xeris Pharmaceuticals recibe la aprobación de la Comisión Europea para la inyección de Ogluo™ (glucagón) para el tratamiento de la hipoglucemia grave en adultos, adolescentes y niños mayores de 2 años con diabetes mellitus","Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), una compañía farmacéutica especializada que aprovecha sus novedosas plataformas tecnológicas de formulación para desarrollar y comercializar formulaciones d...",6.84,7.8,6.71,7.65,XERS,9597863,HISTORICAL_PRICES,XERS,,1.61318E+12,0.255045872,0.255045872,7.65,6.84,7.8,6.71,9597863,7.65,6.84,7.8,6.71,9597863,12-Feb-21,0.21,0.0317
12-Feb-21,ImmunoGen Reports Recent Progress and 2020 Financial Results,"ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today reviewed recent progress in the business and reported financial res...",10.53,10.88,8.4301,8.54,IMGN,17686242,HISTORICAL_PRICES,IMGN,,1.61318E+12,0.5,0.5,8.54,10.53,10.88,8.4301,17686242,8.54,10.53,10.88,8.4301,17686242,12-Feb-21,2.45,0.3032
12-Feb-21,"Xeris Pharmaceuticals Receives European Commission Approval of Ogluo™ (glucagon) Injection for the Treatment of Severe Hypoglycaemia in Adults, Adolescents, and Children Aged 2 Years and Over With Diabetes Mellitus","Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use injectable and infusible...",6.84,7.8,6.71,7.65,XERS,9597863,HISTORICAL_PRICES,XERS,,1.61318E+12,0.255045872,0.255045872,7.65,6.84,7.8,6.71,9597863,7.65,6.84,7.8,6.71,9597863,12-Feb-21,0.21,0.0317
11-Feb-21,"ImmunityBio and NantKwest Announce FDA Authorization to Study hAd5 T-Cell COVID-19 Vaccine for Combination of Subcutaneous, Oral and Sublingual Boost to Induce T-Cell, Mucosal, and Antibody Immunity","ImmunityBio, Inc., a privately-held immunotherapy company, and NantKwest, Inc. (NASDAQ: NK), a clinical-stage, natural killer cell-based therapeutics company, today announced they have received FDA au...",26.04,27.38,25.21,26.35,NK,855593,HISTORICAL_PRICES,NK,,1.61309E+12,0.626483448,0.626483448,26.35,26.04,27.38,25.21,855593,26.35,26.04,27.38,25.21,855593,11-Feb-21,-0.25,-0.0095
11-Feb-21,U.S. Government Purchases Additional 100 Million Doses of Moderna’s COVID-19 Vaccine,"Moderna, Inc., (Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that the U.S. government has purchased an additional 100 million doses...",183.44,184.22,176.2,178.29,MRNA,5464092,HISTORICAL_PRICES,MRNA,,1.61309E+12,0.486668288,0.486668288,178.29,183.44,184.22,176.2,5464092,178.29,183.44,184.22,176.2,5464092,11-Feb-21,4.1,0.0229
11-Feb-21,Puma Biotechnology to Host Conference Call to Discuss Fourth Quarter and Full Year 2020 Financial Results,"Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, will host a conference call at 1:30 p.m. PST/4:30 p.m. EST on Thursday, February 25, 2021, following release of its fourth quarter...",12.5,13.46,12.12,13.16,PBYI,491236,HISTORICAL_PRICES,PBYI,,1.61309E+12,0.093613298,0.093613298,13.16,12.5,13.46,12.12,491236,13.16,12.5,13.46,12.12,491236,11-Feb-21,-0.64,-0.0487
11-Feb-21,Applied DNA Reports First Fiscal Quarter 2021 Revenues at Upper End of Guided Range,"Applied DNA Sciences, Inc. (NASDAQ: APDN) (the “Company”), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing, today announced consolidated financial results for the quarter ended Dec...",12.57,13.64,11.34,12.2,APDN,3346936,HISTORICAL_PRICES,APDN,,1.61309E+12,1.319188192,1.319188192,12.2,12.57,13.64,11.34,3346936,12.2,12.57,13.64,11.34,3346936,11-Feb-21,0.34,0.0278
11-Feb-21,TransAct Secures BOHA!® Solutions Order with International Convenience Store Operator,"TransAct® Technologies Incorporated (Nasdaq: TACT) (“TransAct” or “the Company”), a global leader in software-driven technology and printing solutions for high-growth markets, today announced that it...",8.92,9.19,8.9,8.9,TACT,7268,HISTORICAL_PRICES,TACT,,1.61309E+12,0.211133741,0.211133741,8.9,8.92,9.19,8.9,7268,8.9,8.92,9.19,8.9,7268,11-Feb-21,0.02,0.0022
11-Feb-21,"AbCellera Appoints Ester Falconer, Ph.D., as Chief Technology Officer","AbCellera (Nasdaq: ABCL) announced today that Ester Falconer, Ph.D., has been appointed as Chief Technology Officer (CTO), effective January 28, 2021. As CTO, Dr. Falconer will lead AbCellera’s long-t...",46,48.41,44.5887,48,ABCL,807339,HISTORICAL_PRICES,ABCL,,1.61309E+12,0.084394154,0.084394154,48,46,48.41,44.5887,807339,48,46,48.41,44.5887,807339,11-Feb-21,-0.99,-0.0211
11-Feb-21,Seagen Reports Fourth Quarter and Full Year 2020 Financial Results,"Seagen Inc. (Nasdaq:SGEN) today reported financial results for the fourth quarter and year ended December 31, 2020. The Company also highlighted ADCETRIS® (brentuximab vedotin), PADCEV® (enfortumab ve...",172.02,173.89,168.425,172.15,SGEN,1147396,HISTORICAL_PRICES,SGEN,,1.61309E+12,-0.097528986,-0.097528986,172.15,172.02,173.89,168.425,1147396,172.15,172.02,173.89,168.425,1147396,11-Feb-21,2.67,0.0158
11-Feb-21,AlloVir Research Presented at the 2021 Transplantation & Cellular Therapy Meeting Digital Experience,"AlloVir (Nasdaq: ALVR), a late clinical-stage cell therapy company, today announced results of a subgroup analysis from a Phase 2, proof-of-concept study (CHARMS) evaluating the company’s lead product...",42.53,44.385,41.59,44.06,ALVR,228511,HISTORICAL_PRICES,ALVR,,1.61309E+12,0.051161641,0.051161641,44.06,42.53,44.385,41.59,228511,44.06,42.53,44.385,41.59,228511,11-Feb-21,-0.1,-0.0023
11-Feb-21,Astrotech Announces $9.25 Million Registered Direct Offering Priced At-the-Market,"Astrotech Corporation (NASDAQ: ASTC), today announced that it has entered into definitive agreements with several institutional investors for the purchase and sale of 2,845,535 shares of Astrotech's c...",3.59,3.966,3.3,3.75,ASTC,12886303,HISTORICAL_PRICES,ASTC,,1.61309E+12,0.889473684,0.889473684,3.75,3.59,3.966,3.3,12886303,3.75,3.59,3.966,3.3,12886303,11-Feb-21,-0.46,-0.1136
11-Feb-21,Qatar Ministry of Public Health Issues Emergency Use Authorization for COVID-19 Vaccine Moderna,"Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that the Qatar Ministry of Public Health has issued an emergency use au...",183.44,184.22,176.2,178.29,MRNA,5464092,HISTORICAL_PRICES,MRNA,,1.61309E+12,0.486668288,0.486668288,178.29,183.44,184.22,176.2,5464092,178.29,183.44,184.22,176.2,5464092,11-Feb-21,4.1,0.0229
11-Feb-21,TherapeuticsMD Announces Pricing of $110 Million Public Offering of Common Stock,"TherapeuticsMD, Inc. (NASDAQ:TXMD) today announced the pricing of its underwritten public offering of approximately 59.5 million shares of its common stock for gross proceeds of $110 million, before d...",1.92,2,1.82,1.97,TXMD,59667201,HISTORICAL_PRICES,TXMD,,1.61309E+12,0.613445378,0.613445378,1.97,1.92,2,1.82,59667201,1.97,1.92,2,1.82,59667201,11-Feb-21,-0.25,-0.1152
11-Feb-21,FSD Pharma Announces US$20M At-The-Market Offering,"FSD Pharma Inc. (Nasdaq:HUGE) (CSE:HUGE) (""FSD Pharma"" or the ""Company"") today announced that it has entered into an Equity Distribution Agreement dated February 11, 2021 (the ""Sales Agreement"") with...",3.07,4.44,2.92,4.33,HUGE,14831233,HISTORICAL_PRICES,HUGE,,1.61309E+12,0.816568047,0.816568047,4.33,3.07,4.44,2.92,14831233,4.33,3.07,4.44,2.92,14831233,11-Feb-21,-0.8,-0.2067
11-Feb-21,"Cerus Corporation to Release Fourth Quarter and Full Year 2020 Financial Results on February 25, 2021","Cerus Corporation (Nasdaq: CERS) announced today that its fourth quarter and full year 2020 financial results will be released on Thursday, February 25, 2021, after the close of the stock market. The...",7.5,7.88,7.41,7.85,CERS,1135356,HISTORICAL_PRICES,CERS,,1.61309E+12,-0.07063197,-0.07063197,7.85,7.5,7.88,7.41,1135356,7.85,7.5,7.88,7.41,1135356,11-Feb-21,-0.18,-0.0234
11-Feb-21,Urovant Sciences Announces Progression of URO-902 Phase 2a Trial Following Positive Recommendation from the Data and Safety Monitoring Board,"Urovant Sciences (Nasdaq: UROV) announced today that the independent Data and Safety Monitoring Board (DSMB) has recommended the continuation of the phase 2a study of URO-902, a novel gene therapy pro...",16.17,16.24,16.17,16.21,UROV,131105,HISTORICAL_PRICES,UROV,,1.61309E+12,0.008104738,0.008104738,16.21,16.17,16.24,16.17,131105,16.21,16.17,16.24,16.17,131105,11-Feb-21,-0.02,-0.0012
11-Feb-21,Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Highlights Recent Period Activity,"Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today reported its consolidated financial results for the fourth quarter and full year ended December 31, 2020 and...",165.38,168.88,160.23,166.98,ALNY,617507,HISTORICAL_PRICES,ALNY,,1.61309E+12,0.202239023,0.202239023,166.98,165.38,168.88,160.23,617507,166.98,165.38,168.88,160.23,617507,11-Feb-21,1.22,0.0074
11-Feb-21,Clovis Oncology Presents Data in Advanced Prostate Cancer at ASCO 2021 Genitourinary Cancers Symposium Virtual Meeting,"Clovis Oncology, Inc. (NASDAQ: CLVS) today announced Rubraca data being presented at the American Society for Clinical Oncology (ASCO) Genitourinary Cancers Virtual Symposium 2021. These include data...",8.595,9.68,8.55,9.61,CLVS,11301849,HISTORICAL_PRICES,CLVS,,1.61309E+12,0.761270492,0.761270492,9.61,8.595,9.68,8.55,11301849,9.61,8.595,9.68,8.55,11301849,11-Feb-21,-0.945,-0.0991
11-Feb-21,Dicerna Initiates PHYOX™4 Trial of Nedosiran for Primary Hyperoxaluria Type 3,"Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced initiation of patie...",26.19,27.055,25.5,26.5,DRNA,522249,HISTORICAL_PRICES,DRNA,,1.61309E+12,0.117797695,0.117797695,26.5,26.19,27.055,25.5,522249,26.5,26.19,27.055,25.5,522249,11-Feb-21,0.31,0.012
11-Feb-21,"Infinity Pharmaceuticals Presents Data from Randomized, Placebo-Controlled, Phase 2 MARIO-275 Trial of Eganelisib and Nivolumab in Advanced Urothelial Cancer at ASCO Genitourinary Cancers Symposium","Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) (“Infinity” or the “Company”) today presented data from MARIO-275 (MAcrophage Reprogramming in Immune Oncology), a randomized, placebo-controlled Phase 2...",4.47,5.98,4.2122,4.8311,INFI,72383101,HISTORICAL_PRICES,INFI,,1.61309E+12,1.128571429,1.128571429,4.8311,4.47,5.98,4.2122,72383101,4.8311,4.47,5.98,4.2122,72383101,11-Feb-21,0.52,0.1316
11-Feb-21,Applied DNA and Cytocheck Detect First Instance of SARS-CoV-2 B.1.1.7 Variant in Kansas,"Applied DNA Sciences, Inc. (NASDAQ: APDN) (the “Company”), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing, and Cytocheck Laboratory, LLC (Cytocheck), an anatomic and clinical path...",12.57,13.64,11.34,12.2,APDN,3346936,HISTORICAL_PRICES,APDN,,1.61309E+12,1.319188192,1.319188192,12.2,12.57,13.64,11.34,3346936,12.2,12.57,13.64,11.34,3346936,11-Feb-21,0.34,0.0278
11-Feb-21,AVEO Oncology Announces Presentation of Key Subgroup and Quality of Life Analyses from the Phase 3 TIVO-3 Study of Tivozanib in Renal Cell Carcinoma,"AVEO Oncology (Nasdaq: AVEO) today announced the presentation of two analyses of the Company’s pivotal TIVO-3 study, its Phase 3 trial comparing tivozanib, AVEO’s next-generation vascular endothelial...",8.14,9.1,8.08,9.08,AVEO,654207,HISTORICAL_PRICES,AVEO,,1.61309E+12,0.389078498,0.389078498,9.08,8.14,9.1,8.08,654207,9.08,8.14,9.1,8.08,654207,11-Feb-21,-0.64,-0.0729
11-Feb-21,Intersect ENT Announces Launch of the New Straight Delivery System Packaged with the PROPEL® Mini Sinus Implant,"Intersect ENT®, Inc. (Nasdaq: XENT), a global ear, nose and throat (“ENT”) medical technology leader dedicated to transforming patient care, today announced the U.S. availability of the new Straight D...",24.52,24.655,23.945,24.31,XENT,124749,HISTORICAL_PRICES,XENT,,1.61309E+12,0.066086957,0.066086957,24.31,24.52,24.655,23.945,124749,24.31,24.52,24.655,23.945,124749,11-Feb-21,0.2,0.0082
11-Feb-21,AlloVir Reports Full Year 2020 Financial Results,"AlloVir (Nasdaq: ALVR), a late clinical-stage cell therapy company, today provided a corporate update and reported full-year 2020 financial results for the period ended December 31, 2020. “Since compl...",42.53,44.385,41.59,44.06,ALVR,228511,HISTORICAL_PRICES,ALVR,,1.61309E+12,0.051161641,0.051161641,44.06,42.53,44.385,41.59,228511,44.06,42.53,44.385,41.59,228511,11-Feb-21,-0.1,-0.0023
11-Feb-21,Labcorp Announces 2020 Fourth Quarter and Full Year Results and Provides 2021 Guidance,"Labcorp (NYSE: LH), a leading life sciences company, today announced results for the fourth quarter and year ended December 31, 2020, and full year 2021 guidance. “Labcorp’s science and innovation thr...",237.21,239.5,228.01,235,LH,1181171,HISTORICAL_PRICES,LH,,1.61309E+12,0.163535586,0.163535586,235,237.21,239.5,228.01,1181171,235,237.21,239.5,228.01,1181171,11-Feb-21,8.01,0.0349
11-Feb-21,"U.S. Physicians Can Now Order Lucira Health Self-Administered, Lab Quality, COVID-19 Molecular Test for Home or Office","Lucira Health, Inc. (Nasdaq: LHDX), today announced that U.S. physicians and healthcare providers can now order Lucira COVID-19 All-In-One Test Kits online from lucirahealth.com. This U.S. made and ma...",34.23,35.72,29.01,29.01,LHDX,574777,HISTORICAL_PRICES,LHDX,,1.61309E+12,0.370296237,0.370296237,29.01,34.23,35.72,29.01,574777,29.01,34.23,35.72,29.01,574777,11-Feb-21,3.01,0.0964
10-Feb-21,Kite Announces New ZUMA-1 Cohort Analysis Evaluating Prophylactic Corticosteroid Use With Yescarta® in Patients With Relapsed or Refractory Large B-cell lymphoma,"Kite, a Gilead Company (Nasdaq: GILD), today announced findings from a new analysis of the ZUMA-1 trial of Yescarta® (axicabtagene ciloleucel) in adult patients with relapsed or refractory large B-cel...",67.29,68.32,67.1,67.26,GILD,7667916,HISTORICAL_PRICES,GILD,,1.61552E+12,0.179078325,0.179078325,67.26,67.29,68.32,67.1,7667916,66.5031,66.5327,67.5511,66.3449,7667916,10-Feb-21,-0.01,-0.0001
10-Feb-21,IFF Reports Fourth Quarter and Full Year 2020 Results,"International Flavors & Fragrances Inc. (NYSE: IFF) reported financial results for the fourth quarter and full year ended December 31, 2020. Fourth Quarter 2020 Consolidated Summary: Reported (GAA...",135.57,141.52,128.13,128.14,IFF,8140073,HISTORICAL_PRICES,IFF,,1.61302E+12,0.231782664,0.231782664,128.14,135.57,141.52,128.13,8140073,128.14,135.57,141.52,128.13,8140073,10-Feb-21,7.62,0.0596
10-Feb-21,Zymeworks to Participate in Upcoming Investor Conferences and Events,"Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, announced today that management will participate in five upcoming virtual investor c...",40.98,42.5,40.24,41.28,ZYME,592609,HISTORICAL_PRICES,ZYME,,1.61302E+12,-0.182525434,-0.182525434,41.28,40.98,42.5,40.24,592609,41.28,40.98,42.5,40.24,592609,10-Feb-21,-0.1,-0.0024
10-Feb-21,Cortexyme Announces Leadership Appointments to Support Advancement of Atuzaginstat and Pipeline Expansion,"Cortexyme, Inc. (Nasdaq: CRTX), a company advancing a pivotal trial in Alzheimer's disease on schedule to be announced in Q4 2021 and a pipeline of therapeutics for degenerative diseases, today announ...",49.21,49.89,45.22,45.94,CRTX,270912,HISTORICAL_PRICES,CRTX,,1.61302E+12,0.696896552,0.696896552,45.94,49.21,49.89,45.22,270912,45.94,49.21,49.89,45.22,270912,10-Feb-21,3.11,0.0675
10-Feb-21,Exelixis Announces Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update,"Exelixis, Inc. (Nasdaq: EXEL) today reported financial results for the fourth quarter and full year 2020 and provided an update on progress toward achieving key corporate objectives, as well as commer...",23.03,23.53,22.8268,23.24,EXEL,1375825,HISTORICAL_PRICES,EXEL,,1.61302E+12,0.112023177,0.112023177,23.24,23.03,23.53,22.8268,1375825,23.24,23.03,23.53,22.8268,1375825,10-Feb-21,0.08,0.0035
10-Feb-21,Seagen and Genmab Submit Tisotumab Vedotin Biologics License Application to the U.S. FDA for Patients with Recurrent or Metastatic Cervical Cancer,Seagen Inc. (Nasdaq: SGEN) and Genmab A/S (Nasdaq: GMAB) today announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) seeking accelerated appr...,169.35,176.78,169.01,176.74,SGEN,1218917,HISTORICAL_PRICES,SGEN,,1.61302E+12,-0.111536646,-0.111536646,176.74,169.35,176.78,169.01,1218917,176.74,169.35,176.78,169.01,1218917,10-Feb-21,-6.38,-0.0363
10-Feb-21,TherapeuticsMD Announces Underwritten Public Offering of its Common Stock,"TherapeuticsMD, Inc. (NASDAQ:TXMD) today announced an underwritten public offering of its common stock. The Company has granted the underwriter a 30-day option to purchase up to an additional 15% of t...",2.17,2.65,2.1,2.5901,TXMD,45119140,HISTORICAL_PRICES,TXMD,,1.61302E+12,0.823529412,0.823529412,2.5901,2.17,2.65,2.1,45119140,2.5901,2.17,2.65,2.1,45119140,10-Feb-21,-0.38,-0.149
10-Feb-21,Huami Corp Invests $5 Million in Hyperfine Research D Round to Support Accelerated Application of Disruptive MRI Technology,"Huami Corp. (NYSE: HMI) today announced that it has invested $5 million in Hyperfine Research’s D round of funding, which closed on February 3, 2021. Huami’s mission is to connect health with technolo...",14.91,15.4999,14.85,15.1,HMI,478276,HISTORICAL_PRICES,HMI,,1.61302E+12,0.245614035,0.245614035,15.1,14.91,15.4999,14.85,478276,15.1,14.91,15.4999,14.85,478276,10-Feb-21,-0.11,-0.0073
10-Feb-21,AtriCure to Participate at the SVB Leerink 10th Annual Global Healthcare Conference,"AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that the company will be participat...",62.9,63.55,61.735,62.32,ATRC,246380,HISTORICAL_PRICES,ATRC,,1.61302E+12,0.092962641,0.092962641,62.32,62.9,63.55,61.735,246380,62.32,62.9,63.55,61.735,246380,10-Feb-21,0.75,0.0121
10-Feb-21,PolarityTE Provides Corporate Update,"PolarityTE, Inc. (Nasdaq: PTE), a biotechnology company developing and commercializing regenerative tissue products and biomaterials, is pleased to provide this update. Our focus is on building shareh...",1.64,1.65,1.11,1.58,PTE,16994937,HISTORICAL_PRICES,PTE,,1.61302E+12,1.342857143,1.342857143,1.58,1.64,1.65,1.11,16994937,1.58,1.64,1.65,1.11,16994937,10-Feb-21,0.1,0.0649
10-Feb-21,Turning Point Brands Announces Fourth Quarter and Full Year 2020 Results,"Turning Point Brands, Inc. (“TPB” or “the Company”) (NYSE: TPB), a manufacturer, marketer and distributor of branded consumer products including alternative smoking accessories and consumables with ac...",54.81,57.28,52.3798,55.95,TPB,297258,HISTORICAL_PRICES,TPB,,1.61603E+12,0.166170213,0.166170213,55.95,54.81,57.28,52.3798,297258,55.8909,54.7521,57.2195,52.3245,297258,10-Feb-21,-1.89,-0.0333
10-Feb-21,"Impel NeuroPharma Partners With Veeva Systems to Build Integrated, Digital-First Commercial Foundation",Impel NeuroPharma and Veeva Systems (NYSE: VEEV) today announced a strategic partnership as Impel continues advancing its pipeline of innovative medicines for central nervous system (CNS) diseases wit...,310.95,319.68,305.4601,306.42,VEEV,1031016,HISTORICAL_PRICES,VEEV,,1.61302E+12,0.081264344,0.081264344,306.42,310.95,319.68,305.4601,1031016,306.42,310.95,319.68,305.4601,1031016,10-Feb-21,6.51,0.0214
10-Feb-21,Gemini Therapeutics Completes Enrollment in Phase 2a Trial of GEM103 in Dry Age-Related Macular Degeneration (AMD) in Patients with High-Risk Genetic Variants,"Gemini Therapeutics, Inc. (Nasdaq: GMTX), a clinical stage precision medicine company developing innovative treatments for genetically defined age-related macular degeneration (AMD) and linked ocular...",12.79,13.38,12.03,13.38,GMTX,123103,HISTORICAL_PRICES,GMTX,,1.61302E+12,0.057024793,0.057024793,13.38,12.79,13.38,12.03,123103,13.38,12.79,13.38,12.03,123103,10-Feb-21,-0.1,-0.0078
9-Feb-21,Rhizen Pharmaceuticals AG宣布其合作資產Umbralisib (UKONIQ™)已獲得美國FDA加速核准，用於復發或難治MZL和FL成人患者,(美國商業資訊)--專注於腫瘤的臨床階段生物製藥公司Rhizen Pharmaceuticals今天宣布，美國FDA已加速核准其新型下一代PI3K-δ抑制劑Umbralisib用於治療下列疾病，該藥已授權給TG Therapeutics (NASDAQ:TGTX)： 先前已接受至少一種採用抗CD20方案的復發或難治邊緣區型淋巴瘤(MZL)成人患者，以及 先前已接受至少三線全身治療的復發或難治濾泡性...,51.47,53.0699,51.1,52.38,TGTX,1876043,HISTORICAL_PRICES,TGTX,,1.61293E+12,-0.035058118,-0.035058118,52.38,51.47,53.0699,51.1,1876043,52.38,51.47,53.0699,51.1,1876043,9-Feb-21,-0.96,-0.0183
9-Feb-21,Rhizen Pharmaceuticals AG宣布其合作资产Umbralisib (UKONIQ™)已获得美国FDA加速核准，用于复发或难治MZL和FL成人患者,(美国商业资讯)--专注于肿瘤的临床阶段生物制药公司Rhizen Pharmaceuticals今天宣布，美国FDA已加速核准其新型下一代PI3K-δ抑制剂Umbralisib用于治疗下列疾病，该药已授权给TG Therapeutics (NASDAQ:TGTX)： 先前已接受至少一种基于抗CD20方案的复发或难治边缘区淋巴瘤(MZL)成人患者，以及 先前已接受至少三线全身治疗的复发或难治滤泡性淋...,51.47,53.0699,51.1,52.38,TGTX,1876043,HISTORICAL_PRICES,TGTX,,1.61293E+12,-0.035058118,-0.035058118,52.38,51.47,53.0699,51.1,1876043,52.38,51.47,53.0699,51.1,1876043,9-Feb-21,-0.96,-0.0183
9-Feb-21,"AbCellera-Discovered Antibody, Bamlanivimab, Administered with Etesevimab Receives FDA Emergency Use Authorization for COVID-19","AbCellera (Nasdaq: ABCL) today announced that bamlanivimab (LY-CoV555) 700 mg, a human antibody discovered by AbCellera and developed with Eli Lilly and Company (Lilly), administered with a second Lil...",47,49.7,46.175,47.75,ABCL,973907,HISTORICAL_PRICES,ABCL,,1.61293E+12,0.10796794,0.10796794,47.75,47,49.7,46.175,973907,47.75,47,49.7,46.175,973907,9-Feb-21,1.97,0.0437
9-Feb-21,Moderna Announces COVID-19 Vaccine Supply Agreements with the Government of Taiwan for 5 Million Doses and the Government of Colombia for 10 Million Doses,"Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced two supply agreements for the COVID-19 Vaccine Moderna: one with the go...",179.52,187,177.27,186.21,MRNA,8403123,HISTORICAL_PRICES,MRNA,,1.61293E+12,0.4548991,0.4548991,186.21,179.52,187,177.27,8403123,186.21,179.52,187,177.27,8403123,9-Feb-21,-6.46,-0.0347
9-Feb-21,Gamida Cell Presents Efficacy and Safety Results of Phase 3 Study of Omidubicel in Patients with Hematologic Malignancies at the 2021 TCT Meetings of ASTCT and CIBMTR,"Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to cures for blood cancers and serious hematologic diseases, today announced the results of a Phase 3 clinical study of omid...",9.89,10.6,9.7,10.34,GMDA,4178607,HISTORICAL_PRICES,GMDA,,1.61293E+12,0.075,0.075,10.34,9.89,10.6,9.7,4178607,10.34,9.89,10.6,9.7,4178607,9-Feb-21,-0.24,-0.0237
9-Feb-21,Zymeworks Expands Commercial Team and Creates New R&D Role,"Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that James Priour, former Senior Vice President, Commercial, has bee...",41.08,43.3,40.5,41.53,ZYME,365861,HISTORICAL_PRICES,ZYME,,1.61293E+12,-0.18053062,-0.18053062,41.53,41.08,43.3,40.5,365861,41.53,41.08,43.3,40.5,365861,9-Feb-21,-0.46,-0.0111
9-Feb-21,Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4),"Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on February 4, 2021 the Compensation Committee of Puma’s Board of Directors approved the grant of inducement restri...",13.625,13.99,12.97,12.98,PBYI,609716,HISTORICAL_PRICES,PBYI,,1.61293E+12,0.192038495,0.192038495,12.98,13.625,13.99,12.97,609716,12.98,13.625,13.99,12.97,609716,9-Feb-21,0.695,0.0538
9-Feb-21,"Deciphera Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2020 Financial Results","Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) today announced financial results for the fourth quarter and year ended December 31, 2020, and provided a business update. “We made significant progress i...",48.32,49.86,47.88,49.28,DCPH,352120,HISTORICAL_PRICES,DCPH,,1.61293E+12,-0.179347826,-0.179347826,49.28,48.32,49.86,47.88,352120,49.28,48.32,49.86,47.88,352120,9-Feb-21,-1.18,-0.0238
9-Feb-21,Danimer Scientific Hires Innovative Packaging Expert Brad Rodgers as Vice President – Technology Development R&D,"Danimer Scientific (NYSE: DNMR), a leading developer and manufacturer of biodegradable materials, today announced that sustainable food and beverage packaging expert Brad Rodgers is joining the compan...",61.4,61.75,54.74,56.99,DNMR,1742721,HISTORICAL_PRICES,DNMR,,1.61293E+12,1.611654615,1.611654615,56.99,61.4,61.75,54.74,1742721,56.99,61.4,61.75,54.74,1742721,9-Feb-21,5.61,0.1006
9-Feb-21,Philip Morris International Appoints Business Innovator Bonin Bough to Its Board of Directors,"Philip Morris International Inc. (PMI) (NYSE: PM) today announced that its Board of Directors has appointed a new member, Mr. Bonin Bough, effective immediately. Bonin Bough, 43, an American businessm...",85.63,86.6983,85.57,86.19,PM,4205438,HISTORICAL_PRICES,PM,,1.61612E+12,0.037813598,0.037813598,86.19,85.63,86.6983,85.57,4205438,85.0479,84.4953,85.5495,84.4361,4205438,9-Feb-21,-0.36,-0.0042
9-Feb-21,Establishment Labs Hosts Investor Event for its Motiva MIA® System for Minimally Invasive Augmentation,"Establishment Labs Holdings Inc. (NASDAQ: ESTA), a medical technology company focused on women’s health, initially in the breast aesthetics and reconstruction market, is hosting a virtual investor eve...",65.19,65.47,57.43,57.43,ESTA,201558,HISTORICAL_PRICES,ESTA,,1.61293E+12,0.862571429,0.862571429,57.43,65.19,65.47,57.43,201558,57.43,65.19,65.47,57.43,201558,9-Feb-21,8.17,0.1433
9-Feb-21,Taysha Gene Therapies Announces Collaborations to Advance Next-Generation Mini-Gene Payloads for AAV Gene Therapies for the Treatment of Genetic Epilepsies and Additional CNS Disorders,"Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric, clinical-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic dis...",31.27,31.5799,29.8306,30.72,TSHA,59765,HISTORICAL_PRICES,TSHA,,1.61293E+12,0.149632353,0.149632353,30.72,31.27,31.5799,29.8306,59765,30.72,31.27,31.5799,29.8306,59765,9-Feb-21,0.28,0.009
9-Feb-21,"Incyte Reports 2020 Fourth Quarter and Year-End Financial Results, Provides 2021 Financial Guidance and Updates on Key Clinical Programs","Incyte (Nasdaq: INCY) today reports 2020 fourth quarter and full year financial results, and provides a status update on the Company’s development portfolio. “Our team achieved many important accompli...",89.46,94.5015,89.24,94.34,INCY,1360399,HISTORICAL_PRICES,INCY,,1.61293E+12,0.023921254,0.023921254,94.34,89.46,94.5015,89.24,1360399,94.34,89.46,94.5015,89.24,1360399,9-Feb-21,-4.16,-0.0444
8-Feb-21,Adjuvant Treatment with Opdivo (nivolumab) Demonstrates Statistically Significant and Clinically Meaningful Improvement in Disease-Free Survival in Patients with Muscle-Invasive Urothelial Carcinoma in Phase 3 CheckMate -274 Trial,"Bristol Myers Squibb (NYSE: BMY) today announced results from the Phase 3 CheckMate -274 trial, which showed that Opdivo (nivolumab) significantly improved disease-free survival (DFS) as an adjuvant t...",60.23,61.366,59.67,61.35,BMY,18864254,HISTORICAL_PRICES,BMY,,1.61284E+12,-0.015044971,-0.015044971,61.35,60.23,61.366,59.67,18864254,61.35,60.23,61.366,59.67,18864254,8-Feb-21,-0.69,-0.0113
8-Feb-21,OPDIVO® (nivolumab) in Combination with CABOMETYX® (cabozantinib) Shows Sustained Survival and Response Rate Benefits as First-Line Treatment for Patients with Advanced Renal Cell Carcinoma in the Phase 3 CheckMate -9ER Trial,"Bristol Myers Squibb (NYSE: BMY) and Exelixis, Inc. (NASDAQ: EXEL) today announced results from new analyses from the pivotal Phase 3 CheckMate -9ER trial, demonstrating clinically meaningful, sustain...",60.23,61.366,59.67,61.35,BMY,18864254,HISTORICAL_PRICES,BMY,,1.61284E+12,-0.015044971,-0.015044971,61.35,60.23,61.366,59.67,18864254,61.35,60.23,61.366,59.67,18864254,8-Feb-21,-0.69,-0.0113
8-Feb-21,Exelixis Announces Positive Findings at ASCO GU for CABOMETYX® (cabozantinib) in Patients with Brain Metastases from Renal Cell Carcinoma,"Exelixis, Inc. (NASDAQ: EXEL) today announced results from a retrospective analysis evaluating CABOMETYX® (cabozantinib) activity in brain metastases in patients with renal cell carcinoma (RCC). The f...",23.81,23.97,23.16,23.52,EXEL,1695926,HISTORICAL_PRICES,EXEL,,1.61284E+12,0.149686142,0.149686142,23.52,23.81,23.97,23.16,1695926,23.52,23.81,23.97,23.16,1695926,8-Feb-21,0.64,0.0276
8-Feb-21,"First Patient in Europe Treated With Cardiovascular Systems, Inc. Diamondback 360® Coronary Orbital Atherectomy System","Cardiovascular Systems, Inc. (CSI®) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery...",42.73,42.9,41.5842,42.11,CSII,262624,HISTORICAL_PRICES,CSII,,1.61284E+12,-0.030845997,-0.030845997,42.11,42.73,42.9,41.5842,262624,42.11,42.73,42.9,41.5842,262624,8-Feb-21,1.23,0.0296
8-Feb-21,Ironwood Pharmaceuticals Announces CEO Transition,"Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a GI-focused healthcare company, today announced that Mark Mallon plans to step down as chief executive officer and a member of the Ironwood Board of Dir...",10.66,10.695,10.24,10.31,IRWD,1239179,HISTORICAL_PRICES,IRWD,,1.61284E+12,-0.090443686,-0.090443686,10.31,10.66,10.695,10.24,1239179,10.31,10.66,10.695,10.24,1239179,8-Feb-21,0.35,0.0339
8-Feb-21,Genprex Announces Formation of Clinical Advisory Board,"Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced th...",7.67,7.72,6.323,6.43,GNPX,3563051,HISTORICAL_PRICES,GNPX,,1.61284E+12,0.635394456,0.635394456,6.43,7.67,7.72,6.323,3563051,6.43,7.67,7.72,6.323,3563051,8-Feb-21,1.42,0.2272
8-Feb-21,ProvideGx® Partners with Apotex Corp. to Stabilize Supply of Three Vital Antibiotics,"Premier Inc. (NASDAQ: PINC), through its ProvideGx® program, has partnered with Apotex Corp. to supply three essential antibiotics to healthcare providers, helping to secure the immediate and long-ter...",35.25,35.39,34.86,35.39,PINC,426768,HISTORICAL_PRICES,PINC,,1.61439E+12,-0.009553245,-0.009553245,35.39,35.25,35.39,34.86,426768,35.1934,35.0542,35.1934,34.6663,426768,8-Feb-21,0.07,0.002
8-Feb-21,Kite Appoints Frank Neumann as Worldwide Head of Clinical Development,"Kite, a Gilead Company (Nasdaq: GILD), today announced that Frank Neumann, MD, PhD, has joined the company as Senior Vice President and Global Head of Clinical Development. Dr. Neumann will lead Kite’...",67.97,68.76,67.31,68.5,GILD,9599196,HISTORICAL_PRICES,GILD,,1.61552E+12,0.190993517,0.190993517,68.5,67.97,68.76,67.31,9599196,67.7291,67.2051,67.9862,66.5525,9599196,8-Feb-21,-0.49,-0.0072
8-Feb-21,AVROBIO Announces 100% Kidney Substrate Reduction at 12 Months Post-Gene Therapy in First Patient Dosed with plato® Gene Therapy Platform in Fabry Disease Phase 2 Trial,"AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced a 100% reduction, or complete clearance, o...",19.3,20.07,17.63,20,AVRO,1498411,HISTORICAL_PRICES,AVRO,,1.61284E+12,0.314713896,0.314713896,20,19.3,20.07,17.63,1498411,20,19.3,20.07,17.63,1498411,8-Feb-21,2.19,0.128
8-Feb-21,"全球投資人法律顧問ROSEN鼓勵蒙受損失超過10萬美元的Voyager Therapeutics, Inc.投資人在VYGR訴訟的重要截止日期前聘請律師","(美國商業資訊)--原因：全球投資人權益法律事務所Rosen Law Firm提醒在2017年6月1日至2020年11月9日期間（含上述日期，簡稱「集體訴訟期」）購買Voyager Therapeutics, Inc. (NASDAQ: VYGR)證券的人士牢記，原告代表的截止日期為2021年3月24日。 這意味著什麼：在集體訴訟期購買了Voyager證券的人士可能有資格獲得賠償，而且可以透過勝訴...",7.7,7.84,7.36,7.55,VYGR,544711,HISTORICAL_PRICES,VYGR,,1.61284E+12,-0.035087719,-0.035087719,7.55,7.7,7.84,7.36,544711,7.55,7.7,7.84,7.36,544711,8-Feb-21,0.25,0.0336
8-Feb-21,"全球投资者法律顾问公司ROSEN鼓励蒙受损失超过10万美元的Voyager Therapeutics, Inc.投资者在VYGR诉讼的重要截止日期前聘请律师","(美国商业资讯)--原因：全球投资者权益律师事务所Rosen Law Firm提醒在2017年6月1日至2020年11月9日期间（含上述日期，简称“集体诉讼期”）购买Voyager Therapeutics, Inc. (NASDAQ: VYGR)证券的人士牢记，首席原告的截止日期为2021年3月24日。 这意味着什么：在集体诉讼期购买了Voyager证券的人士可能有资格获得赔偿，而且可以通过风险...",7.7,7.84,7.36,7.55,VYGR,544711,HISTORICAL_PRICES,VYGR,,1.61284E+12,-0.035087719,-0.035087719,7.55,7.7,7.84,7.36,544711,7.55,7.7,7.84,7.36,544711,8-Feb-21,0.25,0.0336
5-Feb-21,"U.S. Food and Drug Administration Approves Bristol Myers Squibb’s Breyanzi (lisocabtagene maraleucel), a New CAR T Cell Therapy for Adults with Relapsed or Refractory Large B-cell Lymphoma","Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) has approved Breyanzi (lisocabtagene maraleucel; liso-cel), a CD19-directed chimeric antigen receptor...",60.92,61.7663,60.505,61.06,BMY,16249169,HISTORICAL_PRICES,BMY,,1.61258E+12,-0.003761243,-0.003761243,61.06,60.92,61.7663,60.505,16249169,61.06,60.92,61.7663,60.505,16249169,5-Feb-21,-0.64,-0.0104
5-Feb-21,ADC Therapeutics bestätigt Teilnahme an Guggenheim Healthcare Talks 2021: Oncology Day,"ADC Therapeutics SA (NYSE:ADCT), ein auf Onkologie spezialisiertes Biotechnologieunternehmen und Pionier bei der Entwicklung und Vermarktung hochwirksamer und zielgerichteter Antikörper-Wirkstoff-Konj...",30.3,30.535,29.25,29.68,ADCT,157974,HISTORICAL_PRICES,ADCT,,1.61258E+12,-0.180859692,-0.180859692,29.68,30.3,30.535,29.25,157974,29.68,30.3,30.535,29.25,157974,5-Feb-21,1.18,0.0405
5-Feb-21,Pfizer Confirms U.S. Patent Term Extension for IBRANCE® (palbociclib) Until March 2027,Pfizer Inc. (NYSE: PFE) today announced that the U.S. Patent and Trademark Office (USPTO) recently issued a U.S. Patent Term Extension (PTE) certificate for IBRANCE® (palbociclib). The certificate ext...,34.92,35.08,34.78,34.92,PFE,31749594,HISTORICAL_PRICES,PFE,,1.61258E+12,-0.063053394,-0.063053394,34.92,34.92,35.08,34.78,31749594,34.92,34.92,35.08,34.78,31749594,5-Feb-21,0.03,0.0009
5-Feb-21,重要通知：备受尊敬的顶尖律所ROSEN鼓励蒙受重大损失的Tricida Inc.投资者在TCDA诉讼的重要截止日期之前聘请律师,"(美国商业资讯)--原因：全球投资者权益律师事务所Rosen Law Firm提醒在2019年9月4日至2020年10月28日期间（含上述日期，简称“集体诉讼期”）购买Tricida, Inc. (NASDAQ: TCDA)证券的人士牢记，首席原告的截止日期为2021年3月8日。 这意味着什么：在集体诉讼期购买了Tricida证券的人士可能有资格获得赔偿，而且可以通过风险代理费安排，免去任何自付费...",7.16,7.37,7.04,7.29,TCDA,753097,HISTORICAL_PRICES,TCDA,,1.61258E+12,-0.074935401,-0.074935401,7.29,7.16,7.37,7.04,753097,7.29,7.16,7.37,7.04,753097,5-Feb-21,0.04,0.0056
5-Feb-21,重要通知：備受尊敬的頂尖法律事務所ROSEN鼓勵蒙受重大損失的Tricida Inc.投資人在TCDA訴訟的重要截止日期之前聘請律師,"(美國商業資訊)--原因：全球投資人權益法律事務所Rosen Law Firm提醒在2019年9月4日至2020年10月28日期間（含上述日期，簡稱「集體訴訟期」）購買Tricida, Inc. (NASDAQ: TCDA)證券的人士牢記，原告代表的截止日期為2021年3月8日。 這意味著什麼：在集體訴訟期購買了Tricida證券的人士可能有資格獲得賠償，而且可以透過勝訴分成安排，免去任何自付費用...",7.16,7.37,7.04,7.29,TCDA,753097,HISTORICAL_PRICES,TCDA,,1.61258E+12,-0.074935401,-0.074935401,7.29,7.16,7.37,7.04,753097,7.29,7.16,7.37,7.04,753097,5-Feb-21,0.04,0.0056
4-Feb-21,Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4),"Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today...",18.93,19.23,18.41,18.83,OCUL,539992,HISTORICAL_PRICES,OCUL,,1.61249E+12,-0.142663043,-0.142663043,18.83,18.93,19.23,18.41,539992,18.83,18.93,19.23,18.41,539992,4-Feb-21,0.2,0.0107
4-Feb-21,ADC Therapeutics schließt Patientenrekrutierung für zulassungsrelevante klinische Phase-2-Studie mit Camidanlumab-Tesirin (Cami) bei rezidiviertem oder refraktärem Hodgkin-Lymphom ab,"ADC Therapeutics SA (NYSE:ADCT), ein auf Onkologie spezialisiertes Biotechnologieunternehmen und Pionier bei der Entwicklung und Vermarktung hochwirksamer und zielgerichteter Antikörper-Wirkstoff-Konj...",29.12,29.47,27.085,28.21,ADCT,699317,HISTORICAL_PRICES,ADCT,,1.61249E+12,-0.212760205,-0.212760205,28.21,29.12,29.47,27.085,699317,28.21,29.12,29.47,27.085,699317,4-Feb-21,1.62,0.0589
4-Feb-21,"NERV Deadline Alert: Bronstein, Gewirtz & Grossman, LLC Reminds Minerva Neurosciences, Inc. Shareholders With Losses Exceeding $50K of Class Action and Lead Plaintiff Deadline: February 8, 2021","Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Minerva Neurosciences, Inc. (""Minerva"" or ""the Company"") (NASDAQ: NERV) and certain of its o...",3.43,3.47,3.31,3.43,NERV,503993,HISTORICAL_PRICES,NERV,,1.61249E+12,0.394308943,0.394308943,3.43,3.43,3.47,3.31,503993,3.43,3.43,3.47,3.31,503993,4-Feb-21,0.05,0.0148
4-Feb-21,Genprex Recognizes World Cancer Day,"Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, announces today th...",6.19,6.86,5.72,6.83,GNPX,5198530,HISTORICAL_PRICES,GNPX,,1.61249E+12,0.319829424,0.319829424,6.83,6.19,6.86,5.72,5198530,6.83,6.19,6.86,5.72,5198530,4-Feb-21,0.56,0.0995
4-Feb-21,Cerus Corporation to Participate in Upcoming Virtual Investor Conferences,"Cerus Corporation (Nasdaq: CERS) announced today that William ‘Obi’ Greenman, Cerus’ president and chief executive officer, and Kevin D. Green, Cerus’ chief financial officer, are scheduled to partici...",7.5,7.62,7.22,7.32,CERS,1614442,HISTORICAL_PRICES,CERS,,1.61249E+12,-0.07063197,-0.07063197,7.32,7.5,7.62,7.22,1614442,7.32,7.5,7.62,7.22,1614442,4-Feb-21,0.25,0.0345
4-Feb-21,Clovis Oncology to Highlight Data at ASCO 2021 Genitourinary Cancers Symposium Virtual Meeting,"Clovis Oncology, Inc. (NASDAQ: CLVS) announced today that two abstracts featuring data from clinical studies evaluating Rubraca® (rucaparib) in metastatic castration-resistant prostate cancer (mCRPC)...",7.99,8.292,7.87,8.25,CLVS,6233949,HISTORICAL_PRICES,CLVS,,1.61249E+12,0.637295082,0.637295082,8.25,7.99,8.292,7.87,6233949,8.25,7.99,8.292,7.87,6233949,4-Feb-21,-0.17,-0.0208
4-Feb-21,Alexion Reports Fourth Quarter and Full Year 2020 Results,"Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced financial results for the fourth quarter and full year of 2020. Total revenues for the full year of 2020 were $6,069.9 million, a 22 percent...",155.59,156.2766,155.1,155.35,ALXN,4270619,HISTORICAL_PRICES,ALXN,,1.61249E+12,0.019393304,0.019393304,155.35,155.59,156.2766,155.1,4270619,155.35,155.59,156.2766,155.1,4270619,4-Feb-21,0.85,0.0055
4-Feb-21,Baxter Reports Fourth-Quarter and Full-Year 2020 Results,"Baxter International Inc. (NYSE:BAX), a leading global medical products company, today reported results for the fourth quarter and full year ended December 31, 2020, and provided its financial guidanc...",77.18,80.49,76.56,76.68,BAX,3495813,HISTORICAL_PRICES,BAX,,1.61422E+12,-0.030280186,-0.030280186,76.68,77.18,80.49,76.56,3495813,76.4407,76.9392,80.2388,76.3211,3495813,4-Feb-21,-0.11,-0.0014
4-Feb-21,"Deciphera Pharmaceuticals, Inc. to Present at the Guggenheim Healthcare Talks 2021 Idea Forum Oncology Day","Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) today announced that Steve Hoerter, President and Chief Executive Officer, will participate in a fireside chat at the Guggenheim Healthcare Talks 2021 Id...",51.66,51.86,47.65,48.39,DCPH,528906,HISTORICAL_PRICES,DCPH,,1.61249E+12,-0.122622283,-0.122622283,48.39,51.66,51.86,47.65,528906,48.39,51.66,51.86,47.65,528906,4-Feb-21,4.25,0.0896
4-Feb-21,Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2020,"Bristol Myers Squibb (NYSE:BMY) today reports results for the fourth quarter and full year of 2020, which reflect robust sales, strong operating performance and advancement of the company’s product pi...",61.56,62.89,61.24,62,BMY,15997011,HISTORICAL_PRICES,BMY,,1.61249E+12,0.006704824,0.006704824,62,61.56,62.89,61.24,15997011,62,61.56,62.89,61.24,15997011,4-Feb-21,-0.47,-0.0076
4-Feb-21,Merck Announces Fourth-Quarter and Full-Year 2020 Financial Results,"Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced financial results for the fourth quarter and full year of 2020. “Despite extraordinary challenges brought on by th...",76.03,77.01,75.54,76.97,MRK,18003423,HISTORICAL_PRICES,MRK,,1.61552E+12,-0.051285251,-0.051285251,76.97,76.03,77.01,75.54,18003423,76.2996,75.3678,76.3393,74.8821,18003423,4-Feb-21,-1.29,-0.0167
3-Feb-21,PolarityTE Receives Allowance for Additional U.S. Patent,"PolarityTE, Inc. (Nasdaq: PTE) is pleased to report the U.S. Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. Application No. 16/165,169 filed on October 19, 2018. This is...",1.235,1.32,1.05,1.12,PTE,28782662,HISTORICAL_PRICES,PTE,,1.6124E+12,0.764285714,0.764285714,1.12,1.235,1.32,1.05,28782662,1.12,1.235,1.32,1.05,28782662,3-Feb-21,0.195,0.1875
3-Feb-21,Quidel Opens New Manufacturing Facility to Mass Produce QuickVue® Rapid Antigen Tests for COVID-19,"Quidel Corporation (NASDAQ: QDEL) (“Quidel”), a leading provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, today announced the opening of...",236.85,238.19,230.84,236,QDEL,373565,HISTORICAL_PRICES,QDEL,,1.6124E+12,0.19930123,0.19930123,236,236.85,238.19,230.84,373565,236,236.85,238.19,230.84,373565,3-Feb-21,3.02,0.0129
3-Feb-21,"Cardiovascular Systems, Inc. Reports Fiscal 2021 Second-quarter Financial Results","Cardiovascular Systems, Inc. (CSI®) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery...",43.07,44.03,41.9,43.81,CSII,336106,HISTORICAL_PRICES,CSII,,1.6124E+12,-0.023134498,-0.023134498,43.81,43.07,44.03,41.9,336106,43.81,43.07,44.03,41.9,336106,3-Feb-21,-0.04,-0.0009
3-Feb-21,"Turning Point Brands Announces Pricing of $250,000,000 of 5.625% Senior Secured Notes due 2026","Turning Point Brands, Inc. (“TPB” or the “Company”) (NYSE: TPB), a manufacturer, marketer and distributor of branded consumer products, today announced that is has priced its previously announced priv...",51.96,53.44,50.89,51.79,TPB,183304,HISTORICAL_PRICES,TPB,,1.61603E+12,0.105531915,0.105531915,51.79,51.96,53.44,50.89,183304,51.7353,51.9051,53.3835,50.8362,183304,3-Feb-21,1.35,0.0267
3-Feb-21,"VYGR Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Notifies Voyager Therapeutics, Inc. Shareholders of Class Action and Encourages Shareholders to Contact the Firm","Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Voyager Therapeutics, Inc. (""Voyager"" or ""the Company"") (NASDAQ: VYGR) and certain of its o...",7.49,7.54,6.75,7,VYGR,1545444,HISTORICAL_PRICES,VYGR,,1.6124E+12,-0.061403509,-0.061403509,7,7.49,7.54,6.75,1545444,7,7.49,7.54,6.75,1545444,3-Feb-21,-0.51,-0.0637
3-Feb-21,Singapore Health Sciences Authority (HSA) Approves Interim Authorization of COVID-19 Vaccine Moderna For Use,"Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that the Singapore Health Sciences Authority (HSA) has approved the int...",165.86,168.39,156.4,156.6,MRNA,11355915,HISTORICAL_PRICES,MRNA,,1.6124E+12,0.344193209,0.344193209,156.6,165.86,168.39,156.4,11355915,156.6,165.86,168.39,156.4,11355915,3-Feb-21,7.28,0.0459
3-Feb-21,Pulse Biosciences Announces FDA Clearance for the CellFX® System,"Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company progressing Nano-Pulse Stimulation™ (NPS™) technology, today announced U.S. Food and Drug Administration (FDA) clearance of...",36.62,37.45,32.75,35.67,PLSE,422899,HISTORICAL_PRICES,PLSE,,1.6124E+12,0.732261116,0.732261116,35.67,36.62,37.45,32.75,422899,35.67,36.62,37.45,32.75,422899,3-Feb-21,2.42,0.0708
3-Feb-21,Moderna Announces Amendment to Supply Agreement with Switzerland for an Additional 6 Million Doses of COVID-19 Vaccine Moderna,"Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced the Swiss Federal Government has increased its confirmed order commitme...",165.86,168.39,156.4,156.6,MRNA,11355915,HISTORICAL_PRICES,MRNA,,1.6124E+12,0.344193209,0.344193209,156.6,165.86,168.39,156.4,11355915,156.6,165.86,168.39,156.4,11355915,3-Feb-21,7.28,0.0459
3-Feb-21,"Establishment Labs Announces Participation in the BTIG Virtual MedTech, Digital Health, Life Science and Diagnostic Tools Conference","Establishment Labs Holdings Inc. (NASDAQ: ESTA), a medical technology company focused on women’s health, initially in the breast aesthetics and reconstruction market, today announced that CEO and Foun...",51.64,52,50,52,ESTA,31528,HISTORICAL_PRICES,ESTA,,1.6124E+12,0.475428571,0.475428571,52,51.64,52,50,31528,52,51.64,52,50,31528,3-Feb-21,-0.02,-0.0004
3-Feb-21,Ligand Reports Fourth Quarter and Full Year 2020 Financial Results,"Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today reported financial results for the three and 12 months ended December 31, 2020 and provided an operating forecast and program updates. Ligand m...",177.5,189.4332,165.3944,180.41,LGND,888172,HISTORICAL_PRICES,LGND,,1.6124E+12,0.673738802,0.673738802,180.41,177.5,189.4332,165.3944,888172,180.41,177.5,189.4332,165.3944,888172,3-Feb-21,0.42,0.0024
2-Feb-21,Transcat Reports Third Quarter Operating Income Increase of 20% on Solid Service Organic Growth and Gross Margin Expansion,"Transcat, Inc. (Nasdaq: TRNS) (“Transcat” or the “Company”), a leading provider of accredited calibration, repair, inspection and laboratory instrument services and value-added distributor of professi...",37.81,37.81,36.82,37.41,TRNS,22810,HISTORICAL_PRICES,TRNS,,1.61232E+12,0.144716924,0.144716924,37.41,37.81,37.81,36.82,22810,37.41,37.81,37.81,36.82,22810,2-Feb-21,0.31,0.0083
2-Feb-21,Ligand Partner Travere Therapeutics Announces Achievement of Interim Proteinuria Endpoint in the Ongoing Phase 3 DUPLEX Study of Sparsentan in Focal Segmental Glomerulosclerosis,"Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) partner Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that their ongoing pivotal Phase 3 DUPLEX Study of sparsentan in focal segmental gl...",177.08,179,168.08,172.42,LGND,1363572,HISTORICAL_PRICES,LGND,,1.61232E+12,0.669778406,0.669778406,172.42,177.08,179,168.08,1363572,172.42,177.08,179,168.08,1363572,2-Feb-21,-2.95,-0.0164
2-Feb-21,Applied DNA Achieves Program Milestone in Development of Linear DNA Veterinary COVID-19 Vaccine,"Applied DNA Sciences, Inc. (NASDAQ: APDN) (the “Company”), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing, today announced that it has qualified a freeze-dried (lyophilized) form...",11.1,12.2775,10.95,12.15,APDN,980190,HISTORICAL_PRICES,APDN,,1.61232E+12,1.04797048,1.04797048,12.15,11.1,12.2775,10.95,980190,12.15,11.1,12.2775,10.95,980190,2-Feb-21,-0.82,-0.0688
2-Feb-21,Arena Pharmaceuticals Completes Full Enrollment of Etrasimod Phase 3 ELEVATE UC 52 Trial,"Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that it has completed full enrollment of the Phase 3 ELEVATE UC 52 trial evaluating the safety and efficacy of etrasimod, a highly selective,...",79.34,80.01,77.52,77.88,ARNA,577012,HISTORICAL_PRICES,ARNA,,1.61232E+12,0.016137295,0.016137295,77.88,79.34,80.01,77.52,577012,77.88,79.34,80.01,77.52,577012,2-Feb-21,2.35,0.0305
2-Feb-21,Masimo Expands Suite of Advanced Measurements Through Acquisition of UK-Based LiDCO Group Plc,"Masimo (NASDAQ: MASI) today announced that it has successfully completed the acquisition of the LiDCO Group Plc, a leading provider of advanced hemodynamic monitoring solutions (LiDCO). The Company co...",264.06,267.7628,263.17,265.3,MASI,251928,HISTORICAL_PRICES,MASI,,1.61232E+12,-0.007069264,-0.007069264,265.3,264.06,267.7628,263.17,251928,265.3,264.06,267.7628,263.17,251928,2-Feb-21,4.58,0.0177
2-Feb-21,AtriCure to Announce Fourth Quarter and Full Year 2020 Financial Results,"AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it will release its fourth quarter and...",60.73,60.96,59.465,59.61,ATRC,434077,HISTORICAL_PRICES,ATRC,,1.61232E+12,0.055256299,0.055256299,59.61,60.73,60.96,59.465,434077,59.61,60.73,60.96,59.465,434077,2-Feb-21,1.76,0.0298
2-Feb-21,VBI Vaccines Announces U.S. FDA Acceptance of BLA Filing for VBI’s 3-Antigen Prophylactic Hepatitis B Vaccine,"VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced that the U.S. Food and...",3.82,4.04,3.5,3.9171,VBIV,16184995,HISTORICAL_PRICES,VBIV,,1.61232E+12,0.224358974,0.224358974,3.9171,3.82,4.04,3.5,16184995,3.9171,3.82,4.04,3.5,16184995,2-Feb-21,-0.14,-0.0354
2-Feb-21,"Deciphera Pharmaceuticals to Announce Fourth Quarter and Full Year 2020 Financial Results and Host Conference Call and Webcast on February 9, 2021","Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) today announced that it will report its fourth quarter and full year 2020 financial results on Tuesday, February 9, 2021. In connection with the earnings...",49.28,49.43,46.3,46.57,DCPH,506183,HISTORICAL_PRICES,DCPH,,1.61232E+12,-0.163043478,-0.163043478,46.57,49.28,49.43,46.3,506183,46.57,49.28,49.43,46.3,506183,2-Feb-21,3.42,0.0746
2-Feb-21,"Eagle Pharmaceuticals Receives Additional FDA Questions Regarding Vasopressin; Court Date Set for July 7, 2021 in Vasopressin Trial","Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that the U.S. Food and Drug Administration (“FDA”) has issued a complete response letter (“CRL”) for its Abbreviat...",49.32,50.895,46.8,47.21,EGRX,232877,HISTORICAL_PRICES,EGRX,,1.61232E+12,0.067763585,0.067763585,47.21,49.32,50.895,46.8,232877,47.21,49.32,50.895,46.8,232877,2-Feb-21,0.83,0.0171
1-Feb-21,Adamas Announces FDA Approval for Second Indication for GOCOVRI® as an Adjunctive Treatment to levodopa/carbidopa in Parkinson’s Disease Patients Experiencing OFF Episodes,"Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced i...",6.79,9.15,6.25,6.665,ADMS,7081863,HISTORICAL_PRICES,ADMS,,1.61224E+12,0.482532751,0.482532751,6.665,6.79,9.15,6.25,7081863,6.665,6.79,9.15,6.25,7081863,1-Feb-21,0.88,0.1489
1-Feb-21,Genprex Issues Shareholder Letter and Provides Corporate Update,"Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, announced today th...",4.84,5.21,4.37,4.6,GNPX,3260016,HISTORICAL_PRICES,GNPX,,1.61224E+12,0.031982942,0.031982942,4.6,4.84,5.21,4.37,3260016,4.6,4.84,5.21,4.37,3260016,1-Feb-21,0.37,0.0828
1-Feb-21,Philip Morris International Inc. to Host Webcast of 2021 Virtual Investor Day,Philip Morris International Inc. (NYSE: PM) will host a live video webcast of presentations and Q&A session by senior management at its 2021 Investor Day at www.pmi.com/2021InvestorDay on Wednesda...,79.06,79.73,78.34,79,PM,6209814,HISTORICAL_PRICES,PM,,1.61612E+12,-0.041813114,-0.041813114,79,79.06,79.73,78.34,6209814,77.9532,78.0124,78.6735,77.3019,6209814,1-Feb-21,-0.59,-0.0074
1-Feb-21,Auf der STS-Jahrestagung vorgestellte umfangreiche klinische Studie zeigt Überlebensrate von 79 % bei Behandlung mit Impella 5.5 mit SmartAssist Herzpumpe,"Abiomed (NASDAQ: ABMD) hat die Ergebnisse aus einer umfangreichen klinischen Studie mit 356 Patienten vorgestellt, die an 16 US-amerikanischen und deutschen Zentren mit der Impella 5.5 mit SmartAssist...",341.86,353.075,341.67,345.64,ABMD,304629,HISTORICAL_PRICES,ABMD,,1.61224E+12,0.126726212,0.126726212,345.64,341.86,353.075,341.67,304629,345.64,341.86,353.075,341.67,304629,1-Feb-21,-6.39,-0.0183
1-Feb-21,Mirum Pharmaceuticals Announces Completion of Rolling NDA Submission for Maralixibat in Alagille Syndrome,"Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced it has completed submission of its rolling New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for maralixibat for the...",18.97,19.16,18.16,18.21,MIRM,80925,HISTORICAL_PRICES,MIRM,,1.61224E+12,0.039452055,0.039452055,18.21,18.97,19.16,18.16,80925,18.21,18.97,19.16,18.16,80925,1-Feb-21,0.85,0.0469
1-Feb-21,Altria Announces Cash Tender Offers for Certain Outstanding Notes,"Altria Group, Inc. (“Altria”) (NYSE: MO) today announced that it is commencing cash tender offers for certain of its outstanding senior unsecured notes. Concurrently, Altria is commencing an underwrit...",40.77,41.36,40.46,41.08,MO,9605977,HISTORICAL_PRICES,MO,,1.61655E+12,-0.022770853,-0.022770853,41.08,40.77,41.36,40.46,9605977,40.3806,40.0758,40.6558,39.7711,9605977,1-Feb-21,-0.31,-0.0075
1-Feb-21,Adamas Announces Settlement of Patent Litigation with Zydus,"Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a clinically meaningful difference to people affected by neurological diseases, today...",6.79,9.15,6.25,6.665,ADMS,7081863,HISTORICAL_PRICES,ADMS,,1.61224E+12,0.482532751,0.482532751,6.665,6.79,9.15,6.25,7081863,6.665,6.79,9.15,6.25,7081863,1-Feb-21,0.88,0.1489
1-Feb-21,Sesen Bio Announces Successful Application Orientation Meeting (AOM) with the FDA for Vicineum™,"Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today reported that on January 29, 2021 the Company p...",1.75,1.8111,1.72,1.75,SESN,3345230,HISTORICAL_PRICES,SESN,,1.61224E+12,0.388888889,0.388888889,1.75,1.75,1.8111,1.72,3345230,1.75,1.75,1.8111,1.72,3345230,1-Feb-21,0.04,0.0234
1-Feb-21,Turning Point Brands Announces Preliminary Fourth Quarter 2020 and Full Year 2020 Results,"Turning Point Brands, Inc. (“TPB”) (NYSE: TPB), a manufacturer, marketer and distributor of branded consumer products, today announced certain preliminary operating results for the fourth quarter and...",51.62,52.31,46.82,48.91,TPB,455449,HISTORICAL_PRICES,TPB,,1.61603E+12,0.098297872,0.098297872,48.91,51.62,52.31,46.82,455449,48.8583,51.5655,52.2547,46.7705,455449,1-Feb-21,4.52,0.096
1-Feb-21,Turning Point Brands Announces Proposed Private Offering of its Senior Secured Notes due 2026,"Turning Point Brands, Inc. (“TPB”) (NYSE: TPB), a manufacturer, marketer and distributor of branded consumer products, today announced the proposed private offering (the “Offering”) of $250 million ag...",51.62,52.31,46.82,48.91,TPB,455449,HISTORICAL_PRICES,TPB,,1.61603E+12,0.098297872,0.098297872,48.91,51.62,52.31,46.82,455449,48.8583,51.5655,52.2547,46.7705,455449,1-Feb-21,4.52,0.096
1-Feb-21,Legend Biotech Announces BCMA CAR-T Therapy Cilta-cel Accepted for Accelerated Assessment in Europe for the Treatment of Relapsed and/or Refractory Multiple Myeloma,"Legend Biotech Corporation (NASDAQ: LEGN) (“Legend Biotech”), a global clinical-stage biopharmaceutical company engaged in the discovery and development of novel cell therapies for oncology and other...",27.21,27.74,26,26.22,LEGN,470033,HISTORICAL_PRICES,LEGN,,1.61224E+12,-0.078564172,-0.078564172,26.22,27.21,27.74,26,470033,26.22,27.21,27.74,26,470033,1-Feb-21,1.94,0.0768
1-Feb-21,"Cardiovascular Systems, Inc. Announces Partnership With Chansu Vascular Techologies, LLC to Develop New Drug-Coated Balloon Technology","Cardiovascular Systems, Inc. (CSI®) (NASDAQ: CSII) announced today that it has partnered with Chansu Vascular Technologies, LLC (CVT) to develop novel peripheral and coronary everolimus drug-coated ba...",43.56,45.85,42.85,45.52,CSII,293066,HISTORICAL_PRICES,CSII,,1.61224E+12,-0.012020866,-0.012020866,45.52,43.56,45.85,42.85,293066,45.52,43.56,45.85,42.85,293066,1-Feb-21,-1.43,-0.0318
1-Feb-21,"Horizon Therapeutics plc to Acquire Viela Bio, Inc. to Significantly Expand Development Pipeline and Grow Rare Disease Medicine Portfolio","Horizon Therapeutics plc (Nasdaq: HZNP) and Viela Bio, Inc. (Nasdaq: VIE) today announced the companies have entered into a definitive agreement under which Horizon will acquire all of the issued and...",77.04,77.48,70.35,73,HZNP,3247169,HISTORICAL_PRICES,HZNP,,1.61224E+12,0.11781776,0.11781776,73,77.04,77.48,70.35,3247169,73,77.04,77.48,70.35,3247169,1-Feb-21,4.56,0.0629
1-Feb-21,Taysha Gene Therapies Highlights Strategic Priorities and Provides 2021 Business Outlook,"Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (“Taysha”), a patient-centric, clinical-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of mo...",26.06,27.33,25.51,26.78,TSHA,47244,HISTORICAL_PRICES,TSHA,,1.61224E+12,-0.041911765,-0.041911765,26.78,26.06,27.33,25.51,47244,26.78,26.06,27.33,25.51,47244,1-Feb-21,0.06,0.0023
1-Feb-21,Bristol Myers Squibb Application for Zeposia® (ozanimod) for the Treatment of Ulcerative Colitis Accepted for Filing with Priority Review by U.S. Food and Drug Administration,Bristol Myers Squibb (NYSE:BMY) today announced that the U.S. Food and Drug Administration (FDA) has accepted its supplemental New Drug Application (sNDA) for Zeposia® (ozanimod) for the treatment of...,62.21,62.865,61.66,61.91,BMY,11240855,HISTORICAL_PRICES,BMY,,1.61224E+12,0.017334424,0.017334424,61.91,62.21,62.865,61.66,11240855,61.91,62.21,62.865,61.66,11240855,1-Feb-21,0.78,0.0127
1-Feb-21,ANI Pharmaceuticals Announces Launch of Prazosin Hydrochloride (“HCl”) Capsules,"ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (Nasdaq: ANIP) today announced the launch of Prazosin HCl Capsules USP, 1mg and 2mg, following the U.S. Food and Drug Administration’s (“FDA”) approv...",29.96,30,28.15,28.4,ANIP,53299,HISTORICAL_PRICES,ANIP,,1.61224E+12,0.07,0.07,28.4,29.96,30,28.15,53299,28.4,29.96,30,28.15,53299,1-Feb-21,1.42,0.0498
1-Feb-21,SQZ Biotechnologies Announces FDA Clearance of IND Application to Allow for Clinical Trial with SQZ Activating Antigen Carriers (SQZ AACs) in Patients with HPV+ Tumors,"SQZ Biotechnologies (NYSE: SQZ), a cell therapy company developing novel treatments for multiple therapeutic areas, today announced that the company’s Investigational New Drug (IND) application for SQ...",24.55,25.4075,24.2,24.2,SQZ,38105,HISTORICAL_PRICES,SQZ,,1.61224E+12,-0.107272727,-0.107272727,24.2,24.55,25.4075,24.2,38105,24.2,24.55,25.4075,24.2,38105,1-Feb-21,0.48,0.0199
1-Feb-21,Merck Receives Positive EU CHMP Opinion for Expanded Approval of KEYTRUDA® (pembrolizumab) in Certain Patients With Relapsed or Refractory Classical Hodgkin Lymphoma,"Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted...",77.36,78.33,77.34,77.99,MRK,7847914,HISTORICAL_PRICES,MRK,,1.61552E+12,-0.034689294,-0.034689294,77.99,77.36,78.33,77.34,7847914,77.3107,76.6862,77.6478,76.6664,7847914,1-Feb-21,0.29,0.0038
29-Jan-21,Une vaste étude clinique présentée lors de la réunion annuelle 2021 de la Society of Thoracic Surgeons (STS) conclut que l'utilisation de la pompe cardiaque Impella 5.5 avec SmartAssist est associée à un taux de survie de 79%,Abiomed (NASDAQ: ABMD) annonce qu'une vaste étude réunissant 356 patients traités avec la pompe cardiaque Impella 5.5 avec SmartAssist dans 16 centres aux Etats-Unis et en Allemagne a montré un taux d...,348.25,354.69,337.93,348.4,ABMD,423266,HISTORICAL_PRICES,ABMD,,1.61197E+12,0.147786823,0.147786823,348.4,348.25,354.69,337.93,423266,348.4,348.25,354.69,337.93,423266,29-Jan-21,-6.88,-0.0194
29-Jan-21,Merck Presents Results From Head-to-Head Phase 3 KEYNOTE-598 Trial Evaluating KEYTRUDA® (pembrolizumab) in Combination With Ipilimumab Versus KEYTRUDA Monotherapy in Certain Patients With Metastatic Non-Small Cell Lung Cancer,"Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced first-time data from the Phase 3 KEYNOTE-598 study evaluating KEYTRUDA, Merck’s anti-PD-1 therapy, in combination...",77.07,78.37,76.39,77.99,MRK,10182720,HISTORICAL_PRICES,MRK,,1.61552E+12,-0.038307961,-0.038307961,77.99,77.07,78.37,76.39,10182720,77.3107,76.3987,77.6874,75.7247,10182720,29-Jan-21,-0.85,-0.0109
29-Jan-21,"Resumen: Vertex anuncia la aprobación por parte de la FDA de la solicitud de nuevo medicamento en investigación (IND) para VX-880, una novedosa terapia celular para el tratamiento de la diabetes tipo 1 (T1D)","Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) ha anunciado hoy que la Administración de Medicamentos y Alimentos (Food and Drug Administration, FDA) de Estados Unidos ha aprobado la solicitud de...",229.08,232.92,227.56,229.45,VRTX,2029485,HISTORICAL_PRICES,VRTX,,1.61197E+12,-0.022946345,-0.022946345,229.45,229.08,232.92,227.56,2029485,229.45,229.08,232.92,227.56,2029485,29-Jan-21,-0.96,-0.0042
29-Jan-21,"Samenvatting: Vertex kondigt FDA-goedkeuring aan van Investigational New Drug (IND) -aanvraag voor VX-880, een nieuwe celtherapie voor de behandeling van type 1 diabetes (T1D)","Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) heeft vandaag aangekondigd dat de Amerikaanse Food and Drug Administration (FDA) de IND heeft goedgekeurd, waardoor het bedrijf kan doorgaan met het...",229.08,232.92,227.56,229.45,VRTX,2029485,HISTORICAL_PRICES,VRTX,,1.61197E+12,-0.022946345,-0.022946345,229.45,229.08,232.92,227.56,2029485,229.45,229.08,232.92,227.56,2029485,29-Jan-21,-0.96,-0.0042
29-Jan-21,PMI Partners with U.S. Department of Homeland Security on Combatting Illicit Trade,Philip Morris International Inc. (PMI) (NYSE: PM) today signed a memorandum of understanding (MOU) with the National Intellectual Property Rights Coordination Center (IPR Center) at the U.S. Departmen...,79.65,81.45,79.54,81.09,PM,5107591,HISTORICAL_PRICES,PM,,1.61612E+12,-0.034662465,-0.034662465,81.09,79.65,81.45,79.54,5107591,80.0155,78.5946,80.3707,78.486,5107591,29-Jan-21,-1.63,-0.0201
29-Jan-21,"Incyte Announces Positive CHMP Opinion for Pemigatinib for the Treatment of Adults With Previously Treated, Unresectable Locally Advanced or Metastatic Cholangiocarcinoma With a Fibroblast Growth Factor Receptor 2 (FGFR2) Fusion or Rearrangement",Incyte (Nasdaq:INCY) today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending the conditional marketi...,89.75,92.16,88.64,90.99,INCY,1396793,HISTORICAL_PRICES,INCY,,1.61197E+12,0.027240472,0.027240472,90.99,89.75,92.16,88.64,1396793,90.99,89.75,92.16,88.64,1396793,29-Jan-21,-1.52,-0.0167
29-Jan-21,Large Clinical Study Presented at STS 2021 Finds 79% Survival Rate with Impella 5.5 with SmartAssist,Abiomed (NASDAQ: ABMD) announces a large study of 356 patients treated with Impella 5.5 with SmartAssist at 16 U.S. and German centers found a 79% survival rate at explant. A majority of surviving pat...,348.25,354.69,337.93,348.4,ABMD,423266,HISTORICAL_PRICES,ABMD,,1.61197E+12,0.147786823,0.147786823,348.4,348.25,354.69,337.93,423266,348.4,348.25,354.69,337.93,423266,29-Jan-21,-6.88,-0.0194
29-Jan-21,"Puma Biotechnology Presents Interim Results from the Phase II SUMMIT Trial of Neratinib for EGFR Exon 18-Mutated, Metastatic Non-Small Cell Lung Cancer at WCLC 2020","Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, presented interim results from the ongoing SUMMIT trial of neratinib in the cohort of metastatic non-small cell lung cancer (NSCLC...",11.74,12.465,11.38,12.26,PBYI,450119,HISTORICAL_PRICES,PBYI,,1.61197E+12,0.02712161,0.02712161,12.26,11.74,12.465,11.38,450119,12.26,11.74,12.465,11.38,450119,29-Jan-21,-0.04,-0.0034
29-Jan-21,"Vertex meldet Annahme des IND-Antrags für VX-880, eine neuartige Zelltherapie zur Behandlung von Typ-1-Diabetes mellitus (T1D), bei der FDA","Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) gab heute bekannt, dass dem IND-Antrag (Investigational New Drug, neues Prüfpräparat) für VX-880 bei der US-amerikanischen Food and Drug Administrati...",229.08,232.92,227.56,229.45,VRTX,2029485,HISTORICAL_PRICES,VRTX,,1.61197E+12,-0.022946345,-0.022946345,229.45,229.08,232.92,227.56,2029485,229.45,229.08,232.92,227.56,2029485,29-Jan-21,-0.96,-0.0042
28-Jan-21,"Vertex annuncia l'approvazione della FDA della domanda di autorizzazione ad avviare la sperimentazione clinica (IND) di VX-880, una nuova terapia cellulare per il diabete di tipo 1","Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) oggi ha annunciato che la Food and Drug Administration (FDA) statunitense ha approvato la domanda di avvio di sperimentazione (IND), consentendo all'...",230.04,234.96,226.57,226.8,VRTX,1593618,HISTORICAL_PRICES,VRTX,,1.61189E+12,-0.01885183,-0.01885183,226.8,230.04,234.96,226.57,1593618,226.8,230.04,234.96,226.57,1593618,28-Jan-21,4.79,0.0213
28-Jan-21,"Vertex Announces FDA Clearance of Investigational New Drug (IND) Application for VX-880, a Novel Cell Therapy for the Treatment of Type 1 Diabetes (T1D)","Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has cleared the IND, enabling the company to proceed with initiating a clinical tria...",230.04,234.96,226.57,226.8,VRTX,1593618,HISTORICAL_PRICES,VRTX,,1.61189E+12,-0.01885183,-0.01885183,226.8,230.04,234.96,226.57,1593618,226.8,230.04,234.96,226.57,1593618,28-Jan-21,4.79,0.0213
28-Jan-21,"Quidel to Hold Fiscal Fourth Quarter and Full Year 2020 Financial Results Conference Call on February 18th, 2021","Quidel Corporation (NASDAQ: QDEL), a leading provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, will report fiscal fourth quarter and full...",227.3,229.9973,221.715,222.55,QDEL,450669,HISTORICAL_PRICES,QDEL,,1.61189E+12,0.150944352,0.150944352,222.55,227.3,229.9973,221.715,450669,222.55,227.3,229.9973,221.715,450669,28-Jan-21,3.09,0.0138
28-Jan-21,PhaseBio Announces Dosing of First Patient in European Union as Part of REVERSE-IT Global Phase 3 Trial of Bentracimab for Reversal of Antiplatelet Effects of Ticagrelor,"PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiopulmonary diseases, today announ...",3.74,3.93,3.62,3.93,PHAS,285106,HISTORICAL_PRICES,PHAS,,1.61189E+12,0.038888889,0.038888889,3.93,3.74,3.93,3.62,285106,3.93,3.74,3.93,3.62,285106,28-Jan-21,-0.15,-0.0386
28-Jan-21,Altria Reports 2020 Fourth-Quarter and Full-Year Results; Provides 2021 Full-Year Earnings Guidance; Announces New $2 Billion Share Repurchase Program,"Altria Group, Inc. (Altria) (NYSE: MO) today reports its 2020 fourth-quarter and full-year business results, provides guidance for 2021 full-year adjusted diluted earnings per share (EPS) and announce...",42.65,43.04,41.78,41.82,MO,9547220,HISTORICAL_PRICES,MO,,1.61655E+12,0.022291467,0.022291467,41.82,42.65,43.04,41.78,9547220,41.108,41.9238,42.3072,41.0686,9547220,28-Jan-21,0.83,0.0198
28-Jan-21,"Abiomed Announces Q3 FY 2021 Record Revenue of $232 Million, up 5% Year Over Year, With 31% Operating Margin","Abiomed, Inc. (NASDAQ: ABMD), a leading provider of breakthrough heart support technologies today reported record revenue in the third quarter fiscal 2021 of $231.7 million, a year over year increase...",355.13,387.4,334.37,340,ABMD,973871,HISTORICAL_PRICES,ABMD,,1.61189E+12,0.170462411,0.170462411,340,355.13,387.4,334.37,973871,340,355.13,387.4,334.37,973871,28-Jan-21,26.53,0.0807
28-Jan-21,Orthofix Announces Publication of Two-Year Data from the M6-C Artificial Cervical Disc Study,"Orthofix Medical Inc. (NASDAQ:OFIX), a global medical device company with a spine and extremities focus, today announced the publication of the full two-year data from its U.S. Investigational Device...",41.89,42.69,41.46,42.33,OFIX,85376,HISTORICAL_PRICES,OFIX,,1.61189E+12,-0.016435783,-0.016435783,42.33,41.89,42.69,41.46,85376,42.33,41.89,42.69,41.46,85376,28-Jan-21,-0.03,-0.0007
28-Jan-21,Avacta Announces Collaboration Agreement With Bruker,"Avacta Group plc (AIM: AVCT), the developer of Affimer® biotherapeutics and reagents, announces that it has entered into a collaboration agreement with Bruker Corporation (Billerica, MA) (NASDAQ: BRKR...",8.7,9,8.6,9,AVCT,50308,HISTORICAL_PRICES,AVCT,,1.61189E+12,0.266375546,0.266375546,9,8.7,9,8.6,50308,9,8.7,9,8.6,50308,28-Jan-21,-0.44,-0.0481
27-Jan-21,"Taro Provides Results for December 31, 2020","Taro Pharmaceutical Industries Ltd. (NYSE: TARO) (“Taro” or the “Company”) today provided unaudited financial results for the quarter and nine months ended December 31, 2020. Quarter ended December 31...",70.48,76.89,68.72,75.95,TARO,35744,HISTORICAL_PRICES,TARO,,1.6118E+12,-0.031868132,-0.031868132,75.95,70.48,76.89,68.72,35744,75.95,70.48,76.89,68.72,35744,27-Jan-21,-6.47,-0.0841
27-Jan-21,"Zymeworks Advances HER2 Bispecific Antibody-Drug Conjugate, ZW49, into Expansion Cohort Stage of Clinical Development","Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, announced today that the Company has begun enrolling patients into the expansion coh...",44.06,47.455,43.62,45.05,ZYME,969937,HISTORICAL_PRICES,ZYME,,1.6118E+12,-0.121085179,-0.121085179,45.05,44.06,47.455,43.62,969937,45.05,44.06,47.455,43.62,969937,27-Jan-21,-2.21,-0.0478
27-Jan-21,PhaseBio Presents Data from Phase 1b/2a Trial of Pemziviptadil for the Treatment of Pulmonary Arterial Hypertension at 15th Pulmonary Vascular Research Institute Virtual World Congress,"PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiopulmonary diseases, today announ...",3.89,4.1,3.83,4.02,PHAS,329386,HISTORICAL_PRICES,PHAS,,1.6118E+12,0.080555556,0.080555556,4.02,3.89,4.1,3.83,329386,4.02,3.89,4.1,3.83,329386,27-Jan-21,-0.23,-0.0558
27-Jan-21,Hologic Announces Financial Results for First Quarter of Fiscal 2021,"Hologic, Inc. (Nasdaq: HOLX) announced today the Company’s financial results for the fiscal first quarter ended December 26, 2020. “Hologic had a strong start to fiscal 2021 across all our businesses...",72.51,73.89,71.08,73.7,HOLX,3162317,HISTORICAL_PRICES,HOLX,,1.6118E+12,-0.030226026,-0.030226026,73.7,72.51,73.89,71.08,3162317,73.7,72.51,73.89,71.08,3162317,27-Jan-21,-2.01,-0.027
27-Jan-21,"Notice of Lead Plaintiff Deadline for Shareholders in the Tricida, Inc. Class Action Lawsuit","Robbins Geller Rudman & Dowd LLP announces that a class action lawsuit has been filed in the Northern District of California on behalf of purchasers of Tricida, Inc. (NASDAQ:TCDA) securities betwe...",6.87,7,6.45,6.85,TCDA,717285,HISTORICAL_PRICES,TCDA,,1.6118E+12,-0.112403101,-0.112403101,6.85,6.87,7,6.45,717285,6.85,6.87,7,6.45,717285,27-Jan-21,-0.05,-0.0072
27-Jan-21,Genprex to Present at the Virtual Investor Conference Small and Microcap Showcase on February 4,"Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced th...",4.26,4.67,4.25,4.5,GNPX,1659248,HISTORICAL_PRICES,GNPX,,1.6118E+12,-0.091684435,-0.091684435,4.5,4.26,4.67,4.25,1659248,4.5,4.26,4.67,4.25,1659248,27-Jan-21,-0.31,-0.0678
27-Jan-21,Moderna Confirms Discussions with U.S. Government for Additional 100 Million Doses of the Moderna COVID-19 Vaccine,"Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines today confirmed that the Company is in discussion with the U.S. government to purchase a...",155.73,164.55,149,151.2,MRNA,20262915,HISTORICAL_PRICES,MRNA,,1.6118E+12,0.262095794,0.262095794,151.2,155.73,164.55,149,20262915,151.2,155.73,164.55,149,20262915,27-Jan-21,3.8,0.025
27-Jan-21,"Philip Morris International Named to the 2021 Bloomberg Gender-Equality Index, Recognizing Company’s Commitment to Advancing Gender Equity",Philip Morris International Inc. (PMI) (NYSE: PM) has today been added to the 2021 Bloomberg Gender-Equality Index (GEI) for its transparency in gender reporting and advancing women’s equity. This rec...,79.8,82.05,79.44,81.1,PM,5295411,HISTORICAL_PRICES,PM,,1.61612E+12,-0.032844504,-0.032844504,81.1,79.8,82.05,79.44,5295411,80.0254,78.7426,80.9628,78.3873,5295411,27-Jan-21,-2.19,-0.0267
27-Jan-21,Head-to-Head Study Shows Guardant360 Liquid Biopsy Outperforms Tissue Biopsy for Comprehensive Genomic Profiling in Advanced Non-Small Cell Lung Cancer with Similar Outcomes,"Guardant Health, Inc. (Nasdaq: GH). Despite guideline recommendations for comprehensive genomic profiling (CGP) of all patients with advanced non-small cell lung cancer (NSCLC), profiling remains subo...",147.39,151.99,142.15,149.21,GH,1360892,HISTORICAL_PRICES,GH,,1.6118E+12,0.101651842,0.101651842,149.21,147.39,151.99,142.15,1360892,149.21,147.39,151.99,142.15,1360892,27-Jan-21,-2.52,-0.0168
27-Jan-21,Scholar Rock Presents Preclinical Data for SRK-181 at the TGFβ for Immuno-Oncology Drug Development Summit,"Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced a presenta...",56.84,58.74,54.84,56.92,SRRK,270798,HISTORICAL_PRICES,SRRK,,1.6118E+12,0.10368932,0.10368932,56.92,56.84,58.74,54.84,270798,56.92,56.84,58.74,54.84,270798,27-Jan-21,-1.97,-0.0335
27-Jan-21,"AbCellera-Discovered Antibody, Bamlanivimab, to be Developed with VIR-7831 for the Treatment of COVID-19","AbCellera (Nasdaq: ABCL) today announced that bamlanivimab (LY-CoV555), a human antibody discovered by AbCellera and developed with Eli Lilly and Company (Lilly), will be evaluated together with VIR-7...",46.85,48.92,45.1,45.89,ABCL,687259,HISTORICAL_PRICES,ABCL,,1.6118E+12,0.104431872,0.104431872,45.89,46.85,48.92,45.1,687259,45.89,46.85,48.92,45.1,687259,27-Jan-21,-0.92,-0.0193
27-Jan-21,Pfizer Shares Co-Primary Endpoint Results from Post-Marketing Required Safety Study of XELJANZ® (tofacitinib) in Subjects with Rheumatoid Arthritis (RA),"Pfizer Inc. (NYSE: PFE) announced today co-primary endpoint results from a recently completed post-marketing required safety study, ORAL Surveillance (A3921133; NCT02092467). The primary objective of...",36.24,37.04,36.17,36.99,PFE,50561180,HISTORICAL_PRICES,PFE,,1.6118E+12,-0.027636169,-0.027636169,36.99,36.24,37.04,36.17,50561180,36.5919,35.85,36.6414,35.7808,50561180,27-Jan-21,-1.07,-0.0287
26-Jan-21,FSD Provides Corporate Update,FSD Pharma Inc. (Nasdaq: HUGE) (CSE: HUGE) (“FSD Pharma” or the “Company”) today announces the following corporate updates. Corporate Update The Company continues to pursue its strategy of completing...,2.21,2.29,2.125,2.23,HUGE,562187,HISTORICAL_PRICES,HUGE,,1.61171E+12,0.307692308,0.307692308,2.23,2.21,2.29,2.125,562187,2.23,2.21,2.29,2.125,562187,26-Jan-21,-0.06,-0.0264
26-Jan-21,Kiromic Announces License Agreement With Longwood University for chPD1,"Kiromic BioPharma, Inc. (Nasdaq: KRBP), an immuno-oncology target discovery and gene-editing company, with a proprietary artificial intelligence neural network platform (Diamond AI) to develop novel o...",9.08,9.27,8.82,8.82,KRBP,34491,HISTORICAL_PRICES,KRBP,,1.61171E+12,-0.044210526,-0.044210526,8.82,9.08,9.27,8.82,34491,8.82,9.08,9.27,8.82,34491,26-Jan-21,0.26,0.0295
26-Jan-21,Omeros Hires Nadia Dac as Chief Commercial Officer,"Omeros Corporation (Nasdaq: OMER) today announced that Nadia Dac has joined Omeros as its Chief Commercial Officer. In this role, Ms. Dac will be responsible for all commercial operations at Omeros, i...",19.23,19.6104,19.18,19.58,OMER,470850,HISTORICAL_PRICES,OMER,,1.61171E+12,0.290604027,0.290604027,19.58,19.23,19.6104,19.18,470850,19.58,19.23,19.6104,19.18,470850,26-Jan-21,-0.27,-0.0138
26-Jan-21,Vertex Announces U.S. FDA Acceptance of Supplemental New Drug Application for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in Children With Cystic Fibrosis Ages 6 through 11 With Certain Mutations,Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has accepted its supplemental New Drug Application (sNDA) to expand the use of TRIKA...,237.64,241.98,236.24,240.43,VRTX,1629293,HISTORICAL_PRICES,VRTX,,1.61171E+12,0.013563081,0.013563081,240.43,237.64,241.98,236.24,1629293,240.43,237.64,241.98,236.24,1629293,26-Jan-21,-3.67,-0.0152
26-Jan-21,"SHAREHOLDER ACTION REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Voyager Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm","The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Voyager Therapeutics, Inc. (“Voyager” or “the Company”) (NASDAQ: VYGR) for vi...",8.41,8.95,8.41,8.77,VYGR,267270,HISTORICAL_PRICES,VYGR,,1.61171E+12,0.053884712,0.053884712,8.77,8.41,8.95,8.41,267270,8.77,8.41,8.95,8.41,267270,26-Jan-21,-0.28,-0.0322
26-Jan-21,Moderna Provides U.S. COVID-19 Vaccine Supply Update,"Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today provided a supply update for the Moderna COVID-19 Vaccine, reporting that 30.4 mi...",151.93,154.55,145,145.15,MRNA,16964726,HISTORICAL_PRICES,MRNA,,1.61171E+12,0.231299133,0.231299133,145.15,151.93,154.55,145,16964726,145.15,151.93,154.55,145,16964726,26-Jan-21,4.93,0.0335
26-Jan-21,Eyenovia to Present at the Ophthalmology Innovation Summit (OIS) Presbyopia Innovation Showcase,"Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose array print (MAP™) therapeutics, today announced that Dr. David Wirta will speak...",6.74,6.88,6.65,6.85,EYEN,128503,HISTORICAL_PRICES,EYEN,,1.61171E+12,0.184534271,0.184534271,6.85,6.74,6.88,6.65,128503,6.85,6.74,6.88,6.65,128503,26-Jan-21,-0.12,-0.0175
26-Jan-21,"AbCellera-Discovered Antibody, Bamlanivimab, Administered with Etesevimab Reduced Risk of COVID-19 Hospitalizations and Death by 70%","AbCellera (Nasdaq: ABCL) today announced that bamlanivimab (LY-CoV555) 2800 mg, a human antibody discovered by AbCellera and developed with Eli Lilly and Company (Lilly), and etesevimab 2800 mg (LY-Co...",47.77,49.96,46.0558,49.29,ABCL,500142,HISTORICAL_PRICES,ABCL,,1.61171E+12,0.126119755,0.126119755,49.29,47.77,49.96,46.0558,500142,49.29,47.77,49.96,46.0558,500142,26-Jan-21,-1.02,-0.0209
26-Jan-21,Marinus Enrolls First Patient in Pivotal Phase 3 Clinical Trial of IV Ganaxolone in Refractory Status Epilepticus,"Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders, today announced the enrollment of the fi...",13.47,14.43,13.42,13.71,MRNS,341934,HISTORICAL_PRICES,MRNS,,1.61171E+12,0.066508314,0.066508314,13.71,13.47,14.43,13.42,341934,13.71,13.47,14.43,13.42,341934,26-Jan-21,-0.34,-0.0246
26-Jan-21,"Yelp Economic Average Shows Early Signs of Recovery for Local Economies with More than 230,000 Reopened Businesses in 2020","Yelp Inc. (NYSE: YELP), the company that connects people with great local businesses, today released the Annual 2020 Yelp Economic Average (YEA) report, a benchmark of local economic strength in the U...",32.64,33.09,31.6,32.01,YELP,911974,HISTORICAL_PRICES,YELP,,1.61171E+12,0.165298108,0.165298108,32.01,32.64,33.09,31.6,911974,32.01,32.64,33.09,31.6,911974,26-Jan-21,0.79,0.0248
26-Jan-21,European Commission Approves KEYTRUDA® (pembrolizumab) as First-Line Treatment in Adult Patients With Metastatic Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Colorectal Cancer,"Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that the European Commission has approved KEYTRUDA, Merck’s anti-PD-1 therapy, as a monotherapy for the first-line...",80.25,81.15,80.13,81.15,MRK,7393373,HISTORICAL_PRICES,MRK,,1.61552E+12,0.001372598,0.001372598,81.15,80.25,81.15,80.13,7393373,80.4432,79.5511,80.4432,79.4321,7393373,26-Jan-21,-0.9,-0.0111
25-Jan-21,"Shareholder Alert: Robbins LLP Announces That Voyager Therapeutics, Inc. (VYGR) is Being Sued for Misleading Shareholders","Shareholder rights law firm Robbins LLP announces that a purchaser of Voyager Therapeutics, Inc. (Nasdaq: VYGR) filed a class action complaint against the Company and its officers and directors for al...",8.69,9.07,8.35,9.05,VYGR,457014,HISTORICAL_PRICES,VYGR,,1.61163E+12,0.088972431,0.088972431,9.05,8.69,9.07,8.35,457014,9.05,8.69,9.07,8.35,457014,25-Jan-21,-0.35,-0.0387
25-Jan-21,"SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Voyager Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm","The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Voyager Therapeutics, Inc. (“Voyager” or “the Company”) (NASDAQ: VYGR) for vi...",8.69,9.07,8.35,9.05,VYGR,457014,HISTORICAL_PRICES,VYGR,,1.61163E+12,0.088972431,0.088972431,9.05,8.69,9.07,8.35,457014,9.05,8.69,9.07,8.35,457014,25-Jan-21,-0.35,-0.0387
25-Jan-21,"VYGR EQUITY ALERT: Rosen Law Firm Announces Filing of Federal Securities Class Action Lawsuit Against Voyager Therapeutics, Inc. – VYGR","Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Voyager Therapeutics, Inc. (NASDAQ: VYGR) between June 1,...",8.69,9.07,8.35,9.05,VYGR,457014,HISTORICAL_PRICES,VYGR,,1.61163E+12,0.088972431,0.088972431,9.05,8.69,9.07,8.35,457014,9.05,8.69,9.07,8.35,457014,25-Jan-21,-0.35,-0.0387
25-Jan-21,Moderna COVID-19 Vaccine Retains Neutralizing Activity Against Emerging Variants First Identified in the U.K. and the Republic of South Africa,"Moderna Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced results from in vitro neutralization studies of sera from individuals va...",147,147.4299,137.25,138.4,MRNA,26970870,HISTORICAL_PRICES,MRNA,,1.61163E+12,0.191344517,0.191344517,138.4,147,147.4299,137.25,26970870,138.4,147,147.4299,137.25,26970870,25-Jan-21,15.98,0.122
25-Jan-21,Pulse Biosciences Announces CE Mark Approval for CellFX® System,"Pulse Biosciences, Inc. (Nasdaq: PLSE) (“Pulse Biosciences” or the “Company”), a novel bioelectric medicine company progressing Nano-Pulse Stimulation™ (NPS™) technology, today announced Conformité Eu...",34.84,36,29.6161,29.9,PLSE,508825,HISTORICAL_PRICES,PLSE,,1.61163E+12,0.648060549,0.648060549,29.9,34.84,36,29.6161,508825,29.9,34.84,36,29.6161,508825,25-Jan-21,5.31,0.1798
25-Jan-21,Revance to Highlight Aesthetic Clinical Data on DaxibotulinumtoxinA for Injection and Hyaluronic Acid Filler Study Results at Maui Derm for Dermatologists 2021,"Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company focused on innovative aesthetic and therapeutic offerings, today announced that three ePosters will be presented at the Maui Derm for...",28.25,28.77,27.66,28.48,RVNC,275674,HISTORICAL_PRICES,RVNC,,1.61163E+12,0.025408348,0.025408348,28.48,28.25,28.77,27.66,275674,28.48,28.25,28.77,27.66,275674,25-Jan-21,-0.34,-0.0119
25-Jan-21,Agilent Announces Enhanced Mass Spectrometry and Automation Software Solutions to Support Regulatory Compliance Guidelines,"Agilent Technologies Inc. (NYSE: A) today announced the release of MassHunter Workstation Plus 11.0, MassHunter Networked Workstation 11.0, and MassHunter BioConfirm. The latest revision of these soft...",125.48,127.48,124.43,126.69,A,1365448,HISTORICAL_PRICES,A,,1.61163E+12,0.069644532,0.069644532,126.69,125.48,127.48,124.43,1365448,126.69,125.48,127.48,124.43,1365448,25-Jan-21,-0.85,-0.0067
25-Jan-21,Arrowhead Pharmaceuticals Files IND for Phase 2b Study of ARO-ANG3 for Treatment of Mixed Dyslipidemia,Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has submitted an Investigational New Drug Application (IND) to the U.S. Food and Drug Administration (FDA) for a Phase 2b dose-fin...,84.13,84.67,80.285,81.85,ARWR,696519,HISTORICAL_PRICES,ARWR,,1.61163E+12,-0.000712674,-0.000712674,81.85,84.13,84.67,80.285,696519,81.85,84.13,84.67,80.285,696519,25-Jan-21,2.06,0.0251
22-Jan-21,"Glancy Prongay & Murray LLP, a National Class Action Law Firm, Continues Investigation of Eos Energy Enterprises, Inc. (EOSE) on Behalf of Investors","Glancy Prongay & Murray LLP (“GPM”), a national investor rights law firm, continues its investigation on behalf of Eos Energy Enterprises, Inc. (“Eos Energy” or the “Company”) (NASDAQ: EOSE) inves...",23.48,24.5199,22.8439,22.9209,EOSE,1255860,HISTORICAL_PRICES,EOSE,,1.61137E+12,0.22100884,0.22100884,22.9209,23.48,24.5199,22.8439,1255860,22.9209,23.48,24.5199,22.8439,1255860,22-Jan-21,-1.47,-0.0589
22-Jan-21,FSD Pharma Sets Date for Annual Meeting,"FSD Pharma Inc. (Nasdaq:HUGE) (CSE:HUGE) (“FSD Pharma” or the “Company”) today announced that it will hold its annual meeting of shareholders (the “Meeting”) on June 29, 2021. The Meeting will address...",2.28,2.28,2.17,2.2,HUGE,431496,HISTORICAL_PRICES,HUGE,,1.61137E+12,0.349112426,0.349112426,2.2,2.28,2.28,2.17,431496,2.2,2.28,2.28,2.17,431496,22-Jan-21,0.03,0.0133
22-Jan-21,Samenvatting: Incyte kondigt acceptatie en prioriteitsbeoordeling aan van BLA voor Retifanlimab als een mogelijke behandeling voor patiënten met plaveiselcelcarcinoom van het anale kanaal (SCAC),"Incyte (Nasdaq: INCY) heeft vandaag aangekondigd dat de Amerikaanse Food and Drug Administration (FDA) zijn Biologics License Application (BLA) voor retifanlimab, een intraveneuze PD-1-remmer, heeft g...",97.89,98.44,94.04,94.12,INCY,1435185,HISTORICAL_PRICES,INCY,,1.61137E+12,0.120407463,0.120407463,94.12,97.89,98.44,94.04,1435185,94.12,97.89,98.44,94.04,1435185,22-Jan-21,3.99,0.0425
22-Jan-21,Resumen: Incyte anuncia una aceptación y revisión prioritaria de la BLA para retifanlimab como posible tratamiento para pacientes con carcinoma de células escamosas del canal anal (SCAC),"Incyte (Nasdaq: INCY) ha anunciado hoy que la Agencia Federal de Alimentos y Medicamentos (Food and Drug Administration, FDA) de EE. UU. ha aceptado una revisión prioritaria de la solicitud de licenci...",97.89,98.44,94.04,94.12,INCY,1435185,HISTORICAL_PRICES,INCY,,1.61137E+12,0.120407463,0.120407463,94.12,97.89,98.44,94.04,1435185,94.12,97.89,98.44,94.04,1435185,22-Jan-21,3.99,0.0425
22-Jan-21,U.S. Food and Drug Administration Approves OPDIVO® (nivolumab) in Combination with CABOMETYX® (cabozantinib) as First-line Treatment for Patients with Advanced Renal Cell Carcinoma,Bristol Myers Squibb (NYSE: BMY) today announced that OPDIVO® (nivolumab) 240 mg (injection for intravenous use) every two weeks or 480 mg every four weeks in combination with CABOMETYX® (cabozantinib...,64.56,65.025,63.76,63.89,BMY,9071894,HISTORICAL_PRICES,BMY,,1.61137E+12,0.055764513,0.055764513,63.89,64.56,65.025,63.76,9071894,63.89,64.56,65.025,63.76,9071894,22-Jan-21,0.38,0.0059
22-Jan-21,Exelixis Announces U.S. FDA Approval of CABOMETYX® (cabozantinib) in Combination with OPDIVO® (nivolumab) as a First-Line Treatment for Patients with Advanced Renal Cell Carcinoma,"Exelixis, Inc. (NASDAQ: EXEL) today announced that the U.S. Food and Drug Administration (FDA) approved CABOMETYX® (cabozantinib) for patients with advanced renal cell carcinoma (RCC) as a first-line...",22.14,22.29,21.13,21.23,EXEL,3736127,HISTORICAL_PRICES,EXEL,,1.61137E+12,0.069048769,0.069048769,21.23,22.14,22.29,21.13,3736127,21.23,22.14,22.29,21.13,3736127,22-Jan-21,0.82,0.0385
22-Jan-21,"FBIO Deadline Alert: Bronstein, Gewirtz & Grossman, LLC Reminds Fortress Biotech, Inc. Investors of Class Action and Lead Plaintiff Deadline: January 26, 2021","Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Fortress Biotech, Inc. (""Fortress Biotech"" or ""the Company"") (NASDAQ: FBIO) and certain of...",3.54,3.56,3.4,3.4,FBIO,623935,HISTORICAL_PRICES,FBIO,,1.61137E+12,0.032069971,0.032069971,3.4,3.54,3.56,3.4,623935,3.4,3.54,3.56,3.4,623935,22-Jan-21,0.09,0.0261
22-Jan-21,"Kessler Topaz Meltzer & Check, LLP Reminds Investors of Deadline for Securities Fraud Class Action Lawsuit Filed Against Penumbra, Inc.","The law firm of Kessler Topaz Meltzer & Check, LLP reminds that an investor securities fraud class action lawsuit has been filed against Penumbra, Inc. (NYSE: PEN) (“Penumbra”) on behalf of those...",244.04,246.33,240.21,244.65,PEN,252643,HISTORICAL_PRICES,PEN,,1.61137E+12,0.302171709,0.302171709,244.65,244.04,246.33,240.21,252643,244.65,244.04,246.33,240.21,252643,22-Jan-21,-1.66,-0.0068
22-Jan-21,"PolarityTE, Inc. Announces Exercise of Warrants for Gross Proceeds of $7.67 Million","PolarityTE, Inc. (Nasdaq: PTE), a company focused on transforming the lives of patients by discovering, designing, and developing a range of regenerative tissue products and biomaterials, today announ...",1.05,1.09,1.03,1.08,PTE,10641106,HISTORICAL_PRICES,PTE,,1.61137E+12,0.5,0.5,1.08,1.05,1.09,1.03,10641106,1.08,1.05,1.09,1.03,10641106,22-Jan-21,-0.03,-0.0278
22-Jan-21,Lyra Therapeutics Provides Corporate Update and Anticipated Milestones for 2021,"Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatme...",11.51,11.98,11.26,11.49,LYRA,46368,HISTORICAL_PRICES,LYRA,,1.61137E+12,0.006118881,0.006118881,11.49,11.51,11.98,11.26,46368,11.49,11.51,11.98,11.26,46368,22-Jan-21,0.04,0.0035
22-Jan-21,"Revance Issues Inaugural Environmental, Social and Governance (ESG) Report","Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company focused on innovative aesthetic and therapeutic offerings, today announced the release of its inaugural ESG Report, which details the...",28.59,28.83,27.87,28.05,RVNC,334541,HISTORICAL_PRICES,RVNC,,1.61137E+12,0.037749546,0.037749546,28.05,28.59,28.83,27.87,334541,28.05,28.59,28.83,27.87,334541,22-Jan-21,0.2,0.007
21-Jan-21,Incyte meldet Annahme und prioritäre Prüfung des BLA-Antrags für Retifanlimab als potenzielle Therapie für Plattenepithelkarzinom des Analkanals (SCAC),"Incyte (Nasdaq:INCY) gab heute bekannt, dass die US-amerikanische Food and Drug Administration (FDA) den Antrag auf Zulassung eines Biologikums (BLA) für Retifanlimab für die prioritäre Prüfung angeno...",93.9,96.41,91.98,96.4,INCY,1175144,HISTORICAL_PRICES,INCY,,1.61128E+12,0.074739613,0.074739613,96.4,93.9,96.41,91.98,1175144,96.4,93.9,96.41,91.98,1175144,21-Jan-21,-2.47,-0.0256
21-Jan-21,Incyte annuncia l’accettazione e la revisione prioritaria della BLA per retifanlimab come potenziale trattamento per pazienti con carcinoma cutaneo spinocellulare del canale anale (SCAC),Incyte (Nasdaq:INCY) oggi ha annunciato che l’agenzia federale statunitense per gli alimenti e i farmaci (FDA) ha accettato per la revisione prioritaria la domanda di concessione della licenza biologi...,93.9,96.41,91.98,96.4,INCY,1175144,HISTORICAL_PRICES,INCY,,1.61128E+12,0.074739613,0.074739613,96.4,93.9,96.41,91.98,1175144,96.4,93.9,96.41,91.98,1175144,21-Jan-21,-2.47,-0.0256
21-Jan-21,Incyte Announces Acceptance and Priority Review of BLA for Retifanlimab as a Potential Treatment for Patients with Squamous Cell Carcinoma of the Anal Canal (SCAC),"Incyte (Nasdaq:INCY) today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review its Biologics License Application (BLA) for retifanlimab, an intravenous PD-1 inh...",93.9,96.41,91.98,96.4,INCY,1175144,HISTORICAL_PRICES,INCY,,1.61128E+12,0.074739613,0.074739613,96.4,93.9,96.41,91.98,1175144,96.4,93.9,96.41,91.98,1175144,21-Jan-21,-2.47,-0.0256
21-Jan-21,Columbia Property Trust Invests in Air Purification Technology Across Portfolio,"Columbia Property Trust, Inc. (NYSE: CXP) announced today that it is installing new bipolar ionization (BPI) air purification technology in properties across its portfolio to enhance overall indoor en...",14.22,14.75,14.15,14.75,CXP,869482,HISTORICAL_PRICES,CXP,,1.61438E+12,-0.009749304,-0.009749304,14.75,14.22,14.75,14.15,869482,14.5399,14.0174,14.5399,13.9484,869482,21-Jan-21,-0.62,-0.0418
21-Jan-21,"Notice of Lead Plaintiff Deadline for Shareholders in the Penumbra, Inc. Class Action Lawsuit","Robbins Geller Rudman & Dowd LLP announces that a class action lawsuit has been filed in the Northern District of California on behalf of purchasers of Penumbra, Inc. (NYSE:PEN) common stock betwe...",245.7,248.37,237.31,242.34,PEN,271355,HISTORICAL_PRICES,PEN,,1.61128E+12,0.311029294,0.311029294,242.34,245.7,248.37,237.31,271355,242.34,245.7,248.37,237.31,271355,21-Jan-21,2.91,0.012
21-Jan-21,Moderna Announces First Participant Dosed in Phase 1/2 Study of Moderna COVID-19 Vaccine in Japan Led by Takeda,"Moderna Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that the first participant has been dosed in the Phase 1/2 study of Mode...",132.98,137,125.25,125.28,MRNA,20880838,HISTORICAL_PRICES,MRNA,,1.61128E+12,0.077721047,0.077721047,125.28,132.98,137,125.25,20880838,125.28,132.98,137,125.25,20880838,21-Jan-21,7.84,0.0626
21-Jan-21,Genprex to Present its Cutting-Edge Gene Therapies at the MoneyShow Accredited Investors Virtual Expo,"Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced th...",3.75,3.95,3.73,3.95,GNPX,856418,HISTORICAL_PRICES,GNPX,,1.61128E+12,-0.200426439,-0.200426439,3.95,3.75,3.95,3.73,856418,3.95,3.75,3.95,3.73,856418,21-Jan-21,-0.12,-0.031
21-Jan-21,AbCellera-Discovered Antibody Prevented COVID-19 in Nursing Homes and Reduced Risks by up to 80% for Residents,"AbCellera (Nasdaq: ABCL) today announced that bamlanivimab (LY-CoV555), a human antibody discovered by AbCellera and developed with Eli Lilly and Company (Lilly), significantly reduced the risk of con...",50.9,51.49,48.07,49,ABCL,1003831,HISTORICAL_PRICES,ABCL,,1.61128E+12,0.199905705,0.199905705,49,50.9,51.49,48.07,1003831,49,50.9,51.49,48.07,1003831,21-Jan-21,2.7,0.056
21-Jan-21,Establishment Labs to Host Investor Event Featuring Its Motiva Mia System,"Establishment Labs Holdings Inc. (NASDAQ: ESTA), a medical technology company focused on women’s health, initially in the breast aesthetics and reconstruction market, today announced it will host a vi...",50.88,52.86,49,49.1,ESTA,282765,HISTORICAL_PRICES,ESTA,,1.61128E+12,0.453714286,0.453714286,49.1,50.88,52.86,49,282765,49.1,50.88,52.86,49,282765,21-Jan-21,2.76,0.0574
21-Jan-21,PolarityTE Announces Completion of Target Enrollment in Diabetic Foot Ulcer Trial,"PolarityTE, Inc. (Nasdaq: PTE), a biotechnology company developing regenerative tissue products and biomaterials, announced today it has completed target enrollment of 100 subjects in a randomized con...",1.08,1.13,1.0313,1.08,PTE,6333827,HISTORICAL_PRICES,PTE,,1.61128E+12,0.542857143,0.542857143,1.08,1.08,1.13,1.0313,6333827,1.08,1.08,1.13,1.0313,6333827,21-Jan-21,0.01,0.0093
20-Jan-21,Transcat Announces Third Quarter Fiscal Year 2021 Conference Call and Webcast,"Transcat, Inc. (Nasdaq: TRNS) (“Transcat” or the “Company”), a leading provider of accredited calibration, repair, inspection and laboratory instrument services and value-added distributor of professi...",36.7,37,36.33,36.96,TRNS,28300,HISTORICAL_PRICES,TRNS,,1.6112E+12,0.111111111,0.111111111,36.96,36.7,37,36.33,28300,36.96,36.7,37,36.33,28300,20-Jan-21,0,0
20-Jan-21,Ocular Therapeutix™ Presents Interim Topline Data from the Phase 1 Clinical Trial of OTX-TIC in Patients with Primary Open Angle Glaucoma or Ocular Hypertension at the 10th Annual Glaucoma 360 New Horizons Forum,"Ocular Therapeutix™, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, tod...",19.91,20.56,19.065,20.22,OCUL,941619,HISTORICAL_PRICES,OCUL,,1.6112E+12,-0.098278986,-0.098278986,20.22,19.91,20.56,19.065,941619,20.22,19.91,20.56,19.065,941619,20-Jan-21,-0.17,-0.0085
20-Jan-21,"AVEO Oncology Announces Commitment for an Incremental $10 Million Loan in Addition to Current Tranched, $35 Million Debt Facility with Hercules Capital","AVEO Oncology (Nasdaq: AVEO) today announced that it has received a commitment letter for an incremental $10 million loan from Hercules Capital, Inc. (NYSE: HTGC, “Hercules”) and its affiliates, to be...",8.58,8.78,7.95,8.55,AVEO,653515,HISTORICAL_PRICES,AVEO,,1.6112E+12,0.464163823,0.464163823,8.55,8.58,8.78,7.95,653515,8.55,8.58,8.78,7.95,653515,20-Jan-21,0.03,0.0035
20-Jan-21,Applied DNA Promotes Judith Murrah to Chief Operating Officer,"Applied DNA Sciences, Inc. (NASDAQ: APDN) (the “Company”), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing, today announced the promotion of Chief Information Officer Judith Murrah...",11.01,11.33,10.4,11.12,APDN,1123995,HISTORICAL_PRICES,APDN,,1.6112E+12,1.031365314,1.031365314,11.12,11.01,11.33,10.4,1123995,11.12,11.01,11.33,10.4,1123995,20-Jan-21,-0.19,-0.017
20-Jan-21,"U.S. Food and Drug Administration Accepts for Priority Review Application for Opdivo® (nivolumab) Combined with Chemotherapy as First-Line Treatment in Metastatic Gastric Cancer, Gastroesophageal Junction Cancer and Esophageal Adenocarcinoma","Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) has accepted its supplemental Biologics License Application (sBLA) for Opdivo® (nivolumab), in combina...",66.25,66.82,66,66.57,BMY,9609597,HISTORICAL_PRICES,BMY,,1.6112E+12,0.083401472,0.083401472,66.57,66.25,66.82,66,9609597,66.57,66.25,66.82,66,9609597,20-Jan-21,-0.49,-0.0073
20-Jan-21,U.S. Food and Drug Administration Accepts for Priority Review Application for Opdivo® (nivolumab) as Adjuvant Therapy for Patients with Resected Esophageal or Gastroesophageal Junction Cancer,Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) has accepted its supplemental Biologics License Application (sBLA) for Opdivo® (nivolumab) for the tre...,66.25,66.82,66,66.57,BMY,9609597,HISTORICAL_PRICES,BMY,,1.6112E+12,0.083401472,0.083401472,66.57,66.25,66.82,66,9609597,66.57,66.25,66.82,66,9609597,20-Jan-21,-0.49,-0.0073
20-Jan-21,Merck Announces U.S. FDA Approval of VERQUVO® (vericiguat),"Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved VERQUVO, a soluble guanylate cyclase (sGC) stimulator...",82.46,83.55,82.265,83.25,MRK,10589557,HISTORICAL_PRICES,MRK,,1.61552E+12,0.028949339,0.028949339,83.25,82.46,83.55,82.265,10589557,82.5249,81.7418,82.8223,81.5485,10589557,20-Jan-21,-0.73,-0.0088
19-Jan-21,"Kiromic Announces the Completion of its GMP Manufacturing Facility in Houston, Texas, to Support the Manufacturing of the First In-Human Allogenic CAR-T Trial","Kiromic BioPharma, Inc. (Nasdaq: KRBP), an immuno-oncology target discovery and gene-editing company, with a proprietary artificial intelligence neural network platform (Diamond AI) to develop novel o...",8.7,8.85,8.41,8.51,KRBP,40840,HISTORICAL_PRICES,KRBP,,1.61111E+12,-0.084210526,-0.084210526,8.51,8.7,8.85,8.41,40840,8.51,8.7,8.85,8.41,40840,19-Jan-21,0.28,0.0333
19-Jan-21,Revance Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4),"Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company focused on innovative aesthetic and therapeutic offerings, including its investigational neuromodulator product, DaxibotulinumtoxinA...",28.5,29.34,27.82,29,RVNC,458877,HISTORICAL_PRICES,RVNC,,1.61111E+12,0.034482759,0.034482759,29,28.5,29.34,27.82,458877,29,28.5,29.34,27.82,458877,19-Jan-21,-0.14,-0.0049
19-Jan-21,Puma Biotechnology to Present at the B. Riley Oncology Investor Conference,"Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder of Puma, will provide an overview of the...",11.04,11.2,10.85,10.85,PBYI,357123,HISTORICAL_PRICES,PBYI,,1.61111E+12,-0.034120735,-0.034120735,10.85,11.04,11.2,10.85,357123,10.85,11.04,11.2,10.85,357123,19-Jan-21,0.26,0.0241
19-Jan-21,Biologics License Application for Narsoplimab in HSCT-TMA Accepted for Priority Review by U.S. FDA,Omeros Corporation (Nasdaq: OMER) announced today that the Biologics License Application (BLA) for narsoplimab for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiop...,19.46,20,18.685,19.4373,OMER,2244946,HISTORICAL_PRICES,OMER,,1.61111E+12,0.306040268,0.306040268,19.4373,19.46,20,18.685,2244946,19.4373,19.46,20,18.685,2244946,19-Jan-21,1.4,0.0775
19-Jan-21,Masimo Announces the iSirona™ Connectivity Hub,"Masimo (NASDAQ: MASI) today announced the global launch of iSirona™, a compact, versatile connectivity hub designed to maximize interoperability across the continuum of care. The iSirona hub offers an...",261,264.36,258.005,263.39,MASI,295159,HISTORICAL_PRICES,MASI,,1.61111E+12,-0.018575619,-0.018575619,263.39,261,264.36,258.005,295159,263.39,261,264.36,258.005,295159,19-Jan-21,-0.37,-0.0014
19-Jan-21,NanoVibronix Issues Letter to Shareholders,"NanoVibronix, Inc., (NASDAQ: NAOV), a medical device company that produces the UroShield®, PainShield® and WoundShield® Surface Acoustic Wave (SAW) Portable Ultrasonic Therapeutic Devices, today issue...",1.02,1.03,0.9707,1.02,NAOV,1362121,HISTORICAL_PRICES,NAOV,,1.61111E+12,0.253071253,0.253071253,1.02,1.02,1.03,0.9707,1362121,1.02,1.02,1.03,0.9707,1362121,19-Jan-21,0.022,0.022
19-Jan-21,"Tenax Therapeutics, Inc. Announces Transformative Acquisition of PH Precision Med","Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceutical company focused on identifying, developing, and commercializing products for the critical care market, today announced the acquisiti...",2.36,2.72,2.31,2.7,TENX,40538542,HISTORICAL_PRICES,TENX,,1.61111E+12,1.126126126,1.126126126,2.7,2.36,2.72,2.31,40538542,2.7,2.36,2.72,2.31,40538542,19-Jan-21,0.58,0.3258
19-Jan-21,Intersect ENT Announces CMS Approval of Coding Application for PROPEL® Sinus Implant,"Intersect ENT®, Inc. (Nasdaq: XENT), a global ear, nose and throat (“ENT”) medical technology leader dedicated to transforming patient care, today announced that the Centers for Medicare and Medicaid...",24.12,24.93,23.98,24.41,XENT,147155,HISTORICAL_PRICES,XENT,,1.61111E+12,0.048695652,0.048695652,24.41,24.12,24.93,23.98,147155,24.41,24.12,24.93,23.98,147155,19-Jan-21,0.14,0.0058
19-Jan-21,Seres Therapeutics to Present SER-109 Phase 3 Mechanistic Data at Keystone Symposium,"Seres Therapeutics, Inc. (Nasdaq: MCRB) announced today that it will present new data from its SER-109 Phase 3 ECOSPOR III clinical study that confirm the intended pharmacological properties of this i...",24.96,25.7677,24.25,25.04,MCRB,1423363,HISTORICAL_PRICES,MCRB,,1.61111E+12,0.02800659,0.02800659,25.04,24.96,25.7677,24.25,1423363,25.04,24.96,25.7677,24.25,1423363,19-Jan-21,0.48,0.0196
19-Jan-21,Applied DNA Linea™ COVID-19 Assay Kit Demonstrates Effectiveness with Detection of Multiple SARS-CoV-2 Variants During Recent Surveillance Testing,"Applied DNA Sciences, Inc. (NASDAQ: APDN) (the “Company”), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing, today announced that its Linea™ COVID-19 Assay Kit (the “Assay Kit”) ide...",11.2,11.69,10.3093,11.2381,APDN,2535348,HISTORICAL_PRICES,APDN,,1.61111E+12,1.066420664,1.066420664,11.2381,11.2,11.69,10.3093,2535348,11.2381,11.2,11.69,10.3093,2535348,19-Jan-21,0.2,0.0182
19-Jan-21,Taysha Gene Therapies Receives Rare Pediatric Disease and Orphan Drug Designations for TSHA-105 for the Treatment of Epilepsy Caused by SLC13A5 Deficiency,"Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the cen...",31,33.35,29.74,30.12,TSHA,138203,HISTORICAL_PRICES,TSHA,,1.61111E+12,0.139705882,0.139705882,30.12,31,33.35,29.74,138203,30.12,31,33.35,29.74,138203,19-Jan-21,1.42,0.048
19-Jan-21,PMI’s Charles Bendotti Recognized by INvolve and Yahoo Finance on OUTstanding 50 Ally Executives List 2020; Nikki Symmons named on LGBT+ Future Leader List 2020,"Charles Bendotti, Senior Vice President, People & Culture at Philip Morris International Inc. (PMI) (NYSE:PM), has today been recognized for his unwavering support for LGBTQ+ inclusion in the work...",81.9,82.29,80.81,81.44,PM,7685327,HISTORICAL_PRICES,PM,,1.61612E+12,-0.007393043,-0.007393043,81.44,81.9,82.29,80.81,7685327,80.3608,80.8148,81.1996,79.7392,7685327,19-Jan-21,0.96,0.0119
19-Jan-21,Guardant Health und das Vall d'Hebron Institute of Oncology geben Partnerschaft zur Einrichtung des ersten Guardant-basierten Flüssigbiopsie-Testservices in Europa bekannt,"Guardant Health, Inc. (Nasdaq: GH), ein führendes Unternehmen im Bereich der Präzisionsonkologie, und das Vall d'Hebron Institute of Oncology (VHIO), eine der führenden Krebsforschungseinrichtungen in...",159.94,162,157.41,161,GH,1093080,HISTORICAL_PRICES,GH,,1.61111E+12,0.195455565,0.195455565,161,159.94,162,157.41,1093080,161,159.94,162,157.41,1093080,19-Jan-21,0.65,0.0041
15-Jan-21,"ROSEN, TRUSTED INVESTOR COUNSEL, Reminds Minerva Neurosciences, Inc. Investors of Important February 8 Deadline in Securities Class Action – NERV","Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Minerva Neurosciences, Inc. (NASDAQ: NERV) between May 15, 2017 and November 30, 2020, inclusive (the ""Class...",2.71,2.8081,2.69,2.74,NERV,459253,HISTORICAL_PRICES,NERV,,1.61076E+12,0.101626016,0.101626016,2.74,2.71,2.8081,2.69,459253,2.74,2.71,2.8081,2.69,459253,15-Jan-21,0.02,0.0074
15-Jan-21,Zanidatamab Data Highlight Durable Antitumor Activity in HER2‑Expressing Biliary Tract and Gastroesophageal Cancers at ASCO Gastrointestinal Cancers Symposium,"Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced new and updated clinical data for the HER2‑targeted bispecific antib...",54.68,57.2,54.22,55.6,ZYME,316600,HISTORICAL_PRICES,ZYME,,1.61076E+12,0.090764014,0.090764014,55.6,54.68,57.2,54.22,316600,55.6,54.68,57.2,54.22,316600,15-Jan-21,-0.75,-0.0135
15-Jan-21,Arcus Biosciences Presents Promising Initial Data from Phase 1 Portion of ARC-8 Study for AB680 in Metastatic Pancreatic Cancer,"Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today presented preliminary data from the dose-escalation portion o...",36.98,40.01,34.83,39.03,RCUS,939455,HISTORICAL_PRICES,RCUS,,1.61076E+12,0.209287116,0.209287116,39.03,36.98,40.01,34.83,939455,39.03,36.98,40.01,34.83,939455,15-Jan-21,-1.85,-0.0476
15-Jan-21,Puma Biotechnology Presents Interim Results from the Biliary Tract Cancers Cohort of the Phase II SUMMIT “Basket” Trial of Neratinib at ASCO GI,"Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced interim results from the biliary tract cancers cohort of the ongoing SUMMIT trial of neratinib at the virtual 2021 Gastr...",10.78,11.2869,10.65,11,PBYI,315963,HISTORICAL_PRICES,PBYI,,1.61076E+12,-0.056867892,-0.056867892,11,10.78,11.2869,10.65,315963,11,10.78,11.2869,10.65,315963,15-Jan-21,-0.22,-0.02
15-Jan-21,AVEO Oncology Announces Results from Phase 1b Portion of DEDUCTIVE Study of Tivozanib (FOTIVDA®) in Combination with IMFINZI® (durvalumab) in Previously Untreated Metastatic Hepatocellular Carcinoma,"AVEO Oncology (Nasdaq: AVEO) today announced the presentation of results from the Phase 1b portion of the Phase 1b/2 DEDUCTIVE clinical trial of tivozanib (FOTIVDA®), AVEO’s vascular endothelial growt...",8.18,8.42,8.0395,8.18,AVEO,376772,HISTORICAL_PRICES,AVEO,,1.61076E+12,0.395904437,0.395904437,8.18,8.18,8.42,8.0395,376772,8.18,8.18,8.42,8.0395,376772,15-Jan-21,-0.03,-0.0037
15-Jan-21,"Desktop Metal to Acquire EnvisionTEC, Entering Market for Volume Production Polymer Additive Manufacturing","Desktop Metal, Inc. (NYSE: DM), a leader in mass production and turnkey additive manufacturing solutions, today announced the signing of a definitive agreement to acquire EnvisionTEC, a leading global...",23.75,25.23,21.6,23.2,DM,7373785,HISTORICAL_PRICES,DM,,1.61076E+12,0.236979167,0.236979167,23.2,23.75,25.23,21.6,7373785,23.2,23.75,25.23,21.6,7373785,15-Jan-21,0.4,0.0171
15-Jan-21,Applied DNA Provides Business Update on COVID-19 Diagnostics and Testing,"Applied DNA Sciences, Inc. (NASDAQ:APDN) (the “Company”), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing, today announced that its safeCircle™ pooled surveillance testing service...",11,12.87,9.13,9.92,APDN,11729702,HISTORICAL_PRICES,APDN,,1.61076E+12,1.029520295,1.029520295,9.92,11,12.87,9.13,11729702,9.92,11,12.87,9.13,11729702,15-Jan-21,2.09,0.2346
14-Jan-21,"Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Tricida, Inc. – TCDA","Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Tricida, Inc. (NASDAQ:TCDA) between September 4, 2019 and...",7.21,7.38,6.9,7.3,TCDA,541265,HISTORICAL_PRICES,TCDA,,1.61068E+12,-0.068475452,-0.068475452,7.3,7.21,7.38,6.9,541265,7.3,7.21,7.38,6.9,541265,14-Jan-21,-0.02,-0.0028
14-Jan-21,Pfizer’s XALKORI® (crizotinib) Approved by FDA for ALK-positive Anaplastic Large Cell Lymphoma in Children and Young Adults,Pfizer Inc. (NYSE:PFE) today announced that the U.S. Food and Drug Administration (FDA) approved the supplemental New Drug Application (sNDA) for XALKORI® (crizotinib) for the treatment of pediatric p...,36.75,36.96,36.61,36.78,PFE,30271992,HISTORICAL_PRICES,PFE,,1.6118E+12,-0.01395224,-0.01395224,36.78,36.75,36.96,36.61,30271992,36.3842,36.3545,36.5623,36.216,30271992,14-Jan-21,-0.11,-0.003
14-Jan-21,PolarityTE Announces Closing of $10.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules,"PolarityTE, Inc. (Nasdaq: PTE), a company focused on transforming the lives of patients by discovering, designing, and developing a range of regenerative tissue products and biomaterials, announced to...",1.21,1.33,1.14,1.32,PTE,22824938,HISTORICAL_PRICES,PTE,,1.61068E+12,0.728571429,0.728571429,1.32,1.21,1.33,1.14,22824938,1.32,1.21,1.33,1.14,22824938,14-Jan-21,0.06,0.0522
14-Jan-21,"TCDA Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Notifies Tricida, Inc. Shareholders of Class Action and Encourages Shareholders to Contact the Firm","Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Tricida, Inc. (""Tricida"" or ""the Company"") (NASDAQ: TCDA) and certain of its officers, on b...",7.21,7.38,6.9,7.3,TCDA,541265,HISTORICAL_PRICES,TCDA,,1.61068E+12,-0.068475452,-0.068475452,7.3,7.21,7.38,6.9,541265,7.3,7.21,7.38,6.9,541265,14-Jan-21,-0.02,-0.0028
14-Jan-21,Mirum Pharmaceuticals Announces First Patient Enrolled in Phase 2b VISTAS Clinical Study Evaluating Volixibat in Adult Patients With Primary Sclerosing Cholangitis,"Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that the first patient has been enrolled in Mirum’s Phase 2b VISTAS study evaluating volixibat in adult patients with primary sclerosing chol...",18.46,20.1468,18.25,19.71,MIRM,259145,HISTORICAL_PRICES,MIRM,,1.61068E+12,0.011506849,0.011506849,19.71,18.46,20.1468,18.25,259145,19.71,18.46,20.1468,18.25,259145,14-Jan-21,-1.02,-0.0524
14-Jan-21,Genprex to Present at NobleCon17 on January 19,"Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced th...",3.83,3.98,3.76,3.9422,GNPX,1094424,HISTORICAL_PRICES,GNPX,,1.61068E+12,-0.18336887,-0.18336887,3.9422,3.83,3.98,3.76,1094424,3.9422,3.83,3.98,3.76,1094424,14-Jan-21,-0.07,-0.0179
14-Jan-21,Charles River Partners with JADE Biomedical to Expand Biologics Capabilities,"Charles River Laboratories International, Inc. (NYSE: CRL) today announced that it has entered into a strategic partnership with JADE Biomedical (JADE), a provider of end-to-end quality management ser...",266.91,273.03,266.5,267.09,CRL,369085,HISTORICAL_PRICES,CRL,,1.61068E+12,0.060386953,0.060386953,267.09,266.91,273.03,266.5,369085,267.09,266.91,273.03,266.5,369085,14-Jan-21,-0.58,-0.0022
14-Jan-21,PerkinElmer SARS-CoV-2 RT-PCR Assay Receives FDA EUA for Asymptomatic Testing,"PerkinElmer, Inc. (NYSE:PKI) announced today that its PerkinElmer® New Coronavirus Nucleic Acid Detection Kit received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA...",148.13,152.78,148.04,152.18,PKI,859481,HISTORICAL_PRICES,PKI,,1.6112E+12,0.060267697,0.060267697,152.18,148.13,152.78,148.04,859481,152.1096,148.0614,152.7093,147.9715,859481,14-Jan-21,-3.39,-0.0224
14-Jan-21,Twist Bioscience Begins Shipping of Synthetic RNA Controls for UK Variant Strain of SARS-CoV-2,"Twist Bioscience Corporation (Nasdaq: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that it has started...",189.43,189.68,168.97,169,TWST,969213,HISTORICAL_PRICES,TWST,,1.61068E+12,0.154779322,0.154779322,169,189.43,189.68,168.97,969213,169,189.43,189.68,168.97,969213,14-Jan-21,21.02,0.1248
13-Jan-21,"NantKwest, ImmunityBio Announce Positive Interim Data on Survival Rates in Metastatic Pancreatic Cancer Trials","NantKwest, Inc. (NASDAQ: NK), a clinical-stage, natural killer cell-based therapeutics company, and ImmunityBio, Inc., a privately-held immunotherapy company, today announced early interim results of...",14.78,16.5,14.14,16.0737,NK,2039598,HISTORICAL_PRICES,NK,,1.61059E+12,-0.076826983,-0.076826983,16.0737,14.78,16.5,14.14,2039598,16.0737,14.78,16.5,14.14,2039598,13-Jan-21,-1.21,-0.0757
13-Jan-21,Alexion Provides Update on Phase 3 Study of ULTOMIRIS® (ravulizumab-cwvz) in Hospitalized Patients with Severe COVID-19,"Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced the decision to pause further enrollment in the global Phase 3 study of ULTOMIRIS® (ravulizumab-cwvz) in adults with severe COVID-19 requiri...",156.44,157.58,156.2,156.53,ALXN,3653360,HISTORICAL_PRICES,ALXN,,1.61059E+12,0.024962327,0.024962327,156.53,156.44,157.58,156.2,3653360,156.53,156.44,157.58,156.2,3653360,13-Jan-21,0.85,0.0055
13-Jan-21,"INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Genfit SA and Encourages Investors with Losses of $100,000 to Contact the Firm","The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Genfit SA (“Genfit” or “the Company”) (NASDAQ: GNFT) for violati...",5.475,5.64,5.34,5.64,GNFT,20972,HISTORICAL_PRICES,GNFT,,1.61059E+12,0.09939759,0.09939759,5.64,5.475,5.64,5.34,20972,5.64,5.475,5.64,5.34,20972,13-Jan-21,0.155,0.0291
13-Jan-21,Applied DNA Announces Closing of $15 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules,"Applied DNA Sciences, Inc. (NASDAQ: APDN) (the “Company”), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing, announced today the closing of its previously announced registered direc...",8.96,9.3999,8.7,9.05,APDN,1310092,HISTORICAL_PRICES,APDN,,1.61059E+12,0.653136531,0.653136531,9.05,8.96,9.3999,8.7,1310092,9.05,8.96,9.3999,8.7,1310092,13-Jan-21,-0.29,-0.0314
13-Jan-21,"INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Tricida, Inc. (TCDA) Investors","Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased Tricida, Inc. (“Tricida” or the “Company”) (NASDAQ: TCDA) securities between Se...",7.23,7.65,7.21,7.61,TCDA,330596,HISTORICAL_PRICES,TCDA,,1.61059E+12,-0.065891473,-0.065891473,7.61,7.23,7.65,7.21,330596,7.61,7.23,7.65,7.21,330596,13-Jan-21,-0.43,-0.0561
13-Jan-21,Genprex Achieves Major Manufacturing Milestone for REQORSA™ Immunogene Therapy for Upcoming Trials to Treat Non-Small Cell Lung Cancer,"Genprex, Inc. (“Genprex” or the “Company”) (Nasdaq: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, announced today th...",3.9,4.05,3.71,3.94,GNPX,2442425,HISTORICAL_PRICES,GNPX,,1.61059E+12,-0.168443497,-0.168443497,3.94,3.9,4.05,3.71,2442425,3.94,3.9,4.05,3.71,2442425,13-Jan-21,0.14,0.0372
13-Jan-21,Ligand Receives Milestone Payment from Merck,Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today reported that the company will receive a $1.5 million milestone payment from Merck triggered by the U.S. Food and Drug Administration’s (FDA’s)...,111.2,115.68,109.225,110.5,LGND,260924,HISTORICAL_PRICES,LGND,,1.61059E+12,0.048561999,0.048561999,110.5,111.2,115.68,109.225,260924,110.5,111.2,115.68,109.225,260924,13-Jan-21,0.8,0.0072
13-Jan-21,Quanterix Provides Operational and Preliminary Financial Highlights,"Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis to advance the science of precision health, today provided operational and preliminary financial highlights for the fourth...",67.82,69.3999,61.19,61.19,QTRX,649840,HISTORICAL_PRICES,QTRX,,1.61059E+12,0.4762734,0.4762734,61.19,67.82,69.3999,61.19,649840,61.19,67.82,69.3999,61.19,649840,13-Jan-21,8.23,0.1381
13-Jan-21,Establishment Labs Announces Participation in the 39th Annual J.P. Morgan Healthcare Conference,"Establishment Labs Holdings Inc. (NASDAQ: ESTA), a medical technology company focused on women’s health, initially in the breast aesthetics and reconstruction market, today announced that CEO and Foun...",49.48,51.21,49.22,50,ESTA,167792,HISTORICAL_PRICES,ESTA,,1.61059E+12,0.413714286,0.413714286,50,49.48,51.21,49.22,167792,50,49.48,51.21,49.22,167792,13-Jan-21,-0.41,-0.0082
13-Jan-21,Sesen Bio and Qilu Pharmaceutical Announce IND Application for Vicineum™ Accepted for Review by the National Medical Products Administration in China,"Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today reported that the Investigational New Drug (IND...",1.48,1.59,1.47,1.59,SESN,5143184,HISTORICAL_PRICES,SESN,,1.61059E+12,0.174603175,0.174603175,1.59,1.48,1.59,1.47,5143184,1.59,1.48,1.59,1.47,5143184,13-Jan-21,-0.12,-0.075
13-Jan-21,Marinus Pharmaceuticals Receives Positive Response from FDA on Sufficiency of One Phase 3 Clinical Trial for Filing of New Drug Application (NDA) for the Use of Ganaxolone in CDKL5 Deficiency Disorder (CDD),"Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders, today announced it has received a positi...",12.62,13.8,12.4,12.89,MRNS,791653,HISTORICAL_PRICES,MRNS,,1.61059E+12,-0.000791766,-0.000791766,12.89,12.62,13.8,12.4,791653,12.89,12.62,13.8,12.4,791653,13-Jan-21,0.48,0.0395
13-Jan-21,U.S. IDE Trial Results for Glaukos’ iStent infinite™ Show Substantial Reduction in IOP,"Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today an...",84.18,84.47,76.32,78.07,GKOS,737100,HISTORICAL_PRICES,GKOS,,1.61059E+12,0.137721314,0.137721314,78.07,84.18,84.47,76.32,737100,78.07,84.18,84.47,76.32,737100,13-Jan-21,6.19,0.0794
13-Jan-21,Glaukos’ iDose® TR Demonstrates Sustained IOP Reduction and Favorable Safety Profile Over 24 Months in Phase 2b Study,"Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today an...",84.18,84.47,76.32,78.07,GKOS,737100,HISTORICAL_PRICES,GKOS,,1.61059E+12,0.137721314,0.137721314,78.07,84.18,84.47,76.32,737100,78.07,84.18,84.47,76.32,737100,13-Jan-21,6.19,0.0794
12-Jan-21,Outset Medical Appoints Karen Drexler to Board of Directors,"Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind device to reduce the cost and complexity of dialysis, is bolstering its board of directors wit...",47.93,49.89,47.18,48.77,OM,162678,HISTORICAL_PRICES,OM,,1.61052E+12,-0.100075103,-0.100075103,48.77,47.93,49.89,47.18,162678,48.77,47.93,49.89,47.18,162678,12-Jan-21,-0.55,-0.0113
12-Jan-21,Mirum Pharmaceuticals Provides Corporate Update,"Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a biopharmaceutical company focused on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases, to...",20.42,20.99,19.68,19.82,MIRM,230302,HISTORICAL_PRICES,MIRM,,1.61052E+12,0.11890411,0.11890411,19.82,20.42,20.99,19.68,230302,19.82,20.42,20.99,19.68,230302,12-Jan-21,0.98,0.0504
12-Jan-21,Lantheus Holdings Announces Submission of Drug Master File for NM-01 in the U.S.,"Lantheus Holdings, Inc. (NASDAQ: LNTH) (Lantheus), the parent company of Lantheus Medical Imaging, Inc. and Progenics Pharmaceuticals, Inc., and a global leader in the development, manufacture and com...",15.77,15.79,14.91,14.99,LNTH,542563,HISTORICAL_PRICES,LNTH,,1.61052E+12,0.069877883,0.069877883,14.99,15.77,15.79,14.91,542563,14.99,15.77,15.79,14.91,542563,12-Jan-21,0.88,0.0591
12-Jan-21,Uber and Moderna Collaborate to Raise Awareness and Increase Access to COVID-19 Vaccines,"Moderna (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, and Uber Technologies, Inc. (NYSE: UBER), the world’s leading ridesharing and delivery platfo...",124.55,124.91,117.12,117.93,MRNA,15300721,HISTORICAL_PRICES,MRNA,,1.61052E+12,0.009401086,0.009401086,117.93,124.55,124.91,117.12,15300721,117.93,124.55,124.91,117.12,15300721,12-Jan-21,7.29,0.0622
12-Jan-21,Gilead and Vir Biotechnology Establish Clinical Collaboration to Explore Combination Strategies for Functional Cure for Chronic Hepatitis B Virus,"Gilead Sciences, Inc. (NASDAQ: GILD) and Vir Biotechnology, Inc. (NASDAQ: VIR) today announced that the companies have entered into a clinical collaboration to evaluate novel therapeutic combination s...",62.08,62.79,61.465,62.66,GILD,9115119,HISTORICAL_PRICES,GILD,,1.61552E+12,0.087786928,0.087786928,62.66,62.08,62.79,61.465,9115119,61.9548,61.3814,62.0834,60.7733,9115119,12-Jan-21,-0.43,-0.0069
12-Jan-21,Swissmedic Authorizes COVID-19 Vaccine Moderna for Use in Switzerland,"Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that Swissmedic, the Swiss Agency for Therapeutic Products, has authori...",124.55,124.91,117.12,117.93,MRNA,15300721,HISTORICAL_PRICES,MRNA,,1.61052E+12,0.009401086,0.009401086,117.93,124.55,124.91,117.12,15300721,117.93,124.55,124.91,117.12,15300721,12-Jan-21,7.29,0.0622
12-Jan-21,La Jolla Pharmaceutical Company Announces Exclusive Licensing Agreement for GIAPREZA™ (Angiotensin II) and XERAVA™ (Eravacycline) in Europe,"La Jolla Pharmaceutical Company (Nasdaq: LJPC), which is dedicated to the development and commercialization of innovative therapies that improve outcomes in patients suffering from life-threatening di...",5.04,6.24,4.86,5.9,LJPC,36922231,HISTORICAL_PRICES,LJPC,,1.61052E+12,0.16937355,0.16937355,5.9,5.04,6.24,4.86,36922231,5.9,5.04,6.24,4.86,36922231,12-Jan-21,1.1,0.2792
12-Jan-21,PolarityTE Announces $10.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules,"PolarityTE, Inc. (Nasdaq: PTE), a company focused on transforming the lives of patients by discovering, designing, and developing a range of regenerative tissue products and biomaterials, announced to...",1.11,1.18,1.01,1.135,PTE,18709171,HISTORICAL_PRICES,PTE,,1.61052E+12,0.585714286,0.585714286,1.135,1.11,1.18,1.01,18709171,1.135,1.11,1.18,1.01,18709171,12-Jan-21,-0.14,-0.112
12-Jan-21,Pulse Biosciences Updates on CellFX System Regulatory and Clinical Study Progress,"Pulse Biosciences, Inc. (Nasdaq: PLSE) (“Pulse Biosciences” or the “Company”), a novel bioelectric medicine company progressing Nano-Pulse Stimulation™ (NPS™) technology, today announced CellFX® Syste...",23.15,24.52,22.69,23.79,PLSE,300946,HISTORICAL_PRICES,PLSE,,1.61052E+12,0.095080416,0.095080416,23.79,23.15,24.52,22.69,300946,23.79,23.15,24.52,22.69,300946,12-Jan-21,-1.52,-0.0616
12-Jan-21,"U.S. FDA Accepts for Priority Review the Biologics License Application for V114, Merck’s Investigational 15-valent Pneumococcal Conjugate Vaccine, for Use in Adults 18 Years of Age and Older","Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the U.S. Food and Drug Administration (FDA) accepted for priority review a Biologics License Application (BLA) for...",83.09,85.14,82.55,85.12,MRK,9664704,HISTORICAL_PRICES,MRK,,1.61552E+12,0.036810581,0.036810581,85.12,83.09,85.14,82.55,9664704,84.3786,82.3663,84.3985,81.831,9664704,12-Jan-21,-1.91,-0.0225
11-Jan-21,Arcus Biosciences to Present Preliminary Data from Phase 1 Portion of ARC-8 Study for AB680 in Metastatic Pancreatic Cancer at ASCO-GI Symposium,"Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that preliminary data from the ongoing dose-escalat...",32.07,33.12,29.575,30.2,RCUS,486546,HISTORICAL_PRICES,RCUS,,1.61042E+12,0.048724657,0.048724657,30.2,32.07,33.12,29.575,486546,30.2,32.07,33.12,29.575,486546,11-Jan-21,1.24,0.0402
11-Jan-21,Omeros to Present at the 39th Annual J.P. Morgan Healthcare Conference,"Omeros Corporation (Nasdaq: OMER) today announced that Gregory A. Demopulos, M.D., chairman and chief executive officer, will present at the 39th Annual J.P. Morgan Healthcare Conference this week. Th...",16.1,16.4,15.7356,15.81,OMER,384022,HISTORICAL_PRICES,OMER,,1.61042E+12,0.080536913,0.080536913,15.81,16.1,16.4,15.7356,384022,15.81,16.1,16.4,15.7356,384022,11-Jan-21,0.09,0.0056
11-Jan-21,Quanterix Receives FDA Emergency Use Authorization for SARS-CoV-2 N Protein Antigen Test,"Quanterix Corporation (NASDAQ:QTRX), a company digitizing biomarker analysis to advance the science of precision health, today announced that the Food and Drug Administration (FDA) has issued an Emerg...",52.85,53.01,46.47,48.4,QTRX,654694,HISTORICAL_PRICES,QTRX,,1.61042E+12,0.150413583,0.150413583,48.4,52.85,53.01,46.47,654694,48.4,52.85,53.01,46.47,654694,11-Jan-21,4.11,0.0843
11-Jan-21,"Gamida Cell to Present Full Data from Phase 3 Study of Omidubicel at TCT, the Combined Transplantation and Cellular Therapy Meetings of ASTCT and CIBMTR","Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to cures for blood cancers and serious hematologic diseases, today announced that the full results of the Phase 3 clinical t...",8.89,9.1799,8.76,9.1,GMDA,541404,HISTORICAL_PRICES,GMDA,,1.61042E+12,-0.033695652,-0.033695652,9.1,8.89,9.1799,8.76,541404,9.1,8.89,9.1799,8.76,541404,11-Jan-21,-0.14,-0.0155
11-Jan-21,AlloVir Announces Data Presentations at the 2021 Transplantation & Cellular Therapy Meeting Digital Experience,"AlloVir (Nasdaq: ALVR), a late clinical-stage cell therapy company, announced that it will present three oral presentations and one poster presentation during the Transplantation & Cellular Therap...",45.5,48.31,42.85,42.85,ALVR,196385,HISTORICAL_PRICES,ALVR,,1.61042E+12,0.124567474,0.124567474,42.85,45.5,48.31,42.85,196385,42.85,45.5,48.31,42.85,196385,11-Jan-21,2.53,0.0589
11-Jan-21,Travelers Institute Kicks Off 2021 Programming,"The Travelers Institute, the public policy division of The Travelers Companies, Inc. (NYSE: TRV), today announced the lineup of its 2021 educational webinars, which will focus on critical issues facin...",137.43,139.35,137.22,138.68,TRV,1017195,HISTORICAL_PRICES,TRV,,1.61529E+12,-0.007653982,-0.007653982,138.68,137.43,139.35,137.22,1017195,137.9232,136.68,138.5895,136.4711,1017195,11-Jan-21,-2.22,-0.0159
11-Jan-21,"Robbins Geller Rudman & Dowd LLP Updates Investors in the Minerva Neurosciences, Inc. Class Action Lawsuit Regarding Lead Plaintiff Motion Deadline","Robbins Geller Rudman & Dowd LLP announces that purchasers of Minerva Neurosciences, Inc. (NASDAQ:NERV) common stock between May 15, 2017 and November 30, 2020, inclusive (the “Class Period”), hav...",2.56,2.6,2.525,2.57,NERV,344412,HISTORICAL_PRICES,NERV,,1.61042E+12,0.040650407,0.040650407,2.57,2.56,2.6,2.525,344412,2.57,2.56,2.6,2.525,344412,11-Jan-21,-0.02,-0.0078
11-Jan-21,"Underscoring Critical Role of Science in a Smoke-Free Future, Philip Morris International Brings on Former Sanofi Exec as Chief Life Sciences Officer","Philip Morris International Inc. (PMI) (NYSE: PM) today announced the appointment of Jorge Insuasty to the position of Chief Life Sciences Officer, effective Jan. 15, 2021. Mr. Insuasty will report to...",82.31,83.69,82.035,83.1,PM,4698115,HISTORICAL_PRICES,PM,,1.61612E+12,-0.002423949,-0.002423949,83.1,82.31,83.69,82.035,4698115,81.9989,81.2193,82.581,80.948,4698115,11-Jan-21,-0.78,-0.0094
11-Jan-21,Cerus Corporation Announces Preliminary Fourth Quarter and Full Year 2020 Product Revenue,Cerus Corporation (Nasdaq: CERS) announced today preliminary product revenue for the fourth quarter and full year 2020 and provided 2021 product revenue guidance. Cerus’ unaudited preliminary product...,7.22,7.55,7.015,7.07,CERS,1781937,HISTORICAL_PRICES,CERS,,1.61042E+12,-0.105328377,-0.105328377,7.07,7.22,7.55,7.015,1781937,7.07,7.22,7.55,7.015,1781937,11-Jan-21,-0.135,-0.0184
11-Jan-21,Establishment Labs Reports Preliminary Results for Fourth Quarter and Fiscal Year 2020,"Establishment Labs Holdings Inc. (NASDAQ: ESTA), a medical technology company focused on women’s health, initially in the breast aesthetics and reconstruction market, today reported preliminary revenu...",40.59,41.04,37.775,37.97,ESTA,206193,HISTORICAL_PRICES,ESTA,,1.61042E+12,0.159714286,0.159714286,37.97,40.59,41.04,37.775,206193,37.97,40.59,41.04,37.775,206193,11-Jan-21,2.68,0.0707
11-Jan-21,Resolution Bioscience Announces Companion Diagnostic Collaboration with Mirati Therapeutics,"Resolution Bioscience, Inc. today announced a companion diagnostic agreement with Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical stage targeted oncology company. As part of the agreement, Resolu...",209.57,215.54,205.92,214.33,MRTX,597602,HISTORICAL_PRICES,MRTX,,1.61042E+12,-0.107567176,-0.107567176,214.33,209.57,215.54,205.92,597602,214.33,209.57,215.54,205.92,597602,11-Jan-21,-7.91,-0.0364
11-Jan-21,PolarityTE Announces Formation of Strategic Review Committee,"PolarityTE, Inc. (Nasdaq: PTE), a biotechnology company developing regenerative tissue products and biomaterials, announced today that the Board of Directors has formed a strategic review committee wi...",1.25,1.73,1.15,1.56,PTE,45808773,HISTORICAL_PRICES,PTE,,1.61042E+12,0.785714286,0.785714286,1.56,1.25,1.73,1.15,45808773,1.56,1.25,1.73,1.15,45808773,11-Jan-21,-0.07,-0.053
11-Jan-21,Zymeworks Highlights 2020 Achievements and Announces Corporate Priorities,"Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today highlighted its key accomplishments in 2020 and updated its corporate prioriti...",56.25,57.78,54.5,56.5,ZYME,950043,HISTORICAL_PRICES,ZYME,,1.61042E+12,0.122082585,0.122082585,56.5,56.25,57.78,54.5,950043,56.5,56.25,57.78,54.5,950043,11-Jan-21,-0.56,-0.0099
11-Jan-21,Clovis Oncology Announces Preliminary Product Revenues for the Fourth Quarter and Full Year 2020,"Clovis Oncology, Inc. (NASDAQ:CLVS) today announced its preliminary, unaudited global product revenues for the fourth quarter and full year ended December 31, 2020. The financial information presented...",5.62,5.74,5.1,5.22,CLVS,9835360,HISTORICAL_PRICES,CLVS,,1.61042E+12,0.151639344,0.151639344,5.22,5.62,5.74,5.1,9835360,5.22,5.62,5.74,5.1,9835360,11-Jan-21,0.57,0.1129
11-Jan-21,"Axcella Announces IND Clearance for AXA1665, Program Updates and 2021 Milestones","Axcella (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases and improve health using endogenous metabolic modulator (EMM) compositions, today ann...",5.24,5.3,5.01,5.01,AXLA,131625,HISTORICAL_PRICES,AXLA,,1.61042E+12,-0.034990792,-0.034990792,5.01,5.24,5.3,5.01,131625,5.01,5.24,5.3,5.01,131625,11-Jan-21,-0.06,-0.0113
11-Jan-21,Moderna Provides Business Update and Announces Three New Development Programs in Infectious Disease Vaccines,"Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that it is expanding its pipeline of innovative vaccines with three new...",117.26,121.24,112.62,112.75,MRNA,16650648,HISTORICAL_PRICES,MRNA,,1.61042E+12,-0.049679877,-0.049679877,112.75,117.26,121.24,112.62,16650648,112.75,117.26,121.24,112.62,16650648,11-Jan-21,4.51,0.04
11-Jan-21,Deciphera Pharmaceuticals Provides Corporate Update and Highlights Key 2021 Corporate Milestones,"Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a commercial-stage biopharmaceutical company developing innovative medicines to improve the lives of people with cancer, today provided a corporate updat...",53.64,56.885,53.12,56.24,DCPH,264220,HISTORICAL_PRICES,DCPH,,1.61042E+12,-0.088994565,-0.088994565,56.24,53.64,56.885,53.12,264220,56.24,53.64,56.885,53.12,264220,11-Jan-21,-2.6,-0.0462
11-Jan-21,"Horizon Therapeutics plc Provides Preliminary 2020 Financial Results, Exceeding Full-Year 2020 Net Sales and Adjusted EBITDA Guidance; Provides Update on TEPEZZA® (teprotumumab-trbw) Supply and New KRYSTEXXA® (pegloticase injection) Trials","Horizon Therapeutics plc (Nasdaq: HZNP) today announced updates on its 2020 financial results, TEPEZZA supply and new KRYSTEXXA trials. “Amid the most challenging environment we have ever faced, we ha...",78.69,78.93,76.67,78.42,HZNP,1460767,HISTORICAL_PRICES,HZNP,,1.61042E+12,0.141758561,0.141758561,78.42,78.69,78.93,76.67,1460767,78.42,78.69,78.93,76.67,1460767,11-Jan-21,-0.85,-0.0107
11-Jan-21,Exicure Granted Two Fast Track Designations for Cavrotolimod (AST-008) from the U.S. Food and Drug Administration,"Exicure, Inc. (NASDAQ: XCUR), a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) technology, today announced that the U.S. Food and Drug Administration (F...",2.3,2.45,2.07,2.12,XCUR,1714090,HISTORICAL_PRICES,XCUR,,1.61042E+12,0.191709845,0.191709845,2.12,2.3,2.45,2.07,1714090,2.12,2.3,2.45,2.07,1714090,11-Jan-21,0.3,0.15
11-Jan-21,Applied DNA Announces Pricing of $15 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules,"Applied DNA Sciences, Inc. (NASDAQ: APDN) (the “Company”), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing, announced today that it has entered into a securities purchase agreement...",8.84,9.67,8.48,9.29,APDN,6213014,HISTORICAL_PRICES,APDN,,1.61042E+12,0.63099631,0.63099631,9.29,8.84,9.67,8.48,6213014,9.29,8.84,9.67,8.48,6213014,11-Jan-21,-2.8,-0.2405
11-Jan-21,AtriCure Reports Preliminary Results for Fourth Quarter and Full Year 2020,"AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, announced preliminary financial results for the fourth quart...",59.52,59.73,55.36,55.91,ATRC,560847,HISTORICAL_PRICES,ATRC,,1.61042E+12,0.034231103,0.034231103,55.91,59.52,59.73,55.36,560847,55.91,59.52,59.73,55.36,560847,11-Jan-21,2.6,0.0457
11-Jan-21,Aerie Pharmaceuticals Receives European Commission Approval for Roclanda® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005%,"Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients w...",13.81,14.185,13.29,14.14,AERI,575300,HISTORICAL_PRICES,AERI,,1.61042E+12,-0.036287509,-0.036287509,14.14,13.81,14.185,13.29,575300,14.14,13.81,14.185,13.29,575300,11-Jan-21,-0.15,-0.0107
11-Jan-21,bluebird bio to Separate Oncology Business into Independent Company,"bluebird bio, Inc. (Nasdaq: BLUE) announced its intent to separate its severe genetic disease and oncology businesses into differentiated and independent publicly traded companies. bluebird bio, Inc....",50.4,50.665,46.58,49.61,BLUE,1791930,HISTORICAL_PRICES,BLUE,,1.61042E+12,0.106719368,0.106719368,49.61,50.4,50.665,46.58,1791930,49.61,50.4,50.665,46.58,1791930,11-Jan-21,1.86,0.0383
8-Jan-21,"Glancy Prongay & Murray LLP, a National Class Action Law Firm, Continues Investigation of OrthoPediatrics Corp. (KIDS) on Behalf of Investors","Glancy Prongay & Murray LLP (“GPM”), a national investor rights law firm, continues its investigation on behalf of OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (NASDAQ: KIDS) investo...",42.59,42.86,41.59,42.52,KIDS,108598,HISTORICAL_PRICES,KIDS,,1.61016E+12,-0.080328223,-0.080328223,42.52,42.59,42.86,41.59,108598,42.52,42.59,42.86,41.59,108598,8-Jan-21,0.34,0.008
8-Jan-21,"INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Tricida, Inc. (TCDA) on Behalf of Investors","Law Offices of Howard G. Smith announces an investigation on behalf of Tricida, Inc. (“Tricida” or the “Company”) (NASDAQ: TCDA) investors concerning the Company’s possible violations of federal secur...",7.8,7.98,7.56,7.59,TCDA,325743,HISTORICAL_PRICES,TCDA,,1.61016E+12,0.007751938,0.007751938,7.59,7.8,7.98,7.56,325743,7.59,7.8,7.98,7.56,325743,8-Jan-21,0.13,0.0169
8-Jan-21,U.S. FDA Lists Applied DNA’s Linea™ COVID-19 Assay Kit as 1 of Only 2 EUA-Authorized Tests Able to Detect S-Gene Mutation Found in SARS-CoV-2 U.K. Variant (B.1.1.7),"Applied DNA Sciences, Inc. (NASDAQ: APDN) (the “Company”), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing, announced today that the U.S. Food and Drug Administration (FDA) publish...",11.64,12.3499,5.56,5.71,APDN,22046212,HISTORICAL_PRICES,APDN,,1.61016E+12,1.147601476,1.147601476,5.71,11.64,12.3499,5.56,22046212,5.71,11.64,12.3499,5.56,22046212,8-Jan-21,5.96,1.0493
8-Jan-21,"SHAREHOLDER ACTION REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Tricida, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm","The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Tricida, Inc. (“Tricida” or “the Company”) (NASDAQ: TCDA) for violations of §...",7.8,7.98,7.56,7.59,TCDA,325743,HISTORICAL_PRICES,TCDA,,1.61016E+12,0.007751938,0.007751938,7.59,7.8,7.98,7.56,325743,7.59,7.8,7.98,7.56,325743,8-Jan-21,0.13,0.0169
8-Jan-21,"The Law Offices of Frank R. Cruz Announces Investigation of Tricida, Inc. (TCDA) on Behalf of Investors","The Law Offices of Frank R. Cruz announces an investigation of Tricida, Inc. (“Tricida” or the “Company”) (NASDAQ: TCDA) on behalf of investors concerning the Company’s possible violations of federal...",7.8,7.98,7.56,7.59,TCDA,325743,HISTORICAL_PRICES,TCDA,,1.61016E+12,0.007751938,0.007751938,7.59,7.8,7.98,7.56,325743,7.59,7.8,7.98,7.56,325743,8-Jan-21,0.13,0.0169
8-Jan-21,"Amneal Launches Generic Abiraterone Acetate Tablets, USP, 500 mg, Following ANDA Approval by FDA","Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) announced that it has received approval of an additional strength of 500 mg to its Abbreviated New Drug Application (ANDA), from t...",4.78,5.02,4.61,4.99,AMRX,1521216,HISTORICAL_PRICES,AMRX,,1.61016E+12,0.079006772,0.079006772,4.99,4.78,5.02,4.61,1521216,4.99,4.78,5.02,4.61,1521216,8-Jan-21,-0.18,-0.0363
8-Jan-21,United Kingdom Medicines and Healthcare products Regulatory Agency Authorizes Use of COVID-19 Vaccine Moderna,"Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that the UK’s Medicines and Healthcare products Regulatory Agency (MHRA...",112.75,117.71,111.49,116.52,MRNA,12376939,HISTORICAL_PRICES,MRNA,,1.61016E+12,-0.086230651,-0.086230651,116.52,112.75,117.71,111.49,12376939,116.52,112.75,117.71,111.49,12376939,8-Jan-21,-2.34,-0.0203
8-Jan-21,Enanta Pharmaceuticals to Provide Updates on its Research and Development Programs and Outlook for 2021 at the 39th Annual J.P. Morgan Healthcare Conference,"Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that Jay R. Luly,...",45.61,46.87,44.6201,45.86,ENTA,153744,HISTORICAL_PRICES,ENTA,,1.61016E+12,0.063170163,0.063170163,45.86,45.61,46.87,44.6201,153744,45.86,45.61,46.87,44.6201,153744,8-Jan-21,-0.2,-0.0044
7-Jan-21,Revance to Participate in the 39th Annual J.P. Morgan Healthcare Conference,"Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company focused on innovative aesthetic and therapeutic offerings, today announced that the company will participate in the 39th Annual J.P....",29.59,29.845,27.38,27.38,RVNC,683070,HISTORICAL_PRICES,RVNC,,1.61007E+12,0.074047187,0.074047187,27.38,29.59,29.845,27.38,683070,27.38,29.59,29.845,27.38,683070,7-Jan-21,2.39,0.0879
7-Jan-21,"SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Tricida, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm","The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Tricida, Inc. (“Tricida” or “the Company”) (NASDAQ: TCDA) for violations of §...",7.67,7.7,7.355,7.42,TCDA,323360,HISTORICAL_PRICES,TCDA,,1.61007E+12,-0.009043928,-0.009043928,7.42,7.67,7.7,7.355,323360,7.42,7.67,7.7,7.355,323360,7-Jan-21,0.31,0.0421
7-Jan-21,ADC Therapeutics startet Expanded-Access-Programm für Loncastuximab-Tesirin in den USA,"ADC Therapeutics SA (NYSE:ADCT), ein auf Onkologie spezialisiertes Biotechnologieunternehmen und Pionier bei der Entwicklung und Vermarktung hochwirksamer und zielgerichteter Antikörper-Wirkstoff-Konj...",31.6,32,30.63,31.1,ADCT,167916,HISTORICAL_PRICES,ADCT,,1.61007E+12,-0.145715058,-0.145715058,31.1,31.6,32,30.63,167916,31.1,31.6,32,30.63,167916,7-Jan-21,1.24,0.0408
7-Jan-21,Quidel Announces Preliminary Revenue for Fourth Quarter 2020; Will Present Virtually at 39th Annual J.P. Morgan Healthcare Conference,"Quidel Corporation (NASDAQ: QDEL) (“Quidel”), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that it expects revenue...",194.95,212,175,205.5,QDEL,3204831,HISTORICAL_PRICES,QDEL,,1.61007E+12,-0.012861411,-0.012861411,205.5,194.95,212,175,3204831,205.5,194.95,212,175,3204831,7-Jan-21,-9.12,-0.0447
7-Jan-21,Zymeworks to Present at J.P. Morgan Healthcare Conference and Host Two Webcasts in January to Provide Updates on its Lead Clinical Programs Zanidatamab and ZW49,"Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that management will present at the upcoming 39th Annual J.P. Morgan...",53.54,53.67,51.67,52.08,ZYME,438872,HISTORICAL_PRICES,ZYME,,1.61007E+12,0.06802314,0.06802314,52.08,53.54,53.67,51.67,438872,52.08,53.54,53.67,51.67,438872,7-Jan-21,1.87,0.0362
7-Jan-21,Revance Provides Corporate Update and Anticipated Milestones for 2021,"Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company focused on innovative aesthetic and therapeutic offerings, today provided a corporate update, product pipeline timing and anticipated...",29.59,29.845,27.38,27.38,RVNC,683070,HISTORICAL_PRICES,RVNC,,1.61007E+12,0.074047187,0.074047187,27.38,29.59,29.845,27.38,683070,27.38,29.59,29.845,27.38,683070,7-Jan-21,2.39,0.0879
7-Jan-21,"Ocular Therapeutix™ Promotes Michael Goldstein, MD, MBA, to President, Ophthalmology and Appoints Rabia Gurses Ozden, MD as Senior Vice President, Clinical Development","Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today...",21.62,22.3,20.9,21,OCUL,758621,HISTORICAL_PRICES,OCUL,,1.61007E+12,-0.020833333,-0.020833333,21,21.62,22.3,20.9,758621,21,21.62,22.3,20.9,758621,7-Jan-21,1.17,0.0572
7-Jan-21,Twist Bioscience Supplies Centers for Disease Control and Prevention with Custom SARS-CoV-2 Synthetic RNA Controls,"Twist Bioscience Corporation (Nasdaq: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced it will supply the U...",156.97,157.68,148.4,151.01,TWST,819543,HISTORICAL_PRICES,TWST,,1.61007E+12,-0.043099244,-0.043099244,151.01,156.97,157.68,148.4,819543,151.01,156.97,157.68,148.4,819543,7-Jan-21,13.55,0.0945
7-Jan-21,ADC Therapeutics Initiates Expanded Access Program for Loncastuximab Tesirine in the U.S.,"ADC Therapeutics SA (NYSE:ADCT), a late clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of highly potent and targeted antibody drug conjugates (A...",31.6,32,30.63,31.1,ADCT,167916,HISTORICAL_PRICES,ADCT,,1.61007E+12,-0.145715058,-0.145715058,31.1,31.6,32,30.63,167916,31.1,31.6,32,30.63,167916,7-Jan-21,1.24,0.0408
7-Jan-21,AngioDynamics Reports Fiscal 2021 Second Quarter Financial Results,"AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced financial resul...",18.57,19.52,16.5,16.51,ANGO,1236383,HISTORICAL_PRICES,ANGO,,1.61007E+12,0.313295615,0.313295615,16.51,18.57,19.52,16.5,1236383,16.51,18.57,19.52,16.5,1236383,7-Jan-21,2.38,0.147
7-Jan-21,Alnylam Reports Positive Topline Results from HELIOS-A Phase 3 Study of Vutrisiran in Patients with hATTR Amyloidosis with Polyneuropathy,"Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that the HELIOS-A Phase 3 study of vutrisiran, an investigational RNAi therapeutic in development f...",139.4,140,132.03,133.62,ALNY,1072701,HISTORICAL_PRICES,ALNY,,1.61007E+12,0.013375981,0.013375981,133.62,139.4,140,132.03,1072701,133.62,139.4,140,132.03,1072701,7-Jan-21,12.57,0.0991
7-Jan-21,Kala Pharmaceuticals Announces Availability of EYSUVISTM for the Treatment of Dry Eye Disease and Provides Update on Development Pipeline,"Kala Pharmaceuticals, Inc., (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced the...",7.08,7.2637,6.92,7.1,KALA,2222215,HISTORICAL_PRICES,KALA,,1.61007E+12,-0.075718016,-0.075718016,7.1,7.08,7.2637,6.92,2222215,7.1,7.08,7.2637,6.92,2222215,7-Jan-21,0.27,0.0396
7-Jan-21,Aldeyra Therapeutics Announces Positive Top-Line Symptom and Sign Results from Run-In Cohort of Phase 3 TRANQUILITY Trial in Dry Eye Disease,"Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced positive top-line symptom, redness, and Schirmer’s test results from the run-in cohort of the Phase 3 TRANQUILITY clinical trial in...",8.47,8.54,7.05,7.32,ALDX,3962267,HISTORICAL_PRICES,ALDX,,1.61007E+12,0.165061898,0.165061898,7.32,8.47,8.54,7.05,3962267,7.32,8.47,8.54,7.05,3962267,7-Jan-21,1.77,0.2642
7-Jan-21,AVEO Oncology Highlights Recent Progress and 2021 Outlook,AVEO Oncology (Nasdaq: AVEO) today highlighted its recent progress and outlined its 2021 outlook. “We remain keenly focused on building out our commercial team ahead of the potential U.S. launch of ti...,7.21,7.24,6.4,6.4,AVEO,941654,HISTORICAL_PRICES,AVEO,,1.61007E+12,0.230375427,0.230375427,6.4,7.21,7.24,6.4,941654,6.4,7.21,7.24,6.4,941654,7-Jan-21,0.9,0.1426
7-Jan-21,Sage Therapeutics Provides 2021 Corporate Strategy Update at J.P. Morgan Healthcare Conference,"Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain...",89.68,92.135,87.5183,88.58,SAGE,532271,HISTORICAL_PRICES,SAGE,,1.61007E+12,0.006961599,0.006961599,88.58,89.68,92.135,87.5183,532271,88.58,89.68,92.135,87.5183,532271,7-Jan-21,2.34,0.0268
6-Jan-21,"Arcus Biosciences Appoints Biotech Industry Veteran, Andrew Perlman, M.D., Ph.D. and Gilead’s SVP of Research Biology, Michael Quigley, Ph.D. to Its Board of Directors","Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that Andrew Perlman, M.D., Ph.D. and Michael Quigle...",28.98,29.74,26.61,26.86,RCUS,950640,HISTORICAL_PRICES,RCUS,,1.60998E+12,-0.052321779,-0.052321779,26.86,28.98,29.74,26.61,950640,26.86,28.98,29.74,26.61,950640,6-Jan-21,2.28,0.0854
6-Jan-21,European Commission Authorizes COVID-19 Vaccine Moderna in Europe,"Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that the European Commission has granted a conditional marketing author...",116.26,116.93,110.28,111.11,MRNA,21590934,HISTORICAL_PRICES,MRNA,,1.60998E+12,-0.057784261,-0.057784261,111.11,116.26,116.93,110.28,21590934,111.11,116.26,116.93,110.28,21590934,6-Jan-21,7.08,0.0648
6-Jan-21,"Verastem Oncology Appoints Frank Neumann, M.D., Ph.D., as Chief Medical Officer","Verastem, Inc. (Nasdaq:VSTM) (also known as Verastem Oncology), a biopharmaceutical company committed to advancing new medicines for patients battling cancer, today announced the appointment of indust...",2.22,2.32,2.17,2.23,VSTM,3753553,HISTORICAL_PRICES,VSTM,,1.60998E+12,-0.034782609,-0.034782609,2.23,2.22,2.32,2.17,3753553,2.23,2.22,2.32,2.17,3753553,6-Jan-21,0.01,0.0045
6-Jan-21,Infinity Pharmaceuticals Provides Update for Eganelisib in Patients with Metastatic Urothelial Cancer,"Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) today provided an update on MARIO-275, the Company’s randomized, placebo controlled Phase 2 study evaluating the benefit of adding eganelisib to nivolumab...",2.06,2.15,1.91,2.05,INFI,1012478,HISTORICAL_PRICES,INFI,,1.60998E+12,-0.019047619,-0.019047619,2.05,2.06,2.15,1.91,1012478,2.05,2.06,2.15,1.91,1012478,6-Jan-21,0.08,0.0404
6-Jan-21,"NantKwest Executive Chairman Dr. Patrick Soon-Shiong to Present at 39th Annual J.P. Morgan Healthcare Conference on January 13, 2021","NantKwest, Inc. (NASDAQ: NK), a clinical-stage, natural killer cell-based therapeutics company, today announced that Dr. Patrick Soon-Shiong M.D., Executive Chairman of the Board of Directors, will pa...",12.83,13.43,12.5,12.9,NK,1393886,HISTORICAL_PRICES,NK,,1.60998E+12,-0.198625859,-0.198625859,12.9,12.83,13.43,12.5,1393886,12.9,12.83,13.43,12.5,1393886,6-Jan-21,-0.07,-0.0054
6-Jan-21,Spruce Biosciences Provides Corporate Update and Outlines Milestones for 2021,"Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet need, toda...",21.58,22.53,21.15,21.56,SPRB,50358,HISTORICAL_PRICES,SPRB,,1.60998E+12,-0.133681253,-0.133681253,21.56,21.58,22.53,21.15,50358,21.56,21.58,22.53,21.15,50358,6-Jan-21,-0.04,-0.0019
6-Jan-21,Seres Therapeutics to Present at 39th Annual J.P. Morgan Healthcare Conference,"Seres Therapeutics, Inc. (Nasdaq: MCRB) today announced that it will present a corporate overview at the 39th Annual J.P. Morgan Healthcare Conference on Thursday, January 14 at 11:40 a.m. ET. A live...",25.71,26.79,24.02,24.02,MCRB,1041577,HISTORICAL_PRICES,MCRB,,1.60998E+12,0.058896211,0.058896211,24.02,25.71,26.79,24.02,1041577,24.02,25.71,26.79,24.02,1041577,6-Jan-21,1.31,0.0537
6-Jan-21,Seres Therapeutics Publishes Positive SER-287 Phase 1b Ulcerative Colitis Study Results in Journal Gastroenterology,"Seres Therapeutics, Inc. (Nasdaq: MCRB) today announced the publication of data analyses from the Company’s Phase 1b trial of SER-287 in patients with active mild-to-moderate ulcerative colitis (UC),...",25.71,26.79,24.02,24.02,MCRB,1041577,HISTORICAL_PRICES,MCRB,,1.60998E+12,0.058896211,0.058896211,24.02,25.71,26.79,24.02,1041577,24.02,25.71,26.79,24.02,1041577,6-Jan-21,1.31,0.0537
6-Jan-21,Genetron Health Announces Exclusive Strategic Partnership with Sino Biopharm Subsidiary for HCCscreen™ in China,"Genetron Holdings Limited (“Genetron Health” or the “Company”) (Nasdaq: GTH), a leading precision oncology company in China that specializes in offering molecular profiling tests, early cancer screeni...",15.65,18.15,14.71,15,GTH,1815417,HISTORICAL_PRICES,GTH,,1.60998E+12,0.200153374,0.200153374,15,15.65,18.15,14.71,1815417,15,15.65,18.15,14.71,1815417,6-Jan-21,1.94,0.1415
5-Jan-21,Puma Biotechnology to Present at the J.P. Morgan Healthcare Conference,"Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder of Puma, will provide an overview of the...",10.65,10.92,10.25,10.33,PBYI,373661,HISTORICAL_PRICES,PBYI,,1.6099E+12,-0.06824147,-0.06824147,10.33,10.65,10.92,10.25,373661,10.33,10.65,10.92,10.25,373661,5-Jan-21,0.32,0.031
5-Jan-21,Dicerna to Participate in the H.C. Wainwright Virtual BioConnect Conference,"Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that Douglas M. Fam...",22,22.1541,21.32,22.11,DRNA,760483,HISTORICAL_PRICES,DRNA,,1.6099E+12,-0.061032864,-0.061032864,22.11,22,22.1541,21.32,760483,22.11,22,22.1541,21.32,760483,5-Jan-21,-0.07,-0.0032
5-Jan-21,"Henry Schein Acquires Majority Interest in Prism Medical Products, Enters Home Medical Supply Market","Henry Schein, Inc. (Nasdaq: HSIC), the world’s largest provider of health care solutions to office-based dental and medical practitioners, today announced the acquisition of a majority ownership posit...",67.78,68.24,66.075,66.075,HSIC,971343,HISTORICAL_PRICES,HSIC,,1.6099E+12,0.029621753,0.029621753,66.075,67.78,68.24,66.075,971343,66.075,67.78,68.24,66.075,971343,5-Jan-21,1.29,0.0194
5-Jan-21,Deciphera Pharmaceuticals to Present at the 39th Annual J.P. Morgan Healthcare Conference,"Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) today announced that Steve Hoerter, President and Chief Executive Officer, will present at the 39th Annual J.P. Morgan Healthcare Conference on Monday, Ja...",53.8,57.55,53.6,56.16,DCPH,326159,HISTORICAL_PRICES,DCPH,,1.6099E+12,-0.086277174,-0.086277174,56.16,53.8,57.55,53.6,326159,56.16,53.8,57.55,53.6,326159,5-Jan-21,-2.93,-0.0516
4-Jan-21,Israeli Ministry of Health Authorizes COVID-19 Vaccine Moderna for Use in Israel,"Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that Israel’s Ministry of Health (MOH) has given authorization to impor...",111.73,113.63,103.26,107.23,MRNA,22439554,HISTORICAL_PRICES,MRNA,,1.60981E+12,-0.094497123,-0.094497123,107.23,111.73,113.63,103.26,22439554,107.23,111.73,113.63,103.26,22439554,4-Jan-21,7.26,0.0695
4-Jan-21,Puma Biotechnology to Present at the H.C. Wainwright VIRTUAL BioConnect Conference,"Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder of Puma, will provide an overview of the...",10.33,10.73,10.16,10.26,PBYI,350058,HISTORICAL_PRICES,PBYI,,1.60981E+12,-0.09623797,-0.09623797,10.26,10.33,10.73,10.16,350058,10.26,10.33,10.73,10.16,350058,4-Jan-21,0.07,0.0068
4-Jan-21,ADC Therapeutics prendra part au SternIR Virtual Corporate Access Event,"ADC Therapeutics SA (NYSE:ADCT), une société biotechnologique spécialisée en oncologie au stade clinique avancé, à l’avant-garde du développement et de la mise sur le marché de conjugués anticorps-méd...",32.22,32.6155,31.66,32.45,ADCT,76058,HISTORICAL_PRICES,ADCT,,1.60981E+12,-0.128953771,-0.128953771,32.45,32.22,32.6155,31.66,76058,32.45,32.22,32.6155,31.66,76058,4-Jan-21,0.21,0.0066
4-Jan-21,ADC Therapeutics nimmt am SternIR Virtual Corporate Access Event teil,"ADC Therapeutics SA (NYSE:ADCT), ein im Bereich der späten klinischen Forschung tätiges Biotechnologieunternehmen mit Schwerpunkt auf Onkologie und Vorreiter bei der Entwicklung und Vermarktung von ho...",32.22,32.6155,31.66,32.45,ADCT,76058,HISTORICAL_PRICES,ADCT,,1.60981E+12,-0.128953771,-0.128953771,32.45,32.22,32.6155,31.66,76058,32.45,32.22,32.6155,31.66,76058,4-Jan-21,0.21,0.0066
4-Jan-21,Moderna Provides COVID-19 Vaccine Supply Update,"Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today provided a supply update for the Moderna COVID-19 Vaccine, increasing its base-ca...",111.73,113.63,103.26,107.23,MRNA,22439554,HISTORICAL_PRICES,MRNA,,1.60981E+12,-0.094497123,-0.094497123,107.23,111.73,113.63,103.26,22439554,107.23,111.73,113.63,103.26,22439554,4-Jan-21,7.26,0.0695
4-Jan-21,Applied DNA Announces Preliminary Estimated First Fiscal Quarter 2021 Revenues in the Range of $1.3 Million to $1.6 Million,"Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA” or the “Company”), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing, announced today that it expects revenues for the first...",5.32,5.37,5.08,5.22,APDN,184080,HISTORICAL_PRICES,APDN,,1.60981E+12,-0.018450185,-0.018450185,5.22,5.32,5.37,5.08,184080,5.22,5.32,5.37,5.08,184080,4-Jan-21,0.22,0.0431
4-Jan-21,AtriCure Announces Labeling Expansion for Cryo Nerve Block Therapy,"AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it has received U.S. Food and Drug Admi...",53.79,56.08,52.54,55.65,ATRC,276098,HISTORICAL_PRICES,ATRC,,1.60981E+12,-0.065334492,-0.065334492,55.65,53.79,56.08,52.54,276098,55.65,53.79,56.08,52.54,276098,4-Jan-21,-1.88,-0.0338
4-Jan-21,Dicerna Announces Enrollment Completion of PHYOX™2 Pivotal Trial of Nedosiran for Treatment of Primary Hyperoxaluria,"Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced enrollment completi...",22.07,22.665,21.83,21.83,DRNA,666624,HISTORICAL_PRICES,DRNA,,1.60981E+12,-0.058045241,-0.058045241,21.83,22.07,22.665,21.83,666624,21.83,22.07,22.665,21.83,666624,4-Jan-21,0.04,0.0018
4-Jan-21,Bruker Introduces MBT Sepsityper® Kit US IVD for Rapid and Affordable Identification of over 400 Microorganisms from Positive Blood Cultures,Bruker Corporation (Nasdaq: BRKR) today announce US FDA clearance and the US launch of the MBT Sepsityper Kit US IVD for rapid microbial identification of more than 425 microorganisms from positive bl...,53.31,55.12,53.06,54.46,BRKR,406723,HISTORICAL_PRICES,BRKR,,1.61482E+12,-0.018774158,-0.018774158,54.46,53.31,55.12,53.06,406723,54.4244,53.2751,55.084,53.0253,406723,4-Jan-21,-0.82,-0.0151
4-Jan-21,Taysha Gene Therapies Announces Collaboration with AllStripes on SURF1-Associated Leigh Syndrome Clinical Development and Natural History,"Taysha Gene Therapies, Inc., (NASDAQ: TSHA), a patient-centric gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the ce...",26.17,27.5726,25.04,26.74,TSHA,130129,HISTORICAL_PRICES,TSHA,,1.60981E+12,-0.037867647,-0.037867647,26.74,26.17,27.5726,25.04,130129,26.74,26.17,27.5726,25.04,130129,4-Jan-21,-0.37,-0.0139
4-Jan-21,"European Medicines Agency Validates Bristol Myers Squibb’s Application for Opdivo (nivolumab) Combined with Chemotherapy as First-Line Treatment in Metastatic Gastric Cancer, Gastroesophageal Junction Cancer and Esophageal Adenocarcinoma",Bristol Myers Squibb (NYSE: BMY) today announced that the European Medicines Agency (EMA) validated its Type II Variation Marketing Authorization Application (MAA) for Opdivo (nivolumab) in combinatio...,61.38,62.15,60.5,61.74,BMY,12429551,HISTORICAL_PRICES,BMY,,1.60981E+12,0.003761243,0.003761243,61.74,61.38,62.15,60.5,12429551,61.74,61.38,62.15,60.5,12429551,4-Jan-21,-0.65,-0.0105
4-Jan-21,European Medicines Agency Validates Bristol Myers Squibb’s Application for Opdivo (nivolumab) as Adjuvant Treatment for Resected Esophageal or Gastroesophageal Junction Cancer Following Chemoradiotherapy,Bristol Myers Squibb (NYSE:BMY) today announced that the European Medicines Agency (EMA) validated its Marketing Authorization Application (MAA) for Opdivo (nivolumab) as an adjuvant treatment for eso...,61.38,62.15,60.5,61.74,BMY,12429551,HISTORICAL_PRICES,BMY,,1.60981E+12,0.003761243,0.003761243,61.74,61.38,62.15,60.5,12429551,61.74,61.38,62.15,60.5,12429551,4-Jan-21,-0.65,-0.0105
4-Jan-21,US FDA Accepts Regulatory Submission from Pfizer and OPKO for Review of Somatrogon to Treat Pediatric Patients with Growth Hormone Deficiency,Pfizer Inc. (NYSE: PFE) and OPKO Health Inc. (NASDAQ: OPK) announced today that the US Food and Drug Administration (FDA) has accepted for filing the initial Biologics License Application (BLA) for so...,36.81,36.94,36.27,36.87,PFE,33565683,HISTORICAL_PRICES,PFE,,1.6118E+12,-0.012342367,-0.012342367,36.87,36.81,36.94,36.27,33565683,36.4732,36.4139,36.5425,35.8797,33565683,4-Jan-21,0,0
31-Dec-20,"INVESTOR ALERT: Kirby McInerney LLP Continues Investigation of Shareholder Claims Against Penumbra, Inc.","The law firm of Kirby McInerney LLP is investigating potential claims against Penumbra, Inc. (“Penumbra” or the “Company”) (NYSE: PEN). The investigation focuses on whether Penumbra issued false and/o...",175,177.89,174.025,177.89,PEN,318055,HISTORICAL_PRICES,PEN,,1.60947E+12,-0.066218452,-0.066218452,177.89,175,177.89,174.025,318055,177.89,175,177.89,174.025,318055,31-Dec-20,-1.91,-0.0108
31-Dec-20,"EQUITY ALERT: ROSEN, A TOP RANKED LAW FIRM, Announces Investigation of Securities Claims Against Liquidia Corporation – LQDA","Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of shareholders of Liquidia Corporation (NASDAQ: LQDA) resulting from allegations...",2.95,2.995,2.845,2.91,LQDA,635418,HISTORICAL_PRICES,LQDA,,1.60947E+12,0.046099291,0.046099291,2.91,2.95,2.995,2.845,635418,2.91,2.95,2.995,2.845,635418,31-Dec-20,0.02,0.0068
31-Dec-20,Moderna Announces Publication of Results from the Pivotal Phase 3 Trial of the Moderna COVID-19 Vaccine in The New England Journal of Medicine,"Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines today announced that interim safety and primary efficacy results from the Phase 3 trial...",104.47,113.55,102.66,110.55,MRNA,23369872,HISTORICAL_PRICES,MRNA,,1.60947E+12,-0.153334954,-0.153334954,110.55,104.47,113.55,102.66,23369872,110.55,104.47,113.55,102.66,23369872,31-Dec-20,-6.66,-0.0599
31-Dec-20,Moderna Confirms 40 Million COVID-19 Vaccine Dose Supply Agreement with the Government of the Republic of Korea,"Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today confirmed the Company has entered into a supply agreement with the government of...",104.47,113.55,102.66,110.55,MRNA,23369872,HISTORICAL_PRICES,MRNA,,1.60947E+12,-0.153334954,-0.153334954,110.55,104.47,113.55,102.66,23369872,110.55,104.47,113.55,102.66,23369872,31-Dec-20,-6.66,-0.0599
30-Dec-20,Recipharm and Moderna Finalize Agreement for Aseptic Drug Product Manufacturing and Fill-Finish for Supply to Countries Outside the U.S.,"Moderna, Inc. (NASDAQ:MRNA), biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, and Recipharm (STO: RECI-B), a leading contract development and manufacturing organization...",111.13,118.9408,108.8,118.4,MRNA,23965535,HISTORICAL_PRICES,MRNA,,1.60938E+12,-0.099359754,-0.099359754,118.4,111.13,118.9408,108.8,23965535,118.4,111.13,118.9408,108.8,23965535,30-Dec-20,-3.26,-0.0285
30-Dec-20,Incyte and Cellenkos Enter into Global Development Collaboration Agreement for CK0804,"Incyte (Nasdaq:INCY) and Cellenkos, Inc., a privately held, clinical stage biotech company, today announced a development collaboration to investigate the combination of ruxolitinib (Jakafi®) and CK08...",86.86,89.35,86.12,86.46,INCY,593983,HISTORICAL_PRICES,INCY,,1.60938E+12,-0.005837244,-0.005837244,86.46,86.86,89.35,86.12,593983,86.46,86.86,89.35,86.12,593983,30-Dec-20,0.99,0.0115
29-Dec-20,Moderna Confirms Discussions With the Government of South Korea to Supply South Korea With 40 Million Doses of COVID-19 Vaccine,"Moderna, Inc. (Nasdaq:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today confirmed that the Company is engaged in discussions with the government of South...",114.39,116.25,106.88,107.7957,MRNA,23718799,HISTORICAL_PRICES,MRNA,,1.60929E+12,0.755255486,0.755255486,107.7957,114.39,116.25,106.88,23718799,107.7957,114.39,116.25,106.88,23718799,29-Dec-20,2.99,0.0268
29-Dec-20,Pfizer and BioNTech to Supply the European Union with 100 Million Additional Doses of COMIRNATY®,"Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced they will supply an additional 100 million doses of COMIRNATY®, the companies’ COVID-19 Vaccine, to the 27 European Union (EU) me...",37.05,37.2,36.79,36.9,PFE,23152070,HISTORICAL_PRICES,PFE,,1.6118E+12,0.036073826,0.036073826,36.9,37.05,37.2,36.79,23152070,36.5029,36.6513,36.7997,36.3941,23152070,29-Dec-20,0.23,0.0062
29-Dec-20,Applied DNA Partners with CLEARED4 on Pooled COVID-19 Surveillance Testing Program,"Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA” or the “Company”), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing, announced today that its wholly-owned subsidiary, Appli...",5.27,5.59,5.11,5.35,APDN,702480,HISTORICAL_PRICES,APDN,,1.60929E+12,-0.327806122,-0.327806122,5.35,5.27,5.59,5.11,702480,5.35,5.27,5.59,5.11,702480,29-Dec-20,0.11,0.0213
29-Dec-20,Clovis Oncology Submits Investigational New Drug Applications for Novel Peptide-Targeted Radionuclide FAP-2286 for Therapeutic and Imaging Clinical Trial,"Clovis Oncology, Inc. (NASDAQ: CLVS) today announced that the company has completed submission of two Investigational New Drug (IND) applications to the U.S. Food and Drug Administration (FDA) for FAP...",4.45,4.74,4.41,4.697,CLVS,6608231,HISTORICAL_PRICES,CLVS,,1.60929E+12,-0.218612818,-0.218612818,4.697,4.45,4.74,4.41,6608231,4.697,4.45,4.74,4.41,6608231,29-Dec-20,-0.195,-0.042
29-Dec-20,Eyenovia Submits New Drug Application to FDA for Pharmacologic Mydriasis with MydCombi Targeting 80 Million Patient Encounters in the U.S. Annually,"Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company with Phase 3 programs in presbyopia, myopia and mydriasis, today announced that it has submitted a New Drug Applica...",5.61,5.86,5.43,5.8,EYEN,254310,HISTORICAL_PRICES,EYEN,,1.60929E+12,0.908163265,0.908163265,5.8,5.61,5.86,5.43,254310,5.8,5.61,5.86,5.43,254310,29-Dec-20,-0.13,-0.0226
29-Dec-20,TherapeuticsMD Announces Participation in Upcoming Investor Conferences,"TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative women’s healthcare company, today announced that the company will participate at the following investor conferences: Conference H.C. Wainwright BioCo...",1.18,1.23,1.15,1.22,TXMD,6573283,HISTORICAL_PRICES,TXMD,,1.60929E+12,-0.099236641,-0.099236641,1.22,1.18,1.23,1.15,6573283,1.22,1.18,1.23,1.15,6573283,29-Dec-20,-0.04,-0.0328
28-Dec-20,Quanterix Receives FDA Emergency Use Authorization for Semi-Quantitative Antibody Test,"Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis to advance the science of precision health, today announced that the Food and Drug Administration (FDA) has issued an Emer...",48.06,48.33,46.59,46.64,QTRX,229023,HISTORICAL_PRICES,QTRX,,1.60921E+12,0.522331327,0.522331327,46.64,48.06,48.33,46.59,229023,46.64,48.06,48.33,46.59,229023,28-Dec-20,2.12,0.0461
28-Dec-20,LORBRENA® (lorlatinib) sNDA in Previously Untreated ALK-Positive Lung Cancer Accepted for Priority Review by U.S. FDA,Pfizer Inc. (NYSE:PFE) today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the supplemental New Drug Application (sNDA) for LORBRENA ® (lorlatinib) as a f...,36.82,37.58,36.68,37.36,PFE,26993685,HISTORICAL_PRICES,PFE,,1.6118E+12,0.029642058,0.029642058,37.36,36.82,37.58,36.68,26993685,36.9579,36.4238,37.1756,36.2853,26993685,28-Dec-20,-0.45,-0.0121
28-Dec-20,Ocular TherapeutixTM Announces Exercise of Underwriters’ Option to Purchase Additional Shares,"Ocular Therapeutix™, Inc. (Nasdaq: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, tod...",20.39,22.14,20.13,21.8,OCUL,1306995,HISTORICAL_PRICES,OCUL,,1.60921E+12,1.60741688,1.60741688,21.8,20.39,22.14,20.13,1306995,21.8,20.39,22.14,20.13,1306995,28-Dec-20,-1.69,-0.0765
28-Dec-20,European Medicines Agency Validates Bristol Myers Squibb’s Application for Zeposia (ozanimod) for the Treatment of Ulcerative Colitis,Bristol Myers Squibb (NYSE:BMY) today announced that the European Medicines Agency (EMA) has validated its Marketing Authorization Application (MAA) for Zeposia (ozanimod) for the treatment of adults...,61.12,61.74,60.805,61.42,BMY,6855650,HISTORICAL_PRICES,BMY,,1.60946E+12,0.049270386,0.049270386,61.42,61.12,61.74,60.805,6855650,60.934,60.6363,61.2514,60.3238,6855650,28-Dec-20,-0.03,-0.0005
28-Dec-20,LYNPARZA® (olaparib) Receives Three New Approvals in Japan,"AstraZeneca and Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that LYNPARZA has been approved in Japan for the treatment of three types of advanced cancer: ovar...",80.45,81.14,80.13,80.65,MRK,4584159,HISTORICAL_PRICES,MRK,,1.61552E+12,-0.032471437,-0.032471437,80.65,80.45,81.14,80.13,4584159,79.9476,79.7493,80.4333,79.4321,4584159,28-Dec-20,0.31,0.0039
24-Dec-20,Greenwich LifeSciences to Ring Nasdaq Opening Bell on December 28,"Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in pati...",39.28,41.9955,39.05,41.95,GLSI,263518,HISTORICAL_PRICES,GLSI,,1.60886E+12,6.856,6.856,41.95,39.28,41.9955,39.05,263518,41.95,39.28,41.9955,39.05,263518,24-Dec-20,-0.79,-0.0197
23-Dec-20,Urovant Sciences Announces U.S. FDA Approval of GEMTESA® (vibegron) 75 mg Tablets for the Treatment of Patients with Overactive Bladder (OAB),"Urovant Sciences (Nasdaq: UROV) announced today that the U.S. Food and Drug Administration (FDA) has approved the New Drug Application (NDA) for once-daily 75 mg GEMTESA® (vibegron), a beta-3 adrenerg...",16.04,16.13,15.88,16.05,UROV,484076,HISTORICAL_PRICES,UROV,,1.60878E+12,0.715508021,0.715508021,16.05,16.04,16.13,15.88,484076,16.05,16.04,16.13,15.88,484076,23-Dec-20,0,0
23-Dec-20,Shareholder Alert: Robbins LLP Announces That Genfit SA (GNFT) is Being Sued for Misleading Shareholders,Shareholder rights law firm Robbins LLP announces that a purchaser of Genfit SA American Depository Shares (NASDAQ: GNFT) filed a class action complaint against the Company and its officers and direct...,5.02,5.1,4.97,4.97,GNFT,11425,HISTORICAL_PRICES,GNFT,,1.60878E+12,0.367847411,0.367847411,4.97,5.02,5.1,4.97,11425,4.97,5.02,5.1,4.97,11425,23-Dec-20,-0.06,-0.0118
23-Dec-20,The Law Offices of Frank R. Cruz Announces Investigation of Genfit S.A. (GNFT) on Behalf of Investors,The Law Offices of Frank R. Cruz announces an investigation of Genfit S.A. (“Genfit” or the “Company”) (NASDAQ: GNFT) on behalf of investors concerning the Company’s possible violations of federal sec...,5.02,5.1,4.97,4.97,GNFT,11425,HISTORICAL_PRICES,GNFT,,1.60878E+12,0.367847411,0.367847411,4.97,5.02,5.1,4.97,11425,4.97,5.02,5.1,4.97,11425,23-Dec-20,-0.06,-0.0118
23-Dec-20,Quidel Receives Emergency Use Authorization for Moderately Complex Solana® SARS Molecular Test for COVID-19 Diagnosis,"Quidel Corporation (NASDAQ: QDEL) (“Quidel”), a leading provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that it has rec...",200.01,202.6,195.38,201.74,QDEL,739450,HISTORICAL_PRICES,QDEL,,1.60878E+12,0.04193582,0.04193582,201.74,200.01,202.6,195.38,739450,201.74,200.01,202.6,195.38,739450,23-Dec-20,-3.59,-0.0176
23-Dec-20,INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Genfit S.A. (GNFT) on Behalf of Investors,Law Offices of Howard G. Smith announces an investigation on behalf of Genfit S.A. (“Genfit” or the “Company”) (NASDAQ: GNFT) investors concerning the Company’s possible violations of federal securiti...,5.02,5.1,4.97,4.97,GNFT,11425,HISTORICAL_PRICES,GNFT,,1.60878E+12,0.367847411,0.367847411,4.97,5.02,5.1,4.97,11425,4.97,5.02,5.1,4.97,11425,23-Dec-20,-0.06,-0.0118
23-Dec-20,Health Canada Authorizes Moderna COVID-19 Vaccine in Canada,"Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced tha...",130.34,132,115,120.05,MRNA,41905043,HISTORICAL_PRICES,MRNA,,1.60878E+12,1,1,120.05,130.34,132,115,41905043,120.05,130.34,132,115,41905043,23-Dec-20,4.46,0.0354
23-Dec-20,Twist Bioscience to Offer Synthetic RNA Control for UK Variant Strain of SARS-CoV-2,"Twist Bioscience Corporation (Nasdaq: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced plans to offer a new...",166.76,170.8599,159.17,168.65,TWST,684883,HISTORICAL_PRICES,TWST,,1.60878E+12,1.508046323,1.508046323,168.65,166.76,170.8599,159.17,684883,168.65,166.76,170.8599,159.17,684883,23-Dec-20,-1.13,-0.0067
23-Dec-20,Pfizer and BioNTech to Supply the U.S. with 100 Million Additional Doses of COVID-19 Vaccine,Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced a second agreement with the U.S. government to supply an additional 100 million doses of the companies’ COVID-19 Vaccine from pro...,37.44,37.65,36.88,37.01,PFE,36181989,HISTORICAL_PRICES,PFE,,1.6118E+12,0.046979866,0.046979866,37.01,37.44,37.65,36.88,36181989,36.6117,37.0371,37.2448,36.4831,36181989,23-Dec-20,0.7,0.0191
23-Dec-20,Bristol Myers Squibb Announces Update on Phase 3 CheckMate -548 Trial Evaluating Patients with Newly Diagnosed MGMT-Methylated Glioblastoma Multiforme,"Bristol Myers Squibb (NYSE: BMY) today announced an update on CheckMate -548, a Phase 3 trial evaluating the addition of Opdivo (nivolumab) to the current standard of care (temozolomide and radiation...",61,61.63,61,61.37,BMY,6235071,HISTORICAL_PRICES,BMY,,1.60946E+12,0.0472103,0.0472103,61.37,61,61.63,61,6235071,60.8844,60.5173,61.1423,60.5173,6235071,23-Dec-20,-0.43,-0.007
23-Dec-20,Merck Announces Supply Agreement with U.S. Government for Initial Doses of Investigational Biological Therapy for the Treatment of Patients with Severe and Critical COVID-19,"Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced it has entered into an agreement with the United States Government to support the development, manufacture and ini...",79.76,80.43,79.57,79.59,MRK,5778679,HISTORICAL_PRICES,MRK,,1.61552E+12,-0.040769693,-0.040769693,79.59,79.76,80.43,79.57,5778679,78.8968,79.0653,79.7295,78.877,5778679,23-Dec-20,0.34,0.0043
23-Dec-20,Erste Patienten – darunter ein COVID-19-Patient – mit der innovativen ECMO Technologie von Abiomed behandelt,"Abiomed (NASDAQ: ABMD) hat die Behandlung der weltweit ersten beiden Patienten mit dem Abiomed Breethe OXY-1 System bekannt gegeben, einem kompakten kardiopulmonalen Bypass-System. Die innovative ECMO...",304.05,309.13,300.81,304.34,ABMD,187556,HISTORICAL_PRICES,ABMD,,1.60878E+12,0.158418105,0.158418105,304.34,304.05,309.13,300.81,187556,304.34,304.05,309.13,300.81,187556,23-Dec-20,1.72,0.0057
22-Dec-20,"Greenwich LifeSciences, Inc. Announces Closing of Public Offering of Common Stock","Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in pati...",37.85,41.19,36.21,38.55,GLSI,895409,HISTORICAL_PRICES,GLSI,,1.60869E+12,6.57,6.57,38.55,37.85,41.19,36.21,895409,38.55,37.85,41.19,36.21,895409,22-Dec-20,1.1,0.0299
22-Dec-20,Genprex Completes Manufacturing Scale-Up for Clinical-Grade Production of REQORSA™ Immunogene Therapy for Upcoming Acclaim-1 and Acclaim-2 Clinical Trials For Lung Cancer,"Genprex, Inc. (“Genprex” or the “Company”) (Nasdaq: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, announced today th...",4.47,5.45,4.09,4.1,GNPX,11620540,HISTORICAL_PRICES,GNPX,,1.60869E+12,0.441935484,0.441935484,4.1,4.47,5.45,4.09,11620540,4.1,4.47,5.45,4.09,11620540,22-Dec-20,0.49,0.1231
22-Dec-20,"Notice of Lead Plaintiff Deadline for Shareholders in the Minerva Neurosciences, Inc. Class Action Lawsuit","Robbins Geller Rudman & Dowd LLP announces that a class action lawsuit has been filed in the District of Massachusetts on behalf of purchasers of Minerva Neurosciences, Inc. (NASDAQ:NERV) common s...",2.6,2.63,2.57,2.6,NERV,474434,HISTORICAL_PRICES,NERV,,1.60869E+12,-0.144736842,-0.144736842,2.6,2.6,2.63,2.57,474434,2.6,2.6,2.63,2.57,474434,22-Dec-20,0.02,0.0078
22-Dec-20,Ocular Therapeutix™ Announces Submission to the FDA of a Supplemental New Drug Application for DEXTENZA® (dexamethasone ophthalmic insert) for the Treatment of Ocular Itching Associated with Allergic Conjunctivitis,"Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today...",22.37,22.73,21.15,21.8,OCUL,1012802,HISTORICAL_PRICES,OCUL,,1.60869E+12,1.860613811,1.860613811,21.8,22.37,22.73,21.15,1012802,21.8,22.37,22.73,21.15,1012802,22-Dec-20,1.12,0.0527
22-Dec-20,PolarityTE Announces $8.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules,"PolarityTE, Inc. (Nasdaq: PTE), a company focused on transforming the lives of patients by discovering, designing, and developing a range of regenerative tissue products and biomaterials, announced to...",0.6199,0.6288,0.6,0.61,PTE,1426250,HISTORICAL_PRICES,PTE,,1.60869E+12,-0.392254902,-0.392254902,0.61,0.6199,0.6288,0.6,1426250,0.61,0.6199,0.6288,0.6,1426250,22-Dec-20,-0.0193,-0.0302
21-Dec-20,Revance Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4),"Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company focused on innovative aesthetic and therapeutic offerings, including its investigational neuromodulator product, DaxibotulinumtoxinA...",27.03,27.3,26.02,26.15,RVNC,389045,HISTORICAL_PRICES,RVNC,,1.6086E+12,0.050524679,0.050524679,26.15,27.03,27.3,26.02,389045,26.15,27.03,27.3,26.02,389045,21-Dec-20,0.28,0.0105
21-Dec-20,"Vertex Announces FDA Approvals of TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor), SYMDEKO® (tezacaftor/ivacaftor and ivacaftor) and KALYDECO® (ivacaftor) for Use in People With CF With Certain Rare Mutations",Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) expanded the eligibility for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) t...,234.55,235.58,228.8,233.02,VRTX,1567185,HISTORICAL_PRICES,VRTX,,1.6086E+12,-0.108615513,-0.108615513,233.02,234.55,235.58,228.8,1567185,233.02,234.55,235.58,228.8,1567185,21-Dec-20,-2.17,-0.0092
21-Dec-20,"Deux premières patientes, dont une atteinte de la COVID-19, ont été traitées avec ECMO, la technologie innovante d’Abiomed","Abiomed (NASDAQ: ABMD) annonce que, pour la première fois au monde, deux patientes ont été traitées avec l'Abiomed Breethe OXY-1 , un système de pontage cardiopulmonaire compact. La technologie avancé...",295.81,296.6,283.73,292.76,ABMD,443192,HISTORICAL_PRICES,ABMD,,1.6086E+12,0.127024041,0.127024041,292.76,295.81,296.6,283.73,443192,292.76,295.81,296.6,283.73,443192,21-Dec-20,2.42,0.0082
21-Dec-20,Pfizer and BioNTech Receive Authorization in the European Union for COVID-19 Vaccine,Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced today that the European Commission (EC) has granted a conditional marketing authorization (CMA) to Pfizer and BioNTech for COMIRNATY® (...,37.38,37.4,36.91,37.28,PFE,40891838,HISTORICAL_PRICES,PFE,,1.6118E+12,0.045302013,0.045302013,37.28,37.38,37.4,36.91,40891838,36.8788,36.9777,36.9975,36.5128,40891838,21-Dec-20,-0.3,-0.008
21-Dec-20,Pfizer and BioNTech Receive CHMP Positive Opinion for their COVID-19 Vaccine,Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a positive opinion t...,37.38,37.4,36.91,37.28,PFE,40891838,HISTORICAL_PRICES,PFE,,1.6118E+12,0.045302013,0.045302013,37.28,37.38,37.4,36.91,40891838,36.8788,36.9777,36.9975,36.5128,40891838,21-Dec-20,-0.3,-0.008
21-Dec-20,Quidel Receives Emergency Use Authorization for QuickVue® SARS Rapid Antigen Test for COVID-19 Diagnosis,"Quidel Corporation (NASDAQ: QDEL) (“Quidel”), a leading provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that Quidel has...",205.45,207.99,194.01,195.5,QDEL,1258557,HISTORICAL_PRICES,QDEL,,1.6086E+12,0.070275057,0.070275057,195.5,205.45,207.99,194.01,1258557,195.5,205.45,207.99,194.01,1258557,21-Dec-20,15.95,0.0842
21-Dec-20,Veracyte Announces ISO 13485:2016 Certification for Its In Vitro Diagnostics Quality Management System,"Veracyte, Inc. (Nasdaq: VCYT) today announced that the company has received ISO 13485:2016 certification for its Quality Management System (QMS) for the design, development and manufacture of genomic...",51.29,52.02,46.8,47.09,VCYT,1117854,HISTORICAL_PRICES,VCYT,,1.6086E+12,0.704553008,0.704553008,47.09,51.29,52.02,46.8,1117854,47.09,51.29,52.02,46.8,1117854,21-Dec-20,3.36,0.0701
21-Dec-20,"First Patients, Including a COVID-19 Patient, Treated with Abiomed’s Innovative ECMO Technology","Abiomed (NASDAQ: ABMD) announces the first two patients in the world have been treated with the Abiomed Breethe OXY-1 System, a compact cardiopulmonary bypass system. The advanced ECMO technology pump...",295.81,296.6,283.73,292.76,ABMD,443192,HISTORICAL_PRICES,ABMD,,1.6086E+12,0.127024041,0.127024041,292.76,295.81,296.6,283.73,443192,292.76,295.81,296.6,283.73,443192,21-Dec-20,2.42,0.0082
21-Dec-20,Clovis Oncology’s Rubraca® (rucaparib) Met the Primary Endpoint of Significantly Improving Progression-Free Survival vs. Chemotherapy in the ARIEL4 Randomized Phase 3 Treatment Study in Later-line Ovarian Cancer Patients with a BRCA mutation,"Clovis Oncology, Inc. (NASDAQ: CLVS), today announced topline data from the randomized Phase 3 ARIEL4 study of Rubraca, which met its primary endpoint of improved investigator-assessed progression-fre...",5.245,5.7,5.11,5.69,CLVS,16587063,HISTORICAL_PRICES,CLVS,,1.6086E+12,-0.079016681,-0.079016681,5.69,5.245,5.7,5.11,16587063,5.69,5.245,5.7,5.11,16587063,21-Dec-20,0.345,0.0704
21-Dec-20,Sesen Bio Submits Completed Biologics License Application to the FDA for Vicineum™ and Has Requested Priority Review,"Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced submission of the completed Biologics...",1.32,1.7,1.29,1.62,SESN,13604662,HISTORICAL_PRICES,SESN,,1.6086E+12,0.073170732,0.073170732,1.62,1.32,1.7,1.29,13604662,1.62,1.32,1.7,1.29,13604662,21-Dec-20,-0.42,-0.2414
21-Dec-20,Masimo Helps Clinicians at Renown Health Manage the COVID-19 Surge,"Masimo (NASDAQ: MASI) announced today that Masimo is helping clinicians at Renown Health in Reno, Nevada, to address the COVID-19 surge, including through use of Masimo SafetyNet™, a remote patient ma...",265.3,265.3,258.01,263.77,MASI,229324,HISTORICAL_PRICES,MASI,,1.6086E+12,0.217251663,0.217251663,263.77,265.3,265.3,258.01,229324,263.77,265.3,265.3,258.01,229324,21-Dec-20,-0.36,-0.0014
21-Dec-20,Exelixis Announces Cabozantinib Significantly Improved Progression-Free Survival in COSMIC-311 Phase 3 Pivotal Trial in Patients with Previously Treated Radioiodine-Refractory Differentiated Thyroid Cancer,"Exelixis, Inc. (NASDAQ: EXEL) today announced that COSMIC-311, the phase 3 pivotal trial evaluating cabozantinib (CABOMETYX®) versus placebo in patients with radioiodine-refractory differentiated thyr...",20.07,20.1,19.26,20.06,EXEL,2467417,HISTORICAL_PRICES,EXEL,,1.6086E+12,-0.136402754,-0.136402754,20.06,20.07,20.1,19.26,2467417,20.06,20.07,20.1,19.26,2467417,21-Dec-20,0.12,0.006
21-Dec-20,Legend Biotech Announces Initiation of Rolling Submission of Biologics License Application to U.S. FDA Seeking Approval of BCMA CAR-T Therapy Cilta-cel for the Treatment of Relapsed and/or Refractory Multiple Myeloma,"Legend Biotech Corporation (NASDAQ: LEGN) (“Legend Biotech”), a global clinical-stage biopharmaceutical company engaged in the discovery and development of novel cell therapies for oncology and other...",31.25,32.3,31.02,31.47,LEGN,286144,HISTORICAL_PRICES,LEGN,,1.6086E+12,0.080193571,0.080193571,31.47,31.25,32.3,31.02,286144,31.47,31.25,32.3,31.02,286144,21-Dec-20,-0.91,-0.0283
21-Dec-20,Taysha Gene Therapies Announces Queen’s University’s Receipt of Clinical Trial Application Approval from Health Canada for Phase 1/2 Clinical Trial of TSHA-101 for the Treatment of Infantile GM2 Gangliosidosis,"Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the cen...",22.11,22.7583,21.53,22.12,TSHA,183880,HISTORICAL_PRICES,TSHA,,1.6086E+12,-0.081047382,-0.081047382,22.12,22.11,22.7583,21.53,183880,22.12,22.11,22.7583,21.53,183880,21-Dec-20,-0.22,-0.0099
21-Dec-20,Walgreens and Labcorp Make Pixel by Labcorp™ At-Home COVID-19 Collection Kit Available Through Walgreens Find Care®,"Labcorp (NYSE: LH), a leading global life sciences company that is focused on advancing health and guiding patient care decisions, and Walgreens today announced that the Pixel by Labcorp™ At-Home COVI...",204.92,205.07,201.1001,202.49,LH,585614,HISTORICAL_PRICES,LH,,1.6086E+12,0.152206916,0.152206916,202.49,204.92,205.07,201.1001,585614,202.49,204.92,205.07,201.1001,585614,21-Dec-20,-0.19,-0.0009
21-Dec-20,"ImmunityBio and NantKwest to Merge, Creating a Leading Immunotherapy and Cell Therapy Company","ImmunityBio, a privately-held immunotherapy company, and NantKwest, Inc. (NASDAQ: NK), a clinical-stage, natural killer cell-based therapeutics company, today announced they have entered into an agree...",16.02,17.79,11.82,13.014,NK,37616708,HISTORICAL_PRICES,NK,,1.60861E+12,1.338686131,1.338686131,13.014,16.02,17.79,11.82,37616708,13.014,16.02,17.79,11.82,37616708,21-Dec-20,5.76,0.5614
18-Dec-20,Moderna Announces FDA Authorization of Moderna COVID-19 Vaccine in U.S.,"Moderna, Inc., (Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines today announced that the U.S. Food and Drug Administration’s (FDA) has authorized the em...",140.23,145,135.06,141.51,MRNA,33157833,HISTORICAL_PRICES,MRNA,,1.60834E+12,1.151756943,1.151756943,141.51,140.23,145,135.06,33157833,141.51,140.23,145,135.06,33157833,18-Dec-20,-3.77,-0.0262
18-Dec-20,"Glancy Prongay & Murray LLP, a National Class Action Law Firm, Continues Investigation of Triterras, Inc. (TRIT) on Behalf of Investors","Glancy Prongay & Murray LLP (“GPM”), a national investor rights law firm, continues its investigation on behalf of Triterras, Inc. (“Triterras” or the “Company”) (NASDAQ: TRIT) investors concernin...",8.45,8.89,8.05,8.85,TRIT,5645400,HISTORICAL_PRICES,TRIT,,1.60834E+12,-0.304526749,-0.304526749,8.85,8.45,8.89,8.05,5645400,8.85,8.45,8.89,8.05,5645400,18-Dec-20,-0.64,-0.0704
18-Dec-20,Frequency Therapeutics to Host Investor Event on the Potential for Restorative Treatments for Acquired Sensorineural Hearing Loss,"Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage biotechnology company focused on harnessing the body’s innate biology to repair or reverse damage caused by a broad range of degenerative...",32.14,41.69,30.35,41.19,FREQ,1851216,HISTORICAL_PRICES,FREQ,,1.60834E+12,0.501869159,0.501869159,41.19,32.14,41.69,30.35,1851216,41.19,32.14,41.69,30.35,1851216,18-Dec-20,-7.56,-0.1904
18-Dec-20,Sesen Bio Announces Positive Cost-Effectiveness Profile for Vicineum™ Based on the Final Evidence Report Issued by the Institute for Clinical and Economic Review (ICER),"Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced favorable results for the cost-effect...",1.74,1.79,1.7,1.7645,SESN,3991401,HISTORICAL_PRICES,SESN,,1.60834E+12,0.414634146,0.414634146,1.7645,1.74,1.79,1.7,3991401,1.7645,1.74,1.79,1.7,3991401,18-Dec-20,0.02,0.0116
18-Dec-20,European Commission Exercises Option for Additional 80 Million Doses of Moderna’s COVID-19 Vaccine Candidate,"Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced tha...",140.23,145,135.06,141.51,MRNA,33157833,HISTORICAL_PRICES,MRNA,,1.60834E+12,1.151756943,1.151756943,141.51,140.23,145,135.06,33157833,141.51,140.23,145,135.06,33157833,18-Dec-20,-3.77,-0.0262
18-Dec-20,"Greenwich LifeSciences, Inc. Prices $26.4 Million Upsized Public Offering of Common Stock","Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in pati...",38.22,41.7699,37.02,40,GLSI,1625280,HISTORICAL_PRICES,GLSI,,1.60834E+12,6.644,6.644,40,38.22,41.7699,37.02,1625280,40,38.22,41.7699,37.02,1625280,18-Dec-20,-6.3,-0.1415
17-Dec-20,Moderna Receives FDA Advisory Committee Vote Supporting Emergency Use for Moderna’s Vaccine Against COVID-19 in the United States,"Moderna, Inc., (Nasdaq:MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today confirmed that...",144,146.97,137.3,137.92,MRNA,32404457,HISTORICAL_PRICES,MRNA,,1.60826E+12,1.209605647,1.209605647,137.92,144,146.97,137.3,32404457,137.92,144,146.97,137.3,32404457,17-Dec-20,6.97,0.0509
17-Dec-20,Applied DNA Reports 2020 Year End and Fiscal Fourth Quarter Financial Results,"Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA” or the ""Company""), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing, today announced consolidated financial results for the...",6.24,6.4,5.83,6,APDN,1519427,HISTORICAL_PRICES,APDN,,1.60826E+12,-0.204081633,-0.204081633,6,6.24,6.4,5.83,1519427,6,6.24,6.4,5.83,1519427,17-Dec-20,0.39,0.0667
17-Dec-20,Applied DNA Awarded Pooled Surveillance Testing Contract Valued at Up to $2.0 Million from Suffolk County (N.Y.) Government,"Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA” or the ""Company""), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing, today announced that its wholly-owned subsidiary, Appli...",6.24,6.4,5.83,6,APDN,1519427,HISTORICAL_PRICES,APDN,,1.60826E+12,-0.204081633,-0.204081633,6,6.24,6.4,5.83,1519427,6,6.24,6.4,5.83,1519427,17-Dec-20,0.39,0.0667
17-Dec-20,Kiromic Announces Submission of Two IND Applications for PD1 Gamma-delta CAR - T cell Therapy with the FDA,"Kiromic BioPharma (“the Company”) (NASDAQ: KRBP), a target discovery and gene-editing company utilizing artificial intelligence and its proprietary neural network platform with a therapeutic focus on...",8.9,18.5,8.9,9.4793,KRBP,1491430,HISTORICAL_PRICES,KRBP,,1.60826E+12,-0.226086957,-0.226086957,9.4793,8.9,18.5,8.9,1491430,9.4793,8.9,18.5,8.9,1491430,17-Dec-20,-0.61,-0.0641
17-Dec-20,"NERV Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Notifies Minerva Neurosciences, Inc. Shareholders of Class Action and Lead Plaintiff Deadline: February 8, 2021","Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Minerva Neurosciences, Inc. (""Minerva"" or ""the Company"") (NASDAQ: NERV) and certain of its o...",2.64,2.69,2.59,2.64,NERV,439405,HISTORICAL_PRICES,NERV,,1.60826E+12,-0.131578947,-0.131578947,2.64,2.64,2.69,2.59,439405,2.64,2.64,2.69,2.59,439405,17-Dec-20,0.02,0.0076
17-Dec-20,Ra Medical Systems Announces Transfer of Listing to NYSE American,"Ra Medical Systems, Inc. (NYSE: RMED) , a medical device company focusing on commercializing excimer laser systems to treat vascular and dermatological diseases, announces that its common stock has be...",7.34,7.41,6.93,6.93,RMED,123664,HISTORICAL_PRICES,RMED,,1.60826E+12,0.255774166,0.255774166,6.93,7.34,7.41,6.93,123664,6.93,7.34,7.41,6.93,123664,17-Dec-20,0.3,0.0426
17-Dec-20,Revance Reports Positive Efficacy and Duration Results from Phase 2 Upper Facial Lines Study,"Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company focused on innovative aesthetic and therapeutic offerings, today announced positive topline efficacy and safety results from its Phas...",28.12,28.5,26.88,27,RVNC,795868,HISTORICAL_PRICES,RVNC,,1.60826E+12,0.09288768,0.09288768,27,28.12,28.5,26.88,795868,27,28.12,28.5,26.88,795868,17-Dec-20,1.55,0.0583
17-Dec-20,"AlloVir Announces FDA Clearance of Investigational New Drug Application for ALVR106, an Allogeneic, Off-the-Shelf, Multi-Virus Specific T Cell Therapy Targeting Four Devastating Respiratory Viruses","AlloVir (Nasdaq: ALVR), a late clinical-stage cell therapy company, announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for ALVR106, a...",43.83,45.45,41.16,43.42,ALVR,365595,HISTORICAL_PRICES,ALVR,,1.60826E+12,0.683826354,0.683826354,43.42,43.83,45.45,41.16,365595,43.42,43.83,45.45,41.16,365595,17-Dec-20,-0.01,-0.0002
17-Dec-20,ANI Pharmaceuticals Announces Approval and Launch of Aminocaproic Acid Tablets,"ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (Nasdaq: ANIP) today announced U.S. Food and Drug Administration (FDA) approval and the launch of Aminocaproic Acid Tablets USP, 500mg. The current a...",31.47,31.7,30,31.03,ANIP,46129,HISTORICAL_PRICES,ANIP,,1.60826E+12,0.171630678,0.171630678,31.03,31.47,31.7,30,46129,31.03,31.47,31.7,30,46129,17-Dec-20,0.71,0.0231
17-Dec-20,FDA Grants Priority Review to Merck’s Supplemental Biologics License Application for KEYTRUDA® (pembrolizumab) Plus Chemotherapy as First-Line Treatment for Locally Advanced Unresectable or Metastatic Esophageal and Gastroesophageal Junction Cancer,"Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted priority review for a new supplemental B...",79.82,80.56,79.68,80.39,MRK,11173677,HISTORICAL_PRICES,MRK,,1.61552E+12,-0.040048106,-0.040048106,80.39,79.82,80.56,79.68,11173677,79.6898,79.1248,79.8584,78.986,11173677,17-Dec-20,-0.01,-0.0001
17-Dec-20,Horizon Therapeutics plc Announces Short-Term TEPEZZA® (teprotumumab-trbw) Supply Disruption Due to Government-Mandated (Operation Warp Speed) COVID-19 Vaccine Production,Horizon Therapeutics plc (Nasdaq: HZNP) announced that it expects a short-term disruption in TEPEZZA (teprotumumab-trbw) supply as a result of recent government-mandated COVID-19 vaccine production or...,69.31,71.277,68.5,71,HZNP,10352639,HISTORICAL_PRICES,HZNP,,1.60826E+12,-0.07991504,-0.07991504,71,69.31,71.277,68.5,10352639,71,69.31,71.277,68.5,10352639,17-Dec-20,-7.38,-0.0962
16-Dec-20,"Glancy Prongay & Murray LLP, a National Class Action Law Firm, Continues Investigation of SolarWinds Corporation (SWI) on Behalf of Investors","Glancy Prongay & Murray LLP (“GPM”), a national investor rights law firm, continues its investigation on behalf of SolarWinds Corporation (“SolarWinds” or the “Company”) (NYSE: SWI) investors conc...",18.03,18.6936,17.47,18,SWI,3367818,HISTORICAL_PRICES,SWI,,1.60817E+12,-0.05848564,-0.05848564,18,18.03,18.6936,17.47,3367818,18,18.03,18.6936,17.47,3367818,16-Dec-20,-0.03,-0.0017
16-Dec-20,Resumen: Se obtienen dos importantes resultados en cuanto al acceso de pequeño calibre con Impella,Abiomed (NASDAQ: ABMD) anuncia haber logrado dos hitos importantes en el desarrollo de un acceso de pequeño calibre para la bomba cardíaca Impella. La bomba cardíaca Impella ECP ha completado la prime...,274.14,282,273.5,274.15,ABMD,303040,HISTORICAL_PRICES,ABMD,,1.60817E+12,0.044462224,0.044462224,274.15,274.14,282,273.5,303040,274.15,274.14,282,273.5,303040,16-Dec-20,-1.22,-0.0044
16-Dec-20,Zwei Meilensteine auf dem Weg zu kleineren Zugängen mit Impella erreicht,"Wie Abiomed (NASDAQ: ABMD) mitteilte, hat das Unternehmen bei der Entwicklung von kleineren Zugängen für die Impella-Herzpumpe zwei Meilensteine erreicht. Die Impella ECP Herzpumpe hat die erste Stufe...",274.14,282,273.5,274.15,ABMD,303040,HISTORICAL_PRICES,ABMD,,1.60817E+12,0.044462224,0.044462224,274.15,274.14,282,273.5,303040,274.15,274.14,282,273.5,303040,16-Dec-20,-1.22,-0.0044
16-Dec-20,Ingles Markets Pharmacy Prepared to Administer COVID-19 Vaccine,"The FDA announced it has granted its first emergency use authorization for COVID-19 vaccine. Ingles Markets, Incorporated (NASDAQ: IMKTA) is enthusiastic about this landmark announcement and continues...",41.71,42.29,41.23,41.9,IMKTA,151218,HISTORICAL_PRICES,IMKTA,,1.6099E+12,0.129434064,0.129434064,41.9,41.71,42.29,41.23,151218,41.7382,41.549,42.1267,41.0708,151218,16-Dec-20,-0.33,-0.0078
16-Dec-20,"Governor Lee, Commissioner Rolfe Announce Revance Therapeutics to Relocate Global Headquarters to Nashville","Tennessee Gov. Bill Lee, Department of Economic and Community Development Commissioner Bob Rolfe and Revance Therapeutics (NASDAQ: RVNC) officials announced today that the company will relocate its he...",26.57,27.05,26.04,27.01,RVNC,467660,HISTORICAL_PRICES,RVNC,,1.60817E+12,0.032646716,0.032646716,27.01,26.57,27.05,26.04,467660,27.01,26.57,27.05,26.04,467660,16-Dec-20,-0.18,-0.0067
16-Dec-20,"Transcat, Inc. Expands Life Science Market Penetration with BioTek Services, Inc. Acquisition","Transcat, Inc. (Nasdaq: TRNS) (“Transcat” or the “Company”), a leading provider of accredited calibration, repair, inspection and laboratory instrument services and value-added distributor of professi...",34.73,35.7991,34.505,35.61,TRNS,27589,HISTORICAL_PRICES,TRNS,,1.60817E+12,0.185728918,0.185728918,35.61,34.73,35.7991,34.505,27589,35.61,34.73,35.7991,34.505,27589,16-Dec-20,-1.16,-0.0323
16-Dec-20,Five Star Senior Living Residents to Receive COVID-19 Vaccinations,Five Star Senior Living Inc. (Nasdaq: FVE) today announced its plan to begin administering the COVID-19 vaccine to Five Star residents and team members this month. As the Pfizer COVID-19 vaccine has r...,8.07,8.4292,8.07,8.18,FVE,168009,HISTORICAL_PRICES,FVE,,1.60817E+12,0.691823899,0.691823899,8.18,8.07,8.4292,8.07,168009,8.18,8.07,8.4292,8.07,168009,16-Dec-20,-0.08,-0.0098
16-Dec-20,Sage Therapeutics Announces the Appointment of Barry Greene as CEO,"Sage Therapeutics (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating brain disorders, today annou...",74.52,75.685,72.8222,73.45,SAGE,628435,HISTORICAL_PRICES,SAGE,,1.60817E+12,0.265195246,0.265195246,73.45,74.52,75.685,72.8222,628435,73.45,74.52,75.685,72.8222,628435,16-Dec-20,2.65,0.0369
15-Dec-20,Ocular TherapeutixTM Announces Pricing of Public Offering of Common Stock,"Ocular Therapeutix™, Inc. (Nasdaq: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, tod...",22.95,23.11,21.56,21.76,OCUL,1032003,HISTORICAL_PRICES,OCUL,,1.60809E+12,1.934782609,1.934782609,21.76,22.95,23.11,21.56,1032003,21.76,22.95,23.11,21.56,1032003,15-Dec-20,0.63,0.0282
15-Dec-20,"Glancy Prongay & Murray LLP, a National Class Action Law Firm, Continues Investigation of Penumbra, Inc. (PEN) on Behalf of Investors","Glancy Prongay & Murray LLP (“GPM”), a national investor rights law firm, continues its investigation on behalf of Penumbra, Inc. (“Penumbra” or the “Company”) (NYSE: PEN) investors concerning the...",188.82,190.44,181.86,189.01,PEN,1216125,HISTORICAL_PRICES,PEN,,1.60809E+12,-0.023631005,-0.023631005,189.01,188.82,190.44,181.86,1216125,189.01,188.82,190.44,181.86,1216125,15-Dec-20,-0.82,-0.0043
15-Dec-20,Riassunto: Conseguiti due risultati importanti verso l'accesso di dimensioni ridotte con Impella,"Abiomed (NASDAQ: ABMD) annuncia di aver ottenuto due risultati importanti nello sviluppo dell'accesso di dimensioni ridotte per la pompa cardiaca Impella ECP, che ha completato la prima fase dello stu...",275.36,277.45,262.91,266.56,ABMD,258957,HISTORICAL_PRICES,ABMD,,1.60809E+12,0.049110375,0.049110375,266.56,275.36,277.45,262.91,258957,266.56,275.36,277.45,262.91,258957,15-Dec-20,7.74,0.0289
15-Dec-20,Gilead and Galapagos Announce New Commercialization and Development Agreement for Jyseleca® (Filgotinib),"Gilead Sciences, Inc. (Nasdaq: GILD) and Galapagos NV (Euronext & Nasdaq: GLPG) today announced that the companies have agreed to amend their existing arrangement for the commercialization and dev...",59.43,60.07,59.265,59.82,GILD,8077712,HISTORICAL_PRICES,GILD,,1.61552E+12,-0.045301205,-0.045301205,59.82,59.43,60.07,59.265,8077712,59.1468,58.7612,59.394,58.598,8077712,15-Dec-20,-0.41,-0.0069
15-Dec-20,"Los investigadores utilizan ORI™, el Índice de Reserva de Oxígeno de Masimo, para ayudar a contener la hiperoxia postoperatoria en pacientes que se sometieron a cirugía de mama","Masimo (NASDAQ: MASI) anunció hoy las conclusiones de un resumen presentado recientemente en Euroanaesthesia 2020, en el que el Dr. Kumagai y sus colegas del Hospital Universitario Iwate en Yahaba-cho...",266.08,268,261.2,263.61,MASI,391722,HISTORICAL_PRICES,MASI,,1.60809E+12,0.220830466,0.220830466,263.61,266.08,268,261.2,391722,263.61,266.08,268,261.2,391722,15-Dec-20,3.08,0.0117
15-Dec-20,Samenvatting: Twee mijlpalen behaald in de richting van toegang tot kleine boringen met Impella,Abiomed (NASDAQ: ABMD) kondigt de verwezenlijking aan van twee mijlpalen in de ontwikkeling van toegang voor kleine boringen voor de Impella-hartpomp. De Impella ECP-hartpomp heeft de eerste fase van...,275.36,277.45,262.91,266.56,ABMD,258957,HISTORICAL_PRICES,ABMD,,1.60809E+12,0.049110375,0.049110375,266.56,275.36,277.45,262.91,258957,266.56,275.36,277.45,262.91,258957,15-Dec-20,7.74,0.0289
15-Dec-20,TFF Pharmaceuticals Announces First Dosing of Asthma Patients with Voriconazole Inhalation Powder in a Phase 1b Clinical Trial,"TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) t...",14.38,14.49,13.73,14.22,TFFP,275948,HISTORICAL_PRICES,TFFP,,1.60809E+12,-0.112345679,-0.112345679,14.22,14.38,14.49,13.73,275948,14.22,14.38,14.49,13.73,275948,15-Dec-20,0.24,0.017
15-Dec-20,FSD Pharma Announces First Patient Randomized in Phase 2 Trial of FSD201 for the Treatment of Hospitalized Patients with COVID-19,FSD Pharma Inc. (Nasdaq: HUGE) (CSE: HUGE) (“FSD Pharma” or the “Company”) today announced the dosing of the first patient in its Phase 2a clinical trial of FSD201 (ultramicronized palmitoylethanolami...,1.77,1.9,1.68,1.88,HUGE,974153,HISTORICAL_PRICES,HUGE,,1.60988E+12,-0.328273245,-0.328273245,1.88,1.77,1.9,1.68,974153,1.88,1.77,1.9,1.68,974153,15-Dec-20,-0.06,-0.0328
15-Dec-20,"Cerus’ Distribution Partner, CEI, Announces Three-Year Tender Award with the Minas Gerais Hematology and Hemotherapy Center Foundation (HemoMinas) in Brazil for the INTERCEPT Blood System for Platelets","Cerus Corporation (Nasdaq: CERS) today announced that its distribution partner, Companhia Energética Integrada (CEI), was awarded a three-year contract with the HemoMinas Foundation (“HemoMinas”) of B...",7.09,7.32,6.91,7.16,CERS,2835852,HISTORICAL_PRICES,CERS,,1.60809E+12,0.201694915,0.201694915,7.16,7.09,7.32,6.91,2835852,7.16,7.09,7.32,6.91,2835852,15-Dec-20,-0.04,-0.0056
15-Dec-20,Comedian Whitney Cummings Partners with TherapeuticsMD to Launch “Just Say Vagina”,"TherapeuticsMD, Inc. (NASDAQ:TXMD), an innovative women’s healthcare company, announced the launch of Just Say Vagina to encourage women to speak clearly and directly about their reproductive health....",1.22,1.23,1.15,1.18,TXMD,6018391,HISTORICAL_PRICES,TXMD,,1.60809E+12,-0.06870229,-0.06870229,1.18,1.22,1.23,1.15,6018391,1.18,1.22,1.23,1.15,6018391,15-Dec-20,0.07,0.0609
15-Dec-20,Two Milestones Achieved Toward Small Bore Access with Impella,Abiomed (NASDAQ: ABMD) announces the achievement of two milestones in the development of small bore access for the Impella heart pump. The Impella ECP heart pump has completed the first stage in its U...,275.36,277.45,262.91,266.56,ABMD,258957,HISTORICAL_PRICES,ABMD,,1.60809E+12,0.049110375,0.049110375,266.56,275.36,277.45,262.91,258957,266.56,275.36,277.45,262.91,258957,15-Dec-20,7.74,0.0289
15-Dec-20,Verastem Oncology Initiates Phase 2 Registration-Directed Trial of VS-6766 and Defactinib in Previously Treated KRAS Mutant Non-Small Cell Lung Cancer,"Verastem, Inc. (Nasdaq:VSTM) (also known as Verastem Oncology), a biopharmaceutical company committed to advancing new medicines for patients battling cancer, today announced the initiation of a Phase...",2.21,2.29,2.11,2.29,VSTM,4626665,HISTORICAL_PRICES,VSTM,,1.60809E+12,0.826446281,0.826446281,2.29,2.21,2.29,2.11,4626665,2.29,2.21,2.29,2.11,4626665,15-Dec-20,-0.06,-0.0264
15-Dec-20,Alnylam Announces 2021 Product and Pipeline Goals and Provides Program Updates at R&D Day,"Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, is kicking off a virtual R&D Day event today. During the two-day event, the Company plans to showcase its comme...",135.7,136.64,133.08,134.07,ALNY,425227,HISTORICAL_PRICES,ALNY,,1.60809E+12,0.017699115,0.017699115,134.07,135.7,136.64,133.08,425227,134.07,135.7,136.64,133.08,425227,15-Dec-20,3.01,0.0227
15-Dec-20,Greenwich LifeSciences Announces Option Agreement for Pre-clinical Coronavirus Vaccine Candidates,"Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in pati...",52.9,65,43,51.5,GLSI,4326366,HISTORICAL_PRICES,GLSI,,1.60809E+12,9.58,9.58,51.5,52.9,65,43,4326366,51.5,52.9,65,43,4326366,15-Dec-20,6.1,0.1303
15-Dec-20,"Forscher verwenden Masimo ORi™, Oxygen Reserve Index, zur Unterdrückung postoperativer Hyperoxie bei Patientinnen, die sich einer Brustoperation unterziehen","Masimo (NASDAQ: MASI) gab heute die Ergebnisse eines kürzlich auf der Euroanaesthesia 2020 vorgestellten Abstracts bekannt, in dem Dr. Kumagai und Kollegen vom Iwate Medical University Hospital in Yah...",266.08,268,261.2,263.61,MASI,391722,HISTORICAL_PRICES,MASI,,1.60809E+12,0.220830466,0.220830466,263.61,266.08,268,261.2,391722,263.61,266.08,268,261.2,391722,15-Dec-20,3.08,0.0117
14-Dec-20,研究人员采用Masimo ORi™（氧储备指数）帮助抑制乳房手术患者的术后高氧,(美国商业资讯)--Masimo (NASDAQ: MASI)今天发布Euroanaesthesia 2020上最新呈报的一篇摘要的发现，该研究中，日本矢巾町岩手医科大学医院Kumagai博士及其同事调查Masimo ORi™（氧储备指数）能否用于限制术后高氧的程度1。研究人员的结论是，ORi可帮助“抑制高氧、预防缺氧”。 ORi在美国境外已有市售，是一种无创连续参数，旨在洞察中度高氧患者的氧气状...,263,271.56,262.59,268.57,MASI,349036,HISTORICAL_PRICES,MASI,,1.608E+12,0.206698784,0.206698784,268.57,263,271.56,262.59,349036,268.57,263,271.56,262.59,349036,14-Dec-20,-2,-0.0075
14-Dec-20,研究人員採用Masimo ORi™（氧儲備指數）幫助抑制乳房手術患者的術後高氧,(美國商業資訊)--Masimo (NASDAQ: MASI)今天發表Euroanaesthesia 2020上最新呈報的一篇摘要的發現，該研究中，日本矢巾町岩手醫科大學附設醫院Kumagai博士及其同事調查Masimo ORi™（氧儲備指數）能否用於限制術後高氧的程度1。研究人員的結論是，ORi可幫助「抑制高氧、預防缺氧」。 ORi在美國境外已有市售，是一種無創連續參數，旨在洞察中度高氧患者的氧...,263,271.56,262.59,268.57,MASI,349036,HISTORICAL_PRICES,MASI,,1.608E+12,0.206698784,0.206698784,268.57,263,271.56,262.59,349036,268.57,263,271.56,262.59,349036,14-Dec-20,-2,-0.0075
14-Dec-20,Ocular Therapeutix™ Announces Proposed Public Offering of Common Stock,"Ocular Therapeutix™, Inc. (Nasdaq: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, tod...",22.32,22.72,20.77,21.34,OCUL,1758577,HISTORICAL_PRICES,OCUL,,1.608E+12,1.854219949,1.854219949,21.34,22.32,22.72,20.77,1758577,21.34,22.32,22.72,20.77,1758577,14-Dec-20,1.59,0.0767
14-Dec-20,Os pesquisadores usam o índice de reserva de oxigênio Masimo ORi™ para ajudar a suprimir a hiperóxia pós-operatória em pacientes submetidos à cirurgia de mama,"Masimo (NASDAQ: MASI) anunciou hoje os resultados de um resumo recentemente apresentado no Euroanaesthesia 2020 em que o Dr. Kumagai e colegas do Iwate Medical University Hospital em Yahaba-cho, no Ja...",263,271.56,262.59,268.57,MASI,349036,HISTORICAL_PRICES,MASI,,1.608E+12,0.206698784,0.206698784,268.57,263,271.56,262.59,349036,268.57,263,271.56,262.59,349036,14-Dec-20,-2,-0.0075
14-Dec-20,ADC Therapeutics und Overland Pharmaceuticals melden Gründung von Overland ADCT BioPharma zur Entwicklung und Vermarktung von Lonca und anderen AWK für hämatologische und solide Tumorindikationen in Großchina und Singapur,"ADC Therapeutics SA (NYSE: ADCT) und Overland Pharmaceuticals, ein voll integriertes biopharmazeutisches Unternehmen, das von Hillhouse Capital finanziert wird, teilten heute mit, dass sie gemeinsam e...",34.24,35.14,33.505,34.25,ADCT,383924,HISTORICAL_PRICES,ADCT,,1.608E+12,0.022089552,0.022089552,34.25,34.24,35.14,33.505,383924,34.25,34.24,35.14,33.505,383924,14-Dec-20,-0.16,-0.0047
14-Dec-20,Moderna Confirms Supply Agreement with the Ministry of Health to Supply Singapore with mRNA Vaccine Against COVID-19 (mRNA-1273),"Moderna, Inc., (Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today confirmed tha...",155.07,163.7611,152.5606,163.4,MRNA,22467742,HISTORICAL_PRICES,MRNA,,1.608E+12,1.379469081,1.379469081,163.4,155.07,163.7611,152.5606,22467742,163.4,155.07,163.7611,152.5606,22467742,14-Dec-20,-1.86,-0.0119
14-Dec-20,"Legend Biotech Announces FDA Clearance of the IND for LB1901, an Investigational Autologous Anti-CD4 CAR-T Therapy for Relapsed or Refractory T-Cell Lymphoma","Legend Biotech Corporation (NASDAQ: LEGN) (“Legend Biotech”), a global clinical-stage biopharmaceutical company engaged in the discovery and development of novel cell therapies for oncology and other...",30,31.29,28.51,28.67,LEGN,471884,HISTORICAL_PRICES,LEGN,,1.608E+12,0.036985828,0.036985828,28.67,30,31.29,28.51,471884,28.67,30,31.29,28.51,471884,14-Dec-20,1.92,0.0684
14-Dec-20,AtriCure to Participate in the 39th Annual J.P. Morgan Healthcare Conference,"AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that the company will be participat...",48.13,49.39,47.53,47.75,ATRC,259802,HISTORICAL_PRICES,ATRC,,1.608E+12,0.254692388,0.254692388,47.75,48.13,49.39,47.53,259802,47.75,48.13,49.39,47.53,259802,14-Dec-20,1.26,0.0269
14-Dec-20,Acceleron Receives Orphan Designation from the European Commission (EC) for Sotatercept in Pulmonary Arterial Hypertension (PAH),"Acceleron Pharma Inc. (Nasdaq: XLRN), a biopharmaceutical company dedicated to the discovery, development, and commercialization of TGF-beta superfamily therapeutics to treat serious and rare diseases...",130.01,132.74,126.83,128,XLRN,569138,HISTORICAL_PRICES,XLRN,,1.608E+12,0.237836809,0.237836809,128,130.01,132.74,126.83,569138,128,130.01,132.74,126.83,569138,14-Dec-20,5.73,0.0461
14-Dec-20,Gamida Cell Provides Regulatory Update on Biologics License Application for Omidubicel,"Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to cures for blood cancers and serious hematologic diseases, today announced that the company conducted a Type B Meeting for...",9.09,9.25,8.14,8.23,GMDA,1718873,HISTORICAL_PRICES,GMDA,,1.608E+12,1.211678832,1.211678832,8.23,9.09,9.25,8.14,1718873,8.23,9.09,9.25,8.14,1718873,14-Dec-20,-0.83,-0.0837
14-Dec-20,ADC Therapeutics and Overland Pharmaceuticals Announce Formation of Overland ADCT BioPharma to Develop and Commercialize Lonca and other ADCs for Hematologic and Solid Tumor Indications in Greater China and Singapore,"ADC Therapeutics SA (NYSE:ADCT) and Overland Pharmaceuticals, a fully integrated biopharmaceutical company backed by Hillhouse Capital, today announced that they have jointly formed a new company, Ove...",34.24,35.14,33.505,34.25,ADCT,383924,HISTORICAL_PRICES,ADCT,,1.608E+12,0.022089552,0.022089552,34.25,34.24,35.14,33.505,383924,34.25,34.24,35.14,33.505,383924,14-Dec-20,-0.16,-0.0047
11-Dec-20,Pfizer and BioNTech Celebrate Historic First Authorization in the U.S. of Vaccine to Prevent COVID-19,"Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced today that the U.S. Food and Drug Administration (FDA) has authorized the emergency use of the mRNA vaccine, BNT162b2, against COVID-19...",41.12,42.07,40.69,41.97,PFE,60737026,HISTORICAL_PRICES,PFE,,1.6118E+12,0.149888143,0.149888143,41.97,41.12,42.07,40.69,60737026,41.5183,40.6775,41.6173,40.2521,60737026,11-Dec-20,-0.61,-0.0146
11-Dec-20,新研究提示，Masimo SpHb®無創連續血紅蛋白監測作為病童血液管理的一部分，可減少ICU留住時間和術後輸血,(美國商業資訊)--Masimo (NASDAQ: MASI)今天發表Euroanaesthesia 2020上最新呈報的一篇摘要的結果，該研究中，土耳其伊斯坦堡瑪律馬拉大學的Saraçoğlu博士及其同事調查Masimo無創連續血紅蛋白監測SpHb®作為接受大手術的病童輸血管理組成部分的有效性1。研究人員發現，使用SpHb可降低術後輸血率、縮短ICU留住時間、改善其他治療成效。 研究人員注意到，...,265,273.33,264.96,271.33,MASI,393020,HISTORICAL_PRICES,MASI,,1.60774E+12,0.215875201,0.215875201,271.33,265,273.33,264.96,393020,271.33,265,273.33,264.96,393020,11-Dec-20,-5.45,-0.0202
11-Dec-20,新研究提示，Masimo SpHb®无创连续血红蛋白监测作为患儿血液管理的一部分，可减少ICU留住时间和术后输血,(美国商业资讯)--Masimo (NASDAQ: MASI)今天发布Euroanaesthesia 2020上最新呈报的一篇摘要的结果，该研究中，土耳其伊斯坦布尔马尔马拉大学的Saraçoğlu博士及其同事调查Masimo无创连续血红蛋白监测SpHb®作为接受大手术的患儿输血管理组成部分的有效性1。研究人员发现，使用SpHb可降低术后输血率、缩短ICU留住时间、改善其他转归。 研究人员注意到，作...,265,273.33,264.96,271.33,MASI,393020,HISTORICAL_PRICES,MASI,,1.60774E+12,0.215875201,0.215875201,271.33,265,273.33,264.96,393020,271.33,265,273.33,264.96,393020,11-Dec-20,-5.45,-0.0202
11-Dec-20,Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4),"Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on December 10, 2020 the Compensation Committee of Puma’s Board of Directors approved the grant of an inducement re...",10.83,12.03,10.57,10.62,PBYI,2115806,HISTORICAL_PRICES,PBYI,,1.60774E+12,0.125779626,0.125779626,10.62,10.83,12.03,10.57,2115806,10.62,10.83,12.03,10.57,2115806,11-Dec-20,0.125,0.0117
11-Dec-20,U.S. Government Exercises 1st Option for Additional 100 Million Doses of Moderna’s COVID-19 Vaccine Candidate,"Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced tha...",156.93,163.75,155.89,159.7,MRNA,22069857,HISTORICAL_PRICES,MRNA,,1.60774E+12,1.40800982,1.40800982,159.7,156.93,163.75,155.89,22069857,159.7,156.93,163.75,155.89,22069857,11-Dec-20,1.24,0.008
11-Dec-20,Puma Biotechnology Presents Efficacy and Safety Outcomes from the Phase III NALA Trial at the 2020 SABCS,"Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, presented efficacy and safety outcomes in a subgroup of patients from the NALA trial who had central nervous system (CNS) metastas...",10.83,12.03,10.57,10.62,PBYI,2115806,HISTORICAL_PRICES,PBYI,,1.60774E+12,0.125779626,0.125779626,10.62,10.83,12.03,10.57,2115806,10.62,10.83,12.03,10.57,2115806,11-Dec-20,0.125,0.0117
11-Dec-20,"Un nuevo estudio asocia a Masimo SpHb®, monitoreo continuo y no invasivo de hemoglobina, como parte de la gestión de sangre en pacientes pediátricos con una reducción del tiempo de internación en la UCI y de las transfusiones postoperatorias","Masimo (NASDAQ: MASI) anunció hoy las conclusiones de un resumen presentado recientemente en Euroanaesthesia 2020 en el que el Dr. Saraçoğlu y sus colegas de la Universidad de Marmara en Estambul, Tur...",265,273.33,264.96,271.33,MASI,393020,HISTORICAL_PRICES,MASI,,1.60774E+12,0.215875201,0.215875201,271.33,265,273.33,264.96,393020,271.33,265,273.33,264.96,393020,11-Dec-20,-5.45,-0.0202
11-Dec-20,"Novo estudo associa o monitoramento não invasivo e contínuo de hemoglobina com o Masimo SpHb®, como parte do gerenciamento de sangue de paciente pediátrico, com redução de estadias e transfusão pós-operatória na UTI","Masimo (NASDAQ: MASI) anunciou hoje os resultados de um resumo recentemente apresentado no Euroanaesthesia 2020 em que o Dr. Saraçoğlu e colegas da Universidade de Marmara em Istambul, na Turquia, inv...",265,273.33,264.96,271.33,MASI,393020,HISTORICAL_PRICES,MASI,,1.60774E+12,0.215875201,0.215875201,271.33,265,273.33,264.96,393020,271.33,265,273.33,264.96,393020,11-Dec-20,-5.45,-0.0202
11-Dec-20,"Positive Results of CONTESSA, a Phase 3 Study of Tesetaxel in Patients with Metastatic Breast Cancer, Presented at the 2020 San Antonio Breast Cancer Symposium (SABCS)","Odonate Therapeutics, Inc. (NASDAQ: ODT), a pharmaceutical company dedicated to the development of best‑in‑class therapeutics that improve and extend the lives of patients with cancer, today announced...",15.56,18.5,15.25,18.3,ODT,791000,HISTORICAL_PRICES,ODT,,1.60774E+12,0.196923077,0.196923077,18.3,15.56,18.5,15.25,791000,18.3,15.56,18.5,15.25,791000,11-Dec-20,-1.245,-0.0741
11-Dec-20,Compliance with New York State Winter COVID-19 Plan Drives Demand for Applied DNA’s Pooled Surveillance Testing Program,"Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA” or the ""Company""), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing, announced that its Applied DNA Clinical Laboratories, L...",6.35,6.57,6.21,6.4,APDN,374985,HISTORICAL_PRICES,APDN,,1.60774E+12,-0.19005102,-0.19005102,6.4,6.35,6.57,6.21,374985,6.4,6.35,6.57,6.21,374985,11-Dec-20,-0.11,-0.017
11-Dec-20,Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) as First-Line Treatment in Adult Patients With Metastatic Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Colorectal Cancer,"Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has adopted a posi...",82.96,83.42,82.52,82.85,MRK,7613715,HISTORICAL_PRICES,MRK,,1.61552E+12,-0.002285027,-0.002285027,82.85,82.96,83.42,82.52,7613715,81.4849,81.5931,82.0455,81.1604,7613715,11-Dec-20,-0.03,-0.0004
11-Dec-20,Ra Medical Systems Announces the Availability of its Webcast Event Discussing the Role of Excimer Lasers in the Treatment of Psoriasis During the Pandemic,"Ra Medical Systems, Inc. (NYSE: RMED) announces the availability of its webcast event, The Inimitable Role of Excimer Lasers During the COVID-19 Pandemic, discussing the use of excimer lasers such as...",6.88,7.42,6.43,6.59,RMED,422808,HISTORICAL_PRICES,RMED,,1.60774E+12,0.177074423,0.177074423,6.59,6.88,7.42,6.43,422808,6.59,6.88,7.42,6.43,422808,11-Dec-20,0.17,0.0253
11-Dec-20,Greenwich LifeSciences Announces Poster Presentation on Its GP2 Phase III Clinical Trial Design for Recurring Breast Cancer,"Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in pati...",56,64.25,42.2,62,GLSI,3768763,HISTORICAL_PRICES,GLSI,,1.60774E+12,10.2,10.2,62,56,64.25,42.2,3768763,62,56,64.25,42.2,3768763,11-Dec-20,-16.22,-0.2246
10-Dec-20,Pfizer and BioNTech Receive FDA Advisory Committee Vote Supporting Potential First Emergency Use Authorization for Vaccine to Combat COVID-19 in the U.S.,Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced today that the U.S. Food and Drug Administration’s (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC) voted 17...,41.73,42.22,41.445,41.82,PFE,57749197,HISTORICAL_PRICES,PFE,,1.6118E+12,0.166946309,0.166946309,41.82,41.73,42.22,41.445,57749197,41.37,41.2809,41.7656,40.999,57749197,10-Dec-20,-0.12,-0.0029
10-Dec-20,Quidel Corporation CEO Douglas Bryant Named Executive of the Year in MedTech Dive Awards For 2020,"Quidel Corporation (NASDAQ: QDEL) (“Quidel”), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that Quidel’s President...",197.09,199.25,187.01,189.0012,QDEL,456177,HISTORICAL_PRICES,QDEL,,1.60765E+12,0.026724318,0.026724318,189.0012,197.09,199.25,187.01,456177,189.0012,197.09,199.25,187.01,456177,10-Dec-20,7.12,0.0375
10-Dec-20,Gilead Advances Oncology Portfolio With New Data From Phase 3 ASCENT Trial of Trodelvy® in Metastatic Triple Negative Breast Cancer,"Gilead Sciences, Inc. (Nasdaq: GILD) is presenting new data from the Phase 3 ASCENT trial of Trodelvy® (sacituzumab govitecan-hziy) in metastatic triple-negative breast cancer (mTNBC) at the 2020 San...",60.45,60.895,60.13,60.66,GILD,7239492,HISTORICAL_PRICES,GILD,,1.61552E+12,-0.028915663,-0.028915663,60.66,60.45,60.895,60.13,7239492,59.3061,59.1008,59.5359,58.7879,7239492,10-Dec-20,-0.37,-0.0061
10-Dec-20,Philip Morris International Announces Planned Leadership Succession,"Philip Morris International Inc. (PMI) (NYSE: PM) today announced a long-planned leadership succession, which will be completed in May 2021. PMI’s current Chief Executive Officer, André Calantzopoulos...",84.97,85.41,83.95,84.04,PM,8787824,HISTORICAL_PRICES,PM,,1.61612E+12,0.112901113,0.112901113,84.04,84.97,85.41,83.95,8787824,81.7441,82.6487,83.0767,81.6566,8787824,10-Dec-20,0.36,0.0043
10-Dec-20,Pfizer and BioNTech Announce Publication of Results from Landmark Phase 3 Trial of BNT162b2 COVID-19 Vaccine Candidate in The New England Journal of Medicine,Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that the New England Journal of Medicine has published safety and final efficacy results from the pivotal Phase 3 trial of BNT162...,41.73,42.22,41.445,41.82,PFE,57749197,HISTORICAL_PRICES,PFE,,1.6118E+12,0.166946309,0.166946309,41.82,41.73,42.22,41.445,57749197,41.37,41.2809,41.7656,40.999,57749197,10-Dec-20,-0.12,-0.0029
10-Dec-20,"SHAREHOLDER ACTION REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Minerva Neurosciences, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm","The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Minerva Neurosciences, Inc. (“Minerva” or “the Company”) (NASDAQ: NERV) for v...",2.65,2.68,2.56,2.64,NERV,617234,HISTORICAL_PRICES,NERV,,1.60765E+12,-0.128289474,-0.128289474,2.64,2.65,2.68,2.56,617234,2.64,2.65,2.68,2.56,617234,10-Dec-20,-0.01,-0.0038
10-Dec-20,Zanidatamab Clinical Data Selected for Oral Presentation at the American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium,"Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced the selection of three abstracts for presentation at the American So...",52.48,53.41,52.21,52.56,ZYME,320396,HISTORICAL_PRICES,ZYME,,1.60765E+12,0.193812557,0.193812557,52.56,52.48,53.41,52.21,320396,52.56,52.48,53.41,52.21,320396,10-Dec-20,-0.36,-0.0068
10-Dec-20,DiaMedica Therapeutics Announces Successful Type B Meeting with FDA for the Study of DM199 in Patients with Acute Ischemic Stroke,DiaMedica Therapeutics Inc. (Nasdaq: DMAC) announced that it recently received written responses from the FDA following a Type B Pre-IND meeting request that the Company submitted in October 2020 rega...,6.85,7.15,6.25,6.98,DMAC,649789,HISTORICAL_PRICES,DMAC,,1.60765E+12,0.751918159,0.751918159,6.98,6.85,7.15,6.25,649789,6.98,6.85,7.15,6.25,649789,10-Dec-20,0.65,0.1048
10-Dec-20,Paysign and ImmunoTek Collaborate in Support of COVID-19 Convalescent Plasma Collection,"Paysign, Inc. (NASDAQ: PAYS), a leading provider of prepaid card programs, digital banking services, and payment processing, along with ImmunoTek Bio Centers LLC, a growing biotech company focused on...",5.03,5.05,4.92,4.98,PAYS,285429,HISTORICAL_PRICES,PAYS,,1.60765E+12,-0.093693694,-0.093693694,4.98,5.03,5.05,4.92,285429,4.98,5.03,5.05,4.92,285429,10-Dec-20,0.04,0.008
10-Dec-20,Gilead Sciences to Acquire MYR GmbH,"Gilead Sciences, Inc. (Nasdaq: GILD) and MYR GmbH, a German biotechnology company focused on the development and commercialization of therapeutics for the treatment of chronic hepatitis delta virus (H...",60.45,60.895,60.13,60.66,GILD,7239492,HISTORICAL_PRICES,GILD,,1.61552E+12,-0.028915663,-0.028915663,60.66,60.45,60.895,60.13,7239492,59.3061,59.1008,59.5359,58.7879,7239492,10-Dec-20,-0.37,-0.0061
10-Dec-20,KalVista Pharmaceuticals Reports Second Fiscal Quarter Results,"KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today provide...",17.53,18.19,17,18.19,KALV,85011,HISTORICAL_PRICES,KALV,,1.60765E+12,0.374901961,0.374901961,18.19,17.53,18.19,17,85011,18.19,17.53,18.19,17,85011,10-Dec-20,-0.37,-0.0207
10-Dec-20,Moderna Announces First Participants Dosed in Phase 2/3 Study of COVID-19 Vaccine Candidate in Adolescents,"Moderna Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced that...",155.69,159.5,148.0101,151.13,MRNA,22059969,HISTORICAL_PRICES,MRNA,,1.60765E+12,1.388982661,1.388982661,151.13,155.69,159.5,148.0101,22059969,151.13,155.69,159.5,148.0101,22059969,10-Dec-20,-0.9,-0.0057
9-Dec-20,"New Study Associates Masimo SpHb®, Noninvasive and Continuous Hemoglobin Monitoring, as Part of Pediatric Patient Blood Management, with Reduced ICU Stays and Postoperative Transfusion","Masimo (NASDAQ: MASI) announced today the findings of an abstract recently presented at Euroanaesthesia 2020 in which Dr. Saraçoğlu and colleagues at Marmara University in Istanbul, Turkey investigate...",267.87,271.87,265.56,270.41,MASI,341938,HISTORICAL_PRICES,MASI,,1.60757E+12,0.229043359,0.229043359,270.41,267.87,271.87,265.56,341938,270.41,267.87,271.87,265.56,341938,9-Dec-20,-3.48,-0.0128
9-Dec-20,Puma Biotechnology Presents Final Overall Survival Analysis from the Phase III ExteNET Trial at the 2020 SABCS,"Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that efficacy results of neratinib in HER2-positive early stage breast cancer (eBC) from the Phase III ExteNET trial wer...",10.56,11.59,10.25,11.49,PBYI,612623,HISTORICAL_PRICES,PBYI,,1.60757E+12,0.097713098,0.097713098,11.49,10.56,11.59,10.25,612623,11.49,10.56,11.59,10.25,612623,9-Dec-20,-0.815,-0.0716
9-Dec-20,LabCorp Receives FDA Authorization to Make At-Home COVID-19 Collection Kits Available Through Retail,"LabCorp (NYSE: LH), a leading global life sciences company that is focused on advancing health and guiding patient care decisions, today announced that the U.S. Food and Drug Administration (FDA) gran...",202.37,202.63,199.69,201.91,LH,506145,HISTORICAL_PRICES,LH,,1.60757E+12,0.137868991,0.137868991,201.91,202.37,202.63,199.69,506145,201.91,202.37,202.63,199.69,506145,9-Dec-20,0.27,0.0013
9-Dec-20,"Puma Biotechnology Presents Updated Results from the Phase II SUMMIT Trial of Neratinib for HER2-Mutant, HR-Positive Metastatic Breast Cancer at SABCS 2020","Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, presented updated results from the ongoing Phase II SUMMIT trial of neratinib at the 2020 Virtual San Antonio Breast Cancer Sympos...",10.56,11.59,10.25,11.49,PBYI,612623,HISTORICAL_PRICES,PBYI,,1.60757E+12,0.097713098,0.097713098,11.49,10.56,11.59,10.25,612623,11.49,10.56,11.59,10.25,612623,9-Dec-20,-0.815,-0.0716
9-Dec-20,"SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Minerva Neurosciences, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm","The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Minerva Neurosciences, Inc. (“Minerva” or “the Company”) (NASDAQ: NERV) for v...",2.66,2.71,2.575,2.71,NERV,1218446,HISTORICAL_PRICES,NERV,,1.60757E+12,-0.125,-0.125,2.71,2.66,2.71,2.575,1218446,2.71,2.66,2.71,2.575,1218446,9-Dec-20,-0.03,-0.0112
9-Dec-20,"Lantheus Holdings Announces Acceptance and Priority Review of New Drug Application for PyLTM (18F-DCFPyL), a PSMA-Targeted Prostate Cancer PET Imaging Agent","Lantheus Holdings, Inc. (NASDAQ: LNTH) (the Company), the parent company of Lantheus Medical Imaging, Inc. and Progenics Pharmaceuticals, Inc., and a global leader in the development, manufacture and...",14.78,14.86,13.95,13.98,LNTH,749510,HISTORICAL_PRICES,LNTH,,1.60757E+12,0.228595179,0.228595179,13.98,14.78,14.86,13.95,749510,13.98,14.78,14.86,13.95,749510,9-Dec-20,0.8,0.0572
9-Dec-20,"Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Minerva Neurosciences, Inc. – NERV","Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Minerva Neurosciences, Inc. (NASDAQ: NERV) between May 15...",2.66,2.71,2.575,2.71,NERV,1218446,HISTORICAL_PRICES,NERV,,1.60757E+12,-0.125,-0.125,2.71,2.66,2.71,2.575,1218446,2.71,2.66,2.71,2.575,1218446,9-Dec-20,-0.03,-0.0112
9-Dec-20,"FBIO Investor Alert: Bronstein, Gewirtz & Grossman, LLC Reminds Fortress Biotech, Inc. Investors of Class Action and Lead Plaintiff Deadline: January 26, 2021","Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Fortress Biotech, Inc. (""Fortress Biotech"" or ""the Company"") (NASDAQ: FBIO) and certain of...",2.43,2.57,2.39,2.555,FBIO,901476,HISTORICAL_PRICES,FBIO,,1.60757E+12,-0.370466321,-0.370466321,2.555,2.43,2.57,2.39,901476,2.555,2.43,2.57,2.39,901476,9-Dec-20,-0.12,-0.0471
9-Dec-20,Infinity Pharmaceuticals Presents Front-Line Triple Negative Breast Cancer Data from Ongoing Phase 2 MARIO-3 Trial at the 2020 San Antonio Breast Cancer Symposium,"Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) today announced that data from the front-line triple negative breast cancer (TNBC) cohort from the ongoing MARIO-3 clinical trial was presented during the...",2.24,3.13,1.77,3.06,INFI,8805695,HISTORICAL_PRICES,INFI,,1.60757E+12,1.113207547,1.113207547,3.06,2.24,3.13,1.77,8805695,3.06,2.24,3.13,1.77,8805695,9-Dec-20,-0.53,-0.1913
9-Dec-20,RRD Announces Vaccination Distribution Toolkit to Support Marketing and Operations for Pending COVID-19 Vaccine,"R.R. Donnelley & Sons Company (RRD) (NYSE: RRD), a leading global provider of marketing and business communications, today introduces a comprehensive vaccination distribution toolkit — for healthc...",1.43,1.465,1.36,1.39,RRD,2908161,HISTORICAL_PRICES,RRD,,1.60757E+12,0.059259259,0.059259259,1.39,1.43,1.465,1.36,2908161,1.39,1.43,1.465,1.36,2908161,9-Dec-20,0.1,0.0752
9-Dec-20,Mirum Pharmaceuticals and Oberland Capital Announce Up to $210 Million Funding Arrangement,"Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) and Oberland Capital Management LLC (Oberland Capital) today announced a $200 million capped, tiered, revenue-based funding agreement based on net revenues o...",24.02,24.3511,22.905,23.81,MIRM,50351,HISTORICAL_PRICES,MIRM,,1.60757E+12,0.267546174,0.267546174,23.81,24.02,24.3511,22.905,50351,23.81,24.02,24.3511,22.905,50351,9-Dec-20,0.16,0.0067
9-Dec-20,"Gamida Cell Provides Pipeline Update, Including Detailed Results of Pivotal Phase 3 Clinical Study of Omidubicel, and Prepares to Start BLA Submission by End of 2020","Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to cures for blood cancers and serious hematologic diseases, today will be providing an update on the Phase 3 clinical study...",9.53,10.94,9.3,10.5,GMDA,992818,HISTORICAL_PRICES,GMDA,,1.60757E+12,1.318734793,1.318734793,10.5,9.53,10.94,9.3,992818,10.5,9.53,10.94,9.3,992818,9-Dec-20,-1.47,-0.1336
8-Dec-20,U.S. FDA Accepts for Priority Review the Biologics License Application for Pfizer’s Investigational 20-valent Pneumococcal Conjugate Vaccine for Adults 18 Years of Age and Older,Pfizer Inc. (NYSE:PFE) today announced that the U.S. Food and Drug Administration (FDA) accepted for priority review a Biologics License Application (BLA) for its 20-valent pneumococcal conjugate vacc...,42.56,42.77,41.35,41.4,PFE,87039307,HISTORICAL_PRICES,PFE,,1.6118E+12,0.1901566,0.1901566,41.4,42.56,42.77,41.35,87039307,40.9545,42.102,42.3097,40.905,87039307,8-Dec-20,1.31,0.0318
8-Dec-20,Jeffrey A. Bluestone Joins Gilead Sciences’ Board of Directors,"Gilead Sciences, Inc. (Nasdaq: GILD) announced today that Jeffrey A. Bluestone, PhD, has been appointed to the company’s Board of Directors. Dr. Bluestone is the President and Chief Executive Officer...",61.17,61.25,60.5294,60.56,GILD,6184976,HISTORICAL_PRICES,GILD,,1.61552E+12,-0.017349398,-0.017349398,60.56,61.17,61.25,60.5294,6184976,59.2083,59.8047,59.8829,59.1784,6184976,8-Dec-20,0.34,0.0056
8-Dec-20,ADC Therapeutics gibt aktualisierte klinische Daten zu den Antikörper-Wirkstoff-Konjugat-Programmen Loncastuximab-Tesirin (Lonca) und Camidanlumab-Tesirin (Cami) bekannt,"ADC Therapeutics SA (NYSE:ADCT), ein auf Onkologie spezialisiertes Biotechnologieunternehmen und Pionier bei der Entwicklung und Vermarktung hochwirksamer und zielgerichteter Antikörper-Wirkstoff-Konj...",35.63,36.16,34.2,34.6,ADCT,135507,HISTORICAL_PRICES,ADCT,,1.60749E+12,0.06358209,0.06358209,34.6,35.63,36.16,34.2,135507,34.6,35.63,36.16,34.2,135507,8-Dec-20,0.96,0.0277
8-Dec-20,Palantir Technologies Expands FDA Partnership With $44m Contract,"Palantir Technologies Inc. (NYSE:PLTR) announced today it was awarded a $44.4m, three-year contract with the U.S. Food and Drug Administration (FDA). The contract will build on Palantir’s existing par...",28.59,31.24,27.25,30.63,PLTR,124754317,HISTORICAL_PRICES,PLTR,,1.60749E+12,2.009473684,2.009473684,30.63,28.59,31.24,27.25,124754317,30.63,28.59,31.24,27.25,124754317,8-Dec-20,-0.35,-0.0121
8-Dec-20,"Incyte meldet Ergebnisse der Behandlung mit Parsaclisib, die bei Patienten mit rezidivierten oder refraktären B-Zell-Nicht-Hodgkin-Lymphomen zu hohen Raten von raschem und nachhaltigem Ansprechen führen","Incyte (Nasdaq:INCY) hat heute Daten aus drei laufenden Phase-2-Studien bekannt gegeben, in denen Parsaclisib, ein potenter, hochselektiver oraler Inhibitor der nächsten Generation von Phosphatidylino...",82.85,83.2,82.09,83.2,INCY,697160,HISTORICAL_PRICES,INCY,,1.60749E+12,-0.026096156,-0.026096156,83.2,82.85,83.2,82.09,697160,83.2,82.85,83.2,82.09,697160,8-Dec-20,-0.21,-0.0025
8-Dec-20,Genprex Completes Manufacturing Technology Transfer for Novel Gene Therapy,"Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, announced today th...",3.41,3.5,3.3062,3.4032,GNPX,705184,HISTORICAL_PRICES,GNPX,,1.60749E+12,0.1,0.1,3.4032,3.41,3.5,3.3062,705184,3.4032,3.41,3.5,3.3062,705184,8-Dec-20,0.09,0.0271
8-Dec-20,NanoVibronix Announces UroShield and PainShield Meet New Zealand Medicines and Medical Devices Safety Authority Regulatory Requirements,"NanoVibronix, Inc. (NASDAQ: NAOV), a medical device company that produces the UroShield® and PainShield® Surface Acoustic Wave (SAW) Portable Ultrasonic Therapeutic Devices, today announced that its U...",1.09,1.11,0.97,0.98,NAOV,2773974,HISTORICAL_PRICES,NAOV,,1.60749E+12,0.265675801,0.265675801,0.98,1.09,1.11,0.97,2773974,0.98,1.09,1.11,0.97,2773974,8-Dec-20,0.09,0.09
8-Dec-20,Seagen Highlights TUKYSA® (tucatinib) Data in Breast Cancer at Virtual 2020 San Antonio Breast Cancer Symposium,"Seagen Inc. (Nasdaq:SGEN) today announced the presentation of new data from TUKYSA (tucatinib), its HER2-positive metastatic breast cancer therapy, at the San Antonio Breast Cancer Symposium (SABCS) V...",184.46,185.44,177.3584,179.66,SGEN,689804,HISTORICAL_PRICES,SGEN,,1.60749E+12,0.028033216,0.028033216,179.66,184.46,185.44,177.3584,689804,179.66,184.46,185.44,177.3584,689804,8-Dec-20,5.22,0.0291
8-Dec-20,Switzerland Exercises Increased Option for 7.5 Million Doses of mRNA Vaccine Against COVID-19 (mRNA-1273),"Moderna, Inc., (Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced the...",169.86,170.51,164.3,165.75,MRNA,27738717,HISTORICAL_PRICES,MRNA,,1.60749E+12,1.606413994,1.606413994,165.75,169.86,170.51,164.3,27738717,165.75,169.86,170.51,164.3,27738717,8-Dec-20,10.34,0.0648
7-Dec-20,Incyte rend publics les résultats du traitement par Parsaclisib : un taux élevé de réponses rapides et durables chez les patients atteints de lymphome non-hodgkinien à cellules B récidivant ou réfractaire.,"Incyte (Nasdaq:INCY) a publié aujourd'hui les données de trois études en cours de phase 2 évaluant parsaclisib, un puissant inhibiteur oral de nouvelle génération et hautement sélectif de la phosphoin...",83.06,83.95,82.22,83.44,INCY,744527,HISTORICAL_PRICES,INCY,,1.60739E+12,-0.023627601,-0.023627601,83.44,83.06,83.95,82.22,744527,83.44,83.06,83.95,82.22,744527,7-Dec-20,-0.08,-0.001
7-Dec-20,The Law Offices of Frank R. Cruz Announces Investigation of Boston Scientific Corporation (BSX) on Behalf of Investors,The Law Offices of Frank R. Cruz announces an investigation of Boston Scientific Corporation (“Boston Scientific” or the “Company”) (NYSE: BSX) on behalf of investors concerning the Company’s possible...,34.25,34.49,33.905,34.36,BSX,18398503,HISTORICAL_PRICES,BSX,,1.60739E+12,-0.07731681,-0.07731681,34.36,34.25,34.49,33.905,18398503,34.36,34.25,34.49,33.905,18398503,7-Dec-20,-0.16,-0.0046
7-Dec-20,Bristol Myers Squibb Presents Analyses from Pivotal QUAZAR® AML-001 Study of Onureg® (azacitidine tablets; CC-486) in Adults with Acute Myeloid Leukemia in First Remission,"Bristol Myers Squibb (NYSE: BMY) today announced new results from the QUAZAR® AML-001 study presented at the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, evaluating Onureg®...",61.2,62.59,60.97,62.19,BMY,8974004,HISTORICAL_PRICES,BMY,,1.60946E+12,0.050643777,0.050643777,62.19,61.2,62.59,60.97,8974004,61.6979,60.7157,62.0947,60.4875,8974004,7-Dec-20,-1.11,-0.0178
7-Dec-20,Positive Phase 2 Proof-of-Concept Data for Viralym-M and Burden of Disease Data Presented in Oral Presentations at the 62nd American Society of Hematology Annual Meeting,"AlloVir (Nasdaq: ALVR), a late clinical-stage cell therapy company, today announced that results from the Phase 2, proof-of-concept CHARMS study demonstrated that an allogeneic, off-the-shelf, multi-v...",43.76,47.55,42.82,47.07,ALVR,146039,HISTORICAL_PRICES,ALVR,,1.60739E+12,0.681137149,0.681137149,47.07,43.76,47.55,42.82,146039,47.07,43.76,47.55,42.82,146039,7-Dec-20,-3.05,-0.0652
7-Dec-20,New Supportive Efficacy Data for GlycoMimetics’ Rivipansel in Sickle Cell Acute Vaso-Occlusive Crisis Presented at 62nd ASH Annual Meeting and Exposition,GlycoMimetics (Nasdaq: GLYC) today in an oral presentation at the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition disclosed new data reinforcing a now comprehensive set of find...,3.8,3.9299,3.7201,3.8,GLYC,1073890,HISTORICAL_PRICES,GLYC,,1.60739E+12,0.176470588,0.176470588,3.8,3.8,3.9299,3.7201,1073890,3.8,3.8,3.9299,3.7201,1073890,7-Dec-20,0.07,0.0188
7-Dec-20,"Forma Therapeutics Presents Clinical Proof-of-Concept Data at the 62nd Annual ASH Meeting Supporting the Potential of its Novel Investigational PKR Activator, FT-4202, to Treat Sickle Cell Disease (SCD)","Forma Therapeutics Holdings, Inc. (Nasdaq: FMTX), a clinical-stage biopharmaceutical company focused on rare hematologic diseases and cancers, today announced that clinical proof-of-concept in patient...",41.8,43.7,40.78,43.5,FMTX,225537,HISTORICAL_PRICES,FMTX,,1.60739E+12,-0.044134461,-0.044134461,43.5,41.8,43.7,40.78,225537,43.5,41.8,43.7,40.78,225537,7-Dec-20,-1.73,-0.0397
7-Dec-20,INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Boston Scientific Corporation (BSX) on Behalf of Investors,Law Offices of Howard G. Smith announces an investigation on behalf of Boston Scientific Corporation (“Boston Scientific” or the “Company”) (NYSE: BSX) investors concerning the Company’s possible viol...,34.25,34.49,33.905,34.36,BSX,18398503,HISTORICAL_PRICES,BSX,,1.60739E+12,-0.07731681,-0.07731681,34.36,34.25,34.49,33.905,18398503,34.36,34.25,34.49,33.905,18398503,7-Dec-20,-0.16,-0.0046
7-Dec-20,FDA Authorizes Sale of the IQOS 3 Tobacco Heating System Device in the United States,"Altria Group, Inc. (Altria) (NYSE: MO) announces today that the U.S. Food and Drug Administration (FDA) authorized commercialization of the next generation of the IQOS tobacco heating system device, I...",41.69,41.77,41.04,41.49,MO,9947486,HISTORICAL_PRICES,MO,,1.61655E+12,0.087659797,0.087659797,41.49,41.69,41.77,41.04,9947486,39.9654,40.1581,40.2351,39.532,9947486,7-Dec-20,0.32,0.0077
7-Dec-20,"ROSEN, A TOP RANKED LAW FIRM, Announces Filing of Securities Class Action Lawsuit Against Boston Scientific Corporation – BSX","Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Boston Scientific Corporation (NYSE: BSX) between April 2...",34.25,34.49,33.905,34.36,BSX,18398503,HISTORICAL_PRICES,BSX,,1.60739E+12,-0.07731681,-0.07731681,34.36,34.25,34.49,33.905,18398503,34.36,34.25,34.49,33.905,18398503,7-Dec-20,-0.16,-0.0046
7-Dec-20,Marinus Pharmaceuticals Provides Additional Ganaxolone Data During Scientific Exhibit at AES2020 Virtual Annual Meeting and Provides Corporate Update,"Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders, today announced it will host a virtual S...",15.61,15.7,14.56,14.56,MRNS,599456,HISTORICAL_PRICES,MRNS,,1.60739E+12,0.458878505,0.458878505,14.56,15.61,15.7,14.56,599456,14.56,15.61,15.7,14.56,599456,7-Dec-20,1.035,0.071
7-Dec-20,Seagen Announces Multiple ADCETRIS® (brentuximab vedotin) Presentations at the 2020 ASH Annual Meeting,"Seagen Inc. (Nasdaq:SGEN) today announced multiple ADCETRIS® (brentuximab vedotin) data presentations at the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, taking place virtu...",179.24,183.6,177.88,179.9,SGEN,783690,HISTORICAL_PRICES,SGEN,,1.60739E+12,-0.001058909,-0.001058909,179.9,179.24,183.6,177.88,783690,179.9,179.24,183.6,177.88,783690,7-Dec-20,0.01,0.0001
7-Dec-20,Data Evaluating Tafasitamab with and without Lenalidomide in Combination with R-CHOP in Patients with DLBCL Presented at ASH 2020,"Incyte (Nasdaq:INCY) and MorphoSys AG (FSE: MOR; Prime Standard Segment; MDAX & TecDAX; NASDAQ:MOR) announce that preliminary data from firstMIND, the ongoing Phase 1b, open-label, randomized stud...",83.06,83.95,82.22,83.44,INCY,744527,HISTORICAL_PRICES,INCY,,1.60739E+12,-0.023627601,-0.023627601,83.44,83.06,83.95,82.22,744527,83.44,83.06,83.95,82.22,744527,7-Dec-20,-0.08,-0.001
7-Dec-20,Incyte Announces Parsaclisib Treatment Results in High Rate of Rapid and Durable Responses in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas,"Incyte (Nasdaq:INCY) today announced data from three ongoing Phase 2 studies evaluating parsaclisib, a potent, highly selective, next-generation oral inhibitor of phosphatidylinositol 3-kinase delta (...",83.06,83.95,82.22,83.44,INCY,744527,HISTORICAL_PRICES,INCY,,1.60739E+12,-0.023627601,-0.023627601,83.44,83.06,83.95,82.22,744527,83.44,83.06,83.95,82.22,744527,7-Dec-20,-0.08,-0.001
7-Dec-20,Canada Exercises Increased Option for Total of 40 Million Doses of mRNA Vaccine Candidate Against COVID-19 (mRNA-1273),"Moderna, Inc., (Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced tha...",159.52,163.98,152.97,155.03,MRNA,31409838,HISTORICAL_PRICES,MRNA,,1.60739E+12,1.447752033,1.447752033,155.03,159.52,163.98,152.97,31409838,155.03,159.52,163.98,152.97,31409838,7-Dec-20,7,0.0459
7-Dec-20,Masimo’s COVID-19 Response Efforts Highlighted at California Life Sciences Association’s Pantheon 2020,"Masimo (NASDAQ: MASI) is proud to have been one of seven California innovators featured at Pantheon 2020, the annual event at which the California Life Sciences Association (CLSA) brings together indu...",267.53,268.17,263.34,265.86,MASI,261685,HISTORICAL_PRICES,MASI,,1.60739E+12,0.227483368,0.227483368,265.86,267.53,268.17,263.34,261685,265.86,267.53,268.17,263.34,261685,7-Dec-20,2.29,0.0086
7-Dec-20,Odonate Therapeutics Initiates Cohort 3 of CONTESSA TRIO to Evaluate Tesetaxel Monotherapy in Patients with Metastatic Breast Cancer,"Odonate Therapeutics, Inc. (NASDAQ: ODT), a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer, today announced...",16.47,17.2,16.35,16.5,ODT,267694,HISTORICAL_PRICES,ODT,,1.60739E+12,0.266923077,0.266923077,16.5,16.47,17.2,16.35,267694,16.5,16.47,17.2,16.35,267694,7-Dec-20,0.16,0.0098
7-Dec-20,Lyra Therapeutics Announces Positive Topline Results for LANTERN Phase 2 Randomized Controlled Study of LYR-210 for the Treatment of Chronic Rhinosinusitis With and Without Nasal Polyps,"Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatme...",9.32,10.05,8.7602,9.49,LYRA,1353961,HISTORICAL_PRICES,LYRA,,1.60739E+12,-0.186026201,-0.186026201,9.49,9.32,10.05,8.7602,1353961,9.49,9.32,10.05,8.7602,1353961,7-Dec-20,-3.15,-0.2526
7-Dec-20,Exelixis In-Licenses Aurigene’s Novel CDK7 Inhibitor and Files Investigational New Drug Application for Phase 1 Clinical Trial in Advanced Solid Tumors,"Exelixis, Inc. (Nasdaq: EXEL) and Aurigene today announced that Exelixis has exercised its exclusive option for Aurigene’s novel CDK7 inhibitor under the companies’ July 2019 agreement. Exelixis has n...",18.85,19.43,18.79,18.88,EXEL,1522877,HISTORICAL_PRICES,EXEL,,1.60739E+12,-0.188898451,-0.188898451,18.88,18.85,19.43,18.79,1522877,18.88,18.85,19.43,18.79,1522877,7-Dec-20,-0.13,-0.0068
7-Dec-20, VBI Vaccines Selects Syneos Health as Commercialization Partner for Prophylactic 3-Antigen Hepatitis B Vaccine,"VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, and Syneos Health (Nasdaq: SYNH), the leading Contract C...",3.3,3.48,3.23,3.2486,VBIV,7181752,HISTORICAL_PRICES,VBIV,,1.60739E+12,0.134020619,0.134020619,3.2486,3.3,3.48,3.23,7181752,3.2486,3.3,3.48,3.23,7181752,7-Dec-20,0.09,0.028
7-Dec-20,Sesen Bio Announces Commercial Manufacturing and Global Supply Partnership with Qilu Pharmaceutical,"Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced that on Friday, December 4, 2020 the...",1.54,1.67,1.51,1.55,SESN,8218636,HISTORICAL_PRICES,SESN,,1.60739E+12,0.25203252,0.25203252,1.55,1.54,1.67,1.51,8218636,1.55,1.54,1.67,1.51,8218636,7-Dec-20,0.01,0.0065
7-Dec-20,"Gossamer Bio to Host Webcast Focused on GB002 and Pulmonary Arterial Hypertension (PAH) on December 15, 2020","Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflamm...",9.08,9.4515,8.95,9.32,GOSS,530752,HISTORICAL_PRICES,GOSS,,1.60739E+12,-0.214532872,-0.214532872,9.32,9.08,9.4515,8.95,530752,9.32,9.08,9.4515,8.95,530752,7-Dec-20,-0.18,-0.0194
7-Dec-20,Marinus Launches Expanded Access Program for Ganaxolone Treatment in CDKL5 Deficiency Disorder,"Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders, today announced the launch of an expande...",15.61,15.7,14.56,14.56,MRNS,599456,HISTORICAL_PRICES,MRNS,,1.60739E+12,0.458878505,0.458878505,14.56,15.61,15.7,14.56,599456,14.56,15.61,15.7,14.56,599456,7-Dec-20,1.035,0.071
7-Dec-20,"Atara Biotherapeutics Presents First Preclinical Evaluation of ATA3219, a Next-Generation Allogeneic CD19 CAR T Cell Therapy, at the 62nd American Society of Hematology (ASH) Annual Meeting","Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious disease...",26.23,28.2,25.89,27.05,ATRA,840952,HISTORICAL_PRICES,ATRA,,1.60739E+12,1.090039841,1.090039841,27.05,26.23,28.2,25.89,840952,27.05,26.23,28.2,25.89,840952,7-Dec-20,1.64,0.0667
7-Dec-20,ADC Therapeutics Announces Updated Clinical Data on Lead Antibody Drug Conjugate Programs Loncastuximab Tesirine (Lonca) and Camidanlumab Tesirine (Cami) Presented at 62nd American Society of Hematology Annual Meeting,"ADC Therapeutics SA (NYSE:ADCT), a late clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of highly potent and targeted antibody drug conjugates (A...",34.67,35.21,32.85,33.33,ADCT,351992,HISTORICAL_PRICES,ADCT,,1.60739E+12,0.034925373,0.034925373,33.33,34.67,35.21,32.85,351992,33.33,34.67,35.21,32.85,351992,7-Dec-20,-1.18,-0.0329
4-Dec-20,Cerus Corporation Announces Presentation of Study Results with INTERCEPT-treated COVID-19 Convalescent Plasma at the American Society of Hematology Annual Meeting,Cerus Corporation (Nasdaq: CERS) today announced the oral presentation of a clinical study: “Efficacy of COVID-19 Pathogen Inactivated Convalescent Plasma for Patients with Moderate to Severe Acute CO...,7.19,7.3,7.03,7.03,CERS,2117985,HISTORICAL_PRICES,CERS,,1.60713E+12,0.218644068,0.218644068,7.03,7.19,7.3,7.03,2117985,7.03,7.19,7.3,7.03,2117985,4-Dec-20,0.19,0.0271
4-Dec-20,"INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Fortress Biotech, Inc. (FBIO) Investors","Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased Fortress Biotech, Inc. (“Fortress” or the “Company”) (NASDAQ: FBIO) securities...",2.78,2.82,2.72,2.77,FBIO,417967,HISTORICAL_PRICES,FBIO,,1.60713E+12,-0.279792746,-0.279792746,2.77,2.78,2.82,2.72,417967,2.77,2.78,2.82,2.72,417967,4-Dec-20,0.05,0.0183
4-Dec-20,"Shareholder Alert: Robbins LLP Announces Fortress Biotech, Inc. (FBIO) is Being Sued for Misleading Shareholders","Shareholder rights law firm Robbins LLP announces that a purchaser of Fortress Biotech, Inc. (NASDAQ: FBIO) filed a class action complaint against the Company and its officers and directors for allege...",2.78,2.82,2.72,2.77,FBIO,417967,HISTORICAL_PRICES,FBIO,,1.60713E+12,-0.279792746,-0.279792746,2.77,2.78,2.82,2.72,417967,2.77,2.78,2.82,2.72,417967,4-Dec-20,0.05,0.0183
4-Dec-20,Incyte Announces First Data from REACH3 Trial Showing Ruxolitinib (Jakafi®) Significantly Improved Outcomes in Patients with Steroid-Refractory or Steroid-Dependent Chronic Graft-Versus-Host Disease,Incyte (Nasdaq:INCY) today announced that detailed results from the pivotal Phase 3 REACH3 study demonstrate Jakafi® (ruxolitinib) significantly improved outcomes across a range of efficacy measures i...,83.14,83.86,82.41,83.06,INCY,862635,HISTORICAL_PRICES,INCY,,1.60713E+12,-0.022687199,-0.022687199,83.06,83.14,83.86,82.41,862635,83.06,83.14,83.86,82.41,862635,4-Dec-20,0.24,0.0029
4-Dec-20,"Stoke Therapeutics Announces Presentations Related to the Company’s Work to Advance STK-001, the First Potential New Medicine to Target the Underlying Cause of Dravet Syndrome at the American Epilepsy Society (AES) 2020 Annual Meeting","Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company pioneering a new way to treat the underlying cause of genetic diseases by precisely upregulating protein expression, today announced hi...",49.17,50,47.22,47.46,STOK,71057,HISTORICAL_PRICES,STOK,,1.60713E+12,0.492714026,0.492714026,47.46,49.17,50,47.22,71057,47.46,49.17,50,47.22,71057,4-Dec-20,1.9,0.0402
4-Dec-20,LivaNova to Host Satellite Symposium on Advances in Neuromodulation at American Epilepsy Society AES2020 Virtual Event,"LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today announced it will host “Updates and Advances in Neuromodulation,” a satellite symposium at AES2020, the vi...",55.24,55.51,54.12,54.88,LIVN,427786,HISTORICAL_PRICES,LIVN,,1.60713E+12,0.315551322,0.315551322,54.88,55.24,55.51,54.12,427786,54.88,55.24,55.51,54.12,427786,4-Dec-20,0.4,0.0073
4-Dec-20,Moderna Announces Amendment to Supply Agreement with the Ministry of Health of Israel to Supply Additional Doses of mRNA Vaccine Against COVID-19 (mRNA-1273),"Moderna, Inc., (Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced an...",152.52,157.82,148.51,157.59,MRNA,27704832,HISTORICAL_PRICES,MRNA,,1.60713E+12,1.340340648,1.340340648,157.59,152.52,157.82,148.51,27704832,157.59,152.52,157.82,148.51,27704832,4-Dec-20,-4.74,-0.0301
4-Dec-20,Pulse Biosciences Presents Update on Nano-Pulse Stimulation™ Technology at Prestigous Energy-Based Devices and Aesthetic Dermatology Conference,"Pulse Biosciences, Inc. (NASDAQ:PLSE), a novel bioelectric medicine company progressing Nano-Pulse Stimulation™ (NPS™) technology, today announced that a scientific update on its non-thermal NPS mecha...",17.14,17.44,16.63,17.14,PLSE,38227,HISTORICAL_PRICES,PLSE,,1.60713E+12,0.546931408,0.546931408,17.14,17.14,17.44,16.63,38227,17.14,17.14,17.44,16.63,38227,4-Dec-20,0.21,0.0124
3-Dec-20,Moderna Provides Updates on the Clinical Development and Production of Its COVID-19 Vaccine Candidate,"Moderna, Inc., (Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today provided an u...",157.26,159.11,143.0101,143.5,MRNA,38656507,HISTORICAL_PRICES,MRNA,,1.60705E+12,1.4130735,1.4130735,143.5,157.26,159.11,143.0101,38656507,143.5,157.26,159.11,143.0101,38656507,3-Dec-20,14.26,0.0997
3-Dec-20,"The Law Offices of Frank R. Cruz Announces Investigation of Fortress Biotech, Inc. (FBIO) on Behalf of Investors","The Law Offices of Frank R. Cruz announces an investigation of Fortress Biotech, Inc. (“Fortress” or the “Company”) (NASDAQ: FBIO) on behalf of investors concerning the Company’s possible violations o...",2.73,2.835,2.69,2.8,FBIO,502789,HISTORICAL_PRICES,FBIO,,1.60705E+12,-0.292746114,-0.292746114,2.8,2.73,2.835,2.69,502789,2.8,2.73,2.835,2.69,502789,3-Dec-20,-0.07,-0.025
3-Dec-20,"INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Fortress Biotech, Inc. (FBIO) on Behalf of Investors","Law Offices of Howard G. Smith announces an investigation on behalf of Fortress Biotech, Inc. (“Fortress” or the “Company”) (NASDAQ: FBIO) investors concerning the Company’s possible violations of fed...",2.73,2.835,2.69,2.8,FBIO,502789,HISTORICAL_PRICES,FBIO,,1.60705E+12,-0.292746114,-0.292746114,2.8,2.73,2.835,2.69,502789,2.8,2.73,2.835,2.69,502789,3-Dec-20,-0.07,-0.025
3-Dec-20,"SHAREHOLDER ACTION REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Fortress Biotech, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm","The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Fortress Biotech, Inc. (“Fortress” or “the Company”) (NASDAQ: FBIO) for viola...",2.73,2.835,2.69,2.8,FBIO,502789,HISTORICAL_PRICES,FBIO,,1.60705E+12,-0.292746114,-0.292746114,2.8,2.73,2.835,2.69,502789,2.8,2.73,2.835,2.69,502789,3-Dec-20,-0.07,-0.025
3-Dec-20,"Notice of Lead Plaintiff Deadline for Shareholders in the Intercept Pharmaceuticals, Inc. Class Action Lawsuit","Robbins Geller Rudman & Dowd LLP announces that a class action lawsuit has been filed in the Eastern District of New York on behalf of purchasers of Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) s...",35.2,36.72,35,36.72,ICPT,453841,HISTORICAL_PRICES,ICPT,,1.60705E+12,-0.114688129,-0.114688129,36.72,35.2,36.72,35,453841,36.72,35.2,36.72,35,453841,3-Dec-20,-1.41,-0.0385
3-Dec-20,Genprex to Present at the Benzinga Global Small Cap Conference on December 8,"Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced th...",3.355,3.47,3.32,3.38,GNPX,411777,HISTORICAL_PRICES,GNPX,,1.60705E+12,0.082258065,0.082258065,3.38,3.355,3.47,3.32,411777,3.38,3.355,3.47,3.32,411777,3-Dec-20,0.015,0.0045
3-Dec-20,UroGen Pharma Announces Podium Presentation of Final Jelmyto® Data From Pivotal OLYMPUS Trial at the Annual Meeting of the Society of Urologic Oncology,"UroGen Pharma Ltd. (Nasdaq: URGN) a biopharmaceutical company dedicated to building and commercializing novel solutions that treat specialty cancers and urologic diseases, today announced the presenta...",19.85,20.48,19.5,20.48,URGN,80119,HISTORICAL_PRICES,URGN,,1.60705E+12,0.028497409,0.028497409,20.48,19.85,20.48,19.5,80119,20.48,19.85,20.48,19.5,80119,3-Dec-20,-0.13,-0.0065
3-Dec-20,"Alnylam Completes Enrollment in ILLUMINATE-C Phase 3 Study of Lumasiran, an RNAi Therapeutic, for the Treatment of Advanced Primary Hyperoxaluria Type 1","Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it has achieved full patient enrollment in its ILLUMINATE-C Phase 3 study of lumasiran, an RNA...",131.17,132.87,129.68,130,ALNY,299566,HISTORICAL_PRICES,ALNY,,1.60705E+12,-0.016274186,-0.016274186,130,131.17,132.87,129.68,299566,130,131.17,132.87,129.68,299566,3-Dec-20,1.7,0.0131
3-Dec-20,CMS Confirms Continued Separate Payment for Omeros’ FDA-Approved OMIDRIA® in Ambulatory Surgery Centers,Omeros Corporation (Nasdaq: OMER) announced today that the Centers for Medicare & Medicaid Services (CMS) confirmed separate payment in ambulatory surgery centers (ASCs) for Omeros’ cataract surge...,14.26,14.8,13.655,14.4038,OMER,4937268,HISTORICAL_PRICES,OMER,,1.60705E+12,0.450661241,0.450661241,14.4038,14.26,14.8,13.655,4937268,14.4038,14.26,14.8,13.655,4937268,3-Dec-20,1.83,0.1472
3-Dec-20,Taysha Gene Therapies Receives Rare Pediatric Disease and Orphan Drug Designations for TSHA-103 for the Treatment of Epilepsy Caused by SLC6A1 Haploinsufficiency,"Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the cen...",20.29,22.08,20.28,21.6,TSHA,91775,HISTORICAL_PRICES,TSHA,,1.60705E+12,-0.156691604,-0.156691604,21.6,20.29,22.08,20.28,91775,21.6,20.29,22.08,20.28,91775,3-Dec-20,-1.35,-0.0624
3-Dec-20,"Eyenovia Announces FDA Acceptance of IND for MicroLine for Presbyopia, Clearing Path to Initiate Phase 3 VISION Trial by Year End","Eyenovia, Inc., (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose array print (MAP™) therapeutics, today announced that the U. S. Food and Drug A...",3.61,3.74,3.55,3.68,EYEN,254435,HISTORICAL_PRICES,EYEN,,1.60705E+12,0.227891156,0.227891156,3.68,3.61,3.74,3.55,254435,3.68,3.61,3.74,3.55,254435,3-Dec-20,0.06,0.0169
3-Dec-20,PMI Commits to Disability Inclusion by Joining The Valuable 500,Philip Morris International Inc.(PMI) (NYSE: PM) today announced that CEO André Calantzopoulos has joined The Valuable 500—a global movement putting disability inclusion on the business leadership age...,78.5,78.67,77.7,78.25,PM,4313433,HISTORICAL_PRICES,PM,,1.61612E+12,0.02815979,0.02815979,78.25,78.5,78.67,77.7,4313433,76.1123,76.3555,76.5208,75.5773,4313433,3-Dec-20,0.43,0.0055
2-Dec-20,Outset Medical Announces Pricing of Secondary Public Offering,"Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, announced today the pricing of an un...",54.94,58.99,52.74,58.01,OM,539189,HISTORICAL_PRICES,OM,,1.607E+12,0.056944979,0.056944979,58.01,54.94,58.99,52.74,539189,58.01,54.94,58.99,52.74,539189,2-Dec-20,-2.78,-0.0482
2-Dec-20,Akers’ Proposed Merger Partner MyMD Pharmaceuticals Announces Issuance of Key Patent,"Akers Biosciences, Inc. (Nasdaq: AKER), today announced that its proposed merger partner MyMD Pharmaceuticals, Inc. (“MyMD”) was issued US Pat. No. 10,835,523 B2, titled “Method of Regulating Tumor Ne...",2.04,2.54,1.98,2.06,AKER,9340494,HISTORICAL_PRICES,AKER,,1.607E+12,-0.004878049,-0.004878049,2.06,2.04,2.54,1.98,9340494,2.06,2.04,2.54,1.98,9340494,2-Dec-20,0.04,0.02
2-Dec-20,"Puma Biotechnology, Inc. Prevails Before European Patent Office Board of Appeals in Decision Upholding European Patent (EP 1848414) as Granted","Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that it has prevailed in final appeal proceedings brought against its licensed European patent EP Patent 1848414, which...",11.45,11.93,11.21,11.93,PBYI,738589,HISTORICAL_PRICES,PBYI,,1.607E+12,0.19022869,0.19022869,11.93,11.45,11.93,11.21,738589,11.93,11.45,11.93,11.21,738589,2-Dec-20,-0.52,-0.0434
2-Dec-20,Exelixis In-Licenses Iconic Therapeutics’ Tissue Factor-Targeting Antibody-Drug Conjugate Ahead of Planned Investigational New Drug Application,"Exelixis, Inc. (Nasdaq: EXEL), Iconic Therapeutics, Inc. (Iconic) and Zymeworks Inc. (NYSE:ZYME) today announced that Exelixis has exercised its exclusive option for Iconic’s lead oncology antibody-dr...",19.33,19.41,18.8,19.07,EXEL,1793575,HISTORICAL_PRICES,EXEL,,1.607E+12,-0.168244406,-0.168244406,19.07,19.33,19.41,18.8,1793575,19.07,19.33,19.41,18.8,1793575,2-Dec-20,0.17,0.0089
2-Dec-20,Altria Participates in the Morgan Stanley Global Consumer and Retail Conference; Reaffirms 2020 Full-Year Earnings Guidance,"Altria Group, Inc. (Altria) (NYSE: MO) is participating today in the Morgan Stanley Global Consumer and Retail Conference. Billy Gifford, Altria’s Chief Executive Officer, and Sal Mancuso, Chief Finan...",40.02,40.83,39.91,40.48,MO,8990240,HISTORICAL_PRICES,MO,,1.61655E+12,0.044090791,0.044090791,40.48,40.02,40.83,39.91,8990240,38.9925,38.5494,39.3297,38.4435,8990240,2-Dec-20,-0.47,-0.0116
1-Dec-20,Pfizer and BioNTech Achieve First Authorization in the World for a Vaccine to Combat COVID-19,Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced today that the Medicines & Healthcare Products Regulatory Agency (MHRA) in the U.K. has granted a temporary authorization for emerg...,39.41,40.5,39.01,39.4,PFE,72660817,HISTORICAL_PRICES,PFE,,1.6118E+12,0.102069351,0.102069351,39.4,39.41,40.5,39.01,72660817,38.976,38.9859,40.0642,38.5902,72660817,1-Dec-20,1.1,0.0287
1-Dec-20,研究比较机械通气患者液体反应性的两种无创指标，发现MasimoPVi®有效且具有优势,(美国商业资讯)--Masimo (NASDAQ: MASI)今天发布《艾因夏姆斯麻醉学杂志》发表的一项研究结果，该研究中，埃及开罗艾因夏姆斯大学(Ain-Shams University)的Diaaeldin Aboelnile博士及其同事比较两种评估机械通气患者液体反应性的无创方法dIVC和Masimo PVi®。他们发现，这两种方法均“有效”，但他们确定PVi有优势，因为它“连续、独立于操作...,253.07,255.99,249.45,255.99,MASI,329027,HISTORICAL_PRICES,MASI,,1.60688E+12,0.161137876,0.161137876,255.99,253.07,255.99,249.45,329027,255.99,253.07,255.99,249.45,329027,1-Dec-20,-1.42,-0.0056
1-Dec-20,研究比較機械通氣患者液體反應性的兩種無創指標，發現MasimoPVi®有效且具有優勢,(美國商業資訊)--Masimo (NASDAQ: MASI)今天發布《艾因夏姆斯麻醉學雜誌》發表的一項研究結果，該研究中，埃及開羅艾因夏姆斯大學(Ain-Shams University)的Diaaeldin Aboelnile博士及其同事比較兩種評估機械通氣患者液體反應性的無創方法dIVC和Masimo PVi®。他們發現，這兩種方法均「有效」，但他們確定PVi有優勢，因為它「連續、獨立於操作...,253.07,255.99,249.45,255.99,MASI,329027,HISTORICAL_PRICES,MASI,,1.60688E+12,0.161137876,0.161137876,255.99,253.07,255.99,249.45,329027,255.99,253.07,255.99,249.45,329027,1-Dec-20,-1.42,-0.0056
1-Dec-20,"SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Neovasc Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm","The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Neovasc Inc. (“Neovasc” or “the Company”) (NASDAQ: NVCN) for violations of §§...",0.8638,0.916,0.8549,0.8741,NVCN,543519,HISTORICAL_PRICES,NVCN,,1.60688E+12,-0.584711538,-0.584711538,0.8741,0.8638,0.916,0.8549,543519,0.8741,0.8638,0.916,0.8549,543519,1-Dec-20,-0.0057,-0.0066
1-Dec-20,"SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Fortress Biotech, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm","The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Fortress Biotech, Inc. (“Fortress” or “the Company”) (NASDAQ: FBIO) for viola...",2.72,2.84,2.715,2.77,FBIO,576457,HISTORICAL_PRICES,FBIO,,1.60688E+12,-0.295336788,-0.295336788,2.77,2.72,2.84,2.715,576457,2.77,2.72,2.84,2.715,576457,1-Dec-20,-0.03,-0.0109
1-Dec-20,Un estudio comparativo entre dos indicadores no invasivos de la capacidad de respuesta a los líquidos en pacientes con ventilación mecánica llega a la conclusión de que Masimo PVi® es eficaz y beneficioso,"Masimo (NASDAQ: MASI) anunció hoy las conclusiones de un estudio publicado en Ain-Shams Journal of Anesthesiology (Revista de Anestesiología de Ain-Shams), en el cual el Dr. Diaaeldin Aboelnile y sus...",253.07,255.99,249.45,255.99,MASI,329027,HISTORICAL_PRICES,MASI,,1.60688E+12,0.161137876,0.161137876,255.99,253.07,255.99,249.45,329027,255.99,253.07,255.99,249.45,329027,1-Dec-20,-1.42,-0.0056
1-Dec-20,"ROSEN, A TOP RANKED LAW FIRM, Announces Filing of Securities Class Action Lawsuit Against Fortress Biotech, Inc.; Encourages Investors with Losses in Excess of $100K to Contact the Firm – FBIO","Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Fortress Biotech, Inc. (NASDAQ: FBIO) between December 11...",2.72,2.84,2.715,2.77,FBIO,576457,HISTORICAL_PRICES,FBIO,,1.60688E+12,-0.295336788,-0.295336788,2.77,2.72,2.84,2.715,576457,2.77,2.72,2.84,2.715,576457,1-Dec-20,-0.03,-0.0109
1-Dec-20,"Studie zum Vergleich zweier nichtinvasiver Indikatoren der Flüssigkeitsreaktion bei mechanisch beatmeten Patienten ergibt, dass Masimo PVi® wirksam und vorteilhaft ist","Masimo (NASDAQ: MASI) gab heute die Ergebnisse einer im Ain-Shams Journal of Anesthesiology veröffentlichten Studie bekannt, in der Dr. Diaaeldin Aboelnile und Kollegen der Ain-Shams-Universität in Ka...",253.07,255.99,249.45,255.99,MASI,329027,HISTORICAL_PRICES,MASI,,1.60688E+12,0.161137876,0.161137876,255.99,253.07,255.99,249.45,329027,255.99,253.07,255.99,249.45,329027,1-Dec-20,-1.42,-0.0056
1-Dec-20,Zymeworks Announces Expansion of Zanidatamab Pivotal Trial in HER2-Amplified Biliary Tract Cancer in Asia in Collaboration With BeiGene,"Zymeworks Inc. (NYSE:ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that its partner, BeiGene, Ltd., has dosed the first patient in South...",54.66,55.745,52.66,53.36,ZYME,516168,HISTORICAL_PRICES,ZYME,,1.60688E+12,0.243403094,0.243403094,53.36,54.66,55.745,52.66,516168,53.36,54.66,55.745,52.66,516168,1-Dec-20,2.01,0.0382
1-Dec-20,"Hologic Receives FDA Clearance for Latest Breakthrough in Early Breast Cancer Detection, Genius AI™ Detection","Hologic, Inc. (Nasdaq: HOLX), an innovative medical technology company primarily focused on improving women’s health, today announced U.S. Food and Drug Administration (FDA) clearance and commercial a...",69.63,70.18,68.9003,69.36,HOLX,1262946,HISTORICAL_PRICES,HOLX,,1.60688E+12,0.105062688,0.105062688,69.36,69.63,70.18,68.9003,1262946,69.36,69.63,70.18,68.9003,1262946,1-Dec-20,0.5,0.0072
1-Dec-20,Applied DNA to Provide COVID-19 Surveillance Testing to Stony Brook Basketball,"Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA” or the ""Company""), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing, announced that its wholly-owned subsidiary, Applied DNA...",7.18,7.47,6.96,7.47,APDN,279774,HISTORICAL_PRICES,APDN,,1.60688E+12,-0.084183673,-0.084183673,7.47,7.18,7.47,6.96,279774,7.47,7.18,7.47,6.96,279774,1-Dec-20,-0.34,-0.0452
1-Dec-20,VBI Vaccines Announces Submission of Biologics License Application to FDA for 3-Antigen Prophylactic Hepatitis B Vaccine,"VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced the submission of a Bio...",3.17,3.6,3.12,3.56,VBIV,12092738,HISTORICAL_PRICES,VBIV,,1.60688E+12,0.089347079,0.089347079,3.56,3.17,3.6,3.12,12092738,3.56,3.17,3.6,3.12,12092738,1-Dec-20,-0.255,-0.0745
1-Dec-20,Sesen Bio Announces Partnership with Hikma Pharmaceuticals for the Commercialization of Vicineum™ in the Middle East and North Africa,"Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, and Hikma Pharmaceuticals, a multi-national pharmaceu...",1.29,1.32,1.255,1.296,SESN,1596922,HISTORICAL_PRICES,SESN,,1.60688E+12,0.048780488,0.048780488,1.296,1.29,1.32,1.255,1596922,1.296,1.29,1.32,1.255,1596922,1-Dec-20,0.05,0.0403
1-Dec-20,Acceleron Receives FDA Orphan Drug Designation for ACE-1334 for the Treatment of Systemic Sclerosis,"Acceleron Pharma Inc. (Nasdaq: XLRN), a biopharmaceutical company dedicated to the discovery, development, and commercialization of TGF-beta superfamily therapeutics to treat serious and rare diseases...",120.01,122.085,117.42,118.91,XLRN,358260,HISTORICAL_PRICES,XLRN,,1.60688E+12,0.142625916,0.142625916,118.91,120.01,122.085,117.42,358260,118.91,120.01,122.085,117.42,358260,1-Dec-20,1.94,0.0164
1-Dec-20,Reminder: Ra Medical Systems to Host Webcast Discussing the Role of Excimer Lasers in the Treatment of Psoriasis during the Pandemic,"Ra Medical Systems, Inc. (NYSE: RMED) is hosting a webcast, The Inimitable Role of Excimer Lasers During the COVID-19 Pandemic, featuring Theodore J. Daly, MD, FAAD, FSPD, FASD, Director of Garden Cit...",5.93,6.162,5.86,6.04,RMED,119910,HISTORICAL_PRICES,RMED,,1.60688E+12,0.014542344,0.014542344,6.04,5.93,6.162,5.86,119910,6.04,5.93,6.162,5.86,119910,1-Dec-20,0.04,0.0068
30-Nov-20,Outset Medical Announces Secondary Offering of Common Stock,"Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, announced today the commencement of...",64,64.8,59,64,OM,293159,HISTORICAL_PRICES,OM,,1.60683E+12,0.231242786,0.231242786,64,64,64.8,59,293159,64,64,64.8,59,293159,30-Nov-20,0.14,0.0022
30-Nov-20,Estudo comparando dois indicadores não invasivos da resposta a fluidos em pacientes ventilados mecanicamente descobre a eficácia e as vantagens do Masimo PVi®,"Masimo (NASDAQ: MASI) anunciou hoje os resultados de um estudo publicado no Ain-Shams Journal of Anesthesiology no qual o Dr. Diaaeldin Aboelnile e colegas da Ain-Shams University no Cairo, Egito comp...",254.49,256.97,248.2,254,MASI,1305013,HISTORICAL_PRICES,MASI,,1.60683E+12,0.167653131,0.167653131,254,254.49,256.97,248.2,1305013,254,254.49,256.97,248.2,1305013,30-Nov-20,0.08,0.0003
30-Nov-20,Kiromic BioPharma Reports Third Quarter 2020 Financial Results and Continued Corporate Progress,"Kiromic BioPharma (“the Company”) (NASDAQ: KRBP), a pre-clinical stage biotechnology company using its proprietary DIAMOND® artificial intelligence (“A.I.”) platform to improve drug discovery and deve...",8.5,8.6,8.05,8.05,KRBP,33178,HISTORICAL_PRICES,KRBP,,1.60683E+12,-0.260869565,-0.260869565,8.05,8.5,8.6,8.05,33178,8.05,8.5,8.6,8.05,33178,30-Nov-20,0.39,0.0481
30-Nov-20,ImmunoGen Announces Conference Call to Discuss Recent Updates for IMGN632 in Blastic Plasmacytoid Dendritic Cell Neoplasm and Acute Myeloid Leukemia,"ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will host a conference call at 8:00am ET...",5.45,5.615,5.24,5.49,IMGN,1662139,HISTORICAL_PRICES,IMGN,,1.60683E+12,0.557142857,0.557142857,5.49,5.45,5.615,5.24,1662139,5.49,5.45,5.615,5.24,1662139,30-Nov-20,-0.07,-0.0127
30-Nov-20,ADC Therapeutics organise une audioconférence au cours de laquelle la société mettra en avant les données de sa nouvelle génération de conjugués anticorps-médicaments qu'elle présentera lors du 62e Congrès annuel de l'American Society of Hematology,"ADC Therapeutics SA (NYSE: ADCT), une société biotechnologique spécialisée en oncologie au stade clinique avancé, à l’avant-garde du développement et de la mise sur le marché de conjugués anticorps-mé...",37.31,37.4799,33.735,34.89,ADCT,350208,HISTORICAL_PRICES,ADCT,,1.60683E+12,0.113731343,0.113731343,34.89,37.31,37.4799,33.735,350208,34.89,37.31,37.4799,33.735,350208,30-Nov-20,2.81,0.0814
30-Nov-20,Genprex Initiates Site Recruitment for Acclaim-1 Clinical Trial for the Treatment of Non-Small Cell Lung Cancer,"Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, is pleased to anno...",3.23,3.34,3.02,3.1,GNPX,1282112,HISTORICAL_PRICES,GNPX,,1.60683E+12,0.041935484,0.041935484,3.1,3.23,3.34,3.02,1282112,3.1,3.23,3.34,3.02,1282112,30-Nov-20,0.14,0.0453
30-Nov-20,"ADC Therapeutics: Konferenzschaltung zu Daten der nächsten Generation von Antikörper-Wirkstoff-Konjugaten, die auf der 62. Jahrestagung der American Society of Hematology vorgestellt werden","ADC Therapeutics SA (NYSE:ADCT), ein im Bereich der späten klinischen Forschung tätiges Biotechnologieunternehmen mit Schwerpunkt auf Onkologie, das Vorreiter bei der Entwicklung und Vermarktung von h...",37.31,37.4799,33.735,34.89,ADCT,350208,HISTORICAL_PRICES,ADCT,,1.60683E+12,0.113731343,0.113731343,34.89,37.31,37.4799,33.735,350208,34.89,37.31,37.4799,33.735,350208,30-Nov-20,2.81,0.0814
30-Nov-20,Cerus Corporation Announces FDA Approval for INTERCEPT Blood System for Cryoprecipitation,Cerus Corporation (Nasdaq: CERS) today announced that the US Food and Drug Administration (FDA) has granted approval of the INTERCEPT Blood System for Cryoprecipitation. The system is used to produce...,6.65,6.8399,6.46,6.7,CERS,2622159,HISTORICAL_PRICES,CERS,,1.60683E+12,0.127118644,0.127118644,6.7,6.65,6.8399,6.46,2622159,6.7,6.65,6.8399,6.46,2622159,30-Nov-20,0.07,0.0106
30-Nov-20,Mirum Pharmaceuticals Announces European Medicines Agency Validation of the Marketing Authorization Application for Maralixibat in Patients with PFIC2,"Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a biopharmaceutical company focused on the development and commercialization of novel therapies for debilitating liver diseases, today announced that the co...",23.45,23.98,22.45,22.59,MIRM,67743,HISTORICAL_PRICES,MIRM,,1.60683E+12,0.237467018,0.237467018,22.59,23.45,23.98,22.45,67743,22.59,23.45,23.98,22.45,67743,30-Nov-20,1.2,0.0539
30-Nov-20,Zymeworks Receives FDA Breakthrough Therapy Designation for HER2-Targeted Bispecific Antibody Zanidatamab in Patients with Biliary Tract Cancer,"Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakth...",52.65,53.17,50.51,50.6,ZYME,592006,HISTORICAL_PRICES,ZYME,,1.60683E+12,0.197679709,0.197679709,50.6,52.65,53.17,50.51,592006,50.6,52.65,53.17,50.51,592006,30-Nov-20,2.79,0.056
30-Nov-20,PolarityTE Receives Allowance for First U.S. Patent,"PolarityTE, Inc. (Nasdaq: PTE) is pleased to report the U.S. Patent and Trademark Office has issued a Notice of Allowance for U.S. Application No. 14/954,335. This is the Company’s first patent allowa...",0.72,0.74,0.68,0.711,PTE,2324852,HISTORICAL_PRICES,PTE,,1.60683E+12,-0.294117647,-0.294117647,0.711,0.72,0.74,0.68,2324852,0.711,0.72,0.74,0.68,2324852,30-Nov-20,0.0285,0.0412
30-Nov-20,ADC Therapeutics to Host Conference Call Highlighting Data from its Next-Generation Antibody Drug Conjugates Being Presented at the 62nd American Society of Hematology Annual Meeting,"ADC Therapeutics SA (NYSE:ADCT), a late clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of highly potent and targeted antibody drug conjugates fo...",37.31,37.4799,33.735,34.89,ADCT,350208,HISTORICAL_PRICES,ADCT,,1.60683E+12,0.113731343,0.113731343,34.89,37.31,37.4799,33.735,350208,34.89,37.31,37.4799,33.735,350208,30-Nov-20,2.81,0.0814
30-Nov-20,"Applied DNA, EvviVax, and GVS Receive Regulatory Approval to Conduct Veterinary Clinical Trial for Linear COVID-19 Vaccine Candidate","Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA” or the ""Company""), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing, EvviVax, S.R.L. (“EvviVax”), a spin-off of Takis Biotec...",7.52,7.7,6.95,7.2,APDN,1064018,HISTORICAL_PRICES,APDN,,1.60683E+12,-0.040816327,-0.040816327,7.2,7.52,7.7,6.95,1064018,7.2,7.52,7.7,6.95,1064018,30-Nov-20,0.34,0.0474
30-Nov-20,Deciphera Pharmaceuticals Completes Target Enrollment in the INTRIGUE Phase 3 Clinical Study of QINLOCK® (Ripretinib) in Patients with Second-Line Gastrointestinal Stromal Tumor,"Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) today announced the completion of its target enrollment in the INTRIGUE Phase 3 clinical study evaluating the efficacy and safety of QINLOCK in patients w...",61.8,62.97,60.61,62.72,DCPH,275518,HISTORICAL_PRICES,DCPH,,1.60683E+12,0.286427977,0.286427977,62.72,61.8,62.97,60.61,275518,62.72,61.8,62.97,60.61,275518,30-Nov-20,-0.55,-0.0088
30-Nov-20,Verastem Oncology Initiates Phase 2 Registration-Directed Trial of VS-6766 and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer,"Verastem, Inc. (Nasdaq:VSTM) (also known as Verastem Oncology), a biopharmaceutical company committed to advancing new medicines for patients battling cancer, today announced the initiation of a Phase...",2.01,2.15,1.87,2.13,VSTM,14187028,HISTORICAL_PRICES,VSTM,,1.60683E+12,0.661157025,0.661157025,2.13,2.01,2.15,1.87,14187028,2.13,2.01,2.15,1.87,14187028,30-Nov-20,0.02,0.0101
30-Nov-20,Moderna Announces Primary Efficacy Analysis in Phase 3 COVE Study for Its COVID-19 Vaccine Candidate and Filing Today with U.S. FDA for Emergency Use Authorization,"Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced tha...",152.74,153.8699,141.05,144,MRNA,73203064,HISTORICAL_PRICES,MRNA,,1.60683E+12,1.343716434,1.343716434,144,152.74,153.8699,141.05,73203064,144,152.74,153.8699,141.05,73203064,30-Nov-20,25.71,0.2024
27-Nov-20,Biogen and Sage Therapeutics Announce Global Collaboration to Develop and Commercialize Potential Breakthrough Therapies in Depression and Movement Disorders,"Biogen Inc. (Nasdaq: BIIB) and Sage Therapeutics, Inc. (Nasdaq: SAGE) announced that they have executed a global collaboration and license agreement to jointly develop and commercialize zuranolone (SA...",243.78,244.33,241,242,BIIB,699227,HISTORICAL_PRICES,BIIB,,1.60683E+12,-0.097244853,-0.097244853,242,243.78,244.33,241,699227,242,243.78,244.33,241,699227,27-Nov-20,2.03,0.0084
25-Nov-20,FDA Defers Approval of DaxibotulinumtoxinA for Injection in Glabellar Lines Due to COVID-19 Related Travel Restrictions Impacting Manufacturing Site Inspection,"Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company focused on innovative aesthetic and therapeutic offerings, today announced that the United States (U.S.) Food and Drug Administration...",24.51,24.98,23.385,23.59,RVNC,558813,HISTORICAL_PRICES,RVNC,,1.60683E+12,-0.047415468,-0.047415468,23.59,24.51,24.98,23.385,558813,23.59,24.51,24.98,23.385,558813,25-Nov-20,1.1,0.047
25-Nov-20,Applied DNA Significantly Expands Addressable Market for Linea™ COVID-19 Assay Kit via Successful Amendment to FDA EUA,"Applied DNA Sciences, Inc. (NASDAQ:APDN) (“Applied DNA” or the ""Company""), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing, announced that the U.S. Food and Drug Administration (FD...",6.73,6.86,6.5,6.81,APDN,150470,HISTORICAL_PRICES,APDN,,1.60683E+12,-0.141581633,-0.141581633,6.81,6.73,6.86,6.5,150470,6.81,6.73,6.86,6.5,150470,25-Nov-20,-0.06,-0.0088
25-Nov-20,Stoke Therapeutics Announces Presentations Related to the Company’s Work in Dravet Syndrome at the American Epilepsy Society 2020 Virtual Annual Meeting,"Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company pioneering a new way to treat the underlying cause of genetic diseases by precisely upregulating protein expression, today announced th...",47.99,50,46.17,46.85,STOK,168061,HISTORICAL_PRICES,STOK,,1.60683E+12,0.456891318,0.456891318,46.85,47.99,50,46.17,168061,46.85,47.99,50,46.17,168061,25-Nov-20,0.66,0.0139
25-Nov-20,Moderna Announces the European Commission’s Approval of Advance Purchase Agreement for Initial 80 Million Doses of mRNA Vaccine Against COVID-19 (mRNA-1273),"Moderna, Inc., (Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced tha...",109.18,109.29,98.65,99.03,MRNA,25850691,HISTORICAL_PRICES,MRNA,,1.60683E+12,0.675310726,0.675310726,99.03,109.18,109.29,98.65,25850691,99.03,109.18,109.29,98.65,25850691,25-Nov-20,10.62,0.1078
24-Nov-20,Urovant Sciences Announces Topline Data from Phase 2a Study of Vibegron for the Treatment of Irritable Bowel Syndrome (IBS) Pain Did Not Meet Primary Endpoint,"Urovant Sciences (Nasdaq: UROV) today reported topline data from the Phase 2a randomized, double blind, placebo-controlled clinical trial evaluating once-daily vibegron 75 mg in women with abdominal p...",16.14,16.2,16.13,16.2,UROV,384085,HISTORICAL_PRICES,UROV,,1.60683E+12,0.726203209,0.726203209,16.2,16.14,16.2,16.13,384085,16.2,16.14,16.2,16.13,384085,24-Nov-20,0,0
24-Nov-20,Revance to Participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference,"Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company focused on innovative aesthetic and therapeutic offerings, today announced that the company’s President and Chief Executive Officer,...",23.41,24.07,22.89,23.55,RVNC,509052,HISTORICAL_PRICES,RVNC,,1.60683E+12,-0.09016712,-0.09016712,23.55,23.41,24.07,22.89,509052,23.55,23.41,24.07,22.89,509052,24-Nov-20,-0.08,-0.0034
24-Nov-20,"Deciphera Pharmaceuticals, Inc. to Participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference","Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a commercial-stage biopharmaceutical company developing innovative medicines to improve the lives of people with cancer, today announced that Steve Hoert...",61.75,62.76,60.89,62,DCPH,393686,HISTORICAL_PRICES,DCPH,,1.60683E+12,0.285387177,0.285387177,62,61.75,62.76,60.89,393686,62,61.75,62.76,60.89,393686,24-Nov-20,0.08,0.0013
24-Nov-20,Humanigen Australia Proprietary Limited成立，旨在促进亚太区增长计划,"(美国商业资讯)--Humanigen, Inc. (NASDAQ: HGEN) (“Humanigen”)是一家临床阶段生物制药公司，专注于通过其先导候选药物lenzilumab™预防和治疗称为“细胞因子风暴”的过度免疫反应，Humanigen今天宣布成立Humanigen Australia Proprietary Limited (“Humanigen Australia Pty Ltd”)...",8.98,9.02,8.575,8.8,HGEN,451426,HISTORICAL_PRICES,HGEN,,1.60683E+12,-0.034408602,-0.034408602,8.8,8.98,9.02,8.575,451426,8.8,8.98,9.02,8.575,451426,24-Nov-20,0.03,0.0034
24-Nov-20,Humanigen Australia Proprietary Limited成立，旨在促進亞太地區成長計畫,"(美國商業資訊)--Humanigen, Inc. (NASDAQ: HGEN) (“Humanigen”)是一家臨床階段生物製藥公司，專注於利用其先導候選藥物lenzilumab™來預防和治療稱為「細胞激素風暴」的過度免疫反應，Humanigen今天宣佈成立Humanigen Australia Proprietary Limited (“Humanigen Australia Pty Ltd”...",8.98,9.02,8.575,8.8,HGEN,451426,HISTORICAL_PRICES,HGEN,,1.60683E+12,-0.034408602,-0.034408602,8.8,8.98,9.02,8.575,451426,8.8,8.98,9.02,8.575,451426,24-Nov-20,0.03,0.0034
24-Nov-20,"INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Biogen, Inc. (BIIB) Investors","Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased Biogen, Inc. (“Biogen” or the “Company”) (NASDAQ: BIIB) securities between Octo...",242.51,244.86,240.07,243.34,BIIB,1605961,HISTORICAL_PRICES,BIIB,,1.60683E+12,-0.10194786,-0.10194786,243.34,242.51,244.86,240.07,1605961,243.34,242.51,244.86,240.07,1605961,24-Nov-20,-0.87,-0.0036
24-Nov-20,Genprex to Participate at the Diamond Equity Research Emerging Growth Invitational on December 1,"Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced th...",3.05,3.0958,3,3.09,GNPX,504671,HISTORICAL_PRICES,GNPX,,1.60683E+12,-0.016129032,-0.016129032,3.09,3.05,3.0958,3,504671,3.09,3.05,3.0958,3,504671,24-Nov-20,-0.02,-0.0065
24-Nov-20,Legend Biotech to Host Virtual Investor KOL Event Reviewing Latest CARTITUDE-1 Data from the 62nd American Society of Hematology (ASH) Annual Meeting,"Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech) today announced that it will host a virtual Key Opinion Leader (KOL) event on Monday, December 7 at 7 pm ET highlighting the latest data from...",28.14,28.88,27.72,28.55,LEGN,151948,HISTORICAL_PRICES,LEGN,,1.60683E+12,-0.027307293,-0.027307293,28.55,28.14,28.88,27.72,151948,28.55,28.14,28.88,27.72,151948,24-Nov-20,-0.23,-0.0081
24-Nov-20,PolarityTE Announces Dismissal of Securities Class Action Complaint with Prejudice,"PolarityTE, Inc. (Nasdaq: PTE), a company focused on transforming the lives of patients by discovering, designing, and developing a range of regenerative tissue products and biomaterials, today announ...",0.668,0.69,0.621,0.675,PTE,3864695,HISTORICAL_PRICES,PTE,,1.60683E+12,-0.345098039,-0.345098039,0.675,0.668,0.69,0.621,3864695,0.675,0.668,0.69,0.621,3864695,24-Nov-20,-0.003,-0.0045
24-Nov-20,Alnylam Announces Innovative Value-Based Agreement Framework for OXLUMO™ (lumasiran) to Accelerate Access for Patients with Primary Hyperoxaluria Type 1 and Deliver Ultra-Rare Orphan Disease Pricing Solutions to U.S. Payers,"Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today a new framework for value-based agreements (VBAs) designed to help people with primary hyperoxaluri...",125.66,128,123.03,125.69,ALNY,872439,HISTORICAL_PRICES,ALNY,,1.60683E+12,-0.05759712,-0.05759712,125.69,125.66,128,123.03,872439,125.69,125.66,128,123.03,872439,24-Nov-20,2.64,0.0215
24-Nov-20,"Alnylam Announces U.S. Food and Drug Administration (FDA) Approval of OXLUMO™ (lumasiran), the First and Only Treatment Approved for Primary Hyperoxaluria Type 1 to Lower Urinary Oxalate Levels in Pediatric and Adult Patients","Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), the leading RNAi therapeutics company, announced today that the U.S. Food and Drug Administration (FDA) approved OXLUMO™ (lumasiran) injection for subcutan...",125.66,128,123.03,125.69,ALNY,872439,HISTORICAL_PRICES,ALNY,,1.60683E+12,-0.05759712,-0.05759712,125.69,125.66,128,123.03,872439,125.69,125.66,128,123.03,872439,24-Nov-20,2.64,0.0215
24-Nov-20,Taysha Gene Therapies Adds Industry-Leading Gene Therapy Executives to Board of Directors,"Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the cen...",21.89,22.48,20.2501,21.16,TSHA,77974,HISTORICAL_PRICES,TSHA,,1.60683E+12,-0.090191189,-0.090191189,21.16,21.89,22.48,20.2501,77974,21.16,21.89,22.48,20.2501,77974,24-Nov-20,0.12,0.0055
24-Nov-20,"Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) as Second-Line Treatment for Unresectable Advanced, Recurrent or Metastatic Esophageal Squamous Cell Carcinoma","Bristol Myers Squibb (NYSE: BMY) today announced that the European Commission (EC) has approved Opdivo (nivolumab) for the treatment of adults with unresectable advanced, recurrent or metastatic esoph...",63.22,63.51,61.88,61.95,BMY,13512667,HISTORICAL_PRICES,BMY,,1.60946E+12,0.085321888,0.085321888,61.95,63.22,63.51,61.88,13512667,61.4598,62.7197,63.0074,61.3903,13512667,24-Nov-20,1.3,0.021
24-Nov-20,Ra Medical Systems to Participate in the Piper Sandler Virtual Health Care Conference,"Ra Medical Systems, Inc. (NYSE: RMED) , a medical device company focusing on commercializing excimer laser systems to treat vascular and dermatological diseases, announces that management will partici...",6.44,7.35,6.36,6.83,RMED,368475,HISTORICAL_PRICES,RMED,,1.60683E+12,0.101796407,0.101796407,6.83,6.44,7.35,6.36,368475,6.83,6.44,7.35,6.36,368475,24-Nov-20,-0.2,-0.0301
23-Nov-20,Apyx Medical Corporation Announces Approval from FDA to Begin Phase II of U.S. IDE Study,"Apyx Medical Corporation (NASDAQ:APYX) (the “Company”), a maker of medical devices and supplies and the developer of Helium Plasma Technology, marketed and sold as Renuvion® in the cosmetic surgery ma...",6.88,6.92,6.77,6.78,APYX,35672,HISTORICAL_PRICES,APYX,,1.60683E+12,0.528888889,0.528888889,6.78,6.88,6.92,6.77,35672,6.78,6.88,6.92,6.77,35672,23-Nov-20,0.11,0.0162
23-Nov-20,Humanigen Australia Proprietary Limited Established to Facilitate Asia-Pacific Growth Plans,"Humanigen, Inc. (NASDAQ: HGEN) (“Humanigen”), a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm’ with its lead drug candidat...",8.95,9.37,8.66,9.15,HGEN,510731,HISTORICAL_PRICES,HGEN,,1.60683E+12,-0.037634409,-0.037634409,9.15,8.95,9.37,8.66,510731,9.15,8.95,9.37,8.66,510731,23-Nov-20,0.1,0.0113
23-Nov-20,"Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year Ended September 30, 2020","Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today reported financial results...",43.67,45.1416,43.24,44.26,ENTA,112872,HISTORICAL_PRICES,ENTA,,1.60683E+12,0.005294659,0.005294659,44.26,43.67,45.1416,43.24,112872,44.26,43.67,45.1416,43.24,112872,23-Nov-20,0.1,0.0023
23-Nov-20,"全球备受认可的投资者法律顾问ROSEN提醒Intercept Pharmaceuticals, Inc.投资者注意ICPT证券集体诉讼的重要截止日期；鼓励损失超过10万美元的投资者联系律所","(美国商业资讯)--全球投资者权益律所Rosen Law Firm提醒在2019年9月28日至2020年10月7日（含上述日期，简称“集体诉讼期”）期间购买Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT)证券的人士注意，本证券集体诉讼中首要原告的重要截止日期为2021年1月4日。诉讼旨在依据联邦证券法弥补Intercept投资者所蒙受的损失。 如需加入I...",35.47,36.7,35.38,36.01,ICPT,595709,HISTORICAL_PRICES,ICPT,,1.60683E+12,-0.107897384,-0.107897384,36.01,35.47,36.7,35.38,595709,36.01,35.47,36.7,35.38,595709,23-Nov-20,-0.18,-0.005
23-Nov-20,"全球備受認可的投資人法律顧問ROSEN提醒Intercept Pharmaceuticals, Inc.投資人注意ICPT證券集體訴訟的重要截止日期；鼓勵損失超過10萬美元的投資人與法律事務所聯絡","(美國商業資訊)--全球投資人權益法律事務所Rosen Law Firm提醒在2019年9月28日至2020年10月7日（含上述日期，簡稱「集體訴訟期」）期間購買Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT)證券的人士注意，本證券集體訴訟中原告代表的重要截止日期為2021年1月4日。訴訟旨在依據聯邦證券法彌補Intercept投資人所蒙受的損失。 如欲...",35.47,36.7,35.38,36.01,ICPT,595709,HISTORICAL_PRICES,ICPT,,1.60683E+12,-0.107897384,-0.107897384,36.01,35.47,36.7,35.38,595709,36.01,35.47,36.7,35.38,595709,23-Nov-20,-0.18,-0.005
23-Nov-20,Ligand Announces Clinical and Regulatory Progress by Multiple Partners with OmniAb® Antibodies,Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces clinical and regulatory progress by multiple partners utilizing antibodies from its OmniAb® discovery platform. Two large multinational pha...,86.25,86.42,81.73,83.47,LGND,349991,HISTORICAL_PRICES,LGND,,1.60683E+12,-0.085559796,-0.085559796,83.47,86.25,86.42,81.73,349991,83.47,86.25,86.42,81.73,349991,23-Nov-20,3.03,0.0364
23-Nov-20,Varex to Showcase New X-Ray Components at RSNA 2020 Virtual Exhibition,"Varex Imaging Corporation (Nasdaq: VREX) will showcase its latest X-ray tubes and sources, digital detectors, connect and control devices and software solutions at the 106th Scientific Assembly and An...",16.17,16.2,14.99,15.2,VREX,411822,HISTORICAL_PRICES,VREX,,1.60683E+12,0.375,0.375,15.2,16.17,16.2,14.99,411822,15.2,16.17,16.2,14.99,411822,23-Nov-20,1.41,0.0955
23-Nov-20,VBI Vaccines Announces Submission of Marketing Authorization Application for 3-Antigen Prophylactic Hepatitis B Vaccine to the European Medicines Agency,"VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced the submission of a Mar...",2.72,2.83,2.68,2.75,VBIV,4658710,HISTORICAL_PRICES,VBIV,,1.60683E+12,-0.065292096,-0.065292096,2.75,2.72,2.83,2.68,4658710,2.75,2.72,2.83,2.68,4658710,23-Nov-20,-0.03,-0.0109
23-Nov-20,Ocular Therapeutix™ to Present at the Piper Sandler 32nd Annual Virtual Healthcare Conference,"Ocular Therapeutix, Inc. (NASDAQ:OCUL) a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today...",14.99,15.61,14.5673,15.082,OCUL,1381887,HISTORICAL_PRICES,OCUL,,1.60683E+12,0.916879795,0.916879795,15.082,14.99,15.61,14.5673,1381887,15.082,14.99,15.61,14.5673,1381887,23-Nov-20,0.33,0.0225
23-Nov-20,Baxter Announces U.S. FDA 510(k) Clearance of Homechoice Claria with Sharesource,"Baxter International Inc. (NYSE:BAX), a global innovator in renal care, today announced U.S. Food and Drug Administration (FDA) clearance of the Homechoice Claria automated peritoneal dialysis (APD) s...",75.77,77.02,75.31,76.74,BAX,3049489,HISTORICAL_PRICES,BAX,,1.61422E+12,-0.037229987,-0.037229987,76.74,75.77,77.02,75.31,3049489,76.255,75.2912,76.5333,74.8341,3049489,23-Nov-20,-1.25,-0.0162
23-Nov-20,Greenwich LifeSciences Announces Second Publication and Second Poster Presentation of Phase III Clinical Trial of Potential Breakthrough Technology for Recurring Breast Cancer,"Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in pati...",5.49,5.58,5.01,5.32,GLSI,54537,HISTORICAL_PRICES,GLSI,,1.60683E+12,0.098,0.098,5.32,5.49,5.58,5.01,54537,5.32,5.49,5.58,5.01,54537,23-Nov-20,0.17,0.032
23-Nov-20,The Boston Globe Names Deciphera a Top Place to Work for 2020,"Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a commercial-stage biopharmaceutical company developing innovative medicines to improve the lives of people with cancer, has been named one of the Top Pl...",61.67,64.325,61.5,62.84,DCPH,334394,HISTORICAL_PRICES,DCPH,,1.60683E+12,0.283721898,0.283721898,62.84,61.67,64.325,61.5,334394,62.84,61.67,64.325,61.5,334394,23-Nov-20,-0.45,-0.0072
23-Nov-20,"Merck Submits Applications for Licensure of V114, the Company’s Investigational 15-valent Pneumococcal Conjugate Vaccine, for Use in Adults to the U.S. FDA and European Medicines Agency","Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the company has submitted applications to the U.S. Food and Drug Administration (FDA) and European Medicines Agenc...",80.28,81.16,79.38,80.61,MRK,9063500,HISTORICAL_PRICES,MRK,,1.61552E+12,-0.034515935,-0.034515935,80.61,80.28,81.16,79.38,9063500,79.2818,78.9573,79.8228,78.0721,9063500,23-Nov-20,-0.17,-0.0021
23-Nov-20,"Pfizer Doses First Participant in Phase 3 Study Evaluating anti-TFPI Investigational Therapy, Marstacimab, for People With Severe Hemophilia A and B With or Without Inhibitors","Pfizer Inc. (NYSE: PFE) today announced that the first participant has been dosed in the Phase 3 BASIS study of marstacimab (PF-06741086), an anti-tissue factor pathway inhibitor (anti-TFPI) being eva...",36.52,37.09,36.21,37.03,PFE,43673118,HISTORICAL_PRICES,PFE,,1.6118E+12,0.021252796,0.021252796,37.03,36.52,37.09,36.21,43673118,36.6315,36.127,36.6909,35.8203,43673118,23-Nov-20,-0.18,-0.0049
20-Nov-20,"ROSEN, GLOBALLY RECOGNIZED INVESTOR COUNSEL, Reminds Intercept Pharmaceuticals, Inc. Investors of Important Deadline in Securities Class Action; Encourages Investors with Losses in Excess of $100K to Contact Firm – ICPT","Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT) between September 28, 2019 and October 7, 2020, inclusive (the...",35.65,37.265,35.36,37.15,ICPT,521506,HISTORICAL_PRICES,ICPT,,1.60683E+12,-0.103370221,-0.103370221,37.15,35.65,37.265,35.36,521506,37.15,35.65,37.265,35.36,521506,20-Nov-20,-1.6,-0.043
20-Nov-20,Revance Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4),"Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company focused on innovative aesthetic and therapeutic offerings, including its investigational neuromodulator product, DaxibotulinumtoxinA...",24.01,24.52,23.58,24.17,RVNC,516231,HISTORICAL_PRICES,RVNC,,1.60683E+12,-0.066848037,-0.066848037,24.17,24.01,24.52,23.58,516231,24.17,24.01,24.52,23.58,516231,20-Nov-20,-0.39,-0.016
20-Nov-20,ADC Therapeutics annonce que la FDA accepte la demande de licence et octroie le statut d’évaluation prioritaire pour le loncastuximab tésirine dans le traitement du lymphome diffus à grandes cellules B récidivant ou réfractaire,"ADC Therapeutics SA (NYSE: ADCT), une société biotechnologique spécialisée en oncologie au stade clinique avancé, pionnière du développement et de la mise sur le marché de conjugués anticorps-médicame...",35.85,36.01,33.66,33.92,ADCT,1021008,HISTORICAL_PRICES,ADCT,,1.60683E+12,0.070149254,0.070149254,33.92,35.85,36.01,33.66,1021008,33.92,35.85,36.01,33.66,1021008,20-Nov-20,2.13,0.0632
20-Nov-20,ADC Therapeutics meldet Annahme der Biologics License Application sowie beschleunigtes Zulassungsverfahren für Loncastuximab-Tesirin zur Behandlung des rezidivierten oder refraktären diffus großzelligen B-Zell-Lymphoms durch die FDA,"ADC Therapeutics SA (NYSE: ADCT), ein im Bereich der späten klinischen Forschung tätiges Biotechnologieunternehmen mit Schwerpunkt auf Onkologie, das Vorreiter bei der Entwicklung und Vermarktung von...",35.85,36.01,33.66,33.92,ADCT,1021008,HISTORICAL_PRICES,ADCT,,1.60683E+12,0.070149254,0.070149254,33.92,35.85,36.01,33.66,1021008,33.92,35.85,36.01,33.66,1021008,20-Nov-20,2.13,0.0632
20-Nov-20,Aptima HIV-1 Quant Dx Assay Receives Additional FDA Approval for Use as an Aid in the Diagnosis of HIV Infection,"Hologic, Inc. (Nasdaq: HOLX) announced today that the U.S. Food and Drug Administration (FDA) has approved a diagnostic claim for its HIV-1 (human immunodeficiency virus type 1) viral load monitoring...",68.99,69.67,68.6,69.26,HOLX,2314514,HISTORICAL_PRICES,HOLX,,1.60683E+12,0.094905571,0.094905571,69.26,68.99,69.67,68.6,2314514,69.26,68.99,69.67,68.6,2314514,20-Nov-20,-1.02,-0.0146
20-Nov-20,Penumbra’s Newest Generation of Indigo Aspiration System Receives FDA Clearance for Pulmonary Embolism,"Penumbra, Inc. (NYSE: PEN), a global healthcare company focused on innovative therapies, today announced U.S. Food and Drug Administration 510(k) clearance for expanded indication of the latest iterat...",259.15,264,255.53,255.97,PEN,346453,HISTORICAL_PRICES,PEN,,1.60683E+12,0.340038265,0.340038265,255.97,259.15,264,255.53,346453,255.97,259.15,264,255.53,346453,20-Nov-20,3.58,0.014
20-Nov-20,Clovis Oncology to Present at the Piper Sandler 32nd Annual Healthcare Conference,"Clovis Oncology, Inc. (Nasdaq: CLVS) today announced that a pre-recorded fireside chat with President and Chief Executive Officer Patrick J. Mahaffy will be available next week for replay as part of t...",4.23,4.34,4.165,4.3,CLVS,3674911,HISTORICAL_PRICES,CLVS,,1.60683E+12,-0.257243196,-0.257243196,4.3,4.23,4.34,4.165,3674911,4.3,4.23,4.34,4.165,3674911,20-Nov-20,-0.06,-0.014
20-Nov-20,ADC Therapeutics Announces FDA Accepts Biologics License Application and Grants Priority Review for Loncastuximab Tesirine for Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma,"ADC Therapeutics SA (NYSE: ADCT), a late clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of highly potent and targeted antibody drug conjugates (...",35.85,36.01,33.66,33.92,ADCT,1021008,HISTORICAL_PRICES,ADCT,,1.60683E+12,0.070149254,0.070149254,33.92,35.85,36.01,33.66,1021008,33.92,35.85,36.01,33.66,1021008,20-Nov-20,2.13,0.0632
20-Nov-20,Pfizer and BioNTech to Submit Emergency Use Authorization Request Today to the U.S. FDA for COVID-19 Vaccine,Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced they will submit a request today to the U.S. Food and Drug Administration (FDA) for Emergency Use Authorization (EUA) of their mRNA vac...,36.7,37.31,36.44,36.7,PFE,60633847,HISTORICAL_PRICES,PFE,,1.6118E+12,0.026286353,0.026286353,36.7,36.7,37.31,36.44,60633847,36.305,36.305,36.9085,36.0478,60633847,20-Nov-20,0.51,0.0141
19-Nov-20,Alexion Receives Marketing Authorization from European Commission for New Formulation of ULTOMIRIS® (ravulizumab) with Significantly Reduced Infusion Time,"Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced that the European Commission (EC) has approved the new 100 mg/mL intravenous (IV) formulation of ULTOMIRIS® (ravulizumab) for the treatment...",122.05,122.985,121.0972,122.43,ALXN,1249815,HISTORICAL_PRICES,ALXN,,1.60683E+12,0.089537583,0.089537583,122.43,122.05,122.985,121.0972,1249815,122.43,122.05,122.985,121.0972,1249815,19-Nov-20,-1.42,-0.0115
19-Nov-20,Alnylam erhält EU-Zulassung für OXLUMO™ (Lumasiran) zur Behandlung der primären Hyperoxalurie Typ 1 in allen Altersgruppen,"Wie Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), das führende Unternehmen für RNAi-Therapeutika, heute mitteilte, hat die Europäische Kommission die Marktzulassung für das RNAi-Therapeutikum OXLUMO™...",123.81,126.62,122.66,126.62,ALNY,689843,HISTORICAL_PRICES,ALNY,,1.60683E+12,-0.071471426,-0.071471426,126.62,123.81,126.62,122.66,689843,126.62,123.81,126.62,122.66,689843,19-Nov-20,-1.64,-0.0131
19-Nov-20,Alnylam reçoit l'approbation de l'Union européenne pour OXLUMO™ (lumasiran) dans le traitement de l'hyperoxalurie primitive de type 1 dans toutes les tranches d'âge,"Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), le chef de file des ARNi thérapeutiques, annonce aujourd'hui l'autorisation de mise sur le marché accordée par la Commission européenne (CE) à OXLUMO™ (lu...",123.81,126.62,122.66,126.62,ALNY,689843,HISTORICAL_PRICES,ALNY,,1.60683E+12,-0.071471426,-0.071471426,126.62,123.81,126.62,122.66,689843,126.62,123.81,126.62,122.66,689843,19-Nov-20,-1.64,-0.0131
19-Nov-20,Le système Dexcom G6 de mesure en continu du glucose bientôt remboursé en France après un accord avec les autorités de santé,"DexCom, Inc. (NASDAQ:DXCM), l'un des leaders du marché de la mesure en continu du glucose (MCG), annonce le remboursement imminent de son système Dexcom G6 en France. Cet accord conclu avec les autori...",330.64,334.4,324.27,326.9,DXCM,851814,HISTORICAL_PRICES,DXCM,,1.60683E+12,-0.134518232,-0.134518232,326.9,330.64,334.4,324.27,851814,326.9,330.64,334.4,324.27,851814,19-Nov-20,1.43,0.0043
19-Nov-20,研究调查采用Masimo SpHb®无创连续血红蛋白监护的患者血液管理项目对术后癌症患者的效应,(美国商业资讯)--Masimo (NASDAQ: MASI)今天发布了《输血》(Blood Transfusion)发表的一项研究结果，该研究中，意大利雷焦艾米利亚省Azienda USL-IRCCS的Lucia Merolle博士及其同事研究应用患者血液管理项目（包括采用Masimo SpHb®无创连续血红蛋白监护）对术后癌症患者医护的影响1。研究发现，采用SpHb作为患者血液管理项目的一部分...,246.47,251.845,244.95,245.95,MASI,319417,HISTORICAL_PRICES,MASI,,1.60683E+12,0.130855701,0.130855701,245.95,246.47,251.845,244.95,319417,245.95,246.47,251.845,244.95,319417,19-Nov-20,2.12,0.0087
19-Nov-20,研究調查採用Masimo SpHb®無創連續血紅蛋白監護的患者血液管理專案對術後癌症患者的效應,(美國商業資訊)--Masimo (NASDAQ: MASI)今天發布了《輸血》(Blood Transfusion)期刊發表的一項研究結果，該研究中，義大利雷焦艾米利亞省Azienda USL-IRCCS的Lucia Merolle博士及其同事研究應用患者血液管理專案（包括採用Masimo SpHb®無創連續血紅蛋白監護）對術後癌症患者醫護的影響1。研究發現，採用SpHb作為患者血液管理專案的一...,246.47,251.845,244.95,245.95,MASI,319417,HISTORICAL_PRICES,MASI,,1.60683E+12,0.130855701,0.130855701,245.95,246.47,251.845,244.95,319417,245.95,246.47,251.845,244.95,319417,19-Nov-20,2.12,0.0087
19-Nov-20,"Zymeworks obtient la désignation de médicament orphelin de la Commission européenne pour le zanidatamab, un anticorps bispécifique ciblant le HER2, dans le traitement du cancer gastrique","Zymeworks Inc. (NYSE:ZYME), une société biopharmaceutique de stade clinique qui développe des produits biothérapeutiques multifonctionnels, a annoncé aujourd'hui que la Commission européenne (CE) a ac...",41.5,42.16,39.84,41.98,ZYME,864661,HISTORICAL_PRICES,ZYME,,1.60683E+12,-0.055959964,-0.055959964,41.98,41.5,42.16,39.84,864661,41.98,41.5,42.16,39.84,864661,19-Nov-20,-0.68,-0.0161
19-Nov-20,"The Law Offices of Frank R. Cruz Announces Investigation of Supernus Pharmaceuticals, Inc. (SUPN) on Behalf of Investors","The Law Offices of Frank R. Cruz announces an investigation of Supernus Pharmaceuticals, Inc. (“Supernus” or the “Company”) (NASDAQ: SUPN) on behalf of investors concerning the Company’s possible viol...",21.11,21.69,20.94,21.48,SUPN,427790,HISTORICAL_PRICES,SUPN,,1.60683E+12,0.045049505,0.045049505,21.48,21.11,21.69,20.94,427790,21.48,21.11,21.69,20.94,427790,19-Nov-20,-0.35,-0.0163
19-Nov-20,"The Law Offices of Frank R. Cruz Announces Investigation of Biogen, Inc. (BIIB) on Behalf of Investors","The Law Offices of Frank R. Cruz announces an investigation of Biogen, Inc. (“Biogen” or the “Company”) (NASDAQ: BIIB) on behalf of investors concerning the Company’s possible violations of federal se...",244.01,245.55,240.5,241.42,BIIB,1222216,HISTORICAL_PRICES,BIIB,,1.60683E+12,-0.096393127,-0.096393127,241.42,244.01,245.55,240.5,1222216,241.42,244.01,245.55,240.5,1222216,19-Nov-20,3.03,0.0126
19-Nov-20,"Zymeworks erhält Orphan-Drug-Status von der Europäischen Kommission für den gegen HER2 gerichteten, bispezifischen Antikörper Zanidatamab bei Patienten mit Magenkrebs","Wie Zymeworks Inc. (NYSE:ZYME), ein biopharmazeutisches Unternehmen, das multifunktionale Biotherapeutika in der klinischen Phase entwickelt, heute bekannt gab, hat die Europäische Kommission den Orph...",41.5,42.16,39.84,41.98,ZYME,864661,HISTORICAL_PRICES,ZYME,,1.60683E+12,-0.055959964,-0.055959964,41.98,41.5,42.16,39.84,864661,41.98,41.5,42.16,39.84,864661,19-Nov-20,-0.68,-0.0161
19-Nov-20,"INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Biogen, Inc. (BIIB) on Behalf of Investors","Law Offices of Howard G. Smith announces an investigation on behalf of Biogen, Inc. (“Biogen” or the “Company”) (NASDAQ: BIIB) investors concerning the Company’s possible violations of federal securit...",244.01,245.55,240.5,241.42,BIIB,1222216,HISTORICAL_PRICES,BIIB,,1.60683E+12,-0.096393127,-0.096393127,241.42,244.01,245.55,240.5,1222216,241.42,244.01,245.55,240.5,1222216,19-Nov-20,3.03,0.0126
19-Nov-20,"INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Supernus Pharmaceuticals, Inc. (SUPN) on Behalf of Investors","Law Offices of Howard G. Smith announces an investigation on behalf of Supernus Pharmaceuticals, Inc. (“Supernus” or the “Company”) (NASDAQ: SUPN) investors concerning the Company’s possible violation...",21.11,21.69,20.94,21.48,SUPN,427790,HISTORICAL_PRICES,SUPN,,1.60683E+12,0.045049505,0.045049505,21.48,21.11,21.69,20.94,427790,21.48,21.11,21.69,20.94,427790,19-Nov-20,-0.35,-0.0163
19-Nov-20,"BMRN Deadline: Bronstein, Gewirtz & Grossman, LLC Reminds BioMarin Pharmaceutical Inc. Shareholders of Class Action and Lead Plaintiff Deadline: November 24, 2020","Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against BioMarin Pharmaceutical Inc. (""BioMarin"" or ""the Company"") (NASDAQ: BMRN) and certain of it...",75.13,75.6,73.85,74.14,BMRN,851348,HISTORICAL_PRICES,BMRN,,1.60683E+12,-0.018934448,-0.018934448,74.14,75.13,75.6,73.85,851348,74.14,75.13,75.6,73.85,851348,19-Nov-20,0.96,0.0129
19-Nov-20,Zymeworks Receives Orphan Drug Designation From the European Commission for HER2-Targeted Bispecific Antibody Zanidatamab in Patients With Gastric Cancer,"Zymeworks Inc. (NYSE:ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that the European Commission (EC) has granted Orphan Drug designation...",41.5,42.16,39.84,41.98,ZYME,864661,HISTORICAL_PRICES,ZYME,,1.60683E+12,-0.055959964,-0.055959964,41.98,41.5,42.16,39.84,864661,41.98,41.5,42.16,39.84,864661,19-Nov-20,-0.68,-0.0161
19-Nov-20,Urovant Sciences Announces Positive Clinical Efficacy and Safety Data from Vibegron EMPOWUR Long Term Extension Study,Urovant Sciences (Nasdaq: UROV) today announced positive efficacy and safety data from the vibegron EMPOWUR long term extension study with patient data over a total exposure of 52 weeks. The data demo...,16.19,16.25,16.06,16.06,UROV,339823,HISTORICAL_PRICES,UROV,,1.60683E+12,0.731550802,0.731550802,16.06,16.19,16.25,16.06,339823,16.06,16.19,16.25,16.06,339823,19-Nov-20,0.05,0.0031
19-Nov-20,Tablo Hemodialysis Systems Deployed to Guam Hospitals by U.S. Department of Health and Human Services for Emergency Response,"Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced along with the U.S....",59,61.48,56.7,56.7,OM,173421,HISTORICAL_PRICES,OM,,1.60683E+12,0.135051943,0.135051943,56.7,59,61.48,56.7,173421,56.7,59,61.48,56.7,173421,19-Nov-20,2.54,0.045
19-Nov-20,AtriCure to Participate in Upcoming Piper Sandler 32nd Annual Virtual Healthcare Conference,"AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that the company will participate i...",42.84,43.79,41.67,42.37,ATRC,546609,HISTORICAL_PRICES,ATRC,,1.60683E+12,0.116788321,0.116788321,42.37,42.84,43.79,41.67,546609,42.37,42.84,43.79,41.67,546609,19-Nov-20,2.04,0.05
19-Nov-20,领先的顶级律所ROSEN提醒Neovasc Inc.投资者注意NVCN证券集体诉讼的重要截止日期,(美国商业资讯)--全球投资者权益律所Rosen Law Firm提醒在2019年11月1日至2020年10月27日（含上述日期，简称“集体诉讼期”）期间购买Neovasc Inc. (NASDAQ: NVCN)证券的人士注意，此案中首要原告的重要截止日期为2021年1月5日。诉讼旨在依据联邦证券法弥补Neovasc投资者所蒙受的损失。 如需加入Neovasc集体诉讼，请访问http://www....,0.84,0.8674,0.8107,0.8626,NVCN,515587,HISTORICAL_PRICES,NVCN,,1.60683E+12,-0.596153846,-0.596153846,0.8626,0.84,0.867375,0.8107,515587,0.8626,0.84,0.8674,0.8107,515587,19-Nov-20,-0.01,-0.0118
19-Nov-20,首屈一指的頂級法律事務所ROSEN提醒Neovasc Inc.投資人注意NVCN證券集體訴訟的重要截止日期,(美國商業資訊)--全球投資人權益法律事務所Rosen Law Firm提醒在2019年11月1日至2020年10月27日（含上述日期，簡稱「集體訴訟期」）期間購買Neovasc Inc. (NASDAQ: NVCN)證券的人士注意，此案中原告代表的重要截止日期為2021年1月5日。訴訟旨在依據聯邦證券法彌補Neovasc投資人所蒙受的損失。 如欲加入Neovasc集體訴訟，請造訪http://w...,0.84,0.8674,0.8107,0.8626,NVCN,515587,HISTORICAL_PRICES,NVCN,,1.60683E+12,-0.596153846,-0.596153846,0.8626,0.84,0.867375,0.8107,515587,0.8626,0.84,0.8674,0.8107,515587,19-Nov-20,-0.01,-0.0118
19-Nov-20,Alnylam Receives Approval for OXLUMO™ (lumasiran) in the European Union for the Treatment of Primary Hyperoxaluria Type 1 in All Age Groups,"Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that the European Commission (EC) has granted marketing authorization for OXLUMO™ (lumasiran), an R...",123.81,126.62,122.66,126.62,ALNY,689843,HISTORICAL_PRICES,ALNY,,1.60683E+12,-0.071471426,-0.071471426,126.62,123.81,126.62,122.66,689843,126.62,123.81,126.62,122.66,689843,19-Nov-20,-1.64,-0.0131
19-Nov-20,Seres Therapeutics to Participate in Upcoming Virtual Investor Conferences,"Seres Therapeutics, Inc. (Nasdaq: MCRB) today announced that management will participate in two upcoming investor conferences: Piper Sandler 32nd Annual Virtual Healthcare Conference on December 1, 20...",32.05,35.075,31.72,34.61,MCRB,856631,HISTORICAL_PRICES,MCRB,,1.60683E+12,0.269306931,0.269306931,34.61,32.05,35.075,31.72,856631,34.61,32.05,35.075,31.72,856631,19-Nov-20,-2.48,-0.0718
19-Nov-20,Results from Phase 3 CROWN Trial of Pfizer’s LORBRENA® (lorlatinib) in Previously Untreated ALK-Positive Lung Cancer Published in the New England Journal of Medicine,"Pfizer Inc. (NYSE:PFE) today announced results from the Phase 3 CROWN trial of LORBRENA® (lorlatinib, available in Europe under the brand name LORVIQUA®) versus XALKORI® (crizotinib) in people with pr...",36.19,36.63,35.86,36.6,PFE,43261829,HISTORICAL_PRICES,PFE,,1.6118E+12,0.012024609,0.012024609,36.6,36.19,36.63,35.86,43261829,36.2061,35.8005,36.2358,35.4741,43261829,19-Nov-20,-0.13,-0.0036
19-Nov-20,PMI’s ESG Performance Recognized by the S&P Dow Jones Indices,"Philip Morris International Inc. (PMI) (NYSE: PM) has been included for the first time in the Dow Jones Sustainability Index (DJSI) North America, recognizing its exemplary sustainability performance....",77.51,77.83,76.39,76.76,PM,3730298,HISTORICAL_PRICES,PM,,1.61612E+12,0.015193189,0.015193189,76.76,77.51,77.83,76.39,3730298,74.663,75.3925,75.7038,74.3031,3730298,19-Nov-20,0.04,0.0005
18-Nov-20,Owens & Minor Prepares for Flu Season with Increased Made-in-Americas Mask and N95 Respirator Capacity,"As the United States prepares to enter flu season under the persistent COVID-19 pandemic, Owens & Minor (NYSE: OMI), the nation’s leading producer of medical-grade facial protection products, cont...",23.17,24.1807,23.1,23.69,OMI,698936,HISTORICAL_PRICES,OMI,,1.61552E+12,0.140817331,0.140817331,23.69,23.17,24.1807,23.1,698936,23.6862,23.1663,24.1768,23.0963,698936,18-Nov-20,-0.34,-0.0145
18-Nov-20,Spruce Biosciences Reports Third Quarter 2020 Financial Results and Provides Corporate Update,"Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical ne...",25.29,27.31,23.92,24.85,SPRB,88850,HISTORICAL_PRICES,SPRB,,1.60683E+12,0.487647059,0.487647059,24.85,25.29,27.31,23.92,88850,24.85,25.29,27.31,23.92,88850,18-Nov-20,0.84,0.0344
18-Nov-20,"Lantheus Holdings, Inc. Announces FDA Approval of DEFINITY® Room Temperature","Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH), the parent company of Lantheus Medical Imaging, Inc. and Progenics Pharmaceuticals, Inc., and a global leader in the development, manufacture an...",12.35,12.67,12.22,12.46,LNTH,740282,HISTORICAL_PRICES,LNTH,,1.60683E+12,0.026600166,0.026600166,12.46,12.35,12.67,12.22,740282,12.46,12.35,12.67,12.22,740282,18-Nov-20,-0.12,-0.0096
18-Nov-20,"ROSEN, A LEADING AND TOP RANKED LAW FIRM, Reminds Neovasc Inc. Investors of Important Deadline in Securities Class Action – NVCN","Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Neovasc Inc. (NASDAQ: NVCN) between November 1, 2019 and October 27, 2020, inclusive (the “Class Period”) of...",0.85,0.89,0.7806,0.79,NVCN,992052,HISTORICAL_PRICES,NVCN,,1.60683E+12,-0.591346154,-0.591346154,0.79,0.85,0.89,0.7806,992052,0.79,0.85,0.89,0.7806,992052,18-Nov-20,0.0711,0.0913
18-Nov-20,NantKwest to Participate in the 32nd Annual Piper Sandler Healthcare Conference,"NantKwest, Inc. (NASDAQ: NK), a clinical-stage, natural killer cell-based therapeutics company, today announced its participation in the virtual 32nd Annual Piper Sandler Healthcare conference, which...",8.26,8.62,8.12,8.28,NK,465601,HISTORICAL_PRICES,NK,,1.60683E+12,0.205839416,0.205839416,8.28,8.26,8.62,8.12,465601,8.28,8.26,8.62,8.12,465601,18-Nov-20,-0.01,-0.0012
18-Nov-20,Omeros Submits its Biologics License Application to U.S. FDA for Narsoplimab in HSCT-TMA,Omeros Corporation (Nasdaq: OMER) announced that it has completed the rolling submission of its Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for narsoplimab for t...,11.89,12.48,11.64,11.64,OMER,1199958,HISTORICAL_PRICES,OMER,,1.60683E+12,0.209562564,0.209562564,11.64,11.89,12.48,11.64,1199958,11.64,11.89,12.48,11.64,1199958,18-Nov-20,0.37,0.0321
18-Nov-20,"Gilead Announces Investigational Long-Acting HIV-1 Capsid Inhibitor, Lenacapavir, Achieves Primary Endpoint in Phase 2/3 Study in Heavily Treatment-Experienced People Living With HIV","Gilead Sciences, Inc. (Nasdaq: GILD) today announced topline results from the Phase 2/3 CAPELLA trial evaluating the company’s investigational, long-acting HIV-1 capsid inhibitor, lenacapavir, in heav...",60.9,61.64,60.56,61.04,GILD,8884204,HISTORICAL_PRICES,GILD,,1.61552E+12,-0.021686747,-0.021686747,61.04,60.9,61.64,60.56,8884204,59.6776,59.5407,60.2642,59.2083,8884204,18-Nov-20,-0.07,-0.0011
18-Nov-20,REMINDER: Akers Biosciences Schedules Conference Call to Discuss Merger with MyMD Pharmaceuticals,"MyMD Pharmaceuticals, Inc. (""MyMD"") and Akers Biosciences, Inc. (""Akers"") (NASDAQ: AKER) jointly announced a definitive merger agreement last week. The companies plan to hold a video conference for in...",1.89,1.92,1.77,1.92,AKER,810667,HISTORICAL_PRICES,AKER,,1.60683E+12,-0.07804878,-0.07804878,1.92,1.89,1.92,1.77,810667,1.92,1.89,1.92,1.77,810667,18-Nov-20,-0.02,-0.0105
18-Nov-20,"ProvideGx® Partners with Fresenius Kabi to Help Stabilize Supply of Heparin, a Vital Medication","Premier Inc. (NASDAQ: PINC), through its ProvideGx® program, has partnered with Fresenius Kabi to supply pre-filled, single-use IV bags of heparin sodium injection, USP to healthcare providers, helpin...",34,34.65,33.91,34.65,PINC,368875,HISTORICAL_PRICES,PINC,,1.61439E+12,0.092194025,0.092194025,34.65,34,34.65,33.91,368875,34.2731,33.6302,34.2731,33.5411,368875,18-Nov-20,-0.39,-0.0113
18-Nov-20,"Pfizer and BioNTech Conclude Phase 3 Study of COVID-19 Vaccine Candidate, Meeting All Primary Efficacy Endpoints","Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that, after conducting the final efficacy analysis in their ongoing Phase 3 study, their mRNA-based COVID-19 vaccine candidate, B...",36.32,37.42,36.3,36.93,PFE,63442680,HISTORICAL_PRICES,PFE,,1.6118E+12,0.015659955,0.015659955,36.93,36.32,37.42,36.3,63442680,36.5326,35.9291,37.0173,35.9094,63442680,18-Nov-20,0.28,0.0078
18-Nov-20,Ra Medical Systems to Feature the Pharos Optimized Excimer Laser at the Virtual New Frontiers in Cosmetic Medicine & Medical Dermatology Symposium,"Ra Medical Systems, Inc. (NYSE: RMED), a medical device company focused on commercializing excimer laser systems to treat vascular and dermatological diseases, announces it will feature the Pharos exc...",5.41,6.22,4.735,4.76,RMED,1572343,HISTORICAL_PRICES,RMED,,1.60683E+12,-0.074422583,-0.074422583,4.76,5.41,6.22,4.735,1572343,4.76,5.41,6.22,4.735,1572343,18-Nov-20,0.79,0.171
17-Nov-20,"Estudo investiga efeitos do programa de gestão do sangue do paciente com o Masimo SpHb®, monitoramento de hemoglobina contínuo não invasivo, no pós operatório de pacientes com câncer","Masimo (NASDAQ: MASI) anunciou hoje os resultados de um estudo publicado na Blood Transfusion no qual a Dra. Lucia Merolle e colegas da Azienda USL-IRCCS de Reggio Emilia, Itália, investigaram o impac...",247.85,249.01,242.515,244.99,MASI,194632,HISTORICAL_PRICES,MASI,,1.60683E+12,0.137187428,0.137187428,244.99,247.85,249.01,242.515,194632,244.99,247.85,249.01,242.515,194632,17-Nov-20,3.08,0.0126
17-Nov-20,Veeva Vault PromoMats unterstützt Bristol Myers Squibb bei der Beschleunigung von konformem Inhalts für das Markt-Engagement,"Veeva Systems (NYSE: VEEV) gab heute bekannt, dass Bristol Myers Squibb (NYSE: BMY) Veeva Vault PromoMats einführt, um schnelle, konforme Inhalte über alle digitalen Kanäle zu liefern und so die Bedür...",265.51,268.97,262,267.67,VEEV,553910,HISTORICAL_PRICES,VEEV,,1.60683E+12,-0.014000297,-0.014000297,267.67,265.51,268.97,262,553910,267.67,265.51,268.97,262,553910,17-Nov-20,0.89,0.0034
17-Nov-20,Puma Biotechnology to Present Neratinib Data at the San Antonio Breast Cancer Symposium (SABCS),"Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, announced the release of 10 abstracts that will be presented at the 2020 Virtual San Antonio Breast Cancer Symposium (SABCS) from...",9.38,9.49,8.91,9.07,PBYI,370609,HISTORICAL_PRICES,PBYI,,1.60683E+12,-0.024948025,-0.024948025,9.07,9.38,9.49,8.91,370609,9.07,9.38,9.49,8.91,370609,17-Nov-20,0.3,0.033
17-Nov-20,"SHAREHOLDER ACTION REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Biogen Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm","The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Biogen Inc. (“Biogen” or “the Company”) (NASDAQ: BIIB) for violations of §§10...",248.81,254.4113,247.91,251.18,BIIB,1371753,HISTORICAL_PRICES,BIIB,,1.60683E+12,-0.078617983,-0.078617983,251.18,248.81,254.4113,247.91,1371753,251.18,248.81,254.4113,247.91,1371753,17-Nov-20,-2.15,-0.0086
17-Nov-20,Un Estudio Investiga los Efectos del Programa de Gestión de Sangre con Monitoreo Continuo y no Invasivo de Hemoglobina con Masimo SpHb® en Pacientes Recién Operados de Cáncer,"Masimo (NASDAQ: MASI) anunció hoy las conclusiones de un estudio publicado en Blood Transfusion en el que la Dra. Lucia Merolle y sus colegas de Azienda USL-IRCCS de Reggio Emilia, Italia, investigaro...",247.85,249.01,242.515,244.99,MASI,194632,HISTORICAL_PRICES,MASI,,1.60683E+12,0.137187428,0.137187428,244.99,247.85,249.01,242.515,194632,244.99,247.85,249.01,242.515,194632,17-Nov-20,3.08,0.0126
17-Nov-20,"Studie untersucht Auswirkungen des Patientenblutmanagementprogramms mit Masimo SpHb®, einem nicht invasiven, kontinuierlichen Hämoglobin-Monitoring, bei postoperativen Krebspatienten","Masimo (NASDAQ: MASI) gab heute die Ergebnisse einer in Blood Transfusion veröffentlichten Studie bekannt, in der Dr. Lucia Merolle und Kollegen der Azienda USL-IRCCS von Reggio Emilia, Italien, die A...",247.85,249.01,242.515,244.99,MASI,194632,HISTORICAL_PRICES,MASI,,1.60683E+12,0.137187428,0.137187428,244.99,247.85,249.01,242.515,194632,244.99,247.85,249.01,242.515,194632,17-Nov-20,3.08,0.0126
17-Nov-20,"NVCN Investor Alert: Bronstein, Gewirtz & Grossman, LLC Notifies Neovasc Inc. Investors of Class Action and Lead Plaintiff Deadline: January 5, 2021","Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Neovasc Inc. (""Neovasc"" or ""the Company"") (NASDAQ: NVCN) and certain of its officers, on be...",0.7789,0.78,0.735,0.738,NVCN,502166,HISTORICAL_PRICES,NVCN,,1.60683E+12,-0.625528846,-0.625528846,0.738,0.7789,0.78,0.735,502166,0.738,0.7789,0.78,0.735,502166,17-Nov-20,0.0446,0.0607
17-Nov-20,"ICPT Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Reminds Intercept Pharmaceuticals, Inc. Shareholders of Class Action and Lead Plaintiff Deadline: January 4, 2021","Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Intercept Pharmaceuticals, Inc. (""Intercept"" or ""the Company"") (NASDAQ: ICPT) and certain o...",38.42,38.9699,36.31,37.06,ICPT,631002,HISTORICAL_PRICES,ICPT,,1.60683E+12,-0.033702213,-0.033702213,37.06,38.42,38.9699,36.31,631002,37.06,38.42,38.9699,36.31,631002,17-Nov-20,0.87,0.0232
17-Nov-20,European Medicines Agency Begins Rolling Review of Moderna’s mRNA Vaccine Candidate Against COVID-19 (mRNA-1273),"Moderna, Inc., (Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced tha...",93.15,97.8,91.6,97.23,MRNA,26171963,HISTORICAL_PRICES,MRNA,,1.60683E+12,0.429338653,0.429338653,97.23,93.15,97.8,91.6,26171963,97.23,93.15,97.8,91.6,26171963,17-Nov-20,-4.8,-0.049
17-Nov-20,Moderna Announces Supply Agreement with United Kingdom Government to Supply mRNA Vaccine Against COVID-19 (mRNA-1273) if Approved for Use,"Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced a s...",93.15,97.8,91.6,97.23,MRNA,26171963,HISTORICAL_PRICES,MRNA,,1.60683E+12,0.429338653,0.429338653,97.23,93.15,97.8,91.6,26171963,97.23,93.15,97.8,91.6,26171963,17-Nov-20,-4.8,-0.049
17-Nov-20,Dropbox Goes All in on Remote Work: Unveils New Features and Tools for Distributed Teams,"Today Dropbox, Inc. (NASDAQ: DBX) unveiled the next iteration of its collaborative workspace—Dropbox Spaces—in addition to several new features that help teams get organized, collaborate, and keep wor...",18.55,18.7,18.34,18.6,DBX,8302139,HISTORICAL_PRICES,DBX,,1.60683E+12,-0.012247071,-0.012247071,18.6,18.55,18.7,18.34,8302139,18.6,18.55,18.7,18.34,8302139,17-Nov-20,-0.14,-0.0075
17-Nov-20,Agilent Presents Thought Leader Award to Drs. Carl H. June and Michael Milone,"Agilent Technologies Inc. (NYSE: A) today announced professors Carl H. June, MD, and Michael Milone, MD, Ph.D., as recipients of an Agilent Thought Leader Award. Both scientists are being recognized f...",109.86,110.77,109.245,110.5,A,1571458,HISTORICAL_PRICES,A,,1.60979E+12,0.140336309,0.140336309,110.5,109.86,110.77,109.245,1571458,110.3191,109.6801,110.5886,109.0661,1571458,17-Nov-20,-0.41,-0.0037
17-Nov-20,NantHealth and ImmunityBio Announce RNA Profiling for Clinical Decision Support Publication In Nature’s Scientific Reports,"NantHealth, Inc. (NASDAQ: NH), a provider of enterprise solutions that help businesses transform complex data into actionable insights, today announced the publication of a study that revealed RNA seq...",2.23,2.25,2.12,2.24,NH,119971,HISTORICAL_PRICES,NH,,1.60683E+12,0.042056075,0.042056075,2.24,2.23,2.25,2.12,119971,2.24,2.23,2.25,2.12,119971,17-Nov-20,0.04,0.0183
17-Nov-20,"Transcat, Inc. Increases Shelf Registration to $75 million","Transcat, Inc. (Nasdaq: TRNS) (“Transcat” or the “Company”), a leading provider of accredited calibration, repair, inspection and laboratory instrument services and value-added distributor of professi...",32.92,33.755,32,32.37,TRNS,43891,HISTORICAL_PRICES,TRNS,,1.60683E+12,0.123933083,0.123933083,32.37,32.92,33.755,32,43891,32.37,32.92,33.755,32,43891,17-Nov-20,0.02,0.0006
17-Nov-20,Samenvatting: Veeva Vault PromoMats ter ondersteuning van Bristol Myers Squibb bij het versnellen van compatibele inhoud naar marktbetrokkenheid,"Veeva Systems (NYSE: VEEV) heeft vandaag aangekondigd dat Bristol Myers Squibb (NYSE: BMY) Veeva Vault PromoMats gebruikt voor het leveren van snelle, conforme content over alle digitale kanalen om aa...",265.51,268.97,262,267.67,VEEV,553910,HISTORICAL_PRICES,VEEV,,1.60683E+12,-0.014000297,-0.014000297,267.67,265.51,268.97,262,553910,267.67,265.51,268.97,262,553910,17-Nov-20,0.89,0.0034
17-Nov-20,Resumen: Veeva Vault PromoMats apoyará a Bristol Myers Squibb para acelerar la compatibilidad de contenidos con el compromiso del mercado,Veeva Systems (NYSE: VEEV) ha anunciado hoy que Bristol Myers Squibb (NYSE: BMY) está adoptando las Veeva Vault PromoMats para ofrecer un contenido rápido y compatible en todos los canales digitales y...,265.51,268.97,262,267.67,VEEV,553910,HISTORICAL_PRICES,VEEV,,1.60683E+12,-0.014000297,-0.014000297,267.67,265.51,268.97,262,553910,267.67,265.51,268.97,262,553910,17-Nov-20,0.89,0.0034
17-Nov-20,Veeva Vault PromoMats to Support Bristol Myers Squibb in Speeding Compliant Content to Market,"Veeva Systems (NYSE: VEEV) today announced that Bristol Myers Squibb (NYSE: BMY) is adopting Veeva Vault PromoMats to deliver fast, compliant content across all digital channels to meet their customer...",265.51,268.97,262,267.67,VEEV,553910,HISTORICAL_PRICES,VEEV,,1.60683E+12,-0.014000297,-0.014000297,267.67,265.51,268.97,262,553910,267.67,265.51,268.97,262,553910,17-Nov-20,0.89,0.0034
17-Nov-20,"AVROBIO Announces New Positive Clinical Data and Preclinical Data, as Well as Expanded Leading Lysosomal Disorder Gene Therapy Pipeline","AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced positive new data across its clinical prog...",16.36,16.64,16.04,16.39,AVRO,187794,HISTORICAL_PRICES,AVRO,,1.60683E+12,0.248854962,0.248854962,16.39,16.36,16.64,16.04,187794,16.39,16.36,16.64,16.04,187794,17-Nov-20,0.14,0.0086
17-Nov-20,Vault PromoMats di Veeva aiuterà Bristol Myers Squibb nell’elaborazione di contenuti conformi orientati al coinvolgimento del mercato,Veeva Systems (NYSE: VEEV) ha annunciato oggi che Bristol Myers Squibb (NYSE: BMY) adotterà Veeva Vault PromoMats per fornire rapidamente contenuti conformi in tutti i canali digitali così da soddisfa...,265.51,268.97,262,267.67,VEEV,553910,HISTORICAL_PRICES,VEEV,,1.60683E+12,-0.014000297,-0.014000297,267.67,265.51,268.97,262,553910,267.67,265.51,268.97,262,553910,17-Nov-20,0.89,0.0034
16-Nov-20,Veeva Vault PromoMats to Support Bristol Myers Squibb in Speeding Compliant Content to Market Engagement,"Veeva Systems (NYSE: VEEV) today announced that Bristol Myers Squibb (NYSE: BMY) is adopting Veeva Vault PromoMats to deliver fast, compliant content across all digital channels to meet their customer...",264.62,268.68,256.5,259.64,VEEV,1076477,HISTORICAL_PRICES,VEEV,,1.60683E+12,-0.017305407,-0.017305407,259.64,264.62,268.68,256.5,1076477,259.64,264.62,268.68,256.5,1076477,16-Nov-20,-0.3,-0.0011
16-Nov-20,Hologic Announces CE Mark of the Genius™ Digital Diagnostics System for Cervical Cancer Screening,"Hologic, Inc. (Nasdaq: HOLX) announced today that its new Genius™ Digital Diagnostics System is now CE marked in Europe. Genius Digital Diagnostics is the first digital cytology platform to combine a...",71.07,71.14,68.97,69.17,HOLX,2073852,HISTORICAL_PRICES,HOLX,,1.60683E+12,0.127916204,0.127916204,69.17,71.07,71.14,68.97,2073852,69.17,71.07,71.14,68.97,2073852,16-Nov-20,1.33,0.0191
16-Nov-20,"NanoVibronix Reports Third Quarter 2020 Financial Results, Provides Business Update","NanoVibronix, Inc., (NASDAQ: NAOV), a medical device company that produces the UroShield®, PainShield® and WoundShield® Surface Acoustic Wave (SAW) Portable Ultrasonic Therapeutic Devices, today repor...",0.5587,0.5881,0.55,0.5881,NAOV,178081,HISTORICAL_PRICES,NAOV,,1.60683E+12,-0.351254064,-0.351254064,0.5881,0.5587,0.5881,0.55,178081,0.5881,0.5587,0.5881,0.55,178081,16-Nov-20,-0.0156,-0.0272
16-Nov-20,Tenax Therapeutics Reports Third Quarter 2020 Results and Provides Business Update,"Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceutical company focused on identifying, developing and commercializing products for the critical care market, today reported financial resul...",1.06,1.07,0.96,1.05,TENX,95049,HISTORICAL_PRICES,TENX,,1.60683E+12,-0.316129032,-0.316129032,1.05,1.06,1.07,0.96,95049,1.05,1.06,1.07,0.96,95049,16-Nov-20,-0.0214,-0.0198
16-Nov-20,Bristol Myers Squibb Provides Regulatory Update on Lisocabtagene Maraleucel (liso-cel),Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) has informed the company that its review of the Biologics License Application (BLA) for lisocabtagene...,64.5,64.93,63.845,64.12,BMY,7199552,HISTORICAL_PRICES,BMY,,1.60946E+12,0.107296137,0.107296137,64.12,64.5,64.93,63.845,7199552,63.6126,63.9896,64.4162,63.3398,7199552,16-Nov-20,0.88,0.0138
16-Nov-20,Ra Medical Systems Announces 1-for-25 Reverse Stock Split,"Ra Medical Systems, Inc. (NYSE: RMED) announced today that its Board of Directors has approved a 1-for-25 reverse stock split of the Company’s common stock, which will be effective at 5:00 p.m. Easter...",5.2175,5.465,5.01,5.225,RMED,176637.28,HISTORICAL_PRICES,RMED,,1.60683E+12,-0.107356715,-0.107356715,0.209,0.2087,0.2186,0.2004,4415932,5.225,5.2175,5.465,5.01,176637.28,16-Nov-20,-0.2625,-0.0479
16-Nov-20,"NNOX Final Deadline: Bronstein, Gewirtz & Grossman, LLC Reminds Nano-X Imaging Ltd. Shareholders of Class Action and Lead Plaintiff Deadline: November 16, 2020","Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Nano-X Imaging Ltd. (""Nano-X"" or ""the Company"") (NASDAQ: NNOX) and certain of its officers,...",38.43,39.1,36.39,36.5,NNOX,810131,HISTORICAL_PRICES,NNOX,,1.60683E+12,0.413387275,0.413387275,36.5,38.43,39.1,36.39,810131,36.5,38.43,39.1,36.39,810131,16-Nov-20,2.36,0.0654
16-Nov-20,"DEADLINE TODAY: The Schall Law Firm Announces It Is Investigating Claims Against Nano-X Imaging Ltd. and Encourages Investors with Losses of $100,000 to Contact the Firm","The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Nano-X Imaging Ltd. (“Nano-X” or “the Company”) (NASDAQ: NNOX) f...",38.43,39.1,36.39,36.5,NNOX,810131,HISTORICAL_PRICES,NNOX,,1.60683E+12,0.413387275,0.413387275,36.5,38.43,39.1,36.39,810131,36.5,38.43,39.1,36.39,810131,16-Nov-20,2.36,0.0654
16-Nov-20,Frequency Therapeutics Provides Business Updates and Reports Third Quarter 2020 Financial Results,"Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage biotechnology company focused on harnessing the body’s innate biology to repair or reverse damage caused by a broad range of degenerative...",23.45,25.5,22.82,25.23,FREQ,242216,HISTORICAL_PRICES,FREQ,,1.60683E+12,0.095794393,0.095794393,25.23,23.45,25.5,22.82,242216,25.23,23.45,25.5,22.82,242216,16-Nov-20,-1.6,-0.0639
16-Nov-20,Dicerna Announces FDA Acceptance of Lilly’s Investigational New Drug (IND) Application for First GalXC™ RNAi Candidate Under Companies’ Global Research Collaboration and Licensing Agreement,"Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA), (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (“RNAi”) therapeutics, today announced U.S. Food and Dr...",22.6,23.17,21.92,22.75,DRNA,519714,HISTORICAL_PRICES,DRNA,,1.60683E+12,0.235647895,0.235647895,22.75,22.6,23.17,21.92,519714,22.75,22.6,23.17,21.92,519714,16-Nov-20,-0.28,-0.0122
16-Nov-20,Kala Pharmaceuticals Provides Update on Launch Plans for EYSUVISTM for the Treatment of Dry Eye Disease,"Kala Pharmaceuticals, Inc., (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today provided an up...",7.42,7.71,7.26,7.62,KALA,1278785,HISTORICAL_PRICES,KALA,,1.60683E+12,-0.014608234,-0.014608234,7.62,7.42,7.71,7.26,1278785,7.62,7.42,7.71,7.26,1278785,16-Nov-20,0,0
16-Nov-20,Legend Biotech Reports Third Quarter 2020 Financial Results,"Legend Biotech Corporation (NASDAQ: LEGN) (“Legend Biotech” or the “Company”), a global clinical-stage biopharmaceutical company engaged in the discovery and development of novel cell therapies for on...",27.62,28,27.04,27.13,LEGN,135096,HISTORICAL_PRICES,LEGN,,1.60683E+12,-0.045281714,-0.045281714,27.13,27.62,28,27.04,135096,27.13,27.62,28,27.04,135096,16-Nov-20,0.12,0.0044
16-Nov-20,Moderna’s COVID-19 Vaccine Candidate Meets its Primary Efficacy Endpoint in the First Interim Analysis of the Phase 3 COVE Study,"Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced tha...",97.95,103.2,93.3,100.31,MRNA,70853055,HISTORICAL_PRICES,MRNA,,1.60683E+12,0.502992174,0.502992174,100.31,97.95,103.2,93.3,70853055,100.31,97.95,103.2,93.3,70853055,16-Nov-20,8.56,0.0958
16-Nov-20,Moderna Announces Longer Shelf Life for its COVID-19 Vaccine Candidate at Refrigerated Temperatures,"Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced new...",97.95,103.2,93.3,100.31,MRNA,70853055,HISTORICAL_PRICES,MRNA,,1.60683E+12,0.502992174,0.502992174,100.31,97.95,103.2,93.3,70853055,100.31,97.95,103.2,93.3,70853055,16-Nov-20,8.56,0.0958
13-Nov-20,Agilent Receives Expanded FDA Approval for PD-L1 IHC 22C3 pharmDx in Triple-Negative Breast Cancer,Agilent Technologies Inc. (NYSE: A) today announced it has received FDA approval for the use of PD-L1 IHC 22C3 pharmDx as an aid in identifying patients with triple-negative breast cancer (TNBC) for t...,110.17,111.54,109.78,110.46,A,1356781,HISTORICAL_PRICES,A,,1.60979E+12,0.143554079,0.143554079,110.46,110.17,111.54,109.78,1356781,110.2791,109.9896,111.3574,109.6003,1356781,13-Nov-20,0.73,0.0067
13-Nov-20,FDA Approves Merck’s KEYTRUDA® (pembrolizumab) in Combination With Chemotherapy for Patients With Locally Recurrent Unresectable or Metastatic Triple‑Negative Breast Cancer Whose Tumors Express PD-L1 (CPS ≥10),"Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved KEYTRUDA, Merck’s anti-PD-1 therapy, in combination...",81.09,81.85,79.72,80.24,MRK,7343207,HISTORICAL_PRICES,MRK,,1.61552E+12,-0.024774504,-0.024774504,80.24,81.09,81.85,79.72,7343207,78.9179,79.7539,80.5014,78.4065,7343207,13-Nov-20,1.23,0.0154
13-Nov-20,"SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Biogen Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm","The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Biogen Inc. (“Biogen” or “the Company”) (NASDAQ: BIIB) for violations of §§10...",248.59,249.13,241.89,243.65,BIIB,1697750,HISTORICAL_PRICES,BIIB,,1.60683E+12,-0.079432677,-0.079432677,243.65,248.59,249.13,241.89,1697750,243.65,248.59,249.13,241.89,1697750,13-Nov-20,7.04,0.0291
13-Nov-20,Acceleron Presents Preliminary Interim Data from the SPECTRA Phase 2 Trial of Sotatercept in Pulmonary Arterial Hypertension (PAH) at the 2020 American Heart Association Scientific Sessions,"Acceleron Pharma Inc. (Nasdaq: XLRN), a leading biopharmaceutical company in the discovery, development, and commercialization of TGF-beta superfamily therapeutics to treat serious and rare diseases,...",114.03,119.67,113.88,118.34,XLRN,260307,HISTORICAL_PRICES,XLRN,,1.60683E+12,0.085689803,0.085689803,118.34,114.03,119.67,113.88,260307,118.34,114.03,119.67,113.88,260307,13-Nov-20,-4.33,-0.0366
13-Nov-20,"Acceleron Presents New Data from the PULSAR Phase 2 Trial, Preclinical Research on Sotatercept in Pulmonary Arterial Hypertension (PAH) at the 2020 American Heart Association (AHA) Scientific Sessions","Acceleron Pharma Inc. (Nasdaq: XLRN), a leading biopharmaceutical company in the discovery, development, and commercialization of TGF-beta superfamily therapeutics to treat serious and rare diseases,...",114.03,119.67,113.88,118.34,XLRN,260307,HISTORICAL_PRICES,XLRN,,1.60683E+12,0.085689803,0.085689803,118.34,114.03,119.67,113.88,260307,118.34,114.03,119.67,113.88,260307,13-Nov-20,-4.33,-0.0366
13-Nov-20,"Alnylam Reports Positive Interim Results from Ongoing Phase 1 Study of ALN-AGT, an Investigational RNAi Therapeutic for the Treatment of Hypertension","Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today positive interim data from the ongoing Phase 1 study of ALN-AGT, a subcutaneous investigational RNA...",135.51,136.67,132.6201,133.35,ALNY,725862,HISTORICAL_PRICES,ALNY,,1.60683E+12,0.016274186,0.016274186,133.35,135.51,136.67,132.6201,725862,133.35,135.51,136.67,132.6201,725862,13-Nov-20,3.07,0.0232
13-Nov-20,"SINTX Technologies and Iwatani Group Announce Agreement to Develop Antipathogenic Surfaces to Help Prevent Spread of the Common Flu, COVID-19, and Other Viral Diseases","SINTX Technologies, Inc. (NASDAQ: SINT) (“SINTX” or the “Company”) (www.sintx.com), an original equipment manufacturer (OEM) of silicon nitride ceramic for medical and non-medical applications, and Iw...",1.76,1.78,1.66,1.72,SINT,1279563,HISTORICAL_PRICES,SINT,,1.60683E+12,-0.027624309,-0.027624309,1.72,1.76,1.78,1.66,1279563,1.72,1.76,1.78,1.66,1279563,13-Nov-20,0.08,0.0476
13-Nov-20,Lantheus Holdings Announces FDA Clearance for AI-Enabled Automated Bone Scan Index (aBSI) in Prostate Cancer on GE Healthcare’s Xeleris Platform,"Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH), the parent company of Lantheus Medical Imaging, Inc., Progenics Pharmaceuticals, Inc., and EXINI Diagnostics AB, and a global leader in the deve...",12.16,12.3499,11.6,11.9,LNTH,723025,HISTORICAL_PRICES,LNTH,,1.60683E+12,0.010806318,0.010806318,11.9,12.16,12.3499,11.6,723025,11.9,12.16,12.3499,11.6,723025,13-Nov-20,0.63,0.0546
13-Nov-20,"New Data Build on Growing Evidence Supporting TEPEZZA® (teprotumumab-trbw) Efficacy in Thyroid Eye Disease (TED), Including in Patients With Less Severe Disease and Longer Disease Duration","Horizon Therapeutics plc (Nasdaq: HZNP) today announced new TEPEZZA® (teprotumumab-trbw) data presented at the American Academy of Ophthalmology Annual Meeting (AAO 2020 Virtual), including findings s...",72.35,75.22,72.18,74.11,HZNP,1406830,HISTORICAL_PRICES,HZNP,,1.60683E+12,-0.039559273,-0.039559273,74.11,72.35,75.22,72.18,1406830,74.11,72.35,75.22,72.18,1406830,13-Nov-20,-1.27,-0.0173
13-Nov-20,Mirum Pharmaceuticals Presents New Data From Its Maralixibat and Volixibat Clinical Studies at AASLD Annual Meeting,"Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a biopharmaceutical company focused on the development and commercialization of novel therapies for debilitating liver diseases, today announced new analyse...",19.19,20.34,18.72,19.7,MIRM,120665,HISTORICAL_PRICES,MIRM,,1.60683E+12,0.012664908,0.012664908,19.7,19.19,20.34,18.72,120665,19.7,19.19,20.34,18.72,120665,13-Nov-20,1.09,0.0602
13-Nov-20,Axcella Presents Data for AXA1125 at The Liver Meeting® 2020,"Axcella (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases and improve health using endogenous metabolic modulator (EMM) compositions, today sha...",5.29,5.43,5.19,5.27,AXLA,112020,HISTORICAL_PRICES,AXLA,,1.60683E+12,0.283980583,0.283980583,5.27,5.29,5.43,5.19,112020,5.27,5.29,5.43,5.19,112020,13-Nov-20,0.14,0.0272
13-Nov-20,Swissmedic Begins Rolling Review of Moderna’s mRNA Vaccine Against COVID-19 (mRNA-1273),"Moderna, Inc., (Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced tha...",89.39,90.53,85.22,86.62,MRNA,14176721,HISTORICAL_PRICES,MRNA,,1.60683E+12,0.371643394,0.371643394,86.62,89.39,90.53,85.22,14176721,86.62,89.39,90.53,85.22,14176721,13-Nov-20,1.58,0.018
13-Nov-20,Rocket Pharmaceuticals Receives Funding from the California Institute for Regenerative Medicine for Phase 1 Clinical Trial of RP-L401 for Infantile Malignant Osteopetrosis,"Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) (“Rocket”), a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders, today announces tha...",31.97,32.6,31.08,31.13,RCKT,369656,HISTORICAL_PRICES,RCKT,,1.60683E+12,0.396679773,0.396679773,31.13,31.97,32.6,31.08,369656,31.13,31.97,32.6,31.08,369656,13-Nov-20,1.02,0.033
13-Nov-20,TherapeuticsMD Announces Participation in the Stifel 2020 Virtual Healthcare Conference,"TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative women’s healthcare company, today announced that the company will participate in the Stifel 2020 Virtual Healthcare Conference. Details for the prese...",1.23,1.3,1.22,1.29,TXMD,4221908,HISTORICAL_PRICES,TXMD,,1.60683E+12,-0.061068702,-0.061068702,1.29,1.23,1.3,1.22,4221908,1.29,1.23,1.3,1.22,4221908,13-Nov-20,-0.03,-0.0238
13-Nov-20,Aerie Pharmaceuticals Receives Positive CHMP Opinion for Roclanda® in the European Union,"Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients w...",12.98,13.32,12.83,13,AERI,431405,HISTORICAL_PRICES,AERI,,1.60683E+12,0.115120275,0.115120275,13,12.98,13.32,12.83,431405,13,12.98,13.32,12.83,431405,13-Nov-20,-0.02,-0.0015
13-Nov-20,Ra Medical Systems to Participate in A.G.P.’s Virtual Healthcare Symposium,"Ra Medical Systems, Inc. (NYSE: RMED) , a medical device company focusing on commercializing excimer laser systems to treat vascular and dermatological diseases, announces that management will partici...",5.48,5.9775,4.75,5.125,RMED,212972.12,HISTORICAL_PRICES,RMED,,1.60683E+12,-0.062446536,-0.062446536,0.205,0.2192,0.2391,0.19,5324303,5.125,5.48,5.9775,4.75,212972.12,13-Nov-20,0.55,0.1116
13-Nov-20,ADC Therapeutics veröffentlicht Finanzergebnisse für das dritte Quartal 2020 und präsentiert aktuelle Highlights seiner Geschäftsentwicklung,"ADC Therapeutics SA (NYSE: ADCT), ein im Bereich der späten klinischen Forschung tätiges Biotechnologieunternehmen mit Spezialisierung auf Onkologie und Pionier bei der Entwicklung und Vermarktung von...",33.7,34.74,33.4115,34.37,ADCT,106965,HISTORICAL_PRICES,ADCT,,1.60683E+12,0.005970149,0.005970149,34.37,33.7,34.74,33.4115,106965,34.37,33.7,34.74,33.4115,106965,13-Nov-20,-0.26,-0.0077
12-Nov-20,ADC Therapeutics publie ses résultats financiers pour le troisième trimestre 2020 et les faits marquants de son actualité,"ADC Therapeutics SA (NYSE: ADCT), une société biotechnologique spécialisée en oncologie au stade clinique avancé, à l’avant-garde du développement et de la mise sur le marché de conjugués anticorps-mé...",33.96,35.08,33.2,34.67,ADCT,151936,HISTORICAL_PRICES,ADCT,,1.60683E+12,0.013731343,0.013731343,34.67,33.96,35.08,33.2,151936,34.67,33.96,35.08,33.2,151936,12-Nov-20,-0.71,-0.0205
12-Nov-20,Urovant Sciences Enters Into Definitive Agreement for Sumitovant Biopharma to Acquire All Outstanding Shares,Urovant Sciences (Nasdaq: UROV) announced today that it has entered into a definitive agreement in which Sumitovant Biopharma will acquire Urovant Sciences for $16.25 per share or approximately $584 m...,8.28,8.3399,7.89,7.97,UROV,573219,HISTORICAL_PRICES,UROV,,1.60683E+12,-0.114438503,-0.114438503,7.97,8.28,8.3399,7.89,573219,7.97,8.28,8.3399,7.89,573219,12-Nov-20,0.37,0.0468
12-Nov-20,FSD Pharma Announces Third Quarter 2020 Financial Results and Provides Corporate Update,"FSD Pharma Inc. (Nasdaq: HUGE) (CSE: HUGE) (“FSD Pharma” or the “Company”) today announced its financial results for the third quarter ending September 30, 2020 and provided a corporate update. The fi...",1.39,1.4299,1.34,1.42,HUGE,413453,HISTORICAL_PRICES,HUGE,,1.60988E+12,-0.472485769,-0.472485769,1.42,1.39,1.4299,1.34,413453,1.42,1.39,1.4299,1.34,413453,12-Nov-20,-0.04,-0.028
12-Nov-20,PhaseBio Reports Recent Business Highlights and Third-Quarter 2020 Financial Results,"PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiovascular and cardiopulmonary dis...",3.67,3.71,3.53,3.6,PHAS,137435,HISTORICAL_PRICES,PHAS,,1.60683E+12,0.15408805,0.15408805,3.6,3.67,3.71,3.53,137435,3.6,3.67,3.71,3.53,137435,12-Nov-20,0.09,0.0251
12-Nov-20,Taysha Gene Therapies Reports Third Quarter 2020 Financial Results and Provides Business Update,"Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the cen...",20.1,20.63,19.53,19.96,TSHA,38786,HISTORICAL_PRICES,TSHA,,1.60683E+12,-0.164588529,-0.164588529,19.96,20.1,20.63,19.53,38786,19.96,20.1,20.63,19.53,38786,12-Nov-20,0.14,0.007
12-Nov-20,Ra Medical Systems Reports 2020 Third Quarter Financial Results,"Ra Medical Systems, Inc. (NYSE: RMED), a medical device company focusing on commercializing excimer laser systems to treat vascular and dermatological diseases, reports financial results for the three...",4.93,5.275,4.8225,5.0025,RMED,55290,HISTORICAL_PRICES,RMED,,1.60683E+12,-0.156544055,-0.156544055,0.2001,0.1972,0.211,0.1929,1382250,5.0025,4.93,5.275,4.8225,55290,12-Nov-20,-0.235,-0.0455
12-Nov-20,Lyra Therapeutics to Participate in Fireside Chat at the Jefferies Virtual London Healthcare Conference,"Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatme...",10.85,11,10.81,10.9,LYRA,37556,HISTORICAL_PRICES,LYRA,,1.60683E+12,-0.052401747,-0.052401747,10.9,10.85,11,10.81,37556,10.9,10.85,11,10.81,37556,12-Nov-20,-0.03,-0.0028
12-Nov-20,Aptinyx Reports Third Quarter 2020 Financial Results and Recent Highlights,"Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today reported financial results fo...",3.25,3.31,3.16,3.19,APTX,595450,HISTORICAL_PRICES,APTX,,1.60683E+12,0.045016077,0.045016077,3.19,3.25,3.31,3.16,595450,3.19,3.25,3.31,3.16,595450,12-Nov-20,0.08,0.0252
12-Nov-20,Astrotech Reports First Quarter of Fiscal Year 2021 Financial Results,"Astrotech Corporation (NASDAQ: ASTC) reported its financial results for the first quarter of fiscal year 2021, which ended September 30, 2020. In October, we completed two strategic capital raises for...",1.68,1.72,1.65,1.69,ASTC,486538,HISTORICAL_PRICES,ASTC,,1.60683E+12,0.112582781,0.112582781,1.69,1.68,1.72,1.65,486538,1.69,1.68,1.72,1.65,486538,12-Nov-20,0,0
12-Nov-20,"Mirum Pharmaceuticals Provides Third Quarter 2020 Financial Results and Business Update, and Announces Virtual Investor Day","Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a biopharmaceutical company focused on the development and commercialization of novel therapies for debilitating liver diseases, today announced financial r...",18.1,18.55,17.56,18.05,MIRM,61071,HISTORICAL_PRICES,MIRM,,1.60683E+12,-0.044854881,-0.044854881,18.05,18.1,18.55,17.56,61071,18.05,18.1,18.55,17.56,61071,12-Nov-20,0.9,0.0523
12-Nov-20,Akers Biosciences and MyMD Pharmaceuticals Sign Definitive Merger Agreement,"MyMD Pharmaceuticals, Inc. (“MyMD”) and Akers Biosciences, Inc. (“Akers”) (NASDAQ: AKER) today jointly announced that they have entered into a definitive merger agreement. Upon closing the transaction...",2.22,2.94,2.08,2.18,AKER,45742360,HISTORICAL_PRICES,AKER,,1.60683E+12,0.082926829,0.082926829,2.18,2.22,2.94,2.08,45742360,2.18,2.22,2.94,2.08,45742360,12-Nov-20,0.5,0.2907
12-Nov-20,"Chewy Launches Compounded Medications for Pets, Plans to Offer it as a Service to Veterinarians in Future","Chewy, Inc. (“Chewy”) (NYSE: CHWY), the leader in pet e-commerce, announced today that it is expanding its Pharmacy (Rx) business to now offer compounded medications that are customized to the specifi...",63.38,65.2,61.8418,63.89,CHWY,3785677,HISTORICAL_PRICES,CHWY,,1.60683E+12,0.153202329,0.153202329,63.89,63.38,65.2,61.8418,3785677,63.89,63.38,65.2,61.8418,3785677,12-Nov-20,-0.58,-0.0091
12-Nov-20,"Atara Biotherapeutics Presents New Preclinical Data on ATA3271, a Next-Generation Allogeneic Mesothelin-Targeted CAR T to Treat Solid Tumors, at the 35th Society for Immunotherapy of Cancer Annual Meeting (SITC 2020)","Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious disease...",18.12,18.38,15.765,15.81,ATRA,1877455,HISTORICAL_PRICES,ATRA,,1.60683E+12,0.443824701,0.443824701,15.81,18.12,18.38,15.765,1877455,15.81,18.12,18.38,15.765,1877455,12-Nov-20,2.38,0.1512
12-Nov-20,Cerus Corporation to Participate in Upcoming Virtual Investor Conferences,"Cerus Corporation (Nasdaq: CERS) announced today that William ‘Obi’ Greenman, Cerus’ president and chief executive officer, and Kevin D. Green, Cerus’ chief financial officer, are scheduled to partici...",6.05,6.07,5.82,5.89,CERS,1196949,HISTORICAL_PRICES,CERS,,1.60683E+12,0.025423729,0.025423729,5.89,6.05,6.07,5.82,1196949,5.89,6.05,6.07,5.82,1196949,12-Nov-20,0.16,0.0272
12-Nov-20,PerkinElmer SARS-CoV-2 RT-PCR Assay Receives CE Mark for Saliva and Sample Pooling to Test Symptomatic and Asymptomatic Individuals,"PerkinElmer, Inc. (NYSE:PKI) announced today that its PerkinElmer® SARS-CoV-2 Real-time RT-PCR Assay received CE-IVD marking for the use of saliva as specimen type and the option to pool up to five sp...",130.64,131.89,129.15,129.21,PKI,634514,HISTORICAL_PRICES,PKI,,1.6112E+12,0.107494066,0.107494066,129.21,130.64,131.89,129.15,634514,129.1502,130.5795,131.829,129.0902,634514,12-Nov-20,1.57,0.0122
12-Nov-20,TYME Provides Business Update and Announces Second Quarter Fiscal 2021 Financial and Operating Results,"Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced financial and operating results for its second quarter ended...",0.9451,0.95,0.9148,0.9184,TYME,120636,HISTORICAL_PRICES,TYME,,1.60683E+12,0.016236559,0.016236559,0.9184,0.9451,0.95,0.9148,120636,0.9184,0.9451,0.95,0.9148,120636,12-Nov-20,0.0157,0.0169
12-Nov-20,"Applied DNA Secures Blanket Purchase Order for 10,000 Linea™ COVID-19 Tests","Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA” or the ""Company""), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing, today announced that it has secured a blanket purchase...",6.89,7.12,6.62,6.93,APDN,160852,HISTORICAL_PRICES,APDN,,1.60683E+12,-0.121173469,-0.121173469,6.93,6.89,7.12,6.62,160852,6.93,6.89,7.12,6.62,160852,12-Nov-20,0.05,0.0073
12-Nov-20,Stoke Therapeutics Reports Third Quarter Financial Results and Provides Business Updates,"Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company pioneering a new way to treat the underlying cause of genetic diseases by precisely upregulating protein expression, today reported fin...",44.16,45.9593,40.75,44,STOK,172651,HISTORICAL_PRICES,STOK,,1.60683E+12,0.340619308,0.340619308,44,44.16,45.9593,40.75,172651,44,44.16,45.9593,40.75,172651,12-Nov-20,-1.06,-0.0234
12-Nov-20,Axcella Reports Third Quarter 2020 Financial Results and Provides Business Update,"Axcella (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases and improve health using endogenous metabolic modulator (EMM) compositions, today ann...",5.15,5.5,4.9,5.45,AXLA,159247,HISTORICAL_PRICES,AXLA,,1.60683E+12,0.25,0.25,5.45,5.15,5.5,4.9,159247,5.45,5.15,5.5,4.9,159247,12-Nov-20,-0.18,-0.0338
12-Nov-20,ADC Therapeutics Reports Third Quarter 2020 Financial Results and Provides Recent Business Highlights,"ADC Therapeutics SA (NYSE: ADCT), a late clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of highly potent and targeted antibody drug conjugates (...",33.96,35.08,33.2,34.67,ADCT,151936,HISTORICAL_PRICES,ADCT,,1.60683E+12,0.013731343,0.013731343,34.67,33.96,35.08,33.2,151936,34.67,33.96,35.08,33.2,151936,12-Nov-20,-0.71,-0.0205
11-Nov-20,Epizyme to Participate in Jefferies Virtual London Healthcare Conference,"Epizyme, (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering novel epigenetic therapies, today announced that Robert Bazemore, president and chief...",11.75,12.45,11.64,12.25,EPZM,745613,HISTORICAL_PRICES,EPZM,,1.60683E+12,0.00170503,0.00170503,12.25,11.75,12.45,11.64,745613,12.25,11.75,12.45,11.64,745613,11-Nov-20,-0.43,-0.0353
11-Nov-20,"Xencor, MorphoSys and Incyte Enter into Global Development Collaboration for Tafasitamab in Combination with Plamotamab","Xencor (NASDAQ: XNCR), MorphoSys AG (FSE: MOR; Prime Standard Segment, MDAX & TecDAX; NASDAQ: MOR) and Incyte (NASDAQ: INCY) today announced a clinical collaboration to investigate the combination...",40.86,41.315,38.99,40.27,XNCR,161529,HISTORICAL_PRICES,XNCR,,1.60683E+12,0.10105093,0.10105093,40.27,40.86,41.315,38.99,161529,40.27,40.86,41.315,38.99,161529,11-Nov-20,0.99,0.0248
11-Nov-20,Outset Medical Reports Third Quarter 2020 Financial Results,"Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today reported financial results for...",49.26,50,46.7,48.58,OM,176290,HISTORICAL_PRICES,OM,,1.60683E+12,-0.052327818,-0.052327818,48.58,49.26,50,46.7,176290,48.58,49.26,50,46.7,176290,11-Nov-20,2.63,0.0564
11-Nov-20,Moderna Has Completed Case Accrual for First Planned Interim Analysis of its mRNA Vaccine Against COVID-19 (mRNA-1273),"Moderna, Inc., (Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced tha...",82.44,83.98,76.13,77.05,MRNA,18576496,HISTORICAL_PRICES,MRNA,,1.60683E+12,0.264999233,0.264999233,77.05,82.44,83.98,76.13,18576496,77.05,82.44,83.98,76.13,18576496,11-Nov-20,6.39,0.084
11-Nov-20,"ZSAN Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Reminds Zosano Pharma Corporation of Class Action and Encourages Shareholders to Contact the Firm","Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Zosano Pharma Corporation (""Zosano"" or the ""Company"") (NASDAQ: ZSAN) and certain of its off...",0.5001,0.59,0.4956,0.565,ZSAN,12868331,HISTORICAL_PRICES,ZSAN,,1.60683E+12,-0.679423077,-0.679423077,0.565,0.5001,0.59,0.4956,12868331,0.565,0.5001,0.59,0.4956,12868331,11-Nov-20,0.012,0.0246
11-Nov-20,Aruba Becomes First Caribbean Nation to Partner with JetBlue on Entry Testing,"JetBlue (NASDAQ: JBLU) today announced Aruba is the first Caribbean nation to partner with the airline for seamless entry testing through JetBlue’s testing partner, Vault. The decision by Aruba to beg...",14.09,14.88,13.95,14.77,JBLU,7936296,HISTORICAL_PRICES,JBLU,,1.60683E+12,0.246902655,0.246902655,14.77,14.09,14.88,13.95,7936296,14.77,14.09,14.88,13.95,7936296,11-Nov-20,-0.85,-0.0569
11-Nov-20,Ocular Therapeutix™ To Present Data at the American Academy of Ophthalmology (AAO) 2020 Virtual Annual Meeting,"Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, annou...",13.27,13.43,12.71,13.4,OCUL,1154690,HISTORICAL_PRICES,OCUL,,1.60683E+12,0.696930946,0.696930946,13.4,13.27,13.43,12.71,1154690,13.4,13.27,13.43,12.71,1154690,11-Nov-20,-0.12,-0.009
11-Nov-20,"Amneal Receives Abbreviated New Drug Application Approval for Acyclovir Cream, 5%","Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal”) today announced that it has received approval for its Abbreviated New Drug Application (ANDA) from the U.S. Food and Drug Administration (FDA) for...",4.16,4.3,4.07,4.23,AMRX,997353,HISTORICAL_PRICES,AMRX,,1.60683E+12,0.089005236,0.089005236,4.23,4.16,4.3,4.07,997353,4.23,4.16,4.3,4.07,997353,11-Nov-20,-0.03,-0.0072
11-Nov-20,Genprex to Participate in Panel at Life Sciences Summit on November 17,"Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced th...",3.18,3.19,3.11,3.18,GNPX,274786,HISTORICAL_PRICES,GNPX,,1.60683E+12,0.025806452,0.025806452,3.18,3.18,3.19,3.11,274786,3.18,3.18,3.19,3.11,274786,11-Nov-20,0.01,0.0032
11-Nov-20,"Centers for Medicare & Medicaid Services (CMS) Issues Permanent J-Code for UroGen’s Jelmyto® Effective January 1, 2021","UroGen Pharma Ltd. (Nasdaq: URGN), a biopharmaceutical company dedicated to building and commercializing novel solutions that treat specialty cancers and urologic diseases, today announced that the Ce...",23.51,24.2,23.11,24.02,URGN,127430,HISTORICAL_PRICES,URGN,,1.60683E+12,0.218134715,0.218134715,24.02,23.51,24.2,23.11,127430,24.02,23.51,24.2,23.11,127430,11-Nov-20,-0.26,-0.0109
11-Nov-20,Novocure Receives CE Mark for NovoTTF-100L™ System,"Novocure (NASDAQ: NVCR), a global oncology company working to extend survival in some of the most aggressive forms of cancer, today announced that it has received the CE Mark for the NovoTTF-100L syst...",122.51,123.96,120.185,120.65,NVCR,828711,HISTORICAL_PRICES,NVCR,,1.60683E+12,0.182072559,0.182072559,120.65,122.51,123.96,120.185,828711,120.65,122.51,123.96,120.185,828711,11-Nov-20,3.77,0.0318
11-Nov-20,Moderna Announces Clinical Updates on Personalized Cancer Vaccine Program,"Moderna, Inc., (Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today shared interi...",82.44,83.98,76.13,77.05,MRNA,18576496,HISTORICAL_PRICES,MRNA,,1.60683E+12,0.264999233,0.264999233,77.05,82.44,83.98,76.13,18576496,77.05,82.44,83.98,76.13,18576496,11-Nov-20,6.39,0.084
11-Nov-20,Deciphera Presents Data from QINLOCK® (Ripretinib) Program at the Connective Tissue Oncology Society (CTOS) 2020 Virtual Annual Meeting,"Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), today announced data presentations from clinical studies of QINLOCK, the Company’s switch-control tyrosine kinase inhibitor approved in the U.S. for four...",65.15,65.175,61.46,64.63,DCPH,229355,HISTORICAL_PRICES,DCPH,,1.60683E+12,0.356161532,0.356161532,64.63,65.15,65.175,61.46,229355,64.63,65.15,65.175,61.46,229355,11-Nov-20,1.3,0.0204
11-Nov-20,"Deciphera Presents Updated Preliminary Data from DCC-3014, its CSF1R Inhibitor Program, in Tenosynovial Giant Cell Tumor Patients at the Connective Tissue Oncology Society (CTOS) 2020 Virtual Annual Meeting","Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), today announced the presentation of encouraging preliminary results from the ongoing Phase 1/2 study of DCC-3014, a highly selective, oral, investigation...",65.15,65.175,61.46,64.63,DCPH,229355,HISTORICAL_PRICES,DCPH,,1.60683E+12,0.356161532,0.356161532,64.63,65.15,65.175,61.46,229355,64.63,65.15,65.175,61.46,229355,11-Nov-20,1.3,0.0204
11-Nov-20,Ra Medical Systems to Host Webcast Discussing the Role of Excimer Lasers in the Treatment of Psoriasis during the Pandemic,"Ra Medical Systems, Inc. (NYSE: RMED) is hosting a webcast, The Inimitable Role of Excimer Lasers During the COVID-19 Pandemic, featuring Theodore J. Daly, MD, FAAD, FSPD, FASD, Director of Garden Cit...",5.165,5.3325,5,5.25,RMED,36012.68,HISTORICAL_PRICES,RMED,,1.60683E+12,-0.116338751,-0.116338751,0.21,0.2066,0.2133,0.2,900317,5.25,5.165,5.3325,5,36012.68,11-Nov-20,-0.0825,-0.0157
11-Nov-20,"Pfizer Announces Positive Results from Fifth Phase 3 Trial of Abrocitinib, Evaluating Safety and Efficacy Across Different Dosing Regimens","Pfizer Inc. (NYSE: PFE) announced today positive top-line results from the Phase 3 JADE REGIMEN study. This 52-week study investigated abrocitinib, an investigational oral once-daily Janus kinase 1 (J...",38.5,40.2,37.9,38.88,PFE,55959195,HISTORICAL_PRICES,PFE,,1.6118E+12,0.076621924,0.076621924,38.88,38.5,40.2,37.9,55959195,38.4616,38.0857,39.7674,37.4921,55959195,11-Nov-20,-0.18,-0.0047
11-Nov-20,Pfizer and BioNTech Reach an Agreement to Supply the EU With 200 Million Doses of Their BNT162b2 mRNA-Based Vaccine Candidate Against SARS-CoV-2,Pfizer (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that they have reached an agreement with the European Commission to supply 200 million doses of their investigational BNT162b2 mRNA-ba...,38.5,40.2,37.9,38.88,PFE,55959195,HISTORICAL_PRICES,PFE,,1.6118E+12,0.076621924,0.076621924,38.88,38.5,40.2,37.9,55959195,38.4616,38.0857,39.7674,37.4921,55959195,11-Nov-20,-0.18,-0.0047
10-Nov-20,Revance to Participate in the Stifel 2020 Virtual Healthcare Conference,"Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company focused on innovative aesthetic and therapeutic offerings, today announced that the company will participate in the Stifel 2020 Virtu...",25.735,26.84,23.4,26.64,RVNC,1332608,HISTORICAL_PRICES,RVNC,,1.60683E+12,0.000194326,0.000194326,26.64,25.735,26.84,23.4,1332608,26.64,25.735,26.84,23.4,1332608,10-Nov-20,-1.865,-0.0676
10-Nov-20,Lyra Therapeutics Reports Third Quarter 2020 Financial Results and Provides Corporate Update,"Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatme...",10.87,11.03,10.81,10.9,LYRA,25400,HISTORICAL_PRICES,LYRA,,1.60683E+12,-0.050655022,-0.050655022,10.9,10.87,11.03,10.81,25400,10.9,10.87,11.03,10.81,25400,10-Nov-20,0.1,0.0093
10-Nov-20,Präsentation von ADC Therapeutics auf der Stifel 2020 Virtual Healthcare Conference,"Wie ADC Therapeutics SA (NYSE: ADCT), ein im Bereich der späten klinischen Forschung tätiges Biotechnologieunternehmen mit Schwerpunkt auf Onkologie und Vorreiter bei der Entwicklung und Vermarktung v...",32.67,33.76,32.11,33.76,ADCT,157846,HISTORICAL_PRICES,ADCT,,1.60683E+12,-0.024776119,-0.024776119,33.76,32.67,33.76,32.11,157846,33.76,32.67,33.76,32.11,157846,10-Nov-20,-0.58,-0.0174
10-Nov-20,"INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Biogen Inc. and Encourages Investors with Losses of $100,000 to Contact the Firm","The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Biogen Inc. (“Biogen” or “the Company”) (NASDAQ: BIIB) for viola...",236.34,244.8375,234.5613,241.24,BIIB,3224124,HISTORICAL_PRICES,BIIB,,1.60683E+12,-0.124796326,-0.124796326,241.24,236.34,244.8375,234.5613,3224124,241.24,236.34,244.8375,234.5613,3224124,10-Nov-20,0.08,0.0003
10-Nov-20,TherapeuticsMD Announces Pricing of $30 Million Public Offering of Common Stock,"TherapeuticsMD, Inc. (NASDAQ:TXMD) today announced the pricing of its underwritten public offering of approximately 23.4 million shares of its common stock for gross proceeds of $30 million, before de...",1.35,1.48,1.24,1.3,TXMD,10199591,HISTORICAL_PRICES,TXMD,,1.60683E+12,0.030534351,0.030534351,1.3,1.35,1.48,1.24,10199591,1.3,1.35,1.48,1.24,10199591,10-Nov-20,-0.17,-0.1118
10-Nov-20,Transcat Appoints Mark A. Doheny as Chief Financial Officer,"Transcat, Inc. (Nasdaq: TRNS) (“Transcat” or the “Company”), a leading provider of accredited calibration, repair, inspection and laboratory instrument services and value-added distributor of professi...",32.17,32.78,30.46,30.86,TRNS,69682,HISTORICAL_PRICES,TRNS,,1.60683E+12,0.098327074,0.098327074,30.86,32.17,32.78,30.46,69682,30.86,32.17,32.78,30.46,69682,10-Nov-20,1.74,0.0572
10-Nov-20,DILIsym Plays Critical Role in Submission to State of California for Common Analgesic Carcinogenicity Risk Assessment,"DILIsym Services, Inc., a Simulations Plus company (Nasdaq: SLP) and a leading provider of modeling and simulation software for pharmaceutical safety and efficacy, today announced that the DILIsym liv...",67.05,74.19,66.81,73.49,SLP,218737,HISTORICAL_PRICES,SLP,,1.61128E+12,0.015293761,0.015293761,73.49,67.05,74.19,66.81,218737,73.4299,66.9952,74.1294,66.7554,218737,10-Nov-20,-7.18,-0.0967
10-Nov-20,"Genprex Strengthens Scientific Advisory Board with Appointment of Lead Researcher of University of Pittsburgh, George K. Gittes, MD","Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced th...",3.17,3.2,3.01,3.17,GNPX,514926,HISTORICAL_PRICES,GNPX,,1.60683E+12,0.022580645,0.022580645,3.17,3.17,3.2,3.01,514926,3.17,3.17,3.2,3.01,514926,10-Nov-20,0.03,0.0096
10-Nov-20,Gamida Cell Reports Third Quarter 2020 Financial Results and Provides Company Update,"Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to finding cures for blood cancers and serious blood diseases, today reported financial results for the quarter ended Septem...",5.86,5.92,4.81,4.87,GMDA,326894,HISTORICAL_PRICES,GMDA,,1.60683E+12,0.425790754,0.425790754,4.87,5.86,5.92,4.81,326894,4.87,5.86,5.92,4.81,326894,10-Nov-20,0.07,0.0121
10-Nov-20,Urovant Sciences to Present at the Jefferies Virtual London Healthcare Conference,"Urovant Sciences (Nasdaq: UROV) announced today that president and chief executive officer James Robinson will give a presentation at 6:10 p.m. GMT (10:10 a.m. PST / 1:10 p.m. EST) on Tuesday, Novembe...",8.02,8.1,7.78,7.97,UROV,66868,HISTORICAL_PRICES,UROV,,1.60683E+12,-0.142245989,-0.142245989,7.97,8.02,8.1,7.78,66868,7.97,8.02,8.1,7.78,66868,10-Nov-20,0.17,0.0217
10-Nov-20,Aerie Pharmaceuticals to Participate in the Stifel 2020 Virtual Healthcare Conference,"Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients w...",12.93,13,11.96,12.5,AERI,713381,HISTORICAL_PRICES,AERI,,1.60683E+12,0.110824742,0.110824742,12.5,12.93,13,11.96,713381,12.5,12.93,13,11.96,713381,10-Nov-20,0.555,0.0448
10-Nov-20,Forma Therapeutics Announces FT-4202 Receives Orphan Drug Designation in Europe for Treatment of Sickle Cell Disease,"Forma Therapeutics Holdings, Inc. (Nasdaq: FMTX), a clinical-stage biopharmaceutical company focused on rare hematologic diseases and cancers, today announced the European Commission granted Orphan Dr...",39.42,41.035,38.76,40.99,FMTX,138640,HISTORICAL_PRICES,FMTX,,1.60683E+12,-0.098559341,-0.098559341,40.99,39.42,41.035,38.76,138640,40.99,39.42,41.035,38.76,138640,10-Nov-20,-0.49,-0.0123
10-Nov-20,"ImmunityBio, NantKwest Announce Positive Interim Phase 1 Safety Data of hAd5 COVID-19 Vaccine Dose Study","ImmunityBio, a privately-held immunotherapy company, and NantKwest, Inc. (NASDAQ: NK), a clinical-stage, natural killer cell-based therapeutics company, today announced they have administered their se...",7.83,7.87,7.05,7.49,NK,950718,HISTORICAL_PRICES,NK,,1.60683E+12,0.143065693,0.143065693,7.49,7.83,7.87,7.05,950718,7.49,7.83,7.87,7.05,950718,10-Nov-20,0.72,0.1013
10-Nov-20,Stony Brook University Hospital Launches COVID-19 Surveillance Testing Program Powered by Applied DNA’s Assay Kit and Services,"Applied DNA Sciences, Inc., (NASDAQ: APDN) (“Applied DNA” or the ""Company"") a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing, today announced that its Linea™ COVID-19 Assay Kit (the...",6.57,6.7567,6.41,6.64,APDN,133564,HISTORICAL_PRICES,APDN,,1.60683E+12,-0.161989796,-0.161989796,6.64,6.57,6.7567,6.41,133564,6.64,6.57,6.7567,6.41,133564,10-Nov-20,-0.05,-0.0076
10-Nov-20,"Deciphera Pharmaceuticals, Inc. to Present at the Jefferies Virtual London Healthcare Conference","Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), today announced that Steve Hoerter, President and Chief Executive Officer, will present at the Jefferies Virtual London Healthcare Conference on Tuesday,...",63.85,65.84,62.58,65.84,DCPH,382098,HISTORICAL_PRICES,DCPH,,1.60683E+12,0.329100749,0.329100749,65.84,63.85,65.84,62.58,382098,65.84,63.85,65.84,62.58,382098,10-Nov-20,-1.03,-0.0159
10-Nov-20,"KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Demonstrated Statistically Significant Improvement in Progression-Free Survival (PFS), Overall Survival (OS) and Objective Response Rate (ORR) Versus Sunitinib as First-Line Treatment for Patients…","Merck (NYSE: MRK): KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Demonstrated Statistically Significant Improvement in Progression-Free Survival (PFS), Overall Survival (OS) and Objective Respo...",81.11,82.025,81.01,81.78,MRK,8200334,HISTORICAL_PRICES,MRK,,1.61552E+12,-0.024533975,-0.024533975,81.78,81.11,82.025,81.01,8200334,80.4326,79.7736,80.6735,79.6752,8200334,10-Nov-20,0.61,0.0076
9-Nov-20,"ROSEN, A LEADING AND LONGSTANDING LAW FIRM, Announces Filing of Securities Class Action Lawsuit Against Intercept Pharmaceuticals, Inc.; Encourages Investors with Losses in Excess of $100K to Contact Firm – ICPT","Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT) between Se...",34.84,35.57,28.14,28.85,ICPT,2992700,HISTORICAL_PRICES,ICPT,,1.60683E+12,-0.123742455,-0.123742455,28.85,34.84,35.57,28.14,2992700,28.85,34.84,35.57,28.14,2992700,9-Nov-20,6.69,0.2377
9-Nov-20,"La Jolla Pharmaceutical Company Announces Financial Results for the Three and Nine Months Ended September 30, 2020","La Jolla Pharmaceutical Company (Nasdaq: LJPC), which is dedicated to the development and commercialization of innovative therapies that improve outcomes in patients suffering from life-threatening di...",4.32,4.37,3.63,3.77,LJPC,810904,HISTORICAL_PRICES,LJPC,,1.60683E+12,0.127937337,0.127937337,3.77,4.32,4.37,3.63,810904,3.77,4.32,4.37,3.63,810904,9-Nov-20,0.75,0.2101
9-Nov-20,Infinity Pharmaceuticals Provides Company Update and Third Quarter 2020 Financial Results,"Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) today announced its third quarter 2020 financial results and provided an update on the Company, including its third quarter progress with eganelisib (IPI-...",1.15,1.23,1.12,1.18,INFI,566327,HISTORICAL_PRICES,INFI,,1.60683E+12,0.08490566,0.08490566,1.18,1.15,1.23,1.12,566327,1.18,1.15,1.23,1.12,566327,9-Nov-20,0.02,0.0177
9-Nov-20,Revance Announces Results of Phase 2 Trial of DaxibotulinumtoxinA for Injection in Plantar Fasciitis,"Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company focused on innovative aesthetic and therapeutic offerings, today announced results from its Phase 2 clinical trial of investigational...",27.6,28.94,27.33,27.33,RVNC,443243,HISTORICAL_PRICES,RVNC,,1.60683E+12,0.072677808,0.072677808,27.33,27.6,28.94,27.33,443243,27.33,27.6,28.94,27.33,443243,9-Nov-20,1.06,0.0399
9-Nov-20,Athersys Reports Third Quarter 2020 Results and Provides Corporate Update,"Athersys, Inc. (NASDAQ: ATHX) announced today its financial results for the three months ended September 30, 2020 and provided a corporate update. Highlights of the third quarter of 2020 and recent ev...",1.83,1.9,1.72,1.78,ATHX,1804446,HISTORICAL_PRICES,ATHX,,1.60683E+12,-0.085,-0.085,1.78,1.83,1.9,1.72,1804446,1.78,1.83,1.9,1.72,1804446,9-Nov-20,0.07,0.0398
9-Nov-20,Revance Reports Third Quarter 2020 Financial Results and Provides Corporate Update,"Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company focused on innovative aesthetic and therapeutic offerings, today reported financial results for the quarter ended September 30, 2020,...",27.6,28.94,27.33,27.33,RVNC,443243,HISTORICAL_PRICES,RVNC,,1.60683E+12,0.072677808,0.072677808,27.33,27.6,28.94,27.33,443243,27.33,27.6,28.94,27.33,443243,9-Nov-20,1.06,0.0399
9-Nov-20,"Forte Biosciences, Inc. Announces Third Quarter 2020 Results and Provides General Business Update","Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company, today announced third quarter 2020 financial results and provided a general business update. “T...",34.92,36.98,33.17,35.38,FBRX,17799,HISTORICAL_PRICES,FBRX,,1.60683E+12,-0.234210526,-0.234210526,35.38,34.92,36.98,33.17,17799,35.38,34.92,36.98,33.17,17799,9-Nov-20,0.31,0.009
9-Nov-20,Verastem Oncology Reports Third Quarter 2020 Financial Results and Highlights Recent Company Progress,"Verastem, Inc. (Nasdaq:VSTM) (also known as Verastem Oncology), a biopharmaceutical company committed to advancing new medicines for patients battling cancer, today reported financial results for the...",1.31,1.33,1.23,1.25,VSTM,2487819,HISTORICAL_PRICES,VSTM,,1.60683E+12,0.082644628,0.082644628,1.25,1.31,1.33,1.23,2487819,1.25,1.31,1.33,1.23,2487819,9-Nov-20,0.09,0.0738
9-Nov-20,Pulse Biosciences Reports Third Quarter 2020 Financial Results,"Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company developing its Nano-Pulse Stimulation™ (NPS™) technology, today announced financial results for the third quarter ended Sep...",11.89,12.75,11.8,12.08,PLSE,96502,HISTORICAL_PRICES,PLSE,,1.60683E+12,0.073104693,0.073104693,12.08,11.89,12.75,11.8,96502,12.08,11.89,12.75,11.8,96502,9-Nov-20,-0.26,-0.0214
9-Nov-20,AVEO Oncology Reports Third Quarter 2020 Financial Results and Provides Business Update,"AVEO Oncology (Nasdaq: AVEO) today reported financial results for the third quarter ended September 30, 2020 and provided a business update. “In advance of the Food and Drug Administration’s (FDA) Mar...",6.02,6.21,5.8,5.94,AVEO,410424,HISTORICAL_PRICES,AVEO,,1.60683E+12,0.065486726,0.065486726,5.94,6.02,6.21,5.8,410424,5.94,6.02,6.21,5.8,410424,9-Nov-20,0.36,0.0636
9-Nov-20,"Tilray, Inc. Reports 2020 Third Quarter Results","Tilray, Inc. (“Tilray” or the “Company”) (Nasdaq: TLRY), a global pioneer in cannabis research, cultivation, production and distribution, reports financial results for the third quarter ended Septembe...",10.1,12.15,9.63,11.82,TLRY,51474926,HISTORICAL_PRICES,TLRY,,1.60683E+12,1.126315789,1.126315789,11.82,10.1,12.15,9.63,51474926,11.82,10.1,12.15,9.63,51474926,9-Nov-20,0.47,0.0488
9-Nov-20,Omeros Corporation Reports Third Quarter 2020 Financial Results,"Omeros Corporation (Nasdaq: OMER), a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as wel...",10.99,11.45,10.55,10.82,OMER,1169715,HISTORICAL_PRICES,OMER,,1.60683E+12,0.118006104,0.118006104,10.82,10.99,11.45,10.55,1169715,10.82,10.99,11.45,10.55,1169715,9-Nov-20,0.55,0.0527
9-Nov-20,Ocular Therapeutix™ to Participate at Two Upcoming Investor Conferences,"Ocular Therapeutix, Inc. (NASDAQ:OCUL) a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today...",12.55,13.462,12.13,13.4,OCUL,1132553,HISTORICAL_PRICES,OCUL,,1.60683E+12,0.604859335,0.604859335,13.4,12.55,13.462,12.13,1132553,13.4,12.55,13.462,12.13,1132553,9-Nov-20,-0.29,-0.0226
9-Nov-20,LENSAR Reports Third Quarter 2020 Financial Results and Provides Business Update,"LENSAR, Inc. (NASDAQ: LNSR) (“LENSAR” or “the Company”), a global medical technology company focused on femtosecond laser surgical solutions for the treatment of cataracts, today announced financial r...",8.84,9.08,8.18,8.18,LNSR,27435,HISTORICAL_PRICES,LNSR,,1.60683E+12,-0.017777778,-0.017777778,8.18,8.84,9.08,8.18,27435,8.18,8.84,9.08,8.18,27435,9-Nov-20,0.62,0.0754
9-Nov-20,TherapeuticsMD Announces Underwritten Public Offering of its Common Stock,"TherapeuticsMD, Inc. (NASDAQ:TXMD) today announced an underwritten public offering of its common stock. The Company has granted the underwriter a 30-day option to purchase up to an additional 15% of t...",1.52,1.58,1.33,1.4,TXMD,8310932,HISTORICAL_PRICES,TXMD,,1.60683E+12,0.160305344,0.160305344,1.4,1.52,1.58,1.33,8310932,1.4,1.52,1.58,1.33,8310932,9-Nov-20,0.3,0.2459
9-Nov-20,Atara Biotherapeutics Announces Third Quarter 2020 Financial Results and Operational Progress,"Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious disease...",14.4,14.88,14.02,14.28,ATRA,692318,HISTORICAL_PRICES,ATRA,,1.60683E+12,0.147410359,0.147410359,14.28,14.4,14.88,14.02,692318,14.28,14.4,14.88,14.02,692318,9-Nov-20,0.95,0.0706
9-Nov-20,Marinus Pharmaceuticals Provides Business Update and Reports Third Quarter 2020 Financial Results,"Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders, today provided an update on its clinical...",13.71,14.1,12.93,13.74,MRNS,473272,HISTORICAL_PRICES,MRNS,,1.60683E+12,0.281308411,0.281308411,13.74,13.71,14.1,12.93,473272,13.74,13.71,14.1,12.93,473272,9-Nov-20,0.29,0.0216
9-Nov-20,"SHAREHOLDER ACTION REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Intercept Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm","The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Intercept Pharmaceuticals, Inc. (“Intercept” or “the Company”) (NASDAQ: ICPT)...",34.84,35.57,28.14,28.85,ICPT,2992700,HISTORICAL_PRICES,ICPT,,1.60683E+12,-0.123742455,-0.123742455,28.85,34.84,35.57,28.14,2992700,28.85,34.84,35.57,28.14,2992700,9-Nov-20,6.69,0.2377
9-Nov-20,"SHAREHOLDER ACTION REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Neovasc Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm","The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Neovasc Inc. (“Neovasc” or “the Company”) (NASDAQ: NVCN) for violations of §§...",0.88,0.958,0.82,0.8999,NVCN,574534,HISTORICAL_PRICES,NVCN,,1.60683E+12,-0.576923077,-0.576923077,0.8999,0.88,0.958,0.82,574534,0.8999,0.88,0.958,0.82,574534,9-Nov-20,0.02,0.0233
9-Nov-20,"INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Biogen Inc. and Encourages Investors with Losses of $100,000 to Contact the Firm","The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Biogen Inc. (“Biogen” or “the Company”) (NASDAQ: BIIB) for viola...",236.26,239.5,223.25,230.82,BIIB,9252638,HISTORICAL_PRICES,BIIB,,1.60683E+12,-0.125092579,-0.125092579,230.82,236.26,239.5,223.25,9252638,230.82,236.26,239.5,223.25,9252638,9-Nov-20,-92.64,-0.2817
9-Nov-20,EQUITY ALERT: Rosen Law Firm Announces Investigation of Securities Claims Against Biogen Inc. – BIIB,"Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Biogen Inc. (NASDAQ: BIIB) resulting from allegations that Bio...",236.26,239.5,223.25,230.82,BIIB,9252638,HISTORICAL_PRICES,BIIB,,1.60683E+12,-0.125092579,-0.125092579,230.82,236.26,239.5,223.25,9252638,230.82,236.26,239.5,223.25,9252638,9-Nov-20,-92.64,-0.2817
9-Nov-20,"ROSEN, A TOP RANKED LAW FIRM, Announces Filing of Securities Class Action Lawsuit Against Neovasc Inc.; Encourages Investors with Losses in Excess of $100K to Contact Firm – NVCN","Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Neovasc Inc. (NASDAQ: NVCN) between November 1, 2019 and...",0.88,0.958,0.82,0.8999,NVCN,574534,HISTORICAL_PRICES,NVCN,,1.60683E+12,-0.576923077,-0.576923077,0.8999,0.88,0.958,0.82,574534,0.8999,0.88,0.958,0.82,574534,9-Nov-20,0.02,0.0233
9-Nov-20,全球投资者法律顾问ROSEN提醒Zosano Pharma Corporation投资者注意ZSAN证券集体诉讼的重要截止日期；鼓励损失超过10万美元的投资者联系律所,(美国商业资讯)--全球投资者权益律所Rosen Law Firm提醒在2017年2月13日至2020年9月30日（含上述日期，简称“集体诉讼期”）期间购买Zosano Pharma Corporation (NASDAQ: ZSAN)证券的人士注意，本证券集体诉讼中首要原告的重要截止日期为2020年12月28日。诉讼旨在依据联邦证券法弥补Zosano投资者所蒙受的损失。 如需加入Zosano集体...,0.4102,0.428,0.341,0.341,ZSAN,8958819,HISTORICAL_PRICES,ZSAN,,1.60683E+12,-0.737051282,-0.737051282,0.341,0.4102,0.428,0.341,8958819,0.341,0.4102,0.428,0.341,8958819,9-Nov-20,0.074,0.2201
9-Nov-20,全球投資人法律顧問ROSEN提醒Zosano Pharma Corporation投資人注意ZSAN證券集體訴訟的重要截止日期；鼓勵損失超過10萬美元的投資人與法律事務所聯絡,(美國商業資訊)--全球投資人權益法律事務所Rosen Law Firm提醒在2017年2月13日至2020年9月30日（含上述日期，簡稱「集體訴訟期」）期間購買Zosano Pharma Corporation (NASDAQ: ZSAN)證券的人士注意，本證券集體訴訟中原告代表的重要截止日期為2020年12月28日。訴訟旨在依據聯邦證券法彌補Zosano投資人所蒙受的損失。 如欲加入Zosan...,0.4102,0.428,0.341,0.341,ZSAN,8958819,HISTORICAL_PRICES,ZSAN,,1.60683E+12,-0.737051282,-0.737051282,0.341,0.4102,0.428,0.341,8958819,0.341,0.4102,0.428,0.341,8958819,9-Nov-20,0.074,0.2201
9-Nov-20,Infinity Pharmaceuticals Presents New MARIO-1 Phase 1/1b Clinical Data at The Society for Immunotherapy of Cancer (SITC) 35th Anniversary Annual Meeting,"Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) today announced the presentation of data from the melanoma and squamous cell carcinoma of the head and neck (SCCHN) cohorts from the MARIO-1 clinical tria...",1.15,1.23,1.12,1.18,INFI,566327,HISTORICAL_PRICES,INFI,,1.60683E+12,0.08490566,0.08490566,1.18,1.15,1.23,1.12,566327,1.18,1.15,1.23,1.12,566327,9-Nov-20,0.02,0.0177
9-Nov-20,"Masimo Founder and CEO and Co-Inventor of Measure-Through-Motion Pulse Oximetry, Joe Kiani, Awarded by the Ibero-American Society of Neonatology for Improvements to Neonatal Health in Latin America","Masimo (NASDAQ: MASI) announced today that its Founder, Chairman, and CEO, Joe Kiani, has been honored by the Ibero-American Society of Neonatology (SIBEN) at its 17th Annual Congress (this year held...",242.2,255.72,240.9,254.94,MASI,672725,HISTORICAL_PRICES,MASI,,1.60683E+12,0.111264051,0.111264051,254.94,242.2,255.72,240.9,672725,254.94,242.2,255.72,240.9,672725,9-Nov-20,-12.74,-0.05
9-Nov-20,UroGen Pharma Reports Third Quarter 2020 Financial Results and Recent Corporate Developments,"UroGen Pharma Ltd. (Nasdaq: URGN), a biopharmaceutical company dedicated to building and commercializing novel solutions that treat specialty cancers and urologic diseases, today announced financial r...",24.89,25.94,23.78,25.94,URGN,145471,HISTORICAL_PRICES,URGN,,1.60683E+12,0.289637306,0.289637306,25.94,24.89,25.94,23.78,145471,25.94,24.89,25.94,23.78,145471,9-Nov-20,1.18,0.0498
9-Nov-20,Outset Medical Appoints Steve Williamson as Chief Commercial Officer,"Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced the appointment of S...",49.04,50.5,48.74,50.3,OM,143297,HISTORICAL_PRICES,OM,,1.60683E+12,-0.056560215,-0.056560215,50.3,49.04,50.5,48.74,143297,50.3,49.04,50.5,48.74,143297,9-Nov-20,0.37,0.0076
9-Nov-20,EUROIMMUN Launches Quantitative ELISA to Measure SARS-CoV-2 Antibodies Against Viral S1 Protein,"PerkinElmer, Inc. (NYSE: PKI), a global leader committed to innovating for a healthier world, announced today that EUROIMMUN, a PerkinElmer company, has launched the Anti-SARS-CoV-2 QuantiVacTM ELISA...",128.09,136.5,123.015,136.5,PKI,3100367,HISTORICAL_PRICES,PKI,,1.6112E+12,0.085876568,0.085876568,136.5,128.09,136.5,123.015,3100367,136.4368,128.0307,136.4368,122.9581,3100367,9-Nov-20,-13.21,-0.0935
9-Nov-20,SiPM dToF LiDAR Platform from ON Semiconductor Provides Ready-to-Use Design for Industrial Range Finding Applications,"ON Semiconductor (Nasdaq:ON), driving energy efficient innovations, has introduced a single point direct Time-of-Flight (dToF) LiDAR solution enabled by the company's Silicon Photomultiplier (SiPM) te...",27.53,28.8,27.49,28,ON,14243685,HISTORICAL_PRICES,ON,,1.60683E+12,0.355489906,0.355489906,28,27.53,28.8,27.49,14243685,28,27.53,28.8,27.49,14243685,9-Nov-20,0.95,0.0357
9-Nov-20,Scholar Rock Reports Third Quarter 2020 Financial Results and Highlights Business Progress,"Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today reported financial r...",41.91,43.4877,41.31,42.02,SRRK,570429,HISTORICAL_PRICES,SRRK,,1.60683E+12,1.423944477,1.423944477,42.02,41.91,43.4877,41.31,570429,42.02,41.91,43.4877,41.31,570429,9-Nov-20,-0.19,-0.0045
9-Nov-20,Krystal Biotech Reports Third Quarter 2020 Financial Results and Provides Update on Operational Progress,"Krystal Biotech, Inc. (Nasdaq:KRYS), a fully integrated gene therapy company driven by its proprietary, engineered herpes simplex virus type 1 vector (HSV-1) platform, today reported financial results...",41.9,45.25,41.6,42.14,KRYS,231092,HISTORICAL_PRICES,KRYS,,1.60683E+12,0.002872188,0.002872188,42.14,41.9,45.25,41.6,231092,42.14,41.9,45.25,41.6,231092,9-Nov-20,1.26,0.031
9-Nov-20,Sesen Bio Reports Third Quarter 2020 Financial Results and Positive Progress Towards Completing the BLA Submission for VicineumTM in December 2020,"Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today reported operating results for the third quarte...",1.11,1.14,1.01,1.03,SESN,1632695,HISTORICAL_PRICES,SESN,,1.60683E+12,-0.097560976,-0.097560976,1.03,1.11,1.14,1.01,1632695,1.03,1.11,1.14,1.01,1632695,9-Nov-20,0.08,0.0777
9-Nov-20,PolarityTE Reports Third Quarter 2020 Results,"PolarityTE, Inc. (Nasdaq: PTE), a biotechnology company developing regenerative tissue products and biomaterials, today reported financial results for the third calendar quarter of 2020. PolarityTE wi...",0.8124,1,0.72,0.97,PTE,3000396,HISTORICAL_PRICES,PTE,,1.60683E+12,-0.203529412,-0.203529412,0.97,0.8124,1,0.72,3000396,0.97,0.8124,1,0.72,3000396,9-Nov-20,-0.1475,-0.1537
9-Nov-20,Apyx Medical Corporation Reports Third Quarter 2020 Financial Results,"Apyx Medical Corporation (NASDAQ:APYX) (the “Company”), a maker of medical devices and supplies and the developer of Helium Plasma Technology, marketed and sold as Renuvion® in the cosmetic surgery ma...",6.32,6.72,5.8619,6.5,APYX,144993,HISTORICAL_PRICES,APYX,,1.60683E+12,0.404444444,0.404444444,6.5,6.32,6.72,5.8619,144993,6.5,6.32,6.72,5.8619,144993,9-Nov-20,0.34,0.0569
9-Nov-20,Xeris Pharmaceuticals Reports Third Quarter 2020 Financial Results and Corporate Highlights,"Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use (RTU) injectable and infu...",5.74,6.0654,5.68,5.98,XERS,2773976,HISTORICAL_PRICES,XERS,,1.60683E+12,0.026833631,0.026833631,5.98,5.74,6.0654,5.68,2773976,5.98,5.74,6.0654,5.68,2773976,9-Nov-20,0.29,0.0532
9-Nov-20,"Acceleron Announces Clinical Trial Updates, Preclinical Presentation on Sotatercept in Pulmonary Arterial Hypertension at the 2020 American Heart Association (AHA) Scientific Sessions","Acceleron Pharma Inc. (Nasdaq:XLRN), a leading biopharmaceutical company in the discovery, development, and commercialization of TGF-beta superfamily therapeutics to treat serious and rare diseases, t...",114.32,115.565,109.3,113.69,XLRN,285856,HISTORICAL_PRICES,XLRN,,1.60683E+12,0.088450919,0.088450919,113.69,114.32,115.565,109.3,285856,113.69,114.32,115.565,109.3,285856,9-Nov-20,0.88,0.0078
9-Nov-20,Seres Therapeutics Reports Third Quarter 2020 Financial Results and Provides Business Updates,"Seres Therapeutics, Inc., (Nasdaq: MCRB) today reported financial results from the third quarter ended September 30, 2020, and provided business updates. “Supported by our positive, highly significant...",33.24,35.89,32.33,34.59,MCRB,714696,HISTORICAL_PRICES,MCRB,,1.60683E+12,0.316435644,0.316435644,34.59,33.24,35.89,32.33,714696,34.59,33.24,35.89,32.33,714696,9-Nov-20,-1.35,-0.039
9-Nov-20,Apyx Medical Corporation Announces Updates on U.S. IDE Clinical Studies,"Apyx Medical Corporation (NASDAQ:APYX) (the “Company”), a maker of medical devices and supplies and the developer of Helium Plasma Technology, marketed and sold as Renuvion® in the cosmetic surgery ma...",6.32,6.72,5.8619,6.5,APYX,144993,HISTORICAL_PRICES,APYX,,1.60683E+12,0.404444444,0.404444444,6.5,6.32,6.72,5.8619,144993,6.5,6.32,6.72,5.8619,144993,9-Nov-20,0.34,0.0569
9-Nov-20,TherapeuticsMD® Announces Third Quarter 2020 Financial Results,"TherapeuticsMD, Inc. (NASDAQ:TXMD), an innovative, leading women’s healthcare company, today reported financial results for the third quarter ended September 30, 2020. “We delivered a strong quarter t...",1.52,1.58,1.33,1.4,TXMD,8310932,HISTORICAL_PRICES,TXMD,,1.60683E+12,0.160305344,0.160305344,1.4,1.52,1.58,1.33,8310932,1.4,1.52,1.58,1.33,8310932,9-Nov-20,0.3,0.2459
9-Nov-20,Ra Medical Systems Hosts Summit with Vascular Physicians to Monitor Progress on Next-Generation DABRA Catheter Design,"Ra Medical Systems, Inc. (NYSE: RMED), a medical device company focused on commercializing excimer laser systems to treat vascular and dermatological diseases, announces a one-day DABRA Summit, during...",5.3975,5.6,4.525,4.525,RMED,126255.12,HISTORICAL_PRICES,RMED,,1.60683E+12,-0.076561163,-0.076561163,0.181,0.2159,0.224,0.181,3156378,4.525,5.3975,5.6,4.525,126255.12,9-Nov-20,0.83,0.1817
9-Nov-20, Pfizer and BioNTech Announce Vaccine Candidate Against COVID-19 Achieved Success in First Interim Analysis from Phase 3 Study,"Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced their mRNA-based vaccine candidate, BNT162b2, against SARS-CoV-2 has demonstrated evidence of efficacy against COVID-19 in partic...",39.2,41.99,38.38,41.86,PFE,218362348,HISTORICAL_PRICES,PFE,,1.6118E+12,0.096196868,0.096196868,41.86,39.2,41.99,38.38,218362348,41.4095,38.7781,41.5381,37.967,218362348,9-Nov-20,2.8,0.0769
9-Nov-20,"Erste 1.000 Patienten mit Impella 5.5 mit SmartAssist, einer für Chirurgen konzipierten Herzpumpe, behandelt","Abiomed (NASDAQ: ABMD) meldet, dass schon im ersten Jahr nachdem die US-Arzneimittelbehörde FDA (Food and Drug Administration) der Impella 5.5 Herzpumpe mit SmartAssist die höchste Stufe der Zulassung...",279.61,292.225,277.22,282.13,ABMD,426392,HISTORICAL_PRICES,ABMD,,1.60683E+12,0.065302701,0.065302701,282.13,279.61,292.225,277.22,426392,282.13,279.61,292.225,277.22,426392,9-Nov-20,7.4,0.0272
6-Nov-20,"Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of HP Inc. (HPQ) on Behalf of Investors","Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of HP Inc. (“HP” or the “Company”) (NYSE: HPQ)...",19.25,19.34,18.97,19.1,HPQ,6515724,HISTORICAL_PRICES,HPQ,,1.61528E+12,0.060606061,0.060606061,19.1,19.25,19.34,18.97,6515724,18.822,18.9698,19.0585,18.6938,6515724,6-Nov-20,0.12,0.0063
6-Nov-20,"INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Intercept Pharmaceuticals, Inc. (ICPT) Investors","Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased Intercept Pharmaceuticals, Inc. (“Intercept” or the “Company”) (NASDAQ: ICPT) s...",28.15,29.55,27.72,29.18,ICPT,603705,HISTORICAL_PRICES,ICPT,,1.60683E+12,-0.292002012,-0.292002012,29.18,28.15,29.55,27.72,603705,29.18,28.15,29.55,27.72,603705,6-Nov-20,-1.27,-0.0432
6-Nov-20,Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4),"Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on November 3, 2020 the Compensation Committee of Puma’s Board of Directors approved the grant of inducement restri...",7.78,7.9889,7.48,7.91,PBYI,1146492,HISTORICAL_PRICES,PBYI,,1.60683E+12,-0.191268191,-0.191268191,7.91,7.78,7.9889,7.48,1146492,7.91,7.78,7.9889,7.48,1146492,6-Nov-20,-0.69,-0.0815
6-Nov-20,"SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Neovasc Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm","The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Neovasc Inc. (“Neovasc” or “the Company”) (NASDAQ: NVCN) for violations of §§...",0.86,0.88,0.8061,0.81,NVCN,480361,HISTORICAL_PRICES,NVCN,,1.60683E+12,-0.586538462,-0.586538462,0.81,0.86,0.88,0.8061,480361,0.81,0.86,0.88,0.8061,480361,6-Nov-20,0.0301,0.0363
6-Nov-20,Ligand’s Partner Sedor Pharmaceuticals Receives FDA Approval for SESQUIENT™ for the Treatment of Status Epilepticus in Adult and Pediatric Patients,"Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced that its partner Sedor Pharmaceuticals, LLC has received approval from the U.S. Food and Drug Administration (FDA) for SESQUIENT, a C...",86.4,88.705,83.94,87.83,LGND,251855,HISTORICAL_PRICES,LGND,,1.60683E+12,-0.083969466,-0.083969466,87.83,86.4,88.705,83.94,251855,87.83,86.4,88.705,83.94,251855,6-Nov-20,-1.65,-0.0187
6-Nov-20,INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Neovasc Inc. (NVCN) Investors,Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ: NVCN) securities between Nov...,0.86,0.88,0.8061,0.81,NVCN,480361,HISTORICAL_PRICES,NVCN,,1.60683E+12,-0.586538462,-0.586538462,0.81,0.86,0.88,0.8061,480361,0.81,0.86,0.88,0.8061,480361,6-Nov-20,0.0301,0.0363
6-Nov-20,"Les 1.000 premiers patients ont été traités avec la pompe Impella 5.5 avec SmartAssist, une pompe cardiaque conçue pour les chirurgiens","Abiomed (NASDAQ: ABMD) annonce que 1.000 patients ont été traités avec la pompe cardiaque Impella 5.5 avec SmartAssist au cours de la première année suivant l'octroi, par la Food and Drug Administrati...",272.21,274.68,264.98,273.21,ABMD,205015,HISTORICAL_PRICES,ABMD,,1.60683E+12,0.037109003,0.037109003,273.21,272.21,274.68,264.98,205015,273.21,272.21,274.68,264.98,205015,6-Nov-20,-0.19,-0.0007
6-Nov-20,GlycoMimetics Reports Highlights and Financial Results for Third Quarter 2020,"GlycoMimetics, Inc. (Nasdaq: GLYC) today reported its financial results for the third quarter ended September 30, 2020, and highlighted recent company events. Cash and cash equivalents at September 30...",2.98,3.08,2.85,3.08,GLYC,477877,HISTORICAL_PRICES,GLYC,,1.60683E+12,-0.077399381,-0.077399381,3.08,2.98,3.08,2.85,477877,3.08,2.98,3.08,2.85,477877,6-Nov-20,-0.07,-0.023
6-Nov-20,Seres Therapeutics Announces Initiation of Phase 1b Trial of SER-301 for the Treatment of Ulcerative Colitis,"Seres Therapeutics, Inc. (Nasdaq: MCRB) today announced that it has dosed the first patient in its Phase 1b trial evaluating SER-301 for the treatment of active mild-to-moderate ulcerative colitis (UC...",34.59,36,33.76,35.75,MCRB,773841,HISTORICAL_PRICES,MCRB,,1.60683E+12,0.36990099,0.36990099,35.75,34.59,36,33.76,773841,35.75,34.59,36,33.76,773841,6-Nov-20,-0.63,-0.0179
6-Nov-20,Humanigen Announces Positive Interim Phase 3 Data of Lenzilumab™ in Patients Hospitalized with COVID-19,"Humanigen, Inc., (Nasdaq: HGEN) (“Humanigen”), a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm’ with its lead investigatio...",11.72,13,11.51,12.42,HGEN,1088076,HISTORICAL_PRICES,HGEN,,1.60683E+12,0.260215054,0.260215054,12.42,11.72,13,11.51,1088076,12.42,11.72,13,11.51,1088076,6-Nov-20,0.52,0.0464
6-Nov-20,Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) plus Yervoy (ipilimumab) with Two Cycles of Chemotherapy for First-Line Treatment of Metastatic Non-Small Cell Lung Cancer,Bristol Myers Squibb (NYSE: BMY) today announced that the European Commission (EC) has approved Opdivo (nivolumab) plus Yervoy (ipilimumab) with two cycles of platinum-based chemotherapy for the first...,63.8,64.92,63.38,63.61,BMY,9680121,HISTORICAL_PRICES,BMY,,1.60946E+12,0.09527897,0.09527897,63.61,63.8,64.92,63.38,9680121,63.1066,63.2951,64.4063,62.8784,9680121,6-Nov-20,0.05,0.0008
6-Nov-20,Pfizer Announces Positive Phase 3 Study Results for XELJANZ ® (tofacitinib) in Ankylosing Spondylitis (AS),Pfizer Inc. (NYSE: PFE) announced today positive results from a Phase 3 investigational study evaluating the safety and efficacy of tofacitinib in adults with active ankylosing spondylitis (AS). Tofac...,36.4,36.72,36.09,36.39,PFE,22647720,HISTORICAL_PRICES,PFE,,1.6118E+12,0.017897092,0.017897092,36.39,36.4,36.72,36.09,22647720,35.9984,36.0083,36.3248,35.7016,22647720,6-Nov-20,0.01,0.0003
6-Nov-20,ImmunoGen Reports Recent Progress and Third Quarter 2020 Financial Results,"ImmunoGen, Inc., (Nasdaq: IMGN) a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today reviewed recent progress in the business and reported financial re...",6.08,6.25,5.84,6.24,IMGN,5272595,HISTORICAL_PRICES,IMGN,,1.60683E+12,0.737142857,0.737142857,6.24,6.08,6.25,5.84,5272595,6.24,6.08,6.25,5.84,5272595,6-Nov-20,0.03,0.005
6-Nov-20,Epizyme Reports Business Progress and Third Quarter 2020 Financial Results,"Epizyme, (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering novel epigenetic therapies, today provided business and portfolio updates and reported...",10.34,11.365,9.9,10.4831,EPZM,3970703,HISTORICAL_PRICES,EPZM,,1.60683E+12,-0.118499574,-0.118499574,10.4831,10.34,11.365,9.9,3970703,10.4831,10.34,11.365,9.9,3970703,6-Nov-20,-3.21,-0.2369
6-Nov-20,Epizyme Announces Expanded Loan Facility with Pharmakon Advisors for Additional $150 Million to Fund its Growth Initiatives,"Epizyme, (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering novel epigenetic therapies, today announced that the company has entered into an amend...",10.34,11.365,9.9,10.4831,EPZM,3970703,HISTORICAL_PRICES,EPZM,,1.60683E+12,-0.118499574,-0.118499574,10.4831,10.34,11.365,9.9,3970703,10.4831,10.34,11.365,9.9,3970703,6-Nov-20,-3.21,-0.2369
6-Nov-20,Amneal Reports Third Quarter 2020 Financial Results,"Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (the “Company”) announced its results today for the third quarter ended September 30, 2020. “Amneal delivered another strong quarter, providing further eviden...",4.13,5,4.11,4.99,AMRX,2775965,HISTORICAL_PRICES,AMRX,,1.60683E+12,0.081151832,0.081151832,4.99,4.13,5,4.11,2775965,4.99,4.13,5,4.11,2775965,6-Nov-20,-0.8,-0.1623
5-Nov-20,"Samenvatting: Eerste 1.000 patiënten behandeld met Impella 5.5 met SmartAssist, een hartpomp ontworpen voor chirurgen",Abiomed (NASDAQ: ABMD) kondigt aan dat 1.000 patiënten zijn behandeld met de Impella 5.5 met SmartAssist-hartpomp in het eerste jaar nadat de Amerikaanse Food and Drug Administration (FDA) Impella 5.5...,272.4,275.8588,267.875,271.52,ABMD,241582,HISTORICAL_PRICES,ABMD,,1.60683E+12,0.037832895,0.037832895,271.52,272.4,275.8588,267.875,241582,271.52,272.4,275.8588,267.875,241582,5-Nov-20,5.96,0.0224
5-Nov-20,"Riassunto: Primi 1.000 pazienti trattati con Impella 5.5 with SmartAssist, una pompa cardiaca progettata per i chirurghi","Abiomed (NASDAQ: ABMD) annuncia che sono 1.000 i pazienti trattati con la pompa cardiaca Impella 5.5 with SmartAssist nel primo anno, a partire dalla data in cui la Food and Drug Administration (FDA)...",272.4,275.8588,267.875,271.52,ABMD,241582,HISTORICAL_PRICES,ABMD,,1.60683E+12,0.037832895,0.037832895,271.52,272.4,275.8588,267.875,241582,271.52,272.4,275.8588,267.875,241582,5-Nov-20,5.96,0.0224
5-Nov-20,"Puma Biotechnology Announces Interim Results from the Phase II SUMMIT Trial of Neratinib for EGFR Exon 18 Mutated, Metastatic Non-Small Cell Lung Cancer","Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced interim results from the ongoing SUMMIT trial of neratinib in the cohort of metastatic non-small cell lung cancer (NSCLC...",8.47,8.93,8.3,8.85,PBYI,499521,HISTORICAL_PRICES,PBYI,,1.60683E+12,-0.11954262,-0.11954262,8.85,8.47,8.93,8.3,499521,8.85,8.47,8.93,8.3,499521,5-Nov-20,-0.27,-0.0309
5-Nov-20,Exelixis Announces Third Quarter 2020 Financial Results and Provides Corporate Update,"Exelixis, Inc. (Nasdaq: EXEL) today reported financial results for the third quarter of 2020 and provided an update on progress toward fulfilling its key corporate objectives, as well as commercial an...",22.16,22.77,21.97,22.65,EXEL,2181255,HISTORICAL_PRICES,EXEL,,1.60683E+12,-0.046471601,-0.046471601,22.65,22.16,22.77,21.97,2181255,22.65,22.16,22.77,21.97,2181255,5-Nov-20,-0.43,-0.019
5-Nov-20,Puma Biotechnology Reports Third Quarter 2020 Financial Results,"Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced financial results for the third quarter ended September 30, 2020. Unless otherwise stated, all comparisons are for the t...",8.47,8.93,8.3,8.85,PBYI,499521,HISTORICAL_PRICES,PBYI,,1.60683E+12,-0.11954262,-0.11954262,8.85,8.47,8.93,8.3,499521,8.85,8.47,8.93,8.3,499521,5-Nov-20,-0.27,-0.0309
5-Nov-20,Guardant Health Reports Third Quarter 2020 Financial Results,"Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics, t...",117.42,118.01,113,116.69,GH,840534,HISTORICAL_PRICES,GH,,1.60683E+12,0.103571429,0.103571429,116.69,117.42,118.01,113,840534,116.69,117.42,118.01,113,840534,5-Nov-20,4.02,0.0354
5-Nov-20,Ironwood Pharmaceuticals Reports Strong Third Quarter 2020 Results and Increases Full Year 2020 Financial Guidance,"Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a GI-focused healthcare company, today provided an update on its third quarter 2020 results and recent business performance. “Ironwood’s strong financial...",10.01,10.24,9.74,10.2,IRWD,3545930,HISTORICAL_PRICES,IRWD,,1.60683E+12,0.058139535,0.058139535,10.2,10.01,10.24,9.74,3545930,10.2,10.01,10.24,9.74,3545930,5-Nov-20,-0.25,-0.0244
5-Nov-20,"Deciphera Pharmaceuticals, Inc. Announces Third Quarter 2020 Financial Results","Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) today announced financial results and provided a business update for the third quarter ended September 30, 2020. “The strong U.S. commercial launch of QIN...",64.94,65.45,62.15,64.81,DCPH,252707,HISTORICAL_PRICES,DCPH,,1.60683E+12,0.351790175,0.351790175,64.81,64.94,65.45,62.15,252707,64.81,64.94,65.45,62.15,252707,5-Nov-20,0.43,0.0067
5-Nov-20,Aerie Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Business Update,"Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients wi...",10.73,11.2,10.71,11.07,AERI,608394,HISTORICAL_PRICES,AERI,,1.60683E+12,-0.078178694,-0.078178694,11.07,10.73,11.2,10.71,608394,11.07,10.73,11.2,10.71,608394,5-Nov-20,-0.16,-0.0147
5-Nov-20,AtriCure Reports Third Quarter 2020 Financial Results,"AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced third quarter 2020 financial results. “We ar...",37.12,37.74,36.685,37.03,ATRC,585159,HISTORICAL_PRICES,ATRC,,1.60683E+12,-0.032325339,-0.032325339,37.03,37.12,37.74,36.685,585159,37.03,37.12,37.74,36.685,585159,5-Nov-20,0.47,0.0128
5-Nov-20,TFF Pharmaceuticals Reports Third Quarter 2020 Financial and Business Results,"TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) t...",14.5,15.16,14.15,14.82,TFFP,135832,HISTORICAL_PRICES,TFFP,,1.60683E+12,-0.104938272,-0.104938272,14.82,14.5,15.16,14.15,135832,14.82,14.5,15.16,14.15,135832,5-Nov-20,-0.2,-0.0136
5-Nov-20,Kezar Life Sciences Reports Third-Quarter 2020 Financial Results and Provides Business Updates,"Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced its thir...",5.47,5.5899,5.29,5.39,KZR,144704,HISTORICAL_PRICES,KZR,,1.60683E+12,0.207505519,0.207505519,5.39,5.47,5.5899,5.29,144704,5.39,5.47,5.5899,5.29,144704,5-Nov-20,0,0
5-Nov-20,Xencor Reports Third Quarter 2020 Financial Results,"Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases, today reported financial results...",41.2,41.93,40.02,41.45,XNCR,151885,HISTORICAL_PRICES,XNCR,,1.60683E+12,0.110212881,0.110212881,41.45,41.2,41.93,40.02,151885,41.45,41.2,41.93,40.02,151885,5-Nov-20,-0.3,-0.0072
5-Nov-20,Ocular Therapeutix™ Reports Third Quarter 2020 Financial Results and Business Update,"Ocular Therapeutix™, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, tod...",12,12.25,11.27,11.64,OCUL,1570102,HISTORICAL_PRICES,OCUL,,1.60683E+12,0.534526854,0.534526854,11.64,12,12.25,11.27,1570102,11.64,12,12.25,11.27,1570102,5-Nov-20,-0.05,-0.0041
5-Nov-20,"TFF Pharmaceuticals and Felix Biotechnology Sign Letter of Intent for a Collaboration, Development and License Agreement","TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) t...",14.5,15.16,14.15,14.82,TFFP,135832,HISTORICAL_PRICES,TFFP,,1.60683E+12,-0.104938272,-0.104938272,14.82,14.5,15.16,14.15,135832,14.82,14.5,15.16,14.15,135832,5-Nov-20,-0.2,-0.0136
5-Nov-20,HanesBrands Proprietary Surgical Face Mask Receives Authorization by U.S. Food and Drug Administration,"HanesBrands (NYSE:HBI) today announced that a proprietary surgical face mask developed in conjunction with North Carolina State University, the University of North Carolina at Chapel Hill and UNC Heal...",13.33,14.4,12.85,14,HBI,30430262,HISTORICAL_PRICES,HBI,,1.61362E+12,-0.144415918,-0.144415918,14,13.33,14.4,12.85,30430262,13.7204,13.0638,14.1124,12.5934,30430262,5-Nov-20,-3.04,-0.1857
5-Nov-20,"Resumen: Primeros 1.000 pacientes tratados con Impella 5.5 with SmartAssist, una bomba cardiaca diseñada por cirujanos",Abiomed (NASDAQ: ABMD) ha anunciado que 1.000 pacientes han sido tratados con la bomba cardiaca Impella 5.5 with SmartAssist en el primer año después de que la Administración de Alimentos y Medicament...,272.4,275.8588,267.875,271.52,ABMD,241582,HISTORICAL_PRICES,ABMD,,1.60683E+12,0.037832895,0.037832895,271.52,272.4,275.8588,267.875,241582,271.52,272.4,275.8588,267.875,241582,5-Nov-20,5.96,0.0224
5-Nov-20,Gilead and Kite to Share Latest Scientific Advances in Hematologic Malignancies at ASH 2020,"Gilead Sciences, Inc. (Nasdaq: GILD) and Kite, a Gilead Company, today announced that 16 abstracts, including three oral presentations from the companies’ combined immuno-oncology research and develop...",59.63,60.47,59.2,60.34,GILD,7519760,HISTORICAL_PRICES,GILD,,1.61552E+12,-0.042088353,-0.042088353,60.34,59.63,60.47,59.2,7519760,58.9932,58.2991,59.1203,57.8787,7519760,5-Nov-20,-0.24,-0.004
5-Nov-20,Mirum Pharmaceuticals Broadens Expanded Access Program for Maralixibat in Alagille Syndrome to Europe and Australia,"Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a biopharmaceutical company focused on the development and commercialization of novel therapies for debilitating liver diseases, today announced it has broa...",17.9,18.49,17.59,18.49,MIRM,38622,HISTORICAL_PRICES,MIRM,,1.60683E+12,-0.055408971,-0.055408971,18.49,17.9,18.49,17.59,38622,18.49,17.9,18.49,17.59,38622,5-Nov-20,-0.12,-0.0067
5-Nov-20,Merrimack Reports Third Quarter 2020 Financial Results,"Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) (“Merrimack” or the “Company”) today announced its third quarter 2020 financial results for the period ended September 30, 2020. “We are pleased that bot...",3.82,3.89,3.82,3.85,MACK,3324,HISTORICAL_PRICES,MACK,,1.60683E+12,0.005263158,0.005263158,3.85,3.82,3.89,3.82,3324,3.85,3.82,3.89,3.82,3324,5-Nov-20,0.02,0.0053
5-Nov-20,Clovis Oncology Announces Third Quarter 2020 Operating Results,"Clovis Oncology, Inc. (NASDAQ:CLVS) reported financial results for the quarter ended September 30, 2020, and provided an update on the Company’s clinical development programs and regulatory and commer...",4.47,4.79,4.45,4.7,CLVS,16441583,HISTORICAL_PRICES,CLVS,,1.60683E+12,-0.215100966,-0.215100966,4.7,4.47,4.79,4.45,16441583,4.7,4.47,4.79,4.45,16441583,5-Nov-20,-1.2,-0.2116
5-Nov-20,"First 1,000 Patients Treated with Impella 5.5 with SmartAssist, a Heart Pump Designed for Surgeons","Abiomed (NASDAQ: ABMD) announces 1,000 patients have been treated with the Impella 5.5 with SmartAssist heart pump in the first year after the U.S. Food and Drug Administration (FDA) granted Impella 5...",272.4,275.8588,267.875,271.52,ABMD,241582,HISTORICAL_PRICES,ABMD,,1.60683E+12,0.037832895,0.037832895,271.52,272.4,275.8588,267.875,241582,271.52,272.4,275.8588,267.875,241582,5-Nov-20,5.96,0.0224
5-Nov-20,Alnylam Pharmaceuticals Reports Third Quarter 2020 Financial Results and Highlights Recent Period Activity,"Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today reported its consolidated financial results for the third quarter 2020 and reviewed recent business highlight...",137.86,144.63,136.33,143.56,ALNY,742696,HISTORICAL_PRICES,ALNY,,1.60683E+12,0.033898305,0.033898305,143.56,137.86,144.63,136.33,742696,143.56,137.86,144.63,136.33,742696,5-Nov-20,-1.63,-0.0117
5-Nov-20,bluebird bio to Present Data from Gene and Cell Therapy Programs During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition,"bluebird bio, Inc. (Nasdaq: BLUE) announced today that data from its gene and cell therapy programs for sickle cell disease (SCD), transfusion-dependent beta-thalassemia (TDT) and multiple myeloma (MM...",48.83,50.82,44.83,48.35,BLUE,7527326,HISTORICAL_PRICES,BLUE,,1.60683E+12,-0.122866894,-0.122866894,48.35,48.83,50.82,44.83,7527326,48.35,48.83,50.82,44.83,7527326,5-Nov-20,-9.72,-0.166
5-Nov-20,"Legend Biotech Announces ASH 2020 Data Presentations for Ciltacabtagene Autoleucel (cilta-cel), an Investigational BCMA CAR-T Cell Therapy in Development for Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM)","Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global clinical-stage biopharmaceutical company engaged in the discovery and development of novel cell therapies for oncology and other in...",27.92,29,27.405,28.5,LEGN,254088,HISTORICAL_PRICES,LEGN,,1.60683E+12,-0.034911856,-0.034911856,28.5,27.92,29,27.405,254088,28.5,27.92,29,27.405,254088,5-Nov-20,-0.24,-0.0085
5-Nov-20,Aldeyra Therapeutics Announces Third-Quarter 2020 Financial Results and Provides Corporate Update,"Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immun...",6.95,7.12,6.68,6.89,ALDX,589079,HISTORICAL_PRICES,ALDX,,1.60683E+12,0.026587888,0.026587888,6.89,6.95,7.12,6.68,589079,6.89,6.95,7.12,6.68,589079,5-Nov-20,0.16,0.0236
5-Nov-20,"Lantheus Holdings, Inc. Reports Third Quarter 2020 Financial Results","Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH), the parent company of Lantheus Medical Imaging, Inc. and Progenics Pharmaceuticals, Inc., and a global leader in the development, manufacture an...",10.75,11.48,10.52,10.97,LNTH,744527,HISTORICAL_PRICES,LNTH,,1.60683E+12,-0.106400665,-0.106400665,10.97,10.75,11.48,10.52,744527,10.97,10.75,11.48,10.52,744527,5-Nov-20,-0.49,-0.0436
5-Nov-20,Incyte Reports 2020 Third Quarter Financial Results and Provides Updates on Key Clinical Programs,"Incyte (Nasdaq: INCY) today reports 2020 third quarter financial results, and provides a status update on the Company’s development portfolio. “We are pleased to report another strong quarter for Incy...",84.65,91.05,84.37,87.25,INCY,3099962,HISTORICAL_PRICES,INCY,,1.60683E+12,-0.004937111,-0.004937111,87.25,84.65,91.05,84.37,3099962,87.25,84.65,91.05,84.37,3099962,5-Nov-20,-6.56,-0.0719
5-Nov-20,AVEO Oncology and EUSA Pharma Announce Annals of Oncology Publication of Data from Phase 1b/2 TiNivo Study in Renal Cell Carcinoma,"AVEO Oncology (NASDAQ: AVEO) and EUSA Pharma today announced that previously reported results from the Phase 1b/2 TiNivo study of oral (PO) tivozanib, AVEO’s next-generation vascular endothelial growt...",5.83,5.928,5.6,5.87,AVEO,161492,HISTORICAL_PRICES,AVEO,,1.60683E+12,0.031858407,0.031858407,5.87,5.83,5.928,5.6,161492,5.87,5.83,5.928,5.6,161492,5-Nov-20,0.04,0.0069
5-Nov-20,Kala Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Corporate Update,"Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today reported financ...",7.26,7.44,6.91,7.23,KALA,1499857,HISTORICAL_PRICES,KALA,,1.60683E+12,-0.035856574,-0.035856574,7.23,7.26,7.44,6.91,1499857,7.23,7.26,7.44,6.91,1499857,5-Nov-20,0.01,0.0014
5-Nov-20,"Omeros Corporation to Announce Third Quarter Financial Results on November 9, 2020","Omeros Corporation (NASDAQ: OMER) today announced that the company will issue its third quarter financial results for the period ended September 30, 2020, on Monday, November 9, 2020, after the market...",10.84,10.97,10.3732,10.58,OMER,402960,HISTORICAL_PRICES,OMER,,1.60683E+12,0.102746694,0.102746694,10.58,10.84,10.97,10.3732,402960,10.58,10.84,10.97,10.3732,402960,5-Nov-20,0.22,0.0207
5-Nov-20,Bristol Myers Squibb Reports Third Quarter 2020 Financial Results,"Bristol Myers Squibb (NYSE:BMY) today reports results for the third quarter of 2020, which reflect strong product sales, continued pipeline advancement and robust operating performance. “I am proud of...",63.75,65.38,63.54,64.99,BMY,17676076,HISTORICAL_PRICES,BMY,,1.60946E+12,0.094420601,0.094420601,64.99,63.75,65.38,63.54,17676076,64.4757,63.2455,64.8626,63.0372,17676076,5-Nov-20,-1.68,-0.0257
5-Nov-20,"Ra Medical Systems to Report Third Quarter 2020 Financial Results on November 12, 2020","Ra Medical Systems, Inc. (NYSE: RMED) announces that it will report third quarter 2020 financial results and provide a business update after market close on Thursday, November 12, 2020. Ra Medical man...",4.75,4.9375,4.45,4.575,RMED,78805.52,HISTORICAL_PRICES,RMED,,1.60683E+12,-0.187339607,-0.187339607,0.183,0.19,0.1975,0.178,1970138,4.575,4.75,4.9375,4.45,78805.52,5-Nov-20,0.2875,0.0644
5-Nov-20,LYNPARZA® (olaparib) Approved in the EU for Treatment of BRCA1/2-Mutated Metastatic Castration-Resistant Prostate Cancer (mCRPC),"AstraZeneca and Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that LYNPARZA has been approved in the European Union (EU) as monotherapy for the treatment of adu...",80.46,82.9,80.44,82.06,MRK,8852325,HISTORICAL_PRICES,MRK,,1.61552E+12,-0.032351173,-0.032351173,82.06,80.46,82.9,80.44,8852325,80.7079,79.1343,81.5341,79.1146,8852325,5-Nov-20,-0.16,-0.002
5-Nov-20,Sage Therapeutics Announces Third Quarter 2020 Financial Results and Highlights Pipeline and Business Progress,"Today, Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of th...",78.11,81,75.4716,75.5,SAGE,578771,HISTORICAL_PRICES,SAGE,,1.60683E+12,0.32614601,0.32614601,75.5,78.11,81,75.4716,578771,75.5,78.11,81,75.4716,578771,5-Nov-20,-0.44,-0.0056
5-Nov-20,Plus de 40 abstracts du portefeuille d'oncologie d'Incyte sont acceptés pour présentation lors du 62e congrès annuel virtuel de l'ASH,Incyte (Nasdaq: INCY) annonce ce jour que de nombreux abstracts mettant en lumière les données de son portefeuille d'oncologie seront présentés dans le cadre du 62e congrès annuel de la Société améric...,84.65,91.05,84.37,87.25,INCY,3099962,HISTORICAL_PRICES,INCY,,1.60683E+12,-0.004937111,-0.004937111,87.25,84.65,91.05,84.37,3099962,87.25,84.65,91.05,84.37,3099962,5-Nov-20,-6.56,-0.0719
5-Nov-20,Mehr als 40 Abstracts aus dem Onkologieportfolio von Incyte zur Präsentation auf der virtuellen 62. ASH-Jahrestagung angenommen,"Incyte (Nasdaq: INCY) gab heute bekannt, dass zahlreiche Abstracts mit Daten aus seinem Onkologieportfolio auf der bevorstehenden 62. Jahrestagung und Ausstellung der American Society of Hematology (A...",84.65,91.05,84.37,87.25,INCY,3099962,HISTORICAL_PRICES,INCY,,1.60683E+12,-0.004937111,-0.004937111,87.25,84.65,91.05,84.37,3099962,87.25,84.65,91.05,84.37,3099962,5-Nov-20,-6.56,-0.0719
5-Nov-20,ADC Therapeutics hält acht Präsentationen von Ergebnissen zu seinen Antikörper-Wirkstoff-Konjugaten der nächsten Generation auf der 62. Jahrestagung der American Society of Hematology,"ADC Therapeutics SA (NYSE:ADCT), ein im Bereich der späten klinischen Forschung tätiges Biotechnologieunternehmen mit Schwerpunkt auf Onkologie, das Vorreiter bei der Entwicklung und Vermarktung von h...",32.14,32.81,30.1381,31.19,ADCT,142118,HISTORICAL_PRICES,ADCT,,1.60683E+12,-0.040597015,-0.040597015,31.19,32.14,32.81,30.1381,142118,31.19,32.14,32.81,30.1381,142118,5-Nov-20,1.27,0.0411
5-Nov-20,Concert Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Company Update,"Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today reported financial results for the third quarter of 2020. “Our focus this year has been to advance our proprietary pipeline. Our team has diligently...",10.9,11.35,9.93,10.65,CNCE,159989,HISTORICAL_PRICES,CNCE,,1.60683E+12,0.178378378,0.178378378,10.65,10.9,11.35,9.93,159989,10.65,10.9,11.35,9.93,159989,5-Nov-20,0.21,0.0196
5-Nov-20,Karuna Therapeutics Reports Third Quarter 2020 Financial Results and Provides General Business Update,"Karuna Therapeutics, Inc. (NASDAQ: KRTX), an innovative clinical-stage biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with disabl...",102.73,103,97.05,99,KRTX,116780,HISTORICAL_PRICES,KRTX,,1.60683E+12,0.361744433,0.361744433,99,102.73,103,97.05,116780,99,102.73,103,97.05,116780,5-Nov-20,3.22,0.0324
5-Nov-20,Axsome Therapeutics und Veeva Systems kooperieren beim Aufbau der digital-zentrierten Commercialization™-Plattform von Axsome,"Axsome Therapeutics, Inc. (NASDAQ: AXSM), ein biopharmazeutisches Unternehmen, das neuartige Therapien für die Behandlung von Erkrankungen des Zentralnervensystems (ZNS) entwickelt, und Veeva Systems...",69.51,75,68.77,75,AXSM,574699,HISTORICAL_PRICES,AXSM,,1.60683E+12,-0.084551561,-0.084551561,75,69.51,75,68.77,574699,75,69.51,75,68.77,574699,5-Nov-20,-5.22,-0.0699
4-Nov-20,"Glancy Prongay & Murray LLP, a National Class Action Law Firm, Continues Investigation of Vasta Platform, Ltd. (VSTA) on Behalf of Investors","Glancy Prongay & Murray LLP (“GPM”), a national investor rights law firm, continues its investigation on behalf of Vasta Platform, Ltd. (""Vasta"" or the ""Company”) (NASDAQ: VSTA) investors concerni...",11.6,12,11.47,11.54,VSTA,104669,HISTORICAL_PRICES,VSTA,,1.60683E+12,-0.244791667,-0.244791667,11.54,11.6,12,11.47,104669,11.54,11.6,12,11.47,104669,4-Nov-20,0.15,0.0131
4-Nov-20,"Glancy Prongay & Murray LLP, a National Class Action Law Firm, Continues Investigation of Alibaba Group Holding Limited (BABA) on Behalf of Investors","Glancy Prongay & Murray LLP (“GPM”), a national investor rights law firm, continues its investigation on behalf of Alibaba Group Holding Limited (“Alibaba” or the “Company”) (NYSE: BABA) investors...",295.71,299.17,285.3,287.79,BABA,28791198,HISTORICAL_PRICES,BABA,,1.60683E+12,0.096318541,0.096318541,287.79,295.71,299.17,285.3,28791198,287.79,295.71,299.17,285.3,28791198,4-Nov-20,10.14,0.0355
4-Nov-20,DiaMedica Provides a Business Update and Third Quarter 2020 Financial Results,"DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for kidney diseases and neurological disorders, today provided a business...",4.58,4.6,4.05,4.57,DMAC,320015,HISTORICAL_PRICES,DMAC,,1.60683E+12,0.171355499,0.171355499,4.57,4.58,4.6,4.05,320015,4.57,4.58,4.6,4.05,320015,4-Nov-20,0,0
4-Nov-20,"Cardiovascular Systems, Inc. Reports Fiscal 2021 First-Quarter Financial Results","Cardiovascular Systems, Inc. (CSI®) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery...",36.25,36.43,34.38,35.21,CSII,373944,HISTORICAL_PRICES,CSII,,1.60683E+12,0.016545149,0.016545149,35.21,36.25,36.43,34.38,373944,35.21,36.25,36.43,34.38,373944,4-Nov-20,0.92,0.026
4-Nov-20,Acadia Pharmaceuticals Reports Third Quarter 2020 Financial Results,"Acadia Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous syste...",49.13,50.08,46.8,46.8,ACAD,1855989,HISTORICAL_PRICES,ACAD,,1.60683E+12,0.272468272,0.272468272,46.8,49.13,50.08,46.8,1855989,46.8,49.13,50.08,46.8,1855989,4-Nov-20,2.53,0.0543
4-Nov-20,bluebird bio Reports Third Quarter 2020 Financial Results and Highlights Operational Progress,"bluebird bio, Inc. (NASDAQ: BLUE) today reported financial results and business highlights for the third quarter ended September 30, 2020 and shared recent operational progress. “While 2020 continues...",58.55,59.32,55.345,55.67,BLUE,1165062,HISTORICAL_PRICES,BLUE,,1.60683E+12,0.051733429,0.051733429,55.67,58.55,59.32,55.345,1165062,55.67,58.55,59.32,55.345,1165062,4-Nov-20,4,0.0733
4-Nov-20,Surmodics Reports Fourth Quarter Fiscal 2020 Results,"Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced results for its fiscal 2020 fourth quarter ended S...",38.36,38.905,36.58,36.58,SRDX,41589,HISTORICAL_PRICES,SRDX,,1.60683E+12,0.009473684,0.009473684,36.58,38.36,38.905,36.58,41589,36.58,38.36,38.905,36.58,41589,4-Nov-20,1.13,0.0304
4-Nov-20,Hologic Announces Financial Results for Fourth Quarter of Fiscal 2020,"Hologic, Inc. (Nasdaq: HOLX) announced today the Company’s financial results for the fiscal fourth quarter ended September 26, 2020. “We capped off an unprecedented fiscal year with remarkable financi...",73.75,74.42,72.415,72.7,HOLX,2177353,HISTORICAL_PRICES,HOLX,,1.60683E+12,0.170449135,0.170449135,72.7,73.75,74.42,72.415,2177353,72.7,73.75,74.42,72.415,2177353,4-Nov-20,1.83,0.0254
4-Nov-20,Axonics® Reports Third Quarter 2020 Results,"Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing novel implantable sacral neuromodulation (SNM) devices for the treatment of...",51.5,51.5,48.05,49.73,AXNX,654280,HISTORICAL_PRICES,AXNX,,1.60683E+12,0.173388015,0.173388015,49.73,51.5,51.5,48.05,654280,49.73,51.5,51.5,48.05,654280,4-Nov-20,2.67,0.0547
4-Nov-20,More than 40 Abstracts from Incyte’s Oncology Portfolio Accepted for Presentation at the 62nd Annual ASH Virtual Meeting,Incyte (Nasdaq: INCY) today announced that numerous abstracts highlighting data from its oncology portfolio will be presented at the upcoming 62nd American Society of Hematology Annual Meeting and Exp...,91.21,92.39,87.48,87.62,INCY,2087441,HISTORICAL_PRICES,INCY,,1.60683E+12,0.072175855,0.072175855,87.62,91.21,92.39,87.48,2087441,87.62,91.21,92.39,87.48,2087441,4-Nov-20,6.26,0.0737
4-Nov-20,GlycoMimetics Program Data to be Highlighted Via Three Oral Presentations and Two Posters at 62nd American Society of Hematology Annual Meeting and Exposition,"GlycoMimetics, Inc. (Nasdaq: GLYC) today announced that three abstracts including data from the Company’s clinical and research portfolio have been accepted for oral presentations and two abstracts ha...",2.96,3.08,2.6,2.77,GLYC,4606971,HISTORICAL_PRICES,GLYC,,1.60683E+12,-0.083591331,-0.083591331,2.77,2.96,3.08,2.6,4606971,2.77,2.96,3.08,2.6,4606971,4-Nov-20,0.27,0.1004
4-Nov-20,Alexion Announces Upcoming Data Presentations at the 62nd American Society of Hematology Annual Meeting and Exposition,"Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced that six abstracts have been accepted for presentation at the 62nd Annual Meeting and Exposition of the American Society of Hematology (ASH)...",123.35,124.29,119.565,119.7,ALXN,2071049,HISTORICAL_PRICES,ALXN,,1.60683E+12,0.101142653,0.101142653,119.7,123.35,124.29,119.565,2071049,119.7,123.35,124.29,119.565,2071049,4-Nov-20,6.33,0.0541
4-Nov-20,ADC Therapeutics Announces Eight Presentations on Data from its Next-Generation Antibody Drug Conjugates at the 62nd American Society of Hematology Annual Meeting,"ADC Therapeutics SA (NYSE:ADCT), a late clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of highly potent and targeted antibody drug conjugates (A...",30.87,31.885,28.99,28.99,ADCT,237516,HISTORICAL_PRICES,ADCT,,1.60683E+12,-0.078507463,-0.078507463,28.99,30.87,31.885,28.99,237516,28.99,30.87,31.885,28.99,237516,4-Nov-20,1.61,0.055
4-Nov-20,Gamida Cell Announces Data to Be Presented at 62nd ASH Annual Virtual Meeting,"Gamida Cell Ltd. (Nasdaq: GMDA), a leading cellular and immune therapeutics company, today announced that updated data from the ongoing Phase 1 clinical study of GDA-201, an investigational, natural k...",5.62,5.74,5.41,5.41,GMDA,191684,HISTORICAL_PRICES,GMDA,,1.60683E+12,0.367396594,0.367396594,5.41,5.62,5.74,5.41,191684,5.41,5.62,5.74,5.41,191684,4-Nov-20,0.24,0.0446
4-Nov-20,Ocular Therapeutix Announces Receipt of a Permanent Category I CPT Code from the American Medical Association for the Insertion of Intracanalicular Inserts,"Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today...",12.05,12.19,10.945,10.95,OCUL,2138115,HISTORICAL_PRICES,OCUL,,1.60683E+12,0.540920716,0.540920716,10.95,12.05,12.19,10.945,2138115,10.95,12.05,12.19,10.945,2138115,4-Nov-20,1.51,0.1433
4-Nov-20,Axsome Therapeutics and Veeva Systems Partner to Build Axsome’s Digital-Centric Commercialization™ Platform,"Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, and Veeva Systems (NYSE: VEEV), today ann...",74.73,75.32,69.44,69.5,AXSM,383186,HISTORICAL_PRICES,AXSM,,1.60683E+12,-0.01580403,-0.01580403,69.5,74.73,75.32,69.44,383186,69.5,74.73,75.32,69.44,383186,4-Nov-20,5.29,0.0762
4-Nov-20,Axsome Therapeutics and Veeva Systems Partner to Build Axsome’s Digital-Centric Commercialization™ Platform,"Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, and Veeva Systems (NYSE: VEEV), today ann...",74.73,75.32,69.44,69.5,AXSM,383186,HISTORICAL_PRICES,AXSM,,1.60683E+12,-0.01580403,-0.01580403,69.5,74.73,75.32,69.44,383186,69.5,74.73,75.32,69.44,383186,4-Nov-20,5.29,0.0762
4-Nov-20,Rocket Pharmaceuticals Reports Third Quarter 2020 Financial Results and Highlights Recent Progress,"Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) (“Rocket”), a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders, today reports finan...",31.5,34,29.11,29.77,RCKT,599669,HISTORICAL_PRICES,RCKT,,1.60683E+12,0.376146789,0.376146789,29.77,31.5,34,29.11,599669,29.77,31.5,34,29.11,599669,4-Nov-20,2.12,0.0722
3-Nov-20,"INVESTOR ALERT: Law Offices of Howard G. Smith Continues Investigation of Neovasc, Inc (NVCN) on Behalf of Investors","Law Offices of Howard G. Smith continues its investigation on behalf of Neovasc, Inc (“Neovasc” or the “Company”) (NASDAQ: NVCN) investors concerning the Company’s possible violations of federal secur...",0.8094,0.848,0.7908,0.81,NVCN,459496,HISTORICAL_PRICES,NVCN,,1.60683E+12,-0.610865385,-0.610865385,0.81,0.8094,0.848,0.7908,459496,0.81,0.8094,0.848,0.7908,459496,3-Nov-20,-0.0006,-0.0007
3-Nov-20,Puma Biotechnology to Present at the Credit Suisse 29th Annual Virtual Healthcare Conference,"Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder of Puma, will provide an overview of the...",7.93,8.06,7.62,7.75,PBYI,604993,HISTORICAL_PRICES,PBYI,,1.60683E+12,-0.175675676,-0.175675676,7.75,7.93,8.06,7.62,604993,7.75,7.93,8.06,7.62,604993,3-Nov-20,0.15,0.0193
3-Nov-20,Revance to Participate in the Credit Suisse 29th Annual Healthcare Conference,"Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company focused on innovative aesthetic and therapeutic offerings, including its investigational neuromodulator product, DaxibotulinumtoxinA...",26.67,26.82,25.65,26.03,RVNC,450634,HISTORICAL_PRICES,RVNC,,1.60683E+12,0.03653323,0.03653323,26.03,26.67,26.82,25.65,450634,26.03,26.67,26.82,25.65,450634,3-Nov-20,0.74,0.0285
3-Nov-20,Masimo宣布Radius VSM™在部分市場上市,(美國商業資訊)--Masimo (NASDAQ: MASI)今天宣布，可穿戴、無纜線生命徵象監護儀Radius VSM™已獲得CE認證，正在部分歐洲市場上市。多功能、可擴展Radius VSM能監測多種生理指標，包括連續SET®脈搏血氧飽和度、無創血壓、體溫、呼吸頻率和心電圖(ECG)。Radius VSM功能是依每例患者的需求和敏銳度在可穿戴、模組化平臺上設計的，能升級以適應患者量激增，用於患...,235,236.15,225.095,226.63,MASI,287285,HISTORICAL_PRICES,MASI,,1.60683E+12,0.078228952,0.078228952,226.63,235,236.15,225.095,287285,226.63,235,236.15,225.095,287285,3-Nov-20,9.64,0.0428
3-Nov-20,Masimo宣布Radius VSM™在部分市场上市,(美国商业资讯)--Masimo (NASDAQ: MASI)今天宣布，可穿戴、无线缆生命体征监护仪Radius VSM™已获得CE认证，正在部分欧洲市场上市。多功能、可扩展Radius VSM能监测多种生理指标，包括连续SET®脉搏血氧饱和度、无创血压、体温、呼吸频率和心电图(ECG)。Radius VSM功能是按每例患者的需求和敏锐度在可穿戴、模块化平台上设计的，能升级以适应患者量激增，用于患...,235,236.15,225.095,226.63,MASI,287285,HISTORICAL_PRICES,MASI,,1.60683E+12,0.078228952,0.078228952,226.63,235,236.15,225.095,287285,226.63,235,236.15,225.095,287285,3-Nov-20,9.64,0.0428
3-Nov-20,"Glancy Prongay & Murray LLP, a National Class Action Law Firm, Continues Investigation of Neovasc, Inc. (NVCN) on Behalf of Investors","Glancy Prongay & Murray LLP (“GPM”), a national investor rights law firm, continues its investigation on behalf of Neovasc, Inc. (“Neovasc” or the “Company”) (NASDAQ: NVCN) investors concerning th...",0.8094,0.848,0.7908,0.81,NVCN,459496,HISTORICAL_PRICES,NVCN,,1.60683E+12,-0.610865385,-0.610865385,0.81,0.8094,0.848,0.7908,459496,0.81,0.8094,0.848,0.7908,459496,3-Nov-20,-0.0006,-0.0007
3-Nov-20,"Glancy Prongay & Murray LLP, a National Class Action Law Firm, Continues Investigation of SAP SE (SAP) on Behalf of Investors","Glancy Prongay & Murray LLP (“GPM”), a national investor rights law firm, continues its investigation on behalf of SAP SE (“SAP” or the “Company”) (NYSE: SAP) investors concerning the Company’s po...",109.71,110.69,108.3435,108.5,SAP,1834539,HISTORICAL_PRICES,SAP,,1.60683E+12,-0.284531107,-0.284531107,108.5,109.71,110.69,108.3435,1834539,108.5,109.71,110.69,108.3435,1834539,3-Nov-20,3.88,0.0367
3-Nov-20,INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Zosano Pharma Corporation (ZSAN) Investors,Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased Zosano Pharma Corporation (“Zosano” or the “Company”) (NASDAQ: ZSAN) securities...,0.3635,0.3771,0.36,0.375,ZSAN,2312682,HISTORICAL_PRICES,ZSAN,,1.60683E+12,-0.766987179,-0.766987179,0.375,0.3635,0.3771,0.36,2312682,0.375,0.3635,0.3771,0.36,2312682,3-Nov-20,-0.0115,-0.0307
3-Nov-20,Masimo Anuncia el Lanzamiento de Radius VSM™ en Mercados Limitados,"Masimo (NASDAQ: MASI) anunció hoy que Radius VSM™, monitor de signos vitales portátil y sin cables, ha recibido la marca CE y será lanzado a mercados europeos limitados. El versátil Radius VSM, que se...",235,236.15,225.095,226.63,MASI,287285,HISTORICAL_PRICES,MASI,,1.60683E+12,0.078228952,0.078228952,226.63,235,236.15,225.095,287285,226.63,235,236.15,225.095,287285,3-Nov-20,9.64,0.0428
3-Nov-20,Masimo anuncia liberação limitada ao mercado do Radius VSM™,"Masimo (NASDAQ: MASI) anunciou hoje que o Radius VSM™, um monitor de sinais vitais vestível sem fios, recebeu a marcação CE e está sendo liberado em mercados europeus limitados. O versátil e expansíve...",235,236.15,225.095,226.63,MASI,287285,HISTORICAL_PRICES,MASI,,1.60683E+12,0.078228952,0.078228952,226.63,235,236.15,225.095,287285,226.63,235,236.15,225.095,287285,3-Nov-20,9.64,0.0428
3-Nov-20,Masimo kündigt die begrenzte Markteinführung von Radius VSM™ an,"Masimo (NASDAQ: MASI) gab heute bekannt, dass Radius VSM™, ein tragbarer, schnurloser Vitalparameter-Monitor, die CE-Kennzeichnung erhalten hat und in begrenzten europäischen Märkten eingeführt wird....",235,236.15,225.095,226.63,MASI,287285,HISTORICAL_PRICES,MASI,,1.60683E+12,0.078228952,0.078228952,226.63,235,236.15,225.095,287285,226.63,235,236.15,225.095,287285,3-Nov-20,9.64,0.0428
3-Nov-20,Concert Pharmaceuticals Initiates THRIVE-AA1 Phase 3 Clinical Trial Evaluating CTP-543 for Alopecia Areata,"Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced it has initiated THRIVE-AA1, the first Phase 3 clinical trial to evaluate the efficacy and safety of CTP-543, an oral Janus kinase inhibito...",9.48,9.94,8.76,9.94,CNCE,265392,HISTORICAL_PRICES,CNCE,,1.60683E+12,0.024864865,0.024864865,9.94,9.48,9.94,8.76,265392,9.94,9.48,9.94,8.76,265392,3-Nov-20,-0.29,-0.0297
2-Nov-20,"NEOVASC ALERT: Bragar Eagel & Squire, P.C. is Investigating Neovasc, Inc. on Behalf of Neovasc Stockholders and Encourages Investors to Contact the Firm","Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Neovasc, Inc. (NASDAQ: NVCN) on behalf of Neovasc stockholders. Our inve...",0.81,0.95,0.7997,0.9101,NVCN,999159,HISTORICAL_PRICES,NVCN,,1.60683E+12,-0.610576923,-0.610576923,0.9101,0.81,0.95,0.7997,999159,0.9101,0.81,0.95,0.7997,999159,2-Nov-20,-0.12,-0.129
2-Nov-20,Shareholder Alert: Robbins LLP Announces Zosano Pharma Corporation (ZSAN) is Being Sued for Misleading Shareholders,Shareholder rights law firm Robbins LLP announces that a purchaser of Zosano Pharma Corporation (NASDAQ: ZSAN) filed a class action complaint against the Company and its officers and directors for all...,0.375,0.43,0.362,0.41,ZSAN,2529141,HISTORICAL_PRICES,ZSAN,,1.60683E+12,-0.759615385,-0.759615385,0.41,0.375,0.43,0.362,2529141,0.41,0.375,0.43,0.362,2529141,2-Nov-20,-0.0074,-0.0194
2-Nov-20,Urovant Sciences Reports Second Quarter Fiscal Year 2020 Results,"Urovant Sciences (Nasdaq: UROV) today reported financial results for its fiscal quarter ended September 30, 2020. During the second quarter of fiscal year 2020, the Company achieved a number of signif...",7.43,7.56,7.15,7.56,UROV,48335,HISTORICAL_PRICES,UROV,,1.60683E+12,-0.205347594,-0.205347594,7.56,7.43,7.56,7.15,48335,7.56,7.43,7.56,7.15,48335,2-Nov-20,0.04,0.0054
2-Nov-20,"Revance to Release Third Quarter 2020 Financial Results on Monday, November 9, 2020","Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company focused on innovative aesthetic and therapeutic offerings, including its investigational neuromodulator product, DaxibotulinumtoxinA...",25.93,26.25,25.33,25.78,RVNC,326634,HISTORICAL_PRICES,RVNC,,1.60683E+12,0.007773028,0.007773028,25.78,25.93,26.25,25.33,326634,25.78,25.93,26.25,25.33,326634,2-Nov-20,0.05,0.0019
2-Nov-20,"INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Neovasc, Inc (NVCN) on Behalf of Investors","Law Offices of Howard G. Smith announces an investigation on behalf of Neovasc, Inc (“Neovasc” or the “Company”) (NASDAQ: NVCN) investors concerning the Company’s possible violations of federal securi...",0.81,0.95,0.7997,0.9101,NVCN,999159,HISTORICAL_PRICES,NVCN,,1.60683E+12,-0.610576923,-0.610576923,0.9101,0.81,0.95,0.7997,999159,0.9101,0.81,0.95,0.7997,999159,2-Nov-20,-0.12,-0.129
2-Nov-20,"Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of SAP SE (SAP) on Behalf of Investors","Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of SAP SE (“SAP” or the “Company”) (NYSE: SAP)...",105.83,106.33,104.64,106.31,SAP,2235645,HISTORICAL_PRICES,SAP,,1.60683E+12,-0.309834355,-0.309834355,106.31,105.83,106.33,104.64,2235645,106.31,105.83,106.33,104.64,2235645,2-Nov-20,-1,-0.0094
2-Nov-20,"SHAREHOLDER ACTION REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Zosano Pharma Corporation and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm","The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Zosano Pharma Corporation (“Zosano” or “the Company”) (NASDAQ: ZSAN) for viol...",0.375,0.43,0.362,0.41,ZSAN,2529141,HISTORICAL_PRICES,ZSAN,,1.60683E+12,-0.759615385,-0.759615385,0.41,0.375,0.43,0.362,2529141,0.41,0.375,0.43,0.362,2529141,2-Nov-20,-0.0074,-0.0194
2-Nov-20,INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Neovasc Inc. and Encourages Investors with Losses to Contact the Firm,"The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Neovasc Inc. (“Neovasc” or “the Company”) (NASDAQ: NVCN) for vio...",0.81,0.95,0.7997,0.9101,NVCN,999159,HISTORICAL_PRICES,NVCN,,1.60683E+12,-0.610576923,-0.610576923,0.9101,0.81,0.95,0.7997,999159,0.9101,0.81,0.95,0.7997,999159,2-Nov-20,-0.12,-0.129
2-Nov-20,"TFF Pharmaceuticals, Inc. and Augmenta Bioworks, Inc. Enter Into a Worldwide Joint Development Agreement for COVID-19 Monoclonal Antibody Therapies","TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company, and Augmenta Bioworks, Inc., a biotechnology company enabling breakthroughs in medicine through immune profiling,...",13.57,13.74,12.85,12.85,TFFP,163648,HISTORICAL_PRICES,TFFP,,1.60683E+12,-0.162345679,-0.162345679,12.85,13.57,13.74,12.85,163648,12.85,13.57,13.74,12.85,163648,2-Nov-20,0.83,0.0651
2-Nov-20,Mirum Pharmaceuticals Announces New Data Being Presented in Late-Breaker Oral and Poster Presentations at the Annual Meeting of the American Association for the Study of Liver Diseases (AASLD),"Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a biopharmaceutical company focused on the development and commercialization of novel therapies for debilitating liver diseases today announced that new dat...",16.47,16.72,15.35,15.75,MIRM,66208,HISTORICAL_PRICES,MIRM,,1.60683E+12,-0.130870712,-0.130870712,15.75,16.47,16.72,15.35,66208,15.75,16.47,16.72,15.35,66208,2-Nov-20,0.72,0.0457
2-Nov-20,PolarityTE Announces Successful Completion of Initial Pre-IND Interaction with U.S. Food and Drug Administration for SkinTE®,"PolarityTE, Inc. (Nasdaq: PTE) announced that it recently received written responses from FDA following a Type B Pre-IND meeting request that the Company submitted in August 2020 regarding an indicati...",0.9565,1.02,0.9232,1.02,PTE,339548,HISTORICAL_PRICES,PTE,,1.60683E+12,-0.062254902,-0.062254902,1.02,0.9565,1.02,0.9232,339548,1.02,0.9565,1.02,0.9232,339548,2-Nov-20,-0.0325,-0.0329
2-Nov-20,Applied DNA Announces Linear DNA Orders from New Contract Research Customers for Use in RNA Vaccine and Adeno-Associated Virus Applications,"Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA” or the ""Company""), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing, announced that it received orders for its linear DNA to...",7,8.3,6.91,8.18,APDN,302639,HISTORICAL_PRICES,APDN,,1.60683E+12,-0.107142857,-0.107142857,8.18,7,8.3,6.91,302639,8.18,7,8.3,6.91,302639,2-Nov-20,-0.71,-0.0921
2-Nov-20,Outset Medical to Present at Upcoming Virtual Investor Conferences,"Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced that members of mana...",44.87,47.1,42.57,47.06,OM,266632,HISTORICAL_PRICES,OM,,1.60683E+12,-0.136783378,-0.136783378,47.06,44.87,47.1,42.57,266632,47.06,44.87,47.1,42.57,266632,2-Nov-20,-1.6,-0.0344
2-Nov-20,Sesen Bio to Host Conference Call to Review Third Quarter Financial Results and Provide an Update on Positive Progress Towards Demonstration of Analytical Comparability,"Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced that Company management will host a c...",1.02,1.04,1,1,SESN,764756,HISTORICAL_PRICES,SESN,,1.60683E+12,-0.170731707,-0.170731707,1,1.02,1.04,1,764756,1,1.02,1.04,1,764756,2-Nov-20,0,0
2-Nov-20,IVERIC bio Reports Third Quarter 2020 Operational Highlights and Financial Results,"IVERIC bio, Inc. (Nasdaq: ISEE) today announced financial and operating results for the fiscal quarter ended September 30, 2020 and provided a general business update. “It has been a landmark year as...",6,6.09,5.41,5.87,ISEE,772232,HISTORICAL_PRICES,ISEE,,1.60683E+12,0.219512195,0.219512195,5.87,6,6.09,5.41,772232,5.87,6,6.09,5.41,772232,2-Nov-20,0.08,0.0135
2-Nov-20,Henry Schein Reports Record Third Quarter 2020 Financial Results From Continuing Operations,"Henry Schein, Inc. (Nasdaq: HSIC), the world’s largest provider of health care solutions to office-based dental and medical practitioners, today reported record third quarter 2020 financial results fr...",62.22,65.78,60.15,63.66,HSIC,2341951,HISTORICAL_PRICES,HSIC,,1.60683E+12,0.067604667,0.067604667,63.66,62.22,65.78,60.15,2341951,63.66,62.22,65.78,60.15,2341951,2-Nov-20,-1.36,-0.0214
2-Nov-20,Horizon Therapeutics plc Reports Record Third-Quarter 2020 Results; Increases TEPEZZA® Full-Year Net Sales Guidance to Greater Than $800 Million; Increases Full-Year 2020 Net Sales and Adjusted EBITDA Guidance,Horizon Therapeutics plc (Nasdaq: HZNP) today announced record third-quarter 2020 financial results and increased both its full-year 2020 net sales and adjusted EBITDA guidance. “We are proud of the f...,73.67,75.36,70.54,73.08,HZNP,5480616,HISTORICAL_PRICES,HZNP,,1.60683E+12,-0.022036373,-0.022036373,73.08,73.67,75.36,70.54,5480616,73.08,73.67,75.36,70.54,5480616,2-Nov-20,-1.26,-0.0168
2-Nov-20,"Seres Therapeutics to Host Third Quarter 2020 Financial Results and Operational Progress Conference Call and Webcast on November 9, 2020","Seres Therapeutics, Inc., (Nasdaq: MCRB), a leading microbiome platform company developing a novel class of multifunctional bacterial therapeutics designed to functionally interact with host cells and...",29.51,29.7,27.8,28.12,MCRB,520580,HISTORICAL_PRICES,MCRB,,1.60683E+12,0.168712871,0.168712871,28.12,29.51,29.7,27.8,520580,28.12,29.51,29.7,27.8,520580,2-Nov-20,1.62,0.0581
2-Nov-20,"Horizon Therapeutics plc Names Karin Rosén, M.D., Ph.D. Executive Vice President, Research and Development and Chief Scientific Officer","Horizon Therapeutics plc (Nasdaq: HZNP) today announced that Karin Rosén, M.D., Ph.D., has joined the company as executive vice president, research and development and chief scientific officer, report...",73.67,75.36,70.54,73.08,HZNP,5480616,HISTORICAL_PRICES,HZNP,,1.60683E+12,-0.022036373,-0.022036373,73.08,73.67,75.36,70.54,5480616,73.08,73.67,75.36,70.54,5480616,2-Nov-20,-1.26,-0.0168
2-Nov-20,Eagle Pharmaceuticals Reports Third Quarter 2020 Results,"Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced financial results for the three and nine months ended September 30, 2020. Business and Recent Highlights: Received...",49.22,51.47,46.2501,49.4,EGRX,276527,HISTORICAL_PRICES,EGRX,,1.60683E+12,0.196984436,0.196984436,49.4,49.22,51.47,46.2501,276527,49.4,49.22,51.47,46.2501,276527,2-Nov-20,2.7,0.058
2-Nov-20,Eagle Pharmaceuticals Strengthens Management Team to Prepare for Future Growth,"Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced four additions to its clinical, formulations and commercialization leadership teams: Judith (“Judi”) Ng-Cashin, M....",49.22,51.47,46.2501,49.4,EGRX,276527,HISTORICAL_PRICES,EGRX,,1.60683E+12,0.196984436,0.196984436,49.4,49.22,51.47,46.2501,276527,49.4,49.22,51.47,46.2501,276527,2-Nov-20,2.7,0.058
2-Nov-20,Easterly Government Properties Reports Third Quarter 2020 Results,"Easterly Government Properties, Inc. (NYSE: DEA) (the “Company” or “Easterly”), a fully integrated real estate investment trust (“REIT”) focused primarily on the acquisition, development and managemen...",21.49,21.49,20.73,20.9,DEA,428815,HISTORICAL_PRICES,DEA,,1.61482E+12,-0.041480821,-0.041480821,20.9,21.49,21.49,20.73,428815,20.3966,20.9724,20.9724,20.2307,428815,2-Nov-20,0.59,0.0282
30-Oct-20,Genmab und ADC Therapeutics melden erweiterte Vereinbarung für Camidanlumab Tesirin (Cami),"Genmab A/S (Nasdaq: GMAB) und ADC Therapeutics SA (NYSE: ADCT) gaben heute den Abschluss eines geänderten Abkommens bekannt, demzufolge ADC Therapeutics die Entwicklung und Vermarktung von Camidanluma...",33.66,34.23,33.29,34.2,GMAB,607261,HISTORICAL_PRICES,GMAB,,1.60683E+12,-0.03801086,-0.03801086,34.2,33.66,34.23,33.29,607261,34.2,33.66,34.23,33.29,607261,30-Oct-20,-0.68,-0.0198
30-Oct-20,"SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Zosano Pharma Corporation and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm","The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Zosano Pharma Corporation (“Zosano” or “the Company”) (NASDAQ: ZSAN) for viol...",0.3824,0.43,0.375,0.419,ZSAN,2655003,HISTORICAL_PRICES,ZSAN,,1.60683E+12,-0.754871795,-0.754871795,0.419,0.3824,0.43,0.375,2655003,0.419,0.3824,0.43,0.375,2655003,30-Oct-20,-0.0276,-0.0673
30-Oct-20,"ROSEN, A TOP RANKED LAW FIRM, Announces Filing of Securities Class Action Lawsuit Against Zosano Pharma Corporation – ZSAN","Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Zosano Pharma Corporation (NASDAQ: ZSAN) between February...",0.3824,0.43,0.375,0.419,ZSAN,2655003,HISTORICAL_PRICES,ZSAN,,1.60683E+12,-0.754871795,-0.754871795,0.419,0.3824,0.43,0.375,2655003,0.419,0.3824,0.43,0.375,2655003,30-Oct-20,-0.0276,-0.0673
30-Oct-20,Hologic Awarded U.S. Government Contract to Expand COVID-19 Test Production Capacity,"Hologic, Inc. (Nasdaq: HOLX) announced today that it has been awarded a $119 million contract from the United States government to expand its production capacity for COVID-19 molecular tests. The cont...",68.82,71.02,67.71,70.45,HOLX,2228798,HISTORICAL_PRICES,HOLX,,1.60683E+12,0.092207586,0.092207586,70.45,68.82,71.02,67.71,2228798,70.45,68.82,71.02,67.71,2228798,30-Oct-20,-1.68,-0.0238
30-Oct-20,INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Neovasc Inc. and Encourages Investors with Losses to Contact the Firm,"The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Neovasc Inc. (“Neovasc” or “the Company”) (NASDAQ: NVCN) for vio...",0.93,1,0.87,1,NVCN,1722528,HISTORICAL_PRICES,NVCN,,1.60683E+12,-0.552884615,-0.552884615,1,0.93,1,0.87,1722528,1,0.93,1,0.87,1722528,30-Oct-20,-0.13,-0.1226
30-Oct-20,Astrotech Announces Closing of $6.2 Million Registered Direct Offering Priced At-the-Market,"Astrotech Corporation (NASDAQ: ASTC), today announced that it has closed its previously announced registered direct offering priced at-the-market under Nasdaq rules of 2,887,906 shares of its common s...",1.99,2.14,1.92,2.03,ASTC,1617641,HISTORICAL_PRICES,ASTC,,1.60683E+12,0.317880795,0.317880795,2.03,1.99,2.14,1.92,1617641,2.03,1.99,2.14,1.92,1617641,30-Oct-20,-0.02,-0.01
30-Oct-20,Incyte Ranked Second Among Science Magazine’s 2020 Top Biopharma Employers,Incyte (Nasdaq:INCY) today announced that the company has again been named a top biopharma employer by Science magazine through its Top Employers Survey of the global pharmaceutical and biotech indust...,86.64,86.84,83.44,86.55,INCY,1105304,HISTORICAL_PRICES,INCY,,1.60683E+12,0.01845539,0.01845539,86.55,86.64,86.84,83.44,1105304,86.55,86.64,86.84,83.44,1105304,30-Oct-20,-0.38,-0.0044
30-Oct-20,Genprex Unveils New Branding for Upcoming Combination Clinical Trials in Non-Small Cell Lung Cancer,"Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced th...",3.25,3.5,3.1263,3.5,GNPX,1688043,HISTORICAL_PRICES,GNPX,,1.60683E+12,0.048387097,0.048387097,3.5,3.25,3.5,3.1263,1688043,3.5,3.25,3.5,3.1263,1688043,30-Oct-20,-0.28,-0.0793
30-Oct-20,Veracyte Announces New Data Published in Journal of Clinical Oncology Suggest the Prosigna Breast Cancer Test’s Genomic Underpinning Drives Prognostic Performance,"Veracyte, Inc., (Nasdaq: VCYT) announced today that findings from the first study evaluating the molecular drivers underlying multiple prognostic genomic breast cancer tests were published in the Jour...",34.66,37,33.85,36.79,VCYT,495845,HISTORICAL_PRICES,VCYT,,1.60683E+12,0.1518777,0.1518777,36.79,34.66,37,33.85,495845,36.79,34.66,37,33.85,495845,30-Oct-20,-2.15,-0.0584
30-Oct-20,New TEPEZZA® (teprotumumab-trbw) Data to Be Presented at the American Academy of Ophthalmology 2020 Annual Meeting,"Horizon Therapeutics plc (Nasdaq: HZNP) today announced new TEPEZZA® (teprotumumab-trbw) data being presented at the American Academy of Ophthalmology Annual Meeting (AAO 2020 Virtual), Nov. 13-15, 20...",74.93,77.94,73.75,76.81,HZNP,2870404,HISTORICAL_PRICES,HZNP,,1.60683E+12,-0.005309969,-0.005309969,76.81,74.93,77.94,73.75,2870404,76.81,74.93,77.94,73.75,2870404,30-Oct-20,-2.79,-0.0359
30-Oct-20,Applied DNA to Increase COVID-19 Surveillance Testing Utility for its Linea™ COVID-19 Assay Kits Through Expanded Use of Robotic Automation,"Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA” or the ""Company""), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing that enables diagnostics in vitro, pre-clinical nucleic...",7.71,7.98,6.6001,6.8,APDN,396155,HISTORICAL_PRICES,APDN,,1.60683E+12,-0.016581633,-0.016581633,6.8,7.71,7.98,6.6001,396155,6.8,7.71,7.98,6.6001,396155,30-Oct-20,0.86,0.1255
30-Oct-20,Ligand Reports Third Quarter 2020 Financial Results,"Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today reported financial results for the three- and nine-months ending September 30, 2020 and provided an operating forecast and program updates. Lig...",82.45,84.64,78.26,80.51,LGND,547689,HISTORICAL_PRICES,LGND,,1.60683E+12,-0.125848176,-0.125848176,80.51,82.45,84.64,78.26,547689,80.51,82.45,84.64,78.26,547689,30-Oct-20,-0.62,-0.0075
30-Oct-20,Ocular Therapeutix™ and AffaMed Therapeutics Announce License Agreement and Collaboration for DEXTENZA® and OTX-TIC in Asia,"Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today...",9.5,9.94,9.36,9.73,OCUL,879121,HISTORICAL_PRICES,OCUL,,1.60683E+12,0.21483376,0.21483376,9.73,9.5,9.94,9.36,879121,9.73,9.5,9.94,9.36,879121,30-Oct-20,0.01,0.0011
30-Oct-20,Genmab and ADC Therapeutics Announce Amended Agreement for Camidanlumab Tesirine (Cami),Genmab A/S (Nasdaq: GMAB) and ADC Therapeutics SA (NYSE: ADCT) today announced that they have executed an amended agreement for ADC Therapeutics to continue the development and commercialization of ca...,33.66,34.23,33.29,34.2,GMAB,607261,HISTORICAL_PRICES,GMAB,,1.60683E+12,-0.03801086,-0.03801086,34.2,33.66,34.23,33.29,607261,34.2,33.66,34.23,33.29,607261,30-Oct-20,-0.68,-0.0198
30-Oct-20,Altria Reports 2020 Third-Quarter and Nine-Months Results; Tobacco Businesses Demonstrate Resilience; Narrows 2020 Full-Year Earnings Guidance,"Altria Group, Inc. (Altria) (NYSE: MO) today announces its 2020 third-quarter and nine-months business results and narrows its 2020 adjusted diluted earnings per share (EPS) guidance. “Altria continue...",36.08,36.75,35.83,36.25,MO,12786623,HISTORICAL_PRICES,MO,,1.61655E+12,-0.058700757,-0.058700757,36.25,36.08,36.75,35.83,12786623,34.918,34.7542,35.3996,34.5134,12786623,30-Oct-20,-0.79,-0.0214
30-Oct-20,"Alnylam Wins Prestigious Prix Galien Award for Best Biotechnology Product with First-Ever Approved RNAi Therapeutic, ONPATTRO® (patisiran)","Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced it has won the 2020 Prix Galien USA Award for Best Biotechnology Product for ONPATTRO® (patisiran)....",122.97,124.6,119.29,122.8,ALNY,733508,HISTORICAL_PRICES,ALNY,,1.60683E+12,-0.077771111,-0.077771111,122.8,122.97,124.6,119.29,733508,122.8,122.97,124.6,119.29,733508,30-Oct-20,-0.35,-0.0028
30-Oct-20,Epizyme Announces Date of Third Quarter 2020 Financial Results,"Epizyme, (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering novel epigenetic therapies, today announced that management will host a conference cal...",12.36,12.645,11.8,12.46,EPZM,746805,HISTORICAL_PRICES,EPZM,,1.60683E+12,0.05370844,0.05370844,12.46,12.36,12.645,11.8,746805,12.46,12.36,12.645,11.8,746805,30-Oct-20,-0.26,-0.0206
29-Oct-20,Zusammengefasste Ergebnisse der Incyte-Studien TRuE-AD1 und TRuE-AD2 zur Behandlung von atopischer Dermatitis mit Ruxolitinib-Creme zeigen klinisch relevante Verbesserungen bei der patientenberichteten Lebensqualität,"Incyte (Nasdaq:INCY) hat heute die Ergebnisse zu Wirksamkeit und Sicherheit aus einer Gesamtanalyse von zwei randomisierten, doppelblinden, vehikelkontrollierten Phase-3-Studien TRuE-AD1 und TRuE-AD2...",87.02,87.99,85.48,86.94,INCY,691772,HISTORICAL_PRICES,INCY,,1.60683E+12,0.022922299,0.022922299,86.94,87.02,87.99,85.48,691772,86.94,87.02,87.99,85.48,691772,29-Oct-20,0.03,0.0003
29-Oct-20,Quidel Reports Third Quarter 2020 Financial Results,"Quidel Corporation (NASDAQ: QDEL), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today financial results for the third qu...",268.78,274.75,263.5,269,QDEL,746425,HISTORICAL_PRICES,QDEL,,1.60683E+12,0.400187539,0.400187539,269,268.78,274.75,263.5,746425,269,268.78,274.75,263.5,746425,29-Oct-20,4.99,0.0189
29-Oct-20,PerkinElmer COVID-19 Test Kit Receives FDA Emergency Use Authorization for Sample Pooling,"PerkinElmer, Inc. (NYSE: PKI) announced today that the U.S. Food and Drug Administration (FDA) has issued Emergency Use Authorization (EUA) to allow sample pooling with PerkinElmer® New Coronavirus Nu...",128.79,132.505,124.4,126.91,PKI,1547036,HISTORICAL_PRICES,PKI,,1.6112E+12,0.091810783,0.091810783,126.91,128.79,132.505,124.4,1547036,126.8513,128.7304,132.4437,124.3424,1547036,29-Oct-20,4.39,0.0353
29-Oct-20,Seagen Reports Third Quarter 2020 Financial Results,"Seagen Inc. (Nasdaq:SGEN) today reported financial results for the third quarter and nine months ended September 30, 2020. The Company also highlighted ADCETRIS® (brentuximab vedotin), PADCEV® (enfort...",192.34,196.105,189.02,194.96,SGEN,787307,HISTORICAL_PRICES,SGEN,,1.60683E+12,0.071950064,0.071950064,194.96,192.34,196.105,189.02,787307,194.96,192.34,196.105,189.02,787307,29-Oct-20,-2.51,-0.0129
29-Oct-20,Cerus Corporation Announces Record Third Quarter 2020 Results,"Cerus Corporation (Nasdaq: CERS) today announced financial results for the third quarter ended September 30, 2020. Recent developments and highlights include: Q3 2020 Total Revenue of $29.2 million -...",5.555,5.57,5.365,5.51,CERS,2004786,HISTORICAL_PRICES,CERS,,1.60683E+12,-0.058474576,-0.058474576,5.51,5.555,5.57,5.365,2004786,5.51,5.555,5.57,5.365,2004786,29-Oct-20,0.005,0.0009
29-Oct-20,Vertex Reports Third-Quarter 2020 Financial Results,"Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the third quarter ended September 30, 2020 and revised upward its full-year 2020 financial guidance...",207.01,210.375,205,209.01,VRTX,1931045,HISTORICAL_PRICES,VRTX,,1.60683E+12,-0.213278608,-0.213278608,209.01,207.01,210.375,205,1931045,209.01,207.01,210.375,205,1931045,29-Oct-20,-1.33,-0.0064
29-Oct-20,Concert Pharmaceuticals Presents CTP-543 Data from Long-Term Extension Study in Alopecia Areata During Late-Breaking Session at EADV Congress,"Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today presented initial data from the ongoing long-term, open-label extension study of the investigational medicine CTP-543 in patients with moderate to se...",10.74,11.0891,10.55,10.92,CNCE,172686,HISTORICAL_PRICES,CNCE,,1.60683E+12,0.161081081,0.161081081,10.92,10.74,11.0891,10.55,172686,10.92,10.74,11.0891,10.55,172686,29-Oct-20,-0.29,-0.0263
29-Oct-20,"Easterly Government Properties Announces Lease Commencement for 59,690 SF FDA Laboratory Re-Development in Lenexa, KS","Easterly Government Properties, Inc. (NYSE: DEA) (“Easterly”), a fully integrated real estate investment trust focused primarily on the acquisition, development and management of Class A commercial pr...",20.69,20.86,20.4,20.86,DEA,422496,HISTORICAL_PRICES,DEA,,1.61482E+12,-0.077163247,-0.077163247,20.86,20.69,20.86,20.4,422496,20.3576,20.1917,20.3576,19.9087,422496,29-Oct-20,-0.23,-0.011
29-Oct-20,Genprex Receives Conditional FDA Acceptance of Proprietary Name REQORSA™ for Lead Drug Candidate for Treatment of Non-Small Cell Lung Cancer,"Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced th...",3.53,3.58,3.12,3.3,GNPX,2364670,HISTORICAL_PRICES,GNPX,,1.60683E+12,0.138709677,0.138709677,3.3,3.53,3.58,3.12,2364670,3.3,3.53,3.58,3.12,2364670,29-Oct-20,0.44,0.1424
29-Oct-20,Pooled Results from Incyte’s TRuE-AD1 and TRuE-AD2 Atopic Dermatitis Studies of Ruxolitinib Cream Show Clinically Meaningful Improvements in Patient-Reported Quality of Life Assessments,"Incyte (Nasdaq:INCY) today announced efficacy and safety results from a pooled analysis of two randomized, double-blind, vehicle-controlled Phase 3 studies – TRuE-AD1 and TRuE-AD2 – evaluating ruxolit...",87.02,87.99,85.48,86.94,INCY,691772,HISTORICAL_PRICES,INCY,,1.60683E+12,0.022922299,0.022922299,86.94,87.02,87.99,85.48,691772,86.94,87.02,87.99,85.48,691772,29-Oct-20,0.03,0.0003
29-Oct-20,Astrotech Announces $6.2 Million Registered Direct Offering Priced At-the-Market,"Astrotech Corporation (NASDAQ: ASTC), today announced that it has entered into definitive agreements with several institutional investors for the purchase and sale of 2,887,906 shares of Astrotech's c...",2.01,2.11,1.95,2.1,ASTC,3686710,HISTORICAL_PRICES,ASTC,,1.60683E+12,0.331125828,0.331125828,2.1,2.01,2.11,1.95,3686710,2.1,2.01,2.11,1.95,3686710,29-Oct-20,-0.42,-0.1728
29-Oct-20,TriMas Announces Agreement to Acquire Affaba & Ferrari,"TriMas (NASDAQ: TRS) announced today that it has signed an agreement to acquire Affaba & Ferrari Srl, a designer and manufacturer of precision caps and closures for food & beverage and industr...",23.89,24.05,22.82,23.44,TRS,121778,HISTORICAL_PRICES,TRS,,1.60683E+12,0.051033876,0.051033876,23.44,23.89,24.05,22.82,121778,23.44,23.89,24.05,22.82,121778,29-Oct-20,0.28,0.0119
29-Oct-20,Tricida Provides Update on FDA Interactions,"Tricida, Inc. (Nasdaq: TCDA), a pharmaceutical company focused on the development and commercialization of its investigational drug candidate, veverimer (TRC101), a non-absorbed, orally-administered p...",4.37,4.552,3.74,4.3965,TCDA,17458215,HISTORICAL_PRICES,TCDA,,1.60683E+12,-0.517127072,-0.517127072,4.3965,4.37,4.552,3.74,17458215,4.3965,4.37,4.552,3.74,17458215,29-Oct-20,-3.9,-0.4716
29-Oct-20,Baxter Reports Third-Quarter 2020 Results,"Baxter International Inc. (NYSE:BAX), a leading global medical products company, today reported earnings for the third quarter of 2020 and updated its outlook for full-year 2020. “Baxter’s third-quart...",78.08,79.91,77.09,79.07,BAX,3326446,HISTORICAL_PRICES,BAX,,1.61422E+12,-0.007878018,-0.007878018,79.07,78.08,79.91,77.09,3326446,78.5703,77.5866,79.405,76.6028,3326446,29-Oct-20,-0.07,-0.0009
29-Oct-20,"AVROBIO Receives Orphan Drug Designation from the European Commission for AVR‑RD‑01, an Investigational Gene Therapy for Fabry Disease","AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that the European Commission (EC) has gran...",14.93,15.31,14.1577,14.51,AVRO,181737,HISTORICAL_PRICES,AVRO,,1.60683E+12,0.139694656,0.139694656,14.51,14.93,15.31,14.1577,181737,14.51,14.93,15.31,14.1577,181737,29-Oct-20,0.32,0.0219
29-Oct-20,Moderna Reports Third Quarter 2020 Financial Results and Provides Business Updates,"Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today reported fina...",71.28,74.539,66.23,68.35,MRNA,13776433,HISTORICAL_PRICES,MRNA,,1.60683E+12,0.093754795,0.093754795,68.35,71.28,74.539,66.23,13776433,68.35,71.28,74.539,66.23,13776433,29-Oct-20,5.54,0.0843
29-Oct-20,"TherapeuticsMD to Report Third Quarter 2020 Results on November 9, 2020","TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative women’s healthcare company, today announced that it will report its third quarter 2020 financial results on Monday, November 9, 2020, before the open...",1.32,1.35,1.27,1.35,TXMD,2169846,HISTORICAL_PRICES,TXMD,,1.60683E+12,0.007633588,0.007633588,1.35,1.32,1.35,1.27,2169846,1.35,1.32,1.35,1.27,2169846,29-Oct-20,0,0
29-Oct-20,"Abiomed Announces Q2 FY 2021 Revenue of $210 Million, Up 27% Over Q1 FY 2021 and Up 2% Over Q2 FY 2020 With 29.2% Operating Margin","Abiomed, Inc. (NASDAQ: ABMD), a leading provider of breakthrough heart support technologies today reported second quarter fiscal 2021 revenue of $209.8 million, a sequential increase of 27% compared t...",254.61,270,254.28,268,ABMD,835818,HISTORICAL_PRICES,ABMD,,1.60683E+12,-0.02994628,-0.02994628,268,254.61,270,254.28,835818,268,254.61,270,254.28,835818,29-Oct-20,-28.39,-0.1003
29-Oct-20,Humanigen Announces First Patient Dosed in NIH ACTIV-5/Big Effect Trial Evaluating Lenzilumab™ for COVID-19,"Humanigen, Inc., (Nasdaq: HGEN) (“Humanigen”), a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm,’ today announced that the...",10.35,11.3355,10.07,11.23,HGEN,558009,HISTORICAL_PRICES,HGEN,,1.60683E+12,0.112903226,0.112903226,11.23,10.35,11.3355,10.07,558009,11.23,10.35,11.3355,10.07,558009,29-Oct-20,-1.04,-0.0913
29-Oct-20,Charles River Laboratories Announces Third-Quarter 2020 Results,"Charles River Laboratories International, Inc. (NYSE: CRL) today reported its results for the third quarter of 2020. For the quarter, revenue was $743.3 million, an increase of 11.3% from $668.0 milli...",228.94,234.71,219.79,221.2,CRL,578505,HISTORICAL_PRICES,CRL,,1.60683E+12,0.080772317,0.080772317,221.2,228.94,234.71,219.79,578505,221.2,228.94,234.71,219.79,578505,29-Oct-20,6.94,0.0313
29-Oct-20,Frequency Therapeutics Announces Expanded FX-322 Clinical Development Program and Upcoming Day-90 Phase 2a Analysis,"Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage biotechnology company focused on harnessing the body’s innate biology to repair or reverse damage caused by a broad range of degenerative...",21.46,22.21,20.01,21.74,FREQ,123277,HISTORICAL_PRICES,FREQ,,1.60683E+12,0.002803738,0.002803738,21.74,21.46,22.21,20.01,123277,21.74,21.46,22.21,20.01,123277,29-Oct-20,-0.46,-0.021
29-Oct-20,Alexion Reports Third Quarter 2020 Results,"Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced financial results for the third quarter of 2020. Total revenues in the third quarter were $1,588.7 million, a 26 percent increase compared t...",118.21,119.98,115.2,118.21,ALXN,2138765,HISTORICAL_PRICES,ALXN,,1.60683E+12,0.05525799,0.05525799,118.21,118.21,119.98,115.2,2138765,118.21,118.21,119.98,115.2,2138765,29-Oct-20,3.36,0.0293
29-Oct-20,Aerie Pharmaceuticals Initiates Phase 2b Clinical Trial of AR-15512 (TRPM8 Agonist) Ophthalmic Solution for the Treatment of Patients with Dry Eye Disease,"Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients w...",10.79,10.87,10.04,10.31,AERI,1110443,HISTORICAL_PRICES,AERI,,1.60683E+12,-0.073024055,-0.073024055,10.31,10.79,10.87,10.04,1110443,10.31,10.79,10.87,10.04,1110443,29-Oct-20,0.5,0.0486
29-Oct-20,Axonics® Submits PMA Supplement to FDA to Further Expand MRI Labeling,"Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing novel implantable sacral neuromodulation (SNM) devices for the treatment of...",48.87,49.07,46.9176,48.6,AXNX,155367,HISTORICAL_PRICES,AXNX,,1.60683E+12,0.113465482,0.113465482,48.6,48.87,49.07,46.9176,155367,48.6,48.87,49.07,46.9176,155367,29-Oct-20,-0.02,-0.0004
29-Oct-20,"Erste Patienten mit 9Fr Impella ECP, der kleinsten Herzpumpe der Welt, behandelt",Abiomed (NASDAQ: ABMD) hat die Behandlung der ersten beiden Patienten mit der expandierbaren perkutanen Herzpumpe Impella ECP bekannt gegeben. Impella ECP ist die kleinste Herzpumpe der Welt. Sie hat...,254.61,270,254.28,268,ABMD,835818,HISTORICAL_PRICES,ABMD,,1.60683E+12,-0.02994628,-0.02994628,268,254.61,270,254.28,835818,268,254.61,270,254.28,835818,29-Oct-20,-28.39,-0.1003
28-Oct-20,Moderna Partners with Takeda and the Government of Japan to Supply 50 Million Doses of mRNA Vaccine Against COVID-19 (mRNA-1273) to Japan,"Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today confirmed tha...",65.74,69.47,65.4899,68.95,MRNA,6043991,HISTORICAL_PRICES,MRNA,,1.60683E+12,0.008746356,0.008746356,68.95,65.74,69.47,65.4899,6043991,68.95,65.74,69.47,65.4899,6043991,28-Oct-20,-4.93,-0.0698
28-Oct-20,"ROSEN, A RESPECTED LAW FIRM, Reminds Reata Pharmaceuticals, Inc. Investors of Important December 14 Deadline in Securities Class Action; Encourages Investors with Losses in Excess of $100K to Contact the Firm – RETA","Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Reata Pharmaceuticals, Inc. (NASDAQ: RETA) between October 15, 2019 and August 7, 2020, inclusive (the “Class...",116.89,118.12,113.69,117.65,RETA,163833,HISTORICAL_PRICES,RETA,,1.60683E+12,0.137726299,0.137726299,117.65,116.89,118.12,113.69,163833,117.65,116.89,118.12,113.69,163833,28-Oct-20,-2.16,-0.0181
28-Oct-20,"Taro Provides Results for September 30, 2020","Taro Pharmaceutical Industries Ltd. (NYSE: TARO) (“Taro” or the “Company”) today provided unaudited financial results for the quarter and six months ended September 30, 2020. Quarter ended September 3...",57.78,61.19,57.78,61.15,TARO,21643,HISTORICAL_PRICES,TARO,,1.60683E+12,0.046549538,0.046549538,61.15,57.78,61.19,57.78,21643,61.15,57.78,61.19,57.78,21643,28-Oct-20,-3.95,-0.064
28-Oct-20,Lyra Therapeutics Appoints Nancy L. Snyderman To Its Board of Directors,"Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatme...",11.5,11.54,11.23,11.54,LYRA,106277,HISTORICAL_PRICES,LYRA,,1.60683E+12,0.004366812,0.004366812,11.54,11.5,11.54,11.23,106277,11.54,11.5,11.54,11.23,106277,28-Oct-20,-0.26,-0.0221
28-Oct-20,Gilead Sciences Announces Third Quarter 2020 Financial Results,"Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the third quarter 2020. “The recent acquisition of Immunomedics has effectively transformed Gilead’s growth story. Bu...",58.72,59.565,58.06,59.31,GILD,12150837,HISTORICAL_PRICES,GILD,,1.61552E+12,-0.056706827,-0.056706827,59.31,58.72,59.565,58.06,12150837,57.9862,57.4094,58.2355,56.7641,12150837,28-Oct-20,-1.29,-0.0215
28-Oct-20,Tricida to Provide Update from its End-of-Review Type A Meeting with the FDA,"Tricida, Inc. (Nasdaq: TCDA), a pharmaceutical company focused on the development and commercialization of its drug candidate, veverimer (TRC101), a non-absorbed, orally-administered polymer designed...",8.27,8.5,7.57,7.73,TCDA,410694,HISTORICAL_PRICES,TCDA,,1.60683E+12,-0.086187845,-0.086187845,7.73,8.27,8.5,7.57,410694,7.73,8.27,8.5,7.57,410694,28-Oct-20,0.33,0.0416
28-Oct-20,Omeros Participates in Investor Conference Focused on COVID-19 Therapeutics in Development,Omeros Corporation (Nasdaq: OMER) announced that results from its compassionate use study evaluating narsoplimab in COVID-19 patients in Italy will be shared during a virtual event being hosted today...,10.46,10.58,10.14,10.52,OMER,675275,HISTORICAL_PRICES,OMER,,1.60683E+12,0.064089522,0.064089522,10.52,10.46,10.58,10.14,675275,10.52,10.46,10.58,10.14,675275,28-Oct-20,-0.08,-0.0076
28-Oct-20,"Odonate Therapeutics Announces Financial Results for the Three and Nine Months Ended September 30, 2020","Odonate Therapeutics, Inc. (NASDAQ: ODT), a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer, today announced...",14.9,15.69,14.6701,15.63,ODT,316884,HISTORICAL_PRICES,ODT,,1.60683E+12,0.146153846,0.146153846,15.63,14.9,15.69,14.6701,316884,15.63,14.9,15.69,14.6701,316884,28-Oct-20,-0.62,-0.0399
28-Oct-20,"First Patients Treated with the World’s Smallest Heart Pump, the 9Fr Impella ECP",Abiomed (NASDAQ: ABMD) announces the first two patients have been treated with the Impella ECP expandable percutaneous heart pump. Impella ECP is the smallest heart pump in the world. It measures 9 Fr...,283,290.67,279.84,286.87,ABMD,448734,HISTORICAL_PRICES,ABMD,,1.60683E+12,0.078218463,0.078218463,286.87,283,290.67,279.84,448734,286.87,283,290.67,279.84,448734,28-Oct-20,-7.51,-0.0259
28-Oct-20,"Deciphera Pharmaceuticals, Inc. to Announce Third Quarter 2020 Financial Results and Host Conference Call and Webcast on November 5, 2020","Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) today announced that it will report its third quarter 2020 financial results on Thursday, November 5, 2020. In connection with the earnings release, Decip...",58.11,60.01,58.01,59.96,DCPH,225295,HISTORICAL_PRICES,DCPH,,1.60683E+12,0.209616986,0.209616986,59.96,58.11,60.01,58.01,225295,59.96,58.11,60.01,58.01,225295,28-Oct-20,-2.89,-0.0474
27-Oct-20,"全球投資人法律顧問ROSEN提醒Reata Pharmaceuticals, Inc.投資人注意RETA證券集體訴訟的重要截止日期；鼓勵損失超過10萬美元的投資人與法律事務所聯絡","(美國商業資訊)--全球投資人權益法律事務所Rosen Law Firm提醒在2019年10月15日至2020年8月7日（含上述日期，簡稱「集體訴訟期」）期間購買Reata Pharmaceuticals, Inc. (NASDAQ: RETA)證券的人士注意，本證券集體訴訟中原告代表的重要截止日期為2020年12月14日。訴訟旨在依據聯邦證券法彌補Reata投資人所蒙受的損失。 如欲加入Reat...",119.05,119.9199,113.4399,114.61,RETA,188387,HISTORICAL_PRICES,RETA,,1.60683E+12,0.158750243,0.158750243,114.61,119.05,119.9199,113.4399,188387,114.61,119.05,119.9199,113.4399,188387,27-Oct-20,4.42,0.0386
27-Oct-20,"全球投资者法律顾问ROSEN提醒Reata Pharmaceuticals, Inc.投资者注意RETA证券集体诉讼的重要截止日期；鼓励损失超过10万美元的投资者联系律所","(美国商业资讯)--全球投资者权益律所Rosen Law Firm提醒在2019年10月15日至2020年8月7日（含上述日期，简称“集体诉讼期”）期间购买Reata Pharmaceuticals, Inc. (NASDAQ: RETA)证券的人士注意，本证券集体诉讼中首要原告的重要截止日期为2020年12月14日。诉讼旨在依据联邦证券法弥补Reata投资者所蒙受的损失。 如需加入Reata集体...",119.05,119.9199,113.4399,114.61,RETA,188387,HISTORICAL_PRICES,RETA,,1.60683E+12,0.158750243,0.158750243,114.61,119.05,119.9199,113.4399,188387,114.61,119.05,119.9199,113.4399,188387,27-Oct-20,4.42,0.0386
27-Oct-20,Transcat Reports Record Second Quarter Operating Income of $3.1 Million on Strong Service Gross Margin,"Transcat, Inc. (Nasdaq: TRNS) (“Transcat” or the “Company”), a leading provider of accredited calibration, repair, inspection and laboratory instrument services and value-added distributor of professi...",27.56,28.8,27.5,28.8,TRNS,7916,HISTORICAL_PRICES,TRNS,,1.60683E+12,-0.059064527,-0.059064527,28.8,27.56,28.8,27.5,7916,28.8,27.56,28.8,27.5,7916,27-Oct-20,0.06,0.0022
27-Oct-20,Aurinia Announces European Investigator-Initiated Trial to Evaluate Antiviral Activity of Voclosporin in Kidney Transplant Recipients with COVID-19,"Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSX:AUP) (“Aurinia” or the “Company”), a late-stage clinical biopharmaceutical company focused on advancing voclosporin across multiple indications, today a...",16.05,16.29,15.44,15.52,AUPH,1065145,HISTORICAL_PRICES,AUPH,,1.60683E+12,0.143162393,0.143162393,15.52,16.05,16.29,15.44,1065145,15.52,16.05,16.29,15.44,1065145,27-Oct-20,0.63,0.0409
27-Oct-20,La FDA accorde l'accréditation 510(k) à la technologie d'assistance cardiopulmonaire innovante d'Abiomed,L'Agence américaine des produits alimentaires et médicamenteux (FDA) vient d'accorder à Abiomed (NASDAQ: ABMD) une autorisation 510(k) pour le système de pontage cardiopulmonaire compact tout en un Ab...,290.51,293.47,285.35,287.91,ABMD,354339,HISTORICAL_PRICES,ABMD,,1.60683E+12,0.106831257,0.106831257,287.91,290.51,293.47,285.35,354339,287.91,290.51,293.47,285.35,354339,27-Oct-20,2.19,0.0076
27-Oct-20,TFF Pharmaceuticals Announces Positive Preclinical Results with University of Georgia Universal Influenza Vaccines,"TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) t...",14.28,15.3389,14.02,14.75,TFFP,448243,HISTORICAL_PRICES,TFFP,,1.60683E+12,-0.118518519,-0.118518519,14.75,14.28,15.3389,14.02,448243,14.75,14.28,15.3389,14.02,448243,27-Oct-20,-0.1,-0.007
27-Oct-20,Baxter Supports New Study Showing Blood Purification With Oxiris Filter Set Can Play a Role in the Management of Severely Ill COVID-19 Patients,"Baxter International Inc. (NYSE:BAX), a global leader in acute care, recognizes the findings of a prospective, multicenter, observational study on data from the OxirisNet Registry evaluating severely...",80.62,82,80.335,80.59,BAX,3333446,HISTORICAL_PRICES,BAX,,1.61422E+12,0.024396442,0.024396442,80.59,80.62,82,80.335,3333446,80.0807,80.1105,81.4818,79.8273,3333446,27-Oct-20,0.61,0.0076
27-Oct-20,Robbins Geller Rudman & Dowd LLP Announces Lead Plaintiff Deadline in the Nano-X Imaging Ltd. Class Action Lawsuit,"Robbins Geller Rudman & Dowd LLP announces that purchasers of Nano-X Imaging Ltd. (NASDAQ:NNOX) securities between August 21, 2020 and September 15, 2020, inclusive (the “Class Period”), have unti...",29.17,30.13,27.61,28.9471,NNOX,553052,HISTORICAL_PRICES,NNOX,,1.60683E+12,0.07282089,0.07282089,28.9471,29.17,30.13,27.61,553052,28.9471,29.17,30.13,27.61,553052,27-Oct-20,0.25,0.0086
27-Oct-20,UK Medicines and Healthcare products Regulatory Agency Begins Rolling Review of Moderna’s mRNA Vaccine Against COVID-19 (mRNA-1273),"Moderna, Inc., (Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced tha...",70.67,71.35,68.81,70.45,MRNA,3812879,HISTORICAL_PRICES,MRNA,,1.60683E+12,0.08439466,0.08439466,70.45,70.67,71.35,68.81,3812879,70.45,70.67,71.35,68.81,3812879,27-Oct-20,0.43,0.0061
27-Oct-20,First Approved Cancer Treatment for TGCT Included DILIsym Simulations in FDA Review,"DILIsym Services, Inc., a Simulations Plus company (Nasdaq: SLP) and a leading provider of modeling and simulation software for pharmaceutical safety and efficacy, today announced that simulations usi...",68.19,70.19,68.16,69.4,SLP,101528,HISTORICAL_PRICES,SLP,,1.61128E+12,0.032556027,0.032556027,69.4,68.19,70.19,68.16,101528,69.3433,68.1343,70.1326,68.1043,101528,27-Oct-20,-0.92,-0.0133
27-Oct-20,Urovant Sciences to Report Second Fiscal Quarter 2020 Financial Results,"Urovant Sciences (Nasdaq: UROV) announced today that it will report financial results for its fiscal quarter ended September 30, 2020 after the close of U.S. financial markets on Monday, November 2, 2...",8.13,8.27,7.935,8.01,UROV,55492,HISTORICAL_PRICES,UROV,,1.60683E+12,-0.130481283,-0.130481283,8.01,8.13,8.27,7.935,55492,8.01,8.13,8.27,7.935,55492,27-Oct-20,0.12,0.015
27-Oct-20,"Aerie Pharmaceuticals to Announce Third Quarter 2020 Financial Results and Host Conference Call on Thursday, November 5, 2020","Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients wi...",9.93,10.07,9.71,9.81,AERI,385114,HISTORICAL_PRICES,AERI,,1.60683E+12,-0.146907216,-0.146907216,9.81,9.93,10.07,9.71,385114,9.81,9.93,10.07,9.71,385114,27-Oct-20,0.12,0.0122
27-Oct-20,Turning Point Brands Makes Strategic Investment into dosist™ A World-Class and Globally Recognized Cannabis Brand,"Turning Point Brands, Inc. (“TPB”) (NYSE: TPB), a manufacturer, marketer and distributor of branded consumer products with active ingredients, today announced a $15 million strategic investment in lea...",37.25,39.42,34.81,34.92,TPB,764327,HISTORICAL_PRICES,TPB,,1.61603E+12,0.313006697,0.313006697,34.92,37.25,39.42,34.81,764327,34.8423,37.1671,39.3322,34.7325,764327,27-Oct-20,4.32,0.1312
27-Oct-20,"Turning Point Brands Announces Third Quarter 2020 Results, Increases 2020 Guidance","Turning Point Brands, Inc. (“TPB”) (NYSE: TPB), a manufacturer, marketer and distributor of branded consumer products with active ingredients, today announced financial results for the third quarter e...",37.25,39.42,34.81,34.92,TPB,764327,HISTORICAL_PRICES,TPB,,1.61603E+12,0.313006697,0.313006697,34.92,37.25,39.42,34.81,764327,34.8423,37.1671,39.3322,34.7325,764327,27-Oct-20,4.32,0.1312
27-Oct-20,Taysha Gene Therapies Receives Rare Pediatric Disease Designation and Orphan Drug Designation for TSHA-104 to Treat SURF1-Associated Leigh Syndrome,"Taysha Gene Therapies Inc. (Nasdaq: TSHA), a patient-centric gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the cent...",21.05,21.5369,20,20.32,TSHA,239586,HISTORICAL_PRICES,TSHA,,1.60683E+12,-0.125103907,-0.125103907,20.32,21.05,21.5369,20,239586,20.32,21.05,21.5369,20,239586,27-Oct-20,0.95,0.0473
27-Oct-20,Kala Pharmaceuticals Announces FDA Approval of EYSUVIS™ for the Short-Term Treatment of the Signs and Symptoms of Dry Eye Disease,"Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced that...",6.275,7.6999,6.07,7.65,KALA,8694559,HISTORICAL_PRICES,KALA,,1.60683E+12,-0.166666667,-0.166666667,7.65,6.275,7.6999,6.07,8694559,7.65,6.275,7.6999,6.07,8694559,27-Oct-20,-1.445,-0.1872
27-Oct-20,Scholar Rock Announces Positive Proof-of-Concept Data from TOPAZ Phase 2 Trial Interim Analysis of SRK-015 in Patients with Type 2 and Type 3 Spinal Muscular Atrophy,"Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced positive s...",30.02,31.69,17.25,17.25,SRRK,53359145,HISTORICAL_PRICES,SRRK,,1.60683E+12,0.736263736,0.736263736,17.25,30.02,31.69,17.25,53359145,17.25,30.02,31.69,17.25,53359145,27-Oct-20,16.3,1.188
27-Oct-20,"FDA Grants Priority Review and EMA Accepts Regulatory Submission for Pfizer’s Abrocitinib, an Oral Once-Daily JAK1 Inhibitor, for Patients 12 and Up with Moderate to Severe Atopic Dermatitis",Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) accepted for filing and granted Priority Review designation to the company’s New Drug Application (NDA) for abr...,37.43,38.12,36.87,37.04,PFE,34963528,HISTORICAL_PRICES,PFE,,1.6118E+12,0.046700224,0.046700224,37.04,37.43,38.12,36.87,34963528,36.2684,36.6503,37.3259,36.1019,34963528,27-Oct-20,-0.49,-0.0129
27-Oct-20,Merck Announces Third-Quarter 2020 Financial Results,"Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced financial results for the third quarter of 2020. “We continue to execute on our strategic priorities and remain co...",77.99,80.23,77.99,78.93,MRK,11680721,HISTORICAL_PRICES,MRK,,1.61552E+12,-0.062056524,-0.062056524,78.93,77.99,80.23,77.99,11680721,77.6295,76.705,78.9081,76.705,11680721,27-Oct-20,-0.85,-0.0108
27-Oct-20,FDA erteilt 510(k)-Genehmigung für innovatives kardiopulmonales Unterstützungssystem von Abiomed,Die US-amerikanische Arzneimittelaufsichtsbehörde FDA hat Abiomed (NASDAQ: ABMD) eine 510(k)-Genehmigung für das kompakte kardiopulmonale All-in-One-Bypass-System Abiomed Breethe OXY-1 System™ erteilt...,290.51,293.47,285.35,287.91,ABMD,354339,HISTORICAL_PRICES,ABMD,,1.60683E+12,0.106831257,0.106831257,287.91,290.51,293.47,285.35,354339,287.91,290.51,293.47,285.35,354339,27-Oct-20,2.19,0.0076
26-Oct-20,"Exelixis Announces Takeda and Ono Submit Supplemental Application for CABOMETYX® (cabozantinib) in Combination with OPDIVO® (nivolumab) for the Treatment of Unresectable, Advanced or Metastatic Renal Cell Carcinoma in Japan","Exelixis, Inc. (NASDAQ: EXEL) today announced that Takeda Pharmaceutical Company Limited (Takeda), its partner responsible for the clinical development and commercialization of CABOMETYX® (cabozantini...",21.9,22.149,21.54,21.83,EXEL,1620570,HISTORICAL_PRICES,EXEL,,1.60683E+12,-0.057659208,-0.057659208,21.83,21.9,22.149,21.54,1620570,21.83,21.9,22.149,21.54,1620570,26-Oct-20,-0.39,-0.0175
26-Oct-20,PerkinElmer riceve il marchio CE per il pannello respiratorio ad analita multiplo che comprende COVID-19,"PerkinElmer, Inc. (NYSE: PKI) ha annunciato oggi che il suo Pannello Respiratorio PKamp™ SARS-CoV-2 RT-PCR ha ricevuto l’autorizzazione ad essere commercializzato come dispositivo diagnostico in vitro...",124.07,124.63,122.1735,123.03,PKI,814036,HISTORICAL_PRICES,PKI,,1.6112E+12,0.051797219,0.051797219,123.03,124.07,124.63,122.1735,814036,122.9731,124.0126,124.5723,122.117,814036,26-Oct-20,-0.38,-0.0031
26-Oct-20,NantKwest Names Richard Adcock Chief Executive Officer,"NantKwest, Inc. (NASDAQ: NK), a clinical-stage, natural killer cell-based therapeutics company, today appointed healthcare industry veteran with proven operational skills Richard Adcock as its Chief E...",9.03,9.22,8.47,8.7,NK,1291532,HISTORICAL_PRICES,NK,,1.60683E+12,0.318248175,0.318248175,8.7,9.03,9.22,8.47,1291532,8.7,9.03,9.22,8.47,1291532,26-Oct-20,0.45,0.0524
26-Oct-20,"POPSUGAR Launches New Women’s Health Destination, “Full Disclosure,” in Collaboration With TherapeuticsMD","POPSUGAR, the #1 most engaged-with Women’s Lifestyle site in the U.S., together with TherapeuticsMD Inc. (NASDAQ: TXMD), launched its new women’s health destination, “Full Disclosure,” utilizing POPSU...",1.44,1.4899,1.37,1.45,TXMD,3477423,HISTORICAL_PRICES,TXMD,,1.60683E+12,0.099236641,0.099236641,1.45,1.44,1.4899,1.37,3477423,1.45,1.44,1.4899,1.37,3477423,26-Oct-20,-0.04,-0.027
26-Oct-20,PerkinElmer obtient le marquage CE pour un panel respiratoire multi-analyses intégrant le COVID-19,"PerkinElmer, Inc. (NYSE: PKI) a annoncé aujourd'hui que son panel RT-PCR PKamp™ Respiratory SARS-CoV-2 a annoncé aujourd'hui que son panel RT-PCR PKamp™ Respiratory SARS-CoV-2 a obtenu l'autorisation...",124.07,124.63,122.1735,123.03,PKI,814036,HISTORICAL_PRICES,PKI,,1.6112E+12,0.051797219,0.051797219,123.03,124.07,124.63,122.1735,814036,122.9731,124.0126,124.5723,122.117,814036,26-Oct-20,-0.38,-0.0031
26-Oct-20,"ROSEN, GLOBAL INVESTOR COUNSEL, Reminds Reata Pharmaceuticals, Inc. Investors of Important Deadline in Securities Class Action; Encourages Investors with Losses in Excess of $100K to Contact the Firm – RETA","Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Reata Pharmaceuticals, Inc. (NASDAQ: RETA) between October 15, 2019 and August 7, 2020, inclusive (the “Class...",114.63,117.48,113.03,116.95,RETA,111553,HISTORICAL_PRICES,RETA,,1.60683E+12,0.115729025,0.115729025,116.95,114.63,117.48,113.03,111553,116.95,114.63,117.48,113.03,111553,26-Oct-20,-2.65,-0.0226
26-Oct-20,Riassunto: FDA concede la clearance 510(k) all'innovativa tecnologia di supporto cardiopolmonare di Abiomed,La Food and Drug Administration (FDA) statunitense ha concesso a Abiomed (NASDAQ: ABMD) una clearance 510(k) per un sistema di bypass cardiopolmonare compatto all-in-one chiamato Abiomed Breethe OXY-1...,288.32,288.58,277.945,279.22,ABMD,291428,HISTORICAL_PRICES,ABMD,,1.60683E+12,0.098487446,0.098487446,279.22,288.32,288.58,277.945,291428,279.22,288.32,288.58,277.945,291428,26-Oct-20,6.9,0.0245
26-Oct-20,"PerkinElmer erhält CE-Kennzeichnung für auf Atemwegsinfektionen, einschließlich COVID-19, ausgerichtetes Multi-Analyt-Panel","PerkinElmer, Inc. (NYSE: PKI) meldete heute, dass sein PKamp™ Respiratory SARS-CoV-2 RT-PCR Panel die Zulassung für die Vermarktung als In-vitro-Diagnostikum (IVD) in mehr als 30 Ländern im Sinne der...",124.07,124.63,122.1735,123.03,PKI,814036,HISTORICAL_PRICES,PKI,,1.6112E+12,0.051797219,0.051797219,123.03,124.07,124.63,122.1735,814036,122.9731,124.0126,124.5723,122.117,814036,26-Oct-20,-0.38,-0.0031
26-Oct-20,"PerkinElmer ontvangt CE-markering voor respiratoir panel voor meerdere analyten, inclusief COVID-19","PerkinElmer, Inc. (NYSE: PKI) heeft vandaag aangekondigd dat zijn PKamp™ Respiratory SARS-CoV-2 RT-PCR Panel toestemming heeft gekregen om in meer dan 30 landen als in-vitro-diagnostisch (IVD) hulpmid...",124.07,124.63,122.1735,123.03,PKI,814036,HISTORICAL_PRICES,PKI,,1.6112E+12,0.051797219,0.051797219,123.03,124.07,124.63,122.1735,814036,122.9731,124.0126,124.5723,122.117,814036,26-Oct-20,-0.38,-0.0031
26-Oct-20,ProvideGx® and Baxter Healthcare Secure the Supply of Critical Shortage Drug for COVID-19 Patients Requiring Ventilation,"Premier Inc. (NASDAQ: PINC), through its ProvideGx® program, has partnered with Baxter Healthcare to supply pre-filled, single-use IV bags of dexmedetomidine hydrochloride to healthcare providers, hel...",34.16,34.5,33.88,34.18,PINC,240302,HISTORICAL_PRICES,PINC,,1.61439E+12,0.097333762,0.097333762,34.18,34.16,34.5,33.88,240302,33.8082,33.7884,34.1247,33.5115,240302,26-Oct-20,-0.23,-0.0067
26-Oct-20,"PerkinElmer recibe el marcado CE para un panel respiratorio multianalito, que incluye la COVID-19","PerkinElmer, Inc. (NYSE: PKI) ha anunciado hoy que su panel PKamp™ Respiratory SARS-CoV-2 RT-PCR ha recibido la autorización para ser comercializado como un dispositivo de diagnóstico in vitro (IVD) e...",124.07,124.63,122.1735,123.03,PKI,814036,HISTORICAL_PRICES,PKI,,1.6112E+12,0.051797219,0.051797219,123.03,124.07,124.63,122.1735,814036,122.9731,124.0126,124.5723,122.117,814036,26-Oct-20,-0.38,-0.0031
26-Oct-20,Resumen: La FDA otorga la autorización 510(k) a la innovadora tecnología de apoyo cardiopulmonar de Abiomed,"La Administración de Alimentos y Medicamentos (Food and Drug Administration, FDA) de Estados Unidos ha concedido a Abiomed (NASDAQ: ABMD) una autorización 510(k) para su sistema de bypass cardiopulmon...",288.32,288.58,277.945,279.22,ABMD,291428,HISTORICAL_PRICES,ABMD,,1.60683E+12,0.098487446,0.098487446,279.22,288.32,288.58,277.945,291428,279.22,288.32,288.58,277.945,291428,26-Oct-20,6.9,0.0245
26-Oct-20,TFF Pharmaceuticals Expands its cGMP Manufacturing Capabilities with Experic,"TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) t...",14.38,15.49,13.68,15.15,TFFP,244571,HISTORICAL_PRICES,TFFP,,1.60683E+12,-0.112345679,-0.112345679,15.15,14.38,15.49,13.68,244571,15.15,14.38,15.49,13.68,244571,26-Oct-20,-0.82,-0.0539
26-Oct-20,New Pediatric and Secondary Endpoint Data from Rivipansel Phase 3 RESET Trial Presented at The Annual Scientific Conference on Sickle Cell and Thalassemia (ASCAT) Meeting,"GlycoMimetics, Inc. (Nasdaq: GLYC) today announced that new post hoc analyses of the Phase 3 RESET study evaluating the efficacy of rivipansel, its wholly-owned product candidate, in VOC show that ped...",3.32,3.39,3.2,3.22,GLYC,187816,HISTORICAL_PRICES,GLYC,,1.60683E+12,0.027863777,0.027863777,3.22,3.32,3.39,3.2,187816,3.22,3.32,3.39,3.2,187816,26-Oct-20,0.09,0.0279
26-Oct-20,Acadia Pharmaceuticals to Present New Scientific Data on Pimavanserin in Neurodegenerative Diseases at the 13th Clinical Trials on Alzheimer's Disease (CTAD) Conference,Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that scientific presentations highlighting new analyses of pimavanserin clinical study data in dementia-related psychosis and neurodegenerati...,44.87,44.914,42.9,42.9,ACAD,1362844,HISTORICAL_PRICES,ACAD,,1.60683E+12,0.162134162,0.162134162,42.9,44.87,44.914,42.9,1362844,42.9,44.87,44.914,42.9,1362844,26-Oct-20,1.7,0.0394
26-Oct-20,Samenvatting: FDA verleent 510 (k) goedkeuring voor de innovatieve cardiopulmonale ondersteuningstechnologie van Abiomed,"De Amerikaanse Food en Drug Administration (FDA) heeft Abiomed (NASDAQ: ABMD) een 510 (k) goedkeuring verleend voor een alles-in-één, compact cardiopulmonair bypass-systeem genaamd Abiomed Breethe OXY...",288.32,288.58,277.945,279.22,ABMD,291428,HISTORICAL_PRICES,ABMD,,1.60683E+12,0.098487446,0.098487446,279.22,288.32,288.58,277.945,291428,279.22,288.32,288.58,277.945,291428,26-Oct-20,6.9,0.0245
26-Oct-20,"  Forte Biosciences, Inc. Announces the FDA Has Granted Fast Track Designation to FB-401 for the Treatment of Atopic Dermatitis","Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designa...",33.27,35.5,33.26,33.93,FBRX,20508,HISTORICAL_PRICES,FBRX,,1.60683E+12,-0.270394737,-0.270394737,33.93,33.27,35.5,33.26,20508,33.93,33.27,35.5,33.26,20508,26-Oct-20,-1.24,-0.0359
26-Oct-20,Mirum Pharmaceuticals to Present Maralixibat Data and Host Symposium at the NASPGHAN Annual Meeting 2020,"Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a biopharmaceutical company focused on the development and commercialization of novel therapies for debilitating liver diseases today announced that data fr...",17.14,18.07,16.84,17.8,MIRM,70047,HISTORICAL_PRICES,MIRM,,1.60683E+12,-0.095514512,-0.095514512,17.8,17.14,18.07,16.84,70047,17.8,17.14,18.07,16.84,70047,26-Oct-20,-0.92,-0.0509
26-Oct-20,Genprex Promotes Eric Chapdelaine to Vice President of Manufacturing,"Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, announced today th...",3.27,3.42,3.14,3.33,GNPX,651159,HISTORICAL_PRICES,GNPX,,1.60683E+12,0.05483871,0.05483871,3.33,3.27,3.42,3.14,651159,3.33,3.27,3.42,3.14,651159,26-Oct-20,-0.12,-0.0354
26-Oct-20,"PolarityTE to Report Third Quarter 2020 Financial Results on November 9, 2020","PolarityTE, Inc. (Nasdaq: PTE) today announced that it will report calendar third quarter 2020 financial results by press release on Monday, November 9, 2020 at approximately 7:00 a.m. Eastern Time. I...",1.13,1.23,0.9849,1,PTE,6687117,HISTORICAL_PRICES,PTE,,1.60683E+12,0.107843137,0.107843137,1,1.13,1.23,0.984901,6687117,1,1.13,1.23,0.9849,6687117,26-Oct-20,0.1305,0.1306
26-Oct-20,AtriCure to Participate in Upcoming Investor Conferences,"AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that the company will be participat...",37.245,37.67,36.64,37.4,ATRC,347771,HISTORICAL_PRICES,ATRC,,1.60683E+12,-0.029066736,-0.029066736,37.4,37.245,37.67,36.64,347771,37.4,37.245,37.67,36.64,347771,26-Oct-20,-0.715,-0.0188
26-Oct-20,Sesen Bio Announces Successful Pre-Submission Meeting with the European Medicines Agency for Vicineum™,"Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced that it has completed a successful pr...",1.11,1.23,1.1,1.23,SESN,2037861,HISTORICAL_PRICES,SESN,,1.60683E+12,-0.097560976,-0.097560976,1.23,1.11,1.23,1.1,2037861,1.23,1.11,1.23,1.1,2037861,26-Oct-20,-0.07,-0.0593
26-Oct-20,PerkinElmer Receives CE Mark for Multi-analyte Respiratory Panel Including COVID-19,"PerkinElmer, Inc. (NYSE: PKI) announced today that its PKamp™ Respiratory SARS-CoV-2 RT-PCR Panel has received clearance to be marketed as an in vitro diagnostic (IVD) device in more than 30 countries...",124.07,124.63,122.1735,123.03,PKI,814036,HISTORICAL_PRICES,PKI,,1.6112E+12,0.051797219,0.051797219,123.03,124.07,124.63,122.1735,814036,122.9731,124.0126,124.5723,122.117,814036,26-Oct-20,-0.38,-0.0031
26-Oct-20,FDA Grants 510(k) Clearance for Abiomed’s Innovative Cardiopulmonary Support Technology,"The United States Food and Drug Administration (FDA) has granted Abiomed (NASDAQ: ABMD) a 510(k) clearance for an all-in-one, compact cardiopulmonary bypass system called the Abiomed Breethe OXY-1 Sys...",288.32,288.58,277.945,279.22,ABMD,291428,HISTORICAL_PRICES,ABMD,,1.60683E+12,0.098487446,0.098487446,279.22,288.32,288.58,277.945,291428,279.22,288.32,288.58,277.945,291428,26-Oct-20,6.9,0.0245
26-Oct-20,Moderna Announces Supply Agreement with the Ministry of Public Health to Supply Qatar with mRNA Vaccine Against COVID-19 (mRNA-1273),"Moderna, Inc., (Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced a s...",70.24,71.32,68.7,70.36,MRNA,3872799,HISTORICAL_PRICES,MRNA,,1.60683E+12,0.077796532,0.077796532,70.36,70.24,71.32,68.7,3872799,70.36,70.24,71.32,68.7,3872799,26-Oct-20,-0.29,-0.0041
23-Oct-20,"Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Continues its Investigation of First American Financial Corporation (FAF) on Behalf of Investors",Glancy Prongay & Murray LLP (“GPM”) continues its investigation on behalf of First American Financial Corporation (“First American Financial” or the “Company”) (NYSE: FAF) investors concerning the...,48.41,48.855,46.41,46.87,FAF,2169807,HISTORICAL_PRICES,FAF,,1.61491E+12,-0.028691814,-0.028691814,46.87,48.41,48.855,46.41,2169807,46.0205,47.5326,47.9696,45.5689,2169807,23-Oct-20,1.66,0.0355
23-Oct-20,Revance Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4),"Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company focused on innovative aesthetic and therapeutic offerings, including its investigational neuromodulator product, DaxibotulinumtoxinA...",25.29,26.3,23.66,24.2,RVNC,519210,HISTORICAL_PRICES,RVNC,,1.60683E+12,-0.017100661,-0.017100661,24.2,25.29,26.3,23.66,519210,24.2,25.29,26.3,23.66,519210,23-Oct-20,1.39,0.0582
23-Oct-20,PMI Announces Medicago to Supply Up to 76 Million Doses of Its Plant-Derived COVID-19 Vaccine Candidate,"Since 2008, Philip Morris Investments B.V. (PMIBV), a subsidiary of Philip Morris International (PMI) (NYSE: PM), has been a shareholder of Medicago (in which it currently holds an approximately one-t...",74.45,75.37,74.31,75.26,PM,3823431,HISTORICAL_PRICES,PM,,1.61612E+12,-0.024885396,-0.024885396,75.26,74.45,75.37,74.31,3823431,73.204,72.4161,73.311,72.2799,3823431,23-Oct-20,-0.41,-0.0055
23-Oct-20,Astrotech Announces Closing of $18.0 Million Upsized Public Offering,"Astrotech Corporation (NASDAQ: ASTC), today announced that it has closed its previously announced public offering of an aggregate of 7,826,086 shares of its common stock at a purchase price of $2.30 p...",2.41,2.6,2.26,2.3447,ASTC,2707672,HISTORICAL_PRICES,ASTC,,1.60683E+12,0.59602649,0.59602649,2.3447,2.41,2.6,2.26,2707672,2.3447,2.41,2.6,2.26,2707672,23-Oct-20,-0.06,-0.0243
23-Oct-20,The Law Offices of Frank R. Cruz Announces Investigation of Zosano Pharma Corporation (ZSAN) on Behalf of Investors,The Law Offices of Frank R. Cruz announces an investigation of Zosano Pharma Corporation (“Zosano” or the “Company”) (NASDAQ: ZSAN) on behalf of investors concerning the Company’s possible violations...,0.4341,0.44,0.4201,0.43,ZSAN,4369838,HISTORICAL_PRICES,ZSAN,,1.60683E+12,-0.721730769,-0.721730769,0.43,0.4341,0.44,0.4201,4369838,0.43,0.4341,0.44,0.4201,4369838,23-Oct-20,0.0091,0.0214
23-Oct-20,"Gilead Sciences Completes Acquisition of Immunomedics, Inc.","Gilead Sciences, Inc. (Nasdaq: GILD) today announced the completion of the previously announced transaction to acquire Immunomedics, Inc. (Nasdaq: IMMU) for approximately $21 billion in the aggregate....",60.79,63.64,60.76,63.38,GILD,30965444,HISTORICAL_PRICES,GILD,,1.61552E+12,-0.023453815,-0.023453815,63.38,60.79,63.64,60.76,30965444,61.9654,59.4332,62.2196,59.4039,30965444,23-Oct-20,0.12,0.002
23-Oct-20,"Ligand’s Captisol Technology Plays Key Role in the Manufacture of Gilead’s Veklury, the First FDA-Approved COVID-19 Treatment","Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today highlighted the company’s role in the manufacturing of Veklury® (remdesivir), Gilead Sciences’ antiviral drug for the treatment of patients wit...",85.02,88.9702,84,88.92,LGND,700343,HISTORICAL_PRICES,LGND,,1.60683E+12,-0.098600509,-0.098600509,88.92,85.02,88.9702,84,700343,88.92,85.02,88.9702,84,700343,23-Oct-20,0.28,0.0033
23-Oct-20,PhaseBio Provides Pemziviptadil (PB1046) Program Update,"PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiopulmonary diseases, today announ...",3.095,3.4,3.05,3.21,PHAS,615493,HISTORICAL_PRICES,PHAS,,1.60683E+12,-0.02672956,-0.02672956,3.21,3.095,3.4,3.05,615493,3.21,3.095,3.4,3.05,615493,23-Oct-20,-0.325,-0.095
23-Oct-20,Ocular Therapeutix™ To Report Third Quarter 2020 Financial Results,"Ocular Therapeutix™, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, tod...",10.18,10.4284,9.82,10.32,OCUL,840112,HISTORICAL_PRICES,OCUL,,1.60683E+12,0.301790281,0.301790281,10.32,10.18,10.4284,9.82,840112,10.32,10.18,10.4284,9.82,840112,23-Oct-20,-0.145,-0.014
23-Oct-20,Kezar Life Sciences Announces Orphan Drug Designations for KZR-616 for the Treatment of Polymyositis and Dermatomyositis,"Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced that the...",5.77,5.9,5.6977,5.8,KZR,104310,HISTORICAL_PRICES,KZR,,1.60683E+12,0.273730684,0.273730684,5.8,5.77,5.9,5.6977,104310,5.8,5.77,5.9,5.6977,104310,23-Oct-20,0.15,0.0267
22-Oct-20,Puma Biotechnology to Host Conference Call to Discuss Third Quarter Financial Results,"Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, will host a conference call at 1:30 p.m. PST/4:30 p.m. EST on Thursday, Nov. 5, 2020, following the release of its third quarter 2...",9.48,9.56,9.33,9.39,PBYI,524902,HISTORICAL_PRICES,PBYI,,1.60683E+12,-0.014553015,-0.014553015,9.39,9.48,9.56,9.33,524902,9.39,9.48,9.56,9.33,524902,22-Oct-20,0.12,0.0128
22-Oct-20,U.S. Food and Drug Administration Approves Gilead’s Antiviral Veklury® (remdesivir) for Treatment of COVID-19,"Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has approved the antiviral drug Veklury® (remdesivir) for the treatment of patients with COVID-19...",60.67,60.9,59.65,59.92,GILD,17061786,HISTORICAL_PRICES,GILD,,1.61552E+12,-0.025381526,-0.025381526,59.92,60.67,60.9,59.65,17061786,58.5826,59.3159,59.5407,58.3186,17061786,22-Oct-20,0.46,0.0076
22-Oct-20,"Outset Medical to Report Third Quarter 2020 Financial Results on Wednesday, November 11, 2020","Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced that it will release...",48.93,49.12,45.32,45.38,OM,116719,HISTORICAL_PRICES,OM,,1.60683E+12,-0.058676414,-0.058676414,45.38,48.93,49.12,45.32,116719,45.38,48.93,49.12,45.32,116719,22-Oct-20,3.68,0.0813
22-Oct-20,INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Zosano Pharma Corporation (ZSAN) on Behalf of Investors,Law Offices of Howard G. Smith announces an investigation on behalf of Zosano Pharma Corporation (“Zosano” or the “Company”) (NASDAQ: ZSAN) investors concerning the Company’s possible violations of fe...,0.425,0.449,0.421,0.441,ZSAN,4496829,HISTORICAL_PRICES,ZSAN,,1.60683E+12,-0.727564103,-0.727564103,0.441,0.425,0.449,0.421,4496829,0.441,0.425,0.449,0.421,4496829,22-Oct-20,-0.0191,-0.043
22-Oct-20,"RETA Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Notifies Reata Pharmaceuticals, Inc. Shareholders of Class Action and Encourages Shareholders to Contact the Firm","Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Reata Pharmaceuticals, Inc. (""Reata"" or ""the Company"") (NASDAQ: RETA) and certain of its of...",116.15,118.04,113.5,114.18,RETA,142633,HISTORICAL_PRICES,RETA,,1.60683E+12,0.130523652,0.130523652,114.18,116.15,118.04,113.5,142633,114.18,116.15,118.04,113.5,142633,22-Oct-20,1.84,0.0161
22-Oct-20,"Dicerna Presents Positive New Interim Data From PHYOX™3 Long-Term, Open-Label Extension Study of Nedosiran for Treatment of Primary Hyperoxaluria (PH)","Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced positive new interi...",19.67,20,19.1,19.17,DRNA,417639,HISTORICAL_PRICES,DRNA,,1.60683E+12,0.075451066,0.075451066,19.17,19.67,20,19.1,417639,19.17,19.67,20,19.1,417639,22-Oct-20,0.62,0.0325
22-Oct-20,Alnylam Presents Positive Results from ILLUMINATE-B Phase 3 Study in Pediatric Patients with Primary Hyperoxaluria Type 1 at the American Society of Nephrology Kidney Week,"Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today positive results from the 6-month primary analysis of the ILLUMINATE-B Phase 3 pediatric study of l...",134.3,140.66,133.7675,136.49,ALNY,481958,HISTORICAL_PRICES,ALNY,,1.60683E+12,0.00719964,0.00719964,136.49,134.3,140.66,133.7675,481958,136.49,134.3,140.66,133.7675,481958,22-Oct-20,-2.18,-0.016
22-Oct-20,Moderna Completes Enrollment of Phase 3 COVE Study of mRNA Vaccine Against COVID-19 (mRNA-1273),"Moderna, Inc., (Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced tha...",70.84,72.53,68.4,68.5035,MRNA,5212065,HISTORICAL_PRICES,MRNA,,1.60683E+12,0.087003222,0.087003222,68.5035,70.84,72.53,68.4,5212065,68.5035,70.84,72.53,68.4,5212065,22-Oct-20,2.47,0.0361
22-Oct-20,Omeros Reports Final Efficacy and Safety Data from the Narsoplimab Pivotal Trial in HSCT-TMA,"Omeros Corporation (Nasdaq: OMER) today announced final data from its pivotal trial for narsoplimab in hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA), an often-let...",11.05,11.52,10.67,11.07,OMER,890979,HISTORICAL_PRICES,OMER,,1.60683E+12,0.124109868,0.124109868,11.07,11.05,11.52,10.67,890979,11.07,11.05,11.52,10.67,890979,22-Oct-20,-0.1,-0.009
22-Oct-20,"Seres Therapeutics Expands Executive Team with Appointments of David S. Ege, Ph.D., as Chief Technology Officer and Jayne M. Gansler as Chief People Officer","Seres Therapeutics, Inc. (Nasdaq: MCRB) today announced the expansion of its leadership team with the appointments of David S. Ege, Ph.D., as Executive Vice President, Chief Technology Officer (CTO) a...",28.45,29.25,27.34,28.08,MCRB,328198,HISTORICAL_PRICES,MCRB,,1.60683E+12,0.126732673,0.126732673,28.08,28.45,29.25,27.34,328198,28.08,28.45,29.25,27.34,328198,22-Oct-20,0.25,0.0089
22-Oct-20,Concert Pharmaceuticals Announces Publication on Alopecia Areata Burden of Disease in Journal of Investigative Dermatology,"Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that the Journal of Investigative Dermatology published results from a survey designed to understand the burden and everyday experience for...",12.08,12.3382,11.32,11.42,CNCE,384293,HISTORICAL_PRICES,CNCE,,1.60683E+12,0.305945946,0.305945946,11.42,12.08,12.3382,11.32,384293,11.42,12.08,12.3382,11.32,384293,22-Oct-20,0.67,0.0587
21-Oct-20,"ImmunityBio, NantKwest Announce First Patient Dosed in Phase 1 Clinical Trial of Second-Generation COVID-19 Vaccine Candidate Delivering Both Spike and Nucleocapsid of SARS-CoV-2","ImmunityBio, a privately-held immunotherapy company, and NantKwest, Inc. (NASDAQ: NK), a clinical-stage, natural killer cell-based therapeutics company, today announced that the first patient has been...",7.61,8.62,7.58,8.27,NK,1011221,HISTORICAL_PRICES,NK,,1.60683E+12,0.110948905,0.110948905,8.27,7.61,8.62,7.58,1011221,8.27,7.61,8.62,7.58,1011221,21-Oct-20,-0.84,-0.0994
21-Oct-20,Astrotech Announces Pricing of $18.0 Million Upsized Public Offering,"Astrotech Corporation (Nasdaq: ASTC), today announced the pricing of a public offering of an aggregate of 7,826,086 shares of common stock, at a purchase price of $2.30 per share of common stock. The...",2.68,6.14,2.13,4.88,ASTC,126368141,HISTORICAL_PRICES,ASTC,,1.60683E+12,0.774834437,0.774834437,4.88,2.68,6.14,2.13,126368141,4.88,2.68,6.14,2.13,126368141,21-Oct-20,0.99,0.5858
21-Oct-20,Data From Pfizer’s Adult and Pediatric Clinical Trial Programs for 20-Valent Pneumococcal Conjugate Vaccine Presented at IDWeek 2020,"Pfizer Inc. (NYSE:PFE) today announced the full analysis from one of its Phase 3 studies (NCT03760146), which evaluated the safety and immunogenicity of its 20-valent pneumococcal conjugate vaccine (2...",37.08,37.45,37.06,37.355,PFE,18012247,HISTORICAL_PRICES,PFE,,1.6118E+12,0.036912752,0.036912752,37.355,37.08,37.45,37.06,18012247,36.5768,36.3076,36.6699,36.288,18012247,21-Oct-20,-0.41,-0.0109
21-Oct-20,FSD Pharma Inc. Announces Closing of US$9.5 Million Registered Direct Offering,"FSD Pharma Inc. (Nasdaq: HUGE) (“FSD Pharma” or the “Company”), today announced the closing of previously announced definitive agreements with investors for the purchase and sale of 4,318,179 Class B...",1.94,2.01,1.9,2.01,HUGE,159681,HISTORICAL_PRICES,HUGE,,1.60988E+12,-0.263757116,-0.263757116,2.01,1.94,2.01,1.9,159681,2.01,1.94,2.01,1.9,159681,21-Oct-20,0,0
21-Oct-20,Gilead Announces New Data on Biktarvy® for the Treatment of HIV in Black Americans,"Gilead Sciences, Inc. (Nasdaq: GILD) today announced 48-week data from the BRAAVE 2020 study, a Phase 3 clinical trial evaluating the safety and efficacy of switching to Biktarvy® (bictegravir 50 mg/e...",60.21,60.495,59.9,60.237,GILD,7493735,HISTORICAL_PRICES,GILD,,1.61552E+12,-0.032771084,-0.032771084,60.237,60.21,60.495,59.9,7493735,58.8925,58.8661,59.1448,58.5631,7493735,21-Oct-20,-0.34,-0.0056
20-Oct-20,Xeris Pharmaceuticals Granted Fast Track Designation by the FDA for Its Novel Concentrated Diazepam Formulation (XP-0863) For Injection,"Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable and infusible drug formula...",5.25,5.72,5.21,5.56,XERS,1714996,HISTORICAL_PRICES,XERS,,1.60683E+12,-0.060822898,-0.060822898,5.56,5.25,5.72,5.21,1714996,5.56,5.25,5.72,5.21,1714996,20-Oct-20,-0.27,-0.0489
20-Oct-20,Astrotech Subsidiary and Cleveland Clinic Partner to Develop a Rapid COVID-19 Breath Test,"Astrotech Corporation’s (NASDAQ: ASTC) subsidiary, BreathTech Corporation announced today that it has signed a joint development agreement (JDA) with Cleveland Clinic to explore leveraging Astrotech’s...",1.69,1.69,1.621,1.65,ASTC,10604006,HISTORICAL_PRICES,ASTC,,1.60683E+12,0.119205298,0.119205298,1.65,1.69,1.69,1.621,10604006,1.65,1.69,1.69,1.621,10604006,20-Oct-20,0.02,0.012
20-Oct-20,The Law Offices of Frank R. Cruz Continues Its Investigation of Eli Lilly and Company (LLY) on Behalf of Investors,The Law Offices of Frank R. Cruz continues its investigation of Eli Lilly and Company (“Eli Lilly” or the “Company”) (NYSE: LLY) on behalf of investors concerning the Company’s possible violations of...,143.59,144.12,142.11,143.36,LLY,2188844,HISTORICAL_PRICES,LLY,,1.61302E+12,-0.035078288,-0.035078288,143.36,143.59,144.12,142.11,2188844,142.034,142.2619,142.787,140.7956,2188844,20-Oct-20,0.79,0.0055
20-Oct-20,INVESTOR ALERT: Law Offices of Howard G. Smith Continues Investigation of Eli Lilly and Company (LLY) on Behalf of Investors,Law Offices of Howard G. Smith continues its investigation on behalf of Eli Lilly and Company (“Eli Lilly” or the “Company”) (NYSE: LLY) investors concerning the Company’s possible violations of feder...,143.59,144.12,142.11,143.36,LLY,2188844,HISTORICAL_PRICES,LLY,,1.61302E+12,-0.035078288,-0.035078288,143.36,143.59,144.12,142.11,2188844,142.034,142.2619,142.787,140.7956,2188844,20-Oct-20,0.79,0.0055
20-Oct-20,"Masimo to Report Third Quarter 2020 Financial Results after Market Close on Tuesday, October 27","Masimo (NASDAQ: MASI) will release third quarter 2020 financial results for the period ended September 26, 2020, after the market closes on Tuesday, October 27, 2020. The conference call to review the...",236.33,240.1,235.28,235.74,MASI,217600,HISTORICAL_PRICES,MASI,,1.60683E+12,0.084331269,0.084331269,235.74,236.33,240.1,235.28,217600,235.74,236.33,240.1,235.28,217600,20-Oct-20,0.59,0.0025
20-Oct-20,TFF Pharmaceuticals Updates Progress of Human Clinical Trial with Tacrolimus Inhalation Powder,"TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) t...",14.45,15.54,14.2496,15.155,TFFP,315844,HISTORICAL_PRICES,TFFP,,1.60683E+12,-0.108024691,-0.108024691,15.155,14.45,15.54,14.2496,315844,15.155,14.45,15.54,14.2496,315844,20-Oct-20,-0.57,-0.0379
20-Oct-20,Horizon Therapeutics plc Announces TEPEZZA® (teprotumumab-trbw) Selected as a Winner of the Chicago Innovation Award,Horizon Therapeutics plc (Nasdaq: HZNP) today announced that TEPEZZA® (teprotumumab-trbw) has been selected as a winner of the 19th Annual Chicago Innovation Award. TEPEZZA is the first and only medic...,74.31,79,73.33,78.47,HZNP,4245974,HISTORICAL_PRICES,HZNP,,1.60683E+12,-0.013540422,-0.013540422,78.47,74.31,79,73.33,4245974,78.47,74.31,79,73.33,4245974,20-Oct-20,-4.15,-0.0529
19-Oct-20,"Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Continues Investigation of Eli Lilly and Company (LLY) on Behalf of Investors","Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, continues its investigation on behalf of Eli Lilly and Company (“Eli Lilly” or the “Company”) (NYSE: LLY) inves...",142.8,147.4088,142.21,147,LLY,3158872,HISTORICAL_PRICES,LLY,,1.61302E+12,-0.040387071,-0.040387071,147,142.8,147.4088,142.21,3158872,145.6403,141.4792,146.0454,140.8946,3158872,19-Oct-20,-3.32,-0.0227
19-Oct-20,"ROSEN, A TOP RANKED LAW FIRM, Announces Filing of Securities Class Action Lawsuit Against Reata Pharmaceuticals, Inc.; Encourages Investors with Losses in Excess of $100K to Contact Firm – RETA","Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Reata Pharmaceuticals, Inc. (NASDAQ: RETA) between Octobe...",113.07,116.88,112.03,112.98,RETA,165026,HISTORICAL_PRICES,RETA,,1.60683E+12,0.100545065,0.100545065,112.98,113.07,116.88,112.03,165026,112.98,113.07,116.88,112.03,165026,19-Oct-20,0.29,0.0026
19-Oct-20,"Aptinyx Reports Positive, Statistically Significant, Top-line Data From Phase 2 Study of NYX-783 in Patients With Post-Traumatic Stress Disorder","Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced positive results fr...",3.66,3.79,3.64,3.72,APTX,3810068,HISTORICAL_PRICES,APTX,,1.60683E+12,0.176848875,0.176848875,3.72,3.66,3.79,3.64,3810068,3.72,3.66,3.79,3.64,3810068,19-Oct-20,-0.07,-0.0188
19-Oct-20,Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4),"Kala Pharmaceuticals, Inc. (NASDAQ:KALA), today announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company’s 2017 Equity Incentive Plan in...",8.13,8.4657,8.05,8.16,KALA,1138835,HISTORICAL_PRICES,KALA,,1.60683E+12,0.079681275,0.079681275,8.16,8.13,8.4657,8.05,1138835,8.16,8.13,8.4657,8.05,1138835,19-Oct-20,0.09,0.0112
19-Oct-20,"SHAREHOLDER ACTION REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Reata Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm","The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Reata Pharmaceuticals, Inc. (“Reata” or “the Company”) (NASDAQ: RETA) for vio...",113.07,116.88,112.03,112.98,RETA,165026,HISTORICAL_PRICES,RETA,,1.60683E+12,0.100545065,0.100545065,112.98,113.07,116.88,112.03,165026,112.98,113.07,116.88,112.03,165026,19-Oct-20,0.29,0.0026
19-Oct-20,"Cerus Corporation to Release Third Quarter 2020 Financial Results on October 29, 2020","Cerus Corporation (Nasdaq:CERS) announced today that its third quarter 2020 financial results will be released on Thursday, October 29, 2020, after the close of the stock market. The Company will host...",6.44,6.75,6.43,6.44,CERS,1015725,HISTORICAL_PRICES,CERS,,1.60683E+12,0.091525424,0.091525424,6.44,6.44,6.75,6.43,1015725,6.44,6.44,6.75,6.43,1015725,19-Oct-20,0.01,0.0016
19-Oct-20,Gilead Presents New Data from Antiviral Development Programs at IDWeek 2020,"Gilead Sciences, Inc. (Nasdaq: GILD) today announced the presentation of 18 abstracts spanning the company’s HIV treatment and prevention and COVID-19 clinical development programs during the virtual...",60.57,62.1,60.205,62,GILD,9643598,HISTORICAL_PRICES,GILD,,1.61552E+12,-0.026987952,-0.026987952,62,60.57,62.1,60.205,9643598,60.6162,59.2181,60.714,58.8613,9643598,19-Oct-20,-1.43,-0.0231
19-Oct-20,Sesen Bio Announces an Exclusive Agreement With Cardinal Health for Third-Party Logistics and Specialty Pharmaceutical Distribution Services for Vicineum™,"Sesen Bio (Nasdaq:SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced that the Company has selected Cardinal...",1.12,1.17,1.1,1.12,SESN,1660635,HISTORICAL_PRICES,SESN,,1.60683E+12,-0.089430894,-0.089430894,1.12,1.12,1.17,1.1,1660635,1.12,1.12,1.17,1.1,1660635,19-Oct-20,-0.01,-0.0088
19-Oct-20,"Dr. Augusto Sola, Masimo VP of Medical Affairs for Neonatology, Honored by the American Academy of Pediatrics with Pioneer Award","Masimo (NASDAQ: MASI) announced today that Augusto Sola, MD, Vice President of Medical Affairs for Neonatology at Masimo, has been awarded the 2020 Pioneer Award, Section of Neonatal Perinatal Medicin...",235.74,242.1071,234.0601,238,MASI,163462,HISTORICAL_PRICES,MASI,,1.60683E+12,0.081624226,0.081624226,238,235.74,242.1071,234.0601,163462,238,235.74,242.1071,234.0601,163462,19-Oct-20,-1.56,-0.0066
19-Oct-20,AVEO Oncology Announces Appointment of David W. Crist as Vice President of Sales,"AVEO Oncology (Nasdaq: AVEO) today announced the appointment of David Crist as Vice President of Sales. In this role, Mr. Crist will be responsible for building out AVEO’s sales force in anticipation...",5.89,6.16,5.84,6.14,AVEO,242832,HISTORICAL_PRICES,AVEO,,1.60683E+12,0.042477876,0.042477876,6.14,5.89,6.16,5.84,242832,6.14,5.89,6.16,5.84,242832,19-Oct-20,-0.22,-0.036
19-Oct-20,SG Blocks and OSANG Healthcare Announce Managed Supply Agreement and Purchase Order to Distribute COVID-19 Rapid Test,"SG Blocks, Inc. (Nasdaq: SGBX) (""SG Blocks"" or the ""Company""), a leader in modular container-based structures and innovator in portable, clinical-grade laboratories for high-capacity testing, and OSAN...",2.57,2.84,2.4552,2.77,SGBX,3021916,HISTORICAL_PRICES,SGBX,,1.60683E+12,0.690789474,0.690789474,2.77,2.57,2.84,2.4552,3021916,2.77,2.57,2.84,2.4552,3021916,19-Oct-20,-0.16,-0.0586
19-Oct-20,U.S. Food and Drug Administration Accepts for Priority Review Applications for OPDIVO® (nivolumab) in Combination with CABOMETYX® (cabozantinib) in Advanced Renal Cell Carcinoma,"Bristol Myers Squibb (NYSE: BMY) and Exelixis, Inc. (NASDAQ: EXEL) today announced that the U.S. Food and Drug Administration (FDA) has accepted the supplemental Biologics License Application (sBLA) a...",60.77,62.42,60.5051,61.8,BMY,10999136,HISTORICAL_PRICES,BMY,,1.60946E+12,0.043261803,0.043261803,61.8,60.77,62.42,60.5051,10999136,61.3109,60.2891,61.926,60.0263,10999136,19-Oct-20,-0.47,-0.0077
19-Oct-20,LabCorp Launches Quantitative Antibody Test to Assess Effectiveness of COVID-19 Vaccines in Clinical Trials,"LabCorp (NYSE: LH), a leading global life sciences company that is focused on advancing health and guiding patient care, today announced a test that provides a quantitative measurement of an individua...",199.91,201.28,198.4,198.87,LH,613296,HISTORICAL_PRICES,LH,,1.60683E+12,0.12403711,0.12403711,198.87,199.91,201.28,198.4,613296,198.87,199.91,201.28,198.4,613296,19-Oct-20,0.82,0.0041
16-Oct-20,Samenvatting: Grootste studie van hemodynamisch ondersteunde hoog-risico PCI-patiënten vindt meer complete revascularisatie met Impella leidt tot betere resultaten,"Abiomed (NASDAQ: ABMD) kondigt nieuwe PROTECT III-studiegegevens aan die lagere percentages MACCE (samenstelling van overlijden, beroerte, myocardinfarct en herhaalde procedures) aantonen wanneer Impe...",286.48,289.31,279.97,283.58,ABMD,262600,HISTORICAL_PRICES,ABMD,,1.60683E+12,0.091477121,0.091477121,283.58,286.48,289.31,279.97,262600,283.58,286.48,289.31,279.97,262600,16-Oct-20,2.91,0.0103
16-Oct-20,Resumen: El mayor estudio de pacientes con ICP de alto riesgo con apoyo hemodinámico muestra que una revascularización más completa con Impella produce mejores resultados,"Abiomed (NASDAQ: ABMD) ha anunciado nuevos datos del estudio PROTECT III que demuestran tasas reducidas de MACCE (resultado compuesto de deceso, ictus, infarto de miocardio y repetición de procedimien...",286.48,289.31,279.97,283.58,ABMD,262600,HISTORICAL_PRICES,ABMD,,1.60683E+12,0.091477121,0.091477121,283.58,286.48,289.31,279.97,262600,283.58,286.48,289.31,279.97,262600,16-Oct-20,2.91,0.0103
16-Oct-20,Merck Presents Three-Year Survival Data for KEYTRUDA® (pembrolizumab) in Combination With Chemotherapy and Updated Phase 1/2 Data for Investigational Quavonlimab (MK-1308) in Combination With KEYTRUDA in Advanced Non‑Small Cell Lung Cancer,"Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced positive results from two studies from the company’s leading lung cancer clinical development program evaluating K...",79.83,80.3,79.11,79.3,MRK,7541600,HISTORICAL_PRICES,MRK,,1.61552E+12,-0.039927841,-0.039927841,79.3,79.83,80.3,79.11,7541600,77.9934,78.5147,78.9769,77.8065,7541600,16-Oct-20,0.77,0.0097
16-Oct-20,"SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Reata Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm","The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Reata Pharmaceuticals, Inc. (“Reata” or “the Company”) (NASDAQ: RETA) for vio...",112.78,114.69,107.74,109.93,RETA,160312,HISTORICAL_PRICES,RETA,,1.60683E+12,0.097722406,0.097722406,109.93,112.78,114.69,107.74,160312,109.93,112.78,114.69,107.74,160312,16-Oct-20,3.87,0.0355
16-Oct-20,Omeros’ OMS906 Data Presented at Complement-based Drug Development Summit,Omeros Corporation (Nasdaq: OMER) presented data from its OMS906 program yesterday at the 4th Complement-based Drug Development Summit. OMS906 is the company’s lead human monoclonal antibody targeting...,11.52,11.81,11.29,11.39,OMER,505165,HISTORICAL_PRICES,OMER,,1.60683E+12,0.171922686,0.171922686,11.39,11.52,11.81,11.29,505165,11.39,11.52,11.81,11.29,505165,16-Oct-20,0.06,0.0052
16-Oct-20,"Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Opdivo (nivolumab) as Second-Line Treatment for Unresectable Advanced, Recurrent or Metastatic Esophageal Squamous Cell Carcinoma",Bristol Myers Squibb (NYSE:BMY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended approval of Opdivo (nivolumab) for...,61.24,61.74,60.65,60.67,BMY,9385613,HISTORICAL_PRICES,BMY,,1.60946E+12,0.051330472,0.051330472,60.67,61.24,61.74,60.65,9385613,60.1899,60.7554,61.2514,60.1701,9385613,16-Oct-20,0.82,0.0136
16-Oct-20,FSD Pharma Inc. Announces US$9.5 Million Registered Direct Offering,"FSD Pharma Inc. (Nasdaq: HUGE) (“FSD Pharma” or the “Company”), today announced that it has entered into definitive agreements with investors for the purchase and sale of 4,318,179 Class B Subordinate...",2.14,2.24,2.06,2.2,HUGE,555267,HISTORICAL_PRICES,HUGE,,1.60988E+12,-0.187855787,-0.187855787,2.2,2.14,2.24,2.06,555267,2.2,2.14,2.24,2.06,555267,16-Oct-20,-0.42,-0.1641
16-Oct-20,Größte Studie zu hämodynamisch unterstützten Hochrisiko-PCI-Patienten zeigt: Vollständigere Revaskularisierung mit Impella führt zu besseren Ergebnissen,"Abiomed (NASDAQ: ABMD) meldet neue Daten aus der Studie PROTECT III. Diese zeigen geringere MACCE-Raten (MACCE = Major Adverse Cerebrovascular and Cardiovascular Event), d. h. Schlaganfall, Tod, Myoka...",286.48,289.31,279.97,283.58,ABMD,262600,HISTORICAL_PRICES,ABMD,,1.60683E+12,0.091477121,0.091477121,283.58,286.48,289.31,279.97,262600,283.58,286.48,289.31,279.97,262600,16-Oct-20,2.91,0.0103
16-Oct-20,Alnylam Receives Positive CHMP Opinion for OXLUMO™ (lumasiran) for the Treatment of Primary Hyperoxaluria Type 1 in All Age Groups,"Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EM...",145.4,148.07,144.12,144.12,ALNY,338564,HISTORICAL_PRICES,ALNY,,1.60683E+12,0.090445478,0.090445478,144.12,145.4,148.07,144.12,338564,144.12,145.4,148.07,144.12,338564,16-Oct-20,1.46,0.0101
15-Oct-20,"Selon la plus grande étude réalisée auprès des patients recevant une ICP à risque élevé sous assistance hémodynamique, une revascularisation plus complète avec Impella conduit à l'amélioration des résultats","Abiomed (NASDAQ: ABMD) annonce que les nouvelles données de l'étude PROTECT III montrent une réduction du taux MACCE (décès, AVC, infarctus du myocarde et procédures de répétition) lorsqu'Impella est...",283.57,285.92,270.03,275.09,ABMD,263968,HISTORICAL_PRICES,ABMD,,1.60683E+12,0.08039014,0.08039014,275.09,283.57,285.92,270.03,263968,275.09,283.57,285.92,270.03,263968,15-Oct-20,2.73,0.0097
15-Oct-20,Riassunto: Il più grande studio sui pazienti PCI ad alto rischio con supporto emodinamico mostra che una rivascolarizzazione più completa con Impella porta a esiti migliori,Abiomed (NASDAQ: ABMD) annuncia nuovi dati dello studio PROTECT III che dimostrano percentuali ridotte di incidenza cumulativa di eventi cardiaci avversi maggiori ed eventi cerebrali (MACCE) quando Im...,283.57,285.92,270.03,275.09,ABMD,263968,HISTORICAL_PRICES,ABMD,,1.60683E+12,0.08039014,0.08039014,275.09,283.57,285.92,270.03,263968,275.09,283.57,285.92,270.03,263968,15-Oct-20,2.73,0.0097
15-Oct-20,"Glancy Prongay & Murray LLP, a National Class Action Law Firm, Announces Investigation of Vasta Platform, Ltd. (VSTA) on Behalf of Investors","Glancy Prongay & Murray LLP (“GPM”), a national investor rights law firm, announces it has commenced an investigation on behalf of Vasta Platform, Ltd. (""Vasta"" or the ""Company”) (NASDAQ: VSTA) in...",13.85,13.94,13.04,13.51,VSTA,68737,HISTORICAL_PRICES,VSTA,,1.60683E+12,-0.098307292,-0.098307292,13.51,13.85,13.94,13.04,68737,13.51,13.85,13.94,13.04,68737,15-Oct-20,0.32,0.0237
15-Oct-20,"INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Eli Lilly and Company and Encourages Investors with Losses of $100,000 to Contact the Firm","The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Eli Lilly and Company (“Eli Lilly” or “the Company”) (NYSE: LLY)...",146.78,146.91,145.38,146.51,LLY,3785950,HISTORICAL_PRICES,LLY,,1.61302E+12,-0.013641556,-0.013641556,146.51,146.78,146.91,145.38,3785950,145.1549,145.4224,145.5512,144.0353,3785950,15-Oct-20,-1.68,-0.0113
15-Oct-20,Notice of Lead Plaintiff Deadline for Shareholders in the Mesoblast Limited Class Action Lawsuit,Robbins Geller Rudman & Dowd LLP announces that a class action lawsuit has been filed in the Southern District of New York on behalf of purchasers or acquirers of Mesoblast Limited (NASDAQ:MESO) s...,11.27,11.5972,11.165,11.53,MESO,488142,HISTORICAL_PRICES,MESO,,1.60683E+12,-0.344004657,-0.344004657,11.53,11.27,11.5972,11.165,488142,11.53,11.27,11.5972,11.165,488142,15-Oct-20,-0.59,-0.0497
15-Oct-20,"Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Continues Investigation of Homology Medicines, Inc. (FIXX) on Behalf of Investors","Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, continues its investigation on behalf of Homology Medicines, Inc. (“Homology” or the “Company”) (NASDAQ: FIXX)...",10.76,10.77,10.3,10.48,FIXX,250262,HISTORICAL_PRICES,FIXX,,1.60683E+12,-0.003703704,-0.003703704,10.48,10.76,10.77,10.3,250262,10.48,10.76,10.77,10.3,250262,15-Oct-20,0.04,0.0037
15-Oct-20,Mirum Pharmaceuticals Announces Partnership With EVERSANA to Support Launch and Commercialization of Maralixibat for Alagille Syndrome in the United States,"Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a biopharmaceutical company focused on the development and commercialization of novel therapies for debilitating liver diseases, today announced it has part...",20.44,20.75,19.71,20.25,MIRM,92084,HISTORICAL_PRICES,MIRM,,1.60683E+12,0.078627968,0.078627968,20.25,20.44,20.75,19.71,92084,20.25,20.44,20.75,19.71,92084,15-Oct-20,0.66,0.0334
15-Oct-20,Tenax Therapeutics Gains North American Rights to Oral Levosimendan through Expanded License Agreement with Orion Corporation,"Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceutical company focused on identifying, developing, and commercializing products for the critical care market, today announced that it has e...",1.34,1.43,1.22,1.43,TENX,650141,HISTORICAL_PRICES,TENX,,1.60683E+12,-0.135483871,-0.135483871,1.43,1.34,1.43,1.22,650141,1.43,1.34,1.43,1.22,650141,15-Oct-20,0.1,0.0806
15-Oct-20,Largest Study of Hemodynamically Supported High-Risk PCI Patients Finds More Complete Revascularization with Impella Leads to Improved Outcomes,"Abiomed (NASDAQ: ABMD) announces new PROTECT III study data that demonstrates reduced rates of MACCE (composite of death, stroke, myocardial infarction and repeat procedures) when Impella is used to a...",283.57,285.92,270.03,275.09,ABMD,263968,HISTORICAL_PRICES,ABMD,,1.60683E+12,0.08039014,0.08039014,275.09,283.57,285.92,270.03,263968,275.09,283.57,285.92,270.03,263968,15-Oct-20,2.73,0.0097
15-Oct-20,Omeros Schedules Webcast to Present Final Efficacy Results from Narsoplimab BLA for the Treatment of HSCT-TMA,Omeros Corporation (Nasdaq: OMER) today announced that the final results of its pivotal trial of narsoplimab in the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopath...,11.46,11.55,10.9,10.93,OMER,604164,HISTORICAL_PRICES,OMER,,1.60683E+12,0.165818922,0.165818922,10.93,11.46,11.55,10.9,604164,10.93,11.46,11.55,10.9,604164,15-Oct-20,0.7,0.0651
15-Oct-20,FDA Approves Expanded Indication for Merck’s KEYTRUDA® (pembrolizumab) in Adult Patients With Relapsed or Refractory Classical Hodgkin Lymphoma (cHL),"Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved an expanded label for KEYTRUDA, Merck’s anti-PD-1 the...",79.06,79.9379,78.78,79.8,MRK,8734836,HISTORICAL_PRICES,MRK,,1.61552E+12,-0.049188214,-0.049188214,79.8,79.06,79.9379,78.78,8734836,78.4852,77.7574,78.6208,77.482,8734836,15-Oct-20,-1.45,-0.018
15-Oct-20,"Sage Therapeutics Announces Positive Interim, Topline Zuranolone Safety and Tolerability Data from Open-Label SHORELINE Study in Patients with MDD","Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating brain disorders, today...",66.39,66.91,62,62.77,SAGE,1123898,HISTORICAL_PRICES,SAGE,,1.60683E+12,0.127164686,0.127164686,62.77,66.39,66.91,62,1123898,62.77,66.39,66.91,62,1123898,15-Oct-20,2.5,0.0391
14-Oct-20,研究人員使用Masimo ORi™（氧儲備指數）來預測阻塞性睡眠呼吸中止病童術後是否需要氧氣治療,(美國商業資訊)-- Masimo (NASDAQ: MASI)今天發布最近在美國麻醉師學會(ASA)年會ANESTHESIOLOGY® 2020上呈報的一篇摘要的結果。這項獨立、回顧性研究調查Masimo ORi™（氧儲備指數）能否預測阻塞性睡眠呼吸中止症(OSAS)病童扁桃體切除術後是否需要氧氣治療。 美國以外已上市的ORi是一種無創連續的參數，旨在深入瞭解中度高氧期間患者的氧氣狀況。透過多波...,231.89,235,229.633,234.04,MASI,286229,HISTORICAL_PRICES,MASI,,1.60683E+12,0.063959624,0.063959624,234.04,231.89,235,229.633,286229,234.04,231.89,235,229.633,286229,14-Oct-20,-0.87,-0.0037
14-Oct-20,研究人员使用Masimo ORi™（氧储备指数）来预测阻塞性睡眠呼吸暂停患儿术后是否需要氧疗,(美国商业资讯)-- Masimo (NASDAQ: MASI)今天发布最近在美国麻醉师学会(ASA)年会ANESTHESIOLOGY® 2020上呈报的一篇摘要的结果。这项独立、回顾性研究调查Masimo ORi™（氧储备指数）能否预测阻塞性睡眠呼吸暂停综合征(OSAS)患儿扁桃体切除术后是否需要氧疗。 美国以外已上市的ORi是一种无创连续的参数，旨在深入了解中度高氧期间患者的氧气状况。通过多波...,231.89,235,229.633,234.04,MASI,286229,HISTORICAL_PRICES,MASI,,1.60683E+12,0.063959624,0.063959624,234.04,231.89,235,229.633,286229,234.04,231.89,235,229.633,286229,14-Oct-20,-0.87,-0.0037
14-Oct-20,"INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Eli Lilly and Company and Encourages Investors with Losses of $100,000 to Contact the Firm","The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Eli Lilly and Company (“Eli Lilly” or “the Company”) (NYSE: LLY)...",148.46,150.6,147.71,150.38,LLY,2710585,HISTORICAL_PRICES,LLY,,1.61302E+12,-0.002351992,-0.002351992,150.38,148.46,150.6,147.71,2710585,148.9891,147.0868,149.207,146.3438,2710585,14-Oct-20,-1.62,-0.0108
14-Oct-20,The Law Offices of Frank R. Cruz Announces Investigation of Eli Lilly and Company (LLY) on Behalf of Investors,The Law Offices of Frank R. Cruz announces an investigation of Eli Lilly and Company (“Eli Lilly” or the “Company”) (NYSE: LLY) on behalf of investors concerning the Company’s possible violations of f...,148.46,150.6,147.71,150.38,LLY,2710585,HISTORICAL_PRICES,LLY,,1.61302E+12,-0.002351992,-0.002351992,150.38,148.46,150.6,147.71,2710585,148.9891,147.0868,149.207,146.3438,2710585,14-Oct-20,-1.62,-0.0108
14-Oct-20,Transcat Announces Second Quarter Fiscal Year 2021 Conference Call and Webcast,"Transcat, Inc. (Nasdaq: TRNS) (“Transcat” or the “Company”), a leading provider of accredited calibration, repair, inspection and laboratory instrument services and value-added distributor of professi...",28.1,28.6,28.0098,28.255,TRNS,33963,HISTORICAL_PRICES,TRNS,,1.60683E+12,-0.040628201,-0.040628201,28.255,28.1,28.6,28.0098,33963,28.255,28.1,28.6,28.0098,33963,14-Oct-20,-0.22,-0.0078
14-Oct-20,Ra Medical Systems Announces 10 Subjects Have Been Enrolled in its DABRA Pivotal Atherectomy Clinical Trial,"Ra Medical Systems, Inc. (NYSE: RMED), a medical device company focused on commercializing excimer laser systems to treat vascular and dermatological diseases, announces enrollment of the 10th subject...",6.475,6.8542,6.375,6.75,RMED,155613.56,HISTORICAL_PRICES,RMED,,1.60683E+12,0.107784431,0.107784431,0.27,0.259,0.274166,0.255,3890339,6.75,6.475,6.8542,6.375,155613.56,14-Oct-20,-0.2625,-0.039
14-Oct-20,INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Eli Lilly and Company (LLY) on Behalf of Investors,Law Offices of Howard G. Smith announces an investigation on behalf of Eli Lilly and Company (“Eli Lilly” or the “Company”) (NYSE: LLY) investors concerning the Company’s possible violations of federa...,148.46,150.6,147.71,150.38,LLY,2710585,HISTORICAL_PRICES,LLY,,1.61302E+12,-0.002351992,-0.002351992,150.38,148.46,150.6,147.71,2710585,148.9891,147.0868,149.207,146.3438,2710585,14-Oct-20,-1.62,-0.0108
14-Oct-20,Gilead Sciences Announces Expiration of Hart-Scott-Rodino Waiting Period for Immunomedics Tender Offer,"Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the required waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR Act) with respect to Gilead’s cash tender offe...",64.05,64.59,63.44,64.41,GILD,7143744,HISTORICAL_PRICES,GILD,,1.61552E+12,0.028915663,0.028915663,64.41,64.05,64.59,63.44,7143744,62.9724,62.6204,63.1484,62.0241,7143744,14-Oct-20,-0.44,-0.0068
14-Oct-20,Moderna Receives Confirmation of Eligibility for Submission of Marketing Authorization Application to the European Medicines Agency for mRNA Vaccine Against COVID-19 (mRNA-1273),"Moderna, Inc., (Nasdaq:MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced that...",76.56,80.01,76.3252,80.01,MRNA,6643833,HISTORICAL_PRICES,MRNA,,1.60683E+12,0.174773669,0.174773669,80.01,76.56,80.01,76.3252,6643833,80.01,76.56,80.01,76.3252,6643833,14-Oct-20,-1.73,-0.0221
14-Oct-20,Baxter Supports New Study Showing Nutritional Needs in Critically Ill COVID-19 Patients and Published Practical Guidelines for Care,"Baxter International Inc. (NYSE:BAX), a global leader in nutrition therapy, supports interim findings of an ongoing prospective study, “Persistent Hypermetabolism and Longitudinal Energy Expenditure i...",80.04,81.34,80,80.32,BAX,1658828,HISTORICAL_PRICES,BAX,,1.61422E+12,0.017026684,0.017026684,80.32,80.04,81.34,80,1658828,79.8124,79.5342,80.826,79.4944,1658828,14-Oct-20,-0.06,-0.0007
14-Oct-20,TEPEZZA® (teprotumumab-trbw) Data from the Phase 2 Clinical Trial Evaluate Longer-Term Responses in People Living with Thyroid Eye Disease (TED),"Horizon Therapeutics plc (Nasdaq: HZNP) today announced new long-term follow-up data from the Phase 2 clinical trial of TEPEZZA® (teprotumumab-trbw), which showed a sustained response up to one year f...",80.31,81.02,78.395,80.35,HZNP,1459999,HISTORICAL_PRICES,HZNP,,1.60683E+12,0.06610912,0.06610912,80.35,80.31,81.02,78.395,1459999,80.35,80.31,81.02,78.395,1459999,14-Oct-20,0.2,0.0025
14-Oct-20,Large Study Demonstrates Exceptional Safety and High Procedural Success With Cardiovascular Systems’ Diamondback 360® Coronary Orbital Atherectomy System (OAS),"Cardiovascular Systems, Inc. (CSI®) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery...",36.77,38.72,36.69,37.38,CSII,139981,HISTORICAL_PRICES,CSII,,1.60683E+12,0.031127314,0.031127314,37.38,36.77,38.72,36.69,139981,37.38,36.77,38.72,36.69,139981,14-Oct-20,-0.49,-0.0132
14-Oct-20,Revance Reports Positive Results from ASPEN-1 Phase 3 Trial of DaxibotulinumtoxinA for Injection in Cervical Dystonia,"Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company focused on innovative aesthetic and therapeutic offerings, today announced positive topline results from its ASPEN-1 Phase 3 randomiz...",25.5,28.195,25.27,27.72,RVNC,1337607,HISTORICAL_PRICES,RVNC,,1.60683E+12,-0.008938982,-0.008938982,27.72,25.5,28.195,25.27,1337607,27.72,25.5,28.195,25.27,1337607,14-Oct-20,-2.12,-0.0768
14-Oct-20,Taysha Gene Therapies Receives Rare Pediatric Disease Designation and Orphan Drug Designation for TSHA-102 as a Treatment for Rett Syndrome,"Taysha Gene Therapies Inc. (Nasdaq: TSHA), a patient-centric gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the cent...",21.38,22.0325,21.04,21.04,TSHA,110724,HISTORICAL_PRICES,TSHA,,1.60683E+12,-0.111388196,-0.111388196,21.04,21.38,22.0325,21.04,110724,21.04,21.38,22.0325,21.04,110724,14-Oct-20,0.13,0.0061
14-Oct-20,Ocular Therapeutix™ Announces Pricing of Public Offering of Common Stock,"Ocular Therapeutix™, Inc. (Nasdaq: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, tod...",11.03,12.42,10.995,12.1415,OCUL,5361238,HISTORICAL_PRICES,OCUL,,1.60683E+12,0.410485934,0.410485934,12.1415,11.03,12.42,10.995,5361238,12.1415,11.03,12.42,10.995,5361238,14-Oct-20,-1.08,-0.0892
13-Oct-20,"Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Continues Investigation of Loop Industries, Inc. (LOOP) on Behalf of Investors","Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, continues its investigation on behalf of Loop Industries, Inc. (“Loop” or the “Company”) (NASDAQ: LOOP) investo...",7.83,8.69,7.1101,7.75,LOOP,5762419,HISTORICAL_PRICES,LOOP,,1.60683E+12,-0.355555556,-0.355555556,7.75,7.83,8.69,7.1101,5762419,7.75,7.83,8.69,7.1101,5762419,13-Oct-20,-3.78,-0.3256
13-Oct-20,Ocular Therapeutix™ Announces Proposed Public Offering of Common Stock,"Ocular Therapeutix™, Inc. (Nasdaq: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, tod...",12.11,12.14,10.9,10.9,OCUL,1449020,HISTORICAL_PRICES,OCUL,,1.60683E+12,0.54859335,0.54859335,10.9,12.11,12.14,10.9,1449020,10.9,12.11,12.14,10.9,1449020,13-Oct-20,1.12,0.1019
13-Oct-20,Moderna Announces Initiation of Rolling Submission to Health Canada for mRNA Vaccine Against COVID-19 (mRNA-1273),"Moderna, Inc., (Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced the...",78.29,81.37,75.52,75.93,MRNA,13669187,HISTORICAL_PRICES,MRNA,,1.60683E+12,0.201319626,0.201319626,75.93,78.29,81.37,75.52,13669187,75.93,78.29,81.37,75.52,13669187,13-Oct-20,2.98,0.0396
13-Oct-20,National Institutes of Health Launches its ACTIV-5 “Big Effect Trial” Evaluating Humanigen’s Lenzilumab™ as Potential COVID-19 Therapy,"Humanigen, Inc., (Nasdaq: HGEN) (“Humanigen”), a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm’ with its lead drug candida...",12.03,12.9108,11.78,12.63,HGEN,569783,HISTORICAL_PRICES,HGEN,,1.60683E+12,0.293548387,0.293548387,12.63,12.03,12.9108,11.78,569783,12.63,12.03,12.9108,11.78,569783,13-Oct-20,-0.52,-0.0414
13-Oct-20,Cerus Corporation Announces Five-Year FDA Contract for the Development of Next Generation Pathogen Reduction Technology to Treat Whole Blood,Cerus Corporation (Nasdaq:CERS) announced today it was awarded a five-year contract with the U.S. Food and Drug Administration (FDA) for the development of next-generation compounds to optimize pathog...,6.72,6.8899,6.52,6.72,CERS,2168608,HISTORICAL_PRICES,CERS,,1.60683E+12,0.138983051,0.138983051,6.72,6.72,6.8899,6.52,2168608,6.72,6.72,6.8899,6.52,2168608,13-Oct-20,0.05,0.0075
13-Oct-20,Simulations Plus Teams Up with the University of Health Sciences and Pharmacy in St. Louis to Secure New Grant Award from the U.S. FDA,"Simulations Plus, Inc. (Nasdaq: SLP), the leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemicals, and consumer goods industries, today announced that, t...",77.18,77.89,76.11,76.5,SLP,201957,HISTORICAL_PRICES,SLP,,1.61128E+12,0.168685645,0.168685645,76.5,77.18,77.89,76.11,201957,76.372,77.0508,77.7596,75.9826,201957,13-Oct-20,0.36,0.0047
13-Oct-20,Gamida Cell and Be The Match BioTherapies® Expand Strategic Collaboration,"Gamida Cell Ltd. (Nasdaq: GMDA), a leading cellular and immune therapeutics company, and Be The Match BioTherapies®, an organization offering solutions for companies developing and commercializing cel...",5.08,5.2,4.9,5.2,GMDA,211331,HISTORICAL_PRICES,GMDA,,1.60683E+12,0.236009732,0.236009732,5.2,5.08,5.2,4.9,211331,5.2,5.08,5.2,4.9,211331,13-Oct-20,0,0
13-Oct-20,AtriCure to Announce Third Quarter 2020 Financial Results,"AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it will release its third quarter 2020...",40.79,41.36,40.38,40.68,ATRC,290930,HISTORICAL_PRICES,ATRC,,1.60683E+12,0.063347237,0.063347237,40.68,40.79,41.36,40.38,290930,40.68,40.79,41.36,40.38,290930,13-Oct-20,-0.17,-0.0042
13-Oct-20,Gossamer Bio Announces Topline Results for Phase 2 Trials of Oral GB001 in Asthma and Chronic Rhinosinusitis,"Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflamm...",10.09,10.74,8.22,9.4357,GOSS,10504021,HISTORICAL_PRICES,GOSS,,1.60683E+12,-0.12716263,-0.12716263,9.4357,10.09,10.74,8.22,10504021,9.4357,10.09,10.74,8.22,10504021,13-Oct-20,-3.5,-0.2575
13-Oct-20,Concert Pharmaceuticals Announces CTP-543 Alopecia Areata Data Selected for Late-Breaker Oral Presentation at 2020 EADV Virtual Congress,"Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will present clinical data on CTP-543 for the treatment of alopecia areata as a late-breaker oral presentation at the 29th European...",11.63,11.84,11.26,11.3,CNCE,186379,HISTORICAL_PRICES,CNCE,,1.60683E+12,0.257297297,0.257297297,11.3,11.63,11.84,11.26,186379,11.3,11.63,11.84,11.26,186379,13-Oct-20,0.34,0.0301
13-Oct-20,Forscher verwenden ORi™ (Oxygen Reserve Index) von Masimo zur Berechnung der Notwendigkeit einer postoperativen Sauerstofftherapie bei pädiatrischen Patienten mit obstruktivem Schlafapnoe-Syndrom,"Masimo (Nasdaq: MASI) hat heute die Erkenntnisse aus einem Abstract bekannt gegeben, das vor Kurzem an der ANESTHESIOLOGY® 2020, der Jahrestagung der American Society of Anesthesiologists (ASA), vorge...",232.76,236.99,230.315,233.64,MASI,321736,HISTORICAL_PRICES,MASI,,1.60683E+12,0.067951365,0.067951365,233.64,232.76,236.99,230.315,321736,233.64,232.76,236.99,230.315,321736,13-Oct-20,-0.02,-0.0001
12-Oct-20,"Investigadores Utilizan Masimo ORi™, Índice de Reserva de Oxígeno, para Predecir la Necesidad de Terapia Postoperatoria con Oxígeno en Pacientes Pediátricos con Apnea Obstructiva del Sueño","Masimo (NASDAQ: MASI) anunció hoy los hallazgos de un resumen presentado recientemente en ANESTHESIOLOGY® 2020, reunión anual de la Asociación norteamericana de anestesiólogos (American Society of Ane...",232.78,244.19,232.36,239.34,MASI,436976,HISTORICAL_PRICES,MASI,,1.60683E+12,0.068043129,0.068043129,239.34,232.78,244.19,232.36,436976,239.34,232.78,244.19,232.36,436976,12-Oct-20,-9.65,-0.0398
12-Oct-20,"SHAREHOLDER ACTION REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Mesoblast Limited and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm","The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Mesoblast Limited (“Mesoblast” or “the Company”) (NASDAQ: MESO) for violation...",12.01,12.08,11.8385,12.06,MESO,574442,HISTORICAL_PRICES,MESO,,1.60683E+12,-0.300931315,-0.300931315,12.06,12.01,12.08,11.8385,574442,12.06,12.01,12.08,11.8385,574442,12-Oct-20,-0.1,-0.0083
12-Oct-20,Os pesquisadores usam o índice de reserva de oxigênio Masimo ORi™ para prever a necessidade de terapia de oxigênio pós-operatória em pacientes pediátricos com apneia obstrutiva do sono,"A Masimo (NASDAQ: MASI) anunciou hoje os resultados de um resumo recentemente apresentado na ANESTHESIOLOGY® 2020, a Reunião Anual da American Society of Anesthesiologists (ASA). Nesse estudo independ...",232.78,244.19,232.36,239.34,MASI,436976,HISTORICAL_PRICES,MASI,,1.60683E+12,0.068043129,0.068043129,239.34,232.78,244.19,232.36,436976,239.34,232.78,244.19,232.36,436976,12-Oct-20,-9.65,-0.0398
12-Oct-20,Alexion Receives FDA Approval for New Advanced Formulation of ULTOMIRIS® (ravulizumab-cwvz) with Significantly Reduced Infusion Time,"Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced the U.S. Food and Drug Administration (FDA) has approved ULTOMIRIS® (ravulizumab-cwvz) 100 mg/mL formulation for the treatment of adults wit...",124.38,125.185,122.25,124.83,ALXN,2380578,HISTORICAL_PRICES,ALXN,,1.60683E+12,0.11033744,0.11033744,124.83,124.38,125.185,122.25,2380578,124.83,124.38,125.185,122.25,2380578,12-Oct-20,-0.14,-0.0011
12-Oct-20,IQVIA Joins FDA to Advance COVID-19 Understanding at Community Level through COVID Active Research Experience (CARE) Project,"IQVIA™ (NYSE: IQV), in scientific partnership with the U.S. Food and Drug Administration, will provide agile analytics from IQVIA’s CARE Project COVID-19 registry to support better understanding of ho...",170.46,171.88,166.49,167.94,IQV,923112,HISTORICAL_PRICES,IQV,,1.60683E+12,0.151212264,0.151212264,167.94,170.46,171.88,166.49,923112,167.94,170.46,171.88,166.49,923112,12-Oct-20,3.7,0.0222
12-Oct-20,"Applied DNA Secures $1.0+ Million in COVID-19 Surveillance Testing Annualized Revenue, Builds Sales Pipeline for Test Kit and Testing-as-a-Service","Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA” or the ""Company""), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing that enables in vitro diagnostics, pre-clinical nucleic...",7.99,8.19,7.66,7.85,APDN,248269,HISTORICAL_PRICES,APDN,,1.60683E+12,0.019132653,0.019132653,7.85,7.99,8.19,7.66,248269,7.85,7.99,8.19,7.66,248269,12-Oct-20,0.35,0.0458
12-Oct-20,Seres Therapeutics to Present SER-109 Phase 3 ECOSPOR III Study Results at American College of Gastroenterology Annual Scientific Meeting ,"Seres Therapeutics, Inc. (Nasdaq: MCRB) today announced the presentation of previously announced positive Phase 3 results from the ECOSPOR III trial of SER-109 at the Virtual American College of Gastr...",31.85,32.92,31.48,32,MCRB,831244,HISTORICAL_PRICES,MCRB,,1.60683E+12,0.261386139,0.261386139,32,31.85,32.92,31.48,831244,32,31.85,32.92,31.48,831244,12-Oct-20,0.05,0.0016
12-Oct-20,Seagen and Astellas Announce Positive Topline Results from Second Cohort of Patients in Phase 2 Pivotal Trial of PADCEV® (enfortumab vedotin-ejfv) in Advanced Urothelial Cancer,"Seagen Inc. (Nasdaq:SGEN) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) today announced positive topline results from the second cohort of patients in the...",205.87,207.92,202.03,204.11,SGEN,957233,HISTORICAL_PRICES,SGEN,,1.60683E+12,0.147355515,0.147355515,204.11,205.87,207.92,202.03,957233,204.11,205.87,207.92,202.03,957233,12-Oct-20,5.09,0.0254
9-Oct-20,ADC Therapeutics meldet vollumfängliche Inanspruchnahme der den Underwritern eingeräumten Option für den Kauf zusätzlicher Stammaktien,"ADC Therapeutics SA (NYSE: ADCT), ein im Bereich der späten klinischen Forschung tätiges Biotechnologieunternehmen mit Schwerpunkt auf Onkologie und Vorreiter in der Entwicklung und Vermarktung von ho...",33.84,36.45,33.6,35.97,ADCT,342520,HISTORICAL_PRICES,ADCT,,1.60683E+12,0.010149254,0.010149254,35.97,33.84,36.45,33.6,342520,35.97,33.84,36.45,33.6,342520,9-Oct-20,-1.8,-0.0505
9-Oct-20,ADC Therapeutics annonce le plein exercice de l'option des souscripteurs à acheter des actions ordinaires supplémentaires,"ADC Therapeutics SA (NYSE: ADCT), une société de biotechnologie axée sur l'oncologie au stade clinique avancé, pionnière dans le développement et la commercialisation de conjugués anticorps-médicament...",33.84,36.45,33.6,35.97,ADCT,342520,HISTORICAL_PRICES,ADCT,,1.60683E+12,0.010149254,0.010149254,35.97,33.84,36.45,33.6,342520,35.97,33.84,36.45,33.6,342520,9-Oct-20,-1.8,-0.0505
9-Oct-20,INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Mesoblast Limited (MESO) Investors,Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased Mesoblast Limited (“Mesoblast” or the “Company”) (NASDAQ: MESO) securities betw...,12.11,12.3,11.99,12.06,MESO,555759,HISTORICAL_PRICES,MESO,,1.60683E+12,-0.295110594,-0.295110594,12.06,12.11,12.3,11.99,555759,12.06,12.11,12.3,11.99,555759,9-Oct-20,0,0
9-Oct-20,"SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Mesoblast Limited and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm","The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Mesoblast Limited (“Mesoblast” or “the Company”) (NASDAQ: MESO) for violation...",12.11,12.3,11.99,12.06,MESO,555759,HISTORICAL_PRICES,MESO,,1.60683E+12,-0.295110594,-0.295110594,12.06,12.11,12.3,11.99,555759,12.06,12.11,12.3,11.99,555759,9-Oct-20,0,0
9-Oct-20,Alexion Announces Upcoming Data Presentations at the American Society of Nephrology’s Virtual Kidney Week 2020,"Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced that four abstracts have been accepted for presentation at the American Society of Nephrology’s Kidney Week 2020, taking place virtually fro...",124.52,128.57,120.78,122.9,ALXN,4586298,HISTORICAL_PRICES,ALXN,,1.60683E+12,0.111587217,0.111587217,122.9,124.52,128.57,120.78,4586298,122.9,124.52,128.57,120.78,4586298,9-Oct-20,1.38,0.0112
9-Oct-20,Tricida Announces Twelve Data Presentations on Veverimer and Metabolic Acidosis to be Given at the Virtual American Society of Nephrology Kidney Week 2020,"Tricida, Inc. (Nasdaq: TCDA), a pharmaceutical company focused on the development and commercialization of its investigational drug candidate, veverimer (TRC101), a non-absorbed, orally-administered p...",9.22,9.6,9.17,9.41,TCDA,404401,HISTORICAL_PRICES,TCDA,,1.60683E+12,0.01878453,0.01878453,9.41,9.22,9.6,9.17,404401,9.41,9.22,9.6,9.17,404401,9-Oct-20,-0.16,-0.0171
9-Oct-20,TherapeuticsMD Supports the Importance of Empowering Women to Make Informed Choices about their Sexual and Reproductive Health,"TherapeuticsMD, Inc. (NASDAQ:TXMD), an innovative women’s healthcare company, is proud to reinforce the importance of empowering women to make informed choices about their sexual and reproductive heal...",1.65,1.85,1.63,1.83,TXMD,4712801,HISTORICAL_PRICES,TXMD,,1.60683E+12,0.259541985,0.259541985,1.83,1.65,1.85,1.63,4712801,1.83,1.65,1.85,1.63,4712801,9-Oct-20,-0.11,-0.0625
9-Oct-20,Exelixis and Aurigene Announce That Promising Preclinical Data to Be Presented at the ENA Symposium Support the Clinical Development of a Novel CDK7 Inhibitor,"Exelixis, Inc. (Nasdaq: EXEL) and Aurigene Discovery Technologies Limited (Aurigene) today disclosed new preclinical data showing that AUR102 has potent anti-tumor activity in a large panel of cancer...",23.91,25.1199,23.7,25.06,EXEL,2454682,HISTORICAL_PRICES,EXEL,,1.60683E+12,0.028829604,0.028829604,25.06,23.91,25.1199,23.7,2454682,25.06,23.91,25.1199,23.7,2454682,9-Oct-20,-0.885,-0.0357
8-Oct-20,"BMRN Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Notifies BioMarin Pharmaceutical Inc. Shareholders of Class Action and Lead Plaintiff Deadline: November 24, 2020","Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against BioMarin Pharmaceutical Inc. (""BioMarin"" or ""the Company"") (NASDAQ: BMRN) and certain of it...",79.61,79.86,77.72,78,BMRN,1236294,HISTORICAL_PRICES,BMRN,,1.60683E+12,0.039566466,0.039566466,78,79.61,79.86,77.72,1236294,78,79.61,79.86,77.72,1236294,8-Oct-20,1.9,0.0244
8-Oct-20,Applied DNA Announces Repayment of Secured Convertible Notes,"Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA” or the ""Company""), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing that enables in vitro diagnostics, pre-clinical nucleic...",7.66,7.7156,7.54,7.65,APDN,55139,HISTORICAL_PRICES,APDN,,1.60683E+12,-0.022959184,-0.022959184,7.65,7.66,7.7156,7.54,55139,7.65,7.66,7.7156,7.54,55139,8-Oct-20,0.12,0.0159
8-Oct-20,BOHA! To Present at Restaurants RISE Powered by MUFSO Virtual Event,"TransAct® Technologies Incorporated (Nasdaq:TACT) (“TransAct” or “the Company”), a global leader in software-driven technology and printing solutions for high-growth markets, today announced Miguel Or...",7.48,7.49,7.1264,7.2,TACT,101121,HISTORICAL_PRICES,TACT,,1.60683E+12,0.502008032,0.502008032,7.2,7.48,7.49,7.1264,101121,7.2,7.48,7.49,7.1264,101121,8-Oct-20,0.37,0.052
8-Oct-20,"Amneal & PL Developments Launch Store Brand Program of Over-the-Counter (“OTC”) Diclofenac Sodium Topical Gel, 1%","Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal’ or the “Company”) and PL Developments (PLD) today announced that they have commenced shipments of store brand equivalent Voltaren® Arthritis Pain Ge...",4.53,4.73,4.387,4.45,AMRX,2024795,HISTORICAL_PRICES,AMRX,,1.60683E+12,0.185863874,0.185863874,4.45,4.53,4.73,4.387,2024795,4.45,4.53,4.73,4.387,2024795,8-Oct-20,0.14,0.0319
8-Oct-20,scPharmaceuticals Provides Business Update,"scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize therapies, advance patient care, and reduce healt...",8.24,8.33,7.5275,8,SCPH,66643,HISTORICAL_PRICES,SCPH,,1.60683E+12,0.149232915,0.149232915,8,8.24,8.33,7.5275,66643,8,8.24,8.33,7.5275,66643,8-Oct-20,0.25,0.0313
8-Oct-20,Ocular Therapeutix™ Announces Topline Phase 1 Clinical Trial Results of OTX-CSI,"Ocular Therapeutix™, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, tod...",11.22,11.47,10,10.81,OCUL,3279454,HISTORICAL_PRICES,OCUL,,1.60683E+12,0.434782609,0.434782609,10.81,11.22,11.47,10,3279454,10.81,11.22,11.47,10,3279454,8-Oct-20,0.4,0.037
8-Oct-20,"Seattle Genetics, Inc. Announces Corporate Name Change to Seagen Inc.","Seagen Inc. is the new corporate name for Seattle Genetics, Inc. (Nasdaq:SGEN), a global biotechnology company dedicated to developing innovative cancer medicines that make a meaningful difference in...",198.73,201.83,197.26,201.83,SGEN,799597,HISTORICAL_PRICES,SGEN,,1.60683E+12,0.107562838,0.107562838,201.83,198.73,201.83,197.26,799597,201.83,198.73,201.83,197.26,799597,8-Oct-20,-2.3,-0.0114
8-Oct-20,"Greenwich LifeSciences, Inc. Announces Acceptance of Two Abstracts at Upcoming Major Breast Cancer Conference","Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in pati...",4.8999,4.92,4.47,4.47,GLSI,16221,HISTORICAL_PRICES,GLSI,,1.60683E+12,-0.02002,-0.02002,4.47,4.8999,4.92,4.47,16221,4.47,4.8999,4.92,4.47,16221,8-Oct-20,0.4,0.0889
8-Oct-20,Moderna Announces Updates on Respiratory Syncytial Virus (RSV) Vaccine Program,"Moderna, Inc., (Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced tha...",72.93,73.76,72.01,73.5,MRNA,4023816,HISTORICAL_PRICES,MRNA,,1.60683E+12,0.119073193,0.119073193,73.5,72.93,73.76,72.01,4023816,73.5,72.93,73.76,72.01,4023816,8-Oct-20,0.56,0.0077
8-Oct-20,Pfizer Announces Positive Phase 3 Top-line Results for Once-Weekly Investigational Long-Acting Human Growth Hormone to Treat Children with Growth Hormone Deficiency,"Pfizer Inc. (NYSE: PFE) and OPKO Health Inc. (NASDAQ: OPK) announced today that C0311002, a Phase 3, randomized, multicenter, open-label, crossover study evaluating somatrogon dosed once-weekly in chi...",36.89,37.18,36.51,36.6,PFE,16942533,HISTORICAL_PRICES,PFE,,1.6118E+12,0.031599553,0.031599553,36.6,36.89,37.18,36.51,16942533,35.8376,36.1215,36.4055,35.7494,16942533,8-Oct-20,0.42,0.0115
8-Oct-20,Gilead Sciences Signs Joint Procurement Agreement With the European Commission for Veklury® (remdesivir),"Gilead Sciences (Nasdaq: GILD) and the European Commission today signed a joint procurement agreement (JPA) that will enable rapid and equitable access to Veklury® (remdesivir), the first antiviral dr...",63.32,64.05,63.02,63.33,GILD,6434899,HISTORICAL_PRICES,GILD,,1.61552E+12,0.017188755,0.017188755,63.33,63.32,64.05,63.02,6434899,61.9165,61.9067,62.6204,61.6134,6434899,8-Oct-20,0.48,0.0076
7-Oct-20,Glancy Prongay & Murray LLP Continues Investigation on Behalf of Las Vegas Sands Corp. (LVS) Investors,Glancy Prongay & Murray LLP (“GPM”) continues its investigation on behalf of Las Vegas Sands Corp. (“Las Vegas Sands ” or the “Company”) (NYSE: LVS) investors concerning the Company’s possible vio...,46.18,47.1,46.11,46.96,LVS,3655378,HISTORICAL_PRICES,LVS,,1.60683E+12,0.005881072,0.005881072,46.96,46.18,47.1,46.11,3655378,46.96,46.18,47.1,46.11,3655378,7-Oct-20,-0.24,-0.0052
7-Oct-20,INVESTOR ALERT: Law Offices of Howard G. Smith Continues Investigation of Mesoblast Limited (MESO) on Behalf of Investors,Law Offices of Howard G. Smith continues its investigation on behalf of Mesoblast Limited (“Mesoblast” or the “Company”) (NASDAQ: MESO) investors concerning the Company’s possible violations of federa...,12.09,12.22,11.93,12.15,MESO,643357,HISTORICAL_PRICES,MESO,,1.60683E+12,-0.296274738,-0.296274738,12.15,12.09,12.22,11.93,643357,12.15,12.09,12.22,11.93,643357,7-Oct-20,-0.02,-0.0017
7-Oct-20,"Glancy Prongay & Murray LLP Continues Investigation on Behalf of Synchronoss Technologies, Inc. (SNCR) Investors","Glancy Prongay & Murray LLP (“GPM”) continues its investigation on behalf of Synchronoss Technologies, Inc. (“Synchronoss” or the “Company”) (NASDAQ: SNCR) investors concerning the Company’s possi...",3.1,3.15,2.93,3.05,SNCR,582790,HISTORICAL_PRICES,SNCR,,1.60683E+12,0.003236246,0.003236246,3.05,3.1,3.15,2.93,582790,3.05,3.1,3.15,2.93,582790,7-Oct-20,0.07,0.0231
7-Oct-20,"Genprex to Present at Zooming with LD Micro on October 14, 2020","Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX), a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes, announced that...",3.71,3.74,3.54,3.54,GNPX,495461,HISTORICAL_PRICES,GNPX,,1.60683E+12,0.196774194,0.196774194,3.54,3.71,3.74,3.54,495461,3.54,3.71,3.74,3.54,495461,7-Oct-20,0.19,0.054
7-Oct-20,"Ocular Therapeutix Announces Preliminary Net Product Revenue of $5.8 Million to $5.9 Million for Third Quarter 2020, Representing Greater Than a 250% Increase Over the Previous Quarter","Ocular Therapeutix, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, toda...",10.82,10.95,9.2,9.4,OCUL,7283732,HISTORICAL_PRICES,OCUL,,1.60683E+12,0.383631714,0.383631714,9.4,10.82,10.95,9.2,7283732,9.4,10.82,10.95,9.2,7283732,7-Oct-20,2.41,0.2866
7-Oct-20,Urovant Sciences Announces Co-Promotion Agreement for Vibegron with Sunovion Pharmaceuticals,Urovant Sciences (Nasdaq: UROV) today announced it has entered into a five-year U.S. co-promotion agreement with Sunovion Pharmaceuticals Inc. to promote vibegron in the primary care segment upon rece...,9.24,9.76,9.05,9.63,UROV,118997,HISTORICAL_PRICES,UROV,,1.60683E+12,-0.011764706,-0.011764706,9.63,9.24,9.76,9.05,118997,9.63,9.24,9.76,9.05,118997,7-Oct-20,-0.3,-0.0314
7-Oct-20,Pulse Biosciences Announces Presentation of Clinical Results Using Nano-Pulse Stimulation Technology for the Clearance of Skin Lesions at the American Society for Dermatologic Surgery (ASDS) Virtual Annual Meeting,"Pulse Biosciences, Inc. (Nasdaq: PLSE) a novel bioelectric medicine company progressing Nano-Pulse Stimulation™ (NPS™) technology, today announced that clinical results from studies spanning the Compa...",15.43,15.55,14.7979,15.2,PLSE,90123,HISTORICAL_PRICES,PLSE,,1.60683E+12,0.392599278,0.392599278,15.2,15.43,15.55,14.7979,90123,15.2,15.43,15.55,14.7979,90123,7-Oct-20,0.6,0.0405
7-Oct-20,Stoke Therapeutics Announces Plans to Move Forward With Dosing of STK-001 in Children and Adolescents in its Ongoing Phase 1/2a MONARCH Study for Dravet Syndrome,"Stoke Therapeutics, Inc., (Nasdaq: STOK), a clinical-stage biotechnology company pioneering a new way to treat the underlying cause of genetic diseases by precisely upregulating protein expression, to...",37.74,38.29,35.6904,35.98,STOK,70173,HISTORICAL_PRICES,STOK,,1.60683E+12,0.14571949,0.14571949,35.98,37.74,38.29,35.6904,70173,35.98,37.74,38.29,35.6904,70173,7-Oct-20,2.3,0.0649
7-Oct-20,Cardiovascular Systems Announces Presentation of Data From Large Coronary Orbital Atherectomy Study at the TCT Connect 2020 Conference,"Cardiovascular Systems, Inc. (CSI®) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery...",37.68,37.9,36.715,37.18,CSII,226095,HISTORICAL_PRICES,CSII,,1.60683E+12,0.056646102,0.056646102,37.18,37.68,37.9,36.715,226095,37.18,37.68,37.9,36.715,226095,7-Oct-20,0.79,0.0214
7-Oct-20,Opdivo (nivolumab) Plus Chemotherapy Shows Statistically Significant Improvement in Pathologic Complete Response as Neoadjuvant Treatment of Resectable Non-Small Cell Lung Cancer in Phase 3 CheckMate -816 Trial,Bristol Myers Squibb (NYSE: BMY) today announced that the Phase 3 CheckMate -816 trial met a primary endpoint of pathologic complete response (pCR) in resectable non-small cell lung cancer (NSCLC). In...,60.42,60.98,57.96,58.15,BMY,14632584,HISTORICAL_PRICES,BMY,,1.60946E+12,0.037253219,0.037253219,58.15,60.42,60.98,57.96,14632584,57.6898,59.9419,60.4974,57.5013,14632584,7-Oct-20,2.68,0.0464
7-Oct-20,Epizyme Announces Two Lancet Oncology Publications on TAZVERIK® (tazemetostat) Phase 2 Data in Epithelioid Sarcoma and Follicular Lymphoma,"Epizyme, (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering novel epigenetic therapies, today announced that The Lancet Oncology published results...",12.61,12.65,12.18,12.18,EPZM,508837,HISTORICAL_PRICES,EPZM,,1.60683E+12,0.075021313,0.075021313,12.18,12.61,12.65,12.18,508837,12.18,12.61,12.65,12.18,508837,7-Oct-20,0.55,0.0456
6-Oct-20,Glancy Prongay & Murray LLP Continues Investigation on Behalf of Mesoblast Limited (MESO) Investors,Glancy Prongay & Murray LLP (“GPM”) continues its investigation on behalf of Mesoblast Limited (“Mesoblast” or the “Company”) (NASDAQ: MESO) investors concerning the Company’s possible violations...,12.11,12.69,11.91,12.69,MESO,956753,HISTORICAL_PRICES,MESO,,1.60683E+12,2.308652769,2.308652769,12.69,12.11,12.69,11.91,956753,12.69,12.11,12.69,11.91,956753,6-Oct-20,-0.69,-0.0539
6-Oct-20,"NantKwest, ImmunityBio Add Third-Line Cohort to Phase 2 Pancreatic Cancer Trial; Opens Study to Patients Who Have Failed All Approved Standards of Care","NantKwest, Inc. (NASDAQ: NK), a clinical-stage, natural killer cell-based therapeutics company, and ImmunityBio, a privately-held immunotherapy company, today announced they have added a third cohort...",7.65,8.1,7.44,7.95,NK,990245,HISTORICAL_PRICES,NK,,1.60683E+12,1.567114094,1.567114094,7.95,7.65,8.1,7.44,990245,7.95,7.65,8.1,7.44,990245,6-Oct-20,-0.24,-0.0304
6-Oct-20,"FDA Amends Emergency Use Authorization for Hologic’s Aptima SARS-CoV-2 Assay to Include COVID-19 Testing of Asymptomatic Individuals, Symptomatic Sample Pooling","Hologic, Inc. (Nasdaq: HOLX) announced today that its Aptima® SARS-CoV-2 assay, which initially received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) in May, is n...",67.29,68.8,67.02,68.18,HOLX,1310558,HISTORICAL_PRICES,HOLX,,1.60683E+12,1.140267176,1.140267176,68.18,67.29,68.8,67.02,1310558,68.18,67.29,68.8,67.02,1310558,6-Oct-20,-0.61,-0.009
6-Oct-20,Herbalife Nutrition Launches MemoryArmor in the U.S. and Puerto Rico To Help With Short-Term Memory,"Herbalife Nutrition (NYSE: HLF), a premier global nutrition company, today launched MemoryArmor supplement, to support mental attention, auditory learning, and short-term working memory, and focus.* M...",50.26,50.975,49.79,50.2,HLF,685336,HISTORICAL_PRICES,HLF,,1.60683E+12,0.870487533,0.870487533,50.2,50.26,50.975,49.79,685336,50.2,50.26,50.975,49.79,685336,6-Oct-20,0.07,0.0014
6-Oct-20,SINTX Technologies Develops New Mask Fabric with Silicon Nitride,"SINTX Technologies, Inc. (www.sintx.com) (NASDAQ: SINT) (“SINTX” or the “Company”), an original equipment manufacturer of silicon nitride ceramic for medical and non-medical applications, announced pr...",1.93,2.22,1.9,2.18,SINT,4019846,HISTORICAL_PRICES,SINT,,1.60683E+12,4.956790123,4.956790123,2.18,1.93,2.22,1.9,4019846,2.18,1.93,2.22,1.9,4019846,6-Oct-20,-0.08,-0.0398
6-Oct-20,The Law Offices of Frank R. Cruz Continues Its Investigation of Mesoblast Limited (MESO) on Behalf of Investors,The Law Offices of Frank R. Cruz continues its investigation of Mesoblast Limited (“Mesoblast” or the “Company”) (NASDAQ: MESO) on behalf of investors concerning the Company’s possible violations of f...,12.11,12.69,11.91,12.69,MESO,956753,HISTORICAL_PRICES,MESO,,1.60683E+12,2.308652769,2.308652769,12.69,12.11,12.69,11.91,956753,12.69,12.11,12.69,11.91,956753,6-Oct-20,-0.69,-0.0539
6-Oct-20,Genprex to Present at the Alliance for Regenerative Medicine’s Virtual Cell and Gene Meeting on the Mesa,"Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX), a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes, today announce...",3.52,3.65,3.51,3.55,GNPX,409590,HISTORICAL_PRICES,GNPX,,1.60683E+12,0.21799308,0.21799308,3.55,3.52,3.65,3.51,409590,3.55,3.52,3.65,3.51,409590,6-Oct-20,-0.02,-0.0056
6-Oct-20,Ocular Therapeutix Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4),"Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today...",8.41,8.77,8.36,8.46,OCUL,461004,HISTORICAL_PRICES,OCUL,,1.60683E+12,0.709349593,0.709349593,8.46,8.41,8.77,8.36,461004,8.46,8.41,8.77,8.36,461004,6-Oct-20,-0.01,-0.0012
6-Oct-20,PhaseBio Doses First Patients in Canada as Part of the REVERSE-IT Global Phase 3 Trial of Bentracimab for Reversal of the Antiplatelet Effects of Ticagrelor,"PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiopulmonary diseases, today announ...",3.335,3.48,3.33,3.42,PHAS,101655,HISTORICAL_PRICES,PHAS,,1.60683E+12,0.100660066,0.100660066,3.42,3.335,3.48,3.33,101655,3.42,3.335,3.48,3.33,101655,6-Oct-20,-0.045,-0.0133
6-Oct-20,Revance to Present Three New Abstracts Evaluating DaxibotulinumtoxinA for Injection and Two ePosters Evaluating the RHA® Collection During the American Society for Dermatologic Surgery (ASDS) Virtual Annual Meeting,"Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company focused on innovative aesthetic and therapeutic offerings, including its investigational neuromodulator product, DaxibotulinumtoxinA...",25.51,26.48,25.39,25.75,RVNC,586450,HISTORICAL_PRICES,RVNC,,1.60683E+12,0.822142857,0.822142857,25.75,25.51,26.48,25.39,586450,25.75,25.51,26.48,25.39,586450,6-Oct-20,-0.15,-0.0058
6-Oct-20,Oncternal Therapeutics Receives Rare Pediatric Disease Designation from U.S. Food and Drug Administration for TK216 for Treatment of Ewing Sarcoma,"Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that the U.S. Food and Drug Administrati...",1.7577,1.97,1.73,1.8,ONCT,422437,HISTORICAL_PRICES,ONCT,,1.60683E+12,-0.29692,-0.29692,1.8,1.7577,1.97,1.73,422437,1.8,1.7577,1.97,1.73,422437,6-Oct-20,-0.0323,-0.018
6-Oct-20,Taysha Gene Therapies Partners with Invitae to Enable Rapid Access to Genetic Testing and Earlier Diagnosis of Patients with CNS Disease for Rare and Large-Market Indications,"Taysha Gene Therapies Inc. (Nasdaq: TSHA), a patient-centric gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the cent...",20.38,21,19.9,20.1,TSHA,112073,HISTORICAL_PRICES,TSHA,,1.60683E+12,-0.152950956,-0.152950956,20.1,20.38,21,19.9,112073,20.1,20.38,21,19.9,112073,6-Oct-20,0.48,0.0241
6-Oct-20,Gamida Cell Announces Positive Topline Data on Secondary Endpoints from Phase 3 Clinical Study of Omidubicel in Patients with Hematologic Malignancies,"Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to cures for blood cancers and serious blood diseases, today announced that the Phase 3 study of omidubicel, an investigatio...",4.6,4.75,4.35,4.55,GMDA,1446756,HISTORICAL_PRICES,GMDA,,1.60683E+12,0.559322034,0.559322034,4.55,4.6,4.75,4.35,1446756,4.55,4.6,4.75,4.35,1446756,6-Oct-20,0.4,0.0952
6-Oct-20,Alexion Highlights Promising Pipeline & Distinguished Rare Disease Capabilities at Virtual Investor Day,"Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced continued progression of the company’s LEAD-EXPAND-DIVERSIFY value-creation strategy and will highlight strategic advancements at today’s Vi...",116.08,119.9,114.69,119.17,ALXN,4189133,HISTORICAL_PRICES,ALXN,,1.60683E+12,0.350866985,0.350866985,119.17,116.08,119.9,114.69,4189133,119.17,116.08,119.9,114.69,4189133,6-Oct-20,0.83,0.0072
5-Oct-20,FDA Grants GlycoMimetics Rare Pediatric Disease Designation for Rivipansel for Treatment of Sickle Cell Disease,"GlycoMimetics, Inc. (Nasdaq: GLYC) today announced that the U.S. Food and Drug Administration (FDA) has granted the Company a Rare Pediatric Disease designation for rivipansel for the treatment of sic...",3.27,3.3,3.17,3.17,GLYC,1301969,HISTORICAL_PRICES,GLYC,,1.60683E+12,0.466367713,0.466367713,3.17,3.27,3.3,3.17,1301969,3.17,3.27,3.3,3.17,1301969,5-Oct-20,0.14,0.0447
5-Oct-20,"Puma Biotechnology Announces Publication of Overall Survival Results from Phase III ExteNET Trial Evaluating Neratinib in HER2-Positive, Hormone Receptor-Positive, Early Stage Breast Cancer","Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that efficacy results of neratinib in HER2-positive, hormone receptor-positive (HR+), early stage breast cancer (eBC) fr...",10.12,10.25,9.9,10.05,PBYI,511030,HISTORICAL_PRICES,PBYI,,1.60683E+12,0.168591224,0.168591224,10.05,10.12,10.25,9.9,511030,10.05,10.12,10.25,9.9,511030,5-Oct-20,0.21,0.0212
5-Oct-20,Large-Scale Study Shows Guardant360 Liquid Biopsy Accelerates Clinical Trial Enrollment Compared to Tissue Biopsy,"Guardant Health, Inc. (Nasdaq: GH). Despite advances in precision oncology, progress is slowed by the limitations of tissue genotyping, which is traditionally used to enroll patients in clinical trial...",110.75,112.1924,108.25,108.5,GH,915047,HISTORICAL_PRICES,GH,,1.60683E+12,0.694202233,0.694202233,108.5,110.75,112.1924,108.25,915047,108.5,110.75,112.1924,108.25,915047,5-Oct-20,2.53,0.0234
5-Oct-20,The Law Offices of Frank R. Cruz Announces Investigation of Mesoblast Limited (MESO) on Behalf of Investors,The Law Offices of Frank R. Cruz announces an investigation of Mesoblast Limited (“Mesoblast” or the “Company”) (NASDAQ: MESO) on behalf of investors concerning the Company’s possible violations of fe...,12.8,13.5,12.52,12.71,MESO,1590171,HISTORICAL_PRICES,MESO,,1.60683E+12,2.497172208,2.497172208,12.71,12.8,13.5,12.52,1590171,12.71,12.8,13.5,12.52,1590171,5-Oct-20,0.77,0.064
5-Oct-20,INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Mesoblast Limited (MESO) on Behalf of Investors,Law Offices of Howard G. Smith announces an investigation on behalf of Mesoblast Limited (“Mesoblast” or the “Company”) (NASDAQ: MESO) investors concerning the Company’s possible violations of federal...,12.8,13.5,12.52,12.71,MESO,1590171,HISTORICAL_PRICES,MESO,,1.60683E+12,2.497172208,2.497172208,12.71,12.8,13.5,12.52,1590171,12.71,12.8,13.5,12.52,1590171,5-Oct-20,0.77,0.064
5-Oct-20,Notice of Lead Plaintiff Deadline for Shareholders in the Nano-X Imaging Ltd. Class Action Lawsuit,Robbins Geller Rudman & Dowd LLP announces that a class action lawsuit has been filed in the Eastern District of New York on behalf of purchasers of Nano-X Imaging Ltd. (NASDAQ:NNOX) securities be...,39.5,45,38.06,39.89,NNOX,12374714,HISTORICAL_PRICES,NNOX,,1.60683E+12,0.820276498,0.820276498,39.89,39.5,45,38.06,12374714,39.89,39.5,45,38.06,12374714,5-Oct-20,2.06,0.055
5-Oct-20,"Masimo Announces Consumer Launch of the Radius Tº™ Continuous Thermometer, a More Convenient Way to Keep Track of Fever","Masimo (NASDAQ: MASI) today announced the launch of the Radius Tº™ Continuous Thermometer for consumers. Unlike spot-check, episodic thermometers, the wearable, wireless Radius Tº measures body temper...",239.61,239.97,234.75,234.75,MASI,259407,HISTORICAL_PRICES,MASI,,1.60683E+12,0.541891892,0.541891892,234.75,239.61,239.97,234.75,259407,234.75,239.61,239.97,234.75,259407,5-Oct-20,5.36,0.0229
5-Oct-20,Horizon Therapeutics plc Announces TEPEZZA® (teprotumumab-trbw) Selected as a Winner of the R&D 100 Award,Horizon Therapeutics plc (Nasdaq: HZNP) today announced that TEPEZZA® (teprotumumab-trbw) was selected as a 2020 R&D World R&D 100 Award recipient in the Process/Prototyping category. TEPEZZA...,81.56,82.79,80.24,80.48,HZNP,1872025,HISTORICAL_PRICES,HZNP,,1.60683E+12,2.017388087,2.017388087,80.48,81.56,82.79,80.24,1872025,80.48,81.56,82.79,80.24,1872025,5-Oct-20,1.74,0.0218
5-Oct-20,FSD Pharma Begins Phase 2 Clinical Trial to Evaluate FSD201 for the Treatment of Hospitalized COVID-19 Patients,FSD Pharma Inc. (Nasdaq: HUGE) (CSE: HUGE.CN) (“FSD Pharma” or the “Company”) announced that the U.S. Food and Drug Administration (“FDA”) has authorized the initiation of a Phase 2 study for the use...,2.55,2.6,2.47,2.6,HUGE,227551,HISTORICAL_PRICES,HUGE,,1.60988E+12,-0.141414141,-0.141414141,2.6,2.55,2.6,2.47,227551,2.6,2.55,2.6,2.47,227551,5-Oct-20,0.07,0.0282
5-Oct-20,"Top FDA Official, Amy Abernethy, to Keynote Veeva R&D and Quality Summit Online","Veeva Systems (NYSE: VEEV) today announced that Amy Abernethy, MD, PhD, principal deputy commissioner of the FDA, is the featured keynote at the 2020 Veeva R&D and Quality Summit Online. In a fire...",278.45,279.77,273.88,275.14,VEEV,721987,HISTORICAL_PRICES,VEEV,,1.60683E+12,0.921272338,0.921272338,275.14,278.45,279.77,273.88,721987,275.14,278.45,279.77,273.88,721987,5-Oct-20,2.89,0.0105
5-Oct-20,Eyenovia to Present Clinical Study Updates at the American Academy of Optometry Annual Meeting,"Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose array print (MAP™) therapeutics, today announced that Drs. Siddarth Rathi and Ap...",3.26,3.33,3.15,3.15,EYEN,157928,HISTORICAL_PRICES,EYEN,,1.60683E+12,0.381355932,0.381355932,3.15,3.26,3.33,3.15,157928,3.15,3.26,3.33,3.15,157928,5-Oct-20,0.13,0.0415
5-Oct-20,Bristol Myers Squibb to Acquire MyoKardia for $13.1 Billion in Cash,"Bristol Myers Squibb (NYSE: BMY) and MyoKardia, Inc. (Nasdaq: MYOK) today announced a definitive merger agreement under which Bristol Myers Squibb will acquire MyoKardia for $13.1 billion, or $225.00...",59.2,59.28,57.95,58.55,BMY,10992264,HISTORICAL_PRICES,BMY,,1.60946E+12,0.202274574,0.202274574,58.55,59.2,59.28,57.95,10992264,58.0867,58.7315,58.8109,57.4914,10992264,5-Oct-20,0.48,0.0082
5-Oct-20,ImmunoGen Announces FDA Breakthrough Therapy Designation for IMGN632 in Relapsed or Refractory Blastic Plasmacytoid Dendritic Cell Neoplasm,"ImmunoGen, Inc., (Nasdaq: IMGN) a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the U.S. Food and Drug Administration (FDA) has gra...",4.42,4.48,3.99,4.307,IMGN,8566559,HISTORICAL_PRICES,IMGN,,1.60683E+12,0.296187683,0.296187683,4.307,4.42,4.48,3.99,8566559,4.307,4.42,4.48,3.99,8566559,5-Oct-20,0.55,0.1421
2-Oct-20,Quidel Receives Emergency Authorization for First Rapid Antigen “ABC Test”: A Combination Diagnostic Assay for Influenza A+B and COVID-19,"Quidel Corporation (NASDAQ: QDEL) (“Quidel”), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that Quidel has receive...",235.34,238.906,221.07,221.85,QDEL,1131861,HISTORICAL_PRICES,QDEL,,1.60683E+12,1.745770622,1.745770622,221.85,235.34,238.906,221.07,1131861,221.85,235.34,238.906,221.07,1131861,2-Oct-20,9.8,0.0435
2-Oct-20,Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4),"Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on October 1, 2020 the Compensation Committee of Puma’s Board of Directors approved the grant of inducement restric...",9.91,10.39,9.89,10.07,PBYI,412547,HISTORICAL_PRICES,PBYI,,1.60683E+12,0.144341801,0.144341801,10.07,9.91,10.39,9.89,412547,10.07,9.91,10.39,9.89,412547,2-Oct-20,-0.31,-0.0303
2-Oct-20,Bristol Myers Squibb Announces Update on CheckMate -915 Evaluating Opdivo (nivolumab) Plus Yervoy (ipilimumab) Versus Opdivo in Resected High-Risk Melanoma Patients,"Bristol Myers Squibb (NYSE: BMY) today announced results for the co-primary endpoint for CheckMate -915, a randomized Phase 3 study evaluating Opdivo (nivolumab) plus Yervoy (ipilimumab) versus Opdivo...",58.72,60.01,58.68,59.39,BMY,12574250,HISTORICAL_PRICES,BMY,,1.60946E+12,0.192526401,0.192526401,59.39,58.72,60.01,58.68,12574250,58.92,58.2553,59.5351,58.2156,12574250,2-Oct-20,-1.1,-0.0184
2-Oct-20,U.S. Food and Drug Administration Approves Opdivo® (nivolumab) + Yervoy® (ipilimumab) as the First and Only Immunotherapy Treatment for Previously Untreated Unresectable Malignant Pleural Mesothelioma,Bristol Myers Squibb (NYSE: BMY) today announced that Opdivo (nivolumab) 360 mg every three weeks plus Yervoy (ipilimumab) 1 mg/kg every six weeks (injections for intravenous use) was approved by the...,58.72,60.01,58.68,59.39,BMY,12574250,HISTORICAL_PRICES,BMY,,1.60946E+12,0.192526401,0.192526401,59.39,58.72,60.01,58.68,12574250,58.92,58.2553,59.5351,58.2156,12574250,2-Oct-20,-1.1,-0.0184
2-Oct-20,INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of BioMarin Pharmaceuticals Inc. (BMRN) on Behalf of Investors,Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased BioMarin Pharmaceuticals Inc. (“BioMarin” or the “Company”) (NASDAQ: BMRN) secu...,74.98,76.04,73.8,75.33,BMRN,2548201,HISTORICAL_PRICES,BMRN,,1.60683E+12,-0.061342013,-0.061342013,75.33,74.98,76.04,73.8,2548201,75.33,74.98,76.04,73.8,2548201,2-Oct-20,-0.84,-0.0111
2-Oct-20,Tenax Therapeutics Announces Late-Breaking Clinical Trial Presentation of Phase 2 HELP Study at Heart Failure Society of America (HFSA) Virtual Annual Scientific Meeting,"Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceutical company focused on identifying, developing and commercializing products for the critical care market, today announced that detailed...",1.37,1.43,1.2387,1.38,TENX,266190,HISTORICAL_PRICES,TENX,,1.60683E+12,1.796489079,1.796489079,1.38,1.37,1.43,1.2387,266190,1.38,1.37,1.43,1.2387,266190,2-Oct-20,-0.06,-0.042
2-Oct-20,Intersect ENT Closes Acquisition of Fiagon AG Medical Technologies,"Intersect ENT, Inc. (Nasdaq: XENT), a company transforming care for patients with ear, nose and throat (“ENT”) conditions, today announced it closed the previously announced transaction to acquire Fia...",16.19,16.41,15.9,15.91,XENT,226298,HISTORICAL_PRICES,XENT,,1.60683E+12,0.359361881,0.359361881,15.91,16.19,16.41,15.9,226298,15.91,16.19,16.41,15.9,226298,2-Oct-20,0.04,0.0025
2-Oct-20,Humanigen Announces COVID-19 Case Report Demonstrating Rapid Resolution and Discharge after Single IND Emergency Use Authorization of Lenzilumab™,"Humanigen, Inc., (Nasdaq: HGEN) (“Humanigen”), a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm,’ today announced that a pa...",9.85,10.55,9.75,10.51,HGEN,491041,HISTORICAL_PRICES,HGEN,,1.60683E+12,0.020725389,0.020725389,10.51,9.85,10.55,9.75,491041,10.51,9.85,10.55,9.75,491041,2-Oct-20,0.25,0.026
2-Oct-20,Humanigen Announces Lenzilumab in COVID-19 Program Updates,"Humanigen, Inc., (Nasdaq: HGEN) (“Humanigen”), a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm’ with its lead drug candida...",9.85,10.55,9.75,10.51,HGEN,491041,HISTORICAL_PRICES,HGEN,,1.60683E+12,0.020725389,0.020725389,10.51,9.85,10.55,9.75,491041,10.51,9.85,10.55,9.75,491041,2-Oct-20,0.25,0.026
2-Oct-20,LabCorp COVID-19 Molecular Test Innovation Receives FDA Authorization,"LabCorp (NYSE: LH), a leading global life sciences company that is focused on advancing health and guiding patient care decisions, today announced that it is the first commercial laboratory to receive...",187.99,189.9,183.41,184.5,LH,449390,HISTORICAL_PRICES,LH,,1.60683E+12,0.596246922,0.596246922,184.5,187.99,189.9,183.41,449390,184.5,187.99,189.9,183.41,449390,2-Oct-20,1.08,0.0058
2-Oct-20,"bluebird bio Announces European Medicines Agency’s Acceptance of Marketing Authorization Application (MAA) for elivaldogene autotemcel (eli-cel, Lenti-D™) Gene Therapy for Cerebral Adrenoleukodystrophy (CALD)","bluebird bio, Inc. (Nasdaq: BLUE) today announced that the European Medicines Agency (EMA) accepted the company’s marketing authorization application (MAA) for its investigational elivaldogene autotem...",51.65,54.06,51.45,53.4,BLUE,819214,HISTORICAL_PRICES,BLUE,,1.60683E+12,0.057968046,0.057968046,53.4,51.65,54.06,51.45,819214,53.4,51.65,54.06,51.45,819214,2-Oct-20,-2.2,-0.0409
1-Oct-20,"Hologic Announces Multi-Year, Multi-Pronged Commitment to Tackling Breast Cancer Screening Disparities for Black Women in Partnership with the Black Women’s Health Imperative and RAD-AID","Hologic, Inc. (Nasdaq: HOLX), an innovative medical technology company primarily focused on improving women’s health, today announced a multi-year commitment to decreasing breast cancer screening disp...",66.35,67.86,65.97,67,HOLX,1493961,HISTORICAL_PRICES,HOLX,,1.60683E+12,1.110368957,1.110368957,67,66.35,67.86,65.97,1493961,67,66.35,67.86,65.97,1493961,1-Oct-20,-0.12,-0.0018
1-Oct-20,INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of BioMarin Pharmaceuticals Inc. (BMRN) on Behalf of Investors,Law Offices of Howard G. Smith announces an investigation on behalf of BioMarin Pharmaceuticals Inc. (“BioMarin” or the “Company”) (NASDAQ: BMRN) investors concerning the Company’s possible violations...,75.82,77.24,75.33,77.02,BMRN,1157203,HISTORICAL_PRICES,BMRN,,1.60683E+12,-0.050826239,-0.050826239,77.02,75.82,77.24,75.33,1157203,77.02,75.82,77.24,75.33,1157203,1-Oct-20,-0.26,-0.0034
1-Oct-20,The Law Offices of Frank R. Cruz Announces Investigation of BioMarin Pharmaceuticals Inc. (BMRN) on Behalf of Investors,The Law Offices of Frank R. Cruz announces an investigation of BioMarin Pharmaceuticals Inc. (“BioMarin” or the “Company”) (NASDAQ: BMRN) on behalf of investors concerning the Company’s possible viola...,75.82,77.24,75.33,77.02,BMRN,1157203,HISTORICAL_PRICES,BMRN,,1.60683E+12,-0.050826239,-0.050826239,77.02,75.82,77.24,75.33,1157203,77.02,75.82,77.24,75.33,1157203,1-Oct-20,-0.26,-0.0034
1-Oct-20,Omeros Provides Update on Separate Payment for OMIDRIA® in the ASCs,Omeros Corporation (Nasdaq: OMER) today provided an update on the status of reimbursement for its cataract surgery drug OMIDRIA® (phenylephrine and ketorolac intraocular solution) 1%/0.3%. The two-yea...,10.34,10.56,9.87,10.11,OMER,1253643,HISTORICAL_PRICES,OMER,,1.60683E+12,-0.067628494,-0.067628494,10.11,10.34,10.56,9.87,1253643,10.11,10.34,10.56,9.87,1253643,1-Oct-20,0.235,0.0233
1-Oct-20,Quidel Announces Preliminary Revenue for Third Quarter 2020,"Quidel Corporation (NASDAQ: QDEL) (“Quidel”), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that it expects revenue...",225.54,244.9,219.61,239,QDEL,2268071,HISTORICAL_PRICES,QDEL,,1.60683E+12,1.631431572,1.631431572,239,225.54,244.9,219.61,2268071,239,225.54,244.9,219.61,2268071,1-Oct-20,6.16,0.0281
1-Oct-20,Ligand Completes Acquisition of Pfenex Inc.,"Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced it has completed its tender offer for all outstanding shares of Pfenex Inc. for $437.5 million in cash, plus one non-transferable con...",98.2,98.4,93.84,96,LGND,186856,HISTORICAL_PRICES,LGND,,1.60683E+12,0.323806956,0.323806956,96,98.2,98.4,93.84,186856,96,98.2,98.4,93.84,186856,1-Oct-20,2.88,0.0302
1-Oct-20,Pulse Biosciences Announces FDA IDE Approval and Initiation of Sebaceous Hyperplasia Study,"Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company progressing Nano-Pulse Stimulation™ (NPS™) technology, today announced FDA Investigational Device Exemption (IDE) approval...",11.66,12.24,11.4,11.86,PLSE,75736,HISTORICAL_PRICES,PLSE,,1.60683E+12,0.850793651,0.850793651,11.86,11.66,12.24,11.4,75736,11.86,11.66,12.24,11.4,75736,1-Oct-20,-0.13,-0.011
1-Oct-20,Orthofix FIREBIRD SI Fusion System Receives Additional FDA Clearance for Nanotechnology,"Orthofix Medical Inc. (NASDAQ:OFIX), a global medical device and biologics company with a spine and extremities focus, today announced the U.S. Food and Drug Administration (FDA) 510(k) clearance for...",31.39,31.8614,30.56,31.32,OFIX,104682,HISTORICAL_PRICES,OFIX,,1.60683E+12,0.149395826,0.149395826,31.32,31.39,31.8614,30.56,104682,31.32,31.39,31.8614,30.56,104682,1-Oct-20,0.25,0.008
1-Oct-20,Pfizer Receives FDA Fast Track Designation for Duchenne Muscular Dystrophy Investigational Gene Therapy,Pfizer Inc. (NYSE: PFE) today announced that its investigational gene therapy candidate (PF-06939926) being developed to treat Duchenne muscular dystrophy (DMD) received Fast Track designation from th...,36.37,37.09,36.1628,36.91,PFE,21366561,HISTORICAL_PRICES,PFE,,1.6118E+12,0.224579125,0.224579125,36.91,36.37,37.09,36.1628,21366561,36.1411,35.6124,36.3174,35.4095,21366561,1-Oct-20,-0.33,-0.009
30-Sep-20,TFF Pharmaceuticals Announces Results of Its 2020 Annual Meeting of Stockholders,"TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) t...",18.47,18.7,16.8258,17.15,TFFP,510589,HISTORICAL_PRICES,TFFP,,1.60683E+12,3.397619048,3.397619048,17.15,18.47,18.7,16.8258,510589,17.15,18.47,18.7,16.8258,510589,30-Sep-20,1.26,0.0732
30-Sep-20,Verastem Oncology Announces Closing of COPIKTRA® (duvelisib) Sale to Secura Bio,"Verastem, Inc. (Nasdaq:VSTM) (also known as Verastem Oncology), a biopharmaceutical company committed to advancing new medicines for patients battling cancer, today announced that it has completed the...",1.21,1.27,1.19,1.23,VSTM,3133404,HISTORICAL_PRICES,VSTM,,1.60683E+12,-0.444954128,-0.444954128,1.23,1.21,1.27,1.19,3133404,1.23,1.21,1.27,1.19,3133404,30-Sep-20,-0.02,-0.0163
30-Sep-20,Gilead Sciences Presents Data From HIV Research and Development Programs at HIV Glasgow 2020,"Gilead Sciences, Inc. (Nasdaq: GILD) today announced its upcoming contributions to the HIV Glasgow 2020 conference, taking place virtually from October 5-8. Gilead will present 13 studies from the com...",63.19,63.425,62.11,62.35,GILD,10072604,HISTORICAL_PRICES,GILD,,1.61552E+12,-0.145619254,-0.145619254,62.35,63.19,63.425,62.11,10072604,60.9584,61.7796,62.0094,60.7237,10072604,30-Sep-20,1.09,0.0176
30-Sep-20,"Lantheus Holdings Submits New Drug Application to the U.S. FDA for PyL™ (18F-DCFPyL), a PSMA-Targeted Prostate Cancer Imaging Agent","Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH), the parent company of Lantheus Medical Imaging, Inc. and Progenics Pharmaceuticals, Inc., and a global leader in the development, manufacture an...",12.67,12.8,12.43,12.45,LNTH,416952,HISTORICAL_PRICES,LNTH,,1.60683E+12,0.080136402,0.080136402,12.45,12.67,12.8,12.43,416952,12.45,12.67,12.8,12.43,416952,30-Sep-20,0.32,0.0259
30-Sep-20,Scholar Rock Presents Data for SRK-015 at the World Muscle Society 2020 Virtual Congress,"Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced two poster...",17.69,18.59,17.56,18.4,SRRK,151707,HISTORICAL_PRICES,SRRK,,1.60683E+12,0.290299052,0.290299052,18.4,17.69,18.59,17.56,151707,18.4,17.69,18.59,17.56,151707,30-Sep-20,-0.78,-0.0422
30-Sep-20,New Publication Highlights Therapeutic Potential of Endogenous Metabolic Modulators (EMMs),"Axcella (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases and improve health using endogenous metabolic modulator (EMM) compositions, today ann...",4.62,4.78,4.55,4.7,AXLA,119880,HISTORICAL_PRICES,AXLA,,1.60683E+12,0.566101695,0.566101695,4.7,4.62,4.78,4.55,119880,4.7,4.62,4.78,4.55,119880,30-Sep-20,-0.07,-0.0149
30-Sep-20,Alnylam Reports Positive Topline Results from ILLUMINATE-B Phase 3 Study of Lumasiran for the Treatment of Primary Hyperoxaluria Type 1 in Children Under the Age of Six,"Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today positive topline results from the ILLUMINATE-B pediatric Phase 3 study of lumasiran, an investigati...",145.6,147,142.37,144.17,ALNY,548027,HISTORICAL_PRICES,ALNY,,1.60683E+12,0.456874124,0.456874124,144.17,145.6,147,142.37,548027,144.17,145.6,147,142.37,548027,30-Sep-20,0.59,0.0041
29-Sep-20,Moderna Announces Publication in The New England Journal of Medicine of Interim Results From Older Adult Age Cohorts in Phase 1 Study of its mRNA Vaccine Against COVID-19 (mRNA-1273),"Moderna, Inc., (Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced the...",70.52,71.34,69.5851,70.46,MRNA,6294318,HISTORICAL_PRICES,MRNA,,1.60683E+12,1.731216112,1.731216112,70.46,70.52,71.34,69.5851,6294318,70.46,70.52,71.34,69.5851,6294318,29-Sep-20,-0.03,-0.0004
29-Sep-20,"Applied DNA Signs Master Services Agreement with Stony Brook University Hospital for COVID-19 Diagnostic Assay Kit and Automated Systems, Receives Initial Purchase Order","Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA” or the ""Company""), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing that enables in vitro diagnostics, pre-clinical nucleic...",7.8,8.94,7.715,8.38,APDN,621718,HISTORICAL_PRICES,APDN,,1.60683E+12,0.95,0.95,8.38,7.8,8.94,7.715,621718,8.38,7.8,8.94,7.715,621718,29-Sep-20,-0.54,-0.0647
29-Sep-20,"SHAREHOLDER ACTION REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against BioMarin Pharmaceutical Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm","The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against BioMarin Pharmaceutical Inc. (“BioMarin” or “the Company”) (NASDAQ: BMRN) for...",76,78.37,75.94,78.12,BMRN,1320921,HISTORICAL_PRICES,BMRN,,1.60683E+12,-0.048572859,-0.048572859,78.12,76,78.37,75.94,1320921,78.12,76,78.37,75.94,1320921,29-Sep-20,-1.99,-0.0255
29-Sep-20,Ocular Therapeutix™ Announces First Patients Dosed in Phase 2 Clinical Trial of OTX-CSI for the Treatment of Dry Eye Disease,"Ocular Therapeutix™, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, tod...",7.81,8.06,7.615,7.96,OCUL,867293,HISTORICAL_PRICES,OCUL,,1.60683E+12,0.587398374,0.587398374,7.96,7.81,8.06,7.615,867293,7.96,7.81,8.06,7.615,867293,29-Sep-20,-0.09,-0.0114
29-Sep-20,TransAct Launches Innovative BOHA!™ Restaurant Operations Platform Based on iPad,"TransAct® Technologies Incorporated (Nasdaq: TACT) (“TransAct” or “the Company”), a global leader in software-driven technology and printing solutions for high-growth markets, today announced the laun...",5.03,5.03,4.8899,4.9,TACT,3179,HISTORICAL_PRICES,TACT,,1.60683E+12,0.27020202,0.27020202,4.9,5.03,5.03,4.8899,3179,4.9,5.03,5.03,4.8899,3179,29-Sep-20,0.08,0.0162
29-Sep-20,PolarityTE Announces Termination of Shareholder Rights Plan,"PolarityTE, Inc. (Nasdaq: PTE) today announced that the Board of Directors voted to terminate the Company’s shareholder rights plan after receiving stockholder input and evaluating that input in the c...",1.02,1.05,1.01,1.01,PTE,127679,HISTORICAL_PRICES,PTE,,1.60683E+12,-0.081081081,-0.081081081,1.01,1.02,1.05,1.01,127679,1.01,1.02,1.05,1.01,127679,29-Sep-20,-0.01,-0.0097
29-Sep-20,Infinity Receives Fast Track Designation for Eganelisib in Combination with a Checkpoint Inhibitor and Chemotherapy for First-Line Treatment of Advanced TNBC,"Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for eganelisib (IPI-549) in combination with a checkpo...",1.15,1.16,1.08,1.14,INFI,1217963,HISTORICAL_PRICES,INFI,,1.60683E+12,0.321231618,0.321231618,1.14,1.15,1.16,1.08,1217963,1.14,1.15,1.16,1.08,1217963,29-Sep-20,0.02,0.0177
29-Sep-20,Pulse Biosciences Announces Receipt of MDSAP Certification,"Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company progressing Nano-Pulse Stimulation™ (NPS™) technology, today announced the receipt of Medical Device Single Audit Program c...",12.23,12.26,11.57,11.8,PLSE,60611,HISTORICAL_PRICES,PLSE,,1.60683E+12,0.941269841,0.941269841,11.8,12.23,12.26,11.57,60611,11.8,12.23,12.26,11.57,60611,29-Sep-20,0.51,0.0435
29-Sep-20,Ironwood to Discontinue IW-3718 Development Program Following Results from Planned Efficacy Assessment,"Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD), a GI-focused healthcare company, today announced that data from IW-3718-302, one of Ironwood’s two identical Phase III trials evaluating IW-3718 in refra...",9.42,9.5,8.63,8.86,IRWD,8059642,HISTORICAL_PRICES,IRWD,,1.60683E+12,-0.060817547,-0.060817547,8.86,9.42,9.5,8.63,8059642,8.86,9.42,9.5,8.63,8059642,29-Sep-20,-0.11,-0.0115
29-Sep-20,AngioDynamics Reports Fiscal 2021 First Quarter Financial Results,"AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced financial resul...",12.74,12.86,10.79,11.06,ANGO,2016990,HISTORICAL_PRICES,ANGO,,1.60683E+12,0.324324324,0.324324324,11.06,12.74,12.86,10.79,2016990,11.06,12.74,12.86,10.79,2016990,29-Sep-20,2.07,0.194
29-Sep-20,Aerie Pharmaceuticals Announces Acceptance of Its Investigational New Drug Application for AR-15512 (TRPM8 Agonist) Eye Drop for Dry Eye Disease,"Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients w...",11.43,11.46,10.97,11.13,AERI,501353,HISTORICAL_PRICES,AERI,,1.60683E+12,-0.152705708,-0.152705708,11.13,11.43,11.46,10.97,501353,11.13,11.43,11.46,10.97,501353,29-Sep-20,0.4,0.0363
28-Sep-20,Quidel Corporation Statement on President Trump’s Announcement of Coronavirus Testing Strategy,"Quidel Corporation (NASDAQ: QDEL) (“Quidel”), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, issued the following statement supporti...",198.64,200.9,194.3292,198.79,QDEL,698544,HISTORICAL_PRICES,QDEL,,1.60683E+12,1.317582546,1.317582546,198.79,198.64,200.9,194.3292,698544,198.79,198.64,200.9,194.3292,698544,28-Sep-20,1.87,0.0095
28-Sep-20,U.S. FDA Approves Pfizer’s XELJANZ® (tofacitinib) for the Treatment of Active Polyarticular Course Juvenile Idiopathic Arthritis,Pfizer Inc. (NYSE: PFE) announced today that the United States (U.S.) Food and Drug Administration (FDA) approved XELJANZ® (tofacitinib) for the treatment of children and adolescents 2 years and older...,36.39,36.575,36.16,36.16,PFE,14273515,HISTORICAL_PRICES,PFE,,1.6118E+12,0.225252525,0.225252525,36.16,36.39,36.575,36.16,14273515,35.4067,35.6319,35.8131,35.4067,14273515,28-Sep-20,0.34,0.0094
28-Sep-20,JetBlue and Vault Health Partner to Make At-Home COVID-19 Tests More Widely Available to Customers,JetBlue (NASDAQ: JBLU) today announced it is partnering with Vault Health to make COVID-19 testing widely available to customers with pending travel plans. The reliable at-home test option provides co...,11.95,12.275,11.6919,11.93,JBLU,8518731,HISTORICAL_PRICES,JBLU,,1.60683E+12,0.271276596,0.271276596,11.93,11.95,12.275,11.6919,8518731,11.93,11.95,12.275,11.6919,8518731,28-Sep-20,0.42,0.0364
28-Sep-20,"SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against BioMarin Pharmaceutical Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm","The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against BioMarin Pharmaceutical Inc. (“BioMarin” or “the Company”) (NASDAQ: BMRN) for...",77.99,79.21,77.72,78.55,BMRN,1458890,HISTORICAL_PRICES,BMRN,,1.60683E+12,-0.023660491,-0.023660491,78.55,77.99,79.21,77.72,1458890,78.55,77.99,79.21,77.72,1458890,28-Sep-20,0.6,0.0078
28-Sep-20,EQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against BioMarin Pharmaceutical Inc. – BMRN,"Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) between Febru...",77.99,79.21,77.72,78.55,BMRN,1458890,HISTORICAL_PRICES,BMRN,,1.60683E+12,-0.023660491,-0.023660491,78.55,77.99,79.21,77.72,1458890,78.55,77.99,79.21,77.72,1458890,28-Sep-20,0.6,0.0078
28-Sep-20,Cerus Corporation Announces Schedule of Presentations at the AABB 2020 Virtual Annual Meeting,"Cerus Corporation (Nasdaq:CERS) announced today its lineup of abstract presentations at the AABB 2020 Virtual Annual Meeting, which will take place on October 3rd through October 5th. This year’s Virt...",6.13,6.215,6.05,6.15,CERS,1490397,HISTORICAL_PRICES,CERS,,1.60683E+12,0.592207792,0.592207792,6.15,6.13,6.215,6.05,1490397,6.15,6.13,6.215,6.05,1490397,28-Sep-20,0.05,0.0082
28-Sep-20,Aptinyx Recommences Patient Recruitment in Phase 2 Study of NYX-2925 in Patients with Fibromyalgia,"Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that it has re-acti...",3.23,3.27,3.09,3.14,APTX,111222,HISTORICAL_PRICES,APTX,,1.60683E+12,0.481651376,0.481651376,3.14,3.23,3.27,3.09,111222,3.14,3.23,3.27,3.09,111222,28-Sep-20,0.09,0.0287
28-Sep-20,Hologic Granted FDA Emergency Use Authorization for Asymptomatic COVID-19 Testing with Panther Fusion SARS-CoV-2 Assay,"Hologic, Inc. (Nasdaq: HOLX) announced today that its Panther Fusion® SARS-CoV-2 assay has received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for testing of in...",65.77,66.61,65.1,65.73,HOLX,1630054,HISTORICAL_PRICES,HOLX,,1.60683E+12,1.09192112,1.09192112,65.73,65.77,66.61,65.1,1630054,65.73,65.77,66.61,65.1,1630054,28-Sep-20,1.42,0.0221
28-Sep-20,"Catabasis Pharmaceuticals Presents Information on Edasalonexent, a Potential Foundational Therapy for Duchenne Muscular Dystrophy, at the Virtual 25th International Congress of the World Muscle Society","Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today shared information on the edasalonexent program in Phase 3 development for Duchenne muscular dystrophy...",6.24,6.49,6.06,6.45,CATB,215990,HISTORICAL_PRICES,CATB,,1.60683E+12,0.616580311,0.616580311,6.45,6.24,6.49,6.06,215990,6.45,6.24,6.49,6.06,215990,28-Sep-20,-0.05,-0.0079
28-Sep-20,Masimo Announces FDA Clearance of the Rad-G™ Pulse Oximeter,"Masimo (NASDAQ: MASI) announced today FDA clearance of the Rad-G™ Pulse Oximeter, a rugged handheld device that provides clinically proven SET® pulse oximetry, respiration rate from the pleth (RRp®),...",230.76,232.5,226.5101,227.01,MASI,367337,HISTORICAL_PRICES,MASI,,1.60683E+12,0.484942085,0.484942085,227.01,230.76,232.5,226.5101,367337,227.01,230.76,232.5,226.5101,367337,28-Sep-20,4.86,0.0215
28-Sep-20,"AVROBIO Receives Orphan Drug Designation from the European Medicines Agency for AVR-RD-02, an Investigational Gene Therapy for Gaucher Disease","AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that the European Commission (EC) has gran...",12.99,14.25,12.92,14.25,AVRO,159459,HISTORICAL_PRICES,AVRO,,1.60683E+12,-0.104137931,-0.104137931,14.25,12.99,14.25,12.92,159459,14.25,12.99,14.25,12.92,159459,28-Sep-20,-0.6,-0.0442
25-Sep-20,Glancy Prongay & Murray LLP Continues Investigation of Huazhu Group Limited (HTHT) on Behalf of Investors,Glancy Prongay & Murray LLP (“GPM”) continues its investigation on behalf of Huazhu Group Limited (“Huazhu” or the “Company”) (NASDAQ: HTHT) investors concerning the Company’s possible violations...,42.69,42.95,41.56,42,HTHT,2102471,HISTORICAL_PRICES,HTHT,,1.60683E+12,0.474611399,0.474611399,42,42.69,42.95,41.56,2102471,42,42.69,42.95,41.56,2102471,25-Sep-20,0.24,0.0057
25-Sep-20,Novocure Honors Mesothelioma Day with Activities to Raise Awareness of Mesothelioma and Support the Community,"Novocure (NASDAQ: NVCR) announced today initiatives to bring attention to Mesothelioma Awareness Day on September 26. In partnership with the Mesothelioma Applied Research Foundation, Novocure has arr...",106.9,107.58,103,103.35,NVCR,546556,HISTORICAL_PRICES,NVCR,,1.60683E+12,0.754760341,0.754760341,103.35,106.9,107.58,103,546556,103.35,106.9,107.58,103,546556,25-Sep-20,3.26,0.0315
25-Sep-20,Vivet Therapeutics y Pfizer Inc. firman un acuerdo para la fabricación del producto de terapia génica en investigación desarrollado por Vivet para la enfermedad de Wilson,"Vivet Therapeutics (""Vivet""), empresa privada de biotecnología enterapia génica dedicada al desarrollo de tratamientos para enfermedades hereditarias hepáticas graves , y Pfizer Inc. (NYSE: PFE) han a...",36.05,36.15,35.52,35.54,PFE,13629626,HISTORICAL_PRICES,PFE,,1.6118E+12,0.213804714,0.213804714,35.54,36.05,36.15,35.52,13629626,34.7996,35.299,35.3969,34.7801,13629626,25-Sep-20,0.29,0.0081
25-Sep-20,TherapeuticsMD Provides Update on Third Quarter Progress,"TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative women’s healthcare company, today announced that the Company is on track to meet or exceed third quarter 2020 total net revenue consensus of $15.1 mi...",1.41,1.49,1.38,1.4157,TXMD,4491164,HISTORICAL_PRICES,TXMD,,1.60683E+12,0.18487395,0.18487395,1.4157,1.41,1.49,1.38,4491164,1.4157,1.41,1.49,1.38,4491164,25-Sep-20,0.1,0.0763
25-Sep-20,FDA Approves KALYDECO® (ivacaftor) as First and Only CFTR Modulator to Treat Eligible Infants With CF as Early as Four Months of Age,Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) approved KALYDECO® (ivacaftor) for use in children with cystic fibrosis (CF) ages four mo...,268.18,268.91,260.52,264.1,VRTX,1345847,HISTORICAL_PRICES,VRTX,,1.60683E+12,0.201900238,0.201900238,264.1,268.18,268.91,260.52,1345847,264.1,268.18,268.91,260.52,1345847,25-Sep-20,5.05,0.0192
25-Sep-20,U.S. MRTP Authorization Pathway Explored in PMI’s Latest Scientific Update,"Philip Morris International (PMI) (NYSE: PM) has released the 11th edition of its Scientific Update, a regularly issued publication on its research efforts to develop and scientifically assess a range...",75.4,76.0059,75.12,75.68,PM,3836607,HISTORICAL_PRICES,PM,,1.61612E+12,0.185534591,0.185534591,75.68,75.4,76.0059,75.12,3836607,73.6125,73.3402,73.9295,73.0678,3836607,25-Sep-20,-0.95,-0.0124
24-Sep-20,"Opdivo (nivolumab) Significantly Improves Disease Free-Survival vs. Placebo as Adjuvant Therapy for Patients with High-Risk, Muscle-Invasive Urothelial Carcinoma in Phase 3 CheckMate -274 Trial","Bristol Myers Squibb (NYSE: BMY) today announced that CheckMate -274, a pivotal Phase 3 trial evaluating Opdivo (nivolumab) after surgery in patients with high-risk, muscle-invasive urothelial carcino...",58.25,58.82,57.7,58.48,BMY,10358751,HISTORICAL_PRICES,BMY,,1.60946E+12,0.182981316,0.182981316,58.48,58.25,58.82,57.7,10358751,57.5842,57.3577,57.919,56.8161,10358751,24-Sep-20,-0.74,-0.0125
24-Sep-20,Marinus Provides Corporate Update on Phase 3 RAISE Trial in Status Epilepticus (SE),"Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders, today announced it has satisfied the FDA...",10.7,11.88,10.61,11.76,MRNS,1404913,HISTORICAL_PRICES,MRNS,,1.60683E+12,0.273809524,0.273809524,11.76,10.7,11.88,10.61,1404913,11.76,10.7,11.88,10.61,1404913,24-Sep-20,-1.86,-0.1481
24-Sep-20,TFF Pharmaceuticals Comments on Animal Studies in the Development of High Potency Remdesivir as a Dry Powder for Inhalation by Thin Film Freezing,"TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) t...",16.2,16.97,15.396,16.25,TFFP,223144,HISTORICAL_PRICES,TFFP,,1.60683E+12,2.857142857,2.857142857,16.25,16.2,16.97,15.396,223144,16.25,16.2,16.97,15.396,223144,24-Sep-20,-0.23,-0.014
24-Sep-20,ADC Therapeutics annonce l'évaluation d'une offre publique,"ADC Therapeutics SA (NYSE:ADCT), une société de biotechnologie axée sur l'oncologie au stade clinique avancé, pionnière dans le développement et la commercialisation de conjugués anticorps-médicaments...",33.5,34.35,32.52,34.26,ADCT,1411770,HISTORICAL_PRICES,ADCT,,1.60683E+12,0.129848229,0.129848229,34.26,33.5,34.35,32.52,1411770,34.26,33.5,34.35,32.52,1411770,24-Sep-20,-0.66,-0.0193
24-Sep-20,Aerie Pharmaceuticals Announces Successful Interim 90-Day Topline Data From Its Six-Month Mercury 3 Clinical Trial in Europe,"Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients wi...",11.64,11.78,11.08,11.265,AERI,706067,HISTORICAL_PRICES,AERI,,1.60683E+12,-0.137138621,-0.137138621,11.265,11.64,11.78,11.08,706067,11.265,11.64,11.78,11.08,706067,24-Sep-20,0.01,0.0009
24-Sep-20,ADC Therapeutics gibt Preisgestaltung des öffentlichen Zeichnungsangebots bekannt,"ADC Therapeutics SA (NYSE:ADCT), ein im Bereich der späten klinischen Forschung tätiges Biotechnologieunternehmen mit Schwerpunkt auf Onkologie und Vorreiter in der Entwicklung und Vermarktung von hoc...",33.5,34.35,32.52,34.26,ADCT,1411770,HISTORICAL_PRICES,ADCT,,1.60683E+12,0.129848229,0.129848229,34.26,33.5,34.35,32.52,1411770,34.26,33.5,34.35,32.52,1411770,24-Sep-20,-0.66,-0.0193
23-Sep-20,ADC Therapeutics Announces Pricing of Public Offering,"ADC Therapeutics SA (NYSE:ADCT), a late clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of highly potent and targeted antibody drug conjugates fo...",34.16,36.93,31.7,36.93,ADCT,685463,HISTORICAL_PRICES,ADCT,,1.60683E+12,0.152107926,0.152107926,36.93,34.16,36.93,31.7,685463,36.93,34.16,36.93,31.7,685463,23-Sep-20,-1.75,-0.0487
23-Sep-20,Glancy Prongay & Murray LLP Continues Investigation on Behalf of Legend Biotech Corporation Investors (LEGN),Glancy Prongay & Murray LLP (“GPM”) continues its investigation on behalf of Legend Biotech Corporation (“Legend” or the “Company”) (NASDAQ: LEGN) investors concerning the Company’s possible viola...,28.9,29.26,28.59,29.15,LEGN,257100,HISTORICAL_PRICES,LEGN,,1.60683E+12,-0.218918919,-0.218918919,29.15,28.9,29.26,28.59,257100,29.15,28.9,29.26,28.59,257100,23-Sep-20,-0.29,-0.0099
23-Sep-20,Revance Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4),"Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company focused on innovative aesthetic and therapeutic offerings, including its investigational neuromodulator product, DaxibotulinumtoxinA...",26.48,28.04,26.41,27.45,RVNC,635782,HISTORICAL_PRICES,RVNC,,1.60683E+12,0.891428571,0.891428571,27.45,26.48,28.04,26.41,635782,27.45,26.48,28.04,26.41,635782,23-Sep-20,-0.96,-0.035
23-Sep-20,Surmodics Receives FDA 510(k) Clearance for Pounce™ Thrombus Retrieval System,"Surmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, announced it has received U.S. Food and Drug Administration (FDA)...",38.54,39.6288,38.13,38.45,SRDX,64759,HISTORICAL_PRICES,SRDX,,1.60683E+12,0.330341733,0.330341733,38.45,38.54,39.6288,38.13,64759,38.45,38.54,39.6288,38.13,64759,23-Sep-20,0.08,0.0021
23-Sep-20, Baxter Announces U.S. FDA Approval of Clinimix and Clinimix E with Higher Protein for Patients Requiring Parenteral Nutrition,"Baxter International Inc. (NYSE: BAX), a global leader in clinical nutrition, today announced the U.S. Food and Drug Administration (FDA) approval of new formulations of Clinimix (amino acids in dextr...",78.33,79.87,78.28,79.4,BAX,2028206,HISTORICAL_PRICES,BAX,,1.61422E+12,0.059802462,0.059802462,79.4,78.33,79.87,78.28,2028206,78.8982,77.835,79.3653,77.7853,2028206,23-Sep-20,-0.72,-0.0091
23-Sep-20,Ligand Announces its Captisol Business is Positioned for Major Growth and Forecasts 2021 Captisol Material Sales of $200 Million,Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces that recent new contracting with partners and investments in manufacturing capacity have contributed to its Captisol business operating at...,93.18,99.6,92.64,99.6,LGND,780034,HISTORICAL_PRICES,LGND,,1.60683E+12,0.256133729,0.256133729,99.6,93.18,99.6,92.64,780034,99.6,93.18,99.6,92.64,780034,23-Sep-20,3.62,0.0404
23-Sep-20,Catabasis Pharmaceuticals to Present During the Virtual 25th International Congress of the World Muscle Society,"Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today announced that it will present information on the edasalonexent program, in Phase 3 development for the...",6.25,6.55,6.2,6.55,CATB,200297,HISTORICAL_PRICES,CATB,,1.60683E+12,0.619170984,0.619170984,6.55,6.25,6.55,6.2,200297,6.55,6.25,6.55,6.2,200297,23-Sep-20,-0.27,-0.0414
23-Sep-20,Veeva and Bioforum Partner with RedHill Biopharma to Maximize Value of Opaganib Phase 2/3 COVID-19 Clinical Data,Veeva Systems (NYSE: VEEV) (“Veeva”) and Bioforum today announced their collaboration with RedHill Biopharma Ltd. (Nasdaq: RDHL) (“RedHill”) on a global Phase 2/3 clinical study evaluating opaganib (Y...,270.57,277.36,269.82,274.52,VEEV,912775,HISTORICAL_PRICES,VEEV,,1.60683E+12,0.866901263,0.866901263,274.52,270.57,277.36,269.82,912775,274.52,270.57,277.36,269.82,912775,23-Sep-20,-2.87,-0.0105
23-Sep-20,Humanigen Announces Thermo Fisher Partnership to Expand Manufacturing for COVID-19 Therapeutic Candidate Lenzilumab,"Humanigen, Inc., (Nasdaq: HGEN) (“Humanigen”), a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm’ with its lead drug candida...",10.31,11.55,10.2,11,HGEN,600088,HISTORICAL_PRICES,HGEN,,1.60683E+12,0.068393782,0.068393782,11,10.31,11.55,10.2,600088,11,10.31,11.55,10.2,600088,23-Sep-20,-0.05,-0.0048
23-Sep-20,FDA Accepts Supplemental New Drug Application for Pfizer’s XALKORI® (crizotinib) for the Treatment of Pediatric ALK-positive Anaplastic Large Cell Lymphoma,Pfizer Inc. (NYSE:PFE) today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted priority review to the Company’s supplemental New Drug Application(sNDA)for XALKORI® (c...,36,36.3779,35.965,36.34,PFE,21918884,HISTORICAL_PRICES,PFE,,1.6118E+12,0.212121212,0.212121212,36.34,36,36.3779,35.965,21918884,35.583,35.2501,35.6201,35.2158,21918884,23-Sep-20,-0.25,-0.0069
23-Sep-20,bluebird bio’s LentiGlobin™ for Sickle Cell Disease Gene Therapy (bb1111) Granted Priority Medicines (PRIME) Designation by European Medicines Agency,"bluebird bio, Inc. (Nasdaq: BLUE) announced today that its investigational treatment for sickle cell disease (SCD), LentiGlobin™ for SCD gene therapy (bb1111), was granted eligibility to the Priority...",55.95,58.48,55.5,55.71,BLUE,821931,HISTORICAL_PRICES,BLUE,,1.60683E+12,0.146046702,0.146046702,55.71,55.95,58.48,55.5,821931,55.71,55.95,58.48,55.5,821931,23-Sep-20,0.37,0.0067
22-Sep-20,Vivet Therapeutics and Pfizer Inc. Enter into Manufacturing Agreement for Vivet’s Investigational Gene Therapy for Wilson Disease,"Vivet Therapeutics (“Vivet”), a privately held gene therapy biotech company dedicated to developing treatments for inherited liver disorders with high unmet medical need, and Pfizer Inc. (NYSE: PFE) a...",36.25,36.33,35.74,35.81,PFE,21562861,HISTORICAL_PRICES,PFE,,1.6118E+12,0.220538721,0.220538721,35.81,36.25,36.33,35.74,21562861,35.064,35.4949,35.5732,34.9955,21562861,22-Sep-20,0.23,0.0064
22-Sep-20,Frequency Therapeutics Completes Enrollment of FX-322 Phase 2a Study for Sensorineural Hearing Loss,"Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage biotechnology company focused on harnessing the body’s innate biology to repair or reverse damage caused by a broad range of degenerative...",22.47,24.27,21.68,23.99,FREQ,153857,HISTORICAL_PRICES,FREQ,,1.60683E+12,0.308677927,0.308677927,23.99,22.47,24.27,21.68,153857,23.99,22.47,24.27,21.68,153857,22-Sep-20,-1.8,-0.0742
22-Sep-20,Seres Therapeutics to Present at the Jefferies Next Generation IBD Therapeutics Summit,"Seres Therapeutics, Inc. (Nasdaq: MCRB) today announced that it will present a corporate overview at the Jefferies Next Generation IBD Therapeutics Summit on Wednesday, September 23 at 8:00 a.m. E.T....",26.49,26.81,25.26,26.62,MCRB,479485,HISTORICAL_PRICES,MCRB,,1.60683E+12,6.504249292,6.504249292,26.62,26.49,26.81,25.26,479485,26.62,26.49,26.81,25.26,479485,22-Sep-20,0.22,0.0084
22-Sep-20,"U.S. Food and Drug Administration (FDA) Accepts for Priority Review Bristol Myers Squibb and bluebird bio Application for Anti-BCMA CAR T Cell Therapy Idecabtagene Vicleucel (Ide-cel, bb2121)","Bristol Myers Squibb (NYSE: BMY) and bluebird bio, Inc. (Nasdaq: BLUE) today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review their Biologics License Applica...",58.76,58.845,57.63,57.77,BMY,12466793,HISTORICAL_PRICES,BMY,,1.60946E+12,0.193338749,0.193338749,57.77,58.76,58.845,57.63,12466793,56.8851,57.8599,57.9436,56.7472,12466793,22-Sep-20,0.99,0.0171
21-Sep-20,ADC Therapeutics stellt Antrag auf Biologikazulassung bei der US-amerikanischen Food and Drug Administration für Loncastuximab Tesirin zur Behandlung von rezidiviertem oder refraktärem diffus großzelligem B-Zell-Lymphom,"ADC Therapeutics SA (NYSE: ADCT), ein im Bereich der späten klinischen Forschung tätiges Biotechnologieunternehmen mit Schwerpunkt auf Onkologie, das Vorreiter bei der Entwicklung und Vermarktung von...",45.25,46.2,41.935,44.27,ADCT,87225,HISTORICAL_PRICES,ADCT,,1.60683E+12,0.52613828,0.52613828,44.27,45.25,46.2,41.935,87225,44.27,45.25,46.2,41.935,87225,21-Sep-20,-0.25,-0.0055
21-Sep-20,ADC Therapeutics kündigt geplantes öffentliches Zeichnungsangebot an,"ADC Therapeutics SA (NYSE: ADCT), ein im Bereich der späten klinischen Forschung tätiges Biotechnologieunternehmen mit Schwerpunkt auf Onkologie und Vorreiter in der Entwicklung und Vermarktung von ho...",45.25,46.2,41.935,44.27,ADCT,87225,HISTORICAL_PRICES,ADCT,,1.60683E+12,0.52613828,0.52613828,44.27,45.25,46.2,41.935,87225,44.27,45.25,46.2,41.935,87225,21-Sep-20,-0.25,-0.0055
21-Sep-20,ADC Therapeutics annonce une proposition d'offre publique de souscription,"ADC Therapeutics SA (NYSE:ADCT), une société biotechnologique spécialisée en oncologie au stade clinique avancé, à l’avant-garde du développement et de la mise sur le marché de conjugués anticorps-méd...",45.25,46.2,41.935,44.27,ADCT,87225,HISTORICAL_PRICES,ADCT,,1.60683E+12,0.52613828,0.52613828,44.27,45.25,46.2,41.935,87225,44.27,45.25,46.2,41.935,87225,21-Sep-20,-0.25,-0.0055
21-Sep-20,ADC Therapeutics Announces Proposed Public Offering,"ADC Therapeutics SA (NYSE:ADCT), a late clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of highly potent and targeted antibody drug conjugates fo...",45.25,46.2,41.935,44.27,ADCT,87225,HISTORICAL_PRICES,ADCT,,1.60683E+12,0.52613828,0.52613828,44.27,45.25,46.2,41.935,87225,44.27,45.25,46.2,41.935,87225,21-Sep-20,-0.25,-0.0055
21-Sep-20,ADC Therapeutics Submits Biologics License Application to the U.S. Food and Drug Administration for Loncastuximab Tesirine for Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma,"ADC Therapeutics SA (NYSE: ADCT), a late clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of highly potent and targeted antibody drug conjugates (...",45.25,46.2,41.935,44.27,ADCT,87225,HISTORICAL_PRICES,ADCT,,1.60683E+12,0.52613828,0.52613828,44.27,45.25,46.2,41.935,87225,44.27,45.25,46.2,41.935,87225,21-Sep-20,-0.25,-0.0055
21-Sep-20,Opdivo (nivolumab) Demonstrated Superior Disease-Free Survival in Patients with Resected Esophageal or Gastroesophageal Junction Cancer Compared to Placebo in the Adjuvant Setting,Bristol Myers Squibb (NYSE: BMY) today announced first results from the Phase 3 CheckMate -577 trial in which adjuvant treatment with Opdivo (nivolumab) showed a statistically significant and clinical...,57.77,58.96,56.9,58.92,BMY,16199704,HISTORICAL_PRICES,BMY,,1.60946E+12,0.173233144,0.173233144,58.92,57.77,58.96,56.9,16199704,58.0174,56.8851,58.0568,56.0284,16199704,21-Sep-20,-1.5,-0.0253
21-Sep-20,Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy Reduced Risk of Death by 27% Versus Chemotherapy as First-Line Treatment for Locally Advanced or Metastatic Esophageal Cancer,"Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced first-time data from the pivotal Phase 3 KEYNOTE-590 trial evaluating KEYTRUDA, Merck’s anti-PD-1 therapy, in comb...",83.13,85.34,82.09,84.92,MRK,9967055,HISTORICAL_PRICES,MRK,,1.61552E+12,0.20391021,0.20391021,84.92,83.13,85.34,82.09,9967055,83.5208,81.7603,83.9339,80.7374,9967055,21-Sep-20,-2.68,-0.0312
21-Sep-20,Opdivo (nivolumab) Plus Chemotherapy Demonstrated Significant Overall and Progression-Free Survival Benefits Versus Chemotherapy in First-Line Treatment of Gastric and Esophageal Cancers,"Bristol Myers Squibb (NYSE: BMY) today announced primary results from CheckMate -649, the pivotal Phase 3 trial in which first-line treatment with Opdivo (nivolumab) plus chemotherapy showed a statist...",57.77,58.96,56.9,58.92,BMY,16199704,HISTORICAL_PRICES,BMY,,1.60946E+12,0.173233144,0.173233144,58.92,57.77,58.96,56.9,16199704,58.0174,56.8851,58.0568,56.0284,16199704,21-Sep-20,-1.5,-0.0253
21-Sep-20,Seattle Genetics and Genmab Present Data from Tisotumab Vedotin innovaTV 204 Pivotal Trial in Recurrent or Metastatic Cervical Cancer at ESMO Virtual Congress 2020,"Seattle Genetics, Inc. (Nasdaq:SGEN) and Genmab A/S (Nasdaq: GMAB) today presented data from the innovaTV 204 pivotal phase 2, single-arm clinical trial evaluating tisotumab vedotin as monotherapy in...",178.83,181.19,177.37,178.74,SGEN,1243931,HISTORICAL_PRICES,SGEN,,1.60683E+12,0.755472661,0.755472661,178.74,178.83,181.19,177.37,1243931,178.74,178.83,181.19,177.37,1243931,21-Sep-20,-2.11,-0.0117
21-Sep-20,NantKwest to Present at the 7th Annual Jefferies Cell Therapy Summit,"NantKwest, Inc. (NASDAQ: NK), a clinical-stage, natural killer cell-based therapeutics company, today announced that Patrick Soon-Shiong, M.D., Chairman and CEO, will present at the virtual Jefferies...",8.05,8.31,7.77,8.13,NK,1070315,HISTORICAL_PRICES,NK,,1.60683E+12,1.701342282,1.701342282,8.13,8.05,8.31,7.77,1070315,8.13,8.05,8.31,7.77,1070315,21-Sep-20,-0.44,-0.0518
21-Sep-20,Applied DNA Enters into Supply Agreement with ITW Pillar Technologies to Bring CertainT® Platform to Textiles Including Those Used in Personal Protective Equipment,"Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA” or the ""Company""), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing that enables in vitro diagnostics, pre-clinical nucleic...",7.74,7.84,7.41,7.69,APDN,141514,HISTORICAL_PRICES,APDN,,1.60683E+12,0.935,0.935,7.69,7.74,7.84,7.41,141514,7.69,7.74,7.84,7.41,141514,21-Sep-20,-0.02,-0.0026
21-Sep-20,First-Line Treatment With Merck’s KEYTRUDA® (pembrolizumab) Doubled Five-Year Survival Rate (31.9%) Versus Chemotherapy (16.3%) in Certain Patients With Metastatic Non-Small Cell Lung Cancer Whose Tumors Express PD-L1 (TPS >50%),"Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced five-year survival results from the pivotal Phase 3 KEYNOTE-024 trial, which demonstrated a sustained, long-term s...",83.13,85.34,82.09,84.92,MRK,9967055,HISTORICAL_PRICES,MRK,,1.61552E+12,0.20391021,0.20391021,84.92,83.13,85.34,82.09,9967055,83.5208,81.7603,83.9339,80.7374,9967055,21-Sep-20,-2.68,-0.0312
21-Sep-20,"Genprex Names Seasoned IP Executive, Thomas C. Gallagher, as Senior Vice President of Intellectual Property and Licensing","Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX), a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes, today announce...",3.61,3.75,3.57,3.75,GNPX,806898,HISTORICAL_PRICES,GNPX,,1.60683E+12,0.249134948,0.249134948,3.75,3.61,3.75,3.57,806898,3.75,3.61,3.75,3.57,806898,21-Sep-20,-0.19,-0.05
21-Sep-20,PolarityTE Receives NIH Grant for a Point-of-Care Device to Treat Chronic Wounds,"PolarityTE, Inc. (Nasdaq: PTE) today announced it has received notification of being awarded a Phase I Small Business Innovation Research grant from the National Institutes of Health (NIH) for an appl...",1.05,1.16,1.05,1.09,PTE,297757,HISTORICAL_PRICES,PTE,,1.60683E+12,-0.054054054,-0.054054054,1.09,1.05,1.16,1.05,297757,1.09,1.05,1.16,1.05,297757,21-Sep-20,-0.05,-0.0455
21-Sep-20,Catabasis Pharmaceuticals Names Noah Clauser Chief Financial Officer,"Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, announced today that it has promoted Noah Clauser to Chief Financial Officer. Mr. Clauser brings close to 20...",6.68,6.83,6.6,6.78,CATB,229083,HISTORICAL_PRICES,CATB,,1.60683E+12,0.730569948,0.730569948,6.78,6.68,6.83,6.6,229083,6.78,6.68,6.83,6.6,229083,21-Sep-20,-0.32,-0.0457
21-Sep-20,AngioDynamics Announces Commercial Launch of Auryon Atherectomy System in United States,"AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced the launch of t...",9.92,9.95,9.47,9.76,ANGO,245526,HISTORICAL_PRICES,ANGO,,1.60683E+12,0.031185031,0.031185031,9.76,9.92,9.95,9.47,245526,9.76,9.92,9.95,9.47,245526,21-Sep-20,-0.05,-0.005
21-Sep-20,Oncternal Therapeutics Announces Presentation of Interim Phase 1 Clinical Trial Data for TK216 in Patients with Relapsed/Refractory Ewing Sarcoma at ESMO Virtual Congress 2020,"Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced the presentation of interim clinical dat...",2.12,2.2,2.0201,2.18,ONCT,89164,HISTORICAL_PRICES,ONCT,,1.60683E+12,-0.152,-0.152,2.18,2.12,2.2,2.0201,89164,2.18,2.12,2.2,2.0201,89164,21-Sep-20,-0.05,-0.023
21-Sep-20,LYNPARZA® (olaparib) Receives Positive Opinion from EU CHMP for Treatment of BRCA1/2 Metastatic Castration-Resistant Prostate Cancer (mCRPC),"AstraZeneca and Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (E...",83.13,85.34,82.09,84.92,MRK,9967055,HISTORICAL_PRICES,MRK,,1.61552E+12,0.20391021,0.20391021,84.92,83.13,85.34,82.09,9967055,83.5208,81.7603,83.9339,80.7374,9967055,21-Sep-20,-2.68,-0.0312
21-Sep-20,Axonics® Receives Health Canada Approval of Next Generation Implantable Neurostimulator,"Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing novel implantable sacral neuromodulation devices for the treatment of urina...",42.76,42.94,40.05,41.8,AXNX,494466,HISTORICAL_PRICES,AXNX,,1.60683E+12,1.039103481,1.039103481,41.8,42.76,42.94,40.05,494466,41.8,42.76,42.94,40.05,494466,21-Sep-20,-0.27,-0.0063
21-Sep-20,Insulet Expands its Offering of Omnipod DASH® Insulin Management System,"Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® Insulin Management System (Omnipod System), today announced it is c...",224.57,226.8614,218.645,222.09,PODD,359561,HISTORICAL_PRICES,PODD,,1.60683E+12,0.425750746,0.425750746,222.09,224.57,226.8614,218.645,359561,222.09,224.57,226.8614,218.645,359561,21-Sep-20,-0.45,-0.002
18-Sep-20,Incyte annonce les résultats encourageants de l'essai de Phase 2 sur le retifanlimab (INCMGA0012) chez des patients atteints d'un carcinome épidermoïde avancé du canal anal déjà traités,"Incyte (Nasdaq:INCY) a annoncé aujourd'hui les résultats de son essai de Phase 2 POD1UM-202 qui évalue le retifanlimab, un inhibiteur de PD-1, chez des patients déjà traités et atteints d'un carcinome...",86.79,91,85.65,90.76,INCY,3301707,HISTORICAL_PRICES,INCY,,1.60683E+12,0.287112561,0.287112561,90.76,86.79,91,85.65,3301707,90.76,86.79,91,85.65,3301707,18-Sep-20,-3.63,-0.0401
18-Sep-20,Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4),"Kala Pharmaceuticals, Inc. (NASDAQ:KALA), today announced that the Company granted non-statutory stock options to a new employee as inducement awards outside the Company’s 2017 Equity Incentive Plan i...",9.83,9.83,8.88,8.9,KALA,2147461,HISTORICAL_PRICES,KALA,,1.60683E+12,0.310666667,0.310666667,8.9,9.83,9.83,8.88,2147461,8.9,9.83,9.83,8.88,2147461,18-Sep-20,1.09,0.1247
18-Sep-20,"SHAREHOLDER ACTION REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Nano-X Imaging Ltd. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm","The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Nano-X Imaging Ltd. (“Nano-X” or “the Company”) (NASDAQ: NNOX) for violations...",34.88,35.97,29.33,31.1,NNOX,9614776,HISTORICAL_PRICES,NNOX,,1.60683E+12,0.607373272,0.607373272,31.1,34.88,35.97,29.33,9614776,31.1,34.88,35.97,29.33,9614776,18-Sep-20,6.78,0.2413
18-Sep-20,Incyte meldet vielversprechende Ergebnisse der Phase-2-Studie mit Retifanlimab (INCMGA0012) bei Patienten mit zuvor behandeltem fortgeschrittenem Plattenepithelkarzinom des Analkanals,"Incyte (Nasdaq:INCY) gab heute die Ergebnisse der Phase-2-Studie POD1UM-202 zur Untersuchung von Retifanlimab, einem PD-1-Inhibitor, bei zuvor behandelten Patienten mit fortgeschrittenem Plattenepithe...",86.79,91,85.65,90.76,INCY,3301707,HISTORICAL_PRICES,INCY,,1.60683E+12,0.287112561,0.287112561,90.76,86.79,91,85.65,3301707,90.76,86.79,91,85.65,3301707,18-Sep-20,-3.63,-0.0401
18-Sep-20,Nemaura Medical Appoints Justin Mclarney as Chief Finance Officer,"Nemaura Medical, Inc. (NASDAQ: NMRD)(“Nemaura” or the “Company”), a medical technology company focused on developing and commercializing non-invasive wearable diagnostic devices and supporting persona...",3.75,4.02,3.75,3.97,NMRD,64668,HISTORICAL_PRICES,NMRD,,1.60683E+12,-0.252988048,-0.252988048,3.97,3.75,4.02,3.75,64668,3.97,3.75,4.02,3.75,64668,18-Sep-20,-0.15,-0.0385
18-Sep-20,Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Approval of Opdivo (nivolumab) Plus Yervoy (ipilimumab) Combined with Two Cycles of Chemotherapy as First-Line Treatment of Metastatic Non-Small Cell Lung Cancer,Bristol Myers Squibb (NYSE: BMY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended approval of Opdivo® (nivolumab) p...,59.27,59.715,58.8275,59.09,BMY,13944502,HISTORICAL_PRICES,BMY,,1.60946E+12,0.203696182,0.203696182,59.09,59.27,59.715,58.8275,13944502,58.1848,58.3621,58.8003,57.9264,13944502,18-Sep-20,-0.13,-0.0022
18-Sep-20,Deciphera Presents Data from QINLOCK™ (Ripretinib) Program in Patients with Gastrointestinal Stromal Tumor at the European Society for Medical Oncology (ESMO) Virtual Congress 2020,"Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), today announced the presentation of nine month follow-up data from the Company’s Phase 3 INVICTUS study of QINLOCK in patients with fourth-line and fourt...",56.07,56.17,52.77,53.9,DCPH,1327034,HISTORICAL_PRICES,DCPH,,1.60683E+12,0.424904701,0.424904701,53.9,56.07,56.17,52.77,1327034,53.9,56.07,56.17,52.77,1327034,18-Sep-20,3.5,0.0666
18-Sep-20,Seattle Genetics and Astellas Announce PADCEV® (enfortumab vedotin-ejfv) Significantly Improved Overall Survival in Phase 3 Trial in Previously Treated Locally Advanced or Metastatic Urothelial Cancer,"Seattle Genetics, Inc. (Nasdaq:SGEN) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) today announced that a phase 3 trial of PADCEV® (enfortumab vedotin-ejfv...",180.94,181.4,172.12,177.32,SGEN,3122356,HISTORICAL_PRICES,SGEN,,1.60683E+12,0.776185334,0.776185334,177.32,180.94,181.4,172.12,3122356,177.32,180.94,181.4,172.12,3122356,18-Sep-20,5.28,0.0301
18-Sep-20,LYNPARZA® (olaparib) Improved Median Progression-Free Survival to Over Four and a Half Years Compared to 13.8 Months with Placebo for Patients with BRCA-Mutated Advanced Ovarian Cancer,"AstraZeneca and Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced positive five-year follow-up data from the Phase 3 SOLO-1 trial which demonstrated a long-term pro...",85.81,86.3,84.94,85.57,MRK,11744659,HISTORICAL_PRICES,MRK,,1.61552E+12,0.242722665,0.242722665,85.57,85.81,86.3,84.94,11744659,84.1601,84.3962,84.8781,83.5405,11744659,18-Sep-20,0.17,0.002
18-Sep-20,"Incyte Announces Encouraging Results From Phase 2 Trial of Retifanlimab (INCMGA0012) in Patients With Previously Treated, Advanced Squamous Cell Carcinoma of the Anal Canal","Incyte (Nasdaq:INCY) today announced results from its Phase 2 POD1UM-202 trial evaluating retifanlimab, a PD-1 inhibitor, in previously treated patients with advanced squamous cell carcinoma of the an...",86.79,91,85.65,90.76,INCY,3301707,HISTORICAL_PRICES,INCY,,1.60683E+12,0.287112561,0.287112561,90.76,86.79,91,85.65,3301707,90.76,86.79,91,85.65,3301707,18-Sep-20,-3.63,-0.0401
17-Sep-20,INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Nano-X Imaging Ltd. (NNOX) Investors,0Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased Nano-X Imaging Ltd. (“Nano-X” or the “Company”) (NASDAQ: NNOX) securities betw...,28.1,36.26,28,34.85,NNOX,7289310,HISTORICAL_PRICES,NNOX,,1.60683E+12,0.294930876,0.294930876,34.85,28.1,36.26,28,7289310,34.85,28.1,36.26,28,7289310,17-Sep-20,-8.7,-0.2364
17-Sep-20,Incyte and MorphoSys to Host Investor Event to Discuss the Unmet Need and Global Opportunities for Tafasitamab in Non-Hodgkin Lymphomas,Incyte (Nasdaq:INCY) and MorphoSys AG (FSE: MOR; Prime Standard Segment; MDAX & TecDAX; NASDAQ:MOR) today announced that the companies intend to host a conference call and webcast to discuss globa...,90.42,91.11,86.5,86.62,INCY,1392690,HISTORICAL_PRICES,INCY,,1.60683E+12,0.340946166,0.340946166,86.62,90.42,91.11,86.5,1392690,86.62,90.42,91.11,86.5,1392690,17-Sep-20,0.48,0.0053
17-Sep-20,"Acceleron to Host Webcast Outlining the Design of Its Registrational Phase 3 STELLAR Trial of Sotatercept in Pulmonary Arterial Hypertension (PAH) on October 2, 2020","Acceleron Pharma Inc. (Nasdaq: XLRN), a leading biopharmaceutical company in the discovery, development, and commercialization of TGF-beta superfamily therapeutics to treat serious and rare diseases,...",104.23,104.6,99.35,100.19,XLRN,468547,HISTORICAL_PRICES,XLRN,,1.60683E+12,0.300598952,0.300598952,100.19,104.23,104.6,99.35,468547,100.19,104.23,104.6,99.35,468547,17-Sep-20,3.01,0.0297
17-Sep-20,"SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Nano-X Imaging Ltd. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm","The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Nano-X Imaging Ltd. (“Nano-X” or “the Company”) (NASDAQ: NNOX) for violations...",28.1,36.26,28,34.85,NNOX,7289310,HISTORICAL_PRICES,NNOX,,1.60683E+12,0.294930876,0.294930876,34.85,28.1,36.26,28,7289310,34.85,28.1,36.26,28,7289310,17-Sep-20,-8.7,-0.2364
17-Sep-20,scPharmaceuticals Hosting Key Opinion Leader Call on FUROSCIX® (furosemide) for subcutaneous administration,"scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patien...",7.55,7.78,7.45,7.525,SCPH,41340,HISTORICAL_PRICES,SCPH,,1.60683E+12,-0.041878173,-0.041878173,7.525,7.55,7.78,7.45,41340,7.525,7.55,7.78,7.45,41340,17-Sep-20,-0.05,-0.0066
17-Sep-20,"Deciphera Presents Data from Rebastinib, its TIE2 Inhibitor Program, at the European Society for Medical Oncology (ESMO) Virtual Congress 2020 ","Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), today announced the presentation of data from the ovarian cancer cohort in Part 2 of the ongoing Phase 1b/2 study of rebastinib, the Company’s selective...",52.57,53.19,50.47,50.83,DCPH,262955,HISTORICAL_PRICES,DCPH,,1.60683E+12,0.335959339,0.335959339,50.83,52.57,53.19,50.47,262955,50.83,52.57,53.19,50.47,262955,17-Sep-20,0.92,0.0178
17-Sep-20,Moderna Announces Progress Across Broad Portfolio and all Three Clinical Stage Therapeutic Areas at 2020 R&D Day,"Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, announced progress...",67.89,70.9,64.6,68.5,MRNA,13275199,HISTORICAL_PRICES,MRNA,,1.60683E+12,1.629357088,1.629357088,68.5,67.89,70.9,64.6,13275199,68.5,67.89,70.9,64.6,13275199,17-Sep-20,-0.95,-0.0138
17-Sep-20,"Four-Year Data Continue to Show Superior, Long-Term Survival Benefit with Opdivo (nivolumab) Plus Yervoy (ipilimumab) in Patients with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma",Bristol Myers Squibb (NYSE: BMY) today announced that more than half of advanced renal cell carcinoma (RCC) patients treated with the Opdivo® (nivolumab) plus Yervoy® (ipilimumab) combination were ali...,59.4,59.43,58.26,59,BMY,6624754,HISTORICAL_PRICES,BMY,,1.60946E+12,0.206336312,0.206336312,59,59.4,59.43,58.26,6624754,58.0962,58.4901,58.5196,57.3676,6624754,17-Sep-20,-0.05,-0.0008
17-Sep-20,New Data Presented at ESMO Virtual Congress 2020 Highlight Breadth and Potential of Clovis Oncology Products and Pipeline,"Clovis Oncology, Inc. (NASDAQ: CLVS) today announced the data being presented as e-posters at the European Society for Medical Oncology (ESMO) Virtual Congress 2020. These include initial data from th...",7.48,7.97,7.24,7.6,CLVS,7028994,HISTORICAL_PRICES,CLVS,,1.60683E+12,0.601713062,0.601713062,7.6,7.48,7.97,7.24,7028994,7.6,7.48,7.97,7.24,7028994,17-Sep-20,-0.235,-0.0305
16-Sep-20, The Law Offices of Frank R. Cruz Announces Investigation of Nano-X Imaging Ltd. (NNOX) on Behalf of Investors,The Law Offices of Frank R. Cruz announces an investigation of Nano-X Imaging Ltd. (“Nano-X” or the “Company”) (NASDAQ: NNOX) on behalf of investors concerning the Company’s possible violations of fed...,36.8,44,34.5,36.27,NNOX,7548479,HISTORICAL_PRICES,NNOX,,1.60683E+12,0.695852535,0.695852535,36.27,36.8,44,34.5,7548479,36.27,36.8,44,34.5,7548479,16-Sep-20,-1.2,-0.0316
16-Sep-20,EQUITY ALERT: Rosen Law Firm Files Securities Class Action Lawsuit Against Nano-X Imaging Ltd. – NNOX,"Rosen Law Firm, a global investor rights law firm, announces it has filed a class action lawsuit on behalf of purchasers of the securities of Nano-X Imaging Ltd. (NASDAQ: NNOX), between August 21, 202...",36.8,44,34.5,36.27,NNOX,7548479,HISTORICAL_PRICES,NNOX,,1.60683E+12,0.695852535,0.695852535,36.27,36.8,44,34.5,7548479,36.27,36.8,44,34.5,7548479,16-Sep-20,-1.2,-0.0316
16-Sep-20,INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Nano-X Imaging Ltd. (NNOX) on Behalf of Investors,Law Offices of Howard G. Smith announces an investigation on behalf of Nano-X Imaging Ltd. (“Nano-X” or the “Company”) (NASDAQ: NNOX) investors concerning the Company’s possible violations of federal...,36.8,44,34.5,36.27,NNOX,7548479,HISTORICAL_PRICES,NNOX,,1.60683E+12,0.695852535,0.695852535,36.27,36.8,44,34.5,7548479,36.27,36.8,44,34.5,7548479,16-Sep-20,-1.2,-0.0316
16-Sep-20,"INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Nano-X Imaging Ltd. and Encourages Investors with Losses of $100,000 to Contact the Firm","The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Nano-X Imaging Ltd. (“Nano-X” or “the Company”) (NASDAQ: NNOX) f...",36.8,44,34.5,36.27,NNOX,7548479,HISTORICAL_PRICES,NNOX,,1.60683E+12,0.695852535,0.695852535,36.27,36.8,44,34.5,7548479,36.27,36.8,44,34.5,7548479,16-Sep-20,-1.2,-0.0316
16-Sep-20,EQUITY ALERT: Rosen Law Firm Announces Investigation of Securities Claims Against Nano-X Imaging Ltd. – NNOX,"Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of shareholders of Nano-X Imaging Ltd. (NASDAQ: NNOX) resulting from allegations...",36.8,44,34.5,36.27,NNOX,7548479,HISTORICAL_PRICES,NNOX,,1.60683E+12,0.695852535,0.695852535,36.27,36.8,44,34.5,7548479,36.27,36.8,44,34.5,7548479,16-Sep-20,-1.2,-0.0316
16-Sep-20,Dexcom Announces First-Ever Registry Dedicated to Tracking Outcomes of In-Hospital Real-Time CGM Use in Response to the COVID-19 Pandemic,"DexCom, Inc. (NASDAQ:DXCM), the leader in real-time continuous glucose monitoring (rtCGM) for people with diabetes, announced today the first ever registry dedicated to tracking the outcomes of patien...",393.92,403.97,391.52,399.83,DXCM,641633,HISTORICAL_PRICES,DXCM,,1.60683E+12,0.6676686,0.6676686,399.83,393.92,403.97,391.52,641633,399.83,393.92,403.97,391.52,641633,16-Sep-20,-4.05,-0.0102
16-Sep-20,SkinTE™ Health Economics—DFU Interim Analysis Data Demonstrates Potential for Cost Savings and Improved Wound Closure,"PolarityTE, Inc. (Nasdaq: PTE) today announced cost per product data from the protocol-specified interim analysis in the Company’s ongoing randomized controlled trial (RCT) evaluating SkinTE for the t...",1.08,1.16,1.0737,1.09,PTE,240988,HISTORICAL_PRICES,PTE,,1.60683E+12,-0.027027027,-0.027027027,1.09,1.08,1.16,1.0737,240988,1.09,1.08,1.16,1.0737,240988,16-Sep-20,-0.03,-0.027
16-Sep-20,Verastem Oncology Announces Presentation of Updated Phase 1/2 FRAME Study Data at the 2nd Annual RAS-Targeted Drug Development Summit,"Verastem, Inc. (Nasdaq:VSTM) (also known as Verastem Oncology), a biopharmaceutical company committed to advancing new medicines for patients battling cancer, today announced updated results from the...",1.38,1.39,1.25,1.3,VSTM,8291144,HISTORICAL_PRICES,VSTM,,1.60683E+12,-0.366972477,-0.366972477,1.3,1.38,1.39,1.25,8291144,1.3,1.38,1.39,1.25,8291144,16-Sep-20,-0.03,-0.0213
16-Sep-20,Intersect ENT kündigt Vereinbarung zur Übernahme der Fiagon AG Medical Technologies für 60 Millionen Euro über einen Zahlungszeitraum von drei Jahren an,"Intersect ENT, Inc. (Nasdaq: XENT), ein Unternehmen, das die Versorgung von Patienten mit Hals-Nasen-Ohren-Erkrankungen (HNO) umgestaltet, gab heute den Abschluss einer Vereinbarung zur Übernahme der...",18.08,18.93,17.76,18.93,XENT,297568,HISTORICAL_PRICES,XENT,,1.60683E+12,0.518052057,0.518052057,18.93,18.08,18.93,17.76,297568,18.93,18.08,18.93,17.76,297568,16-Sep-20,-0.66,-0.0352
16-Sep-20,Applied DNA and Takis Biotech/Evvivax to Launch Clinical Trial for Veterinary Use of Linear COVID-19 Vaccine Candidate,"Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA” or the ""Company""), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing that enables in vitro diagnostics, preclinical nucleic a...",8.41,8.43,8.03,8.15,APDN,280991,HISTORICAL_PRICES,APDN,,1.60683E+12,1.1025,1.1025,8.15,8.41,8.43,8.03,280991,8.15,8.41,8.43,8.03,280991,16-Sep-20,0.25,0.0306
15-Sep-20,Fitbit erhält in den USA und Europa behördliche Genehmigung für die EKG-App zur Erkennung von Vorhofflattern (VHF),"Fitbit (NYSE: FIT) hat von der US-amerikanischen Lebensmittel- und Arzneimittelbehörde (FDA, Food and Drug Administration) die 510(k)-Zulassung sowie von der EU das CE-Kennzeichen (Conformité Européen...",6.38,6.41,6.33,6.37,FIT,1777670,HISTORICAL_PRICES,FIT,,1.60683E+12,0.004724409,0.004724409,6.37,6.38,6.41,6.33,1777670,6.37,6.38,6.41,6.33,1777670,15-Sep-20,0.01,0.0016
15-Sep-20,"Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Continues Its Investigation of Encore Capital Group, Inc. (ECPG) on Behalf of Investors","Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, continues its investigation on behalf of Encore Capital Group, Inc. (“Encore” or the “Company”) (NASDAQ: ECPG)...",40.16,42.3,40.05,42.01,ECPG,272668,HISTORICAL_PRICES,ECPG,,1.60683E+12,0.734773218,0.734773218,42.01,40.16,42.3,40.05,272668,42.01,40.16,42.3,40.05,272668,15-Sep-20,-1.67,-0.0399
15-Sep-20,"Transcat, Inc. to Present at Sidoti Fall 2020 Virtual Conference","Transcat, Inc. (Nasdaq: TRNS) (“Transcat” or the “Company”), a leading provider of accredited calibration, repair, inspection and laboratory instrument services and value-added distributor of professi...",29.11,29.3077,28.85,29.08,TRNS,13093,HISTORICAL_PRICES,TRNS,,1.60683E+12,0.04038599,0.04038599,29.08,29.11,29.3077,28.85,13093,29.08,29.11,29.3077,28.85,13093,15-Sep-20,-0.09,-0.0031
15-Sep-20,AVEO Oncology Announces European Urology Publication of Final Overall Survival Data from Phase 3 TIVO-3 Study of Tivozanib in Renal Cell Carcinoma,AVEO Oncology (Nasdaq: AVEO) today announced that final overall survival (OS) results from its Phase 3 TIVO-3 study were published in the journal European Urology. TIVO-3 is the Company’s pivotal Phas...,5.76,6.24,5.68,6.01,AVEO,777854,HISTORICAL_PRICES,AVEO,,1.60683E+12,1.10989011,1.10989011,6.01,5.76,6.24,5.68,777854,6.01,5.76,6.24,5.68,777854,15-Sep-20,-0.14,-0.0237
15-Sep-20,Pfizer Investor Day Features Significant Number of Pipeline Advances for COVID-19 Programs and Across Numerous Therapeutic Areas,"As part of a two-day virtual Investor Day, Pfizer Inc. (NYSE: PFE) provided an extensive overview of pipeline advances and shared updates on the Company’s efforts to battle the COVID-19 pandemic on mu...",36.96,37.35,36.81,37.19,PFE,20876431,HISTORICAL_PRICES,PFE,,1.6118E+12,0.244444444,0.244444444,37.19,36.96,37.35,36.81,20876431,36.4153,36.1901,36.5719,36.0432,20876431,15-Sep-20,-0.05,-0.0014
15-Sep-20,Notice of Lead Plaintiff Deadline for Shareholders in the Fennec Pharmaceuticals Inc. Class Action Lawsuit,Robbins Geller Rudman & Dowd LLP announces that a class action lawsuit has been filed in the Middle District of North Carolina on behalf of purchasers of Fennec Pharmaceuticals Inc. (NASDAQ:FENC)...,6.1,6.27,5.8102,5.88,FENC,377821,HISTORICAL_PRICES,FENC,,1.60683E+12,0.077738516,0.077738516,5.88,6.1,6.27,5.8102,377821,5.88,6.1,6.27,5.8102,377821,15-Sep-20,0.28,0.0481
15-Sep-20,TFF Pharmaceuticals Announces Topline Results of Voriconazole Inhalation Powder Phase 1 Clinical Trial,"TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) t...",14.97,15.4,14.501,15.01,TFFP,287280,HISTORICAL_PRICES,TFFP,,1.60683E+12,2.564285714,2.564285714,15.01,14.97,15.4,14.501,287280,15.01,14.97,15.4,14.501,287280,15-Sep-20,0.43,0.0296
15-Sep-20,Intersect ENT Announces Agreement to Acquire Fiagon AG Medical Technologies for €60 Million Paid Over Three Years,"Intersect ENT, Inc. (Nasdaq: XENT), a company transforming care for patients with ear, nose and throat (“ENT”) conditions, today announced it has entered into an agreement to acquire Fiagon AG Medical...",18.74,19.2,18.1,18.98,XENT,641721,HISTORICAL_PRICES,XENT,,1.60683E+12,0.573467674,0.573467674,18.98,18.74,19.2,18.1,641721,18.98,18.74,19.2,18.1,641721,15-Sep-20,-0.75,-0.0385
15-Sep-20,HLTH and Evercore ISI Partner for 2nd Year to Host Innovative Therapeutic Leaders,"HLTH, the leading platform bringing together the health ecosystem, and Evercore (NYSE: EVR) announced today they will collaborate for the second consecutive year to host a dedicated program on Digital...",65.97,66.45,64.23,64.74,EVR,709636,HISTORICAL_PRICES,EVR,,1.61422E+12,0.506508335,0.506508335,64.74,65.97,66.45,64.23,709636,64.0012,65.2172,65.6917,63.497,709636,15-Sep-20,1.47,0.0228
15-Sep-20,"Gilead’s Magrolimab, an Investigational Anti-CD47 Monoclonal Antibody, Receives FDA Breakthrough Therapy Designation for Treatment of Myelodysplastic Syndrome","Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for magrolimab, a first-in-class, investigational ant...",66.2,67.13,65.92,67.04,GILD,8327670,HISTORICAL_PRICES,GILD,,1.61552E+12,-0.104921579,-0.104921579,67.04,66.2,67.13,65.92,8327670,65.5437,64.7225,65.6317,64.4487,8327670,15-Sep-20,-0.14,-0.0021
15-Sep-20,European Medicines Agency Validates Bristol Myers Squibb’s Type II Variation Application for Opdivo (nivolumab) Plus Yervoy (ipilimumab) for First-line Treatment of Malignant Pleural Mesothelioma,Bristol Myers Squibb (NYSE: BMY) today announced that the European Medicines Agency (EMA) validated a type II variation application for Opdivo® (nivolumab) plus Yervoy® (ipilimumab) for the treatment...,59.53,60.11,59.39,59.97,BMY,8259337,HISTORICAL_PRICES,BMY,,1.60946E+12,0.208976442,0.208976442,59.97,59.53,60.11,59.39,8259337,59.0514,58.6181,59.1892,58.4802,8259337,15-Sep-20,-0.17,-0.0028
15-Sep-20,"Aerie Pharmaceuticals Announces U.S. Food and Drug Administration Approval of its Athlone, Ireland Facility for Production of Rhopressa® (netarsudil ophthalmic solution) 0.02%","Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients w...",11.55,11.9,11.18,11.27,AERI,1238422,HISTORICAL_PRICES,AERI,,1.60683E+12,-0.14381023,-0.14381023,11.27,11.55,11.9,11.18,1238422,11.27,11.55,11.9,11.18,1238422,15-Sep-20,0.43,0.0387
14-Sep-20,"Ganaxolone Achieves Primary Endpoint in Phase 3 Trial for CDKL5 Deficiency Disorder (CDD), a Rare Form of Genetic Epilepsy","Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders, today announced positive top-line result...",8.44,8.6,8.12,8.36,MRNS,2046495.25,HISTORICAL_PRICES,MRNS,,1.60809E+12,0.004761905,0.004761905,2.09,2.11,2.15,2.03,8185981,8.36,8.44,8.6,8.12,2046495.25,14-Sep-20,0.44,0.055
14-Sep-20,"TFF Pharmaceuticals to Participate in Anti-fungal Webinar Presented by Maxim Group LLC on September 17th, 2020","TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) t...",14.54,15.03,13.89,14.09,TFFP,241001,HISTORICAL_PRICES,TFFP,,1.60683E+12,2.461904762,2.461904762,14.09,14.54,15.03,13.89,241001,14.09,14.54,15.03,13.89,241001,14-Sep-20,0.56,0.0401
14-Sep-20,PolarityTE Expects Third Quarter Revenue to Meet or Exceed High-End of Guidance,"PolarityTE, Inc. (Nasdaq: PTE) today announced that third quarter 2020 revenues will likely meet or exceed top end of the previous guided range of $2.7M to $3.2M. David Seaburg, CEO, commented, “We co...",1.05,1.08,1,1.02,PTE,501880,HISTORICAL_PRICES,PTE,,1.60683E+12,-0.054054054,-0.054054054,1.02,1.05,1.08,1,501880,1.02,1.05,1.08,1,501880,14-Sep-20,0.03,0.0294
14-Sep-20,Seres Therapeutics to Present at Upcoming Investor Conferences,"Seres Therapeutics, Inc. (Nasdaq:MCRB) today announced that management will present at two upcoming investor conferences: H.C. Wainwright 22nd Annual Global Investment Conference: Seres will present a...",27,27.79,25.24,25.57,MCRB,676155,HISTORICAL_PRICES,MCRB,,1.60683E+12,6.648725212,6.648725212,25.57,27,27.79,25.24,676155,25.57,27,27.79,25.24,676155,14-Sep-20,1.5,0.0588
14-Sep-20,"Enanta Pharmaceuticals Initiates Phase 1 Clinical Study of EDP-297, its Highly Potent and Targeted Follow-On Farnesoid X Receptor Agonist for the Treatment of Non-Alcoholic Steatohepatitis","Enanta Pharmaceuticals, Inc., (NASDAQ: ENTA), a clinical stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that it has dos...",47.47,48.17,46.41,46.84,ENTA,167682,HISTORICAL_PRICES,ENTA,,1.60683E+12,0.003806302,0.003806302,46.84,47.47,48.17,46.41,167682,46.84,47.47,48.17,46.41,167682,14-Sep-20,1.09,0.0235
14-Sep-20,STAAR Surgical Announces Completion of Patient Enrollment in EVO Implantable Lens US Clinical Trial,"STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye, is today announcing that patient enrollment for...",52.96,54.55,51.24,51.24,STAA,667346,HISTORICAL_PRICES,STAA,,1.60683E+12,0.971705138,0.971705138,51.24,52.96,54.55,51.24,667346,51.24,52.96,54.55,51.24,667346,14-Sep-20,1.96,0.0384
14-Sep-20,Seattle Genetics and Merck Announce Two Strategic Oncology Collaborations,"Seattle Genetics, Inc. (Nasdaq: SGEN) and Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced two new strategic oncology collaborations. The companies will globally d...",171.79,173.32,160.17,165.24,SGEN,3448357,HISTORICAL_PRICES,SGEN,,1.60683E+12,0.686364975,0.686364975,165.24,171.79,173.32,160.17,3448357,165.24,171.79,173.32,160.17,3448357,14-Sep-20,21.82,0.1455
14-Sep-20,Fitbit Receives Regulatory Clearance in Both the United States and Europe for ECG App to Identify Atrial Fibrillation (AFib),"Fitbit (NYSE:FIT) has received 510(k) clearance from the U.S. Food and Drug Administration (FDA), as well as Conformité Européenne (CE) marking in the European Union, for its electrocardiogram (ECG) a...",6.37,6.39,6.3,6.32,FIT,2949535,HISTORICAL_PRICES,FIT,,1.60683E+12,0.003149606,0.003149606,6.32,6.37,6.39,6.3,2949535,6.32,6.37,6.39,6.3,2949535,14-Sep-20,0.08,0.0127
11-Sep-20,Seres Therapeutics Announces U.S. Food and Drug Administration Correspondence Following Positive SER-109 Phase 3 Study Results,"Seres Therapeutics, Inc. (Nasdaq: MCRB) today announced that it has obtained correspondence from the Office of Vaccines Research and Review of the U.S. Food and Drug Administration (FDA) regarding the...",25.5,25.51,24.16,24.4,MCRB,992270,HISTORICAL_PRICES,MCRB,,1.60683E+12,6.223796034,6.223796034,24.4,25.5,25.51,24.16,992270,24.4,25.5,25.51,24.16,992270,11-Sep-20,0.19,0.0075
11-Sep-20,Omeros to Present at the Cantor Virtual Global Healthcare Conference,"Omeros Corporation (Nasdaq: OMER) today announced that Gregory A. Demopulos, M.D., chairman and chief executive officer, will present at the Cantor Virtual Global Healthcare Conference next week. The...",11.61,12.26,11.5,11.84,OMER,1415439,HISTORICAL_PRICES,OMER,,1.60683E+12,0.046889089,0.046889089,11.84,11.61,12.26,11.5,1415439,11.84,11.61,12.26,11.5,1415439,11-Sep-20,-0.05,-0.0043
10-Sep-20,Intersect ENT Announces Specialty Pharmacy Partnership Agreement with AllianceRx Walgreens Prime to Distribute SINUVA® Sinus Implant,"Intersect ENT, Inc. (Nasdaq: XENT), a company transforming care for patients with ear, nose and throat (ENT) conditions, today announced that it has executed a pharmacy services agreement with Allianc...",18.18,18.47,17.32,18.03,XENT,343786,HISTORICAL_PRICES,XENT,,1.60683E+12,0.526448363,0.526448363,18.03,18.18,18.47,17.32,343786,18.03,18.18,18.47,17.32,343786,10-Sep-20,0.2,0.0111
10-Sep-20,Gamida Cell Presents Analysis of Observational Data Demonstrating the Impact of Donor Age in Hematopoietic Stem Cell Transplant Outcomes at the Virtual Cord Blood Connect Meeting,"Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to cures for blood cancers and serious blood diseases, today announced data from an observational study demonstrating that y...",4.12,4.25,4.1,4.17,GMDA,70690,HISTORICAL_PRICES,GMDA,,1.60683E+12,0.396610169,0.396610169,4.17,4.12,4.25,4.1,70690,4.17,4.12,4.25,4.1,70690,10-Sep-20,-0.02,-0.0048
10-Sep-20,Brink Biologics Announces License Agreement with Global Healthcare Company Fresenius Kabi SwissBioSim GmbH,"Brink Biologics, Inc. (“Brink”), a NantKwest, Inc. (NASDAQ: NK) affiliate and exclusively-licensed distributor of NantKwest’s proprietary off-the-shelf NK-92® natural killer cells in certain fields, a...",6.54,6.94,6.52,6.68,NK,882782,HISTORICAL_PRICES,NK,,1.60683E+12,1.194630872,1.194630872,6.68,6.54,6.94,6.52,882782,6.68,6.54,6.94,6.52,882782,10-Sep-20,-0.04,-0.0061
10-Sep-20,Vertex Announces Positive Phase 3 Study for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in Children Ages 6-11 Years With Cystic Fibrosis to Support Submissions for Global Regulatory Approvals,Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the company has completed a global Phase 3 study of TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in children ages 6 thr...,255.65,263.5816,253.97,262.95,VRTX,1231917,HISTORICAL_PRICES,VRTX,,1.60683E+12,0.145744633,0.145744633,262.95,255.65,263.5816,253.97,1231917,262.95,255.65,263.5816,253.97,1231917,10-Sep-20,-7.39,-0.0281
10-Sep-20,"Gary J. Haseley Appointed Chairman of the Board at Transcat, Inc.","Transcat, Inc. (Nasdaq: TRNS) (“Transcat” or the “Company”), a leading provider of accredited calibration, repair, inspection and laboratory instrument services and value-added distributor of professi...",28.48,28.77,28.25,28.25,TRNS,4577,HISTORICAL_PRICES,TRNS,,1.60683E+12,0.017869907,0.017869907,28.25,28.48,28.77,28.25,4577,28.25,28.48,28.77,28.25,4577,10-Sep-20,-0.02,-0.0007
10-Sep-20,Clovis Oncology Announces Oral Plenary Session Presentation at International Gynecologic Cancer Society (IGCS) Digital Annual Global Meeting,"Clovis Oncology, Inc. (NASDAQ: CLVS), announced today that an abstract featuring data from an exploratory analysis of the ARIEL3 clinical study evaluating Rubraca® (rucaparib) as maintenance treatment...",5.725,5.955,5.42,5.42,CLVS,6357700,HISTORICAL_PRICES,CLVS,,1.60683E+12,0.225910064,0.225910064,5.42,5.725,5.955,5.42,6357700,5.42,5.725,5.955,5.42,6357700,10-Sep-20,0.305,0.0563
10-Sep-20,Ligand Expands OmniAb® Antibody Discovery Platform Through the Acquisitions of xCella Biosciences and Taurus Biosciences,Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces the acquisition of two privately held companies that strengthen and complement its OmniAb® technology platform. Ligand acquired xCella Bios...,100.02,102.89,98.78,102.48,LGND,366859,HISTORICAL_PRICES,LGND,,1.60683E+12,0.348341871,0.348341871,102.48,100.02,102.89,98.78,366859,102.48,100.02,102.89,98.78,366859,10-Sep-20,-1.02,-0.0101
10-Sep-20,Kala Pharmaceuticals to Host Key Opinion Leader Symposium on Unmet Need in Dry Eye Disease and Potential for EYSUVIS™,"Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced that...",8.91,9.26,8.584,8.68,KALA,964645,HISTORICAL_PRICES,KALA,,1.60683E+12,0.188,0.188,8.68,8.91,9.26,8.584,964645,8.68,8.91,9.26,8.584,964645,10-Sep-20,0.3,0.0348
10-Sep-20,Ocular Therapeutix™ Announces First Patient Dosed in Phase 3 Clinical Trial of DEXTENZA® for the Treatment of Post-Surgical Ocular Inflammation and Pain in Children,"Ocular Therapeutix™, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, tod...",8.31,8.58,8.12,8.2,OCUL,598872,HISTORICAL_PRICES,OCUL,,1.60683E+12,0.68902439,0.68902439,8.2,8.31,8.58,8.12,598872,8.2,8.31,8.58,8.12,598872,10-Sep-20,0.05,0.0061
10-Sep-20,TherapeuticsMD Announces Participation at Two Upcoming Virtual Investor Conferences,"TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative women’s healthcare company, today announced that the company will participate in two upcoming virtual investor conferences. Chief Executive Officer R...",1.34,1.4099,1.34,1.37,TXMD,1739620,HISTORICAL_PRICES,TXMD,,1.60683E+12,0.12605042,0.12605042,1.37,1.34,1.4099,1.34,1739620,1.37,1.34,1.4099,1.34,1739620,10-Sep-20,0,0
10-Sep-20,Sage Therapeutics’ FutureCast to Provide Update on Pipeline Progression and Additional Insights into Potential of Brain Health Franchises,"Today, Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of th...",54.25,57.98,51.51,52.39,SAGE,1708140,HISTORICAL_PRICES,SAGE,,1.60683E+12,0.847752044,0.847752044,52.39,54.25,57.98,51.51,1708140,52.39,54.25,57.98,51.51,1708140,10-Sep-20,2.65,0.0514
9-Sep-20,FDA Approves Trelegy Ellipta as the First Once-Daily Single Inhaler Triple Therapy for the Treatment of Both Asthma and COPD in the US,"GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) announced the US Food and Drug Administration (FDA) has approved a new indication for Trelegy Ellipta (fluticasone furoate / umecl...",39.75,40.13,39.75,39.93,GSK,3274022,HISTORICAL_PRICES,GSK,,1.61362E+12,0.169117647,0.169117647,39.93,39.75,40.13,39.75,3274022,38.7352,38.5606,38.9292,38.5606,3274022,9-Sep-20,0.78,0.02
9-Sep-20,FDA Approves Trelegy Ellipta as the First Once-Daily Single Inhaler Triple Therapy for the Treatment of Both Asthma and COPD in the US,"GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) announced the US Food and Drug Administration (FDA) has approved a new indication for Trelegy Ellipta (fluticasone furoate / umecl...",39.75,40.13,39.75,39.93,GSK,3274022,HISTORICAL_PRICES,GSK,,1.61362E+12,0.169117647,0.169117647,39.93,39.75,40.13,39.75,3274022,38.7352,38.5606,38.9292,38.5606,3274022,9-Sep-20,0.78,0.02
9-Sep-20,TherapeuticsMD Announces Patent Updates for ANNOVERA®,"TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative women’s healthcare company, today announced patent updates for ANNOVERA (segesterone acetate and ethinyl estradiol vaginal system), the first and onl...",1.34,1.385,1.3,1.34,TXMD,2192828,HISTORICAL_PRICES,TXMD,,1.60683E+12,0.12605042,0.12605042,1.34,1.34,1.385,1.3,2192828,1.34,1.34,1.385,1.3,2192828,9-Sep-20,0.01,0.0075
9-Sep-20,"Syros Announces Appointment of S. Gail Eckhardt, M.D., to its Board of Directors","Syros Pharmaceuticals (NASDAQ: SYRS), a leader in the development of medicines that control the expression of genes, today announced the appointment of S. Gail Eckhardt, M.D., to the Company’s Board o...",9.22,9.45,8.95,8.9514,SYRS,307734,HISTORICAL_PRICES,SYRS,,1.60683E+12,0.646428571,0.646428571,8.9514,9.22,9.45,8.95,307734,8.9514,9.22,9.45,8.95,307734,9-Sep-20,0.28,0.0313
9-Sep-20," Alexion Announces Upcoming Data Presentations at MSVirtual2020, the 8th Joint ACTRIMS – ECTRIMS Meeting","Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced that 11 abstracts will be presented at MSVirtual2020, the 8th joint Americas Committee for Treatment and Research in Multiple Sclerosis and...",108.28,110.11,102.82,108.5,ALXN,2512230,HISTORICAL_PRICES,ALXN,,1.60683E+12,0.260095427,0.260095427,108.5,108.28,110.11,102.82,2512230,108.5,108.28,110.11,102.82,2512230,9-Sep-20,0.09,0.0008
9-Sep-20,Altria Participates in the Barclays Global Consumer Staples Conference; Reaffirms 2020 Full-Year Earnings Guidance,"Altria Group, Inc. (Altria) (NYSE: MO) is participating today in the Barclays Global Consumer Staples Conference. Billy Gifford, Altria’s Chief Executive Officer, and Sal Mancuso, Chief Financial Offi...",43.79,44.17,43.31,43.37,MO,16628810,HISTORICAL_PRICES,MO,,1.61655E+12,0.352378011,0.352378011,43.37,43.79,44.17,43.31,16628810,40.9521,41.3487,41.7075,40.8955,16628810,9-Sep-20,0.72,0.0167
9-Sep-20,Cerus Corporation to Participate in Upcoming Virtual Investor Conferences,"Cerus Corporation (Nasdaq:CERS) announced today that William ‘Obi’ Greenman, Cerus’ president and chief executive officer, and Kevin D. Green, Cerus’ chief financial officer, are scheduled to particip...",6.08,6.14,5.81,5.85,CERS,1289470,HISTORICAL_PRICES,CERS,,1.60683E+12,0.579220779,0.579220779,5.85,6.08,6.14,5.81,1289470,5.85,6.08,6.14,5.81,1289470,9-Sep-20,0.305,0.0528
9-Sep-20,Clovis Oncology to Highlight Data for its Three Portfolio Compounds at the ESMO Virtual Congress 2020,"Clovis Oncology, Inc. (NASDAQ: CLVS) today announced that six e-posters highlighting clinical data from the lucitanib and Rubraca® (rucaparib) clinical development programs, as well as preclinical dat...",5.42,5.53,5.2,5.25,CLVS,3266406,HISTORICAL_PRICES,CLVS,,1.60683E+12,0.160599572,0.160599572,5.25,5.42,5.53,5.2,3266406,5.25,5.42,5.53,5.2,3266406,9-Sep-20,0.24,0.0463
9-Sep-20,Aldeyra Receives Study May Proceed Letter from FDA to Initiate Clinical Trial of ADX-629 in COVID-19 Patients,"Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced that it has received a Study May Proceed letter from the U.S. Food and Drug Administration (FDA) to begin a Phase 2 clinical trial e...",6.45,6.47,5.815,6.05,ALDX,608888,HISTORICAL_PRICES,ALDX,,1.60683E+12,1.792207792,1.792207792,6.05,6.45,6.47,5.815,608888,6.05,6.45,6.47,5.815,608888,9-Sep-20,0.56,0.0951
9-Sep-20,Scholar Rock Announces First Patient Dosed in Part A2 of DRAGON Phase 1 Proof-of-Concept Trial of SRK-181 to Overcome Primary Resistance to Anti-PD-(L)1 Therapy,"Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced that the f...",14.9,15.08,14.3,14.3,SRRK,228826,HISTORICAL_PRICES,SRRK,,1.60683E+12,0.086797958,0.086797958,14.3,14.9,15.08,14.3,228826,14.3,14.9,15.08,14.3,228826,9-Sep-20,0.72,0.0508
9-Sep-20,"Dr. Sanjay Gupta Joins NIH and CDC Officials as well as Fortune 500 and International C-Level Business Executives Presenting at the Everbridge COVID-19 Road to Recovery (R2R) Virtual Summit, October 14-15, 2020","Everbridge, Inc. (NASDAQ: EVBG), the global leader in critical event management (CEM), today announced its Autumn 2020 “COVID-19 R2R: The Road to Recovery” virtual leadership summit to be held October...",121,124.9515,120,124.19,EVBG,577805,HISTORICAL_PRICES,EVBG,,1.60683E+12,-0.012970063,-0.012970063,124.19,121,124.9515,120,577805,124.19,121,124.9515,120,577805,9-Sep-20,-0.4,-0.0033
9-Sep-20,FDA Advisory Panel Recommends Pre-Market Clinical Evidence Requirement in Proposed Reclassification of Bone Growth Stimulators,"Orthofix Medical Inc. (NASDAQ:OFIX), a global medical device company focused on musculoskeletal healing products, today announced support for the U.S. Food and Drug Administration (FDA) Medical Device...",28.46,28.98,28.03,28.63,OFIX,118875,HISTORICAL_PRICES,OFIX,,1.60683E+12,0.042109118,0.042109118,28.63,28.46,28.98,28.03,118875,28.63,28.46,28.98,28.03,118875,9-Sep-20,0.02,0.0007
9-Sep-20,Ra Medical Systems to Present at H.C. Wainwright 22nd Annual Global Investment Conference on September 16,"Ra Medical Systems, Inc. (NYSE: RMED), a medical device company focusing on commercializing excimer laser systems to treat vascular and dermatological diseases, announces that management will present...",6.34,6.75,5.7625,6.75,RMED,198446.28,HISTORICAL_PRICES,RMED,,1.60683E+12,-0.769454545,-0.769454545,0.27,0.2536,0.27,0.2305,4961157,6.75,6.34,6.75,5.7625,198446.28,9-Sep-20,-0.2175,-0.0332
9-Sep-20,Pfizer and BioNTech to Potentially Supply the EU with 200 Million Doses of mRNA-based Vaccine Candidate Against SARS-CoV-2,Pfizer (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that they had concluded exploratory talks with the European Commission for a proposed supply of 200 million doses of their investigati...,36.18,36.65,36.14,36.29,PFE,26082113,HISTORICAL_PRICES,PFE,,1.6118E+12,0.218181818,0.218181818,36.29,36.18,36.65,36.14,26082113,35.534,35.4263,35.8865,35.3871,26082113,9-Sep-20,0.25,0.007
8-Sep-20,Puma Biotechnology to Present at the H.C. Wainwright 22nd Annual Global Investment Conference,"Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder of Puma, will provide an overview of the...",9.65,9.7627,9.27,9.46,PBYI,391731,HISTORICAL_PRICES,PBYI,,1.60683E+12,0.114318707,0.114318707,9.46,9.65,9.7627,9.27,391731,9.46,9.65,9.7627,9.27,391731,8-Sep-20,0.02,0.0021
8-Sep-20,Revance to Participate in the Morgan Stanley 18th Annual Global Healthcare Conference,"Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company focused on innovative aesthetic and therapeutic offerings, including its investigational neuromodulator product, DaxibotulinumtoxinA...",27.21,28.12,26.5918,26.74,RVNC,458227,HISTORICAL_PRICES,RVNC,,1.60683E+12,0.943571429,0.943571429,26.74,27.21,28.12,26.5918,458227,26.74,27.21,28.12,26.5918,458227,8-Sep-20,0.09,0.0033
8-Sep-20,INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Fennec Pharmaceuticals Inc. (FENC) Investors,Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased Fennec Pharmaceuticals Inc. (“Fennec” or the “Company”) (NASDAQ: FENC) securiti...,5.31,5.42,5,5.08,FENC,226621,HISTORICAL_PRICES,FENC,,1.60683E+12,-0.061837456,-0.061837456,5.08,5.31,5.42,5,226621,5.08,5.31,5.42,5,226621,8-Sep-20,0.12,0.0231
8-Sep-20,Cintas Survey Shows Majority of Americans Value COVID-19 Precautions,A new online survey commissioned by Cintas Corporation (NASDAQ: CTAS) revealed that more than two-thirds (68%) of Americans would feel more confident entering public facilities during the COVID-19 pan...,318.78,328.8819,317.89,328.8819,CTAS,641372,HISTORICAL_PRICES,CTAS,,1.61302E+12,0.834177215,0.834177215,328.8819,318.78,328.8819,317.89,641372,327.4942,317.4349,327.4942,316.5487,641372,8-Sep-20,-12.33,-0.0372
8-Sep-20,Savara Announces New England Journal of Medicine (NEJM) Publication of IMPALA Study Results,"Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today announced that results from the Phase 3 IMPALA study were published online in NEJM. The manuscript, titled “Inhaled Molgramostim Thera...",1.34,1.35,1.2198,1.27,SVRA,219770,HISTORICAL_PRICES,SVRA,,1.60683E+12,-0.358851675,-0.358851675,1.27,1.34,1.35,1.2198,219770,1.27,1.34,1.35,1.2198,219770,8-Sep-20,0.09,0.072
8-Sep-20,Kala Pharmaceuticals to Present at Upcoming Investor Conferences in September,"Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced that...",8.23,8.45,7.71,7.86,KALA,963545,HISTORICAL_PRICES,KALA,,1.60683E+12,0.097333333,0.097333333,7.86,8.23,8.45,7.71,963545,7.86,8.23,8.45,7.71,963545,8-Sep-20,0.27,0.0339
8-Sep-20,Turning Point Brands Files Premarket Tobacco Applications Covering 250 Products,"Turning Point Brands, Inc. (“TPB”) (NYSE: TPB), a leading provider of Other Tobacco Products (“OTP”) and adult consumer alternatives, today announced it has submitted to the U.S. Food and Drug Adminis...",29.53,29.79,27.78,28.46,TPB,188562,HISTORICAL_PRICES,TPB,,1.61603E+12,0.50050813,0.50050813,28.46,29.53,29.79,27.78,188562,28.3512,29.4171,29.6761,27.6738,188562,8-Sep-20,1.14,0.0402
8-Sep-20,Urovant Sciences to Present at the H.C. Wainwright & Co. Annual Global Investment Conference,"Urovant Sciences (Nasdaq: UROV) announced today that president and chief executive officer James Robinson will give a presentation at 7:30 a.m. Pacific / 10:30 a.m. Eastern on Tuesday, September 15, 2...",9.05,9.44,8.75,9,UROV,137271,HISTORICAL_PRICES,UROV,,1.60683E+12,-0.15735568,-0.15735568,9,9.05,9.44,8.75,137271,9,9.05,9.44,8.75,137271,8-Sep-20,0.2,0.0226
8-Sep-20,PolarityTE Announces Strategic Partnership with Co-Diagnostics to Expand COVID-19 Testing Platform,"PolarityTE, Inc. (Nasdaq: PTE), a biotechnology company developing regenerative tissue products and biomaterials, today announced that its subsidiary, Arches Research, Inc., has entered into a strateg...",1.18,1.2699,1.03,1.03,PTE,4338416,HISTORICAL_PRICES,PTE,,1.60683E+12,0.063063063,0.063063063,1.03,1.18,1.2699,1.03,4338416,1.03,1.18,1.2699,1.03,4338416,8-Sep-20,0.14,0.1346
8-Sep-20,Catabasis Pharmaceuticals to Present at Upcoming Virtual Investor Conferences,"Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today announced that Jill C. Milne, Ph.D., Chief Executive Officer, plans to present a corporate overview and...",6.52,6.69,5.9,6.02,CATB,390738,HISTORICAL_PRICES,CATB,,1.60683E+12,0.689119171,0.689119171,6.02,6.52,6.69,5.9,390738,6.02,6.52,6.69,5.9,390738,8-Sep-20,0.56,0.094
8-Sep-20,Aerie Pharmaceuticals to Participate in Upcoming Virtual Investor Conferences,"Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients w...",11.95,12.22,11.58,11.7,AERI,640357,HISTORICAL_PRICES,AERI,,1.60683E+12,-0.114158636,-0.114158636,11.7,11.95,12.22,11.58,640357,11.7,11.95,12.22,11.58,640357,8-Sep-20,0.28,0.024
8-Sep-20,"LabCorp Launches First Combined Test for Covid-19, Flu and RSV in Time for Flu Season","LabCorp (NYSE: LH), a leading global life sciences company that is deeply integrated in guiding patient care, today announced the launch of the first testing method to simultaneously detect COVID-19,...",173.73,176,171.18,174.42,LH,751492,HISTORICAL_PRICES,LH,,1.60683E+12,0.475163454,0.475163454,174.42,173.73,176,171.18,751492,174.42,173.73,176,171.18,751492,8-Sep-20,-1.99,-0.0113
8-Sep-20,Ocular Therapeutix™ Announces Successful Resolution of FDA Warning Letter Related to ReSure® Sealant,"Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, annou...",7.905,8.27,7.51,7.6,OCUL,925374,HISTORICAL_PRICES,OCUL,,1.60683E+12,0.606707317,0.606707317,7.6,7.905,8.27,7.51,925374,7.6,7.905,8.27,7.51,925374,8-Sep-20,0.185,0.024
8-Sep-20,Sesen Bio to Provide Business Update at the H. C. Wainwright 22nd Annual Global Investment Conference,"Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced it will be featured as a presenting c...",0.97,1,0.96,1,SESN,469409,HISTORICAL_PRICES,SESN,,1.60683E+12,0.678200692,0.678200692,1,0.97,1,0.96,469409,1,0.97,1,0.96,469409,8-Sep-20,-0.0294,-0.0294
8-Sep-20,"Atara Biotherapeutics Announces FDA Clearance of IND for ATA2271, a Next-Generation Autologous Mesothelin-Targeted CAR T with Novel PD1DNR and 1XX Technologies Combined to Treat Solid Tumors","Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop treatments for patients with severe diseases including soli...",13.46,13.92,12.59,12.75,ATRA,994229,HISTORICAL_PRICES,ATRA,,1.60683E+12,0.439572193,0.439572193,12.75,13.46,13.92,12.59,994229,12.75,13.46,13.92,12.59,994229,8-Sep-20,0.55,0.0426
8-Sep-20,AVEO Oncology Regains Full Global Rights to Ficlatuzumab,"AVEO Oncology (Nasdaq: AVEO) today announced that it has regained full global rights to ficlatuzumab, AVEO’s potent hepatocyte growth factor (HGF) inhibitory antibody which binds to the HGF ligand wit...",5.24,5.37,4.74,4.765,AVEO,1341890,HISTORICAL_PRICES,AVEO,,1.60683E+12,0.919413919,0.919413919,4.765,5.24,5.37,4.74,1341890,4.765,5.24,5.37,4.74,1341890,8-Sep-20,0.51,0.1078
8-Sep-20,Bristol Myers Squibb Research at ESMO Virtual Congress 2020 Highlights Significant Progress in Cancers with High Unmet Medical Need,"Bristol Myers Squibb (NYSE:BMY) today announced the presentation of research spanning 15 different cancers at the upcoming European Society for Medical Oncology (ESMO) Virtual Congress 2020, reinforci...",58.53,60,58.14,59.87,BMY,11735877,HISTORICAL_PRICES,BMY,,1.60946E+12,0.18866775,0.18866775,59.87,58.53,60,58.14,11735877,58.9529,57.6334,59.0809,57.2494,11735877,8-Sep-20,-1.42,-0.0237
8-Sep-20,Biopharma Leaders Unite to Stand With Science,"The CEOs of AstraZeneca (LSE/STO/NYSE: AZN), BioNTech (NASDAQ: BNTX), GlaxoSmithKline plc (LSE/NYSE: GSK), Johnson & Johnson (NYSE: JNJ), Merck (NYSE: MRK), known as MSD outside the United States...",54.71,54.94,53.76,54.14,AZN,6735611,HISTORICAL_PRICES,AZN,,1.61422E+12,0.337979946,0.337979946,54.14,54.71,54.94,53.76,6735611,53.1134,53.6726,53.8982,52.7406,6735611,8-Sep-20,1.13,0.0211
8-Sep-20,Biopharma Leaders Unite To Stand With Science,"The CEOs of AstraZeneca (LSE/STO/NYSE: AZN), BioNTech (NASDAQ: BNTX), GlaxoSmithKline plc (LSE/NYSE: GSK), Johnson & Johnson (NYSE: JNJ), Merck (NYSE: MRK), known as MSD outside the United States...",54.71,54.94,53.76,54.14,AZN,6735611,HISTORICAL_PRICES,AZN,,1.61422E+12,0.337979946,0.337979946,54.14,54.71,54.94,53.76,6735611,53.1134,53.6726,53.8982,52.7406,6735611,8-Sep-20,1.13,0.0211
8-Sep-20,Biopharma Leaders Unite to Stand with Science,"The CEOs of AstraZeneca (LSE/STO/NYSE: AZN), BioNTech (NASDAQ: BNTX), GlaxoSmithKline plc (LSE/NYSE: GSK), Johnson & Johnson (NYSE: JNJ), Merck (NYSE: MRK), known as MSD outside the United States...",54.71,54.94,53.76,54.14,AZN,6735611,HISTORICAL_PRICES,AZN,,1.61422E+12,0.337979946,0.337979946,54.14,54.71,54.94,53.76,6735611,53.1134,53.6726,53.8982,52.7406,6735611,8-Sep-20,1.13,0.0211
8-Sep-20,Epizyme to Participate in Morgan Stanley 18th Annual Global Healthcare Conference,"Epizyme, Inc. (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering novel epigenetic therapies, today announced that Robert Bazemore, president and c...",12.67,13.12,12.44,12.62,EPZM,770519,HISTORICAL_PRICES,EPZM,,1.60683E+12,-0.214993804,-0.214993804,12.62,12.67,13.12,12.44,770519,12.62,12.67,13.12,12.44,770519,8-Sep-20,-0.11,-0.0086
8-Sep-20,Astrotech Reports Fiscal Year 2020 Financial Results,"Astrotech Corporation (Nasdaq:ASTC) reported its financial results for the fiscal year ended June 30, 2020. Fiscal year 2020 has been a pivotal year for Astrotech Corporation. We had the first sales o...",1.71,1.83,1.6,1.79,ASTC,263661,HISTORICAL_PRICES,ASTC,,1.60683E+12,0.526785714,0.526785714,1.79,1.71,1.83,1.6,263661,1.79,1.71,1.83,1.6,263661,8-Sep-20,-0.01,-0.0058
4-Sep-20,Kite Submits Supplemental Biologics License Application to U.S. Food and Drug Administration for Yescarta® in Relapsed or Refractory Indolent Non-Hodgkin Lymphomas,"Kite, a Gilead Company (Nasdaq: GILD), today announced that it has submitted a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) for Yescarta® (axicabtag...",66.01,66.94,65.58,65.72,GILD,8762248,HISTORICAL_PRICES,GILD,,1.61552E+12,-0.107490535,-0.107490535,65.72,66.01,66.94,65.58,8762248,63.5869,63.8675,64.7673,63.4515,8762248,4-Sep-20,0.1,0.0015
4-Sep-20,Ocular Therapeutix Announces Third Medicare Administrative Contractor to Establish New Published Physician Fee Schedule for Administration of Intracanalicular Inserts,"Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today...",7.72,8.18,7.14,8.16,OCUL,1765199,HISTORICAL_PRICES,OCUL,,1.60683E+12,0.569105691,0.569105691,8.16,7.72,8.18,7.14,1765199,8.16,7.72,8.18,7.14,1765199,4-Sep-20,-0.08,-0.0103
3-Sep-20,Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4),"Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on September 2, 2020 the Compensation Committee of Puma’s Board of Directors approved the grant of inducement restr...",9.67,10.08,9.66,9.87,PBYI,529572,HISTORICAL_PRICES,PBYI,,1.60683E+12,0.116628176,0.116628176,9.87,9.67,10.08,9.66,529572,9.87,9.67,10.08,9.66,529572,3-Sep-20,-0.2,-0.0203
3-Sep-20,Expert Panel Points to Central Role of Endothelial Injury and Lectin Pathway Activation in Critically Ill COVID-19 Patients,"Omeros Corporation (Nasdaq: OMER) today announced that the Demy-Colton Virtual Salon Series featured an expert discussion of developments in the treatment of severe COVID-19. The panel session, entitl...",10.32,10.77,9.982,10.7,OMER,2076448,HISTORICAL_PRICES,OMER,,1.60683E+12,-0.069431921,-0.069431921,10.7,10.32,10.77,9.982,2076448,10.7,10.32,10.77,9.982,2076448,3-Sep-20,-0.24,-0.0227
3-Sep-20,Gamida Cell Announces Two-Part Virtual Miniseries Focused on Omidubicel to Take Place in September,"Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to cures for blood cancers and serious blood diseases, today announced that it will host a two-part virtual miniseries in Se...",4.19,4.25,4.05,4.21,GMDA,113429,HISTORICAL_PRICES,GMDA,,1.60683E+12,0.420338983,0.420338983,4.21,4.19,4.25,4.05,113429,4.21,4.19,4.25,4.05,113429,3-Sep-20,0.01,0.0024
3-Sep-20,Alnylam Highlights Prospects for Building an Industry-Leading ATTR Amyloidosis Franchise at RNAi Roundtable,"Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, will host an “RNAi Roundtable” webinar today at 12:00 p.m. ET, which will focus on progress across its ATTR amyloid...",125.19,131.63,124.665,129.75,ALNY,310861,HISTORICAL_PRICES,ALNY,,1.60683E+12,0.252651591,0.252651591,129.75,125.19,131.63,124.665,310861,129.75,125.19,131.63,124.665,310861,3-Sep-20,-5.47,-0.0419
3-Sep-20,Ocular Therapeutix™ to Present at Two Upcoming Investor Conferences,"Ocular Therapeutix, Inc. (NASDAQ:OCUL) a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today...",7.8,8.47,7.66,8.38,OCUL,1551783,HISTORICAL_PRICES,OCUL,,1.60683E+12,0.585365854,0.585365854,8.38,7.8,8.47,7.66,1551783,8.38,7.8,8.47,7.66,1551783,3-Sep-20,-0.58,-0.0692
3-Sep-20,Nemaura Medical to Provide US proBEAT™ Launch Update at The LD 500 Virtual Conference,"Nemaura Medical, Inc. (NASDAQ: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing micro-systems-based wearable diagnostic devices and currently commercializing suga...",4.05,4.6825,3.935,4.36,NMRD,146198,HISTORICAL_PRICES,NMRD,,1.60683E+12,-0.193227092,-0.193227092,4.36,4.05,4.6825,3.935,146198,4.36,4.05,4.6825,3.935,146198,3-Sep-20,-0.36,-0.0816
2-Sep-20,Incyte Announces Pivotal GEOMETRY mono-1 Study Results of Capmatinib (Tabrecta™) in Patients with METex14 Metastatic Non-Small Cell Lung Cancer Published in NEJM,Incyte (Nasdaq: INCY) today announced that data from the Novartis pivotal Phase 2 GEOMETRY mono-1 study demonstrating that treatment with Tabrecta™ (capmatinib) resulted in positive overall response r...,95.44,95.51,92.765,93.09,INCY,807231,HISTORICAL_PRICES,INCY,,1.60683E+12,0.415393742,0.415393742,93.09,95.44,95.51,92.765,807231,93.09,95.44,95.51,92.765,807231,2-Sep-20,2.47,0.0266
2-Sep-20,Modern Healthcare Honors Dr. Peter Pronovost as a Top 25 Innovator for Spearheading Remote Monitoring Program at University Hospitals Using Masimo’s Technology,"Masimo (NASDAQ: MASI) today announced that Peter J. Pronovost, MD, PhD, Chief Quality and Clinical Transformation Officer at University Hospitals in Cleveland (UH), has been named a “Top 25 Innovator”...",232.46,232.9699,224.24,225,MASI,401553,HISTORICAL_PRICES,MASI,,1.60683E+12,0.495881596,0.495881596,225,232.46,232.9699,224.24,401553,225,232.46,232.9699,224.24,401553,2-Sep-20,8.81,0.0394
2-Sep-20,SINTX Technologies Announces New Antiviral Test Results,"SINTX Technologies, Inc. (NASDAQ: SINT) (“SINTX” or the “Company”), an original equipment manufacturer of silicon nitride ceramic for medical and non-medical applications, announced new studies confir...",1.755,1.85,1.67,1.8394,SINT,4663574,HISTORICAL_PRICES,SINT,,1.60683E+12,4.416666667,4.416666667,1.8394,1.755,1.85,1.67,4663574,1.8394,1.755,1.85,1.67,4663574,2-Sep-20,0.115,0.0701
2-Sep-20,"FDA Review of Approved Drug, Ubrogepant, Included DILIsym Simulations","DILIsym Services, Inc., a Simulations Plus company (Nasdaq: SLP) and a leading provider of modeling and simulation software for pharmaceutical safety and efficacy, today announced that simulations usi...",62.36,62.8766,59.619,60.88,SLP,208019,HISTORICAL_PRICES,SLP,,1.61128E+12,0.948141206,0.948141206,60.88,62.36,62.8766,59.619,208019,60.7781,62.2556,62.7714,59.5192,208019,2-Sep-20,1.33,0.0218
2-Sep-20,"Everbridge Risk Intelligence Provides Major Corporations, Healthcare Organizations and Government Entities with Situational Awareness to Mitigate Threats from COVID-19","Everbridge, Inc. (NASDAQ: EVBG), the global leader in critical event management (CEM), today announced widescale adoption for its Risk Intelligence situation reports, providing organizations across in...",148.71,156.99,146.35,156.99,EVBG,376544,HISTORICAL_PRICES,EVBG,,1.60683E+12,0.21306795,0.21306795,156.99,148.71,156.99,146.35,376544,156.99,148.71,156.99,146.35,376544,2-Sep-20,-5.79,-0.0375
2-Sep-20,"Genprex Appoints William E. Gannon, Jr., MD, MBA, as Vice President of Regulatory Affairs","Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX), a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes, today announce...",3.94,4.05,3.84,4.05,GNPX,1042726,HISTORICAL_PRICES,GNPX,,1.60683E+12,0.363321799,0.363321799,4.05,3.94,4.05,3.84,1042726,4.05,3.94,4.05,3.84,1042726,2-Sep-20,-0.06,-0.015
2-Sep-20,Revance to Participate in the Wells Fargo Securities Healthcare Conference,"Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company focused on innovative aesthetic and therapeutic offerings, including its investigational neuromodulator product, DaxibotulinumtoxinA...",28.55,28.655,27.3,27.89,RVNC,427307,HISTORICAL_PRICES,RVNC,,1.60683E+12,1.039285714,1.039285714,27.89,28.55,28.655,27.3,427307,27.89,28.55,28.655,27.3,427307,2-Sep-20,0.81,0.0292
2-Sep-20,Catabasis Pharmaceuticals to Host Virtual KOL Event on Edasalonexent and Duchenne Muscular Dystrophy,"Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, will be holding a virtual key opinion leader (KOL) event to discuss edasalonexent, currently in Phase 3 clini...",6.36,6.42,6.15,6.32,CATB,307061,HISTORICAL_PRICES,CATB,,1.60683E+12,0.647668394,0.647668394,6.32,6.36,6.42,6.15,307061,6.32,6.36,6.42,6.15,307061,2-Sep-20,0.06,0.0095
2-Sep-20,Applied DNA to Present at H.C. Wainwright 22nd Annual Global Investment Conference on September 15,"Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA” or the ""Company""), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing that enables in vitro diagnostics, pre-clinical nucleic...",7.3,7.51,7.16,7.38,APDN,204645,HISTORICAL_PRICES,APDN,,1.60683E+12,0.825,0.825,7.38,7.3,7.51,7.16,204645,7.38,7.3,7.51,7.16,204645,2-Sep-20,-0.09,-0.0122
2-Sep-20,"Magenta Therapeutics Appoints Lisa M. Olson as Chief Scientific Officer and Kevin B. Johnson as Senior Vice President, Head of Regulatory and Quality; Announces Transition of Jason Ryan, Chief Operating and Financial Officer","Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of immune reset to more patients, today announced the appointment of...",7.12,7.18,6.77,7.05,MGTA,364726,HISTORICAL_PRICES,MGTA,,1.60683E+12,0.135566188,0.135566188,7.05,7.12,7.18,6.77,364726,7.05,7.12,7.18,6.77,364726,2-Sep-20,-0.02,-0.0028
2-Sep-20,Rocket Pharmaceuticals Announces First Patient Treated in Higher Dose Cohort in Phase 1 Clinical Trial of RP-A501 for Danon Disease,"Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) (“Rocket”), a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare pediatric disorders, today announces it...",24.78,25.21,24.39,25.21,RCKT,155275,HISTORICAL_PRICES,RCKT,,1.60683E+12,0.798258345,0.798258345,25.21,24.78,25.21,24.39,155275,25.21,24.78,25.21,24.39,155275,2-Sep-20,-0.32,-0.0127
2-Sep-20,New Scientific Data at the ESMO Virtual Congress 2020 Reflect Merck’s Commitment to Advancing Cancer Research and Care,"Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that new data from its broad and diverse oncology development program will be presented at the European Society fo...",86.93,87.21,84.27,84.48,MRK,11041565,HISTORICAL_PRICES,MRK,,1.61552E+12,0.258942795,0.258942795,84.48,86.93,87.21,84.27,11041565,82.4881,84.8803,85.1537,82.2831,11041565,2-Sep-20,2.5,0.0296
1-Sep-20,"U.S. Food and Drug Administration Approves Onureg® (azacitidine tablets), a New Oral Therapy, as Continued Treatment for Adults in First Remission with Acute Myeloid Leukemia","Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) has approved Onureg® (azacitidine 300 mg tablets, CC-486) for the continued treatment of adult patient...",60.97,62.26,60.69,62.2,BMY,12155651,HISTORICAL_PRICES,BMY,,1.60946E+12,0.238220959,0.238220959,62.2,60.97,62.26,60.69,12155651,61.2472,60.036,61.3063,59.7603,12155651,1-Sep-20,-1.23,-0.0198
1-Sep-20,Bristol Myers Squibb Announces Interim Results from Long-Term Study Reinforcing Efficacy and Safety Profile of Zeposia (ozanimod) in Patients with Relapsing Forms of Multiple Sclerosis,"Bristol Myers Squibb (NYSE:BMY) today announced interim results from the Phase 3 open-label extension trial DAYBREAK, demonstrating the long-term efficacy and safety profile of Zeposia (ozanimod) in p...",60.97,62.26,60.69,62.2,BMY,12155651,HISTORICAL_PRICES,BMY,,1.60946E+12,0.238220959,0.238220959,62.2,60.97,62.26,60.69,12155651,61.2472,60.036,61.3063,59.7603,12155651,1-Sep-20,-1.23,-0.0198
1-Sep-20,"FDA Accepts Vertex’s Supplemental New Drug Applications for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor), SYMDEKO® (tezacaftor/ivacaftor and ivacaftor) and KALYDECO® (ivacaftor) for Additional CFTR Mutations",Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) accepted three supplemental New Drug Applications (sNDAs) for TRIKAFTA® (elexacaftor/teza...,275.49,279.96,271.77,277.87,VRTX,1252788,HISTORICAL_PRICES,VRTX,,1.60683E+12,0.234661408,0.234661408,277.87,275.49,279.96,271.77,1252788,277.87,275.49,279.96,271.77,1252788,1-Sep-20,-3.63,-0.013
1-Sep-20,Mirum Pharmaceuticals Initiates Rolling Submission of a New Drug Application for Maralixibat for the Treatment of Cholestatic Pruritus in Patients with Alagille Syndrome and Launches Expanded Access Program,"Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a biopharmaceutical company focused on the development and commercialization of novel therapies for debilitating liver diseases today announced that it has...",23.89,26.99,23.41,26.99,MIRM,121233,HISTORICAL_PRICES,MIRM,,1.60683E+12,0.928167877,0.928167877,26.99,23.89,26.99,23.41,121233,26.99,23.89,26.99,23.41,121233,1-Sep-20,-2.07,-0.0797
1-Sep-20,"IVERIC bio Announces Publication of GATHER1 Phase 3 Clinical Trial Results for Zimura® in Geographic Atrophy Secondary to Age-related Macular Degeneration, in Ophthalmology®, the Journal of the American Academy of Ophthalmology","IVERIC bio, Inc. (Nasdaq: ISEE) today announced that the positive Phase 3 results from its GATHER1 clinical trial with Zimura® (avacincaptad pegol), a novel complement C5 inhibitor, in development for...",4.53,4.67,4.32,4.57,ISEE,760265,HISTORICAL_PRICES,ISEE,,1.60683E+12,0.348214286,0.348214286,4.57,4.53,4.67,4.32,760265,4.57,4.53,4.67,4.32,760265,1-Sep-20,0.04,0.0089
1-Sep-20,AtriCure to Participate at the Morgan Stanley 18th Annual Global Healthcare Conference,"AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that the company will be participating in th...",44.89,45.83,43.83,44.62,ATRC,281623,HISTORICAL_PRICES,ATRC,,1.60683E+12,0.560305874,0.560305874,44.62,44.89,45.83,43.83,281623,44.62,44.89,45.83,43.83,281623,1-Sep-20,0.16,0.0036
31-Aug-20,Masimo O3® Regional Oximetry Receives FDA Clearance for Somatic Applications and Measurement of Relative Changes in Cerebral Hemoglobin,Masimo (NASDAQ: MASI) today announced that O3® Regional Oximetry has received FDA clearance for expanded use in monitoring somatic tissue oxygenation saturation in all patient populations and monitori...,224,225.09,216.79,216.79,MASI,414213,HISTORICAL_PRICES,MASI,,1.60683E+12,0.441441441,0.441441441,216.79,224,225.09,216.79,414213,216.79,224,225.09,216.79,414213,31-Aug-20,4.22,0.0192
31-Aug-20,"INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Tricida, Inc. and Encourages Investors with Losses of $100,000 to Contact the Firm","The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Tricida, Inc. (“Tricida” or “the Company”) (NASDAQ: TCDA) for vi...",10.57,10.75,10.01,10.11,TCDA,710017,HISTORICAL_PRICES,TCDA,,1.60683E+12,-0.528125,-0.528125,10.11,10.57,10.75,10.01,710017,10.11,10.57,10.75,10.01,710017,31-Aug-20,0.39,0.0383
31-Aug-20,New Preclinical GlycoMimetics Data Suggests Uproleselan With Venetoclax/HMA in AML May Prolong Survival,"GlycoMimetics, Inc. (Nasdaq: GLYC) today announced new preclinical data providing the first evidence that an E-selectin targeting strategy with uproleselan may help patients with acute myeloid leukemi...",3.69,3.85,3.6633,3.77,GLYC,141251,HISTORICAL_PRICES,GLYC,,1.60683E+12,0.65470852,0.65470852,3.77,3.69,3.85,3.6633,141251,3.77,3.69,3.85,3.6633,141251,31-Aug-20,-0.08,-0.0212
31-Aug-20,Baxter Announces U.S. FDA De Novo Authorization for Theranova Dialyzers Enabling HDx Therapy,"Baxter International Inc. (NYSE:BAX), a global innovator in renal care, today announced the U.S. Food and Drug Administration (FDA) has granted the De Novo application for Theranova, the company’s nov...",87.07,87.245,86.18,86.25,BAX,2736883,HISTORICAL_PRICES,BAX,,1.61422E+12,0.17805439,0.17805439,86.25,87.07,87.245,86.18,2736883,85.7049,86.5198,86.6937,85.6354,2736883,31-Aug-20,1.04,0.0121
28-Aug-20,Gilead’s Investigational Antiviral Veklury® (Remdesivir) Receives U.S. Food and Drug Administration Emergency Use Authorization for the Treatment of Patients With Moderate COVID-19,"Gilead Sciences, Inc. (Nasdaq: GILD) today announced the U.S. Food and Drug Administration (FDA) expanded the Emergency Use Authorization (EUA) enabling use of the investigational antiviral Veklury® (...",65.26,65.745,64.98,65.22,GILD,6820958,HISTORICAL_PRICES,GILD,,1.61552E+12,-0.117631152,-0.117631152,65.22,65.26,65.745,64.98,6820958,63.1032,63.1419,63.6111,62.8709,6820958,28-Aug-20,-0.29,-0.0044
28-Aug-20,Legend Biotech Reports Second Quarter 2020 Financial Results,"Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global clinical-stage biopharmaceutical company engaged in the discovery and development of novel cell therapies for oncology and other in...",34,34.24,33.91,34,LEGN,75869,HISTORICAL_PRICES,LEGN,,1.60683E+12,-0.081081081,-0.081081081,34,34,34.24,33.91,75869,34,34,34.24,33.91,75869,28-Aug-20,-0.34,-0.0099
28-Aug-20,"INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Tricida, Inc. and Encourages Investors with Losses of $100,000 to Contact the Firm","The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Tricida, Inc. (“Tricida” or “the Company”) (NASDAQ: TCDA) for vi...",10.18,10.48,9.954,10.33,TCDA,668571,HISTORICAL_PRICES,TCDA,,1.60683E+12,-0.545535714,-0.545535714,10.33,10.18,10.48,9.954,668571,10.33,10.18,10.48,9.954,668571,28-Aug-20,-0.21,-0.0202
28-Aug-20,"EQUITY ALERT: ROSEN, A LEADING AND LONGSTANDING LAW FIRM, Announces Investigation of Securities Claims Against Tricida, Inc. – TCDA","Rosen Law Firm, a global investor rights law firm, announces investigation of potential securities claims on behalf of shareholders of Tricida, Inc. (NASDAQ: TCDA) resulting from allegations that Tric...",10.18,10.48,9.954,10.33,TCDA,668571,HISTORICAL_PRICES,TCDA,,1.60683E+12,-0.545535714,-0.545535714,10.33,10.18,10.48,9.954,668571,10.33,10.18,10.48,9.954,668571,28-Aug-20,-0.21,-0.0202
28-Aug-20,"Moderna Confirms Discussions with the Ministry of Health, Labour and Welfare to Supply Japan with 40 Million Doses of mRNA Vaccine Against COVID-19 (mRNA-1273)","Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today confirmed tha...",67.49,68.95,67.15,68.04,MRNA,6383705,HISTORICAL_PRICES,MRNA,,1.60683E+12,1.613865221,1.613865221,68.04,67.49,68.95,67.15,6383705,68.04,67.49,68.95,67.15,6383705,28-Aug-20,-0.54,-0.0079
27-Aug-20,Quidel Provides Business Update at 13th Annual Piper Sandler Med-Tech and Diagnostic California Bus Tour; Another SARS Antigen Entrant Does Not Change Quidel’s Strategy,"Quidel Corporation (NASDAQ: QDEL) (“Quidel”), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today the following business...",174.56,182,135.02,168.01,QDEL,13439065,HISTORICAL_PRICES,QDEL,,1.60683E+12,1.036635165,1.036635165,168.01,174.56,182,135.02,13439065,168.01,174.56,182,135.02,13439065,27-Aug-20,-48.38,-0.217
27-Aug-20,Quidel to Present Today at 13th Annual Piper Sandler Med-Tech and Diagnostics California Bus Tour,"Quidel Corporation (NASDAQ: QDEL) (“Quidel”), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that it will present at...",174.56,182,135.02,168.01,QDEL,13439065,HISTORICAL_PRICES,QDEL,,1.60683E+12,1.036635165,1.036635165,168.01,174.56,182,135.02,13439065,168.01,174.56,182,135.02,13439065,27-Aug-20,-48.38,-0.217
27-Aug-20,Applied DNA Provides Update on Status of New York State Laboratory Permit for Clinical Labs Subsidiary,"Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA” or the ""Company""), announced that the Company’s wholly owned diagnostics testing subsidiary, Applied DNA Clinical Labs, LLC (“ADCL”), has compl...",7.35,8.58,7.08,8.39,APDN,1085698,HISTORICAL_PRICES,APDN,,1.60683E+12,0.8375,0.8375,8.39,7.35,8.58,7.08,1085698,8.39,7.35,8.58,7.08,1085698,27-Aug-20,-1.26,-0.1463
27-Aug-20,Tandem Diabetes Care Announces NEJM Publication of Pediatric Study Demonstrating Increased Time-In-Range using the t:slim X2 Insulin Pump with Control-IQ Technology,"Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced publication by the New England Journal of Medicine (NEJM) of results from the Pro...",111.34,112.8449,106.006,107.91,TNDM,994589,HISTORICAL_PRICES,TNDM,,1.60683E+12,1.012653651,1.012653651,107.91,111.34,112.8449,106.006,994589,107.91,111.34,112.8449,106.006,994589,27-Aug-20,3.98,0.0371
27-Aug-20,Seattle Genetics to Receive Milestone Payment Under ADC Collaboration with GlaxoSmithKline Following European Commission Approval of BLENREP (belantamab mafodotin),"Seattle Genetics, Inc. (Nasdaq:SGEN) today announced that it will receive a milestone payment from GlaxoSmithKline (GSK) triggered by European Commission conditional marketing authorisation for GSK’s...",154.11,156.12,152.97,155.11,SGEN,651851,HISTORICAL_PRICES,SGEN,,1.60683E+12,0.512810445,0.512810445,155.11,154.11,156.12,152.97,651851,155.11,154.11,156.12,152.97,651851,27-Aug-20,-0.37,-0.0024
27-Aug-20,Axcella’s Late-Breaker Data from AXA1125-003 Clinical Study Presented at the EASL Digital International Liver Congress,"Axcella (Nasdaq: AXLA), a clinical-stage biotechnology company focused on leveraging endogenous metabolic modulators (EMMs) to pioneer a new approach for treating complex diseases and improving health...",5.17,5.4,5.06,5.37,AXLA,239497,HISTORICAL_PRICES,AXLA,,1.60683E+12,0.752542373,0.752542373,5.37,5.17,5.4,5.06,239497,5.37,5.17,5.4,5.06,239497,27-Aug-20,-0.15,-0.0282
27-Aug-20,UroGen Pharma Announces Update on the Phase 2 Trial of an RTGel™ Hydrogel Formulation in Combination with BOTOX® (onabotulinumtoxinA) Intravesical Instillation for Overactive Bladder and Urinary Incontinence,"UroGen Pharma Ltd. (Nasdaq: URGN), a biopharmaceutical company dedicated to building and commercializing novel solutions that treat specialty cancers and urologic diseases, today announced that the Ph...",19.86,21.8,19.51,21.5,URGN,512059,HISTORICAL_PRICES,URGN,,1.60683E+12,0.099059214,0.099059214,21.5,19.86,21.8,19.51,512059,21.5,19.86,21.8,19.51,512059,27-Aug-20,-2.39,-0.1074
27-Aug-20,Scholar Rock Announces Issuance of U.S. Patent Providing Composition of Matter Protection for SRK-015,"Scholar Rock (NASDAQ:SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced that the Un...",14.9,15.1912,14.2,15.11,SRRK,145632,HISTORICAL_PRICES,SRRK,,1.60683E+12,0.086797958,0.086797958,15.11,14.9,15.1912,14.2,145632,15.11,14.9,15.1912,14.2,145632,27-Aug-20,-0.52,-0.0337
27-Aug-20,Rocket Pharmaceuticals Receives FDA Fast Track Designation for RP-L401 Gene Therapy for Infantile Malignant Osteopetrosis,"Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) (“Rocket”), a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders, today announces tha...",25.22,25.915,24.84,25.73,RCKT,212728,HISTORICAL_PRICES,RCKT,,1.60683E+12,0.830188679,0.830188679,25.73,25.22,25.915,24.84,212728,25.73,25.22,25.915,24.84,212728,27-Aug-20,-0.55,-0.0213
26-Aug-20,"ROSEN, A LEADING NATIONAL LAW FIRM, Continues Investigation of Securities Claims Against Mesoblast Limited; Encourages Investors with Losses in Excess of $100K to Contact the Firm – MESO","Rosen Law Firm, a global investor rights law firm, continues its investigation of potential securities claims on behalf of shareholders of Mesoblast Limited (NASDAQ: MESO) resulting from allegations t...",18.33,18.69,17.86,18.24,MESO,940667,HISTORICAL_PRICES,MESO,,1.60683E+12,4.008059889,4.008059889,18.24,18.33,18.69,17.86,940667,18.24,18.33,18.69,17.86,940667,26-Aug-20,0.67,0.0379
26-Aug-20,"FDA Approves FoundationOne® Liquid CDx to Serve as Rubraca® (rucaparib) Companion Diagnostic to Identify Eligible Patients with BRCA1/2-Mutant, Metastatic Castration-Resistant Prostate Cancer (mCRPC)","Clovis Oncology, Inc. (NASDAQ: CLVS) announced today that the U.S. Food and Drug Administration (FDA) approved the FoundationOne® Liquid CDx, Foundation Medicine’s comprehensive liquid biopsy test for...",4.96,5.17,4.96,5.07,CLVS,3892760,HISTORICAL_PRICES,CLVS,,1.60683E+12,0.062098501,0.062098501,5.07,4.96,5.17,4.96,3892760,5.07,4.96,5.17,4.96,3892760,26-Aug-20,-0.13,-0.0255
26-Aug-20,Stoke Therapeutics Announces Publication of Preclinical Data on STK-001 in the Journal Science Translational Medicine that Demonstrate Significant Improvements in Survival and Reductions in Seizure Frequency in a Dravet Syndrome Mouse Model,"Stoke Therapeutics, Inc., (Nasdaq: STOK), a biotechnology company pioneering a new way to treat the underlying cause of genetic diseases by precisely upregulating protein expression, today announced t...",29,29.43,28.76,29,STOK,57847,HISTORICAL_PRICES,STOK,,1.60683E+12,0.358313817,0.358313817,29,29,29.43,28.76,57847,29,29,29.43,28.76,57847,26-Aug-20,0.03,0.001
26-Aug-20,Genprex to Present at The LD 500 Virtual Conference,"Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX), a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes, today announce...",3.86,4.13,3.86,4.02,GNPX,1294110,HISTORICAL_PRICES,GNPX,,1.60683E+12,0.335640138,0.335640138,4.02,3.86,4.13,3.86,1294110,4.02,3.86,4.13,3.86,1294110,26-Aug-20,-0.26,-0.0631
25-Aug-20,"Ligand OmniAb® Partner Immunovant Announced Positive Topline Results from Multicenter, Placebo-Controlled Phase 2a Trial of IMVT-1401 in Myasthenia Gravis","Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) OmniAb® partner Immunovant, Inc. (NASDAQ: IMVT) announced positive topline results from ASCEND MG, a Phase 2a study of OmniAb-derived IMVT-1401 in pa...",108.4,109,106.335,108.09,LGND,144464,HISTORICAL_PRICES,LGND,,1.60683E+12,0.461310326,0.461310326,108.09,108.4,109,106.335,144464,108.09,108.4,109,106.335,144464,25-Aug-20,1,0.0093
25-Aug-20,"ACADIA Pharmaceuticals Acquires CerSci Therapeutics, Adds Novel Pain Program to Portfolio","ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the acquisition of CerSci Therapeutics, a clinical-stage biotechnology company with worldwide rights to a portfolio of novel compounds for ne...",38.37,38.565,37.87,38.29,ACAD,1455092,HISTORICAL_PRICES,ACAD,,1.60683E+12,0.008145034,0.008145034,38.29,38.37,38.565,37.87,1455092,38.29,38.37,38.565,37.87,1455092,25-Aug-20,0.37,0.0097
25-Aug-20,"Fitbit Debuts Sense, Its Most Advanced Health Smartwatch; World’s First With EDA Sensor for Stress Management,1 Plus ECG App,2 SpO2 and Skin Temperature Sensors","Fitbit (NYSE:FIT) today announced Fitbit SenseTM, the company’s most advanced health smartwatch, bringing innovative sensor and software technology with the world’s first electrodermal activity (EDA)...",6.46,6.53,6.32,6.37,FIT,4309873,HISTORICAL_PRICES,FIT,,1.60683E+12,0.017322835,0.017322835,6.37,6.46,6.53,6.32,4309873,6.37,6.46,6.53,6.32,4309873,25-Aug-20,0.09,0.0141
25-Aug-20,"Amneal Receives Abbreviated New Drug Application Approval for Lidocaine Patch, 5%","Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced that it has received Abbreviated New Drug Application (ANDA) approval from the U.S. Food and Drug Administration (...",4.01,4.1,3.93,4.1,AMRX,1007820,HISTORICAL_PRICES,AMRX,,1.60683E+12,0.110803324,0.110803324,4.1,4.01,4.1,3.93,1007820,4.1,4.01,4.1,3.93,1007820,25-Aug-20,0.03,0.0075
25-Aug-20,Revance Commercial Infrastructure Established and Positioned to Launch Prestige Aesthetics Portfolio with the RHA® Collection of Dermal Fillers,"Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company focused on innovative aesthetic and therapeutic offerings, including its investigational neuromodulator product, DaxibotulinumtoxinA...",28.26,28.77,27.03,27.39,RVNC,646505,HISTORICAL_PRICES,RVNC,,1.60683E+12,1.018571429,1.018571429,27.39,28.26,28.77,27.03,646505,27.39,28.26,28.77,27.03,646505,25-Aug-20,0.32,0.0115
25-Aug-20,TransAct Technologies Announces Partnership With Nutrition Software Leader ESHA Research,"TransAct® Technologies Incorporated (Nasdaq: TACT) (“TransAct” or the “Company”), a global leader in software-driven technology and printing solutions for high-growth markets, today announced a new pa...",5.08,5.17,4.89,4.89,TACT,15394,HISTORICAL_PRICES,TACT,,1.60683E+12,0.282828283,0.282828283,4.89,5.08,5.17,4.89,15394,4.89,5.08,5.17,4.89,15394,25-Aug-20,0.06,0.012
25-Aug-20,Nemaura Medical to Present at The LD 500 Virtual Conference,"Nemaura Medical, Inc. (NASDAQ: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing micro-systems-based wearable diagnostic devices and currently commercializing suga...",4.7,4.805,4.55,4.76,NMRD,62018,HISTORICAL_PRICES,NMRD,,1.60683E+12,-0.06374502,-0.06374502,4.76,4.7,4.805,4.55,62018,4.76,4.7,4.805,4.55,62018,25-Aug-20,-0.15,-0.0309
25-Aug-20,Bristol Myers Squibb Provides Update on Phase 3 IDHENTIFY Trial in Patients with Relapsed or Refractory Acute Myeloid Leukemia,"Bristol Myers Squibb (NYSE:BMY) today announced that the Phase 3 IDHENTIFY study evaluating IDHIFA® (enasidenib) plus best supportive care (BSC) versus conventional care regimens, which include best s...",62.71,63.365,62.5,62.75,BMY,6620701,HISTORICAL_PRICES,BMY,,1.60946E+12,0.273558083,0.273558083,62.75,62.71,63.365,62.5,6620701,61.7888,61.7494,62.3944,61.5426,6620701,25-Aug-20,0.3,0.0048
24-Aug-20,Gilead Announces Presentation of More Than 40 Abstracts From Extensive Liver Disease Programs at the Digital International Liver Congress™ 2020,"Gilead Sciences, Inc. (Nasdaq: GILD) announced the presentation of more than 40 abstracts reflecting the breadth of research from the company’s programs addressing significant challenges in viral hepa...",66.08,66.96,65.55,66.355,GILD,8566231,HISTORICAL_PRICES,GILD,,1.61552E+12,-0.106544078,-0.106544078,66.355,66.08,66.96,65.55,8566231,64.2013,63.9352,64.7867,63.4224,8566231,24-Aug-20,-0.42,-0.0063
24-Aug-20,Moderna Confirms Advanced Discussions with European Commission to Supply Europe with 80 Million Doses of mRNA Vaccine Against COVID-19 (mRNA-1273),"Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced tha...",64.88,67.85,62.88,67.15,MRNA,13143244,HISTORICAL_PRICES,MRNA,,1.60683E+12,1.51278079,1.51278079,67.15,64.88,67.85,62.88,13143244,67.15,64.88,67.85,62.88,13143244,24-Aug-20,-1.57,-0.0236
24-Aug-20,"NantKwest and ImmunityBio Sign Collaboration Agreement for Joint Development, Manufacturing, Marketing, and Commercialization of COVID-19 Vaccine and Related Therapeutics","NantKwest, Inc. (Nasdaq: NK), a clinical-stage, natural killer cell-based therapeutics company, and ImmunityBio, a privately held immunotherapy company, today announced the signing of a definitive agr...",7.77,8.42,7.62,8.29,NK,1281884,HISTORICAL_PRICES,NK,,1.60683E+12,1.60738255,1.60738255,8.29,7.77,8.42,7.62,1281884,8.29,7.77,8.42,7.62,1281884,24-Aug-20,-0.27,-0.0336
24-Aug-20,Ligand Announces Amgen’s KYPROLIS® Approved by FDA as Combination Regimen with DARZALEX® and Dexamethasone in Once- and Twice-Weekly Dosing Regimens for Patients with Relapsed/Refractory Multiple Myeloma,Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces that a major Captisol customer Amgen (NASDAQ: AMGN) has received U.S. Food and Drug Administration (FDA) approval for the expansion of the...,107.4,111.7,107.27,110.89,LGND,191921,HISTORICAL_PRICES,LGND,,1.60683E+12,0.447829604,0.447829604,110.89,107.4,111.7,107.27,191921,110.89,107.4,111.7,107.27,191921,24-Aug-20,-4.58,-0.0409
24-Aug-20,Tricida Receives Complete Response Letter from the FDA for its New Drug Application for Veverimer for the Treatment of Metabolic Acidosis and Slowing of Kidney Disease Progression in Patients with Metabolic Acidosis Associated with CKD,"Tricida, Inc. (Nasdaq: TCDA), a pharmaceutical company focused on the development and commercialization of its drug candidate, veverimer (TRC101), a non-absorbed, orally-administered polymer designed...",10.11,12.5,9.5601,10.48,TCDA,5524581,HISTORICAL_PRICES,TCDA,,1.60683E+12,-0.548660714,-0.548660714,10.48,10.11,12.5,9.5601,5524581,10.48,10.11,12.5,9.5601,5524581,24-Aug-20,-3.13,-0.2364
24-Aug-20,Exelixis Announces Submission of Supplemental New Drug Application to U.S. Food and Drug Administration for CABOMETYX® (cabozantinib) in Combination With Opdivo® (nivolumab) for Advanced Renal Cell Carcinoma,"Exelixis, Inc. (NASDAQ:EXEL) today announced the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for CABOMETYX® (cabozantinib) in combination wi...",21.64,22.49,21.37,22.31,EXEL,1652361,HISTORICAL_PRICES,EXEL,,1.60683E+12,0.365299685,0.365299685,22.31,21.64,22.49,21.37,1652361,22.31,21.64,22.49,21.37,1652361,24-Aug-20,-0.61,-0.0274
24-Aug-20,Catalent Signs Agreement with AstraZeneca to Expand Manufacturing Support for COVID-19 Vaccine AZD1222,"Catalent, Inc. (NYSE: CTLT), the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health...",88.46,89.6885,87.98,88,CTLT,885161,HISTORICAL_PRICES,CTLT,,1.60683E+12,0.923043478,0.923043478,88,88.46,89.6885,87.98,885161,88,88.46,89.6885,87.98,885161,24-Aug-20,1.97,0.0228
24-Aug-20,"Odonate Therapeutics Announces Positive Top-line Results from CONTESSA, a Phase 3 Study of Tesetaxel in Patients with Metastatic Breast Cancer","Odonate Therapeutics, Inc. (NASDAQ: ODT), a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer, today announced...",18.33,24.94,18.08,24.51,ODT,3378618,HISTORICAL_PRICES,ODT,,1.60683E+12,-0.247536946,-0.247536946,24.51,18.33,24.94,18.08,3378618,24.51,18.33,24.94,18.08,3378618,24-Aug-20,-15.21,-0.4535
24-Aug-20,Merck’s KEYTRUDA® (pembrolizumab) Receives Two New Approvals in Japan,"Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that KEYTRUDA, Merck’s anti-PD-1 therapy, has received two new approvals from the Japan Pharmaceuticals and Medica...",85.42,85.47,84.48,85.2,MRK,7234978,HISTORICAL_PRICES,MRK,,1.61552E+12,0.237074584,0.237074584,85.2,85.42,85.47,84.48,7234978,83.1911,83.406,83.4548,82.4881,7234978,24-Aug-20,0.44,0.0052
20-Aug-20,INVESTOR ALERT: Law Offices of Howard G. Smith Continues Investigation of Fennec Pharmaceuticals Inc. (FENC) on Behalf of Investors,"Law Offices of Howard G. Smith continues its investigation on behalf of Fennec Pharmaceuticals Inc. (""Fennec"" or the ""Company"") (NASDAQ: FENC) investors concerning the Company’s possible violations of...",5.66,5.86,5.64,5.8,FENC,251690,HISTORICAL_PRICES,FENC,,1.60683E+12,0,0,5.8,5.66,5.86,5.64,251690,5.8,5.66,5.86,5.64,251690,20-Aug-20,-0.17,-0.0292
20-Aug-20,"Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Continues Investigation of HDFC Bank Limited (HDB) on Behalf of Investors","Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, continues its investigation on behalf of HDFC Bank Limited (""HDFC Bank"" or the ""Company"") (NYSE: HDB) investors...",47.72,47.89,46.69,46.78,HDB,1030372,HISTORICAL_PRICES,HDB,,1.60683E+12,0.446498939,0.446498939,46.78,47.72,47.89,46.69,1030372,46.78,47.72,47.89,46.69,1030372,20-Aug-20,0.53,0.0112
20-Aug-20,新研究調查Masimo SpHb®無創連續監測新生兒血紅蛋白的精度,(美國商業資訊)--Masimo (NASDAQ: MASI)今天宣布，《熱帶兒科學雜誌》(Journal of Tropical Pediatrics)最近發表的一項研究中，研究人員評估新生兒患者Masimo SpHb®（無創連續血紅蛋白監測）的結論是，該技術「可提供可靠的Hb [血紅蛋白]數值，等同於較傳統的tHb [有創靜脈血採樣]。」1 土耳其尚勒烏爾法哈蘭大學(Harran Univer...,223,223.5,217.15,218.5,MASI,356920,HISTORICAL_PRICES,MASI,,1.60683E+12,0.435006435,0.435006435,218.5,223,223.5,217.15,356920,218.5,223,223.5,217.15,356920,20-Aug-20,4.84,0.0222
20-Aug-20,新研究调查Masimo SpHb®无创连续监测新生儿血红蛋白的精度,(美国商业资讯)--Masimo (NASDAQ: MASI)今天宣布，《热带儿科学杂志》(Journal of Tropical Pediatrics)最近发表的一项研究中，研究人员评估新生儿患者Masimo SpHb®（无创连续血红蛋白监测）的结论是，该技术“可提供可靠的Hb [血红蛋白]数值，等同于较传统的tHb [有创静脉血采样]。”1 土耳其尚勒乌尔法哈兰大学(Harran Univer...,223,223.5,217.15,218.5,MASI,356920,HISTORICAL_PRICES,MASI,,1.60683E+12,0.435006435,0.435006435,218.5,223,223.5,217.15,356920,218.5,223,223.5,217.15,356920,20-Aug-20,4.84,0.0222
20-Aug-20,The Law Offices of Frank R. Cruz Continues Its Investigation of Fennec Pharmaceuticals Inc. (FENC) on Behalf of Investors,"The Law Offices of Frank R. Cruz continues its investigation on behalf of Fennec Pharmaceuticals Inc. (""Fennec"" or the ""Company"") (NASDAQ: FENC) investors concerning the Company’s possible violations...",5.66,5.86,5.64,5.8,FENC,251690,HISTORICAL_PRICES,FENC,,1.60683E+12,0,0,5.8,5.66,5.86,5.64,251690,5.8,5.66,5.86,5.64,251690,20-Aug-20,-0.17,-0.0292
20-Aug-20,"Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Continues Investigation of STAAR Surgical Company (STAA) on Behalf of Investors","Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, continues its investigation on behalf of STAAR Surgical Company (""STAAR"" or the ""Company"") (NASDAQ: STAA) inves...",48.06,48.5,47.8,47.89,STAA,258443,HISTORICAL_PRICES,STAA,,1.60683E+12,0.789277736,0.789277736,47.89,48.06,48.5,47.8,258443,47.89,48.06,48.5,47.8,258443,20-Aug-20,-0.04,-0.0008
20-Aug-20,Quidel Concludes Sofia® SARS Antigen Investigation From Vermont,"Quidel Corporation (NASDAQ: QDEL) (“Quidel”), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that Quidel has complet...",247.6,251.42,238.07,240.57,QDEL,616271,HISTORICAL_PRICES,QDEL,,1.60683E+12,1.888811107,1.888811107,240.57,247.6,251.42,238.07,616271,240.57,247.6,251.42,238.07,616271,20-Aug-20,6.52,0.027
20-Aug-20,Nuevos estudios investigan la exactitud del monitoreo continuo y no invasivo de la hemoglobina con Masimo SpHb® en neonatos,"Masimo (NASDAQ: MASI) anunció hoy que en un estudio publicado recientemente en el Journal of Tropical Pediatrics, los investigadores que evalúan SpHb® de Masimo (monitoreo no invasivo y continuo de la...",223,223.5,217.15,218.5,MASI,356920,HISTORICAL_PRICES,MASI,,1.60683E+12,0.435006435,0.435006435,218.5,223,223.5,217.15,356920,218.5,223,223.5,217.15,356920,20-Aug-20,4.84,0.0222
20-Aug-20,"Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Continues Investigation of OneSpan Inc. (OSPN) on Behalf of Investors","Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, continues its investigation on behalf of OneSpan Inc. (""OneSpan"" or the ""Company"") (NASDAQ: OSPN) investors con...",20.55,20.6422,19.81,20.46,OSPN,339204,HISTORICAL_PRICES,OSPN,,1.60683E+12,0.291640478,0.291640478,20.46,20.55,20.6422,19.81,339204,20.46,20.55,20.6422,19.81,339204,20-Aug-20,0.03,0.0015
20-Aug-20,"Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Continues Investigation of Fennec Pharmaceuticals Inc. (FENC) on Behalf of Investors","Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, continues its investigation on behalf of Fennec Pharmaceuticals Inc. (""Fennec"" or the ""Company"") (NASDAQ: FENC)...",5.66,5.86,5.64,5.8,FENC,251690,HISTORICAL_PRICES,FENC,,1.60683E+12,0,0,5.8,5.66,5.86,5.64,251690,5.8,5.66,5.86,5.64,251690,20-Aug-20,-0.17,-0.0292
20-Aug-20,"Neue Studien untersuchen die Genauigkeit der nichtinvasiven, kontinuierlichen Hämoglobinüberwachung mit Masimo SpHb® bei Neugeborenen","Masimo (NASDAQ: MASI) gab heute bekannt, dass Forscher, die Masimo SpHb® (nichtinvasive, kontinuierliche Hämoglobinüberwachung) bei Neugeborenen evaluierten, in einer kürzlich im Journal of Tropical P...",223,223.5,217.15,218.5,MASI,356920,HISTORICAL_PRICES,MASI,,1.60683E+12,0.435006435,0.435006435,218.5,223,223.5,217.15,356920,218.5,223,223.5,217.15,356920,20-Aug-20,4.84,0.0222
20-Aug-20,Oragenics Signs Process Development and Manufacturing Agreement With Avid Bioservices for Coronavirus Vaccine,"Oragenics, Inc. (NYSE American: OGEN) and Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), today announced that the companies have entered into a process development and drug substance manufacturi...",0.92,1.09,0.881,1.02,OGEN,18507400,HISTORICAL_PRICES,OGEN,,1.60683E+12,0.704019263,0.704019263,1.02,0.92,1.09,0.881,18507400,1.02,0.92,1.09,0.881,18507400,20-Aug-20,0.0524,0.0604
20-Aug-20,Ryder Named Among Food Logistics’ Top 3PL & Cold Storage Providers to Food & Beverage Industry,"Ryder System, Inc. (NYSE: R), a leader in supply chain, dedicated transportation, and commercial fleet management solutions, announces it is listed among Food Logistics’ Top Third-Party Logistics (3PL...",39.21,39.64,38.46,39.18,R,506896,HISTORICAL_PRICES,R,,1.61312E+12,0.478506787,0.478506787,39.18,39.21,39.64,38.46,506896,37.9377,37.9667,38.3831,37.2405,506896,20-Aug-20,-0.36,-0.0091
19-Aug-20,Quidel to Update Packaging of Point-of-Care Sofia® SARS Antigen Test for COVID-19 to Include Either Nasal or Nasopharyngeal Swabs,"Quidel Corporation (NASDAQ: QDEL) (“Quidel”), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that labeling for Quide...",241.08,250,239.09,248.87,QDEL,637157,HISTORICAL_PRICES,QDEL,,1.60683E+12,1.812740637,1.812740637,248.87,241.08,250,239.09,637157,248.87,241.08,250,239.09,637157,19-Aug-20,-7.75,-0.0311
19-Aug-20,Novos estudos investigam a precisão do monitoramento contínuo de hemoglobina não invasivo com Masimo SpHb® em neonatos,"Masimo (NASDAQ: MASI) anunciou hoje que, em um estudo publicado recentemente no Journal of Tropical Pediatrics, pesquisadores avaliando o Masimo SpHb® (monitoramento de hemoglobina não invasivo e cont...",218.16,221.33,216.49,220.3,MASI,426599,HISTORICAL_PRICES,MASI,,1.60683E+12,0.403861004,0.403861004,220.3,218.16,221.33,216.49,426599,220.3,218.16,221.33,216.49,426599,19-Aug-20,-0.73,-0.0033
19-Aug-20,Puma Biotechnology Announces Publication of Interim Results of Phase II CONTROL Trial in Annals of Oncology,"Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced the publication of interim results from its Phase II CONTROL trial of neratinib in the September 2020 Issue (Volume 31,...",10.92,11.08,10.5952,10.8,PBYI,701301,HISTORICAL_PRICES,PBYI,,1.60683E+12,0.260969977,0.260969977,10.8,10.92,11.08,10.5952,701301,10.8,10.92,11.08,10.5952,701301,19-Aug-20,0.13,0.012
19-Aug-20,ADC Therapeutics publie ses résultats financiers pour le deuxième trimestre 2020 et les faits marquants de son actualité,"ADC Therapeutics SA (NYSE: ADCT), une société biotechnologique spécialisée en oncologie au stade clinique avancé, à l’avant-garde du développement et de la mise sur le marché de conjugués anticorps-mé...",39.7,40.36,38.57,38.57,ADCT,193154,HISTORICAL_PRICES,ADCT,,1.60683E+12,0.338954469,0.338954469,38.57,39.7,40.36,38.57,193154,38.57,39.7,40.36,38.57,193154,19-Aug-20,0.7,0.0179
19-Aug-20,"EQUITY ALERT: ROSEN, A LEADING AND RANKED LAW FIRM, Announces Investigation of Securities Claims Against Applied Therapeutics, Inc. – APLT","Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Applied Therapeutics, Inc. (NASDAQ: APLT) resulting from alleg...",27.82,28.78,25.8101,26.41,APLT,156234,HISTORICAL_PRICES,APLT,,1.60683E+12,-0.059499662,-0.059499662,26.41,27.82,28.78,25.8101,156234,26.41,27.82,28.78,25.8101,156234,19-Aug-20,1.64,0.0626
19-Aug-20,Nemaura Medical Issues Presentation Pertaining to the use of Continuous Glucose Monitoring in COVID-19 Patients,"Nemaura Medical, Inc. (NASDAQ: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing micro-systems-based wearable diagnostic devices and currently commercializing suga...",5.13,5.2987,5.06,5.25,NMRD,113273,HISTORICAL_PRICES,NMRD,,1.60683E+12,0.021912351,0.021912351,5.25,5.13,5.2987,5.06,113273,5.25,5.13,5.2987,5.06,113273,19-Aug-20,-0.02,-0.0039
19-Aug-20,Merck’s KEYTRUDA® (pembrolizumab) in Combination With Chemotherapy Significantly Improved Overall Survival and Progression-Free Survival Compared With Chemotherapy in Locally Advanced or First-Line Metastatic Esophageal Cancer,"Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the pivotal Phase 3 KEYNOTE-590 trial evaluating KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with che...",85.03,85.71,84.56,84.56,MRK,6580198,HISTORICAL_PRICES,MRK,,1.61552E+12,0.231426503,0.231426503,84.56,85.03,85.71,84.56,6580198,82.5662,83.0251,83.6891,82.5662,6580198,19-Aug-20,0.47,0.0056
18-Aug-20,ADC Therapeutics gibt Finanzergebnisse für das zweite Quartal 2020 und Highlights zur jüngsten Geschäftsentwicklung bekannt,"ADC Therapeutics SA (NYSE: ADCT), ein im Bereich der späten klinischen Forschung tätiges Biotechnologieunternehmen mit Schwerpunkt Onkologie und Vorreiter in der Entwicklung und Vermarktung von hochwi...",39,40.48,36.75,37.95,ADCT,204962,HISTORICAL_PRICES,ADCT,,1.60683E+12,0.3153457,0.3153457,37.95,39,40.48,36.75,204962,37.95,39,40.48,36.75,204962,18-Aug-20,0.38,0.0098
18-Aug-20,"New Studies Investigate the Accuracy of Noninvasive, Continuous Hemoglobin Monitoring with Masimo SpHb® on Neonates","Masimo (NASDAQ: MASI) today announced that in a study recently published in the Journal of Tropical Pediatrics, researchers evaluating Masimo SpHb® (noninvasive, continuous hemoglobin monitoring) on n...",218.89,222,217,220.74,MASI,425192,HISTORICAL_PRICES,MASI,,1.60683E+12,0.408558559,0.408558559,220.74,218.89,222,217,425192,220.74,218.89,222,217,425192,18-Aug-20,-1.16,-0.0053
18-Aug-20,INVESTOR ALERT: Kirby McInerney LLP Continues Investigation of Shareholder Claims Against Fennec Pharmaceuticals Inc.,The law firm of Kirby McInerney LLP is investigating potential claims against Fennec Pharmaceuticals Inc. (“Fennec” or the “Company”) (NASDAQ: FENC). The investigation concerns whether Fennec and cert...,5.93,6.16,5.63,5.8,FENC,550330,HISTORICAL_PRICES,FENC,,1.60683E+12,0.04770318,0.04770318,5.8,5.93,6.16,5.63,550330,5.8,5.93,6.16,5.63,550330,18-Aug-20,0.1,0.0172
18-Aug-20,Gilead Receives Complete Response Letter for Filgotinib for the Treatment of Moderately to Severely Active Rheumatoid Arthritis,"Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has issued a complete response letter (CRL) for the New Drug Application (NDA) for filgotinib, an...",69.06,69.75,68.98,69.23,GILD,6327465,HISTORICAL_PRICES,GILD,,1.61552E+12,-0.066252028,-0.066252028,69.23,69.06,69.75,68.98,6327465,66.983,66.8185,67.4861,66.7411,6327465,18-Aug-20,-0.09,-0.0013
18-Aug-20,"FENNEC ALERT: Bragar Eagel & Squire, P.C. is Investigating Fennec Pharmaceuticals, Inc. on Behalf of Stockholders and Encourages Investors to Contact the Firm","Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Fennec Pharmaceuticals, Inc. (NASDAQ: FENC) on behalf of Fennec stockhol...",5.93,6.16,5.63,5.8,FENC,550330,HISTORICAL_PRICES,FENC,,1.60683E+12,0.04770318,0.04770318,5.8,5.93,6.16,5.63,550330,5.8,5.93,6.16,5.63,550330,18-Aug-20,0.1,0.0172
18-Aug-20,"INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Mesoblast Limited and Encourages Investors with Losses of $100,000 to Contact the Firm","The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Mesoblast Limited (“Mesoblast” or “the Company”) (NASDAQ: MESO)...",18.92,19.49,18.18,19.36,MESO,1181529,HISTORICAL_PRICES,MESO,,1.60683E+12,4.169257671,4.169257671,19.36,18.92,19.49,18.18,1181529,19.36,18.92,19.49,18.18,1181529,18-Aug-20,-0.89,-0.0449
18-Aug-20,ADC Therapeutics Reports Second Quarter 2020 Financial Results and Provides Recent Business Highlights,"ADC Therapeutics SA (NYSE: ADCT), a late clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of highly potent and targeted antibody drug conjugates (...",39,40.48,36.75,37.95,ADCT,204962,HISTORICAL_PRICES,ADCT,,1.60683E+12,0.3153457,0.3153457,37.95,39,40.48,36.75,204962,37.95,39,40.48,36.75,204962,18-Aug-20,0.38,0.0098
17-Aug-20,Deciphera Announces Publication of QINLOCK™ (ripretinib) Phase 1 Study Results in Patients with Gastrointestinal Stromal Tumor in Journal of Clinical Oncology,"Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), today announced that the Journal of Clinical Oncology has published results from its Phase 1 study of QINLOCK, the Company’s switch-control tyrosine kina...",46.34,46.74,45.1265,45.22,DCPH,229557,HISTORICAL_PRICES,DCPH,,1.60683E+12,0.177636595,0.177636595,45.22,46.34,46.74,45.1265,229557,45.22,46.34,46.74,45.1265,229557,17-Aug-20,1.07,0.0236
17-Aug-20,The Law Offices of Frank R. Cruz Announces Investigation of Fennec Pharmaceuticals Inc. (FENC) on Behalf of Investors,"The Law Offices of Frank R. Cruz announces an investigation on behalf of Fennec Pharmaceuticals Inc. (""Fennec"" or the ""Company"") (NASDAQ: FENC) investors concerning the Company’s possible violations o...",5.83,5.89,5.62,5.68,FENC,460791,HISTORICAL_PRICES,FENC,,1.60683E+12,0.030035336,0.030035336,5.68,5.83,5.89,5.62,460791,5.68,5.83,5.89,5.62,460791,17-Aug-20,0.16,0.0282
17-Aug-20,INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Fennec Pharmaceuticals Inc. (FENC) on Behalf of Investors,"Law Offices of Howard G. Smith announces an investigation on behalf of Fennec Pharmaceuticals Inc. (""Fennec"" or the ""Company"") (NASDAQ: FENC) investors concerning the Company’s possible violations of...",5.83,5.89,5.62,5.68,FENC,460791,HISTORICAL_PRICES,FENC,,1.60683E+12,0.030035336,0.030035336,5.68,5.83,5.89,5.62,460791,5.68,5.83,5.89,5.62,460791,17-Aug-20,0.16,0.0282
17-Aug-20,"EQUITY ALERT: ROSEN, A LEADING AND RANKED FIRM, Announces Investigation of Securities Claims Against Fennec Pharmaceuticals Inc. – FENC","Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Fennec Pharmaceuticals Inc. (NASDAQ: FENC) resulting from alle...",5.83,5.89,5.62,5.68,FENC,460791,HISTORICAL_PRICES,FENC,,1.60683E+12,0.030035336,0.030035336,5.68,5.83,5.89,5.62,460791,5.68,5.83,5.89,5.62,460791,17-Aug-20,0.16,0.0282
17-Aug-20,Philip Morris International Inc. Begins Commercialization of KT&G Products Outside of South Korea to Accelerate the Achievement of a Smoke-Free Future,Philip Morris International Inc. (PMI) (NYSE: PM) today announced it will begin commercialization of KT&G’s smoke-free alternatives outside of South Korea. The announcement follows an agreement si...,78.26,78.54,77.06,77.46,PM,2543014,HISTORICAL_PRICES,PM,,1.61612E+12,0.230503145,0.230503145,77.46,78.26,78.54,77.06,2543014,74.1698,74.9359,75.204,73.7868,2543014,17-Aug-20,0.55,0.0071
17-Aug-20,Journal of Clinical Oncology Publishes Additional Data from Clovis Oncology’s TRITON2 Clinical Trial Evaluating Rubraca® (rucaparib) for the Treatment of mCRPC in Patients with BRCA1/2 Gene Mutations,"Clovis Oncology, Inc. (NASDAQ: CLVS), announced today that data from the Phase 2 TRITON2 study of Rubraca® (rucaparib) for the treatment of metastatic castration-resistant prostate cancer (mCRPC) harb...",5.79,6.08,4.86,4.95,CLVS,14707095,HISTORICAL_PRICES,CLVS,,1.60683E+12,0.239828694,0.239828694,4.95,5.79,6.08,4.86,14707095,4.95,5.79,6.08,4.86,14707095,17-Aug-20,0.97,0.2012
17-Aug-20,AngioDynamics Announces First Patient Enrolled in PATHFINDER I Registry Examining Long-Term Effectiveness and Safety of Auryon Atherectomy System,"AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced the enrollment...",9.275,9.36,9.2,9.31,ANGO,170318,HISTORICAL_PRICES,ANGO,,1.60683E+12,-0.035862786,-0.035862786,9.31,9.275,9.36,9.2,170318,9.31,9.275,9.36,9.2,170318,17-Aug-20,-0.055,-0.0059
17-Aug-20,Results of Axcella’s AXA1665-001 Clinical Study Published in Clinical and Translational Gastroenterology,"Axcella (Nasdaq: AXLA), a clinical-stage biotechnology company focused on leveraging endogenous metabolic modulators (EMMs) to pioneer a new approach for treating complex diseases and improving health...",5.91,5.99,5.72,5.99,AXLA,401138,HISTORICAL_PRICES,AXLA,,1.60683E+12,1.003389831,1.003389831,5.99,5.91,5.99,5.72,401138,5.99,5.91,5.99,5.72,401138,17-Aug-20,0.2,0.035
17-Aug-20,"bluebird bio to Present New Data from Clinical Studies of elivaldogene autotemcel (eli-cel, Lenti-D™) Gene Therapy for Cerebral Adrenoleukodystrophy (CALD) at the Virtual Edition of the 46th EBMT Annual Meeting","bluebird bio, Inc. (Nasdaq: BLUE) today announced that new data from the clinical development program for its investigational elivaldogene autotemcel (eli-cel, Lenti-D™) gene therapy in patients with...",62.26,62.74,59.355,60.05,BLUE,578433,HISTORICAL_PRICES,BLUE,,1.60683E+12,0.275297009,0.275297009,60.05,62.26,62.74,59.355,578433,60.05,62.26,62.74,59.355,578433,17-Aug-20,2.59,0.0434
17-Aug-20,"Nemaura Medical Reports Results and Provides Business Update for the First Quarter Ended June 30, 2020","Nemaura Medical Inc. (NASDAQ: NMRD) (“Nemaura”), a medical technology company commercializing sugarBEAT®, a non-invasive and flexible continuous glucose monitor (CGM), together with BEAT™diabetes, a h...",5.4,5.64,5.28,5.64,NMRD,67486,HISTORICAL_PRICES,NMRD,,1.60683E+12,0.075697211,0.075697211,5.64,5.4,5.64,5.28,67486,5.64,5.4,5.64,5.28,67486,17-Aug-20,-0.14,-0.0253
17-Aug-20,Applied DNA Positions LinearDNA™ Platform as the Next Generation Manufacturing Platform for Adeno-Associated Virus-based Gene Therapies Through New Patent Filing,"Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA” or the ""Company""), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing that enables in vitro diagnostics, pre-clinical nucleic...",9.48,9.6802,9.2,9.31,APDN,611955,HISTORICAL_PRICES,APDN,,1.60683E+12,1.37,1.37,9.31,9.48,9.6802,9.2,611955,9.31,9.48,9.6802,9.2,611955,17-Aug-20,0.19,0.0205
14-Aug-20,Baxter Obtains U.S. FDA Emergency Use Authorization for Regiocit Replacement Solution Used in CRRT,"Baxter International Inc. (NYSE:BAX), a global leader in acute care, announced it has received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for Regiocit, the comp...",83.5,84.73,83.18,84.49,BAX,2757068,HISTORICAL_PRICES,BAX,,1.61422E+12,0.129752402,0.129752402,84.49,83.5,84.73,83.18,2757068,83.7176,82.7367,83.9554,82.4196,2757068,14-Aug-20,-1.14,-0.0135
14-Aug-20,"SHAREHOLDER ALERT: Investigation of Reata Announced by Holzer & Holzer, LLC","Holzer & Holzer, LLC is investigating whether Reata Pharmaceuticals, Inc. (“Reata” or the “Company”) (NASDAQ: RETA) complied with federal securities laws. On August 10, 2020, Reata disclosed in it...",102.21,104.59,99.5,103.2,RETA,553165,HISTORICAL_PRICES,RETA,,1.60683E+12,-0.262021661,-0.262021661,103.2,102.21,104.59,99.5,553165,103.2,102.21,104.59,99.5,553165,14-Aug-20,-2.21,-0.0212
14-Aug-20,Masimo PVi® Receives FDA Clearance as an Indicator of Fluid Responsiveness on Mechanically Ventilated Patients,"Masimo (NASDAQ: MASI) today announced that PVi® has received FDA clearance as a continuous, noninvasive, dynamic indicator of fluid responsiveness in select populations of mechanically ventilated adul...",214.09,216.74,212.22,215.4,MASI,264503,HISTORICAL_PRICES,MASI,,1.60683E+12,0.377670528,0.377670528,215.4,214.09,216.74,212.22,264503,215.4,214.09,216.74,212.22,264503,14-Aug-20,0.14,0.0007
14-Aug-20,"Organigram Sends First Shipment of Indoor-Grown Dried Flower to Israeli Cannabis Producer, Canndoc Ltd.","Organigram Holdings Inc. (NASDAQ: OGI) (TSX: OGI), the parent company of Organigram Inc. (the “Company” or “Organigram”), a leading licensed producer of cannabis, today announced that it has sent its...",1.47,1.48,1.36,1.41,OGI,5504156,HISTORICAL_PRICES,OGI,,1.60683E+12,-0.098159509,-0.098159509,1.41,1.47,1.48,1.36,5504156,1.41,1.47,1.48,1.36,5504156,14-Aug-20,0.08,0.0576
13-Aug-20,SG Blocks Reports Second Quarter 2020 Financial Results,"SG Blocks, Inc. (Nasdaq: SGBX) (“SG Blocks” or the “Company”), a leading designer, innovator and fabricator of container-based structures, reported its financial results for the second quarter ended J...",2.6,2.68,2.52,2.64,SGBX,737326,HISTORICAL_PRICES,SGBX,,1.60683E+12,0.368061037,0.368061037,2.64,2.6,2.68,2.52,737326,2.64,2.6,2.68,2.52,737326,13-Aug-20,-0.12,-0.0441
13-Aug-20,Urovant Sciences Reports Fiscal First Quarter 2020 Results,"Urovant Sciences (Nasdaq: UROV) today reported financial results for the three months ended June 30, 2020. The first quarter of fiscal 2020 saw the Company achieve a number of significant operational...",8.15,8.392,7.58,7.6,UROV,96278,HISTORICAL_PRICES,UROV,,1.60683E+12,-0.241154562,-0.241154562,7.6,8.15,8.392,7.58,96278,7.6,8.15,8.392,7.58,96278,13-Aug-20,0.48,0.0626
13-Aug-20,Repare Therapeutics Reports Second Quarter 2020 Financial Results and Operational Highlights,"Repare Therapeutics Inc. (“Repare”) (Nasdaq: RPTX), a leading precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics,...",24.06,24.06,22.8875,23.28,RPTX,63958,HISTORICAL_PRICES,RPTX,,1.60683E+12,-0.218831169,-0.218831169,23.28,24.06,24.06,22.8875,63958,23.28,24.06,24.06,22.8875,63958,13-Aug-20,0.78,0.0335
13-Aug-20,TFF Pharmaceuticals Reports Second Quarter 2020 Financial and Business Results,"TFF Pharmaceuticals, Inc. (NASDAQ:TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) te...",10.28,10.5,9.2201,9.57,TFFP,1769802,HISTORICAL_PRICES,TFFP,,1.60683E+12,1.447619048,1.447619048,9.57,10.28,10.5,9.2201,1769802,9.57,10.28,10.5,9.2201,1769802,13-Aug-20,0.82,0.0867
13-Aug-20,TFF Pharmaceuticals Enters into Worldwide Licensing Agreement with UNION therapeutics for its Thin Film Freezing Technology in Combination with niclosamide,"TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) t...",10.28,10.5,9.2201,9.57,TFFP,1769802,HISTORICAL_PRICES,TFFP,,1.60683E+12,1.447619048,1.447619048,9.57,10.28,10.5,9.2201,1769802,9.57,10.28,10.5,9.2201,1769802,13-Aug-20,0.82,0.0867
13-Aug-20,"INVESTOR REMINDER: Kessler Topaz Meltzer & Check, LLP Announces Deadline in Securities Fraud Class Action Lawsuit Filed Against Chembio Diagnostics, Inc.","The law firm of Kessler Topaz Meltzer & Check, LLP reminds Chembio Diagnostics, Inc. (NASDAQ: CEMI) (“Chembio”) investors that a securities fraud class action lawsuit has been filed on behalf of t...",5.09,5.37,5.08,5.37,CEMI,4929547,HISTORICAL_PRICES,CEMI,,1.60683E+12,0.298469388,0.298469388,5.37,5.09,5.37,5.08,4929547,5.37,5.09,5.37,5.08,4929547,13-Aug-20,-0.34,-0.0626
13-Aug-20,"NYC Healthcare Heroes Successfully Delivers More Than 400,000 Care Packages with More Than 15 Million Products to 100 Hospitals and Healthcare Facilities Across NYC’s Five Boroughs","NYC Healthcare Heroes, a city-wide philanthropic program launched by the Debra and Leon Black Family in partnership with Aramark (NYSE:ARMK), the American Red Cross, Robin Hood, and the Mayor’s Fund t...",24.97,25.45,24.75,25.1,ARMK,4034991,HISTORICAL_PRICES,ARMK,,1.61344E+12,0.338156484,0.338156484,25.1,24.97,25.45,24.75,4034991,24.9105,24.7814,25.2578,24.5631,4034991,13-Aug-20,-0.31,-0.0123
13-Aug-20,Scholar Rock Announces that SRK-015 has Received Rare Pediatric Disease Designation from U.S. FDA for the Treatment of Spinal Muscular Atrophy,"Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced that the U...",13.73,14.0732,12.79,13.27,SRRK,91055,HISTORICAL_PRICES,SRRK,,1.60683E+12,0.001458789,0.001458789,13.27,13.73,14.0732,12.79,91055,13.27,13.73,14.0732,12.79,91055,13-Aug-20,0.53,0.0402
13-Aug-20,Forma Therapeutics Reports Second Quarter 2020 Financial Results and Provides Business Update,"Forma Therapeutics Holdings, Inc. (Nasdaq: FMTX), a clinical-stage biopharmaceutical company focused on rare hematologic diseases and cancers, today reported financial results for the second quarter e...",33.11,33.9407,32.69,33.32,FMTX,104300,HISTORICAL_PRICES,FMTX,,1.60683E+12,-0.151025641,-0.151025641,33.32,33.11,33.9407,32.69,104300,33.32,33.11,33.9407,32.69,104300,13-Aug-20,-0.89,-0.0262
13-Aug-20,scPharmaceuticals Inc. Reports Second Quarter 2020 Financial Results and Provides Business Update,"scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patien...",8.44,8.59,8.05,8.05,SCPH,69260,HISTORICAL_PRICES,SCPH,,1.60683E+12,0.07106599,0.07106599,8.05,8.44,8.59,8.05,69260,8.05,8.44,8.59,8.05,69260,13-Aug-20,0.36,0.0446
12-Aug-20,Quidel’s Lyra® Direct SARS-CoV-2 Assay Receives Health Canada Authorization,"Quidel Corporation (NASDAQ: QDEL) (“Quidel”), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that Quidel has receive...",239.59,247.32,230.16,237.2,QDEL,1035794,HISTORICAL_PRICES,QDEL,,1.60683E+12,1.795356434,1.795356434,237.2,239.59,247.32,230.16,1035794,237.2,239.59,247.32,230.16,1035794,12-Aug-20,10,0.0436
12-Aug-20,"Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Continues Investigation of Qutoutiao Inc. (QTT) on Behalf of Investors","Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, continues its investigation on behalf of Qutoutiao Inc. (""Qutoutiao"" or the ""Company"") (NASDAQ: QTT) investors...",2.9,2.96,2.81,2.94,QTT,1492853,HISTORICAL_PRICES,QTT,,1.60683E+12,0.028368794,0.028368794,2.94,2.9,2.96,2.81,1492853,2.94,2.9,2.96,2.81,1492853,12-Aug-20,-0.11,-0.0365
12-Aug-20,LivaNova to Present Autonomic Regulation Therapy Findings for Heart Failure During European Society of Cardiology Congress 2020,"LivaNova PLC (NASDAQ:LIVN) a market-leading medical technology and innovation company, today announced it will present a poster at the European Society of Cardiology (ESC) Congress 2020 on the potenti...",48.82,48.99,48.27,48.48,LIVN,355441,HISTORICAL_PRICES,LIVN,,1.60683E+12,0.240345528,0.240345528,48.48,48.82,48.99,48.27,355441,48.48,48.82,48.99,48.27,355441,12-Aug-20,0.84,0.0175
12-Aug-20,Baxter Obtains U.S. FDA Emergency Use Authorizations for HF20 Set and ST Set Used in CRRT During Covid-19 Pandemic,"Baxter International Inc. (NYSE:BAX), a global leader in acute care, announced it has received Emergency Use Authorizations (EUAs) from the U.S. Food and Drug Administration (FDA) for the company’s HF...",83.48,83.82,82.42,83.17,BAX,3170036,HISTORICAL_PRICES,BAX,,1.61422E+12,0.129481802,0.129481802,83.17,83.48,83.82,82.42,3170036,82.4097,82.7169,83.0538,81.6666,3170036,12-Aug-20,0.54,0.0065
12-Aug-20,Applied DNA Receives Notice of Allowance on Second Patent Protecting Proprietary DNA Transfer System for Large-Scale Cotton Tagging,"Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA” or the “Company”) a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing for product authenticity and traceability solutions, anno...",8.84,10.11,8.8,9.84,APDN,811362,HISTORICAL_PRICES,APDN,,1.60683E+12,1.21,1.21,9.84,8.84,10.11,8.8,811362,9.84,8.84,10.11,8.8,811362,12-Aug-20,-0.98,-0.0998
12-Aug-20,"Lantheus Holdings, Inc. Announces FDA Approval of VIALMIX® RFID Device for DEFINITY®","Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH), the parent company of Lantheus Medical Imaging, Inc. and Progenics Pharmaceuticals, Inc., and a global leader in the development, manufacture an...",13.53,13.8643,13.43,13.79,LNTH,488575,HISTORICAL_PRICES,LNTH,,1.60683E+12,0.153452685,0.153452685,13.79,13.53,13.8643,13.43,488575,13.79,13.53,13.8643,13.43,488575,12-Aug-20,-0.15,-0.011
12-Aug-20,Seattle Genetics Announces TUKYSA® (tucatinib) Approved Within Months for All Countries Participating in FDA’s Project Orbis Initiative,"Seattle Genetics, Inc. (Nasdaq:SGEN) today announced that Australian regulatory authorities have approved TUKYSA® (tucatinib) in combination with trastuzumab and capecitabine for the treatment of pati...",158.79,158.89,153.69,153.93,SGEN,730116,HISTORICAL_PRICES,SGEN,,1.60683E+12,0.55875135,0.55875135,153.93,158.79,158.89,153.69,730116,153.93,158.79,158.89,153.69,730116,12-Aug-20,5.31,0.0346
12-Aug-20,Frequency Therapeutics Provides Business Updates and Reports Second Quarter 2020 Financial Results,"Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage biotechnology company focused on harnessing the body’s innate biology to repair or reverse damage caused by a broad range of degenerative...",23.19,24.29,22.66,23.6,FREQ,164296,HISTORICAL_PRICES,FREQ,,1.60683E+12,0.350611532,0.350611532,23.6,23.19,24.29,22.66,164296,23.6,23.19,24.29,22.66,164296,12-Aug-20,-0.39,-0.0165
11-Aug-20,Moderna Announces Supply Agreement with U.S. Government for Initial 100 Million Doses of mRNA Vaccine Against COVID-19 (mRNA-1273),"Moderna, Inc., (Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced tha...",68.97,71.4,67,69.52,MRNA,18118727,HISTORICAL_PRICES,MRNA,,1.60683E+12,1.671185128,1.671185128,69.52,68.97,71.4,67,18118727,69.52,68.97,71.4,67,18118727,11-Aug-20,-3.04,-0.0422
11-Aug-20,DiaMedica Provides a Business Update and Second Quarter 2020 Financial Results,"DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for kidney diseases and neurological disorders, today provided a business...",5.4,5.705,5.35,5.57,DMAC,73867,HISTORICAL_PRICES,DMAC,,1.60683E+12,1.4,1.4,5.57,5.4,5.705,5.35,73867,5.57,5.4,5.705,5.35,73867,11-Aug-20,-0.32,-0.0559
11-Aug-20,Ra Medical Systems Reports 2020 Second Quarter Financial Results,"Ra Medical Systems, Inc. (NYSE: RMED), a medical device company focusing on commercializing excimer laser systems to treat vascular and dermatological diseases, reports financial results for the three...",8.6525,10.25,8.4,9.75,RMED,1079195.04,HISTORICAL_PRICES,RMED,,1.60683E+12,-0.685363636,-0.685363636,0.39,0.3461,0.41,0.336,26979876,9.75,8.6525,10.25,8.4,1079195.04,11-Aug-20,-0.5975,-0.0646
11-Aug-20,PhaseBio Reports Recent Business Highlights and Second-Quarter 2020 Financial Results,"PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiovascular and cardiopulmonary dis...",3.91,4.3,3.895,4.3,PHAS,656919,HISTORICAL_PRICES,PHAS,,1.60683E+12,0.290429043,0.290429043,4.3,3.91,4.3,3.895,656919,4.3,3.91,4.3,3.895,656919,11-Aug-20,-0.32,-0.0757
11-Aug-20,"CEMI UPCOMING DEADLINE: Bronstein, Gewirtz & Grossman, LLC Reminds Shareholders of Class Action Against Chembio Diagnostics, Inc. and Lead Plaintiff Deadline: August 17, 2020","Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Chembio Diagnostics, Inc. (""Chembio"" or ""the Company"") (NASDAQ: CEMI) and certain of its off...",5.35,5.74,5.29,5.69,CEMI,3606910,HISTORICAL_PRICES,CEMI,,1.60683E+12,0.364795918,0.364795918,5.69,5.35,5.74,5.29,3606910,5.69,5.35,5.74,5.29,3606910,11-Aug-20,-0.34,-0.0598
11-Aug-20,Revance Announces Two Peer-Reviewed Publications Reporting Safety and Efficacy Results from the SAKURA 3 Open-Label Safety Study in Dermatologic Surgery,"Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company focused on innovative aesthetic and therapeutic offerings, including its investigational neuromodulator product, DaxibotulinumtoxinA...",24.37,25.725,24.25,25.57,RVNC,399338,HISTORICAL_PRICES,RVNC,,1.60683E+12,0.740714286,0.740714286,25.57,24.37,25.725,24.25,399338,25.57,24.37,25.725,24.25,399338,11-Aug-20,-0.85,-0.0337
11-Aug-20,China National Medical Products Administration Approves Truvada® for HIV Pre-Exposure Prophylaxis (PrEP),"Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the China National Medical Products Administration (NMPA) has approved a pre-exposure prophylaxis indication for Truvada (emtricitabine 200 mg...",68.1,69.175,67.92,68.45,GILD,10236935,HISTORICAL_PRICES,GILD,,1.61552E+12,-0.079232017,-0.079232017,68.45,68.1,69.175,67.92,10236935,66.2283,65.8897,66.9298,65.7155,10236935,11-Aug-20,-0.41,-0.006
11-Aug-20,Hologic Launches Validated Pooling Protocol for COVID-19 Testing,"Hologic, Inc. (Nasdaq: HOLX) announced today that it has validated use of its Aptima® and Panther Fusion® molecular diagnostic COVID-19 assays with pooled patient samples and completed an emergency us...",65.79,66.34,64.1732,66.34,HOLX,2864237,HISTORICAL_PRICES,HOLX,,1.60683E+12,1.092557252,1.092557252,66.34,65.79,66.34,64.1732,2864237,66.34,65.79,66.34,64.1732,2864237,11-Aug-20,-0.11,-0.0017
11-Aug-20,Gamida Cell Reports Second Quarter 2020 Financial Results and Provides Company Update,"Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to finding cures for blood cancers and serious blood diseases, today reported financial results for the quarter ended June 3...",4.15,4.48,4,4,GMDA,321824,HISTORICAL_PRICES,GMDA,,1.60683E+12,0.406779661,0.406779661,4,4.15,4.48,4,321824,4,4.15,4.48,4,321824,11-Aug-20,-0.14,-0.0326
11-Aug-20,LabCorp Will Perform Antibody Test at No Charge to Accelerate COVID-19 Blood Plasma Donation,"LabCorp (NYSE: LH), a leading global life sciences company that is deeply integrated in guiding patient care, today announced details of a no charge antibody testing program in response to federal hea...",186.13,189.72,182.06,187.6,LH,903921,HISTORICAL_PRICES,LH,,1.60683E+12,0.580453426,0.580453426,187.6,186.13,189.72,182.06,903921,187.6,186.13,189.72,182.06,903921,11-Aug-20,-1.25,-0.0067
11-Aug-20,"CheckMate -577, a Phase 3 Trial Evaluating Opdivo (nivolumab) as Adjuvant Therapy for Patients with Resected Esophageal or Gastroesophageal Junction Cancer, Meets Primary Endpoint of Disease-Free Survival",Bristol Myers Squibb (NYSE: BMY) today announced the Phase 3 CheckMate -577 trial evaluating Opdivo (nivolumab) as an adjuvant therapy for patients with resected esophageal or gastroesophageal junctio...,63.13,64.25,62.69,62.97,BMY,20736042,HISTORICAL_PRICES,BMY,,1.60946E+12,0.282087734,0.282087734,62.97,63.13,64.25,62.69,20736042,62.0054,62.163,63.2658,61.7297,20736042,11-Aug-20,1.31,0.0212
11-Aug-20,"CheckMate -649, a Phase 3 Trial Evaluating Opdivo (nivolumab) Plus Chemotherapy vs. Chemotherapy, Meets Primary Endpoints Demonstrating Superior Overall Survival and Progression-Free Survival in First-Line Treatment of Gastric and Esophageal Cancers","Bristol Myers Squibb (NYSE: BMY) today announced that CheckMate -649, a pivotal Phase 3 trial evaluating Opdivo (nivolumab) plus chemotherapy compared to chemotherapy alone as a first-line treatment f...",63.13,64.25,62.69,62.97,BMY,20736042,HISTORICAL_PRICES,BMY,,1.60946E+12,0.282087734,0.282087734,62.97,63.13,64.25,62.69,20736042,62.0054,62.163,63.2658,61.7297,20736042,11-Aug-20,1.31,0.0212
10-Aug-20,State of Maryland Allows Point-of-Care Testing for COVID-19; Quidel Expands Training Program,"Quidel Corporation (NASDAQ: QDEL) (“Quidel”), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced that the State of Maryland ha...",229.69,272.9399,227.6,272.76,QDEL,1906143,HISTORICAL_PRICES,QDEL,,1.60683E+12,1.679850659,1.679850659,272.76,229.69,272.9399,227.6,1906143,272.76,229.69,272.9399,227.6,1906143,10-Aug-20,-43.07,-0.1579
10-Aug-20,Ligand to Acquire Pfenex Inc.,Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) and Pfenex Inc. (NYSE American: PFNX) today announced the signing of a definitive agreement for Ligand to acquire all outstanding shares of Pfenex fo...,118.66,118.99,116.5458,117.93,LGND,143839,HISTORICAL_PRICES,LGND,,1.60683E+12,0.59962254,0.59962254,117.93,118.66,118.99,116.5458,143839,117.93,118.66,118.99,116.5458,143839,10-Aug-20,1,0.0085
10-Aug-20,Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4),"Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on August 4, 2020 the Compensation Committee of Puma’s Board of Directors approved the grant of inducement restrict...",10.54,10.75,10.09,10.12,PBYI,937548,HISTORICAL_PRICES,PBYI,,1.60683E+12,0.217090069,0.217090069,10.12,10.54,10.75,10.09,937548,10.12,10.54,10.75,10.09,937548,10-Aug-20,0.27,0.0263
10-Aug-20,Catabasis Pharmaceuticals Reports Second Quarter 2020 Financial Results and Reviews Business Progress,"Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today reported financial results for the second quarter ended June 30, 2020 and reviewed recent business prog...",6.64,6.89,6.57,6.64,CATB,131250,HISTORICAL_PRICES,CATB,,1.60683E+12,0.720207254,0.720207254,6.64,6.64,6.89,6.57,131250,6.64,6.64,6.89,6.57,131250,10-Aug-20,0.13,0.02
10-Aug-20,"AVEO Oncology Announces Restructuring of Existing Term Loan with Closing of New Tranched, $35 Million Debt Facility","AVEO Oncology (Nasdaq: AVEO) today announced the closing of a tranched, $35 million debt facility with Hercules Capital, Inc. (NYSE: HTGC) and its affiliates. The new facility has a maturity of 36 mon...",4.64,4.73,4.49,4.59,AVEO,300057,HISTORICAL_PRICES,AVEO,,1.60683E+12,0.6996337,0.6996337,4.59,4.64,4.73,4.49,300057,4.59,4.64,4.73,4.49,300057,10-Aug-20,0.04,0.0087
10-Aug-20,Pulse Biosciences Reports Second Quarter 2020 Financial Results,"Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company progressing Nano-Pulse Stimulation™ (NPS™) technology, today announced financial results for the second quarter ended June...",10.59,11.57,10.1,11.26,PLSE,83952,HISTORICAL_PRICES,PLSE,,1.60683E+12,0.680952381,0.680952381,11.26,10.59,11.57,10.1,83952,11.26,10.59,11.57,10.1,83952,10-Aug-20,-0.54,-0.0485
10-Aug-20,AVEO Oncology Reports Second Quarter 2020 Financial Results and Provides Business Update,"AVEO Oncology (Nasdaq: AVEO) today reported financial results for the second quarter ended June 30, 2020 and provided a business update. “The first half of 2020 was one of the most important periods i...",4.64,4.73,4.49,4.59,AVEO,300057,HISTORICAL_PRICES,AVEO,,1.60683E+12,0.6996337,0.6996337,4.59,4.64,4.73,4.49,300057,4.59,4.64,4.73,4.49,300057,10-Aug-20,0.04,0.0087
10-Aug-20,Athersys Reports Second Quarter 2020 Results,"Athersys, Inc. (NASDAQ: ATHX) announced today its financial results for the three months ended June 30, 2020. Highlights of the second quarter of 2020 and recent events include: Initiated and advanced...",2.59,2.63,2.47,2.61,ATHX,3144911,HISTORICAL_PRICES,ATHX,,1.60683E+12,0.363157895,0.363157895,2.61,2.59,2.63,2.47,3144911,2.61,2.59,2.63,2.47,3144911,10-Aug-20,-0.03,-0.0115
10-Aug-20,Gilead Submits New Drug Application to U.S. Food and Drug Administration for Veklury® (Remdesivir) for the Treatment of COVID-19,"Gilead Sciences, Inc. (Nasdaq: GILD) announced today that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for Veklury® (remdesivir), an investigational ant...",68.51,69.25,67.96,69.145,GILD,10278040,HISTORICAL_PRICES,GILD,,1.61552E+12,-0.07368848,-0.07368848,69.145,68.51,69.25,67.96,10278040,66.9008,66.2864,67.0024,65.7542,10278040,10-Aug-20,-0.84,-0.0121
10-Aug-20,Verastem Oncology Reports Second Quarter 2020 Financial Results and Highlights Recent Company Progress,"Verastem, Inc. (Nasdaq:VSTM) (also known as Verastem Oncology), a biopharmaceutical company committed to developing and commercializing new medicines for patients battling cancer, today reported finan...",1.48,1.65,1.44,1.6,VSTM,19643086,HISTORICAL_PRICES,VSTM,,1.60683E+12,-0.321100917,-0.321100917,1.6,1.48,1.65,1.44,19643086,1.6,1.48,1.65,1.44,19643086,10-Aug-20,0,0
10-Aug-20,Verastem Oncology Signs Definitive Agreement to Sell COPIKTRA® (duvelisib) Rights to Secura Bio to Focus on Development of VS-6766 and Defactinib in KRAS Mutant Solid Tumors,"Verastem, Inc. (Nasdaq:VSTM) (also known as Verastem Oncology), a biopharmaceutical company committed to advancing new medicines for patients battling cancer, today announced that it has entered into...",1.48,1.65,1.44,1.6,VSTM,19643086,HISTORICAL_PRICES,VSTM,,1.60683E+12,-0.321100917,-0.321100917,1.6,1.48,1.65,1.44,19643086,1.6,1.48,1.65,1.44,19643086,10-Aug-20,0,0
10-Aug-20,UroGen Pharma Reports Second Quarter 2020 Financial Results and Recent Corporate Developments,"UroGen Pharma Ltd. (Nasdaq: URGN), a biopharmaceutical company dedicated to building and commercializing novel solutions that treat specialty cancers and urologic diseases, today announced financial r...",26.42,26.52,23.52,24.5,URGN,431989,HISTORICAL_PRICES,URGN,,1.60683E+12,0.462091865,0.462091865,24.5,26.42,26.52,23.52,431989,24.5,26.42,26.52,23.52,431989,10-Aug-20,3.26,0.1408
10-Aug-20,Sesen Bio Reports Second Quarter 2020 Financial Results and Business Update,"Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today reported operating results for the second quart...",1.06,1.12,0.98,0.9985,SESN,2489747,HISTORICAL_PRICES,SESN,,1.60683E+12,0.833910035,0.833910035,0.9985,1.06,1.12,0.98,2489747,0.9985,1.06,1.12,0.98,2489747,10-Aug-20,0.06,0.06
10-Aug-20,Stoke Therapeutics Reports Second Quarter Financial Results and Provides Business Updates,"Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company pioneering a new way to treat the underlying cause of genetic diseases by precisely upregulating protein expression, today reported fin...",28.19,28.4,26.2,27,STOK,139309,HISTORICAL_PRICES,STOK,,1.60683E+12,0.320374707,0.320374707,27,28.19,28.4,26.2,139309,27,28.19,28.4,26.2,139309,10-Aug-20,1.38,0.0515
10-Aug-20,Xeris Pharmaceuticals Reports Second Quarter 2020 Financial Results and Corporate Highlights,"Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use (RTU) injectable and infu...",3.52,3.67,3.4,3.5,XERS,5062555,HISTORICAL_PRICES,XERS,,1.60683E+12,0.76,0.76,3.5,3.52,3.67,3.4,5062555,3.5,3.52,3.67,3.4,5062555,10-Aug-20,0.17,0.0507
10-Aug-20,Eagle Pharmaceuticals Reports Second Quarter 2020 Results,"Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced financial results for the three and six months ended June 30, 2020. Business and Recent Highlights: Centers for Me...",43.26,47.37,38.5,47,EGRX,646616,HISTORICAL_PRICES,EGRX,,1.60683E+12,0.056668295,0.056668295,47,43.26,47.37,38.5,646616,47,43.26,47.37,38.5,646616,10-Aug-20,-3.74,-0.0796
10-Aug-20,Sage Therapeutics Announces Second Quarter 2020 Financial Results and Highlights Pipeline and Business Progress,"Today, Sage Therapeutics, Inc. (NASDAQ:SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the...",53.31,54.13,48.59,51.28,SAGE,1226429,HISTORICAL_PRICES,SAGE,,1.60683E+12,0.815735695,0.815735695,51.28,53.31,54.13,48.59,1226429,51.28,53.31,54.13,48.59,1226429,10-Aug-20,2.61,0.0515
7-Aug-20,FSD Pharma Reports Second Quarter 2020 Financial Results,FSD Pharma Inc. (Nasdaq: HUGE) (CSE: HUGE.CN) (FRA: 0K9A) (“FSD Pharma” or the “Company”) today reported that management’s discussion and analysis of financial condition and results of operations (“MD...,3.09,3.15,2.9301,3.1,HUGE,289211,HISTORICAL_PRICES,HUGE,,1.60988E+12,0.04040404,0.04040404,3.1,3.09,3.15,2.9301,289211,3.1,3.09,3.15,2.9301,289211,7-Aug-20,0.07,0.0232
7-Aug-20,Cerus INTERCEPT Blood System Kit Shipments Surpass 7.5 Million Treatable Platelet and Plasma Doses Since Launch,Cerus Corporation (Nasdaq:CERS) announced today that INTERCEPT Blood Systems disposable kit shipments have surpassed 7.5 million treatable platelet and plasma doses globally since commercial launch. “...,7.06,7.23,6.995,7.22,CERS,1185776,HISTORICAL_PRICES,CERS,,1.60683E+12,0.833766234,0.833766234,7.22,7.06,7.23,6.995,1185776,7.22,7.06,7.23,6.995,1185776,7-Aug-20,-0.04,-0.0056
7-Aug-20,CStone Announces That OmniAb-derived CS1001 (Anti-PD-L1) Phase 3 Trial Met the Primary Endpoint as First-Line Treatment in Stage IV Squamous and Non-squamous Non-Small Cell Lung Cancer and Announces Plans to Submit a New Drug Application,"Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces CStone Pharmaceuticals (“CStone”, HKEX: 2616) recently reported that its OmniAb-derived anti-PD-L1 mAb CS1001 combined with platinum-based...",117.66,117.73,115,115.36,LGND,169422,HISTORICAL_PRICES,LGND,,1.60683E+12,0.586141817,0.586141817,115.36,117.66,117.73,115,169422,115.36,117.66,117.73,115,169422,7-Aug-20,2.21,0.0191
7-Aug-20,Merrimack Reports Second Quarter 2020 Financial Results,"Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) (“Merrimack” or the “Company”) today announced its second quarter 2020 financial results for the period ended June 30, 2020. “We are pleased by recent ne...",3.37,3.41,3.34,3.4,MACK,11106,HISTORICAL_PRICES,MACK,,1.60683E+12,0.792553191,0.792553191,3.4,3.37,3.41,3.34,11106,3.4,3.37,3.41,3.34,11106,7-Aug-20,0.06,0.0181
7-Aug-20,Ocular Therapeutix™ Reports Second Quarter 2020 Financial Results and Business Update,"Ocular Therapeutix™, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, tod...",8.21,8.78,8.0101,8.53,OCUL,780529,HISTORICAL_PRICES,OCUL,,1.60683E+12,0.668699187,0.668699187,8.53,8.21,8.78,8.0101,780529,8.53,8.21,8.78,8.0101,780529,7-Aug-20,-0.25,-0.0296
6-Aug-20,Oncternal Provides Business Update and Announces Second Quarter 2020 Financial Results,"Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today provided a business update and reported second qua...",2.87,2.97,2.82,2.88,ONCT,31850,HISTORICAL_PRICES,ONCT,,1.60683E+12,0.148,0.148,2.88,2.87,2.97,2.82,31850,2.88,2.87,2.97,2.82,31850,6-Aug-20,-0.08,-0.0271
6-Aug-20,Clovis Oncology Announces Second Quarter 2020 Operating Results,"Clovis Oncology, Inc. (NASDAQ:CLVS) reported financial results for the quarter ended June 30, 2020, and provided an update on the Company’s clinical development programs and regulatory and commercial...",6.23,6.56,6.15,6.45,CLVS,4936891,HISTORICAL_PRICES,CLVS,,1.60683E+12,0.334047109,0.334047109,6.45,6.23,6.56,6.15,4936891,6.45,6.23,6.56,6.15,4936891,6-Aug-20,-0.235,-0.0363
6-Aug-20,Applied DNA Reports Fiscal Third Quarter 2020 Financial Results,"Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA” or the ""Company""), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing that enables in vitro diagnostics, pre-clinical nucleic...",10.97,10.989,10.57,10.64,APDN,709358,HISTORICAL_PRICES,APDN,,1.60683E+12,1.7425,1.7425,10.64,10.97,10.989,10.57,709358,10.64,10.97,10.989,10.57,709358,6-Aug-20,0.37,0.0349
6-Aug-20,Mirum Pharmaceuticals Announces Second Quarter 2020 Financial Results and Provides Clinical Program Updates,"Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a biopharmaceutical company focused on the development and commercialization of novel therapies for debilitating liver diseases, today announced financial r...",23.51,24.49,21.83,22.75,MIRM,62387,HISTORICAL_PRICES,MIRM,,1.60683E+12,0.897497982,0.897497982,22.75,23.51,24.49,21.83,62387,22.75,23.51,24.49,21.83,62387,6-Aug-20,1.14,0.051
6-Aug-20,"Revance Reports Second Quarter 2020 Financial Results, Provides Corporate Update","Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company focused on innovative aesthetic and therapeutic offerings, including its investigational neuromodulator product, DaxibotulinumtoxinA...",23.58,24.82,23.48,24.15,RVNC,447152,HISTORICAL_PRICES,RVNC,,1.60683E+12,0.684285714,0.684285714,24.15,23.58,24.82,23.48,447152,24.15,23.58,24.82,23.48,447152,6-Aug-20,-0.54,-0.0224
6-Aug-20,Illumina Reports Financial Results for Second Quarter of Fiscal Year 2020,"Illumina, Inc. (NASDAQ: ILMN) today announced its financial results for the second quarter of fiscal year 2020. Second quarter 2020 results reflect the impact of the global COVID-19 pandemic: Revenue...",399.33,403.66,393.13,400.74,ILMN,853082,HISTORICAL_PRICES,ILMN,,1.60683E+12,0.57105201,0.57105201,400.74,399.33,403.66,393.13,853082,400.74,399.33,403.66,393.13,853082,6-Aug-20,-1.41,-0.0035
6-Aug-20,Geron Corporation Reports Second Quarter 2020 Financial Results and Current Events,"Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today reported financial results for the second quarter ended June 30, 2020. The Company will host a conference call...",1.66,1.76,1.64,1.76,GERN,2232027,HISTORICAL_PRICES,GERN,,1.60683E+12,0.52293578,0.52293578,1.76,1.66,1.76,1.64,2232027,1.76,1.66,1.76,1.64,2232027,6-Aug-20,-0.06,-0.0349
6-Aug-20,Exelixis Announces Second Quarter 2020 Financial Results and Provides Corporate Update,"Exelixis, Inc. (Nasdaq: EXEL) today reported financial results for the second quarter of 2020 and provided an update on progress toward fulfilling its key corporate objectives, as well as commercial a...",22.81,23.1,22.43,23.03,EXEL,2145137,HISTORICAL_PRICES,EXEL,,1.60683E+12,0.439116719,0.439116719,23.03,22.81,23.1,22.43,2145137,23.03,22.81,23.1,22.43,2145137,6-Aug-20,-0.24,-0.0104
6-Aug-20,Puma Biotechnology Reports Second Quarter 2020 Financial Results,"Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced financial results for the second quarter ended June 30, 2020. Unless otherwise stated, all comparisons are for the secon...",10.38,10.86,10.26,10.82,PBYI,1467766,HISTORICAL_PRICES,PBYI,,1.60683E+12,0.198614319,0.198614319,10.82,10.38,10.86,10.26,1467766,10.82,10.38,10.86,10.26,1467766,6-Aug-20,-0.51,-0.0468
6-Aug-20,Savara Reports Second Quarter 2020 Financial Results and Provides Business Update,"Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today reported financial results for the second quarter ending June 30, 2020 and provided a business update. “With a final design for IMPALA...",2.04,2.1259,2.03,2.12,SVRA,92316,HISTORICAL_PRICES,SVRA,,1.60683E+12,-0.023923445,-0.023923445,2.12,2.04,2.1259,2.03,92316,2.12,2.04,2.1259,2.03,92316,6-Aug-20,-0.08,-0.0377
6-Aug-20,Aerie Pharmaceuticals Reports Second Quarter 2020 Financial Results and Provides Business Update,"Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients wi...",12.1,12.14,11.7,11.92,AERI,878744,HISTORICAL_PRICES,AERI,,1.60683E+12,-0.103039288,-0.103039288,11.92,12.1,12.14,11.7,878744,11.92,12.1,12.14,11.7,878744,6-Aug-20,0.16,0.0134
6-Aug-20,Acceleron Reports Second Quarter 2020 Operating and Financial Results,"Acceleron Pharma Inc. (Nasdaq:XLRN), a biopharmaceutical company dedicated to the discovery, development, and commercialization of TGF-beta superfamily therapeutics to treat serious and rare diseases,...",106.46,108.06,105.02,107.43,XLRN,429139,HISTORICAL_PRICES,XLRN,,1.60683E+12,0.328425256,0.328425256,107.43,106.46,108.06,105.02,429139,107.43,106.46,108.06,105.02,429139,6-Aug-20,-0.09,-0.0008
6-Aug-20,Axonics® Reports Second Quarter 2020 Results,"Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing novel implantable sacral neuromodulation (SNM) devices for the treatment of...",43.3,45.23,42.67,44.96,AXNX,500821,HISTORICAL_PRICES,AXNX,,1.60683E+12,1.064854554,1.064854554,44.96,43.3,45.23,42.67,500821,44.96,43.3,45.23,42.67,500821,6-Aug-20,-1.18,-0.0265
6-Aug-20,AtriCure Announces Angie Wirick as Chief Financial Officer,"AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, announced today that Andy Wade is stepping down from the pos...",42.48,43.25,42.05,42.43,ATRC,262233,HISTORICAL_PRICES,ATRC,,1.60683E+12,0.47653806,0.47653806,42.43,42.48,43.25,42.05,262233,42.43,42.48,43.25,42.05,262233,6-Aug-20,-0.08,-0.0019
6-Aug-20,"Deciphera Pharmaceuticals, Inc. to Present at the Canaccord Genuity 40th Annual Growth Conference","Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), today announced that Steve Hoerter, President and Chief Executive Officer, will present at the Canaccord Genuity 40th Annual Growth Conference on Thursda...",47.9,49.2,45.66,48.3,DCPH,344366,HISTORICAL_PRICES,DCPH,,1.60683E+12,0.217280813,0.217280813,48.3,47.9,49.2,45.66,344366,48.3,47.9,49.2,45.66,344366,6-Aug-20,-0.5,-0.0103
6-Aug-20,Magenta Therapeutics Reports Recent Business Highlights and Second Quarter Financial Results,"Magenta Therapeutics (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of immune reset to more patients, today reported recent business high...",7.15,7.23,7,7.01,MGTA,394244,HISTORICAL_PRICES,MGTA,,1.60683E+12,0.140350877,0.140350877,7.01,7.15,7.23,7,394244,7.01,7.15,7.23,7,394244,6-Aug-20,0.04,0.0056
6-Aug-20,Seattle Genetics Achieves Milestone Payment Under Antibody-Drug Conjugate Collaboration with GlaxoSmithKline Triggered by BLENREP (belantamab mafodotin-blmf) FDA Approval,"Seattle Genetics, Inc. (Nasdaq:SGEN) today announced U.S. Food and Drug Administration (FDA) approval of GlaxoSmithKline‚Äôs (GSK) BLENREP‚Ñ¢ (belantamab mafodotin-blmf), an antibody-drug conjugate (ADC)...",161.8,164.1663,159.25,163.8,SGEN,733405,HISTORICAL_PRICES,SGEN,,1.60683E+12,0.534230988,0.534230988,163.8,161.8,164.1663,159.25,733405,163.8,161.8,164.1663,159.25,733405,6-Aug-20,-0.79,-0.0049
6-Aug-20,Alnylam Pharmaceuticals Reports Second Quarter 2020 Financial Results and Highlights Recent Period Activity,"Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today reported its consolidated financial results for the second quarter 2020 and reviewed recent business highligh...",144.12,149.21,141.5,148.64,ALNY,705527,HISTORICAL_PRICES,ALNY,,1.60683E+12,0.458999798,0.458999798,148.64,144.12,149.21,141.5,705527,148.64,144.12,149.21,141.5,705527,6-Aug-20,-6.32,-0.042
6-Aug-20,Urovant Sciences to Report First Fiscal Quarter 2020 Financial Results,"Urovant Sciences (Nasdaq: UROV) announced today that it will report 2020 first fiscal quarter financial results after the close of U.S. financial markets on Thursday, August 13, 2020. Management will...",8.25,8.615,8.0347,8.4,UROV,42632,HISTORICAL_PRICES,UROV,,1.60683E+12,-0.179104478,-0.179104478,8.4,8.25,8.615,8.0347,42632,8.4,8.25,8.615,8.0347,42632,6-Aug-20,-0.04,-0.0048
6-Aug-20,Marinus Pharmaceuticals Provides Business Update and Reports Second Quarter 2020 Financial Results,"Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders, today provided an update on its clinical...",8.36,8.4,7.18,7.2,MRNS,828770.75,HISTORICAL_PRICES,MRNS,,1.60809E+12,0.024509804,0.024509804,1.8,2.09,2.1,1.795,3315083,7.2,8.36,8.4,7.18,828770.75,6-Aug-20,1.28,0.1808
6-Aug-20,Aldeyra Therapeutics Announces Second-Quarter 2020 Financial Results and Provides Corporate Update,"Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immun...",6.76,7.2,6.51,7.01,ALDX,1316441,HISTORICAL_PRICES,ALDX,,1.60683E+12,2.414141414,2.414141414,7.01,6.76,7.2,6.51,1316441,7.01,6.76,7.2,6.51,1316441,6-Aug-20,-0.7,-0.0938
6-Aug-20,Abiomed Announces Q1 FY 2021 Revenue of $165 Million and 21% Operating Margin,"Abiomed, Inc. (NASDAQ: ABMD), a leading provider of breakthrough heart support technologies today reported first quarter fiscal 2021 revenue of $164.9 million compared to revenue of $207.7 million for...",314.98,318.46,308.4844,317.04,ABMD,442425,HISTORICAL_PRICES,ABMD,,1.60683E+12,1.144325686,1.144325686,317.04,314.98,318.46,308.4844,442425,317.04,314.98,318.46,308.4844,442425,6-Aug-20,-2.02,-0.0064
6-Aug-20,Ironwood Pharmaceuticals Reports Second Quarter 2020 Results; Delivered GAAP Net Income of $25 Million and Adjusted EBITDA of $33 Million,"Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a GI-focused healthcare company, today provided an update on its second quarter 2020 results and recent business performance, as well as an update relate...",10.09,10.45,9.7182,10.1,IRWD,1857251,HISTORICAL_PRICES,IRWD,,1.60683E+12,-0.010784314,-0.010784314,10.1,10.09,10.45,9.7182,1857251,10.1,10.09,10.45,9.7182,1857251,6-Aug-20,0.45,0.0467
6-Aug-20,PolarityTE Reports Second Quarter 2020 Results,"PolarityTE, Inc. (Nasdaq: PTE), a biotechnology company developing regenerative tissue products and biomaterials, today reported financial results for the second calendar quarter of 2020. PolarityTE w...",1.6,1.72,1.48,1.72,PTE,862015,HISTORICAL_PRICES,PTE,,1.60683E+12,0.379310345,0.379310345,1.72,1.6,1.72,1.48,862015,1.72,1.6,1.72,1.48,862015,6-Aug-20,-0.03,-0.0184
6-Aug-20,Concert Pharmaceuticals Reports Second Quarter 2020 Financial Results and Provides Company Update,"Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today reported financial results for the second quarter of 2020. ‚ÄúWe continue to be committed to advancing both of our lead programs as we embark on moving...",9.35,9.8,8.86,9.56,CNCE,187439,HISTORICAL_PRICES,CNCE,,1.60683E+12,0.06613455,0.06613455,9.56,9.35,9.8,8.86,187439,9.56,9.35,9.8,8.86,187439,6-Aug-20,-0.21,-0.022
6-Aug-20,Kala Pharmaceuticals Reports Second Quarter 2020 Financial Results and Provides Corporate Update,"Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today reported financ...",9.17,9.7,9.01,9.33,KALA,918829,HISTORICAL_PRICES,KALA,,1.60683E+12,0.249318801,0.249318801,9.33,9.17,9.7,9.01,918829,9.33,9.17,9.7,9.01,918829,6-Aug-20,0,0
6-Aug-20,Dicerna Announces Second Quarter 2020 Financial Results and Provides a Business Update,"Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (the ‚ÄúCompany‚Äù or ‚ÄúDicerna‚Äù), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today reported its financial result...",20,22.26,19.59,22.03,DRNA,1160491,HISTORICAL_PRICES,DRNA,,1.60683E+12,0.11049417,0.11049417,22.03,20,22.26,19.59,1160491,22.03,20,22.26,19.59,1160491,6-Aug-20,-1.78,-0.0817
6-Aug-20,Bristol Myers Squibb Reports Second Quarter 2020 Financial Results,"Bristol Myers Squibb (NYSE:BMY) today reports results for the second quarter of 2020, which reflect strong product sales, continued advancement of the pipeline and robust operating performance. ‚ÄúOur s...",61.33,62.97,60.42,62,BMY,18961905,HISTORICAL_PRICES,BMY,,1.60946E+12,0.242755826,0.242755826,62,61.33,62.97,60.42,18961905,61.0503,60.3905,62.0054,59.4945,18961905,6-Aug-20,1.64,0.0275
6-Aug-20,TherapeuticsMD¬Æ Announces Second Quarter 2020 Financial Results,"TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative, leading women‚Äôs healthcare company, today reported financial results for the second quarter ended June 30, 2020. ‚ÄúOur organization made significant...",1.61,1.85,1.58,1.79,TXMD,13660469,HISTORICAL_PRICES,TXMD,,1.60683E+12,0.267716535,0.267716535,1.79,1.61,1.85,1.58,13660469,1.79,1.61,1.85,1.58,13660469,6-Aug-20,-0.44,-0.2146
6-Aug-20,ANI Pharmaceuticals Reports Second Quarter 2020 Results,"ANI Pharmaceuticals, Inc. (‚ÄúANI‚Äù or the ‚ÄúCompany‚Äù) (NASDAQ: ANIP) today announced business highlights and financial results for the three and six months ended June 30, 2020. Business and Recent Highli...",29.5,31.42,29.23,30.51,ANIP,119340,HISTORICAL_PRICES,ANIP,,1.60683E+12,-0.261207112,-0.261207112,30.51,29.5,31.42,29.23,119340,30.51,29.5,31.42,29.23,119340,6-Aug-20,-1.5,-0.0484
6-Aug-20,NanoString and Bio-Techne Announce Offering of RNAscope Reagents Validated for Use With the GeoMx Digital Spatial Profiler,"NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for discovery and translational research, and Bio-Techne (NASDAQ:TECH), a global life sciences company providing i...",36.04,37.8193,35.71,37.44,NSTG,169316,HISTORICAL_PRICES,NSTG,,1.60683E+12,0.429024584,0.429024584,37.44,36.04,37.8193,35.71,169316,37.44,36.04,37.8193,35.71,169316,6-Aug-20,-1.3,-0.0348
6-Aug-20,Amneal Reports Second Quarter 2020 Financial Results,"Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (the ‚ÄúCompany‚Äù) announced its results today for the second quarter ended June 30, 2020. ‚ÄúAmneal executed well against our operational and strategic goals in t...",4.67,4.95,4.42,4.53,AMRX,2921620,HISTORICAL_PRICES,AMRX,,1.60683E+12,0.338108883,0.338108883,4.53,4.67,4.95,4.42,2921620,4.53,4.67,4.95,4.42,2921620,6-Aug-20,-0.6,-0.1139
5-Aug-20,"The China Center for Drug Evaluation, National Medical Products Administration Has Recommended Breakthrough Therapy Designation for ciltacabtagene autoleucel (cilta-cel, LCAR-B38M CAR-T Cells), an Investigational BCMA CAR-T Cell Therapy","Legend Biotech Corporation (NASDAQ:LEGN) announced today that the China Center for Drug Evaluation, National Medical Products Administration (CDE, NMPA) has recommended Breakthrough Therapy Designatio...",33.81,35,33.76,34.43,LEGN,454333,HISTORICAL_PRICES,LEGN,,1.60683E+12,-0.086216216,-0.086216216,34.43,33.81,35,33.76,454333,34.43,33.81,35,33.76,454333,5-Aug-20,-0.19,-0.0056
5-Aug-20,Sesen Bio to Present Regulatory and Business Development Update at the Canaccord Genuity 40th Annual Growth Conference,"August 5, 2020 ‚Äì Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced it will be featured...",1,1.05,0.99,1.05,SESN,1451591,HISTORICAL_PRICES,SESN,,1.60683E+12,0.754385965,0.754385965,1.05,1,1.05,0.99,1451591,1.05,1,1.05,0.99,1451591,5-Aug-20,-0.05,-0.0476
5-Aug-20,bluebird bio Reports Second Quarter 2020 Financial Results and Recent Operational Progress,"bluebird bio, Inc. (NASDAQ: BLUE) today reported financial results and business highlights for the second quarter ended June 30, 2020 and shared recent operational progress. ‚ÄúI am incredibly proud of...",62.06,63.8,61.9046,62.95,BLUE,476738,HISTORICAL_PRICES,BLUE,,1.60683E+12,0.311496196,0.311496196,62.95,62.06,63.8,61.9046,476738,62.95,62.06,63.8,61.9046,476738,5-Aug-20,-0.38,-0.0061
5-Aug-20,AVEO Oncology Announces $2.8M Development Milestone Earned from Kyowa Kirin,"AVEO Oncology (Nasdaq: AVEO) today announced that it has earned a $2.8 million development milestone payment from partner Kyowa Kirin Co., Ltd. (Kyowa Kirin). The milestone relates to acceptance by th...",4.44,4.5,4.25,4.48,AVEO,501546,HISTORICAL_PRICES,AVEO,,1.60683E+12,0.460526316,0.460526316,4.48,4.44,4.5,4.25,501546,4.48,4.44,4.5,4.25,501546,5-Aug-20,0.01,0.0023
5-Aug-20,ACADIA Pharmaceuticals Reports Second Quarter 2020 Financial Results,"ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous syste...",42.87,43.9291,42.69,43.62,ACAD,1191734,HISTORICAL_PRICES,ACAD,,1.60683E+12,0.126379401,0.126379401,43.62,42.87,43.9291,42.69,1191734,43.62,42.87,43.9291,42.69,1191734,5-Aug-20,-0.65,-0.0149
5-Aug-20,Tricida Announces Second Quarter 2020 Financial Results,"Tricida, Inc. (Nasdaq: TCDA), a pharmaceutical company focused on the development and commercialization of its drug candidate, veverimer (TRC101), a non-absorbed, orally-administered polymer designed...",13.8,14.5953,13.56,14.49,TCDA,929863,HISTORICAL_PRICES,TCDA,,1.60683E+12,-0.393139842,-0.393139842,14.49,13.8,14.5953,13.56,929863,14.49,13.8,14.5953,13.56,929863,5-Aug-20,-0.46,-0.0323
5-Aug-20,Surmodics Receives FDA 510(k) Clearance for Sublime‚Ñ¢ Radial Access 0.014 RX PTA Dilatation Catheter,"Surmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, announced it has received U.S. Food and Drug Administration (FDA)...",48.48,48.86,46.985,47.62,SRDX,58113,HISTORICAL_PRICES,SRDX,,1.60683E+12,0.567917206,0.567917206,47.62,48.48,48.86,46.985,58113,47.62,48.48,48.86,46.985,58113,5-Aug-20,1.42,0.0302
5-Aug-20,Surmodics Reports Third Quarter Fiscal 2020 Results,"Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced results for its fiscal 2020 third quarter ended Ju...",48.48,48.86,46.985,47.62,SRDX,58113,HISTORICAL_PRICES,SRDX,,1.60683E+12,0.567917206,0.567917206,47.62,48.48,48.86,46.985,58113,47.62,48.48,48.86,46.985,58113,5-Aug-20,1.42,0.0302
5-Aug-20,Atara Biotherapeutics Announces Second Quarter 2020 Financial Results and Operational Progress,"Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with severe diseases...",12.71,13.07,12.1,12.66,ATRA,503840,HISTORICAL_PRICES,ATRA,,1.60683E+12,0.407530454,0.407530454,12.66,12.71,13.07,12.1,503840,12.66,12.71,13.07,12.1,503840,5-Aug-20,0.39,0.0317
5-Aug-20,Clovis Oncology Announces First Patient Enrolled in the Phase 2 Portion of the LIO-1 Trial Evaluating the Combination of Lucitanib and Opdivo in Gynecologic Cancers,"Clovis Oncology, Inc. (NASDAQ: CLVS) announced today treatment of the first patient in the Phase 2 portion of the LIO-1 trial evaluating the combination of lucitanib, Clovis‚Äô investigational angiogene...",6.465,6.48,6.25,6.33,CLVS,2745072,HISTORICAL_PRICES,CLVS,,1.60683E+12,0.459367946,0.459367946,6.33,6.465,6.48,6.25,2745072,6.33,6.465,6.48,6.25,2745072,5-Aug-20,0.215,0.0344
5-Aug-20,LORBRENA¬Æ (lorlatinib) Significantly Improves Progression-Free Survival in First-Line ALK-Positive Lung Cancer,Pfizer Inc. (NYSE:PFE) today announced that the Phase 3 CROWN study of LORBRENA¬Æ (lorlatinib) in people with previously untreated advanced anaplastic lymphoma kinase (ALK)-positive non-small cell lung...,38.45,38.53,38.13,38.47,PFE,23344231,HISTORICAL_PRICES,PFE,,1.6118E+12,0.292436975,0.292436975,38.47,38.45,38.53,38.13,23344231,37.6686,37.649,37.7274,37.3357,23344231,5-Aug-20,0.06,0.0016
5-Aug-20,Charles River Laboratories Announces Second-Quarter 2020 Results,"Charles River Laboratories International, Inc. (NYSE: CRL) today reported its results for the second quarter of 2020. For the quarter, revenue was $682.6 million, an increase of 3.8% from $657.6 milli...",217.97,220.01,204.56,206.68,CRL,713262,HISTORICAL_PRICES,CRL,,1.60683E+12,0.826309175,0.826309175,206.68,217.97,220.01,204.56,713262,206.68,217.97,220.01,204.56,713262,5-Aug-20,14.05,0.0689
5-Aug-20,Rocket Pharmaceuticals Reports Second Quarter 2020 Financial Results and Highlights Recent Progress,"Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) (‚ÄúRocket‚Äù), a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders, today reports finan...",25.26,25.48,23.6,25.22,RCKT,405941,HISTORICAL_PRICES,RCKT,,1.60683E+12,0.687374749,0.687374749,25.22,25.26,25.48,23.6,405941,25.22,25.26,25.48,23.6,405941,5-Aug-20,0.38,0.0153
5-Aug-20,IVERIC bio Reports Second Quarter 2020 Operational Highlights and Financial Results,"IVERIC bio, Inc. (Nasdaq: ISEE) today announced financial and operating results for the fiscal quarter ended June 30, 2020 and provided a general business update. ‚ÄúFollowing the positive results from...",4.41,4.55,4.29,4.4,ISEE,531014,HISTORICAL_PRICES,ISEE,,1.60683E+12,0.320359281,0.320359281,4.4,4.41,4.55,4.29,531014,4.4,4.41,4.55,4.29,531014,5-Aug-20,0.11,0.0256
5-Aug-20,Moderna Reports Second Quarter 2020 Financial Results and Provides Business Updates,"Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today reported fina...",75.8,77.49,73.69,77.49,MRNA,19859902,HISTORICAL_PRICES,MRNA,,1.60683E+12,1.793955031,1.793955031,77.49,75.8,77.49,73.69,19859902,77.49,75.8,77.49,73.69,19859902,5-Aug-20,-2.66,-0.0339
5-Aug-20,Horizon Therapeutics plc Reports Record Second-Quarter 2020 Results; Increases TEPEZZA¬Æ Full-Year Net Sales Guidance to Greater Than $650 Million; Increases Full‚ÄêYear 2020 Net Sales and Adjusted EBITDA Guidance,Horizon Therapeutics plc (Nasdaq: HZNP) today announced record second-quarter 2020 financial results. The Company increased its full-year 2020 net sales and adjusted EBITDA guidance on continued stren...,76.38,77.4499,70,73.35,HZNP,7813740,HISTORICAL_PRICES,HZNP,,1.60683E+12,1.702760085,1.702760085,73.35,76.38,77.4499,70,7813740,73.35,76.38,77.4499,70,7813740,5-Aug-20,14.59,0.2361
5-Aug-20, Karuna Therapeutics Reports Second Quarter 2020 Financial Results and Business Highlights,"Karuna Therapeutics, Inc. (NASDAQ: KRTX), an innovative clinical-stage biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with disabl...",84.04,87,80.81,84.61,KRTX,116699,HISTORICAL_PRICES,KRTX,,1.60683E+12,0.254328358,0.254328358,84.61,84.04,87,80.81,116699,84.61,84.04,87,80.81,116699,5-Aug-20,-1.87,-0.0218
4-Aug-20,"SHAREHOLDER ALERT: Investigation of DBV Technologies Announced by Holzer & Holzer, LLC","Holzer & Holzer, LLC is investigating whether DBV Technologies S.A. (‚ÄúDBV Technologies‚Äù or the ‚ÄúCompany‚Äù) (NASDAQ: DBVT) complied with federal securities laws. On August 4, 2020, DBV Technologies...",2.34,2.6,2.32,2.58,DBVT,6226581,HISTORICAL_PRICES,DBVT,,1.60683E+12,-0.4,-0.4,2.58,2.34,2.6,2.32,6226581,2.58,2.34,2.6,2.32,6226581,4-Aug-20,-1.76,-0.4293
4-Aug-20,"Glancy Prongay & Murray LLP, a National Class Action Law Firm, Continues Investigation of Tactile Systems Technology, Inc. (TCMD) on Behalf of Investors","Glancy Prongay & Murray LLP (‚ÄúGPM‚Äù), a national investor rights law firm, continues its investigation on behalf of Tactile Systems Technology, Inc. (""Tactile"" or the ""Company"") (NASDAQ: TCMD) inve...",35.52,42.03,34.85,41.63,TCMD,1149890,HISTORICAL_PRICES,TCMD,,1.60683E+12,-0.068694284,-0.068694284,41.63,35.52,42.03,34.85,1149890,41.63,35.52,42.03,34.85,1149890,4-Aug-20,-7.76,-0.1793
4-Aug-20,Quanterix Corporation Releases Operating Results for Second Quarter 2020,"Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis to advance the science of precision health, today announced financial results for the three months ending June 30, 2020. ‚Äú...",33,34.2099,31.66,32.18,QTRX,286390,HISTORICAL_PRICES,QTRX,,1.60683E+12,1.205882353,1.205882353,32.18,33,34.2099,31.66,286390,32.18,33,34.2099,31.66,286390,4-Aug-20,0.71,0.022
4-Aug-20,"Deciphera Pharmaceuticals, Inc. Announces Second Quarter 2020 Financial Results","Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) today announced financial results for the second quarter ended June 30, 2020 and provided an update on clinical and corporate developments. ‚ÄúThe second qu...",48.53,49.07,47.51,48.99,DCPH,328096,HISTORICAL_PRICES,DCPH,,1.60683E+12,0.173923561,0.173923561,48.99,48.53,49.07,47.51,328096,48.99,48.53,49.07,47.51,328096,4-Aug-20,-0.93,-0.0188
4-Aug-20,"Cardiovascular Systems, Inc. Reports Fiscal 2020 Fourth-Quarter Financial Results","Cardiovascular Systems, Inc. (CSI¬Æ) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery...",30.8,31.4,30.6,31.05,CSII,389065,HISTORICAL_PRICES,CSII,,1.60683E+12,-0.06468266,-0.06468266,31.05,30.8,31.4,30.6,389065,31.05,30.8,31.4,30.6,389065,4-Aug-20,-0.45,-0.0144
4-Aug-20,Cerus Corporation Announces Record Second Quarter 2020 Results,"Cerus Corporation (Nasdaq: CERS) today announced financial results for the second quarter ended June 30, 2020. Recent developments and highlights include: Q2 2020 Total Revenue of $26.8 million - driv...",7.47,7.56,7.21,7.43,CERS,1500438,HISTORICAL_PRICES,CERS,,1.60683E+12,0.849009901,0.849009901,7.43,7.47,7.56,7.21,1500438,7.43,7.47,7.56,7.21,1500438,4-Aug-20,0.06,0.0081
4-Aug-20,Xencor Reports Second Quarter 2020 Financial Results,"Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases, today reported financial results...",30.92,32.245,30.54,31.94,XNCR,204985,HISTORICAL_PRICES,XNCR,,1.60683E+12,0.074730622,0.074730622,31.94,30.92,32.245,30.54,204985,31.94,30.92,32.245,30.54,204985,4-Aug-20,-0.91,-0.0286
4-Aug-20,Kala Pharmaceuticals to Present at 2020 Wedbush PacGrow Healthcare Virtual Conference,"Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced that...",9.33,9.49,8.95,9.19,KALA,849622,HISTORICAL_PRICES,KALA,,1.60683E+12,0.271117166,0.271117166,9.19,9.33,9.49,8.95,849622,9.19,9.33,9.49,8.95,849622,4-Aug-20,0.06,0.0065
4-Aug-20,Henry Schein Reports Second Quarter 2020 Financial Results,"Henry Schein, Inc. (Nasdaq: HSIC), the world‚Äôs largest provider of health care solutions to office-based dental and medical practitioners, today reported second quarter 2020 financial results from con...",69.13,71.6,64.91,68.25,HSIC,4119372,HISTORICAL_PRICES,HSIC,,1.60683E+12,0.381770937,0.381770937,68.25,69.13,71.6,64.91,4119372,68.25,69.13,71.6,64.91,4119372,4-Aug-20,-1.77,-0.025
4-Aug-20,Incyte Reports 2020 Second Quarter Financial Results and Provides Updates on Key Clinical Programs,"Incyte (Nasdaq: INCY) today reports 2020 second quarter financial results, and provides a status update on the Company‚Äôs development portfolio. ‚ÄúWe continue to execute successfully across all aspects...",99.95,101.96,96.89,101,INCY,1976367,HISTORICAL_PRICES,INCY,,1.60683E+12,0.436269579,0.436269579,101,99.95,101.96,96.89,1976367,101,99.95,101.96,96.89,1976367,4-Aug-20,-1.84,-0.0181
4-Aug-20,"Ra Medical Systems to Report Second Quarter 2020 Financial Results on August 11, 2020","Ra Medical Systems, Inc. (NYSE: RMED) announces that it will report second quarter 2020 financial results and provide a business update after market close on Tuesday, August 11, 2020. Ra Medical manag...",7.4075,7.5775,7.25,7.4975,RMED,260330.04,HISTORICAL_PRICES,RMED,,1.60683E+12,-0.729406393,-0.729406393,0.2999,0.2963,0.3031,0.29,6508251,7.4975,7.4075,7.5775,7.25,260330.04,4-Aug-20,0.1725,0.0238
4-Aug-20,Epizyme Reports Business Progress and Second Quarter 2020 Financial Results,"Epizyme, (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering novel epigenetic therapies, today provided business and portfolio updates and reported...",12.3,14.37,12.285,14.17,EPZM,3190593,HISTORICAL_PRICES,EPZM,,1.60683E+12,-0.189189189,-0.189189189,14.17,12.3,14.37,12.285,3190593,14.17,12.3,14.37,12.285,3190593,4-Aug-20,-2.07,-0.1441
4-Aug-20,Easterly Government Properties Reports Second Quarter 2020 Results,"Easterly Government Properties, Inc. (NYSE: DEA) (the ‚ÄúCompany‚Äù or ‚ÄúEasterly‚Äù), a fully integrated real estate investment trust (‚ÄúREIT‚Äù) focused primarily on the acquisition, development and managemen...",25.37,25.54,24.07,24.08,DEA,610593,HISTORICAL_PRICES,DEA,,1.61482E+12,0.118606702,0.118606702,24.08,25.37,25.54,24.07,610593,23.2524,24.498,24.6622,23.2427,610593,4-Aug-20,1.32,0.0549
3-Aug-20,Karuna Therapeutics Announces Topline Data From Phase 1b Trial Evaluating KarXT on Experimentally Induced Pain in Healthy Volunteers,"Karuna Therapeutics, Inc. (NASDAQ: KRTX), an innovative clinical-stage biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with disabl...",87.64,87.92,81.81,82.1,KRTX,169536,HISTORICAL_PRICES,KRTX,,1.60683E+12,0.308059701,0.308059701,82.1,87.64,87.92,81.81,169536,82.1,87.64,87.92,81.81,169536,3-Aug-20,5.84,0.0714
3-Aug-20,Hologic Announces ‚ÄòBack to Screening‚Äô Campaign Encouraging Women to Prioritize Mammograms Delayed due to COVID-19 Pandemic,"Hologic, Inc. (Nasdaq: HOLX), an innovative medical technology company, today launched the Back to Screening campaign encouraging women to schedule their annual mammograms now that healthcare faciliti...",71.32,71.49,70.08,70.6,HOLX,2654992,HISTORICAL_PRICES,HOLX,,1.60683E+12,1.210787353,1.210787353,70.6,71.32,71.49,70.08,2654992,70.6,71.32,71.49,70.08,2654992,3-Aug-20,1.54,0.0221
3-Aug-20,TYME Announces Orphan Drug Designation for SM-88 as Potential Treatment for Patients with Pancreatic Cancer,"Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs‚Ñ¢) announced that the U.S. Food and Drug Administration (FDA) has granted t...",1.35,1.44,1.21,1.36,TYME,4350512,HISTORICAL_PRICES,TYME,,1.60683E+12,0.227272727,0.227272727,1.36,1.35,1.44,1.21,4350512,1.36,1.35,1.44,1.21,4350512,3-Aug-20,0.16,0.1345
3-Aug-20,New Blinded Observational Study Shows Greater Depth of Patient Sedation Than Intended During Procedural Colonoscopy,"Masimo (NASDAQ: MASI) today announced that in a new study published in Anesthesia Research and Practice, researchers used Masimo SedLine¬Æ Brain Function Monitoring to investigate the depth of anesthes...",218.25,223.9,217.51,222.15,MASI,400237,HISTORICAL_PRICES,MASI,,1.60683E+12,0.36568425,0.36568425,222.15,218.25,223.9,217.51,400237,222.15,218.25,223.9,217.51,400237,3-Aug-20,-1.87,-0.0085
3-Aug-20,"Alnylam Submits CTA Application for ALN-HSD, an Investigational RNAi Therapeutic for the Treatment of Nonalcoholic Steatohepatitis (NASH)","Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that the Company has submitted a clinical trial authorization (CTA) application to The Medicines an...",152.3,153.01,145.58,146.79,ALNY,415576,HISTORICAL_PRICES,ALNY,,1.60683E+12,0.541810083,0.541810083,146.79,152.3,153.01,145.58,415576,146.79,152.3,153.01,145.58,415576,3-Aug-20,6.54,0.0449
3-Aug-20,Ligand Reports Second Quarter 2020 Financial Results,"Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today reported financial results for the three and six months ending June 30, 2020 and provided an operating forecast and program updates. Ligand man...",119.08,120,111.25,120,LGND,607366,HISTORICAL_PRICES,LGND,,1.60683E+12,0.703332857,0.703332857,120,119.08,120,111.25,607366,120,119.08,120,111.25,607366,3-Aug-20,1.9,0.0162
31-Jul-20,Xencor Earns Milestone Payment from MorphoSys for FDA Approval of Monjuvi¬Æ (tafasitamab-cxix) in the United States,"Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases, announced that the U.S. Food an...",30.09,31.76,29.28,31.54,XNCR,357979,HISTORICAL_PRICES,XNCR,,1.60683E+12,0.045881126,0.045881126,31.54,30.09,31.76,29.28,357979,31.54,30.09,31.76,29.28,357979,31-Jul-20,-1.55,-0.049
31-Jul-20,Quidel Receives Preliminary Contract Leading to Definitive Agreement for $71 Million Under NIH‚Äôs RADx-ATP Program to Accelerate the Expansion of Its Manufacturing Capacity for Sofia¬Æ SARS-CoV-2 Antigen Detection Test for Rapid Diagnosis of COVID-19,"Quidel Corporation (NASDAQ: QDEL) (‚ÄúQuidel‚Äù), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that Quidel has entered...",282.47,287.88,267.12,277.19,QDEL,936109,HISTORICAL_PRICES,QDEL,,1.60683E+12,2.500681621,2.500681621,277.19,282.47,287.88,267.12,936109,277.19,282.47,287.88,267.12,936109,31-Jul-20,11.97,0.0443
31-Jul-20,"Genprex to Present at Proactive‚Äôs One2One Virtual Investor Forum on August 4, 2020","Genprex, Inc. (‚ÄúGenprex‚Äù or the ‚ÄúCompany‚Äù) (NASDAQ: GNPX), a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes, announced toda...",3.37,3.5713,3.26,3.55,GNPX,777962,HISTORICAL_PRICES,GNPX,,1.60683E+12,0.207885305,0.207885305,3.55,3.37,3.5713,3.26,777962,3.55,3.37,3.5713,3.26,777962,31-Jul-20,-0.11,-0.0316
31-Jul-20,FDA Approves EUA Amendment Increasing Applied DNA‚Äôs COVID-19 Diagnostic Kit Testing Capacity Through Use of Automated RNA Extraction and Expands Supported Platforms,"Applied DNA Sciences Inc. (NASDAQ: APDN) (‚ÄúApplied DNA‚Äù or the ‚ÄúCompany‚Äù) a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing that enables in vitro diagnostics, and pre-clinical nuclei...",10,13.08,9.3,13.05,APDN,18595860,HISTORICAL_PRICES,APDN,,1.60683E+12,1.450980392,1.450980392,13.05,10,13.08,9.3,18595860,13.05,10,13.08,9.3,18595860,31-Jul-20,1.29,0.1481
31-Jul-20,GlycoMimetics Reports Highlights and Financial Results for Second Quarter 2020,"GlycoMimetics, Inc. (Nasdaq: GLYC) today reported its financial results for the second quarter ended June 30, 2020, and highlighted recent company events. Cash and cash equivalents at June 30, 2020 we...",3.94,4.25,3.87,4.18,GLYC,664698,HISTORICAL_PRICES,GLYC,,1.60683E+12,0.662447257,0.662447257,4.18,3.94,4.25,3.87,664698,4.18,3.94,4.25,3.87,664698,31-Jul-20,-0.21,-0.0506
31-Jul-20,VBI Vaccines Announces Second Quarter 2020 Financial Results and Provides Corporate Update,"VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today reported financial results for th...",4.07,4.59,3.9,4.4728,VBIV,12393965,HISTORICAL_PRICES,VBIV,,1.60683E+12,3.651428571,3.651428571,4.4728,4.07,4.59,3.9,12393965,4.4728,4.07,4.59,3.9,12393965,31-Jul-20,-0.25,-0.0579
31-Jul-20,Sesen Bio announces an exclusive license agreement with Qilu Pharmaceutical for the development and commercialization of Vicineum‚Ñ¢ in Greater China,"Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, and Qilu Pharmaceutical, a leading vertically integra...",1.04,1.22,1.01,1.19,SESN,9650366,HISTORICAL_PRICES,SESN,,1.60683E+12,0.824561404,0.824561404,1.19,1.04,1.22,1.01,9650366,1.19,1.04,1.22,1.01,9650366,31-Jul-20,0.03,0.0297
31-Jul-20,Ocular Therapeutix‚Ñ¢ To Report Second Quarter 2020 Financial Results,"Ocular Therapeutix‚Ñ¢, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, tod...",7.84,8.21,7.63,8.1,OCUL,604011,HISTORICAL_PRICES,OCUL,,1.60683E+12,0.561752988,0.561752988,8.1,7.84,8.21,7.63,604011,8.1,7.84,8.21,7.63,604011,31-Jul-20,-0.27,-0.0333
31-Jul-20,"New Topline TEPEZZA¬Æ (teprotumumab-trbw) Data Underscore its Efficacy in Longer Disease Duration, Long-Term Durability and Potential for Retreatment in People Living with Thyroid Eye Disease (TED)",Horizon Therapeutics plc (Nasdaq: HZNP) today announced positive topline data from two clinical trials that add to the growing body of evidence supporting the efficacy and safety of TEPEZZA¬Æ (teprotum...,61.19,63.72,60.3,63.72,HZNP,1955728,HISTORICAL_PRICES,HZNP,,1.60683E+12,1.165251238,1.165251238,63.72,61.19,63.72,60.3,1955728,63.72,61.19,63.72,60.3,1955728,31-Jul-20,-0.84,-0.0135
31-Jul-20,Church & Dwight Reports Q2 Results,"Church & Dwight Co., Inc. (NYSE: CHD) today announced reported second quarter 2020 EPS of $0.75, a 36.4% increase versus year ago. Adjusted EPS, which excludes an acquisition related earn-out adju...",96.33,96.4,92.04,93.77,CHD,4193050,HISTORICAL_PRICES,CHD,,1.6131E+12,0.597512438,0.597512438,93.77,96.33,96.4,92.04,4193050,92.9914,95.5302,95.5996,91.2758,4193050,31-Jul-20,6.27,0.0696
31-Jul-20, Merck Announces Second-Quarter 2020 Financial Results,"Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced financial results for the second quarter of 2020. ‚ÄúDespite the impact COVID-19 had on patient access to health car...",80.24,81.68,79.15,80.89,MRK,11726443,HISTORICAL_PRICES,MRK,,1.61552E+12,0.176194664,0.176194664,80.89,80.24,81.68,79.15,11726443,78.9828,78.3481,79.7541,77.2838,11726443,31-Jul-20,1.25,0.0158
31-Jul-20,ImmunoGen Reports Recent Progress and Second Quarter 2020 Financial Results,"ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today reviewed recent progress in the business and reported financial re...",4.11,4.5313,3.93,4.5313,IMGN,2957467,HISTORICAL_PRICES,IMGN,,1.60683E+12,0.121418827,0.121418827,4.5313,4.11,4.5313,3.93,2957467,4.5313,4.11,4.5313,3.93,2957467,31-Jul-20,-0.26,-0.0595
31-Jul-20,Pfizer and BioNTech to Supply Japan with 120 Million Doses of their BNT162 mRNA-based Vaccine Candidate,"Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced an agreement with the Ministry of Health, Labour and Welfare (MHLW) in Japan to supply 120 million doses of BNT162 mRNA-based vac...",38.48,38.75,37.86,38.67,PFE,27042691,HISTORICAL_PRICES,PFE,,1.6118E+12,0.293445378,0.293445378,38.67,38.48,38.75,37.86,27042691,37.8644,37.6784,37.9428,37.0713,27042691,31-Jul-20,-0.26,-0.0067
30-Jul-20,Quidel Reports Second Quarter 2020 Financial Results,"Quidel Corporation (NASDAQ: QDEL), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today financial results for the second q...",270.5,272.99,256.36,257.88,QDEL,623161,HISTORICAL_PRICES,QDEL,,1.60683E+12,2.352336101,2.352336101,257.88,270.5,272.99,256.36,623161,257.88,270.5,272.99,256.36,623161,30-Jul-20,11.03,0.0425
30-Jul-20,Veracyte Announces Second Quarter 2020 Financial Results,"Veracyte, Inc. (Nasdaq: VCYT) today announced financial results for the second quarter ended June 30, 2020 and provided an update on recent business progress. ‚ÄúWe delivered solid second quarter result...",33.21,33.49,29.72,29.76,VCYT,714314,HISTORICAL_PRICES,VCYT,,1.60683E+12,0.509202454,0.509202454,29.76,33.21,33.49,29.72,714314,29.76,33.21,33.49,29.72,714314,30-Jul-20,3.03,0.1004
30-Jul-20,Infinity Pharmaceuticals Provides Company Update and Second Quarter 2020 Financial Results,"Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) today announced its second quarter 2020 financial results and provided an update on the company, including its second quarter progress with eganelisib (al...",0.8282,0.858,0.82,0.84,INFI,226514,HISTORICAL_PRICES,INFI,,1.60683E+12,-0.150825387,-0.150825387,0.84,0.8282,0.857999,0.82,226514,0.84,0.8282,0.858,0.82,226514,30-Jul-20,0.0032,0.0039
30-Jul-20,"Revance to Release Second Quarter 2020 Financial Results on Thursday, August 6, 2020","Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company focused on innovative aesthetic and therapeutic offerings, including its next-generation neuromodulator product, DaxibotulinumtoxinA...",24.14,24.54,23.71,23.9,RVNC,437227,HISTORICAL_PRICES,RVNC,,1.60683E+12,0.636610169,0.636610169,23.9,24.14,24.54,23.71,437227,23.9,24.14,24.54,23.71,437227,30-Jul-20,-0.12,-0.0049
30-Jul-20,Seattle Genetics Reports Second Quarter 2020 Financial Results,"Seattle Genetics, Inc. (Nasdaq:SGEN) today reported financial results for the second quarter and six months ended June 30, 2020. The Company also highlighted ADCETRIS (brentuximab vedotin), PADCEV (en...",171.14,172.82,167.22,167.95,SGEN,918880,HISTORICAL_PRICES,SGEN,,1.60683E+12,0.622795373,0.622795373,167.95,171.14,172.82,167.22,918880,167.95,171.14,172.82,167.22,918880,30-Jul-20,2.72,0.0162
30-Jul-20,Kala Pharmaceuticals to Report Second Quarter 2020 Financial Results and Host Conference Call,"Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced that...",8.86,8.99,8.36,8.55,KALA,1016164,HISTORICAL_PRICES,KALA,,1.60683E+12,0.207084469,0.207084469,8.55,8.86,8.99,8.36,1016164,8.55,8.86,8.99,8.36,1016164,30-Jul-20,0.31,0.0363
30-Jul-20,Vertex Reports Second-Quarter 2020 Financial Results,"Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the second quarter ended June 30, 2020 and revised upward its full-year 2020 financial guidance for...",279.4,282.28,274.662,275.0753,VRTX,1538387,HISTORICAL_PRICES,VRTX,,1.60683E+12,0.329906231,0.329906231,275.0753,279.4,282.28,274.662,1538387,275.0753,279.4,282.28,274.662,1538387,30-Jul-20,0.68,0.0024
30-Jul-20,Gilead Sciences Announces Second Quarter and First Half 2020 Financial Results,"Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the second quarter and first half 2020. ‚ÄúGilead‚Äôs first half performance demonstrates the strength and durability of...",72.33,72.6,71.71,72.55,GILD,9274113,HISTORICAL_PRICES,GILD,,1.61552E+12,0.038329027,0.038329027,72.55,72.33,72.6,71.71,9274113,70.1952,69.9824,70.2436,69.3825,9274113,30-Jul-20,-0.68,-0.0093
30-Jul-20,"Applied DNA to Report Fiscal 2020 Third Quarter Financial Results After Market Close on August 6, 2020","Applied DNA Sciences, Inc. (NASDAQ: APDN) announced today that it will report fiscal 2020 third quarter financial results after market close on Thursday, August 6, 2020. The Company‚Äôs management will...",8.71,9.0299,8.44,8.8,APDN,338787,HISTORICAL_PRICES,APDN,,1.60683E+12,1.134803922,1.134803922,8.8,8.71,9.0299,8.44,338787,8.8,8.71,9.0299,8.44,338787,30-Jul-20,-0.16,-0.018
30-Jul-20,Masimo Named NBA Supplier of Pulse Oximetry,"Masimo (NASDAQ: MASI) today announced that it has entered into a partnership with the National Basketball Association (NBA) to be its official supplier of pulse oximetry. As teams return to play, Masi...",220.1,221.05,213.21,216.3,MASI,608229,HISTORICAL_PRICES,MASI,,1.60683E+12,0.377260497,0.377260497,216.3,220.1,221.05,213.21,608229,216.3,220.1,221.05,213.21,608229,30-Jul-20,1.33,0.0061
30-Jul-20,TFF Pharmaceuticals Announces Completion of Dosing for Voriconazole Inhalation Powder Phase 1 Clinical Trial,"TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) t...",9.04,9.5,8.1001,8.21,TFFP,1147798,HISTORICAL_PRICES,TFFP,,1.60683E+12,1.26,1.26,8.21,9.04,9.5,8.1001,1147798,8.21,9.04,9.5,8.1001,1147798,30-Jul-20,0.96,0.1188
30-Jul-20,Cerus Corporation Announces a Five-Year Tender Award by the Hong Kong Red Cross Blood Transfusion Service for INTERCEPT Blood Systems,Cerus Corporation (Nasdaq:CERS) today announced it has been awarded a five-year tender by the Hong Kong Red Cross Blood Transfusion Services (BTS) for INTERCEPT Blood System for platelets. The Hong Ko...,7.19,7.43,6.875,7.11,CERS,3562727,HISTORICAL_PRICES,CERS,,1.60683E+12,0.77970297,0.77970297,7.11,7.19,7.43,6.875,3562727,7.11,7.19,7.43,6.875,3562727,30-Jul-20,0.17,0.0242
30-Jul-20,Genprex CEO Participates in a Second-Round Live Interview on the ‚ÄúBig Biz Show‚Äù,"Genprex, Inc. (‚ÄúGenprex‚Äù or the ‚ÄúCompany‚Äù) (Nasdaq: GNPX), a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes, today announce...",3.48,3.49,3.36,3.42,GNPX,621224,HISTORICAL_PRICES,GNPX,,1.60683E+12,0.247311828,0.247311828,3.42,3.48,3.49,3.36,621224,3.42,3.48,3.49,3.36,621224,30-Jul-20,0.01,0.0029
30-Jul-20,"Odonate Therapeutics Announces Financial Results for the Three and Six Months Ended June 30, 2020","Odonate Therapeutics, Inc. (NASDAQ: ODT), a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer, today announced...",36.23,37.56,35,35.94,ODT,146717,HISTORICAL_PRICES,ODT,,1.60683E+12,0.378614916,0.378614916,35.94,36.23,37.56,35,146717,35.94,36.23,37.56,35,146717,30-Jul-20,-0.14,-0.0038
30-Jul-20,Sesen Bio to Host Conference Call to Provide OUS Business Update,"Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced that Company management will host a c...",1.01,1.09,1,1.04,SESN,2417642,HISTORICAL_PRICES,SESN,,1.60683E+12,0.771929825,0.771929825,1.04,1.01,1.09,1,2417642,1.04,1.01,1.09,1,2417642,30-Jul-20,0.01,0.01
30-Jul-20,Xeris Pharmaceuticals Announces Additional Data From a Phase 1b Comparative Study of Its Novel Concentrated Diazepam Formulation (XP-0863) and an Expedited Clinical Path Forward,"Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable and infusible drug formula...",2.9,2.97,2.7,2.79,XERS,4283790,HISTORICAL_PRICES,XERS,,1.60683E+12,0.542553191,0.542553191,2.79,2.9,2.97,2.7,4283790,2.79,2.9,2.97,2.7,4283790,30-Jul-20,0.2,0.0741
30-Jul-20,"PolarityTE Announces the Addition of Clinical Development and Regulatory Affairs Executive Jessica Shen, MD, MS to Board of Directors","PolarityTE, Inc. (Nasdaq: PTE) today announced the appointment of Jessica Shen, MD, MS to the Company‚Äôs Board of Directors. Dr. Shen brings extensive clinical development, medical, health economics, r...",1.55,1.63,1.43,1.51,PTE,1070862,HISTORICAL_PRICES,PTE,,1.60683E+12,0.336206897,0.336206897,1.51,1.55,1.63,1.43,1070862,1.51,1.55,1.63,1.43,1070862,30-Jul-20,0.07,0.0473
30-Jul-20,Marinus Pharmaceuticals Receives Rare Pediatric Disease Designation from FDA for Ganaxolone for the Treatment of CDKL5 Deficiency Disorder (CDD),"Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders, announced today that the U.S. Food and D...",6.84,7.52,6.2,7,MRNS,979813.5,HISTORICAL_PRICES,MRNS,,1.60809E+12,-0.161764706,-0.161764706,1.75,1.71,1.88,1.55,3919254,7,6.84,7.52,6.2,979813.5,30-Jul-20,0.48,0.0755
30-Jul-20,"Aerie Pharmaceuticals to Announce Second Quarter 2020 Financial Results and Host Conference Call on Thursday, August 6, 2020","Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients wi...",11.73,11.8977,11.37,11.73,AERI,774296,HISTORICAL_PRICES,AERI,,1.60683E+12,-0.096997691,-0.096997691,11.73,11.73,11.8977,11.37,774296,11.73,11.73,11.8977,11.37,774296,30-Jul-20,-0.14,-0.0118
30-Jul-20,Baxter Reports Second-Quarter 2020 Results,"Baxter International Inc. (NYSE:BAX), a leading global medical products company, today reported results for the second quarter of 2020 and provided its outlook for full-year 2020. ‚ÄúBaxter colleagues w...",86.01,86.11,82.92,85,BAX,8532630,HISTORICAL_PRICES,BAX,,1.61422E+12,0.169090662,0.169090662,85,86.01,86.11,82.92,8532630,84.223,85.2237,85.3228,82.162,8532630,30-Jul-20,-4.72,-0.052
30-Jul-20,"Lantheus Holdings, Inc. Reports Second Quarter 2020 Financial Results","Lantheus Holdings, Inc. (the ‚ÄúCompany‚Äù) (NASDAQ: LNTH), the parent company of Lantheus Medical Imaging, Inc. and Progenics Pharmaceuticals, Inc., and a global leader in the development, manufacture an...",14.65,15.7,14.39,15.7,LNTH,670643,HISTORICAL_PRICES,LNTH,,1.60683E+12,0.278359511,0.278359511,15.7,14.65,15.7,14.39,670643,15.7,14.65,15.7,14.39,670643,30-Jul-20,-1.06,-0.0675
30-Jul-20,Merck Announces Two US Regulatory Milestones for KEYTRUDA¬Æ (pembrolizumab) in Triple-Negative Breast Cancer (TNBC),"Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has accepted two new supplemental Biologics License Applications...",78.99,79.28,77.63,78.73,MRK,6824952,HISTORICAL_PRICES,MRK,,1.61552E+12,0.157871592,0.157871592,78.73,78.99,79.28,77.63,6824952,76.8737,77.1276,77.4107,75.7996,6824952,30-Jul-20,-0.36,-0.0045
30-Jul-20,Alexion Reports Second Quarter 2020 Results,"Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced financial results for the second quarter of 2020. Total revenues in the second quarter were $1,444.6 million, a 20 percent increase compared...",104.81,108.48,104.52,105.2,ALXN,2128688,HISTORICAL_PRICES,ALXN,,1.60683E+12,0.240795549,0.240795549,105.2,104.81,108.48,104.52,2128688,105.2,104.81,108.48,104.52,2128688,30-Jul-20,0.21,0.002
29-Jul-20,FSD Pharma Announces Decision to Surrender Health Canada Licenses for Subsidiary FV Pharma Inc.,FSD Pharma Inc. (Nasdaq: HUGE) (CSE: HUGE.CN) (FRA: 0K9A) (‚ÄúFSD Pharma‚Äù or the ‚ÄúCompany‚Äù) today announced that it has notified Health Canada of the Company‚Äôs decision to forfeit the licenses of its wh...,3.74,3.9,3.7201,3.73,HUGE,44379,HISTORICAL_PRICES,HUGE,,1.60988E+12,0.242524917,0.242524917,3.73,3.74,3.9,3.7201,44379,3.73,3.74,3.9,3.7201,44379,29-Jul-20,-0.03,-0.008
29-Jul-20,"Taro Provides Results for Quarter Ended June 30, 2020","Taro Pharmaceutical Industries Ltd. (NYSE: TARO) (‚ÄúTaro‚Äù) today provided unaudited financial results for the quarter ended June 30, 2020. Quarter ended June 30, 2020 Highlights - compared to Quarter e...",67.99,68.35,66.3295,67.81,TARO,48027,HISTORICAL_PRICES,TARO,,1.60683E+12,0.138479571,0.138479571,67.81,67.99,68.35,66.3295,48027,67.81,67.99,68.35,66.3295,48027,29-Jul-20,0.69,0.0103
29-Jul-20,"Bristol Myers Squibb and bluebird bio Announce Submission of Biologics License Application (BLA) to FDA for Idecabtagene Vicleucel (Ide-cel, bb2121) for Adults with Relapsed and Refractory Multiple Myeloma","Bristol Myers Squibb (NYSE: BMY) and bluebird bio, Inc. (Nasdaq: BLUE) today announced the submission of their Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for id...",59.15,59.4,58.59,59.16,BMY,7358112,HISTORICAL_PRICES,BMY,,1.60946E+12,0.19858156,0.19858156,59.16,59.15,59.4,58.59,7358112,58.2538,58.2439,58.4901,57.6925,7358112,29-Jul-20,-0.28,-0.0047
29-Jul-20,Transcat Announces Management Changes,"Transcat, Inc. (Nasdaq: TRNS) (‚ÄúTranscat‚Äù or the ‚ÄúCompany‚Äù), a leading provider of accredited calibration, repair, inspection and laboratory instrument services and value-added distributor of professi...",29,29.6571,28.525,29.49,TRNS,10340,HISTORICAL_PRICES,TRNS,,1.60683E+12,0.076466221,0.076466221,29.49,29,29.6571,28.525,10340,29.49,29,29.6571,28.525,10340,29-Jul-20,-0.49,-0.0166
29-Jul-20,AVITA Therapeutics to Participate at the Canaccord Genuity 40th Annual Growth Conference,"AVITA Therapeutics, Inc. (NASDAQ: RCEL) (ASX:AVH), a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration f...",22.39,23.24,22.38,23.24,RCEL,102203,HISTORICAL_PRICES,RCEL,,1.60683E+12,-0.26686313,-0.26686313,23.24,22.39,23.24,22.38,102203,23.24,22.39,23.24,22.38,102203,29-Jul-20,-0.87,-0.0374
29-Jul-20,Hologic Announces Financial Results for Third Quarter of Fiscal 2020,"Hologic, Inc. (Nasdaq: HOLX) announced today the Company‚Äôs financial results for the fiscal third quarter ended June 27, 2020. ‚ÄúOur strong third quarter financial results reflect the incredible contri...",64,64.21,62.15,62.45,HOLX,2220463,HISTORICAL_PRICES,HOLX,,1.60683E+12,0.983880967,0.983880967,62.45,64,64.21,62.15,2220463,62.45,64,64.21,62.15,2220463,29-Jul-20,1.9,0.0306
29-Jul-20,TFF Pharmaceuticals Comments on Research on the Re-formulation of Remdesivir to a Dry Powder Form for COVID-19 Antiviral Treatment,"TFF Pharmaceuticals, Inc. (NASDAQ:TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) te...",8.08,8.49,7.5,7.6,TFFP,1105660,HISTORICAL_PRICES,TFFP,,1.60683E+12,1.02,1.02,7.6,8.08,8.49,7.5,1105660,7.6,8.08,8.49,7.5,1105660,29-Jul-20,0.47,0.0618
29-Jul-20,"People with Dementia and Caregivers Share the Significant Burden of Visual Hallucinations and Paranoid Delusions, New Survey Highlights","UsAgainstAlzheimer‚Äôs, the Lewy Body Dementia Association and ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the results of a qualitative and quantitative survey that explored the impact of...",42.53,43.97,42.45,43.53,ACAD,1110356,HISTORICAL_PRICES,ACAD,,1.60683E+12,0.117446138,0.117446138,43.53,42.53,43.97,42.45,1110356,43.53,42.53,43.97,42.45,1110356,29-Jul-20,-0.62,-0.0144
29-Jul-20,AtriCure to Participate at Upcoming Investor Conferences,"AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that the company will be participat...",42.38,44.67,41.28,44.66,ATRC,945132,HISTORICAL_PRICES,ATRC,,1.60683E+12,0.439538043,0.439538043,44.66,42.38,44.67,41.28,945132,44.66,42.38,44.67,41.28,945132,29-Jul-20,-2.29,-0.0513
29-Jul-20,"PolarityTE to Report Second Quarter 2020 Financial Results on August 6, 2020","PolarityTE, Inc. (Nasdaq: PTE) today announced that it will report calendar second quarter 2020 financial results by press release on Thursday, August 6, 2020 at approximately 7:00 a.m. Eastern Time....",1.48,1.57,1.43,1.55,PTE,1461291,HISTORICAL_PRICES,PTE,,1.60683E+12,0.275862069,0.275862069,1.55,1.48,1.57,1.43,1461291,1.55,1.48,1.57,1.43,1461291,29-Jul-20,-0.09,-0.0573
29-Jul-20,"Deciphera Pharmaceuticals, Inc. to Announce Second Quarter 2020 Financial Results and Host Conference Call and Webcast on August 4, 2020","Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) today announced that it will report its second quarter 2020 financial results on Tuesday, August 4, 2020. In connection with the earnings release, Deciphe...",46.07,47.39,44.3,47.17,DCPH,552661,HISTORICAL_PRICES,DCPH,,1.60683E+12,0.11441703,0.11441703,47.17,46.07,47.39,44.3,552661,47.17,46.07,47.39,44.3,552661,29-Jul-20,-0.79,-0.0169
29-Jul-20,"TherapeuticsMD to Report Second Quarter 2020 Results on August 6, 2020","TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative women‚Äôs healthcare company, today announced that it will report its second quarter 2020 financial results on Thursday, August 6, 2020, before the ope...",1.96,2.045,1.8299,1.87,TXMD,3566123,HISTORICAL_PRICES,TXMD,,1.60683E+12,0.543307087,0.543307087,1.87,1.96,2.045,1.8299,3566123,1.87,1.96,2.045,1.8299,3566123,29-Jul-20,0.09,0.0481
29-Jul-20,FDA Grants Breakthrough Therapy Designation to Merck‚Äôs Novel HIF-2Œ± Inhibitor MK-6482 for Treatment of Certain Patients With Von Hippel-Lindau Disease- Associated Renal Cell Carcinoma,"Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to the hypoxia-induc...",79.35,79.74,78.74,79.25,MRK,6105298,HISTORICAL_PRICES,MRK,,1.61552E+12,0.163148637,0.163148637,79.25,79.35,79.74,78.74,6105298,77.3814,77.4791,77.8599,76.8835,6105298,29-Jul-20,-0.34,-0.0043
29-Jul-20,Repare Therapeutics Announces Dosing of First Patient in Phase 1/2 Clinical Trial of RP-3500,"Repare Therapeutics Inc. (‚ÄúRepare‚Äù or the ‚ÄúCompany‚Äù) (Nasdaq: RPTX), a leading precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of no...",24.57,24.57,22.9,22.9,RPTX,70712,HISTORICAL_PRICES,RPTX,,1.60683E+12,-0.202272727,-0.202272727,22.9,24.57,24.57,22.9,70712,22.9,24.57,24.57,22.9,70712,29-Jul-20,1.83,0.0805
28-Jul-20,AtriCure Reports Second Quarter 2020 Financial Results,"AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced second quarter 2020 financial results. ‚ÄúAmid...",44.67,45.655,44.44,45.36,ATRC,274197,HISTORICAL_PRICES,ATRC,,1.60683E+12,0.51732337,0.51732337,45.36,44.67,45.655,44.44,274197,45.36,44.67,45.655,44.44,274197,28-Jul-20,-1.01,-0.0221
28-Jul-20,Moderna Announces Publication in The New England Journal of Medicine of Non-Human Primate Preclinical Viral Challenge Study of its mRNA Vaccine Against COVID-19 (mRNA-1273),"Moderna, Inc. (Nasdaq: MRNA), a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, toda...",81.49,83.85,79.5,81,MRNA,32946885,HISTORICAL_PRICES,MRNA,,1.60683E+12,2.003685957,2.003685957,81,81.49,83.85,79.5,32946885,81,81.49,83.85,79.5,32946885,28-Jul-20,1.58,0.0198
28-Jul-20,Nemaura Announces Correction and Pricing of Public Offering,"Nemaura Medical Inc. (NASDAQ: NMRD) (‚ÄúNemaura‚Äù or the ‚ÄúCompany‚Äù), a medical technology company focused on developing micro-systems-based wearable diagnostic devices and currently commercializing sugar...",6.675,7,6.65,6.9,NMRD,278747,HISTORICAL_PRICES,NMRD,,1.60683E+12,0.123737374,0.123737374,6.9,6.675,7,6.65,278747,6.9,6.675,7,6.65,278747,28-Jul-20,-2.585,-0.2792
28-Jul-20,"Turning Point Brands Announces Second Quarter 2020 Results, Increases 2020 Guidance","Turning Point Brands, Inc. (‚ÄúTPB‚Äù) (NYSE: TPB), a leading provider of Other Tobacco Products (‚ÄúOTP‚Äù) and adult consumer alternatives, today announced financial results for the second quarter ended Jun...",33.24,34.32,31.1,31.1,TPB,666371,HISTORICAL_PRICES,TPB,,1.61603E+12,0.524770642,0.524770642,31.1,33.24,34.32,31.1,666371,30.9811,33.1129,34.1888,30.9811,666371,28-Jul-20,2.86,0.0941
28-Jul-20,Altria Reports 2020 Second Quarter and First-Half Results; Reestablishes 2020 Full-Year Earnings Guidance; Announces IQOS Expansion Plans; Board Declares Dividend Increase,"Altria Group, Inc. (Altria) (NYSE: MO) today announces its 2020 second-quarter and first-half business results. Altria reestablishes 2020 adjusted diluted earnings per share (EPS) guidance and announc...",42.52,43.2,42.21,42.98,MO,10794221,HISTORICAL_PRICES,MO,,1.61655E+12,0.2371254,0.2371254,42.98,42.52,43.2,42.21,10794221,40.5839,40.1495,40.7916,39.8568,10794221,28-Jul-20,0.39,0.0093
28-Jul-20,Seres Therapeutics Reports Second Quarter 2020 Financial Results and Provides Business Updates,"Seres Therapeutics, Inc. (Nasdaq: MCRB) today reported financial results from the second quarter ended June 30, 2020, and provided an operational update. ‚ÄúIn the coming weeks, we are eagerly looking f...",3.99,4.34,3.75,4.2,MCRB,912716,HISTORICAL_PRICES,MCRB,,1.60683E+12,0.163265306,0.163265306,4.2,3.99,4.34,3.75,912716,4.2,3.99,4.34,3.75,912716,28-Jul-20,-0.21,-0.05
28-Jul-20,Pfizer Reports Second-Quarter 2020 Results,"Pfizer Inc. (NYSE: PFE) reported financial results for second-quarter 2020, increased its 2020 financial guidance for revenues and Adjusted diluted EPS(3) and reaffirmed all other components of its 20...",39.02,39.335,38.06,38.54,PFE,53504653,HISTORICAL_PRICES,PFE,,1.6118E+12,0.311596639,0.311596639,38.54,39.02,39.335,38.06,53504653,37.3719,37.8373,38.1428,36.9064,53504653,28-Jul-20,1.48,0.0394
28-Jul-20,Epizyme Announces Date of Second Quarter 2020 Financial Results and Participation at 2020 Wedbush PacGrow Healthcare Virtual Conference,"Epizyme, Inc. (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering novel epigenetic therapies, today announced that management will host a conferenc...",14.47,14.85,14.28,14.79,EPZM,545748,HISTORICAL_PRICES,EPZM,,1.60683E+12,-0.046143705,-0.046143705,14.79,14.47,14.85,14.28,545748,14.79,14.47,14.85,14.28,545748,28-Jul-20,-0.34,-0.023
28-Jul-20,Xerox Releases Second-Quarter Results,Xerox Holdings Corporation (NYSE: XRX) announced its second-quarter 2020 financial results. ‚ÄúI am proud of our employees who did what was necessary during this unprecedented disruption to support our...,15.21,16.38,15.035,16.03,XRX,4701589,HISTORICAL_PRICES,XRX,,1.60938E+12,-0.183136412,-0.183136412,16.03,15.21,16.38,15.035,4701589,15.6417,14.8416,15.9833,14.6708,4701589,28-Jul-20,-0.61,-0.0386
27-Jul-20,Shareholder Alert: Robbins LLP Announces the Shareholder Class Action Against Acer Therapeutics Inc. (ACER) Survives Motion to Dismiss,Shareholder rights law firm Robbins LLP announces that Acer Therapeutics Inc. (NASDAQ: ACER) may face damages caused by a pending securities class action. Acer Therapeutics is a pharmaceutical company...,3.46,3.6682,3.3,3.65,ACER,362088,HISTORICAL_PRICES,ACER,,1.60683E+12,0.756345178,0.756345178,3.65,3.46,3.6682,3.3,362088,3.65,3.46,3.6682,3.3,362088,27-Jul-20,0.15,0.0453
27-Jul-20,Pfizer and BioNTech Choose Lead mRNA Vaccine Candidate Against COVID-19 and Commence Pivotal Phase 2/3 Global Study,Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced the start of a global (except for China) Phase 2/3 safety and efficacy clinical study to evaluate a single nucleoside-modified me...,37.54,37.75,37.23,37.36,PFE,26224224,HISTORICAL_PRICES,PFE,,1.6118E+12,0.261848739,0.261848739,37.36,37.54,37.75,37.23,26224224,36.2277,36.4022,36.6058,36.1016,26224224,27-Jul-20,-0.12,-0.0032
27-Jul-20,Cardiovascular Systems Presents REACH PVI Study at the New Cardiovascular Horizons Conference,"Cardiovascular Systems, Inc. (CSI¬Æ) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery...",30.68,30.85,29.2146,29.54,CSII,405582,HISTORICAL_PRICES,CSII,,1.60683E+12,-0.068326754,-0.068326754,29.54,30.68,30.85,29.2146,405582,29.54,30.68,30.85,29.2146,405582,27-Jul-20,1.07,0.0361
27-Jul-20,"Nemaura Enters into Letter of Intent to Acquire Healthimation, LLC to Augment proBEAT‚Ñ¢ Launch in the U.S.","Nemaura Medical, Inc. (NASDAQ: NMRD) (‚ÄúNemaura‚Äù or the ‚ÄúCompany‚Äù), a medical technology company focused on developing micro-systems-based wearable diagnostic devices and currently commercializing suga...",9.26,10.66,9.0001,9.33,NMRD,111460,HISTORICAL_PRICES,NMRD,,1.60683E+12,0.558922559,0.558922559,9.33,9.26,10.66,9.0001,111460,9.33,9.26,10.66,9.0001,111460,27-Jul-20,-0.21,-0.0222
27-Jul-20,"Puma Biotechnology Announces Publication of Results from Phase II SUMMIT Trial Evaluating Neratinib in HER2-Mutant, Metastatic Cervical Cancers","Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that data from the cervical cancer cohort of SUMMIT, an ongoing Phase II basket trial examining the safety and efficacy...",10.05,10.13,9.77,9.82,PBYI,533585,HISTORICAL_PRICES,PBYI,,1.60683E+12,0.086486486,0.086486486,9.82,10.05,10.13,9.77,533585,9.82,10.05,10.13,9.77,533585,27-Jul-20,0.22,0.0224
27-Jul-20,Oncternal Therapeutics to Host Call on Cirmtuzumab and the Current Treatment Landscape for Mantle Cell Lymphoma,"Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that it will host a call with a key opin...",3.04,3.09,2.89,3.05,ONCT,175731,HISTORICAL_PRICES,ONCT,,1.60683E+12,0.164750958,0.164750958,3.05,3.04,3.09,2.89,175731,3.05,3.04,3.09,2.89,175731,27-Jul-20,0.14,0.0483
27-Jul-20,Masimo Expands the Masimo SafetyNet‚Ñ¢ Remote Patient Management Solution with Continuous Body Temperature Measurement,"Masimo (NASDAQ: MASI) today announced a significant expansion to the Masimo SafetyNet‚Ñ¢ platform with the introduction of Radius T¬∫‚Ñ¢, a wearable, wireless sensor that provides continuous body temperatu...",235.71,237.9092,233.565,234.37,MASI,343129,HISTORICAL_PRICES,MASI,,1.60683E+12,0.47493899,0.47493899,234.37,235.71,237.9092,233.565,343129,234.37,235.71,237.9092,233.565,343129,27-Jul-20,2.25,0.0096
27-Jul-20,scPharmaceuticals Announces FDA Acceptance of FUROSCIX¬Æ New Drug Application Resubmission,"scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patien...",7.37,7.705,7.21,7.51,SCPH,206614,HISTORICAL_PRICES,SCPH,,1.60683E+12,-0.138011696,-0.138011696,7.51,7.37,7.705,7.21,206614,7.51,7.37,7.705,7.21,206614,27-Jul-20,0.06,0.0082
27-Jul-20,Moderna Announces Phase 3 COVE Study of mRNA Vaccine Against COVID-19 (mRNA-1273) Begins,"Moderna, Inc., (Nasdaq: MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, toda...",79.91,80.98,76.16,80.63,MRNA,44710713,HISTORICAL_PRICES,MRNA,,1.60683E+12,1.945447844,1.945447844,80.63,79.91,80.98,76.16,44710713,80.63,79.91,80.98,76.16,44710713,27-Jul-20,6.7,0.0915
27-Jul-20,Aerie Pharmaceuticals Reports Positive Topline Results for AR-1105 (Dexamethasone Intravitreal Implant) Phase 2 Clinical Trial in Patients with Macular Edema Due to Retinal Vein Occlusion,"Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients wi...",12.37,13.2221,11.84,13.12,AERI,830744,HISTORICAL_PRICES,AERI,,1.60683E+12,-0.047729022,-0.047729022,13.12,12.37,13.2221,11.84,830744,13.12,12.37,13.2221,11.84,830744,27-Jul-20,0.19,0.0156
24-Jul-20,"U.S. FDA Approves Kite‚Äôs Tecartus‚Ñ¢, the First and Only CAR T Treatment for Relapsed or Refractory Mantle Cell Lymphoma","Kite, a Gilead Company (Nasdaq: GILD), today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval to Tecartus‚Ñ¢ (brexucabtagene autoleucel, formerly KTE-X19), the...",73.64,75.65,73.12,75.47,GILD,8148980,HISTORICAL_PRICES,GILD,,1.61552E+12,0.057134654,0.057134654,75.47,73.64,75.65,73.12,8148980,73.0205,71.2499,73.1946,70.7467,8148980,24-Jul-20,-1.92,-0.0254
24-Jul-20,Baxter and VIPUN Medical Announce Collaboration to Commercialize Innovative Gastric Monitoring System to Help Enhance Clinical Nutrition,"Baxter International Inc. (NYSE: BAX), a global leader in clinical nutrition, and VIPUN Medical, a company developing technology solutions to help improve medical nutrition, today announced an agreeme...",89.26,89.42,88.33,89.32,BAX,2362021,HISTORICAL_PRICES,BAX,,1.61422E+12,0.213266277,0.213266277,89.32,89.26,89.42,88.33,2362021,88.5035,88.444,88.6026,87.5225,2362021,24-Jul-20,-0.23,-0.0026
24-Jul-20,PolarityTE Announces Positive Top-Line Data from Interim Analysis of SkinTE‚Ñ¢ Diabetic Foot Ulcer Trial,"PolarityTE, Inc. (Nasdaq: PTE) announced positive results from a protocol-specified interim analysis of the first 50 patients enrolled in a multi-center randomized controlled trial evaluating treatmen...",1.78,2.38,1.67,2.04,PTE,23589473,HISTORICAL_PRICES,PTE,,1.60683E+12,0.534482759,0.534482759,2.04,1.78,2.38,1.67,23589473,2.04,1.78,2.38,1.67,23589473,24-Jul-20,0.17,0.1056
23-Jul-20,Revance Completes Previously Announced Acquisition of HintMD and its Proprietary Fintech Platform for Aesthetic Practices,"Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company focused on innovative aesthetic and therapeutic offerings, including its investigational neuromodulator product, DaxibotulinumtoxinA...",23.5,24.15,23.25,24.03,RVNC,290070,HISTORICAL_PRICES,RVNC,,1.60683E+12,0.593220339,0.593220339,24.03,23.5,24.15,23.25,290070,24.03,23.5,24.15,23.25,290070,23-Jul-20,-0.53,-0.0221
23-Jul-20,Puma Biotechnology to Host Conference Call to Discuss Second Quarter Financial Results,"Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, will host a conference call at 1:30 p.m. PDT/4:30 p.m. EDT on Thursday, August 6, 2020, following the release of its second quarte...",9.96,10.3745,9.885,10.09,PBYI,400077,HISTORICAL_PRICES,PBYI,,1.60683E+12,0.076756757,0.076756757,10.09,9.96,10.3745,9.885,400077,10.09,9.96,10.3745,9.885,400077,23-Jul-20,-0.17,-0.0168
23-Jul-20,"Premier Inc. Recommends FDA, DEA Reforms to Prevent Drug Shortages",Premier Inc. (NASDAQ: PINC) today provided the U.S. Food and Drug Administration (FDA) and the U.S. Drug Enforcement Administration (DEA) with a list of reforms and regulatory waivers that the company...,35.11,35.42,34.6294,34.93,PINC,610301,HISTORICAL_PRICES,PINC,,1.61439E+12,0.243271955,0.243271955,34.93,35.11,35.42,34.6294,610301,34.3412,34.5182,34.823,34.0457,610301,23-Jul-20,0.28,0.008
23-Jul-20,The Importance of Science-Based Decision-Making Highlighted in Latest Issue of Philip Morris International‚Äôs Scientific Update,"Philip Morris International Inc. (PMI) (NYSE: PM) has published the 10th issue of its Scientific Update, a regularly issued report on the company‚Äôs efforts to develop and scientifically assess a range...",76.3,76.39,75.23,75.88,PM,5117127,HISTORICAL_PRICES,PM,,1.61612E+12,0.15483578,0.15483578,75.88,76.3,76.39,75.23,5117127,72.657,73.0591,73.1453,72.0346,5117127,23-Jul-20,0.3,0.0039
23-Jul-20,"Cerus Corporation to Release Second Quarter 2020 Financial Results on August 4, 2020","Cerus Corporation (Nasdaq:CERS) announced today that its second quarter 2020 financial results will be released on Tuesday, August 4, 2020, after the close of the stock market. The Company will host a...",6.61,6.895,6.59,6.64,CERS,1434914,HISTORICAL_PRICES,CERS,,1.60683E+12,0.636138614,0.636138614,6.64,6.61,6.895,6.59,1434914,6.64,6.61,6.895,6.59,1434914,23-Jul-20,-0.07,-0.0105
23-Jul-20,Nemaura Medical to Integrate Activity Data From Third Party Wearable Devices to Its proBEAT‚Ñ¢ App,"Nemaura Medical, Inc. (NASDAQ: NMRD) (‚ÄúNemaura‚Äù or the ‚ÄúCompany‚Äù), a medical technology company focused on developing micro-systems-based wearable diagnostic devices and currently commercializing suga...",9.73,10.4299,8.4,8.6,NMRD,127223,HISTORICAL_PRICES,NMRD,,1.60683E+12,0.638047138,0.638047138,8.6,9.73,10.4299,8.4,127223,8.6,9.73,10.4299,8.4,127223,23-Jul-20,1.13,0.1314
23-Jul-20,Incyte Announces REACH3 Trial of Ruxolitinib (Jakafi¬Æ) in Patients with Chronic Graft-Versus-Host Disease Met Primary and Both Key Secondary Endpoints,Incyte (Nasdaq:INCY) today announced that the Phase 3 REACH3 study evaluating ruxolitinib (Jakafi¬Æ) in patients with moderate or severe steroid-refractory or steroid dependent chronic graft-versus-hos...,101.68,107.09,101.405,106.33,INCY,1154260,HISTORICAL_PRICES,INCY,,1.60683E+12,0.461129473,0.461129473,106.33,101.68,107.09,101.405,1154260,106.33,101.68,107.09,101.405,1154260,23-Jul-20,-3.69,-0.035
23-Jul-20,Ocular Therapeutix Announces Second Medicare Administrative Contractor to Establish New Published Physician Fee Schedule for Administration of Intracanalicular Inserts,"Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today...",8.64,9.2111,8.46,8.9,OCUL,831188,HISTORICAL_PRICES,OCUL,,1.60683E+12,0.721115538,0.721115538,8.9,8.64,9.2111,8.46,831188,8.9,8.64,9.2111,8.46,831188,23-Jul-20,-0.11,-0.0126
22-Jul-20,Pfizer and BioNTech Announce an Agreement with U.S. Government for up to 600 Million Doses of mRNA-based Vaccine Candidate Against SARS-CoV-2,Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced the execution of an agreement with the U.S. Department of Health and Human Services and the Department of Defense to meet the U.S...,38.56,38.73,37.52,38.23,PFE,86058379,HISTORICAL_PRICES,PFE,,1.6118E+12,0.296134454,0.296134454,38.23,38.56,38.73,37.52,86058379,37.0713,37.3913,37.5561,36.3828,86058379,22-Jul-20,1.87,0.051
21-Jul-20,Transcat Reports Operating Income of $1.0 Million from Service Segment Revenue and Margin Growth for Fiscal 2021 First Quarter,"Transcat, Inc. (Nasdaq: TRNS) (‚ÄúTranscat‚Äù or the ‚ÄúCompany‚Äù), a leading provider of accredited calibration, repair, inspection and laboratory instrument services and value-added distributor of professi...",27.08,28.07,26.55,28.06,TRNS,18505,HISTORICAL_PRICES,TRNS,,1.60683E+12,0.005196733,0.005196733,28.06,27.08,28.07,26.55,18505,28.06,27.08,28.07,26.55,18505,21-Jul-20,-0.62,-0.0224
21-Jul-20,Shareholder Alert: Robbins LLP Is Investigating the Officers and Directors of Vanda Pharmaceuticals Inc. (VNDA),"Shareholder rights law firm Robbins LLP announces that it is investigating the officers and directors of Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) for breaches of fiduciary duties, unjust enrichment,...",10.87,11.13,10.74,11.1,VNDA,853252,HISTORICAL_PRICES,VNDA,,1.60683E+12,0.175135135,0.175135135,11.1,10.87,11.13,10.74,853252,11.1,10.87,11.13,10.74,853252,21-Jul-20,-0.23,-0.0207
21-Jul-20,Novo estudo expande evid√™ncias que demonstram os benef√≠cios da triagem para cardiopatia cong√™nita cr√≠tica (CCC) usando a oximetria de pulso Masimo SET¬Æ,"A Masimo (NASDAQ: MASI) anunciou hoje os resultados de um estudo prospectivo publicado no International Journal of Neonatal Screening, no qual pesquisadores de Marraquexe, Marrocos, realizaram o prime...",245.25,248.875,240.6,247.96,MASI,613383,HISTORICAL_PRICES,MASI,,1.60683E+12,0.534634879,0.534634879,247.96,245.25,248.875,240.6,613383,247.96,245.25,248.875,240.6,613383,21-Jul-20,-1.56,-0.0063
21-Jul-20,National Institutes of Health (NIH) Awards Research Grant of $2.59 Million to University of Pittsburgh for Diabetes Gene Therapy Technology Licensed by Genprex,"Genprex, Inc. (‚ÄúGenprex‚Äù or the ‚ÄúCompany‚Äù) (NASDAQ: GNPX), a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes, today announce...",3.41,3.77,3.32,3.4,GNPX,5532788,HISTORICAL_PRICES,GNPX,,1.60683E+12,0.222222222,0.222222222,3.4,3.41,3.77,3.32,5532788,3.4,3.41,3.77,3.32,5532788,21-Jul-20,0.31,0.1
21-Jul-20,Gamida Cell Announces Appointment of Michele Korfin as Chief Operating and Chief Commercial Officer,"Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to finding cures for blood cancers and serious blood diseases, today announced the appointment of Michele Korfin as chief op...",4.53,4.59,4.48,4.55,GMDA,174120,HISTORICAL_PRICES,GMDA,,1.60683E+12,0.372727273,0.372727273,4.55,4.53,4.59,4.48,174120,4.55,4.53,4.59,4.48,174120,21-Jul-20,0,0
21-Jul-20,PerkinElmer Releases New Dried Blood Spot Based COVID-19 Serology Test,"PerkinElmer, Inc. (NYSE:PKI), a global leader committed to innovating for a healthier world, today announced the launch of a dry blood spot (DBS) based test for SARS-CoV-2 IgG using its GSP¬Æ/DELFIA¬Æ p...",111.59,112.96,110,110.47,PKI,1027098,HISTORICAL_PRICES,PKI,,1.6112E+12,0.487866667,0.487866667,110.47,111.59,112.96,110,1027098,110.3555,111.4744,112.843,109.886,1027098,21-Jul-20,1.78,0.0162
21-Jul-20,Ironwood Announces Updates Designed to Strengthen IW-3718 Phase III Program for Refractory Gastroesophageal Reflux Disease (GERD),"Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD), a leading GI-focused healthcare company, today announced that it has reached alignment with the U.S. Food and Drug Administration (FDA) on certain update...",9.86,10.84,9.7801,10.73,IRWD,3424865,HISTORICAL_PRICES,IRWD,,1.60683E+12,-0.033333333,-0.033333333,10.73,9.86,10.84,9.7801,3424865,10.73,9.86,10.84,9.7801,3424865,21-Jul-20,-0.74,-0.0698
21-Jul-20,Êñ∞Á†îÁ©∂ÁöÑÊâ©Â§ßËØÅÊçÆÊòæÁ§∫Masimo SET¬ÆËÑâÊêèÊ∞ßÈ•±ÂíåÂ∫¶‰ª™Á≠õÊü•Âç±ÈáçÂûãÂÖàÂ§©ÊÄßÂøÉËÑèÁóÖ(CCHD)ÁöÑÊî∂Áõä,(ÁæéÂõΩÂïÜ‰∏öËµÑËÆØ)--Masimo (NASDAQ: MASI)‰ªäÂ§©ÂèëÂ∏É„ÄäÂõΩÈôÖÊñ∞ÁîüÂÑøÁ≠õÊü•ÊùÇÂøó„Äã(International Journal of Neonatal Screening)ÂèëË°®ÁöÑ‰∏ÄÈ°πÂâçÁûªÊÄßÁ†îÁ©∂ÁªìÊûúÔºåËØ•Á†îÁ©∂‰∏≠ÔºåÊë©Ê¥õÂì•È©¨ÊãâÂñÄ‰ªÄÁöÑÁ†îÁ©∂‰∫∫ÂëòÂºÄÂ±ïÊë©Ê¥õÂì•È¶ñÊ¨°Masimo SET¬ÆËÑâÊêèÊ∞ßÈ•±ÂíåÂ∫¶‰ª™Á≠õÊü•Êñ∞ÁîüÂÑøÂç±ÈáçÂûãÂÖàÂ§©ÊÄßÂøÉËÑèÁóÖ(CCHD)ÁöÑÁ†îÁ©∂1„ÄÇ‰ΩúËÄÖÁöÑÁªìËÆ∫ÊòØÔºö‚ÄúÊàë‰ª¨ÁöÑÁªìÊûúÈºìÂä±Êàë‰ª¨Âú®Êñ∞ÁîüÂÑøÂ∏∏ËßÑÁ≠õÊü•Â∑•ÂÖ∑‰∏≠Ê∑ª...,245.25,248.875,240.6,247.96,MASI,613383,HISTORICAL_PRICES,MASI,,1.60683E+12,0.534634879,0.534634879,247.96,245.25,248.875,240.6,613383,247.96,245.25,248.875,240.6,613383,21-Jul-20,-1.56,-0.0063
21-Jul-20,Êñ∞Á†îÁ©∂ÁöÑÊì¥Â§ßË≠âÊìöÈ°ØÁ§∫Masimo SET¬ÆËÑàÊêèË°ÄÊ∞ßÈ£ΩÂíåÂ∫¶ÂÑÄÁØ©Ê™¢Âç±ÊÄ•ÂûãÂÖàÂ§©ÊÄßÂøÉËáüÁóÖ(CCHD)ÁöÑÊïàÁõä,(ÁæéÂúãÂïÜÊ•≠Ë≥áË®ä)--Masimo (NASDAQ: MASI)‰ªäÂ§©ÁôºÂ∏É„ÄäÂúãÈöõÊñ∞ÁîüÂÖíÁØ©Ê™¢ÈõúË™å„Äã(International Journal of Neonatal Screening)ÁôºË°®ÁöÑ‰∏ÄÈ†ÖÂâçÁûªÊÄßÁ†îÁ©∂ÁµêÊûúÔºåË©≤Á†îÁ©∂‰∏≠ÔºåÊë©Ê¥õÂì•È¶¨ÊãâÂñÄ‰ªÄÁöÑÁ†îÁ©∂‰∫∫Âì°Â±ïÈñãÊë©Ê¥õÂì•È¶ñÊ¨°Masimo SET¬ÆËÑàÊêèË°ÄÊ∞ßÈ£ΩÂíåÂ∫¶ÂÑÄÁØ©Ê™¢Êñ∞ÁîüÂÖíÂç±ÊÄ•ÂûãÂÖàÂ§©ÊÄßÂøÉËáüÁóÖ(CCHD)ÁöÑÁ†îÁ©∂1„ÄÇ‰ΩúËÄÖÁöÑÁµêË´ñÊòØÔºö„ÄåÊàëÂÄëÁöÑÁµêÊûúÈºìÂãµÊàëÂÄëÂú®Êñ∞ÁîüÂÖíÂ∏∏Ë¶èÁØ©Ê™¢Â∑•ÂÖ∑‰∏≠...,245.25,248.875,240.6,247.96,MASI,613383,HISTORICAL_PRICES,MASI,,1.60683E+12,0.534634879,0.534634879,247.96,245.25,248.875,240.6,613383,247.96,245.25,248.875,240.6,613383,21-Jul-20,-1.56,-0.0063
20-Jul-20,Un nuevo estudio ampl√≠a la evidencia que demuestra los beneficios de la prueba de detecci√≥n de cardiopat√≠as cong√©nitas cr√≠ticas (CCHD) con la oximetr√≠a de pulso Masimo SET¬Æ,"Masimo (NASDAQ: MASI) anunci√≥ hoy los resultados de un estudio prospectivo que se public√≥ en la International Journal of Neonatal Screening (Revista internacional de pruebas de detecci√≥n neonatales),...",246.81,247.42,234.55,234.55,MASI,821978,HISTORICAL_PRICES,MASI,,1.60683E+12,0.544396471,0.544396471,234.55,246.81,247.42,234.55,821978,234.55,246.81,247.42,234.55,821978,20-Jul-20,11.86,0.0505
20-Jul-20,ACADIA Pharmaceuticals Announces U.S. FDA Accepted for Filing the Supplemental New Drug Application for NUPLAZID¬Æ (pimavanserin) for the Treatment of Hallucinations and Delusions Associated with Dementia-Related Psychosis,ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing its supplemental New Drug Application (sNDA) for NUPLAZID¬Æ (pimavans...,55.42,55.965,54.92,55.3,ACAD,956502,HISTORICAL_PRICES,ACAD,,1.60683E+12,0.456121913,0.456121913,55.3,55.42,55.965,54.92,956502,55.3,55.42,55.965,54.92,956502,20-Jul-20,0.45,0.0082
20-Jul-20,ACADIA Pharmaceuticals Announces Top-line Results from the Phase 3 CLARITY Study Evaluating Pimavanserin for the Adjunctive Treatment of Major Depressive Disorder,"ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) today announced top-line results from its 298 patient Phase 3 CLARITY study which combined two identical, double-blind, placebo-controlled studies evaluating...",55.42,55.965,54.92,55.3,ACAD,956502,HISTORICAL_PRICES,ACAD,,1.60683E+12,0.456121913,0.456121913,55.3,55.42,55.965,54.92,956502,55.3,55.42,55.965,54.92,956502,20-Jul-20,0.45,0.0082
20-Jul-20,"Erkenntnisse aus neuer Studie geben weitere Hinweise auf die Vorteile des Screenings schwerer angeborener Herzfehler (Critical Congenital Heart Disease, CCHD) mit Masimo SET¬Æ Pulsoximetrie","Masimo (NASDAQ: MASI) ver√∂ffentlichte heute die Ergebnisse einer prospektiven Studie, die im International Journal of Neonatal Screening erschienen ist, in welcher Forscher in Marrakesch, Marokko, die...",246.81,247.42,234.55,234.55,MASI,821978,HISTORICAL_PRICES,MASI,,1.60683E+12,0.544396471,0.544396471,234.55,246.81,247.42,234.55,821978,234.55,246.81,247.42,234.55,821978,20-Jul-20,11.86,0.0505
20-Jul-20,Positive Phase 3 Study Results for TRIKAFTA¬Æ (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in People Ages 12 and Older With Cystic Fibrosis Who Have One Copy of the F508del Mutation and One Gating or Residual Function Mutation,Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced results of a global Phase 3 study of TRIKAFTA¬Æ (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in people with cystic fibrosis (CF) a...,303.1,304,292.69,292.69,VRTX,1256143,HISTORICAL_PRICES,VRTX,,1.60683E+12,0.442715027,0.442715027,292.69,303.1,304,292.69,1256143,292.69,303.1,304,292.69,1256143,20-Jul-20,8.57,0.0291
20-Jul-20,"Tenax Therapeutics Expands Board of Directors with the Appointment of Two New Directors, Steven Boyd and Keith Maher, MD","Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceutical company focused on identifying, developing and commercializing products that address cardiovascular and pulmonary diseases with high...",1.2,1.24,1.1,1.24,TENX,435237,HISTORICAL_PRICES,TENX,,1.60683E+12,1.227171492,1.227171492,1.24,1.2,1.24,1.1,435237,1.24,1.2,1.24,1.1,435237,20-Jul-20,-0.01,-0.0083
20-Jul-20,"PolarityTE Announces Interim Data from Diabetic Foot Ulcer Trial will be Presented at Symposium on Advanced Wound Care to be Held July 24-26, 2020","PolarityTE, Inc. (Nasdaq: PTE) announced that data from a protocol-specified interim analysis of the first 50 patients enrolled in a multi-center randomized controlled trial (RCT) entitled ‚ÄúSkinTE‚Ñ¢ in...",1.85,2.04,1.5,1.51,PTE,9707624,HISTORICAL_PRICES,PTE,,1.60683E+12,0.594827586,0.594827586,1.51,1.85,2.04,1.5,9707624,1.51,1.85,2.04,1.5,9707624,20-Jul-20,0.4,0.2759
20-Jul-20,Orthofix Receives FDA Clearance and CE Mark for the JuniOrtho Plating System,"Orthofix Medical Inc. (NASDAQ:OFIX), a global medical device company focused on musculoskeletal healing products, today announced it has received the U.S. Food and Drug Administration (FDA) 510(k) cle...",31.17,32.52,31.055,31.73,OFIX,57734,HISTORICAL_PRICES,OFIX,,1.60683E+12,0.171364149,0.171364149,31.73,31.17,32.52,31.055,57734,31.73,31.17,32.52,31.055,57734,20-Jul-20,-0.74,-0.0232
17-Jul-20,Quidel‚Äôs Sofia¬Æ SARS Antigen FIA Updates EUA Performance Data to 96.7% PPA Versus PCR; Product Supports U.S. Initiatives to Expand Access to COVID-19 Testing in Nursing Homes; Receives CE Mark for Use With Sofia¬Æ and Sofia¬Æ 2 Instruments,"Quidel Corporation (NASDAQ: QDEL) (‚ÄúQuidel‚Äù), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that Quidel has updated...",267,268.2099,243.56,244.29,QDEL,1102430,HISTORICAL_PRICES,QDEL,,1.60683E+12,2.308960218,2.308960218,244.29,267,268.2099,243.56,1102430,244.29,267,268.2099,243.56,1102430,17-Jul-20,24.27,0.1
17-Jul-20,Frequency Therapeutics Announces $42 Million Private Placement,"Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage biotechnology company focused on harnessing the body‚Äôs innate biology to repair or reverse damage caused by a broad range of degenerative...",21.53,22.217,20.89,21.38,FREQ,84172,HISTORICAL_PRICES,FREQ,,1.60683E+12,0.098469388,0.098469388,21.38,21.53,22.217,20.89,84172,21.38,21.53,22.217,20.89,84172,17-Jul-20,0.06,0.0028
17-Jul-20,Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4),"Kala Pharmaceuticals, Inc. (NASDAQ:KALA), today announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company‚Äôs 2017 Equity Incentive Plan in...",11.11,11.185,10.91,10.95,KALA,471032,HISTORICAL_PRICES,KALA,,1.60683E+12,0.513623978,0.513623978,10.95,11.11,11.185,10.91,471032,10.95,11.11,11.185,10.91,471032,17-Jul-20,0.14,0.0128
17-Jul-20,ADC Therapeutics gibt Dosierung des ersten Patienten im zulassungsrelevanten Phase-II-Teil der klinischen Studie LOTIS 3 von Loncastuximab-Tesirin (Lonca) in Kombination mit Ibrutinib bekannt,"ADC Therapeutics SA (NYSE: ADCT), ein im Bereich der sp√§ten klinischen Forschung t√§tiges Biotechnologieunternehmen mit Schwerpunkt auf Onkologie, das Vorreiter bei der Entwicklung und Vermarktung von...",49,50.34,46.75,48.01,ADCT,155218,HISTORICAL_PRICES,ADCT,,1.60683E+12,0.652613828,0.652613828,48.01,49,50.34,46.75,155218,48.01,49,50.34,46.75,155218,17-Jul-20,1.51,0.0318
17-Jul-20,ADC Therapeutics annonce qu'un premier dosage a √©t√© d√©termin√© en phase II de l'essai clinique pivot LOTIS 3 du loncastuximab t√©sirine (Lonca) combin√© √† l'ibrutinib,"ADC Therapeutics SA (NYSE:ADCT), une soci√©t√© de biotechnologie sp√©cialis√©e dans l'oncologie au stade clinique avanc√©, pionni√®re du d√©veloppement et de la commercialisation de conjugu√©s anticorps-m√©dic...",49,50.34,46.75,48.01,ADCT,155218,HISTORICAL_PRICES,ADCT,,1.60683E+12,0.652613828,0.652613828,48.01,49,50.34,46.75,155218,48.01,49,50.34,46.75,155218,17-Jul-20,1.51,0.0318
17-Jul-20,"Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Verrica Pharmaceuticals, Inc. ‚Äì VRCA","Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Verrica Pharmaceuticals, Inc. (NASDAQ: VRCA) between Sept...",8.57,8.7,8.1959,8.22,VRCA,97470,HISTORICAL_PRICES,VRCA,,1.60683E+12,-0.243601059,-0.243601059,8.22,8.57,8.7,8.1959,97470,8.22,8.57,8.7,8.1959,97470,17-Jul-20,0.39,0.0477
17-Jul-20,Phibro Animal Health Corporation Reiterates Safety of Mecadox¬Æ,"(NASDAQ:PAHC) Today, the Food and Drug Administration (FDA) provided notice of Federal Register publication of its intention to take a number of actions related to its ongoing review of the regulatory...",25.43,26.3599,25.34,25.34,PAHC,85807,HISTORICAL_PRICES,PAHC,,1.61469E+12,0.42945475,0.42945475,25.34,25.43,26.3599,25.34,85807,24.9045,24.993,25.9069,24.9045,85807,17-Jul-20,-0.46,-0.0178
17-Jul-20,Ocular Therapeutix Presents at the 12th Annual Ophthalmology Innovation Summit (OIS),"Ocular Therapeutix, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, part...",8.845,9,8.52,8.56,OCUL,898507,HISTORICAL_PRICES,OCUL,,1.60683E+12,0.761952191,0.761952191,8.56,8.845,9,8.52,898507,8.56,8.845,9,8.52,898507,17-Jul-20,0.315,0.0369
17-Jul-20,ADC Therapeutics Announces First Patient Dosed in Pivotal Phase 2 Portion of LOTIS 3 Clinical Trial of Loncastuximab Tesirine (Lonca) in Combination With Ibrutinib,"ADC Therapeutics SA (NYSE:ADCT), a late clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of highly potent and targeted antibody drug conjugates (A...",49,50.34,46.75,48.01,ADCT,155218,HISTORICAL_PRICES,ADCT,,1.60683E+12,0.652613828,0.652613828,48.01,49,50.34,46.75,155218,48.01,49,50.34,46.75,155218,17-Jul-20,1.51,0.0318
17-Jul-20,Applied DNA and Takis Report Positive Preclinical Results from LineaDNA‚Ñ¢ Vaccine Candidates for COVID-19,"Applied DNA Sciences Inc. (NASDAQ: APDN) (‚ÄúApplied DNA‚Äù or the ‚ÄúCompany‚Äù) a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing that enables in vitro diagnostics, pre-clinical nucleic ac...",10.73,14.84,10.07,13.05,APDN,22577999,HISTORICAL_PRICES,APDN,,1.60683E+12,1.629901961,1.629901961,13.05,10.73,14.84,10.07,22577999,13.05,10.73,14.84,10.07,22577999,17-Jul-20,1.74,0.1935
16-Jul-20,Puma Biotechnology Licensing Partner Specialised Therapeutics Receives Marketing Approval in Malaysia for NERLYNX¬Æ (neratinib) for Extended Adjuvant Treatment of Early Stage HER2-Positive Breast Cancer,"Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that its licensing partner Specialised Therapeutics Asia (STA) has received marketing approval of NERLYNX¬Æ (neratinib) i...",9.77,10.02,9.6,9.86,PBYI,536535,HISTORICAL_PRICES,PBYI,,1.60683E+12,0.056216216,0.056216216,9.86,9.77,10.02,9.6,536535,9.86,9.77,10.02,9.6,536535,16-Jul-20,-0.1,-0.0101
16-Jul-20,PhaseBio Doses First Patient in VANGARD Phase 2 Clinical Trial to Evaluate PB1046 for Hospitalized COVID-19 Patients,"PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiopulmonary diseases, today announ...",4.7,4.92,4.63,4.78,PHAS,817170,HISTORICAL_PRICES,PHAS,,1.60683E+12,0.631944444,0.631944444,4.78,4.7,4.92,4.63,817170,4.78,4.7,4.92,4.63,817170,16-Jul-20,-0.17,-0.0349
16-Jul-20,"Shareholder Alert: Robbins LLP Reminds Investors Chembio Diagnostics, Inc. (CEMI) Sued for Misleading Shareholders","Shareholder rights law firm Robbins LLP reminds investors that a purchaser of Chembio Diagnostics, Inc. (NASDAQ: CEMI) filed a class action complaint against the Company for alleged violations of the...",5.01,5.27,4.9,4.98,CEMI,4611848,HISTORICAL_PRICES,CEMI,,1.60683E+12,0.024539877,0.024539877,4.98,5.01,5.27,4.9,4611848,4.98,5.01,5.27,4.9,4611848,16-Jul-20,-0.09,-0.0176
16-Jul-20,Shareholder Alert: Robbins LLP Announces Verrica Pharmaceuticals Inc. (VRCA) Accused of Misleading Shareholders,Shareholder rights law firm Robbins LLP announces that a purchaser of Verrica Pharmaceuticals Inc. (NASDAQ: VRCA) filed a class action complaint against the Company for alleged violations of the Secur...,8.18,8.5,7.97,8.39,VRCA,170928,HISTORICAL_PRICES,VRCA,,1.60683E+12,-0.278022948,-0.278022948,8.39,8.18,8.5,7.97,170928,8.39,8.18,8.5,7.97,170928,16-Jul-20,0.26,0.0328
16-Jul-20,"Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Continues Investigation of Kirby Corporation (KEX) on Behalf of Investors","Glancy Prongay & Murray LLP (‚ÄúGPM‚Äù), a leading national shareholder rights law firm, continues its investigation on behalf of Kirby Corporation (‚ÄúKirby‚Äù or the ‚ÄúCompany‚Äù) (NYSE: KEX) investors con...",47.02,48.4,46.56,47.43,KEX,420817,HISTORICAL_PRICES,KEX,,1.60683E+12,0.137947725,0.137947725,47.43,47.02,48.4,46.56,420817,47.43,47.02,48.4,46.56,420817,16-Jul-20,-0.67,-0.014
16-Jul-20,"VRCA Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Verrica Pharmaceuticals Inc. and Encourages Investors to Contact the Firm","Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Verrica Pharmaceuticals Inc. (‚ÄúVerrica‚Äù or ""the Company"") (NASDAQ: VRCA) and certain of its...",8.18,8.5,7.97,8.39,VRCA,170928,HISTORICAL_PRICES,VRCA,,1.60683E+12,-0.278022948,-0.278022948,8.39,8.18,8.5,7.97,170928,8.39,8.18,8.5,7.97,170928,16-Jul-20,0.26,0.0328
16-Jul-20,Samenvatting: FDA keurt gegevensstreaming vanuit de Impella-console goed en zet de toon voor kunstmatige intelligentie-algoritmen om de pati√´ntresultaten verder te verbeteren,"De Amerikaanse Food and Drug Administration (FDA) heeft eenzijdige digitale datastreaming goedgekeurd tijdens pati√´ntenondersteuning door Abiomed‚Äôs (NASDAQ: ABMD) Automated Impella Controller (AIC), d...",273.04,276.795,271.22,273.55,ABMD,176802,HISTORICAL_PRICES,ABMD,,1.60683E+12,0.858805909,0.858805909,273.55,273.04,276.795,271.22,176802,273.55,273.04,276.795,271.22,176802,16-Jul-20,-3.6,-0.013
16-Jul-20,Turning Point Brands Completes Merger With Standard Diversified,"Turning Point Brands, Inc. (‚ÄúTPB‚Äù) (NYSE: TPB), a leading provider of Other Tobacco Products (‚ÄúOTP‚Äù) and adult consumer alternatives, and Standard Diversified Inc. (‚ÄúSDI‚Äù) (NYSE: SDI) announced today...",29.53,30.38,28.82,29.19,TPB,151481,HISTORICAL_PRICES,TPB,,1.61603E+12,0.354587156,0.354587156,29.19,29.53,30.38,28.82,151481,29.0784,29.4171,30.2639,28.7098,151481,16-Jul-20,0.4,0.0137
16-Jul-20,AngioDynamics Reports Fiscal 2020 Fourth Quarter and Full-Year Financial Results,"AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced financial resul...",9.455,10.44,9.01,10.26,ANGO,740239,HISTORICAL_PRICES,ANGO,,1.60683E+12,-0.014077164,-0.014077164,10.26,9.455,10.44,9.01,740239,10.26,9.455,10.44,9.01,740239,16-Jul-20,-1.23,-0.1151
16-Jul-20,"FDA Approves Data Streaming from the Impella Console, Setting the Stage for Artificial Intelligence Algorithms to Further Improve Patient Outcomes","The United States Food and Drug Administration (FDA) has approved one-way digital data streaming during patient support from Abiomed's (NASDAQ: ABMD) Automated Impella Controller (AIC), the external c...",273.04,276.795,271.22,273.55,ABMD,176802,HISTORICAL_PRICES,ABMD,,1.60683E+12,0.858805909,0.858805909,273.55,273.04,276.795,271.22,176802,273.55,273.04,276.795,271.22,176802,16-Jul-20,-3.6,-0.013
16-Jul-20,FDA Grants Priority Review to Merck‚Äôs New Drug Application for Vericiguat,"Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) has accepted for priority review the New Drug Application (NDA) f...",79.4,79.81,78.75,79.78,MRK,5582878,HISTORICAL_PRICES,MRK,,1.61552E+12,0.16388156,0.16388156,79.78,79.4,79.81,78.75,5582878,77.8989,77.5279,77.9282,76.8932,5582878,16-Jul-20,-0.04,-0.0005
15-Jul-20,Tricida Provides Regulatory Update on Veverimer,"Tricida, Inc. (Nasdaq: TCDA), a pharmaceutical company focused on the development and commercialization of its drug candidate, veverimer (TRC101), a non-absorbed, orally-administered polymer designed...",26.2,26.62,25.91,26.19,TCDA,393151,HISTORICAL_PRICES,TCDA,,1.60683E+12,0.152154793,0.152154793,26.19,26.2,26.62,25.91,393151,26.19,26.2,26.62,25.91,393151,15-Jul-20,0.25,0.0096
15-Jul-20,INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Verrica Pharmaceuticals Inc. (VRCA) Investors,"Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased Verrica Pharmaceuticals Inc. (""Verrica"" or the ""Company"") (NASDAQ: VRCA) securi...",7.92,8.99,7.8,8.35,VRCA,292117,HISTORICAL_PRICES,VRCA,,1.60683E+12,-0.300970874,-0.300970874,8.35,7.92,8.99,7.8,292117,8.35,7.92,8.99,7.8,292117,15-Jul-20,-0.55,-0.0649
15-Jul-20,Varex to Showcase New X-Ray Components at ECR 2020 Virtual Exhibition,"Varex Imaging Corporation (Nasdaq: VREX) today announced that it will showcase its latest X-ray tubes and sources, digital detectors, connect and control devices, and software solutions at the 32nd an...",16.39,16.47,15.67,15.77,VREX,784096,HISTORICAL_PRICES,VREX,,1.60683E+12,-0.180090045,-0.180090045,15.77,16.39,16.47,15.67,784096,15.77,16.39,16.47,15.67,784096,15-Jul-20,1.01,0.0657
15-Jul-20,Henry Schein Announces Exclusive Distribution Agreement of Radic8 Air Purifier Systems in the U.S. and Canada,"Henry Schein (Nasdaq: HSIC) today announced that it has entered into an exclusive agreement with Radic8, a UK-based manufacturer of air purifier systems, to distribute their devices in the U.S. and Ca...",63.68,63.86,60.43,60.58,HSIC,1503089,HISTORICAL_PRICES,HSIC,,1.60683E+12,0.272836298,0.272836298,60.58,63.68,63.86,60.43,1503089,60.58,63.68,63.86,60.43,1503089,15-Jul-20,3.99,0.0668
15-Jul-20,Catabasis Pharmaceuticals to Present at Parent Project Muscular Dystrophy Virtual Annual Conference,"Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, announced today that it will present information on the edasalonexent program in Phase 3 development for the...",6.65,6.79,6.42,6.64,CATB,116896,HISTORICAL_PRICES,CATB,,1.60683E+12,0.629901961,0.629901961,6.64,6.65,6.79,6.42,116896,6.64,6.65,6.79,6.42,116896,15-Jul-20,0.12,0.0184
15-Jul-20,Ocular Therapeutix Announces Its First Published Physician Fee Schedule for Administration of Intracanalicular Inserts,"Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today...",8.37,8.52,7.8,7.8,OCUL,1219505,HISTORICAL_PRICES,OCUL,,1.60683E+12,0.667330677,0.667330677,7.8,8.37,8.52,7.8,1219505,7.8,8.37,8.52,7.8,1219505,15-Jul-20,0.82,0.1086
15-Jul-20,Applied DNA Appoints New Head of Investor Relations and Corporate Communications,"Applied DNA Sciences Inc. (NASDAQ: APDN) (‚ÄúApplied DNA‚Äù or the ‚ÄúCompany‚Äù) a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing that enables in vitro diagnostics, and pre-clinical nuclei...",8.03,8.0999,7.61,7.88,APDN,404865,HISTORICAL_PRICES,APDN,,1.60683E+12,0.968137255,0.968137255,7.88,8.03,8.0999,7.61,404865,7.88,8.03,8.0999,7.61,404865,15-Jul-20,0.22,0.0282
15-Jul-20,"UnitedHealth Group Continues Efforts to Combat COVID-19, Reports Second Quarter Performance","During the second quarter of 2020, UnitedHealth Group (NYSE: UNH) expanded its COVID-19 response efforts, proactively supporting patients, customers, care providers and communities, including investin...",304.07,310.69,298.66,301.12,UNH,5116869,HISTORICAL_PRICES,UNH,,1.61552E+12,0.296729072,0.296729072,301.12,304.07,310.69,298.66,5116869,297.7514,300.6684,307.2143,295.3189,5116869,15-Jul-20,-4.45,-0.0144
14-Jul-20,Moderna Announces Publication in The New England Journal of Medicine of Interim Results From Phase 1 Study of Its mRNA Vaccine Against COVID-19 (mRNA-1273),"Moderna, Inc., (Nasdaq:MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today...",75.04,76.9486,70.6201,74,MRNA,38708760,HISTORICAL_PRICES,MRNA,,1.60683E+12,1.765941762,1.765941762,74,75.04,76.9486,70.6201,38708760,74,75.04,76.9486,70.6201,38708760,14-Jul-20,3.26,0.0454
14-Jul-20,"Masimo to Report Second Quarter 2020 Financial Results after Market Close on Tuesday, July 28","Masimo (NASDAQ: MASI) will release second quarter 2020 financial results for the period ended June 27, 2020, after the market closes on Tuesday, July 28, 2020. The conference call to review the result...",224.35,224.58,215.24,220.04,MASI,368422,HISTORICAL_PRICES,MASI,,1.60683E+12,0.403854577,0.403854577,220.04,224.35,224.58,215.24,368422,220.04,224.35,224.58,215.24,368422,14-Jul-20,3.82,0.0173
14-Jul-20,Masimo Announces UniView: 60‚Ñ¢ Digital Charting Solution,"Masimo (NASDAQ: MASI) today announced its latest automation and connectivity solution, UniView: 60‚Ñ¢. UniView: 60 uses the Masimo Hospital Automation‚Ñ¢ platform to aggregate and display pertinent patien...",224.35,224.58,215.24,220.04,MASI,368422,HISTORICAL_PRICES,MASI,,1.60683E+12,0.403854577,0.403854577,220.04,224.35,224.58,215.24,368422,220.04,224.35,224.58,215.24,368422,14-Jul-20,3.82,0.0173
14-Jul-20,Nemaura Medical Evaluates New Applications for Continuous Lactate Monitoring Using its BEAT‚Ñ¢ Platform,"Nemaura Medical, Inc. (NASDAQ: NMRD) (‚ÄúNemaura‚Äù or the ‚ÄúCompany‚Äù), a medical technology company focused on developing micro-systems-based wearable diagnostic devices and currently commercializing suga...",7.97,8.01,7.69,7.98,NMRD,19264,HISTORICAL_PRICES,NMRD,,1.60683E+12,0.341750842,0.341750842,7.98,7.97,8.01,7.69,19264,7.98,7.97,8.01,7.69,19264,14-Jul-20,-0.02,-0.0025
14-Jul-20,Deciphera Announces Australian Therapeutic Goods Administration‚Äôs Approval of QINLOCK‚Ñ¢ (ripretinib) for the Treatment of Fourth-Line Gastrointestinal Stromal Tumor,"Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) today announced that the Australian Therapeutic Goods Administration (TGA) has approved QINLOCK‚Ñ¢ (ripretinib), a switch-control tyrosine kinase inhibitor,...",52.46,52.77,50.37,52.39,DCPH,363124,HISTORICAL_PRICES,DCPH,,1.60683E+12,0.268988873,0.268988873,52.39,52.46,52.77,50.37,363124,52.39,52.46,52.77,50.37,363124,14-Jul-20,0.23,0.0044
13-Jul-20,Invacare Corporation Announces Preliminary Financial Results for 2Q20 and Provides Business Update,"Invacare Corporation (‚ÄúInvacare‚Äù)(NYSE:IVC) will participate on Tuesday, July 14, 2020 in the 20th Annual CJS Securities New Ideas Summer Conference where the company's management will provide a busin...",6.33,6.62,6.1,6.25,IVC,519627,HISTORICAL_PRICES,IVC,,1.60683E+12,0.104712042,0.104712042,6.25,6.33,6.62,6.1,519627,6.25,6.33,6.62,6.1,519627,13-Jul-20,0.17,0.0276
13-Jul-20,Alnylam Announces that the United Kingdom‚Äôs MHRA Grants Early Access to Lumasiran,"Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that the UK‚Äôs Medicines and Healthcare Products Regulatory Agency (MHRA) has granted lumasiran, an...",152.74,162.89,152.01,162.66,ALNY,667921,HISTORICAL_PRICES,ALNY,,1.60683E+12,0.546264426,0.546264426,162.66,152.74,162.89,152.01,667921,162.66,152.74,162.89,152.01,667921,13-Jul-20,-9.51,-0.0586
13-Jul-20,Premier Inc. ProvideGx‚Ñ¢ Program Partners with Fresenius Kabi to Secure the Supply of Sedation Drug Essential for COVID-19 Care,"Premier Inc. (NASDAQ: PINC), through its ProvideGx‚Ñ¢ program, has partnered with Fresenius Kabi to supply Diprivan¬Æ (propofol) injectable emulsion, USP to healthcare providers, helping to stabilize the...",31.2,31.905,31.17,31.87,PINC,363181,HISTORICAL_PRICES,PINC,,1.61439E+12,0.104815864,0.104815864,31.87,31.2,31.905,31.17,363181,31.3328,30.6741,31.3672,30.6446,363181,13-Jul-20,-0.48,-0.0152
13-Jul-20,Pfizer and BioNTech Granted FDA Fast Track Designation for Two Investigational mRNA-based Vaccine Candidates Against SARS-CoV-2,"Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX, ‚ÄúBioNTech‚Äù) today announced that two of the companies‚Äô four investigational vaccine candidates from their BNT162 mRNA-based vaccine program (BNT1...",35.21,35.72,34.52,34.73,PFE,53670893,HISTORICAL_PRICES,PFE,,1.6118E+12,0.183529412,0.183529412,34.73,35.21,35.72,34.52,53670893,33.6774,34.1428,34.6374,33.4737,53670893,13-Jul-20,1.38,0.0408
13-Jul-20,Axonics¬Æ Reports Preliminary Second Quarter 2020 Revenue,"Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing novel implantable sacral neuromodulation (SNM) devices for the treatment of...",37.71,41.845,37.43,40.9,AXNX,1267809,HISTORICAL_PRICES,AXNX,,1.60683E+12,0.69027342,0.69027342,40.9,37.71,41.845,37.43,1267809,40.9,37.71,41.845,37.43,1267809,13-Jul-20,-1.63,-0.0414
10-Jul-20,Gilead Presents Additional Data on Investigational Antiviral Remdesivir for the Treatment of COVID-19,"Gilead Sciences, Inc. (Nasdaq: GILD) today announced additional data on remdesivir, an investigational antiviral for the treatment of COVID-19, adding to the available body of knowledge on treatment o...",76.32,76.85,75.52,76.1,GILD,9553834,HISTORICAL_PRICES,GILD,,1.61552E+12,0.095607235,0.095607235,76.1,76.32,76.85,75.52,9553834,73.63,73.8429,74.3557,73.0688,9553834,10-Jul-20,1.61,0.0215
10-Jul-20,Amneal Launches Generic Fluphenazine Following ANDA Approval by FDA,"Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (‚ÄúAmneal‚Äù or the ‚ÄúCompany‚Äù) today announced that it has received Abbreviated New Drug Application (ANDA) approval from the U.S. Food and Drug Administration (...",4.65,4.72,4.3,4.31,AMRX,1536202,HISTORICAL_PRICES,AMRX,,1.60683E+12,0.332378223,0.332378223,4.31,4.65,4.72,4.3,1536202,4.31,4.65,4.72,4.3,1536202,10-Jul-20,0.29,0.0665
9-Jul-20,Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4),"Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on July 8, 2020 the Compensation Committee of Puma‚Äôs Board of Directors approved the grant of inducement restricted...",10.24,10.41,9.97,10.2,PBYI,1212123,HISTORICAL_PRICES,PBYI,,1.60683E+12,0.107027027,0.107027027,10.2,10.24,10.41,9.97,1212123,10.2,10.24,10.41,9.97,1212123,9-Jul-20,0.01,0.001
9-Jul-20,Shareholder Alert: Robbins LLP Reminds Investors Co-Diagnostics Inc. (CODX) Sued for Misleading Shareholders,Shareholder rights law firm Robbins LLP reminds investors that a purchaser of Co-Diagnostics Inc. (NASDAQ: CODX) filed a class action complaint against the Company for alleged violations of the Securi...,18.01,19,17.56,18.82,CODX,2182945,HISTORICAL_PRICES,CODX,,1.60683E+12,1.010044643,1.010044643,18.82,18.01,19,17.56,2182945,18.82,18.01,19,17.56,2182945,9-Jul-20,-0.96,-0.0506
9-Jul-20,Shareholder Alert: Robbins LLP Is Investigating the Officers and Directors of Acer Therapeutics Inc. (ACER),"Shareholder rights law firm Robbins LLP announces that it is investigating the officers and directors of Acer Therapeutics Inc. (NYSE: ACER) for breaches of fiduciary duty, waste of corporate assets,...",3.63,3.78,3.33,3.75,ACER,871029,HISTORICAL_PRICES,ACER,,1.60683E+12,0.842639594,0.842639594,3.75,3.63,3.78,3.33,871029,3.75,3.63,3.78,3.33,871029,9-Jul-20,0.41,0.1273
9-Jul-20,CMS Establishes Unique J-Code for Eagle Pharmaceuticals‚Äô PEMFEXY‚Ñ¢ (Pemetrexed for Injection),"Eagle Pharmaceuticals, Inc. (‚ÄúEagle‚Äù or the ‚ÄúCompany‚Äù) (NASDAQ: EGRX) today announced that the Centers for Medicare & Medicaid Services (CMS) has established a unique, product-specific billing cod...",47.22,47.85,45.04,46.37,EGRX,153446,HISTORICAL_PRICES,EGRX,,1.60683E+12,0.138929088,0.138929088,46.37,47.22,47.85,45.04,153446,46.37,47.22,47.85,45.04,153446,9-Jul-20,0.87,0.0188
9-Jul-20,The Law Offices of Frank R. Cruz Continues Its Investigation of Verrica Pharmaceuticals Inc. (VRCA) on Behalf of Investors,"The Law Offices of Frank R. Cruz continues its investigation on behalf of Verrica Pharmaceuticals Inc. (""Verrica"" or the ""Company"") (NASDAQ: VRCA) investors concerning the Company and its officers‚Äô po...",8.76,9.0666,8.2924,8.9,VRCA,154351,HISTORICAL_PRICES,VRCA,,1.60683E+12,-0.226831421,-0.226831421,8.9,8.76,9.0666,8.2924,154351,8.9,8.76,9.0666,8.2924,154351,9-Jul-20,-0.04,-0.0045
9-Jul-20,Baxter Announces U.S. FDA Clearance of Altapore Shape Bioactive Bone Graft for Use in Surgery,"Baxter International Inc. (NYSE:BAX), a global leader in advancing surgical innovation, today announced U.S. Food and Drug Administration (FDA) clearance of Altapore Shape Bioactive Bone Graft, the la...",85.69,86.01,84.2,84.2,BAX,2445834,HISTORICAL_PRICES,BAX,,1.61422E+12,0.164741063,0.164741063,84.2,85.69,86.01,84.2,2445834,83.4303,84.9067,85.2237,83.4303,2445834,9-Jul-20,1.51,0.0179
9-Jul-20,"Centers for Medicare & Medicaid Services (CMS) Issues Permanent J-Code for TEPEZZA¬Æ (teprotumumab-trbw) Effective Oct. 1, 2020","Horizon Therapeutics plc (Nasdaq: HZNP) today announced that the U.S. Centers for Medicare and Medicaid Services (CMS) has assigned a permanent, product-specific Healthcare Common Procedure Coding Sys...",58,59.21,56.89,59.02,HZNP,1905287,HISTORICAL_PRICES,HZNP,,1.60683E+12,1.052370842,1.052370842,59.02,58,59.21,56.89,1905287,59.02,58,59.21,56.89,1905287,9-Jul-20,-0.76,-0.0129
9-Jul-20,"Enanta Pharmaceuticals Announces Clinical Trial Progress for EDP-514, its Lead Core Inhibitor for Hepatitis B Virus","Enanta Pharmaceuticals, Inc., (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced advancements in...",51.1,51.99,49.99,49.99,ENTA,156408,HISTORICAL_PRICES,ENTA,,1.60683E+12,0.095861034,0.095861034,49.99,51.1,51.99,49.99,156408,49.99,51.1,51.99,49.99,156408,9-Jul-20,0.78,0.0155
9-Jul-20,FDA Grants Priority Review to Merck‚Äôs Supplemental Biologics License Application for KEYTRUDA¬Æ (pembrolizumab) for Second-Line Treatment of Patients With Relapsed or Refractory Classical Hodgkin Lymphoma,"Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted priority review for a new supplemental B...",76.69,78.35,76.04,77.94,MRK,7601213,HISTORICAL_PRICES,MRK,,1.61552E+12,0.124157139,0.124157139,77.94,76.69,78.35,76.04,7601213,76.1023,74.8818,76.5027,74.2471,7601213,9-Jul-20,-1.23,-0.0158
9-Jul-20,Applied DNA Forms Clinical Testing Subsidiary to Maximize Utility of FDA EUA-Approved Linea‚Ñ¢ COVID-19 Assay Kit and Expands Utility with Successful EUA Amendment,"Applied DNA Sciences Inc. (NASDAQ: APDN) (‚ÄúApplied DNA‚Äù or the ‚ÄúCompany‚Äù) a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing that enables in vitro diagnostics, and pre-clinical nuclei...",8.135,8.71,7.82,8.6,APDN,1318856,HISTORICAL_PRICES,APDN,,1.60683E+12,0.993872549,0.993872549,8.6,8.135,8.71,7.82,1318856,8.6,8.135,8.71,7.82,1318856,9-Jul-20,0.115,0.0143
8-Jul-20,Turning Point Brands Announces Pricing of Secondary Offering of Two Million Shares of Common Stock by its Significant Stockholders,"Turning Point Brands, Inc. (‚ÄúTPB‚Äù or the ‚ÄúCompany‚Äù) (NYSE: TPB) today announced the pricing of the previously announced underwritten public offering of 1,800,000 shares of Company common stock by Stan...",26.46,26.58,24.85,24.99,TPB,228686,HISTORICAL_PRICES,TPB,,1.61603E+12,0.213761468,0.213761468,24.99,26.46,26.58,24.85,228686,24.8945,26.3589,26.4784,24.755,228686,8-Jul-20,2.04,0.0835
8-Jul-20, Turning Point Brands Announces Preliminary Second Quarter 2020 Results,"Turning Point Brands, Inc. (‚ÄúTPB‚Äù or the ‚ÄúCompany‚Äù) (NYSE: TPB), a leading provider of Other Tobacco Products (‚ÄúOTP‚Äù) and adult consumer alternatives, today announced preliminary sales results for the...",26.46,26.58,24.85,24.99,TPB,228686,HISTORICAL_PRICES,TPB,,1.61603E+12,0.213761468,0.213761468,24.99,26.46,26.58,24.85,228686,24.8945,26.3589,26.4784,24.755,228686,8-Jul-20,2.04,0.0835
8-Jul-20,Turning Point Brands Announces Proposed Secondary Offering of Two Million Shares of Common Stock by its Significant Stockholders,"Turning Point Brands, Inc. (‚ÄúTPB‚Äù or the ‚ÄúCompany‚Äù) (NYSE: TPB), a leading provider of Other Tobacco Products and adult consumer alternatives, today announced the proposed underwritten public offering...",26.46,26.58,24.85,24.99,TPB,228686,HISTORICAL_PRICES,TPB,,1.61603E+12,0.213761468,0.213761468,24.99,26.46,26.58,24.85,228686,24.8945,26.3589,26.4784,24.755,228686,8-Jul-20,2.04,0.0835
8-Jul-20,Moderna Completes Enrollment of Phase 2 Study of its mRNA Vaccine Against COVID-19 (mRNA-1273),"Moderna, Inc., (Nasdaq: MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, toda...",61.58,62.46,59.45,60.79,MRNA,7590861,HISTORICAL_PRICES,MRNA,,1.60683E+12,1.269812016,1.269812016,60.79,61.58,62.46,59.45,7590861,60.79,61.58,62.46,59.45,7590861,8-Jul-20,0.49,0.008
8-Jul-20,Novocure Announces Over 100 Physicians in the U.S. Now Certified to Prescribe Optune Lua‚Ñ¢,"Novocure (NASDAQ: NVCR) today announced that over 100 physicians from more than 50 cancer treatment centers in the U.S. are now certified to prescribe Optune Lua, which is approved for the first-line...",60.97,61.1,59.37,59.37,NVCR,856364,HISTORICAL_PRICES,NVCR,,1.60683E+12,-0.021819349,-0.021819349,59.37,60.97,61.1,59.37,856364,59.37,60.97,61.1,59.37,856364,8-Jul-20,1.39,0.0233
8-Jul-20,Concert Pharmaceuticals Receives FDA Breakthrough Therapy Designation for CTP-543 for the Treatment of Alopecia Areata,"Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation for the Company‚Äôs oral Janus kinase inhibitor, CT...",10.56,11.63,10.19,11.25,CNCE,420699,HISTORICAL_PRICES,CNCE,,1.60683E+12,0.204104903,0.204104903,11.25,10.56,11.63,10.19,420699,11.25,10.56,11.63,10.19,420699,8-Jul-20,0.57,0.0571
8-Jul-20,LYNPARZA¬Æ (olaparib) Approved in the EU for Germline BRCA-mutated Metastatic Pancreatic Cancer,"AstraZeneca and Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that LYNPARZA has been approved in the European Union (EU) as a monotherapy for the maintenance tr...",77.92,78.9642,77.48,78.63,MRK,7831109,HISTORICAL_PRICES,MRK,,1.61552E+12,0.142187042,0.142187042,78.63,77.92,78.9642,77.48,7831109,76.776,76.0828,77.1024,75.6532,7831109,8-Jul-20,-0.8,-0.0102
8-Jul-20,Merck and Eisai Receive Complete Response Letter for KEYTRUDA¬Æ (pembrolizumab) plus LENVIMA¬Æ (lenvatinib) Combination as First-Line Treatment for Unresectable Hepatocellular Carcinoma,"Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Eisai today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) regarding M...",77.92,78.9642,77.48,78.63,MRK,7831109,HISTORICAL_PRICES,MRK,,1.61552E+12,0.142187042,0.142187042,78.63,77.92,78.9642,77.48,7831109,76.776,76.0828,77.1024,75.6532,7831109,8-Jul-20,-0.8,-0.0102
8-Jul-20,Gilead Sciences Presents Survey Findings on PrEP Access and Utilization in the U.S. During COVID-19 Shelter-in-Place Orders,"Gilead Sciences, Inc. (Nasdaq: GILD) today announced data presented at the 23rd International AIDS Conference (AIDS 2020: Virtual) evaluating the impact of COVID-19 shelter-in-place orders (SIPOs) and...",75.61,77,74.93,76.7,GILD,6293450,HISTORICAL_PRICES,GILD,,1.61552E+12,0.085414872,0.085414872,76.7,75.61,77,74.93,6293450,74.2105,73.1559,74.5008,72.498,6293450,8-Jul-20,-0.81,-0.0106
7-Jul-20,INVESTOR ALERT: Law Offices of Howard G. Smith Continues Investigation of Verrica Pharmaceuticals Inc. (VRCA) on Behalf of Investors,"Law Offices of Howard G. Smith continues its investigation on behalf of Verrica Pharmaceuticals Inc. (""Verrica"" or the ""Company"") (NASDAQ: VRCA) investors concerning the Company and its officers‚Äô poss...",9.66,10.397,9.01,10.1,VRCA,179027,HISTORICAL_PRICES,VRCA,,1.60683E+12,-0.147396293,-0.147396293,10.1,9.66,10.397,9.01,179027,10.1,9.66,10.397,9.01,179027,7-Jul-20,-0.34,-0.034
7-Jul-20,FDA Authorizes Marketing of the IQOS Tobacco Heating System as a Modified Risk Tobacco Product,"Altria Group, Inc. (Altria) (NYSE: MO) announces today that the U.S. Food and Drug Administration (FDA) authorized the marketing of the IQOS tobacco heating system as a modified risk tobacco product w...",39.94,40.24,39.12,39.19,MO,8659898,HISTORICAL_PRICES,MO,,1.61655E+12,0.162059936,0.162059936,39.19,39.94,40.24,39.12,8659898,37.0052,37.7134,37.9966,36.9391,8659898,7-Jul-20,0.34,0.0086
7-Jul-20,Á†îÁ©∂Ë™øÊü•ËÑàÊêèË°ÄÊ∞ßÈ£ΩÂíåÂ∫¶ÂÑÄ‰ΩøÁî®Masimo RRp¬ÆËÆÄÂèñÂÖíÁßëÊÇ£ËÄÖÂëºÂê∏ÁéáÁöÑÁ≤æÂ∫¶,(ÁæéÂúãÂïÜÊ•≠Ë≥áË®ä)--Masimo (NASDAQ: MASI)‰ªäÂ§©ÁôºÂ∏É„ÄäËÇ∫ÁÇé„Äã(Pneumonia)ÈõúË™åÁôºË°®ÁöÑ‰∏ÄÈ†ÖÁ†îÁ©∂ÁµêÊûúÔºåË©≤Á†îÁ©∂‰∏≠ÔºåÂç∞Â∫¶Êñ∞Âæ∑ÈáåÁöÑÁç®Á´ãÁ†îÁ©∂‰∫∫Âì°Ë™øÊü•Rad-G‚Ñ¢ËÑàÊêèË°ÄÊ∞ßÈ£ΩÂíåÂ∫¶ÂÑÄÊê≠ÈÖçMasimo RRp¬ÆÂú®ÂÖíÁßëÊÇ£ËÄÖ‰∏≠ÁöÑÁ≤æÂ∫¶Ôºå‰∏¶ÂèäÈñòÊÄ•Ë®∫Êî∂‰ΩèÊÇ£ÂÖíÂ±ïÈñãÂ∏∏Ë¶èË©ï‰º∞ÊôÇËá®Â∫äÂ∑•‰ΩúËÄÖÁ¢∫ÂÆöÁöÑÊï∏ÂÄºÈÄ≤Ë°åÊØîËºÉ1„ÄÇRRpÊèê‰æõÁöÑÂëºÂê∏ÁéáÁî±ËÑàÊêèË°ÄÊ∞ßÈ£ΩÂíåÂ∫¶ÂÑÄ‰∏≠‰ΩøÁî®ÁöÑÈ´îÁ©çÊèèË®òÊ≥ïÁ¢∫ÂÆö„ÄÇ AlwadhiÂçöÂ£´ÂèäÂÖ∂Âêå‰∫ãÊåáÂá∫Ôºå‰∏ñÁïåË®±...,233.89,241.14,233.69,234.34,MASI,586023,HISTORICAL_PRICES,MASI,,1.60683E+12,0.463550466,0.463550466,234.34,233.89,241.14,233.69,586023,234.34,233.89,241.14,233.69,586023,7-Jul-20,-0.71,-0.003
7-Jul-20,Á†îÁ©∂Ë∞ÉÊü•ËÑâÊêèË°ÄÊ∞ßÈ•±ÂíåÂ∫¶‰ª™‰ΩøÁî®Masimo RRp¬ÆËØªÂèñÂÑøÁßëÊÇ£ËÄÖÂëºÂê∏ÁéáÁöÑÁ≤æÂ∫¶,(ÁæéÂõΩÂïÜ‰∏öËµÑËÆØ)--Masimo (NASDAQ: MASI)‰ªäÂ§©ÂèëÂ∏É„ÄäËÇ∫ÁÇé„Äã(Pneumonia)ÊùÇÂøóÂèëË°®ÁöÑ‰∏ÄÈ°πÁ†îÁ©∂ÁªìÊûúÔºåËØ•Á†îÁ©∂‰∏≠ÔºåÂç∞Â∫¶Êñ∞Âæ∑ÈáåÁöÑÁã¨Á´ãÁ†îÁ©∂‰∫∫ÂëòË∞ÉÊü•Rad-G‚Ñ¢ËÑâÊêèË°ÄÊ∞ßÈ•±ÂíåÂ∫¶‰ª™Êê≠ÈÖçMasimo RRp¬ÆÂú®ÂÑøÁßëÊÇ£ËÄÖ‰∏≠ÁöÑÁ≤æÂ∫¶ÔºåÂπ∂‰∏éÈó®ÊÄ•ËØäÊî∂‰ΩèÊÇ£ÂÑøÂºÄÂ±ïÂ∏∏ËßÑËØÑ‰º∞Êó∂‰∏¥Â∫äÂ∑•‰ΩúËÄÖÁ°ÆÂÆöÁöÑÊï∞ÂÄºËøõË°åÊØîËæÉ1„ÄÇRRpÊèê‰æõÁöÑÂëºÂê∏ÁéáÁî±ËÑâÊêèË°ÄÊ∞ßÈ•±ÂíåÂ∫¶‰ª™‰∏≠‰ΩøÁî®ÁöÑ‰ΩìÁßØÊèèËÆ∞Ê≥ïÁ°ÆÂÆö„ÄÇ AlwadhiÂçöÂ£´ÂèäÂÖ∂Âêå‰∫ãÊåáÂá∫Ôºå‰∏ñÁïåËÆ∏...,233.89,241.14,233.69,234.34,MASI,586023,HISTORICAL_PRICES,MASI,,1.60683E+12,0.463550466,0.463550466,234.34,233.89,241.14,233.69,586023,234.34,233.89,241.14,233.69,586023,7-Jul-20,-0.71,-0.003
7-Jul-20,"Gap Inc. Launches B2B Sales for Organizations to Purchase Reusable, Non-Medical Grade Cloth Face Masks","Gap Inc. (NYSE: GPS) today announced it has launched a B2B product program focused on offering large organizations high-quality reusable, non-medical grade cloth face masks* to supply to their employe...",11.97,12.34,11.82,12.29,GPS,16663616,HISTORICAL_PRICES,GPS,,1.60683E+12,0.332962138,0.332962138,12.29,11.97,12.34,11.82,16663616,12.29,11.97,12.34,11.82,16663616,7-Jul-20,-0.54,-0.0432
7-Jul-20,Cerus Corporation Reports Successful Inactivation of SARS-CoV-2 with the INTERCEPT Blood System for Plasma,"Cerus Corporation (Nasdaq:CERS) announced today study results demonstrating that the INTERCEPT Blood System inactivates SARS-CoV-2, the causative agent for COVID-19, in plasma components intended for...",7.12,7.49,6.94,7.21,CERS,4458317,HISTORICAL_PRICES,CERS,,1.60683E+12,0.762376238,0.762376238,7.21,7.12,7.49,6.94,4458317,7.21,7.12,7.49,6.94,4458317,7-Jul-20,0.26,0.0379
7-Jul-20,AtriCure to Announce Second Quarter 2020 Financial Results,"AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it will release its second quarter 2020...",43.25,47.385,43.075,45.73,ATRC,358009,HISTORICAL_PRICES,ATRC,,1.60683E+12,0.469089674,0.469089674,45.73,43.25,47.385,43.075,358009,45.73,43.25,47.385,43.075,358009,7-Jul-20,-2.95,-0.0639
7-Jul-20,Aldeyra Therapeutics Announces New Drug Application (NDA) Development Plans for Dry Eye Disease,"Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immun...",4.33,4.6,4.21,4.6,ALDX,1877848,HISTORICAL_PRICES,ALDX,,1.60683E+12,1.186868687,1.186868687,4.6,4.33,4.6,4.21,1877848,4.6,4.33,4.6,4.21,1877848,7-Jul-20,0.33,0.0825
7-Jul-20,LabCorp Launches First Digital COVID-19 Service That Improves the Doctor and Patient Experience,"LabCorp (NYSE: LH) today launched the LabCorp At Home COVID-19 Test Collection Service, the first seamless digital service aimed at helping doctors protect patients by testing them for COVID-19 before...",173.12,174.51,171.745,171.87,LH,991966,HISTORICAL_PRICES,LH,,1.60683E+12,0.40954242,0.40954242,171.87,173.12,174.51,171.745,991966,171.87,173.12,174.51,171.745,991966,7-Jul-20,0.53,0.0031
7-Jul-20,"Whole Earth Brands, Inc. Launches New Whole Earth¬Æ Allulose Baking Blends and Provides Update on Brand Growth","Whole Earth Brands, Inc. (Nasdaq: FREE), Just in time for the fall baking season, Whole Earth Brands, Inc. is launching new Whole Earth¬Æ Allulose Baking Blends. The launch is the latest for Whole Eart...",7.06,7.63,7.06,7.47,FREE,1370097,HISTORICAL_PRICES,FREE,,1.60683E+12,-0.286147624,-0.286147624,7.47,7.06,7.63,7.06,1370097,7.47,7.06,7.63,7.06,1370097,7-Jul-20,-0.36,-0.0485
7-Jul-20,Nemaura Medical Submits PMA Application for sugarBEAT¬Æ to U.S. FDA,"Nemaura Medical, Inc. (NASDAQ: NMRD) (‚ÄúNemaura‚Äù or the ‚ÄúCompany‚Äù), a medical technology company focused on developing micro-systems-based wearable diagnostic devices and currently commercializing suga...",7.82,9.24,7.8,8.4,NMRD,36882,HISTORICAL_PRICES,NMRD,,1.60683E+12,0.316498316,0.316498316,8.4,7.82,9.24,7.8,36882,8.4,7.82,9.24,7.8,36882,7-Jul-20,-0.3,-0.0369
7-Jul-20,Estudo investiga a precis√£o da frequ√™ncia respirat√≥ria obtida pela oximetria de pulso em pacientes pedi√°tricos que usam RRp¬Æ da Masimo,"Masimo (NASDAQ: MASI) anunciou hoje os resultados de um estudo publicado na Pneumonia no qual pesquisadores independentes em Nova Delhi, √çndia, investigaram a precis√£o do RRp¬Æ da Masimo em pacientes p...",233.89,241.14,233.69,234.34,MASI,586023,HISTORICAL_PRICES,MASI,,1.60683E+12,0.463550466,0.463550466,234.34,233.89,241.14,233.69,586023,234.34,233.89,241.14,233.69,586023,7-Jul-20,-0.71,-0.003
7-Jul-20,Studie zur Genauigkeit der durch Pulsoximetrie mit Hilfe von RRp¬Æ gemessenen Atemfrequenz an p√§diatrischen Patienten,"Masimo (NASDAQ: MASI) gab heute die Ergebnisse einer in Pneumonia ver√∂ffentlichten Studie bekannte, bei der unabh√§ngige Forscher in Neu-Delhi, Indien, die Genauigkeit von Masimo RRp¬Æ an p√§diatrischen...",233.89,241.14,233.69,234.34,MASI,586023,HISTORICAL_PRICES,MASI,,1.60683E+12,0.463550466,0.463550466,234.34,233.89,241.14,233.69,586023,234.34,233.89,241.14,233.69,586023,7-Jul-20,-0.71,-0.003
6-Jul-20,Un estudio investiga la precisi√≥n de la frecuencia respiratoria obtenida de la oximetr√≠a de pulso en pacientes pedi√°tricos que usan Masimo RRp¬Æ,"Masimo (NASDAQ: MASI) anunci√≥ hoy los resultados de un estudio publicado en Pneumonia, donde investigadores independientes de Nueva Delhi, India, investigaron la precisi√≥n de Masimo RRp¬Æ en pacientes...",234.6,238.02,233,233.69,MASI,505293,HISTORICAL_PRICES,MASI,,1.60683E+12,0.467993242,0.467993242,233.69,234.6,238.02,233,505293,233.69,234.6,238.02,233,505293,6-Jul-20,2.88,0.0124
6-Jul-20,Shareholder Alert: Robbins LLP Announces It Is Investigating the Officers and Directors of Verrica Pharmaceuticals Inc. (VRCA) on Behalf of Shareholders,Shareholder rights law firm Robbins LLP announces it is investigating whether certain officers and directors of Verrica Pharmaceuticals Inc. (NYSE: VRCA) violated federal securities laws. Verrica is a...,10,10.6599,10,10.6,VRCA,72134,HISTORICAL_PRICES,VRCA,,1.60683E+12,-0.117387467,-0.117387467,10.6,10,10.6599,10,72134,10.6,10,10.6599,10,72134,6-Jul-20,-0.3,-0.0291
6-Jul-20,Quidel Announces Preliminary Revenue for Second Quarter 2020,"Quidel Corporation (NASDAQ: QDEL) (‚ÄúQuidel‚Äù), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that it expects revenue...",235.57,236.7599,226.8,227.5,QDEL,1145150,HISTORICAL_PRICES,QDEL,,1.60683E+12,1.919444789,1.919444789,227.5,235.57,236.7599,226.8,1145150,227.5,235.57,236.7599,226.8,1145150,6-Jul-20,8.53,0.0376
6-Jul-20,ADC Therapeutics annonce que l'Agence am√©ricaine des produits alimentaires et m√©dicamenteux a lev√© la suspension clinique partielle dont faisait l‚Äôobjet l‚Äô√©tude clinique pivot de Phase 2 sur le camidanlumab t√©sirine,"ADC Therapeutics SA (NYSE:ADCT), une soci√©t√© de biotechnologie sp√©cialis√©e dans l‚Äôoncologie au stade clinique avanc√©, pionni√®re du d√©veloppement et de la mise sur le march√© de conjugu√©s anticorps-m√©di...",48.93,53.61,48.17,52.22,ADCT,113984,HISTORICAL_PRICES,ADCT,,1.60683E+12,0.650252951,0.650252951,52.22,48.93,53.61,48.17,113984,52.22,48.93,53.61,48.17,113984,6-Jul-20,-2.12,-0.0415
6-Jul-20,ADC Therapeutics meldet Aufhebung der teilweisen Unterbrechung der zulassungsrelevanten klinischen Phase-2-Studie mit Camidanlumab-Tesirin durch die US-Zulassungsbeh√∂rde FDA,"ADC Therapeutics SA (NYSE:ADCT), ein in der klinischen Forschung t√§tiges Biotechnologieunternehmen mit Schwerpunkt auf Onkologie und Vorreiter in der Entwicklung und Vermarktung von Antik√∂rper-Wirksto...",48.93,53.61,48.17,52.22,ADCT,113984,HISTORICAL_PRICES,ADCT,,1.60683E+12,0.650252951,0.650252951,52.22,48.93,53.61,48.17,113984,52.22,48.93,53.61,48.17,113984,6-Jul-20,-2.12,-0.0415
6-Jul-20,"Notice of Lead Plaintiff Deadline for Shareholders in the Co-Diagnostics, Inc. Class Action Lawsuit","Robbins Geller Rudman & Dowd LLP announces that a class action lawsuit has been filed in the District of Utah on behalf of purchasers of Co-Diagnostics, Inc. (NASDAQ:CODX) securities between Febru...",18.07,19.22,18,19.1,CODX,2332529,HISTORICAL_PRICES,CODX,,1.60683E+12,1.016741071,1.016741071,19.1,18.07,19.22,18,2332529,19.1,18.07,19.22,18,2332529,6-Jul-20,-0.82,-0.0434
6-Jul-20,ADC Therapeutics Announces U.S. Food and Drug Administration Has Lifted Partial Clinical Hold on Pivotal Phase 2 Clinical Trial of Camidanlumab Tesirine,"ADC Therapeutics SA (NYSE:ADCT), a clinical-stage oncology-focused biotechnology company leading the development and commercialization of next-generation antibody drug conjugates (ADCs) with highly po...",48.93,53.61,48.17,52.22,ADCT,113984,HISTORICAL_PRICES,ADCT,,1.60683E+12,0.650252951,0.650252951,52.22,48.93,53.61,48.17,113984,52.22,48.93,53.61,48.17,113984,6-Jul-20,-2.12,-0.0415
6-Jul-20,Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4),"Verastem, Inc. (Nasdaq:VSTM) (also known as Verastem Oncology), a biopharmaceutical company committed to developing and commercializing new medicines for patients battling cancer, today announced the...",1.61,1.7,1.58,1.69,VSTM,5759824,HISTORICAL_PRICES,VSTM,,1.60683E+12,-0.293859649,-0.293859649,1.69,1.61,1.7,1.58,5759824,1.69,1.61,1.7,1.58,5759824,6-Jul-20,-0.06,-0.0359
2-Jul-20,Deciphera Announces Presentation of Analysis of Crossover Population from the INVICTUS Phase 3 Study of QINLOCK‚Ñ¢ (ripretinib) in Patients with Fourth-Line Advanced GIST,"Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) today announced the presentation of new data from an exploratory analysis of progression-free survival (PFS) and overall survival (OS) for patients who cr...",56.71,58.64,55.42,58.6,DCPH,327329,HISTORICAL_PRICES,DCPH,,1.60683E+12,0.371794872,0.371794872,58.6,56.71,58.64,55.42,327329,58.6,56.71,58.64,55.42,327329,2-Jul-20,-1.45,-0.0249
2-Jul-20,HanesBrands Introduces Consumer Face Masks and Completes Production of Cloth Face Coverings for U.S. Government,HanesBrands (NYSE:HBI) has completed production and distribution of more than 450 million all-cotton cloth face coverings and more than 20 million medical gowns supplied to the U.S. government for use...,11.46,11.88,11.33,11.37,HBI,7614406,HISTORICAL_PRICES,HBI,,1.61362E+12,0.284753363,0.284753363,11.37,11.46,11.88,11.33,7614406,11.0318,11.1191,11.5266,10.993,7614406,2-Jul-20,0.4,0.0362
2-Jul-20,Alexion Completes Acquisition of Portola,"Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced the successful completion of its acquisition of Portola Pharmaceuticals, Inc. (NASDAQ:PTLA). The acquisition adds Factor Xa inhibitor revers...",112.3,114.49,111.72,114.49,ALXN,1283159,HISTORICAL_PRICES,ALXN,,1.60683E+12,0.329466083,0.329466083,114.49,112.3,114.49,111.72,1283159,114.49,112.3,114.49,111.72,1283159,2-Jul-20,-0.09,-0.0008
1-Jul-20,"Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Continues Investigation of J2 Global, Inc. (JCOM) on Behalf of Investors","Glancy Prongay & Murray LLP (‚ÄúGPM‚Äù), a leading national shareholder rights law firm, continues its investigation on behalf of J2 Global, Inc. (""J2"" or ""the Company"") (NASDAQ: JCOM) investors conce...",64.1,65.815,64,64.11,JCOM,2302024,HISTORICAL_PRICES,JCOM,,1.60683E+12,-0.027018822,-0.027018822,64.11,64.1,65.815,64,2302024,64.11,64.1,65.815,64,2302024,1-Jul-20,0.89,0.0141
1-Jul-20,"ROSEN, A LEADING LAW FIRM, Reminds Chembio Diagnostics, Inc. Investors of Important Deadline in Securities Class Action; Encourages Investors with Losses in Excess of $100K to Contact the Firm ‚Äì CEMI","Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Chembio Diagnostics, Inc. (NASDAQ: CEMI) between March 12, 2020 and June 16, 2020, inclusive (the ‚ÄúClass Peri...",3.28,3.32,3.08,3.22,CEMI,4404786,HISTORICAL_PRICES,CEMI,,1.60683E+12,-0.329243354,-0.329243354,3.22,3.28,3.32,3.08,4404786,3.22,3.28,3.32,3.08,4404786,1-Jul-20,0.03,0.0092
1-Jul-20,Axonics¬Æ Receives FDA Approval for 3T Full-Body MRI Scans,"Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing novel implantable sacral neuromodulation (SNM) devices for the treatment of...",36.41,36.57,34.48,35.02,AXNX,604536,HISTORICAL_PRICES,AXNX,,1.60683E+12,0.632003586,0.632003586,35.02,36.41,36.57,34.48,604536,35.02,36.41,36.57,34.48,604536,1-Jul-20,1.3,0.037
1-Jul-20,"Gilead Sciences Demonstrates Commitment to Scientific Innovation In HIV With New Prevention, Treatment and Cure Research Data Presented At AIDS 2020: Virtual","Gilead Sciences, Inc. (Nasdaq:GILD) today announced that new data from the company‚Äôs HIV research and development program will be presented at the 23rd International AIDS Conference (AIDS 2020: Virtua...",76.06,77.23,75.9,77.1,GILD,7786921,HISTORICAL_PRICES,GILD,,1.61552E+12,0.091874821,0.091874821,77.1,76.06,77.23,75.9,7786921,74.5976,73.5913,74.7233,73.4365,7786921,1-Jul-20,-0.88,-0.0114
1-Jul-20,"Everbridge Launches Industry‚Äôs First COVID-19 Return-to-Work Connectivity Hub, Everbridge Control Center‚Ñ¢, for Automating Health and Safety Monitoring and Mitigation","Everbridge, Inc. (NASDAQ: EVBG), the global leader in critical event management (CEM), today announced Everbridge Control Center, the industry‚Äôs first and proven off-the-shelf physical security inform...",147.97,149.485,137.0001,137.98,EVBG,529912,HISTORICAL_PRICES,EVBG,,1.60683E+12,0.337038041,0.337038041,137.98,147.97,149.485,137.0001,529912,137.98,147.97,149.485,137.0001,529912,1-Jul-20,9.61,0.0695
1-Jul-20,scPharmaceuticals Announces FUROSCIX¬Æ NDA Resubmission,"scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patien...",7.17,7.5,7.06,7.34,SCPH,86758,HISTORICAL_PRICES,SCPH,,1.60683E+12,-0.161403509,-0.161403509,7.34,7.17,7.5,7.06,86758,7.34,7.17,7.5,7.06,86758,1-Jul-20,-0.19,-0.0258
1-Jul-20,Lantheus Holdings to Showcase the Potential of PyL‚Ñ¢ Imaging Agent at the Virtual Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2020 Annual Meeting,"Lantheus Holdings, Inc. (the ‚ÄúCompany‚Äù) (NASDAQ: LNTH), the parent company of Lantheus Medical Imaging, Inc. and Progenics Pharmaceuticals, Inc., and a global leader in the development, manufacture an...",14.1,14.65,13.95,14.32,LNTH,536629,HISTORICAL_PRICES,LNTH,,1.60683E+12,0.230366492,0.230366492,14.32,14.1,14.65,13.95,536629,14.32,14.1,14.65,13.95,536629,1-Jul-20,-0.2,-0.014
1-Jul-20,KalVista Pharmaceuticals Provides Operational Update and Fiscal Year Financial Results,"KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors today provided...",12.12,12.59,11.91,12.59,KALV,146624,HISTORICAL_PRICES,KALV,,1.60683E+12,0.66255144,0.66255144,12.59,12.12,12.59,11.91,146624,12.59,12.12,12.59,11.91,146624,1-Jul-20,0.02,0.0017
30-Jun-20,Revance Announces Last Patient Enrolled in Modified JUNIPER Phase 2 Upper Limb Spasticity Trial of DaxibotulinumtoxinA for Injection,"Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company focused on innovative aesthetic and therapeutic offerings, including its next-generation neuromodulator product, DaxibotulinumtoxinA...",24.42,26.02,24.18,25.54,RVNC,1457116,HISTORICAL_PRICES,RVNC,,1.60683E+12,0.65559322,0.65559322,25.54,24.42,26.02,24.18,1457116,25.54,24.42,26.02,24.18,1457116,30-Jun-20,-1.15,-0.045
30-Jun-20,The Law Offices of Frank R. Cruz Announces Investigation on Behalf of Verrica Pharmaceuticals Inc. Investors (VRCA),"The Law Offices of Frank R. Cruz announces an investigation on behalf of Verrica Pharmaceuticals Inc. (""Verrica"" or the ""Company"") (NASDAQ: VRCA) investors concerning the Company and its officers‚Äô pos...",11.01,11.43,10.29,11.3,VRCA,356539,HISTORICAL_PRICES,VRCA,,1.60683E+12,-0.028243601,-0.028243601,11.3,11.01,11.43,10.29,356539,11.3,11.01,11.43,10.29,356539,30-Jun-20,-3.06,-0.2175
30-Jun-20,INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Verrica Pharmaceuticals Inc. (VRCA) on Behalf of Investors,"Law Offices of Howard G. Smith announces an investigation on behalf of Verrica Pharmaceuticals Inc. (""Verrica"" or the ""Company"") (NASDAQ: VRCA) investors concerning the Company and its officers‚Äô possi...",11.01,11.43,10.29,11.3,VRCA,356539,HISTORICAL_PRICES,VRCA,,1.60683E+12,-0.028243601,-0.028243601,11.3,11.01,11.43,10.29,356539,11.3,11.01,11.43,10.29,356539,30-Jun-20,-3.06,-0.2175
30-Jun-20,Humana to Offer LabCorp At-Home COVID-19 Test Collection and Collaborate with Walmart and Quest Diagnostics to Offer Drive-Thru Testing for Humana Members,"Leading health and well-being company Humana Inc. (NYSE: HUM) announced a pilot home-testing program today that will enable at-home COVID-19 test collection for members, making Humana the first insure...",387.75,389.3,379,381.03,HUM,909248,HISTORICAL_PRICES,HUM,,1.60938E+12,0.441396231,0.441396231,381.03,387.75,389.3,379,909248,379.8519,386.5512,388.0964,377.8282,909248,30-Jun-20,8.39,0.0221
30-Jun-20,Everbridge Receives FedRAMP Authorization Renewal as Company Continues Rapid Growth in Federal Market; Helps Government Agencies Mitigate the Impacts of COVID-19,"Everbridge, Inc. (NASDAQ: EVBG), the global leader in Critical Event Management (CEM), today announced the company successfully renewed its Federal Risk and Authorization Management Program (FedRAMP)...",138.36,138.71,135.56,136.41,EVBG,575998,HISTORICAL_PRICES,EVBG,,1.60683E+12,0.250203307,0.250203307,136.41,138.36,138.71,135.56,575998,136.41,138.36,138.71,135.56,575998,30-Jun-20,3.17,0.0234
30-Jun-20,Jabil Launches High-Volume Mask Production in the United States,Jabil Inc. (NYSE: JBL) today announced the launch of a substantial face mask manufacturing operation in the United States to address demand for face masks and other personal protective equipment (PPE)...,32.08,32.49,31.6,31.85,JBL,1461302,HISTORICAL_PRICES,JBL,,1.61302E+12,0.357596276,0.357596276,31.85,32.08,32.49,31.6,1461302,31.6502,31.8787,32.2862,31.4017,1461302,30-Jun-20,-0.19,-0.0059
30-Jun-20,"Revance Announces Positive Results in Two Phase 2a Studies of DaxibotulinumtoxinA For Injection for the Treatment of Forehead Lines and Crow‚Äôs Feet, Respectively","Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company focused on innovative aesthetic and therapeutic offerings, including its next-generation neuromodulator product, DaxibotulinumtoxinA...",24.42,26.02,24.18,25.54,RVNC,1457116,HISTORICAL_PRICES,RVNC,,1.60683E+12,0.65559322,0.65559322,25.54,24.42,26.02,24.18,1457116,25.54,24.42,26.02,24.18,1457116,30-Jun-20,-1.15,-0.045
30-Jun-20,Oncternal Therapeutics Announces Orphan Drug Designations of Cirmtuzumab ROR1 Antibody for Treatment of Mantle Cell Lymphoma and for Treatment of Chronic Lymphocytic Leukemia,"Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that the United States Food and Drug Adm...",2.84,3.21,2.7601,3.1,ONCT,125218,HISTORICAL_PRICES,ONCT,,1.60683E+12,0.088122605,0.088122605,3.1,2.84,3.21,2.7601,125218,3.1,2.84,3.21,2.7601,125218,30-Jun-20,-0.14,-0.047
30-Jun-20,Oncternal Therapeutics Announces Increased Focus of the Cirmtuzumab ROR1 Antibody Program on Mantle Cell Lymphoma,"Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced an updated clinical strategy for its inv...",2.84,3.21,2.7601,3.1,ONCT,125218,HISTORICAL_PRICES,ONCT,,1.60683E+12,0.088122605,0.088122605,3.1,2.84,3.21,2.7601,125218,3.1,2.84,3.21,2.7601,125218,30-Jun-20,-0.14,-0.047
30-Jun-20,IVERIC bio Announces First Patient Dosed in Second Zimura¬Æ Phase 3 Clinical Trial for the Treatment of Geographic Atrophy Secondary to Age-Related Macular Degeneration,"IVERIC bio, Inc. (Nasdaq: ISEE) today announced the first patient has been dosed in GATHER2, also known as ISEE2008, the second Phase 3 clinical trial for Zimura¬Æ (avacincaptad pegol), a novel complem...",5.1,5.3717,4.75,5.34,ISEE,1543905,HISTORICAL_PRICES,ISEE,,1.60683E+12,0.526946108,0.526946108,5.34,5.1,5.3717,4.75,1543905,5.34,5.1,5.3717,4.75,1543905,30-Jun-20,-0.26,-0.0485
30-Jun-20,"Nemaura Medical Reports Results and Provides Business Update for the Fiscal Year Ended March 31, 2020","Nemaura Medical Inc. (NASDAQ: NMRD) (‚ÄúNemaura‚Äù), a medical technology company commercializing sugarBEAT¬Æ, a non-invasive and flexible continuous glucose monitor (CGM), together with BEAT¬Ædiabetes, a h...",9.25,9.9799,9.03,9.03,NMRD,29770,HISTORICAL_PRICES,NMRD,,1.60683E+12,0.557239057,0.557239057,9.03,9.25,9.9799,9.03,29770,9.03,9.25,9.9799,9.03,29770,30-Jun-20,0.24,0.0266
29-Jun-20,Seattle Genetics Announces Positive Topline Results from Phase 2 Clinical Trial of Tisotumab Vedotin in Recurrent or Metastatic Cervical Cancer,"Seattle Genetics, Inc. (Nasdaq:SGEN) today announced positive topline results from the phase 2 single-arm clinical trial known as innovaTV 204 evaluating tisotumab vedotin administered every three wee...",164.37,166.58,163.23,165.78,SGEN,1010114,HISTORICAL_PRICES,SGEN,,1.60683E+12,0.558600417,0.558600417,165.78,164.37,166.58,163.23,1010114,165.78,164.37,166.58,163.23,1010114,29-Jun-20,-1.22,-0.0074
29-Jun-20,FDA Approves Merck‚Äôs KEYTRUDA¬Æ (pembrolizumab) for First-Line Treatment of Patients With Unresectable or Metastatic MSI-H or dMMR Colorectal Cancer,"Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved KEYTRUDA, Merck‚Äôs anti-PD-1 therapy, as monotherapy...",76.12,76.51,75.52,75.9,MRK,6899781,HISTORICAL_PRICES,MRK,,1.61552E+12,0.115801818,0.115801818,75.9,76.12,76.51,75.52,6899781,74.1104,74.3252,74.706,73.7394,6899781,29-Jun-20,0.93,0.0124
29-Jun-20,"The Law Offices of Frank R. Cruz Announces Investigation on Behalf of Intercept Pharmaceuticals, Inc. Investors (ICPT)","The Law Offices of Frank R. Cruz announces an investigation on behalf of Intercept Pharmaceuticals, Inc. (""Intercept"" or the ""Company"") (NASDAQ: ICPT) investors concerning the Company and its officers...",46.7,50,44.5,47.25,ICPT,10289656,HISTORICAL_PRICES,ICPT,,1.60683E+12,-0.246895662,-0.246895662,47.25,46.7,50,44.5,10289656,47.25,46.7,50,44.5,10289656,29-Jun-20,-30.79,-0.3973
29-Jun-20,"INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Intercept Pharmaceuticals, Inc. (ICPT) on Behalf of Investors","Law Offices of Howard G. Smith announces an investigation on behalf of Intercept Pharmaceuticals, Inc. (""Intercept"" or the ""Company"") (NASDAQ: ICPT) investors concerning the Company and its officers‚Äô...",46.7,50,44.5,47.25,ICPT,10289656,HISTORICAL_PRICES,ICPT,,1.60683E+12,-0.246895662,-0.246895662,47.25,46.7,50,44.5,10289656,47.25,46.7,50,44.5,10289656,29-Jun-20,-30.79,-0.3973
29-Jun-20,TFF Pharmaceuticals Announces First Human Dosing With Tacrolimus Inhalation Powder and Topline Data for Voriconazole Inhalation Powder,"TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) t...",5.7,5.99,5.7,5.865,TFFP,90835,HISTORICAL_PRICES,TFFP,,1.60683E+12,0.425,0.425,5.865,5.7,5.99,5.7,90835,5.865,5.7,5.99,5.7,90835,29-Jun-20,-0.03,-0.0052
29-Jun-20,Genprex Added to Russell 3000¬Æ Index,"Genprex, Inc. (‚ÄúGenprex‚Äù or the ‚ÄúCompany‚Äù) (NASDAQ: GNPX), a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes, today announce...",3.15,3.28,3.09,3.2,GNPX,1102008,HISTORICAL_PRICES,GNPX,,1.60683E+12,0.129032258,0.129032258,3.2,3.15,3.28,3.09,1102008,3.2,3.15,3.28,3.09,1102008,29-Jun-20,0.02,0.0064
29-Jun-20,Masimo Announces Bridge‚Ñ¢,"Masimo (NASDAQ: MASI) today announced Bridge‚Ñ¢, an opioid withdrawal solution that uses neuromodulation to aid in the reduction of symptoms associated with opioid withdrawal. Bridge, which has been gra...",219.73,220.13,212.58,216.65,MASI,435448,HISTORICAL_PRICES,MASI,,1.60683E+12,0.374945247,0.374945247,216.65,219.73,220.13,212.58,435448,216.65,219.73,220.13,212.58,435448,29-Jun-20,2.23,0.0103
29-Jun-20,Incyte Announces Approval of Tabrecta‚Ñ¢ (capmatinib) in Japan for the Treatment of Patients with Advanced Non-Small Cell Lung Cancer with METex14,"Incyte (Nasdaq: INCY) today announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) approved Tabrecta‚Ñ¢ (capmatinib) for MET exon 14 skipping (METex14) mutation-positive advanced and/...",102.48,103.87,100.08,101.48,INCY,1075728,HISTORICAL_PRICES,INCY,,1.60683E+12,0.472625377,0.472625377,101.48,102.48,103.87,100.08,1075728,101.48,102.48,103.87,100.08,1075728,29-Jun-20,1.05,0.0104
29-Jun-20,Orthofix Announces FDA Clearance and First Patient Implants of FIREBIRD SI Fusion System for Low Back Pain,"Orthofix Medical Inc. (NASDAQ:OFIX), a global medical device company focused on musculoskeletal healing products, announced the U.S. Food and Drug Administration (FDA) 510(k) clearance and the first p...",31.04,31.18,29.84,30.06,OFIX,113721,HISTORICAL_PRICES,OFIX,,1.60683E+12,0.166478767,0.166478767,30.06,31.04,31.18,29.84,113721,30.06,31.04,31.18,29.84,113721,29-Jun-20,1.17,0.0392
29-Jun-20,Rocket Pharmaceuticals Announces FDA Clearance of IND for RP-L401 Gene Therapy for Infantile Malignant Osteopetrosis,"Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) (‚ÄúRocket‚Äù), a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders, today announces tha...",21.09,21.69,20.5,21.18,RCKT,954750,HISTORICAL_PRICES,RCKT,,1.60683E+12,0.408817635,0.408817635,21.18,21.09,21.69,20.5,954750,21.18,21.09,21.69,20.5,954750,29-Jun-20,-0.02,-0.0009
26-Jun-20,"Shareholder Alert: Robbins LLP Announces Chembio Diagnostics, Inc. (CEMI) Sued for Misleading Shareholders","Shareholder rights law firm Robbins LLP announces that a purchaser of Chembio Diagnostics, Inc. (NASDAQ: CEMI) filed a class action complaint against the Company for alleged violations of the Securiti...",3.27,3.42,3.22,3.39,CEMI,4043292,HISTORICAL_PRICES,CEMI,,1.60683E+12,-0.331288344,-0.331288344,3.39,3.27,3.42,3.22,4043292,3.39,3.27,3.42,3.22,4043292,26-Jun-20,-0.19,-0.0549
26-Jun-20,"Phunware Announces Joint Venture with AnyPlace MD to Provide an End-to-End, Tech-Enabled Solution to COVID-19","Phunware, Inc. (NASDAQ: PHUN) (the ‚ÄúCompany‚Äù), a fully-integrated enterprise cloud platform for mobile that provides products, solutions, data and services for brands worldwide, announced today a join...",1.34,1.39,1.26,1.38,PHUN,8289674,HISTORICAL_PRICES,PHUN,,1.60683E+12,0.887323944,0.887323944,1.38,1.34,1.39,1.26,8289674,1.38,1.34,1.39,1.26,8289674,26-Jun-20,0.11,0.0894
26-Jun-20,Nemaura Medical Interview to Air on Bloomberg International on the RedChip Money Report,"Nemaura Medical, Inc. (NASDAQ: NMRD) (‚ÄúNemaura‚Äù or the ‚ÄúCompany‚Äù), a medical technology company focused on developing micro-systems-based wearable diagnostic devices and currently commercializing suga...",9.6,10.64,9.49,10.6,NMRD,858112,HISTORICAL_PRICES,NMRD,,1.60683E+12,0.616161616,0.616161616,10.6,9.6,10.64,9.49,858112,10.6,9.6,10.64,9.49,858112,26-Jun-20,-1,-0.0943
26-Jun-20,Applied DNA Sciences Set to Join Russell Microcap Index,"Applied DNA Sciences Inc. (NASDAQ: APDN) (‚ÄúApplied DNA‚Äù or the ‚ÄúCompany‚Äù) a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing that enables in vitro diagnostics, pre-clinical nucleic ac...",9.09,9.4,8.3,9.4,APDN,1047092,HISTORICAL_PRICES,APDN,,1.60683E+12,1.227941176,1.227941176,9.4,9.09,9.4,8.3,1047092,9.4,9.09,9.4,8.3,1047092,26-Jun-20,-0.19,-0.0205
25-Jun-20,Masimo Announces FDA Clearance of Centroid‚Ñ¢,"Masimo (NASDAQ: MASI) announced today that Centroid‚Ñ¢, a wearable, wireless patient orientation, activity, and respiration rate sensor, has received FDA clearance. Centroid helps clinicians monitor pat...",220.55,222.44,216.98,222.44,MASI,478853,HISTORICAL_PRICES,MASI,,1.60683E+12,0.380076341,0.380076341,222.44,220.55,222.44,216.98,478853,222.44,220.55,222.44,216.98,478853,25-Jun-20,-1.52,-0.0068
25-Jun-20,"Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Continues Investigation of ECMOHO Limited Investors (MOHO) on Behalf of Investors","Glancy Prongay & Murray LLP (‚ÄúGPM‚Äù), a leading national shareholder rights law firm, continues its investigation on behalf of ECMOHO Limited (""ECMOHO"" or the ""Company"") (NASDAQ: MOHO) investors co...",2.88,2.9,2.74,2.85,MOHO,236921,HISTORICAL_PRICES,MOHO,,1.60683E+12,-0.661176471,-0.661176471,2.85,2.88,2.9,2.74,236921,2.85,2.88,2.9,2.74,236921,25-Jun-20,0.01,0.0035
25-Jun-20,Genprex Receives USAN Approval of Non-Proprietary Name for Lead Drug Candidate,"Genprex, Inc. (‚ÄúGenprex‚Äù or the ‚ÄúCompany‚Äù) (Nasdaq: GNPX), a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes, today announce...",3.48,3.8,3.33,3.7,GNPX,3266278,HISTORICAL_PRICES,GNPX,,1.60683E+12,0.247311828,0.247311828,3.7,3.48,3.8,3.33,3266278,3.7,3.48,3.8,3.33,3266278,25-Jun-20,-0.16,-0.044
25-Jun-20,Moderna and Catalent Announce Collaboration for Fill-Finish Manufacturing of Moderna‚Äôs COVID-19 Vaccine Candidate,"Moderna, Inc. (Nasdaq: MRNA), a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, and...",62,67,58.51,67,MRNA,26905664,HISTORICAL_PRICES,MRNA,,1.60683E+12,1.285293034,1.285293034,67,62,67,58.51,26905664,67,62,67,58.51,26905664,25-Jun-20,-2.84,-0.0438
25-Jun-20,Moderna and Catalent Announce Collaboration for Fill-Finish Manufacturing of Moderna‚Äôs COVID-19 Vaccine Candidate,"Moderna, Inc. (Nasdaq: MRNA), a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, and...",62,67,58.51,67,MRNA,26905664,HISTORICAL_PRICES,MRNA,,1.60683E+12,1.285293034,1.285293034,67,62,67,58.51,26905664,67,62,67,58.51,26905664,25-Jun-20,-2.84,-0.0438
24-Jun-20,FDA Approves Merck‚Äôs KEYTRUDA¬Æ (pembrolizumab) for the Treatment of Patients with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (cSCC) that is Not Curable by Surgery or Radiation,"Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) has approved KEYTRUDA, Merck‚Äôs anti-PD-1 therapy, as monotherapy...",75.87,76.89,75.45,76.73,MRK,7714623,HISTORICAL_PRICES,MRK,,1.61552E+12,0.112137203,0.112137203,76.73,75.87,76.89,75.45,7714623,74.9208,74.0811,75.0771,73.671,7714623,24-Jun-20,-1.25,-0.0162
24-Jun-20,SINTX Technologies Announces Publication of Study to Reduce the Spread and Transfer of Coronavirus,"SINTX Technologies, Inc. (NASDAQ: SINT) (‚ÄúSINTX‚Äù or the ‚ÄúCompany‚Äù), an original equipment manufacturer (OEM) ceramics company focused on silicon nitride and its applications, today announced positive...",2.1,2.57,1.53,1.6,SINT,134763899,HISTORICAL_PRICES,SINT,,1.60683E+12,5.461538462,5.461538462,1.6,2.1,2.57,1.53,134763899,1.6,2.1,2.57,1.53,134763899,24-Jun-20,0.68,0.4789
24-Jun-20,Alexion Announces Phase 3 Study of Weekly Subcutaneous ULTOMIRIS¬Æ (ravulizumab-cwvz) Met Primary Endpoint,"Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced topline results from a Phase 3 study of weekly self-administered subcutaneous (SC) ULTOMIRIS¬Æ (ravulizumab-cwvz) in adults with paroxysmal n...",111.95,115.75,111.36,113.96,ALXN,2096673,HISTORICAL_PRICES,ALXN,,1.60683E+12,0.3253226,0.3253226,113.96,111.95,115.75,111.36,2096673,113.96,111.95,115.75,111.36,2096673,24-Jun-20,-3.54,-0.0307
24-Jun-20,UCI Health Deploys Everbridge‚Äôs Industry-Leading Mobile Wayfinding Solution to Improve Patient Experience and Safety Amid COVID-19 Precautions,"Everbridge, Inc. (NASDAQ: EVBG), the global leader in Critical Event Management (CEM), today announced that UCI Health in Orange County, California integrated the Everbridge MediNav‚Ñ¢ solution with its...",134.33,142.83,132.23,140.31,EVBG,787412,HISTORICAL_PRICES,EVBG,,1.60683E+12,0.213788741,0.213788741,140.31,134.33,142.83,132.23,787412,140.31,134.33,142.83,132.23,787412,24-Jun-20,-6.17,-0.0439
24-Jun-20,Genprex CEO to Interview Live on ‚ÄúThe Big Biz Show‚Äù,"Genprex, Inc. (‚ÄúGenprex‚Äù or the ‚ÄúCompany‚Äù) (Nasdaq: GNPX), a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes, today announce...",3.64,3.75,3.1258,3.19,GNPX,5493741,HISTORICAL_PRICES,GNPX,,1.60683E+12,0.304659498,0.304659498,3.19,3.64,3.75,3.1258,5493741,3.19,3.64,3.75,3.1258,5493741,24-Jun-20,0.54,0.1742
23-Jun-20,"EQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Chembio Diagnostics, Inc. ‚Äì CEMI","Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Chembio Diagnostics, Inc. (NASDAQ: CEMI) between March 12...",3.41,3.59,3.36,3.56,CEMI,3013778,HISTORICAL_PRICES,CEMI,,1.60683E+12,-0.302658487,-0.302658487,3.56,3.41,3.59,3.36,3013778,3.56,3.41,3.59,3.36,3013778,23-Jun-20,-0.26,-0.0708
23-Jun-20,"CEMI INVESTOR ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Class Action Against Chembio Diagnostics, Inc. and Encourages Investors to Contact the Firm","Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Chembio Diagnostics, Inc. (""Chembio"" or ""the Company"") (NASDAQ: CEMI) and certain of its of...",3.41,3.59,3.36,3.56,CEMI,3013778,HISTORICAL_PRICES,CEMI,,1.60683E+12,-0.302658487,-0.302658487,3.56,3.41,3.59,3.36,3013778,3.56,3.41,3.59,3.36,3013778,23-Jun-20,-0.26,-0.0708
23-Jun-20,"Nemaura Medical CEO to Participate in Investor Webinar and Q&A Session on July 7, 2020","Nemaura Medical, Inc. (NASDAQ: NMRD) (‚ÄúNemaura‚Äù or the ‚ÄúCompany‚Äù), a medical technology company focused on developing micro-systems-based wearable diagnostic devices and currently commercializing suga...",11.76,15.66,10.8399,15.66,NMRD,187425,HISTORICAL_PRICES,NMRD,,1.60683E+12,0.97979798,0.97979798,15.66,11.76,15.66,10.8399,187425,15.66,11.76,15.66,10.8399,187425,23-Jun-20,-3.62,-0.2354
23-Jun-20,Karuna Therapeutics Announces Positive Outcome of End-of-Phase 2 Meeting with the FDA for KarXT for the Treatment of Acute Psychosis in Patients with Schizophrenia,"Karuna Therapeutics, Inc. (NASDAQ: KRTX), an innovative clinical-stage biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with disabl...",105.74,107.65,103.5,106.18,KRTX,419656,HISTORICAL_PRICES,KRTX,,1.60683E+12,0.578208955,0.578208955,106.18,105.74,107.65,103.5,419656,106.18,105.74,107.65,103.5,419656,23-Jun-20,1.7,0.0163
22-Jun-20,Verastem Oncology Announces Presentation of Preclinical Data Supporting the Combination of VS-6766 and Defactinib in Metastatic Uveal Melanoma,"Verastem, Inc. (Nasdaq:VSTM) (also known as Verastem Oncology), a biopharmaceutical company committed to developing and commercializing new medicines for patients battling cancer, today announced resu...",1.85,1.88,1.76,1.8,VSTM,6099698,HISTORICAL_PRICES,VSTM,,1.60683E+12,-0.188596491,-0.188596491,1.8,1.85,1.88,1.76,6099698,1.8,1.85,1.88,1.76,6099698,22-Jun-20,0.05,0.0278
22-Jun-20,"SHAREHOLDER ACTION REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Chembio Diagnostics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm","The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Chembio Diagnostics, Inc. (‚ÄúChembio‚Äù or ‚Äúthe Company‚Äù) (NASDAQ: CEMI) for vio...",3.67,3.73,3.245,3.54,CEMI,6484194,HISTORICAL_PRICES,CEMI,,1.60683E+12,-0.249488753,-0.249488753,3.54,3.67,3.73,3.245,6484194,3.54,3.67,3.73,3.245,6484194,22-Jun-20,0.12,0.0338
22-Jun-20,Everbridge Recognized as One of The Fastest-Growing Public Companies in Massachusetts,"Everbridge, Inc. (NASDAQ: EVBG), the global leader in Critical Event Management (CEM), today announced its recognition on the 2020 Boston Business Journal list of Fastest-Growing Public Companies in M...",134.29,135.32,130,131,EVBG,394885,HISTORICAL_PRICES,EVBG,,1.60683E+12,0.213427306,0.213427306,131,134.29,135.32,130,394885,131,134.29,135.32,130,394885,22-Jun-20,4.17,0.032
22-Jun-20,Pfizer Announces Start of Four Phase 3 Clinical Trials for Investigational Vaccines,Pfizer Inc. (NYSE:PFE) today announced the initiation of four Phase 3 clinical trials within its current pipeline of investigational vaccines: Two studies (NCT04382326 and NCT04379713) of the 20-valen...,33.11,33.36,32.91,33.33,PFE,22137128,HISTORICAL_PRICES,PFE,,1.6118E+12,0.112941176,0.112941176,33.33,33.11,33.36,32.91,22137128,32.3198,32.1065,32.3489,31.9125,22137128,22-Jun-20,-0.31,-0.0093
22-Jun-20,"Seres Therapeutics Appoints Terri Young, Ph.D., R.Ph., Experienced Commercial Leader, as Executive Vice President, Chief Commercial and Strategy Officer","Seres Therapeutics, Inc. (Nasdaq: MCRB) today announced the appointment of Terri Young, Ph.D., R.Ph., as Executive Vice President, Chief Commercial and Strategy Officer, effective June 29, 2020. Dr. Y...",4.86,5.02,4.62,4.81,MCRB,559975,HISTORICAL_PRICES,MCRB,,1.60683E+12,0.416909621,0.416909621,4.81,4.86,5.02,4.62,559975,4.81,4.86,5.02,4.62,559975,22-Jun-20,0.06,0.0125
22-Jun-20,Deciphera Announces Health Canada‚Äôs Authorization of QINLOCK‚Ñ¢ (ripretinib) for the Treatment of Fourth-Line Gastrointestinal Stromal Tumor,"Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) today announced that Health Canada has authorized QINLOCK‚Ñ¢ (ripretinib), a switch-control tyrosine kinase inhibitor, for sale in Canada for the treatment...",65.03,65.58,61.91,62.52,DCPH,708645,HISTORICAL_PRICES,DCPH,,1.60683E+12,0.573052733,0.573052733,62.52,65.03,65.58,61.91,708645,62.52,65.03,65.58,61.91,708645,22-Jun-20,2.31,0.0368
22-Jun-20,Lantheus Completes Merger with Progenics,"Lantheus Holdings, Inc. (the ‚ÄúCompany‚Äù) (NASDAQ: LNTH), the parent company of Lantheus Medical Imaging, Inc. (‚ÄúLMI‚Äù), a global leader in the development, manufacture and commercialization of innovativ...",13.98,14.5,13.499,14.44,LNTH,1534412,HISTORICAL_PRICES,LNTH,,1.60683E+12,0.219895288,0.219895288,14.44,13.98,14.5,13.499,1534412,14.44,13.98,14.5,13.499,1534412,22-Jun-20,-0.85,-0.0573
22-Jun-20,"Merck Announces That V114, Its Investigational 15-valent Pneumococcal Conjugate Vaccine, Met Safety and Immunogenicity Objectives in Initial Phase 3 Studies in Adults","Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced results from two initial Phase 3 studies evaluating the safety, tolerability and immunogenicity of V114, the compa...",76.75,77.63,76.43,77.37,MRK,7131940,HISTORICAL_PRICES,MRK,,1.61552E+12,0.125036646,0.125036646,77.37,76.75,77.63,76.43,7131940,75.5458,74.9404,75.7996,74.6279,7131940,22-Jun-20,-1.15,-0.0148
22-Jun-20,Merck‚Äôs KEYTRUDA¬Æ (pembrolizumab) Approved in China for Second-Line Treatment of Patients with Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma Whose Tumors Express PD-L1 (CPS ‚â•10),"Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that KEYTRUDA, Merck‚Äôs anti-PD-1 therapy, has been approved by the National Medical Products Administration (NMPA)...",76.75,77.63,76.43,77.37,MRK,7131940,HISTORICAL_PRICES,MRK,,1.61552E+12,0.125036646,0.125036646,77.37,76.75,77.63,76.43,7131940,75.5458,74.9404,75.7996,74.6279,7131940,22-Jun-20,-1.15,-0.0148
19-Jun-20,"SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Chembio Diagnostics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm","The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Chembio Diagnostics, Inc. (‚ÄúChembio‚Äù or ‚Äúthe Company‚Äù) (NASDAQ: CEMI) for vio...",3.55,3.83,3.53,3.77,CEMI,7133916,HISTORICAL_PRICES,CEMI,,1.60683E+12,-0.27402863,-0.27402863,3.77,3.55,3.83,3.53,7133916,3.77,3.55,3.83,3.53,7133916,19-Jun-20,-0.205,-0.0546
19-Jun-20,"INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Co-Diagnostics, Inc. (CODX) Investors","Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased Co-Diagnostics, Inc. (""Co-Diagnostics"" or the ""Company"") (NASDAQ: CODX) securit...",17.24,17.8,15.82,15.95,CODX,3213618,HISTORICAL_PRICES,CODX,,1.60683E+12,0.924107143,0.924107143,15.95,17.24,17.8,15.82,3213618,15.95,17.24,17.8,15.82,3213618,19-Jun-20,1.31,0.0822
19-Jun-20,Masimo Announces Masimo SafetyNet-Open‚Ñ¢,"Masimo (NASDAQ: MASI) today announced Masimo SafetyNet-Open‚Ñ¢, designed to help businesses, governments, and schools more responsibly manage employee and student health and safety during COVID-19. As t...",226.03,226.87,220.3525,223.13,MASI,878581,HISTORICAL_PRICES,MASI,,1.60683E+12,0.414367061,0.414367061,223.13,226.03,226.87,220.3525,878581,223.13,226.03,226.87,220.3525,878581,19-Jun-20,4.62,0.0209
19-Jun-20,"Masimo Announces Masimo Sleep‚Ñ¢, a New Wellness Solution That Allows Users to Better Understand Their Sleep Quality","Masimo (NASDAQ: MASI) announced today a new health and wellness home monitoring solution, Masimo Sleep‚Ñ¢, designed to help consumers better understand the quality of their sleep. Masimo Sleep is fueled...",226.03,226.87,220.3525,223.13,MASI,878581,HISTORICAL_PRICES,MASI,,1.60683E+12,0.414367061,0.414367061,223.13,226.03,226.87,220.3525,878581,223.13,226.03,226.87,220.3525,878581,19-Jun-20,4.62,0.0209
18-Jun-20,"INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Chembio Diagnostics, Inc. (CEMI) Investors","Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased Chembio Diagnostics, Inc. (""Chembio"" or the ""Company"") (NASDAQ: CEMI) common st...",3.755,4.3,3.73,3.98,CEMI,13968644,HISTORICAL_PRICES,CEMI,,1.60683E+12,-0.232106339,-0.232106339,3.98,3.755,4.3,3.73,13968644,3.98,3.755,4.3,3.73,13968644,18-Jun-20,-0.135,-0.0347
18-Jun-20,"The Law Offices of Frank R. Cruz Announces Investigation on Behalf of Chembio Diagnostics, Inc. Investors (CEMI)","The Law Offices of Frank R. Cruz announces an investigation on behalf of Chembio Diagnostics, Inc. (""Chembio"" or the ""Company"") (NASDAQ: CEMI) investors concerning the Company and its officers‚Äô possib...",3.755,4.3,3.73,3.98,CEMI,13968644,HISTORICAL_PRICES,CEMI,,1.60683E+12,-0.232106339,-0.232106339,3.98,3.755,4.3,3.73,13968644,3.98,3.755,4.3,3.73,13968644,18-Jun-20,-0.135,-0.0347
18-Jun-20,Urovant Sciences Reports Fiscal Year and Fourth Quarter 2019 Results,"Urovant Sciences (Nasdaq: UROV) today reported financial results for the three months and 2019 fiscal year ended March 31, 2020. The fiscal fourth quarter of 2019 marked achievement of key milestones...",11.5,12.06,10.95,11,UROV,78088,HISTORICAL_PRICES,UROV,,1.60683E+12,0.144278607,0.144278607,11,11.5,12.06,10.95,78088,11,11.5,12.06,10.95,78088,18-Jun-20,0.56,0.0512
18-Jun-20,Shareholder Alert: Robbins LLP Announces Co-Diagnostics Inc. (CODX) Sued for Misleading Shareholders,Shareholder rights law firm Robbins LLP announces that a purchaser of Co-Diagnostics Inc. (NASDAQ: CODX) filed a class action complaint against the Company for alleged violations of the Securities Exc...,15.93,16.57,15.7752,16.15,CODX,1971992,HISTORICAL_PRICES,CODX,,1.60683E+12,0.777901786,0.777901786,16.15,15.93,16.57,15.7752,1971992,16.15,15.93,16.57,15.7752,1971992,18-Jun-20,-0.58,-0.0351
18-Jun-20, Epizyme Announces U.S. FDA Accelerated Approval of TAZVERIK‚Ñ¢ (tazemetostat) for Relapsed/Refractory Follicular Lymphoma,"Epizyme, Inc. (Nasdaq:EPZM), a fully integrated, commercial-stage biopharmaceutical company developing novel epigenetic therapies, today announced that the U.S. Food and Drug Administration (FDA) has...",20.46,22,18.02,19.7,EPZM,6255850,HISTORICAL_PRICES,EPZM,,1.60683E+12,0.348714568,0.348714568,19.7,20.46,22,18.02,6255850,19.7,20.46,22,18.02,6255850,18-Jun-20,0.94,0.0482
18-Jun-20,"INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Chembio Diagnostics, Inc. (CEMI) on Behalf of Investors","Law Offices of Howard G. Smith announces an investigation on behalf of Chembio Diagnostics, Inc. (""Chembio"" or the ""Company"") (NASDAQ: CEMI) investors concerning the Company and its officers‚Äô possible...",3.755,4.3,3.73,3.98,CEMI,13968644,HISTORICAL_PRICES,CEMI,,1.60683E+12,-0.232106339,-0.232106339,3.98,3.755,4.3,3.73,13968644,3.98,3.755,4.3,3.73,13968644,18-Jun-20,-0.135,-0.0347
18-Jun-20,TFF Pharmaceuticals Receives Orphan Drug Designation for Tacrolimus Inhalation Powder,"TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) t...",6.02,6.24,5.91,6.1,TFFP,168482,HISTORICAL_PRICES,TFFP,,1.60683E+12,0.505,0.505,6.1,6.02,6.24,5.91,168482,6.1,6.02,6.24,5.91,168482,18-Jun-20,-0.06,-0.0099
18-Jun-20,Xeris Pharmaceuticals Announces Positive Topline Results from the Phase 2 Comparative Study of a Novel Pramlintide-insulin Co-formulation (XP-3924) in Adults with Type 1 Diabetes Mellitus,"Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable and infusible drug formula...",5.49,5.67,5.18,5.2,XERS,411288,HISTORICAL_PRICES,XERS,,1.60683E+12,1.920212766,1.920212766,5.2,5.49,5.67,5.18,411288,5.2,5.49,5.67,5.18,411288,18-Jun-20,0.33,0.064
18-Jun-20,Urovant Sciences Announces Collaboration with Sunovion Pharmaceuticals,Urovant Sciences (Nasdaq: UROV) today announced it has entered into an exclusive three-year distribution agreement with Sunovion Pharmaceuticals Inc. (Sunovion) for services to support the commerciali...,11.5,12.06,10.95,11,UROV,78088,HISTORICAL_PRICES,UROV,,1.60683E+12,0.144278607,0.144278607,11,11.5,12.06,10.95,78088,11,11.5,12.06,10.95,78088,18-Jun-20,0.56,0.0512
18-Jun-20,Dicerna Receives Rare Pediatric Disease Designation From U.S. Food and Drug Administration for Nedosiran for Treatment of Primary Hyperoxaluria,"Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (the ‚ÄúCompany‚Äù or ‚ÄúDicerna‚Äù), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that the U.S. Food...",24.56,24.73,23.04,23.15,DRNA,568116,HISTORICAL_PRICES,DRNA,,1.60683E+12,0.363686841,0.363686841,23.15,24.56,24.73,23.04,568116,23.15,24.56,24.73,23.04,568116,18-Jun-20,1.27,0.0545
18-Jun-20,Neurocrine BiosciencesÂíåÊ≠¶Áî∞ÂÆ£Â∏ÉÂêà‰ΩúÂºÄÂèëÂíåÂïÜ‰∏öÂåñÁ≤æÁ•ûÁñæÁóÖÊΩúÂú®Ê≤ªÁñóËçØÁâ©,"(ÁæéÂõΩÂïÜ‰∏öËµÑËÆØ)--Neurocrine Biosciences, Inc. (Nasdaq:NBIX)ÂíåÊ≠¶Áî∞ËçØÂìÅÂ∑•‰∏öÊ†™Âºè‰ºöÁ§æ(Takeda Pharmaceutical Company Limited, TSE:4502/NYSE:TAK)Ôºà‚ÄúÊ≠¶Áî∞‚ÄùÔºâ‰ªäÂ§©ÂÆ£Â∏É‰∏ÄÈ°πÊó®Âú®ÂºÄÂèëÂíåÂïÜ‰∏öÂåñÊ≠¶Áî∞Êó©ÊúüËá≥‰∏≠ÊúüÁ≤æÁ•ûÁßë‰∫ßÂìÅÁÆ°Á∫øÁöÑÊàòÁï•Âêà‰Ωú„ÄÇÂÖ∑‰ΩìËÄåË®ÄÔºåÊ≠¶Áî∞ÂêëNeurocrine BiosciencesÊéí‰ªñÊÄßÊéàÊùÉ‰∏É‰∏™ÁÆ°Á∫ø...",121.03,121.47,118.41,118.41,NBIX,530957,HISTORICAL_PRICES,NBIX,,1.60683E+12,0.341349884,0.341349884,118.41,121.03,121.47,118.41,530957,118.41,121.03,121.47,118.41,530957,18-Jun-20,1.76,0.0148
18-Jun-20,Neurocrine BiosciencesÂíåÊ≠¶Áî∞ÂÆ£‰ΩàÂêà‰ΩúÈñãÁôºÁ≤æÁ•ûÁñæÁóÖÊΩõÂú®Ê≤ªÁôÇËó•Áâ©‰∏¶ÈÄ≤Ë°åÂïÜÊ•≠Âåñ,"(ÁæéÂúãÂïÜÊ•≠Ë≥áË®ä)--Neurocrine Biosciences, Inc. (Nasdaq:NBIX)ÂíåÊ≠¶Áî∞Ëó•ÂìÅÂ∑•Ê•≠Ê†™ÂºèÊúÉÁ§æ(Takeda Pharmaceutical Company Limited, TSE:4502/NYSE:TAK)Ôºà„ÄåÊ≠¶Áî∞„ÄçÔºâ‰ªäÂ§©ÂÆ£‰ΩàÁ≠ñÁï•ÊÄßÂêà‰ΩúÔºåÊó®Âú®ÈñãÁôºÊ≠¶Áî∞Êó©ÊúüËá≥‰∏≠ÊúüÁ≤æÁ•ûÁßëÁî¢ÂìÅÁ∑ö‰∏¶ÈÄ≤Ë°åÂïÜÊ•≠Âåñ„ÄÇÂÖ∑È´îËÄåË®ÄÔºåÊ≠¶Áî∞Â∞çNeurocrine BiosciencesÊèê‰æõ‰∏ÉÂÄãÁî¢ÂìÅÁ∑öË®àÁï´...",121.03,121.47,118.41,118.41,NBIX,530957,HISTORICAL_PRICES,NBIX,,1.60683E+12,0.341349884,0.341349884,118.41,121.03,121.47,118.41,530957,118.41,121.03,121.47,118.41,530957,18-Jun-20,1.76,0.0148
17-Jun-20,"Abiomed lance un programme d‚Äô√©ducation m√©dicale en ligne, CAMP PCI, afin d‚Äôam√©liorer les r√©sultats pour les patients subissant une ICP √† haut risque","Aujourd‚Äôhui, Abiomed (NASDAQ: ABMD) a lanc√© sa plateforme d‚Äô√©ducation num√©rique ultra-moderne CAMP PCI, qui signifie en anglais Coronary Artery & Myocardial Protected Percutaneous Coronary Interve...",254.73,256,249.153,252.04,ABMD,381594,HISTORICAL_PRICES,ABMD,,1.60683E+12,0.73415481,0.73415481,252.04,254.73,256,249.153,381594,252.04,254.73,256,249.153,381594,17-Jun-20,5.59,0.0224
17-Jun-20,Tandem Diabetes Care Announces Expanded Pediatric Indication of the t:slim X2 Insulin Pump with Control-IQ Advanced Hybrid Closed-Loop Technology,"Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced U.S. Food and Drug Administration (FDA) clearance of an expanded pediatric indica...",86.71,89.53,80.51,81.34,TNDM,3140075,HISTORICAL_PRICES,TNDM,,1.60683E+12,0.508,0.508,81.34,86.71,89.53,80.51,3140075,81.34,86.71,89.53,80.51,3140075,17-Jun-20,5.32,0.0654
17-Jun-20,Clovis Oncology to Highlight Rubraca¬Æ (rucaparib) and Lucitanib Non-Clinical Data at the AACR Virtual Annual Meeting II 2020,"Clovis Oncology, Inc. (NASDAQ: CLVS) announced today that four abstracts showcasing non-clinical data from rucaparib and lucitanib development programs have been accepted for on-demand viewing and pub...",6.965,7.41,6.92,7.25,CLVS,3524171,HISTORICAL_PRICES,CLVS,,1.60683E+12,0.572234763,0.572234763,7.25,6.965,7.41,6.92,3524171,7.25,6.965,7.41,6.92,3524171,17-Jun-20,-0.385,-0.0524
17-Jun-20,"FDA Approves Second Biomarker-Based Indication for Merck‚Äôs KEYTRUDA¬Æ (pembrolizumab), Regardless of Tumor Type","Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved KEYTRUDA, Merck‚Äôs anti-PD-1 therapy, as monotherapy...",76.29,77.45,75.625,77.36,MRK,13342640,HISTORICAL_PRICES,MRK,,1.61552E+12,0.118293755,0.118293755,77.36,76.29,77.45,75.625,13342640,75.536,74.4912,75.6239,73.8419,13342640,17-Jun-20,-0.68,-0.0088
17-Jun-20,ChromaDex Research & Development Facility Earns ISO/IEC 17025:2017 Accreditation,"ChromaDex Corp. (NASDAQ:CDXC) announced today it has achieved ISO/IEC 17025:2017 quality standard for laboratory testing, the world‚Äôs most respected quality management standard. This accreditation cov...",4.25,4.4,4.22,4.39,CDXC,144521,HISTORICAL_PRICES,CDXC,,1.60683E+12,0.440677966,0.440677966,4.39,4.25,4.4,4.22,144521,4.39,4.25,4.4,4.22,144521,17-Jun-20,-0.11,-0.0252
16-Jun-20,"Abiomed f√ºhrt das virtuelle Fortbildungsprogamm CAMP PCI f√ºr √Ñrzte ein, um die Ergebnisse bei Hochrisiko-PCI-Patienten zu verbessern","Heute f√ºhrte Abiomed (NASDAQ: ABMD), eine hochmoderne Ausbildungsplattform unter dem Namen CAMP PCI ein. Dies steht f√ºr ‚ÄûCoronary Artery & Myocardial Protected Percutaneous Coronary Intervention‚Äù,...",249.14,252.49,246.295,252.49,ABMD,419003,HISTORICAL_PRICES,ABMD,,1.60683E+12,0.696099122,0.696099122,252.49,249.14,252.49,246.295,419003,252.49,249.14,252.49,246.295,419003,16-Jun-20,2.81,0.0114
16-Jun-20,Neurocrine Biosciences und Takeda k√ºndigen Zusammenarbeit bei der Entwicklung und Vermarktung m√∂glicher Therapien f√ºr psychische St√∂rungen an,"Neurocrine Biosciences, Inc. (Nasdaq:NBIX) und die Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (‚ÄûTakeda‚Äù) gaben heute eine strategische Zusammenarbeit bei der Entwicklung und Vermarktung...",118.89,119.42,114.75,117.72,NBIX,778445,HISTORICAL_PRICES,NBIX,,1.60683E+12,0.317632716,0.317632716,117.72,118.89,119.42,114.75,778445,117.72,118.89,119.42,114.75,778445,16-Jun-20,3.56,0.0309
16-Jun-20,Neurocrine Biosciences et Takeda annoncent une collaboration pour le d√©veloppement et la mise sur le march√© de th√©rapies potentielles contre les troubles psychiatriques,"Neurocrine Biosciences, Inc. (Nasdaq:NBIX) et Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (¬´ Takeda ¬ª) annoncent ce jour une collaboration strat√©gique pour le d√©veloppement et la mise su...",118.89,119.42,114.75,117.72,NBIX,778445,HISTORICAL_PRICES,NBIX,,1.60683E+12,0.317632716,0.317632716,117.72,118.89,119.42,114.75,778445,117.72,118.89,119.42,114.75,778445,16-Jun-20,3.56,0.0309
16-Jun-20,Merck and Pfizer‚Äôs SGLT2 Inhibitor STEGLATROTM (ertugliflozin) Meets Primary Endpoint in VERTIS CV Trial for Patients with Type 2 Diabetes and Atherosclerotic Cardiovascular Disease,"Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Pfizer Inc. (NYSE:PFE), today announced the presentation of results from the Phase 3 VERTIS CV cardiovascular (CV) outcomes tr...",76.97,77.41,74.83,75.38,MRK,20460690,HISTORICAL_PRICES,MRK,,1.61552E+12,0.128261507,0.128261507,75.38,76.97,77.41,74.83,20460690,73.6027,75.1552,75.5848,73.0656,20460690,16-Jun-20,2.95,0.0399
16-Jun-20,Neurocrine Biosciences y Takeda anuncian una colaboraci√≥n para desarrollar y comercializar posibles tratamientos para trastornos psiqui√°tricos,"Neurocrine Biosciences, Inc. (Nasdaq:NBIX) y Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (¬´Takeda¬ª) acaban de anunciar una colaboraci√≥n estrat√©gica para desarrollar y comercializar compu...",118.89,119.42,114.75,117.72,NBIX,778445,HISTORICAL_PRICES,NBIX,,1.60683E+12,0.317632716,0.317632716,117.72,118.89,119.42,114.75,778445,117.72,118.89,119.42,114.75,778445,16-Jun-20,3.56,0.0309
16-Jun-20,Neurocrine Biosciences e Takeda anunciam colabora√ß√£o para desenvolver e comercializar potenciais terapias para dist√∫rbios psiqui√°tricos,"A Neurocrine Biosciences, Inc. (Nasdaq:NBIX) e a Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (‚ÄúTakeda‚Äù) anunciaram hoje uma colabora√ß√£o estrat√©gica para desenvolver e comercializar produ...",118.89,119.42,114.75,117.72,NBIX,778445,HISTORICAL_PRICES,NBIX,,1.60683E+12,0.317632716,0.317632716,117.72,118.89,119.42,114.75,778445,117.72,118.89,119.42,114.75,778445,16-Jun-20,3.56,0.0309
16-Jun-20,Abiomed ernennt Dr. med. Charles Simonton zum neuen Chief Medical Officer,"Abiomed (Nasdaq: ABMD), Hersteller der Impella Herzpumpe, gab heute die Ernennung von Dr. med. Charles (Chuck) Simonton zum Vice President und Chief Medical Officer bekannt. Dr. Simonton ist f√ºr seine...",249.14,252.49,246.295,252.49,ABMD,419003,HISTORICAL_PRICES,ABMD,,1.60683E+12,0.696099122,0.696099122,252.49,249.14,252.49,246.295,419003,252.49,249.14,252.49,246.295,419003,16-Jun-20,2.81,0.0114
16-Jun-20,Genprex Expands Manufacturing Program with Aldevron to Advance Oncoprex‚Ñ¢ Clinical Development,"Genprex, Inc. (‚ÄúGenprex‚Äù or the ‚ÄúCompany‚Äù) (Nasdaq: GNPX), a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes, announced toda...",3,3.12,2.91,3.09,GNPX,1280518,HISTORICAL_PRICES,GNPX,,1.60683E+12,0.075268817,0.075268817,3.09,3,3.12,2.91,1280518,3.09,3,3.12,2.91,1280518,16-Jun-20,-0.02,-0.0066
16-Jun-20,Neurocrine Biosciences and Takeda Announce Collaboration to Develop and Commercialize Potential Therapies for Psychiatric Disorders,"Neurocrine Biosciences, Inc. (Nasdaq:NBIX) and Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (‚ÄúTakeda‚Äù) today announced a strategic collaboration to develop and commercialize compounds in...",118.89,119.42,114.75,117.72,NBIX,778445,HISTORICAL_PRICES,NBIX,,1.60683E+12,0.317632716,0.317632716,117.72,118.89,119.42,114.75,778445,117.72,118.89,119.42,114.75,778445,16-Jun-20,3.56,0.0309
16-Jun-20,"Abiomed Launches Virtual Physician Education Program, CAMP PCI, to Improve High-Risk PCI Patient Outcomes","Today, Abiomed (NASDAQ: ABMD) launches a cutting-edge digital education platform called CAMP PCI, which stands for Coronary Artery & Myocardial Protected Percutaneous Coronary Intervention, to imp...",249.14,252.49,246.295,252.49,ABMD,419003,HISTORICAL_PRICES,ABMD,,1.60683E+12,0.696099122,0.696099122,252.49,249.14,252.49,246.295,419003,252.49,249.14,252.49,246.295,419003,16-Jun-20,2.81,0.0114
16-Jun-20,Nemaura Participated as Guest Speaker at DiabetesMine‚Ñ¢ D-Data ExChange 2020,"Nemaura Medical, Inc. (NASDAQ: NMRD) (‚ÄúNemaura‚Äù or the ‚ÄúCompany‚Äù), a medical technology company focused on developing micro-systems-based wearable diagnostic devices and currently commercializing suga...",11.9,14,10.51,10.55,NMRD,202393,HISTORICAL_PRICES,NMRD,,1.60683E+12,1.003367003,1.003367003,10.55,11.9,14,10.51,202393,10.55,11.9,14,10.51,202393,16-Jun-20,1.52,0.1464
15-Jun-20,Riassunto: Abiomed sceglie il Dott. Charles Simonton come nuovo Responsabile medico,"Abiomed (Nasdaq: ABMD), produttore della pompa cardiaca Impella, oggi ha annunciato la nomina del Dott. Charles (Chuck) Simonton alla carica di vicepresidente e responsabile medico dell'azienda. Il Do...",246.33,246.94,236.35,239.96,ABMD,402058,HISTORICAL_PRICES,ABMD,,1.60683E+12,0.676969161,0.676969161,239.96,246.33,246.94,236.35,402058,239.96,246.33,246.94,236.35,402058,15-Jun-20,4.65,0.0192
15-Jun-20,Ocular Therapeutix‚Ñ¢ to Hold Virtual 2020 Annual Meeting Of Stockholders,"Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today...",8.255,8.395,7.22,7.25,OCUL,1704133,HISTORICAL_PRICES,OCUL,,1.60683E+12,0.644422311,0.644422311,7.25,8.255,8.395,7.22,1704133,7.25,8.255,8.395,7.22,1704133,15-Jun-20,0.805,0.1081
15-Jun-20,"Abiomed nomme son nouveau m√©decin-chef, le Dr. Charles Simonton","Abiomed (Nasdaq: ABMD), fabricant de la pompe cardiaque Impella, a annonc√© aujourd‚Äôhui la nomination de Charles (Chuck) Simonton, D.M., au poste de vice-pr√©sident et m√©decin-chef de la soci√©t√©. Le Dr...",246.33,246.94,236.35,239.96,ABMD,402058,HISTORICAL_PRICES,ABMD,,1.60683E+12,0.676969161,0.676969161,239.96,246.33,246.94,236.35,402058,239.96,246.33,246.94,236.35,402058,15-Jun-20,4.65,0.0192
15-Jun-20,"Samenvatting: Abiomed benoemt nieuwe chief medical officer Charles Simonton, M.D.","Abiomed (Nasdaq: ABMD), maker van de Impella hartpomp, heeft vandaag aangekondigd dat het Charles (Chuck) Simonton, M.D., heeft aangesteld als vice-president en chief medical officer. Dr. Simonton sta...",246.33,246.94,236.35,239.96,ABMD,402058,HISTORICAL_PRICES,ABMD,,1.60683E+12,0.676969161,0.676969161,239.96,246.33,246.94,236.35,402058,239.96,246.33,246.94,236.35,402058,15-Jun-20,4.65,0.0192
15-Jun-20,ACADIA Pharmaceuticals Submits Supplemental New Drug Application to U.S. FDA for NUPLAZID¬Æ (pimavanserin) for the Treatment of Hallucinations and Delusions Associated with Dementia-Related Psychosis,ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) announced today that the company submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) to support a potential n...,46.49,46.88,44.55,44.9,ACAD,929607,HISTORICAL_PRICES,ACAD,,1.60683E+12,0.22149238,0.22149238,44.9,46.49,46.88,44.55,929607,44.9,46.49,46.88,44.55,929607,15-Jun-20,0.64,0.014
15-Jun-20,Ocular Therapeutix‚Ñ¢ to Present Data at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting,"Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, annou...",8.255,8.395,7.22,7.25,OCUL,1704133,HISTORICAL_PRICES,OCUL,,1.60683E+12,0.644422311,0.644422311,7.25,8.255,8.395,7.22,1704133,7.25,8.255,8.395,7.22,1704133,15-Jun-20,0.805,0.1081
15-Jun-20,"Resumen: Abiomed nombra a Charles Simonton, doctor en medicina, como su nuevo director m√©dico","Abiomed (Nasdaq: ABMD), fabricante de la bomba cardiaca Impella, ha anunciado hoy que ha nombrado vicepresidente y director m√©dico al Dr. Charles (Chuck) Simonton. El Dr. Simonton es reconocido por su...",246.33,246.94,236.35,239.96,ABMD,402058,HISTORICAL_PRICES,ABMD,,1.60683E+12,0.676969161,0.676969161,239.96,246.33,246.94,236.35,402058,239.96,246.33,246.94,236.35,402058,15-Jun-20,4.65,0.0192
15-Jun-20,Catalent Signs Agreement with AstraZeneca to Manufacture COVID-19 Vaccine Candidate,"Catalent, Inc. (NYSE: CTLT), the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health...",70.32,71.46,68.86,71,CTLT,3573566,HISTORICAL_PRICES,CTLT,,1.60683E+12,0.454996896,0.454996896,71,70.32,71.46,68.86,3573566,71,70.32,71.46,68.86,3573566,15-Jun-20,0.75,0.0108
15-Jun-20,"Abiomed Appoints New Chief Medical Officer Charles Simonton, M.D.","Abiomed (Nasdaq: ABMD), maker of the Impella heart pump, announced today it has appointed Charles (Chuck) Simonton, M.D., as vice president and chief medical officer. Dr. Simonton is renowned for his...",246.33,246.94,236.35,239.96,ABMD,402058,HISTORICAL_PRICES,ABMD,,1.60683E+12,0.676969161,0.676969161,239.96,246.33,246.94,236.35,402058,239.96,246.33,246.94,236.35,402058,15-Jun-20,4.65,0.0192
15-Jun-20,Xeris Pharmaceuticals Announces Positive Results From the Outpatient Stage of a Phase 2 Study of Its Developmental Gvoke Ready-to-Use (RTU) Micro‚Ñ¢ Glucagon in Adults at Risk of Hypoglycemia During and After Aerobic Exercise,"Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable and infusible drug formula...",4.51,4.58,4.12,4.56,XERS,386458,HISTORICAL_PRICES,XERS,,1.60683E+12,1.39893617,1.39893617,4.56,4.51,4.58,4.12,386458,4.56,4.51,4.58,4.12,386458,15-Jun-20,0.02,0.0045
15-Jun-20,COVID-19 Home Testing Kit Provider LetsGetChecked Deploys 8x8 Contact Centre for Vital Support,"8x8, Inc. (NYSE: EGHT), a leading integrated cloud communications platform provider, today announced LetsGetChecked, the at-home health testing and insights company, deployed 8x8 Contact Centre to con...",15.07,15.42,13.9356,14.02,EGHT,2196635,HISTORICAL_PRICES,EGHT,,1.60683E+12,-0.164634146,-0.164634146,14.02,15.07,15.42,13.9356,2196635,14.02,15.07,15.42,13.9356,2196635,15-Jun-20,0.8,0.0561
12-Jun-20,FDA Approves Merck‚Äôs GARDASIL 9 for the Prevention of Certain HPV-Related Head and Neck Cancers,"Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved an expanded indication for GARDASIL 9 for the preven...",76.3,77.93,75.47,77.89,MRK,16221985,HISTORICAL_PRICES,MRK,,1.61552E+12,0.11844034,0.11844034,77.89,76.3,77.93,75.47,16221985,76.0535,74.501,76.0926,73.6906,16221985,12-Jun-20,-1.05,-0.0136
12-Jun-20,Concert Pharmaceuticals Releases Additional Data from Phase 2 Clinical Trial of CTP-543 in Alopecia Areata,"Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today released new data analyses from its Phase 2 dose-ranging clinical trial of its investigational agent CTP‚Äë543 for the treatment of moderate-to-severe...",9.83,9.85,9.41,9.48,CNCE,197699,HISTORICAL_PRICES,CNCE,,1.60683E+12,0.120866591,0.120866591,9.48,9.83,9.85,9.41,197699,9.48,9.83,9.85,9.41,197699,12-Jun-20,0.67,0.0731
12-Jun-20,New Efficacy and Biomarker Data From Rivipansel Phase 3 RESET Trial to Be Presented at Sickle Cell Meeting,"GlycoMimetics, Inc. (Nasdaq: GLYC) today announced that a post hoc analysis of the Phase 3 RESET study evaluating the efficacy of rivipansel , its wholly-owned development candidate, in acute vaso-occ...",3,4.26,2.62,2.75,GLYC,13168441,HISTORICAL_PRICES,GLYC,,1.60683E+12,0.265822785,0.265822785,2.75,3,4.26,2.62,13168441,2.75,3,4.26,2.62,13168441,12-Jun-20,0.33,0.1236
12-Jun-20,"Glancy Prongay & Murray LLP, a National Class Action Law Firm, Continues Investigation of Pilgrim's Pride Corporation (PPC) on Behalf of Investors","Glancy Prongay & Murray LLP (‚ÄúGPM‚Äù), a national investor rights law firm, continues its investigation on behalf of Pilgrim's Pride Corporation (""Pilgrim‚Äôs Pride"" or the ""Company"") (NASDAQ: PPC) in...",18.14,18.465,17.73,18.35,PPC,1355397,HISTORICAL_PRICES,PPC,,1.60683E+12,-0.003296703,-0.003296703,18.35,18.14,18.465,17.73,1355397,18.35,18.14,18.465,17.73,1355397,12-Jun-20,0.25,0.014
12-Jun-20,"Glancy Prongay & Murray LLP, a National Class Action Law Firm, Continues Investigation of Tactile Systems Technology, Inc. (TCMD) on Behalf of Investors","Glancy Prongay & Murray LLP (‚ÄúGPM‚Äù), a national investor rights law firm, continues its investigation on behalf of Tactile Systems Technology, Inc. (""Tactile"" or the ""Company"") (NASDAQ: TCMD) inve...",40.77,42.08,39.675,40.99,TCMD,405386,HISTORICAL_PRICES,TCMD,,1.60683E+12,0.068956476,0.068956476,40.99,40.77,42.08,39.675,405386,40.99,40.77,42.08,39.675,405386,12-Jun-20,1.21,0.0306
12-Jun-20,"Glancy Prongay & Murray LLP, a National Class Action Law Firm, Continues Investigation of Townsquare Media, Inc. (TSQ) on Behalf of Investors","Glancy Prongay & Murray LLP (‚ÄúGPM‚Äù), a national investor rights law firm, continues its investigation on behalf of Townsquare Media, Inc. (""Townsquare Media"" or the ""Company"") (NYSE: TSQ) investor...",5.09,5.226,4.88,4.88,TSQ,50936,HISTORICAL_PRICES,TSQ,,1.60683E+12,0.053830228,0.053830228,4.88,5.09,5.226,4.88,50936,4.88,5.09,5.226,4.88,50936,12-Jun-20,0.21,0.043
12-Jun-20,Omeros‚Äô Narsoplimab Pivotal Trial Data Shared in Oral Presentation at Annual European Hematology Association Congress,Omeros Corporation (Nasdaq: OMER) today announced that the results of its pivotal trial of narsoplimab in the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSC...,14.635,15.65,14.16,15.65,OMER,794202,HISTORICAL_PRICES,OMER,,1.60683E+12,0.380660377,0.380660377,15.65,14.635,15.65,14.16,794202,15.65,14.635,15.65,14.16,794202,12-Jun-20,-0.525,-0.0346
12-Jun-20,Cerus Corporation Celebrates World Blood Donor Day,"Cerus Corporation (Nasdaq:CERS) celebrates World Blood Donor Day this Sunday, June 14, 2020. Enacted by the World Health Organization (WHO), World Blood Donor Day highlights the need for safe blood an...",6.04,6.12,5.75,5.94,CERS,2513802,HISTORICAL_PRICES,CERS,,1.60683E+12,0.495049505,0.495049505,5.94,6.04,6.12,5.75,2513802,5.94,6.04,6.12,5.75,2513802,12-Jun-20,0.44,0.0786
12-Jun-20,"Catabasis Pharmaceuticals Names Ben Harshbarger Senior Vice President, General Counsel","Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, announced today that it has named Ben Harshbarger as Senior Vice President, General Counsel. Mr. Harshbarger...",6.55,6.58,6.25,6.42,CATB,97127,HISTORICAL_PRICES,CATB,,1.60683E+12,0.605392157,0.605392157,6.42,6.55,6.58,6.25,97127,6.42,6.55,6.58,6.25,97127,12-Jun-20,0.38,0.0616
12-Jun-20,Kite Receives European Medicines Agency Approval for CAR T Cell Therapy Manufacturing Facility in Europe,"Kite, a Gilead Company (Nasdaq: GILD), today announced it has received approval to implement a variation to the Yescarta¬Æ (axicabtagene ciloleucel) Marketing Authorization from the European Medicine A...",73.2,73.72,71.91,73.33,GILD,8375593,HISTORICAL_PRICES,GILD,,1.61552E+12,0.05081826,0.05081826,73.33,73.2,73.72,71.91,8375593,70.9499,70.8241,71.3273,69.576,8375593,12-Jun-20,0.36,0.0049
12-Jun-20,Scholar Rock Presents Clinical and Preclinical Data for SRK-015 at the 2020 Virtual Cure SMA Research and Clinical Care Meeting,"Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced two presen...",17.27,17.5,15.85,16.27,SRRK,96950,HISTORICAL_PRICES,SRRK,,1.60683E+12,0.320336391,0.320336391,16.27,17.27,17.5,15.85,96950,16.27,17.27,17.5,15.85,96950,12-Jun-20,1.44,0.091
12-Jun-20,New Data Show Near Elimination of Sickle Cell Disease-Related Vaso-Occlusive Crises and Acute Chest Syndrome in Phase 1/2 Clinical Study of bluebird bio‚Äôs LentiGlobin‚Ñ¢ Gene Therapy for Sickle Cell Disease at 25th EHA Congress,"bluebird bio, Inc. (Nasdaq: BLUE) announced that new data from its ongoing Phase 1/2 HGB-206 study of investigational LentiGlobin‚Ñ¢ gene therapy for adult and adolescent patients with sickle cell disea...",63.93,68,62.11,67.84,BLUE,2060682,HISTORICAL_PRICES,BLUE,,1.60683E+12,0.35101437,0.35101437,67.84,63.93,68,62.11,2060682,67.84,63.93,68,62.11,2060682,12-Jun-20,0.81,0.0128
12-Jun-20,Majority of Evaluable Patients Across Genotypes Achieve Transfusion Independence and Maintain It with Near-Normal Hemoglobin Levels in Phase 3 Studies of betibeglogene autotemcel (LentiGlobin‚Ñ¢ for Œ≤-thalassemia) Gene Therapy Presented at EHA Congress,"bluebird bio, Inc. (Nasdaq: BLUE) today announced that new data from ongoing Phase 3 studies of betibeglogene autotemcel (beti-cel; formerly LentiGlobin‚Ñ¢ for Œ≤-thalassemia gene therapy) show pediatric...",63.93,68,62.11,67.84,BLUE,2060682,HISTORICAL_PRICES,BLUE,,1.60683E+12,0.35101437,0.35101437,67.84,63.93,68,62.11,2060682,67.84,63.93,68,62.11,2060682,12-Jun-20,0.81,0.0128
11-Jun-20,Quidel Receives BARDA Funding to Develop Point-of-Care Diagnostic Assay That Includes COVID-19,"Quidel Corporation (NASDAQ: QDEL) (‚ÄúQuidel‚Äù), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that Quidel has receive...",158.37,170.99,158.34,165.21,QDEL,1122786,HISTORICAL_PRICES,QDEL,,1.60683E+12,0.962696741,0.962696741,165.21,158.37,170.99,158.34,1122786,165.21,158.37,170.99,158.34,1122786,11-Jun-20,-8.39,-0.0503
11-Jun-20,Quidel Announces Jack Schuler Will Retire From Quidel‚Äôs Board of Directors,"Quidel Corporation (NASDAQ: QDEL) (‚ÄúQuidel‚Äù), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that Jack W. Schuler ha...",158.37,170.99,158.34,165.21,QDEL,1122786,HISTORICAL_PRICES,QDEL,,1.60683E+12,0.962696741,0.962696741,165.21,158.37,170.99,158.34,1122786,165.21,158.37,170.99,158.34,1122786,11-Jun-20,-8.39,-0.0503
11-Jun-20,Omeros‚Äô Narsoplimab Pivotal Trial Data to be Shared as an Oral Presentation at Annual European Hematology Association Congress,Omeros Corporation (Nasdaq: OMER): The results of Omeros‚Äô pivotal trial of narsoplimab for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA) will be...,15.16,15.74,15,15.1,OMER,562145,HISTORICAL_PRICES,OMER,,1.60683E+12,0.430188679,0.430188679,15.1,15.16,15.74,15,562145,15.1,15.16,15.74,15,562145,11-Jun-20,-0.485,-0.031
11-Jun-20,Urovant Sciences to Report Fiscal Year and Fourth Quarter 2019 Results,"Urovant Sciences (Nasdaq: UROV) announced today that it will report fiscal year and fourth quarter 2019 results after the close of U.S. financial markets on Thursday, June 18, 2020. Management will ho...",10.73,11.0665,10.15,11,UROV,147086,HISTORICAL_PRICES,UROV,,1.60683E+12,0.067661692,0.067661692,11,10.73,11.0665,10.15,147086,11,10.73,11.0665,10.15,147086,11-Jun-20,-0.16,-0.0147
11-Jun-20,"FDA Approves Pfizer‚Äôs Oncology Supportive Care Biosimilar, NYVEPRIA‚Ñ¢ (pegfilgrastim-apgf)","Pfizer Inc. (NYSE: PFE) today announced the United States (U.S.) Food and Drug Administration (FDA) has approved NYVEPRIA‚Ñ¢ (pegfilgrastim-apgf), a biosimilar to Neulasta¬Æ (pegfilgrastim).1 NYVEPRIA is...",33.3,35.68,33.28,35.6,PFE,59930390,HISTORICAL_PRICES,PFE,,1.6118E+12,0.119327731,0.119327731,35.6,33.3,35.68,33.28,59930390,34.521,32.2907,34.5986,32.2713,59930390,11-Jun-20,-2.62,-0.0729
11-Jun-20,Twist Bioscience Expands Offering of Synthetic SARS-CoV-2 RNA Controls,"Twist Bioscience Corporation (Nasdaq: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced the addition of four...",36.01,38.7,35.5,37.49,TWST,515210,HISTORICAL_PRICES,TWST,,1.60683E+12,0.297657658,0.297657658,37.49,36.01,38.7,35.5,515210,37.49,36.01,38.7,35.5,515210,11-Jun-20,-2.95,-0.0757
11-Jun-20,Moderna Advances Late-Stage Development of its Vaccine (mRNA-1273) Against COVID-19,"Moderna, Inc., (Nasdaq: MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, toda...",60.2,66.6867,58.77,62.95,MRNA,32085168,HISTORICAL_PRICES,MRNA,,1.60683E+12,1.218945816,1.218945816,62.95,60.2,66.6867,58.77,32085168,62.95,60.2,66.6867,58.77,32085168,11-Jun-20,0.13,0.0022
11-Jun-20,Magenta Therapeutics Provides Portfolio Update: Stem Cell Mobilization and Conditioning Programs Prioritized and Advancing Toward Clinical Milestones,"Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplant to more patients, today provided a portfolio...",9.035,10,8.93,10,MGTA,245350,HISTORICAL_PRICES,MGTA,,1.60683E+12,0.429588608,0.429588608,10,9.035,10,8.93,245350,10,9.035,10,8.93,245350,11-Jun-20,-1.365,-0.1313
11-Jun-20,Deciphera Pharmaceuticals to Present at the JMP Securities Hematology and Oncology Forum,"Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) today announced that Tucker Kelly, Executive Vice President, Chief Financial Officer and Treasurer, will present at the JMP Securities Hematology and Onco...",52.55,55.305,52.49,54.73,DCPH,372133,HISTORICAL_PRICES,DCPH,,1.60683E+12,0.271165941,0.271165941,54.73,52.55,55.305,52.49,372133,54.73,52.55,55.305,52.49,372133,11-Jun-20,-3.91,-0.0693
11-Jun-20,"Aerie Pharmaceuticals Appoints Peter J. McDonnell, M.D., to the Company‚Äôs Board of Directors","Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients wi...",13.27,14.575,12.79,14.5,AERI,1157402,HISTORICAL_PRICES,AERI,,1.60683E+12,0.021555042,0.021555042,14.5,13.27,14.575,12.79,1157402,14.5,13.27,14.575,12.79,1157402,11-Jun-20,-1.69,-0.113
10-Jun-20,U.S. Food and Drug Administration Approves Opdivo¬Æ (nivolumab) for the Treatment of Patients with Advanced Esophageal Squamous Cell Carcinoma (ESCC) After Prior Fluoropyrimidine- and Platinum-based Chemotherapy,"Bristol Myers Squibb (NYSE: BMY) today announced that Opdivo¬Æ (nivolumab) was approved by the U.S. Food and Drug Administration (FDA) for the treatment of patients with unresectable advanced, recurren...",60.16,61.42,59.9,61.24,BMY,13343689,HISTORICAL_PRICES,BMY,,1.60946E+12,0.219047619,0.219047619,61.24,60.16,61.42,59.9,13343689,59.8453,58.7899,60.0212,58.5358,13343689,10-Jun-20,-0.77,-0.0126
10-Jun-20,"Glancy Prongay & Murray LLP, a National Class Action Law Firm, Continues Investigation of Casper Sleep Inc. (CSPR) on Behalf of Investors","Glancy Prongay & Murray LLP (‚ÄúGPM‚Äù), a national investor rights law firm, continues its an investigation on behalf of Casper Sleep Inc. (""Casper"" or the ""Company"") (NYSE: CSPR) investors concernin...",8.22,8.87,7.895,8.75,CSPR,307122,HISTORICAL_PRICES,CSPR,,1.60683E+12,1.096938776,1.096938776,8.75,8.22,8.87,7.895,307122,8.75,8.22,8.87,7.895,307122,10-Jun-20,-0.44,-0.0508
10-Jun-20,"Clovis Oncology Announces Completion of Target Enrollment in the ATHENA Trial, a Phase 3 Maintenance Treatment Study in Front-line, Newly-Diagnosed Advanced Ovarian Cancer","Clovis Oncology, Inc. (NASDAQ: CLVS) announced today the completion of target patient enrollment in the Clovis-sponsored Phase 3 ATHENA trial evaluating the combination of Clovis‚Äô Rubraca¬Æ (rucaparib)...",7.14,7.36,7.0791,7.32,CLVS,3735770,HISTORICAL_PRICES,CLVS,,1.60683E+12,0.611738149,0.611738149,7.32,7.14,7.36,7.0791,3735770,7.32,7.14,7.36,7.0791,3735770,10-Jun-20,-0.19,-0.0259
10-Jun-20,Turning Point Brands Announces Acquisition of Assets From Durfort Holdings,"Turning Point Brands, Inc. (‚ÄúTPB‚Äù) (NYSE: TPB), a leading provider of Other Tobacco Products (‚ÄúOTP‚Äù) and adult consumer alternatives, today announced the acquisition of certain tobacco assets and dist...",24.71,25.52,24.22,25.26,TPB,55499,HISTORICAL_PRICES,TPB,,1.61603E+12,0.133486239,0.133486239,25.26,24.71,25.52,24.22,55499,25.1135,24.5667,25.372,24.0796,55499,10-Jun-20,-0.69,-0.0272
10-Jun-20, NantKwest Announces Studies in Collaboration with the National Cancer Institute Demonstrating Enhanced Killing Activity of First-in-Class PD-L1 t-haNK Natural Killer Cell Across Every Cancer Cell Line Tested,"NantKwest, Inc. (Nasdaq: NK), a clinical-stage, natural killer cell-based therapeutics company, today announced the publication of two peer-reviewed manuscripts in the Journal of Immunotherapy of Canc...",6.21,6.63,6.0301,6.447,NK,1838216,HISTORICAL_PRICES,NK,,1.60683E+12,1.076923077,1.076923077,6.447,6.21,6.63,6.0301,1838216,6.447,6.21,6.63,6.0301,1838216,10-Jun-20,0.56,0.0991
10-Jun-20,Kala Pharmaceuticals Announces Virtual-Only Format for 2020 Annual Meeting of Stockholders,"Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced that...",13.6,13.97,13.36,13.46,KALA,552677,HISTORICAL_PRICES,KALA,,1.60683E+12,0.852861035,0.852861035,13.46,13.6,13.97,13.36,552677,13.46,13.6,13.97,13.36,552677,10-Jun-20,0.35,0.0264
10-Jun-20,TransAct Secures BOHA! Solutions Order for Regional Convenience Store Chain,"TransAct¬Æ Technologies Incorporated (Nasdaq: TACT) (‚ÄúTransAct‚Äù or ‚Äúthe Company‚Äù), a global leader in software-driven technology and printing solutions for high-growth markets, today announced that it...",5.5001,6.27,5.35,6.27,TACT,36986,HISTORICAL_PRICES,TACT,,1.60683E+12,0.388914141,0.388914141,6.27,5.5001,6.27,5.35,36986,6.27,5.5001,6.27,5.35,36986,10-Jun-20,-0.2699,-0.0468
10-Jun-20,Ocular Therapeutix‚Ñ¢ to Present at the 2020 Raymond James Human Health Innovation Conference,"Ocular Therapeutix, Inc. (NASDAQ:OCUL) a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today...",7.345,7.78,7.26,7.7,OCUL,780716,HISTORICAL_PRICES,OCUL,,1.60683E+12,0.46314741,0.46314741,7.7,7.345,7.78,7.26,780716,7.7,7.345,7.78,7.26,780716,10-Jun-20,-0.305,-0.0399
10-Jun-20,Pfizer Announces Positive Top-Line Results from JADE TEEN Trial of Abrocitinib in Adolescents with Moderate-to-Severe Atopic Dermatitis,"Pfizer Inc. (NYSE: PFE) announced today positive top-line results from the Phase 3 JADE TEEN study of abrocitinib, an investigational oral once-daily Janus kinase 1 (JAK1) inhibitor, in patients 12 to...",35.92,36.45,35.89,36.36,PFE,28042861,HISTORICAL_PRICES,PFE,,1.6118E+12,0.207394958,0.207394958,36.36,35.92,36.45,35.89,28042861,35.258,34.8313,35.3452,34.8022,28042861,10-Jun-20,-0.29,-0.008
10-Jun-20,Veeva k√ºndigt neue L√∂sung zur Beschleunigung von Erkenntnissen im Key Account Management an,"Auf dem heutigen Veeva Summit Online k√ºndigte Veeva Systems (NYSE: VEEV) Veeva Link f√ºr KAM an, eine neue L√∂sung, die kaufm√§nnischen und medizinischen Teams genaue Kundendaten und Echtzeit-Einblicke f...",226.55,227.86,215.26,215.45,VEEV,2023075,HISTORICAL_PRICES,VEEV,,1.60683E+12,0.686769414,0.686769414,215.45,226.55,227.86,215.26,2023075,215.45,226.55,227.86,215.26,2023075,10-Jun-20,13,0.0609
10-Jun-20,Everbridge Launches Fully Integrated Critical Event Management (CEM) Solution in Europe That Helps Organizations Mitigate Crises and Manage the Safe Return to Work After COVID-19 Lockdowns,"Everbridge, Inc. (NASDAQ: EVBG), the global leader in critical event management (CEM), today announced the expansion of its award-winning software platform in Europe, just as businesses, healthcare fa...",135.72,137.9392,132.32,134.37,EVBG,609969,HISTORICAL_PRICES,EVBG,,1.60683E+12,0.226348604,0.226348604,134.37,135.72,137.9392,132.32,609969,134.37,135.72,137.9392,132.32,609969,10-Jun-20,3.76,0.0285
9-Jun-20,Illumina Receives First FDA Emergency Use Authorization for a Sequencing-Based COVID-19 Diagnostic Test,"Illumina, Inc. (NASDAQ: ILMN) is paving the way for large-scale, next-generation sequencing-based (NGS) COVID-19 testing. Today, the U.S. Food and Drug Administration (FDA) issued an Emergency Use Aut...",357.78,361.58,354,357.6,ILMN,655903,HISTORICAL_PRICES,ILMN,,1.60683E+12,0.440802191,0.440802191,357.6,357.78,361.58,354,655903,357.6,357.78,361.58,354,655903,9-Jun-20,-1.03,-0.0029
9-Jun-20,Neue Funktion in Vault PromoMats zur Beschleunigung der Zusammenstellung von Werbematerialien f√ºr die Einreichung bei der FDA,"Veeva Systems (NYSE: VEEV) k√ºndigte heute beim Veeva Summit Online eine neue Funktion in Veeva Vault PromoMats an, mit der die digitale Einreichung von Werbematerialien f√ºr Produkte mit beschleunigter...",213.55,220,212.91,220,VEEV,1113374,HISTORICAL_PRICES,VEEV,,1.60683E+12,0.589978408,0.589978408,220,213.55,220,212.91,1113374,220,213.55,220,212.91,1113374,9-Jun-20,-4.81,-0.022
9-Jun-20,Quidel Receives Amended Emergency Authorization for Rapid Antigen COVID-19 Diagnostic Assay Using Sofia 1 Instrument,"Quidel Corporation (NASDAQ: QDEL) (‚ÄúQuidel‚Äù), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that Quidel has receive...",155.8,160.01,154.39,155.26,QDEL,683291,HISTORICAL_PRICES,QDEL,,1.60683E+12,0.930846449,0.930846449,155.26,155.8,160.01,154.39,683291,155.26,155.8,160.01,154.39,683291,9-Jun-20,-0.52,-0.0033
9-Jun-20,Merck Provides Update on Phase 3 KEYNOTE-361 Trial Evaluating KEYTRUDA¬Æ (pembrolizumab) as Monotherapy and in Combination with Chemotherapy in Patients with Advanced or Metastatic Urothelial Carcinoma,"Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the Phase 3 KEYNOTE-361 trial evaluating KEYTRUDA, Merck‚Äôs anti-PD-1 therapy, in combination with chemotherap...",82.26,83.51,82.12,83.19,MRK,8440980,HISTORICAL_PRICES,MRK,,1.61552E+12,0.205804749,0.205804749,83.19,82.26,83.51,82.12,8440980,80.5879,79.687,80.8979,79.5514,8440980,9-Jun-20,-0.64,-0.0077
9-Jun-20,Samenvatting: Nieuwe mogelijkheid in Vault PromoMats om promotiemateriaal voor verpakkingen te versnellen voor FDA-indiening,Veeva Systems (NYSE: VEEV) heeft vandaag op Veeva Summit Online een nieuwe mogelijkheid aangekondigd in Veeva Vault PromoMats om de digitale indiening van promotiemateriaal voor versnelde goedkeurings...,213.55,220,212.91,220,VEEV,1113374,HISTORICAL_PRICES,VEEV,,1.60683E+12,0.589978408,0.589978408,220,213.55,220,212.91,1113374,220,213.55,220,212.91,1113374,9-Jun-20,-4.81,-0.022
9-Jun-20,Applied DNA Secures Grant from National Grid Partnered with the New York State MEP to Support Manufacture of COVID-19 Diagnostic Kits and Vaccine Candidates,"Applied DNA Sciences Inc. (NASDAQ: APDN) (‚ÄúApplied DNA‚Äù or the ‚ÄúCompany,‚Äù ‚Äúour‚Äù) announced today it secured a $40,000 economic development grant from National Grid to support the Company‚Äôs efforts ass...",7.82,9.03,7.26,7.66,APDN,1621216,HISTORICAL_PRICES,APDN,,1.60683E+12,0.916666667,0.916666667,7.66,7.82,9.03,7.26,1621216,7.66,7.82,9.03,7.26,1621216,9-Jun-20,-0.04,-0.0051
9-Jun-20,FSD Pharma Announces Closing of C$10.125 Million Private Placement to Institutional Investors,"FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE.CN) (FRA: 0K9A) (the ‚ÄúCompany‚Äù) announces the closing of a previously announced private placement of 1,500,000 of the Company‚Äôs Class B Subordinate Voting Sha...",4.65,4.99,4.53,4.89,HUGE,252466,HISTORICAL_PRICES,HUGE,,1.60988E+12,0.544850498,0.544850498,4.89,4.65,4.99,4.53,252466,4.89,4.65,4.99,4.53,252466,9-Jun-20,-0.39,-0.0774
9-Jun-20,Riassunto: Nuova funzionalit√† in Vault PromoMats velocizza la preparazione del materiale promozionale per la presentazione di prodotti alla FDA,Veeva Systems (NYSE: VEEV) ha annunciato oggi nel corso del Veeva Summit Online (vertice Veeva online) l‚Äôintroduzione di una nuova funzionalit√† in Veeva Vault PromoMats atta a velocizzare la presentaz...,213.55,220,212.91,220,VEEV,1113374,HISTORICAL_PRICES,VEEV,,1.60683E+12,0.589978408,0.589978408,220,213.55,220,212.91,1113374,220,213.55,220,212.91,1113374,9-Jun-20,-4.81,-0.022
9-Jun-20,Resumen: Nueva capacidad de Vault PromoMats para acelerar el packaging de materiales promocionales para su presentaci√≥n a la FDA,"Veeva Systems (NYSE: VEEV) ha anunciado hoy en Veeva Summit Online, la cumbre online de Veeva, una nueva capacidad de Vault PromoMats de Veeva para acelerar la presentaci√≥n digital de materiales promo...",213.55,220,212.91,220,VEEV,1113374,HISTORICAL_PRICES,VEEV,,1.60683E+12,0.589978408,0.589978408,220,213.55,220,212.91,1113374,220,213.55,220,212.91,1113374,9-Jun-20,-4.81,-0.022
9-Jun-20,Genprex Scheduled to Join Russell 3000¬Æ Index,"Genprex, Inc. (‚ÄúGenprex‚Äù or the ‚ÄúCompany‚Äù) (Nasdaq: GNPX), a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes, today announce...",3.36,3.39,3.05,3.15,GNPX,3128625,HISTORICAL_PRICES,GNPX,,1.60683E+12,0.204301075,0.204301075,3.15,3.36,3.39,3.05,3128625,3.15,3.36,3.39,3.05,3128625,9-Jun-20,0.3,0.098
9-Jun-20,Veracyte Announces De Novo Classification Request to FDA for the nCounter Dx LymphMark Assay,"Veracyte, Inc. (Nasdaq: VCYT) today announced its submission of a De Novo classification request to the U.S. Food & Drug Administration (FDA) for the nCounter¬Æ Dx LymphMark‚Ñ¢ Assay, a novel, genomi...",26.79,27.17,25.85,25.85,VCYT,345024,HISTORICAL_PRICES,VCYT,,1.60683E+12,0.217450579,0.217450579,25.85,26.79,27.17,25.85,345024,25.85,26.79,27.17,25.85,345024,9-Jun-20,0.49,0.0186
9-Jun-20,Leading BioSciences Teams with Donnelley Financial Solutions to Create Innovative Study Tool for Clinical Trial Monitoring During COVID-19 Pandemic,"Donnelley Financial Solutions (NYSE: DFIN), a leading risk and compliance company, today announced that Leading BioSciences, Inc. (LBS), a drug development company focused on improving human health th...",9.06,9.99,8.81,9.9,DFIN,356160,HISTORICAL_PRICES,DFIN,,1.60683E+12,1.199029126,1.199029126,9.9,9.06,9.99,8.81,356160,9.9,9.06,9.99,8.81,356160,9-Jun-20,-0.96,-0.0958
9-Jun-20,"Everbridge Wins New Patent for its Critical Event Management Solution, Expanding its Technology Leadership Amid COVID-19","Everbridge, Inc. (NASDAQ: EVBG), the global leader in critical event management (CEM), today announced that the U.S. Patent and Trademark Office (USPTO) awarded Everbridge Patent No. 10,652,080 for it...",131.96,133.535,127.73,131.23,EVBG,776230,HISTORICAL_PRICES,EVBG,,1.60683E+12,0.192373724,0.192373724,131.23,131.96,133.535,127.73,776230,131.23,131.96,133.535,127.73,776230,9-Jun-20,1.3,0.0099